<SEC-DOCUMENT>0001104506-21-000005.txt : 20210225
<SEC-HEADER>0001104506-21-000005.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225072931
ACCESSION NUMBER:		0001104506-21-000005
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30739
		FILM NUMBER:		21676415

	BUSINESS ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		700 US HIGHWAY 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>insm-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad,d:b70075c4f5c143bda8e7fff17e62c779--><html xmlns:insm="http://www.insmed.com/20201231" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>insm-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF80LTEtMS0xLTA_a7d358ff-bf07-469a-8604-4bf6470e3ea0">false</ix:nonNumeric><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF82LTEtMS0xLTA_72385ca4-8b52-48fe-a293-5c5307c58779">2020</ix:nonNumeric><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF83LTEtMS0xLTA_58dfc4b2-4db6-43e3-9283-2a29d4070239">FY</ix:nonNumeric><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGV4dHJlZ2lvbjo4ZDQ1NWZlYTBkMjk0OTU0YTIyZmFhYWVhMzE3OTliMF8yOQ_640f2eeb-3a5b-4dc4-87d1-3054937dc026">0001104506</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="if478c817a20d48b1b85b1cda7a7158cd_D20180101-20180131" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjAvZnJhZzpjNDRiNWNmZjE3MGQ0NTMzOGVjYjllZDRiMDhmODUwNS90YWJsZTpjM2Y0ODllM2VkNWQ0Mzg3OGQ1ZmE3YzBkMjIzZjA4Yi90YWJsZXJhbmdlOmMzZjQ4OWUzZWQ1ZDQzODc4ZDVmYTdjMGQyMjNmMDhiXzItMS0xLTEtMA_8be4a2bc-5739-4307-8611-c7cf686365d6">0.0255384</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="insm-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i568098e806134d1ebaedc445a945607c_I20210222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebde4d2934ac45c684584d4c433bdde3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ee174a408b4a3e956206fe10d829f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf2af78768043e6a6d0f7f80a56687d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9883789f34af48faa49839a2c46e2971_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20647d4d256549fcb9f6d47074842d0c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85fc514b5b74bbebdde290e2e17f393_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0573aa1bb72428a95e7d4716d768ca1_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253f9191270b47bbb377a3e554382848_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a0bbd8f14f48d9891d78182180a475_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546efb7b63d14554aa9bfdf739cebc90_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib76325e7c3734939be7e498355efe724_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1515d5bd1d4ee4b52a34eebff6fa4b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872a79a3298a4fc0935733317644b8f7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6225cad52544c692427c26bd334021_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib081213375dc485f8d419cd32e77ad21_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5326db554c74c3e8b3751c9d9d6fd9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805a071174014bd59c6cd5891fc33d9d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b58797f08d4181a4d8d4f76c2b948e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie973139e8f3f474ba01ec72a33d057c2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86609ec5e2274f059fdd63ee245fc9cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e12ab6a629456d98e9c2642ad51f4b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9b120d293904c698a3d259c3e643e2b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e65405df6f448b786cddb256251701b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i968e32794a5c4430ae11c1b0b3884003_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0897592bf8bb4a21931904c230db9a43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia665daf63d884a34b3a03848ca8720da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1b38925e110b406fb8d690af86e404ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ff79db52eb84c4598d7b7afcb119dfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5f902b0ea148debdd39b7e096ed23b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad75b5ff0eb42f79faddf5ae9746ddb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0818f19ecc45e8bffe1b74c6ecc287_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if33069948ada4260b9525905a9028722_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefdcf33de75d49cba0e70cc7853c3280_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f8752f81b5546f6aac228d90c7b03d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c48b09e6691416abc16070aff6792d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>insm:security</xbrli:measure></xbrli:unit><xbrli:context id="i9bd7a24933d64c00a17e23166ddcb249_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93c687c71117495bbb85688c2e6da53f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2557ec52f167465a9db110f78f63cea9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017d5966090a4b0ab4fb5abb56c17d5c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b1b88435bd44aeb678f80443f3d14c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84af194151234369a03dc3fdf9ff1c60_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9ad5a7b26844352bc3de93a1fa02e5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b33cfe7496472887a9b46f5bb1a64e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if411584126e147579c1290e85b019267_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d80ecd614a347319af9d2f44019b7f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84042da0fe82481489bbac6622c413bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d6098b4cd2462ea2fe95fdcfff87a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed9d4ebbe0c4a5c90652308ad3ede36_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if454ac4f869c4464a82f74996dd1dcae_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7d083f6da0458181337d318c54b702_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e32e7ead80245768a4215e36f3d013e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a17ed1cbdfb44299c8d6329a58ecd20_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b73eefc9dfc4da4b954ad4f37d36401_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7daa5829bc564872bab33523184cce28_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb953793f734b5fa4ff72faaca69bed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1e8f8d82d740f2a0b6f1636a4984fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e26a169ca6447e1bbd8420534209dd4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff567a613c140aa9f850be249a8a85f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1b35f80d7c4963a103aa9c2ed57381_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1f6e025d01493c8f016b27c71e8c6c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d0d45f93fd42eaa738fe0fc6f368ff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8918052cbd746439e9093c317f861e3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib892164ea751411ca150501c187370ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida80845cbee243b2815d745facfea2d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9ed33bf5454a7d8711743ff01550c0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>insm:segment</xbrli:measure></xbrli:unit><xbrli:context id="iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-28</xbrli:startDate><xbrli:endDate>2018-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd637936ab04afab59656afc255fd17_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42ea68e2b42646b1959bc8837fbc4bcf_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc7b7bc070a40c891c23f07c65ed05a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f4981464504148bd4aa06dc574e5ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ded28353bf643aa99d3cb05cc110533_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19cd90bf12b4d9eb4da95674aef4152_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0bd03488004153b5268b5e73764e14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48973993a3149f79721dd24b81a822b_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief073ee95b334197863c0f30058817dc_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eb4c16988e4465da82e7f50e0573676_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia660e683387d45a2ac6386d394562fcc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cfb89dc31514ee5a530da7763685f22_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83673d124194183900e1755392dbac3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e98f2e617b543ad8b634db7a4621957_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a79104934c4503861efdd407cf050b_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a83453ffc34b6295f8aff4ef7b27d1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1633bbde7149ff91f24bafaf35316e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd0f2ffc22f44e4bddc73e49309d010_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fda285397a42e19d6a260af7e5f67d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e287d9cd08c41e0b6d0fd2c3d4b5fc8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b08ca4050e48bf96bdaea7bcd7c871_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i955be7a501ea48619d13734d6154f45e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i641fb1bda4d041b9b0710d36df07d468_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcda52d10cc646e78962f9e2486e8cbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68616dc8974c4009a3f605818d4e3333_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05db6e937b5d40acb4c6da58c96aed34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3620656a3d74b50befaf129855bc9d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85c99f6855754004b7860cc3f26ae215_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829ced73ae454a818b994f29cf817fb7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17adbf61f3554994afc5c8d08ee421ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie336952f723a45f7aad277d34fd71fc0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0653aae9e65348feaa6920fe60047862_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad290bf1da9470cbb52bc0838395dc6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f74877e573149a898ea49344d4209eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a7dcb8a06842e7ad8e6b069114005d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca69534f44544678e6345d4061172bd_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7789efc1fa15465a824da338e733666d_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>insm:day</xbrli:measure></xbrli:unit><xbrli:context id="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e454efc09a14c9f9b4641cc444070e4_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia962faac0e554b0eade20b47d690b557_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermivMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f292dc67c894e10a48cb3e934955825_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207c67bfeb704bc880cce0755881858e_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea99db509d54adeb7486a066eb4eb62_D20180101-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if478c817a20d48b1b85b1cda7a7158cd_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9654b342b1b943d1b4904dcb5401b4a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632484c618934954b43bf3c619cf75d9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff5a8670240445378f8c05d86d5621bb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i349a3db24a104296871f679b48d0727b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-24</xbrli:startDate><xbrli:endDate>2019-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7d4ce336b0d4998950db423777b2a69_D20190524-20190524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-24</xbrli:startDate><xbrli:endDate>2019-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefb0a77979724e36a4b8762928d10239_I20190524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e46a7dfb16496c852ec9544e1b781f_D20190524-20190524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-24</xbrli:startDate><xbrli:endDate>2019-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i818541d9894e4786bafa4a7f073c56da_D20190524-20190524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-24</xbrli:startDate><xbrli:endDate>2019-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab005c49d7049b480307e85adfed0ea_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb14027d5bff4fac80225d11be8c578f_I20190516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cb5fa6b23cb4fad903933f28e806e98_D20200512-20200512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-12</xbrli:startDate><xbrli:endDate>2020-05-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b05e9462b7490284e2dec768389895_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d986e645bf145889f874249c82e4942_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1015f33ba83642e796387fad13fc1078_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i827d3608f7854deb81221457676b5339_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29981174a85438ab8f4063d1cd73795_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0be8cbb20b3e471da2e0aead19d7a176_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce04f79cefd429f9fa32b6a5866706c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96db1220ab75430ab3c6ae0bc9042f63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74916538d9974ba79e0b9d63850374aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364ee03e6c7541a69698fc45ca2ba4ce_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib38d1bbcd50f449aa39ec92d1409abba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93060279fbe94fc7a1a08779106fc2f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba3be11a88b4bfca6f5772ebff95bcb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0e4ce89f3d4ea4bb96ff17f982a182_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic353257bd6e34e7dbe0b8636bd5d2538_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa29866a032b4f66bcfd69a12e24036c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b57931b8a04017a81e641841a99233_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd1672f5e51546618f0cf07a08a28df1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f3c32373d84f8d8b6e8ad92ddfe7a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21187a96ab01431487e85f22a31a8d4d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc948d8df4a94b7eb93b753074d45f0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">insm:IrelandTaxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c1a8f856324526bc222644c67d2afb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5509be6b4fb84159b9c6b41efd84a675_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i6cf490c2bd404047bb4076dfbe4a9035_D20080401-20080430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneNewDrugApplicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-04-01</xbrli:startDate><xbrli:endDate>2008-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if80ed6a320744417ad76e4542ce13f86_D20080401-20080430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneFDAApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-04-01</xbrli:startDate><xbrli:endDate>2008-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e1cd387ddb44953ad773aa9410675d5_D20080401-20080430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneEMAApprovalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-04-01</xbrli:startDate><xbrli:endDate>2008-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579a8c2c42bf45ff98f87f2c584c06ea_D20040101-20041231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2004-01-01</xbrli:startDate><xbrli:endDate>2004-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea44e908cf7e4040bb2902ceff09e1f2_D20090101-20091231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-01-01</xbrli:startDate><xbrli:endDate>2009-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad33e6bc291434cbfb0f351cbf0d854_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cfcedfa9eec4b33b05c236c449b48a7_D20040101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2004-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4bec08f1b8439f95f590be3ffee05d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:ResilienceBiotechnologiesIncContractManufacturingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-02-01</xbrli:startDate><xbrli:endDate>2014-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b84c0ce9224662b5305154df7099d8_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:ResilienceBiotechnologiesIncContractManufacturingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id633afd47e954538a26c547411ecfe02_D20140701-20140731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-07-01</xbrli:startDate><xbrli:endDate>2014-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib05c0670068f485e8afcc6417da49edf_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e3ed8648004855b71e7b4adb845d68_I20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if28faba5eb55435f9579cbc04ed74d86_D20161001-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1957ada0d9cd42738836fe4ca797ec73_D20161001-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PPDDevelopmentLPAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667f6be698f043288e59286e0ec72ad8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001104506</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib70075c4f5c143bda8e7fff17e62c779_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY184Mg_33127434-6b58-43c2-adb7-1a8c8e646515">10-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8xLTAtMS0xLTA_2f8922a1-dbe9-4c1b-b7f8-10cd105d7762">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the fiscal year ended <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDBjZTVhNDdiNGU0OWI2ODQ0OGQ2MzU0MTgwOGUyOF8zMA_bd7968e0-23c5-47b5-87a6-61ff8c2bf082"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDBjZTVhNDdiNGU0OWI2ODQ0OGQ2MzU0MTgwOGUyOF8zMA_3f226756-83ab-4981-a3ae-7a507774c5c5">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OR</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl80LTAtMS0xLTA_86fdccc1-836a-49a5-b015-873e05cc5b7b">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMTE_afa3118f-0e71-4441-ba48-db33d7cbafc1">0-30739</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMTQ_ac843779-20e2-4463-84fb-b084ca62939a">INSMED INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.111%"><tr><td style="width:1.0%"></td><td style="width:45.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.469%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8wLTAtMS0xLTAvdGV4dHJlZ2lvbjoyNTA2MDdkZjVkNmQ0YjVkYjliNGY5OWI5ZGYyOWU4Zl80_341f3111-695a-4606-853f-b986f86d69a0">Virginia</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8wLTItMS0xLTAvdGV4dHJlZ2lvbjo1OTdmMDI5OWE1ODg0NGYwYTdmZGRmOTEwMzM5NTdiYV80_2eae7162-aa62-4491-9da8-c0bc1075ba36">54-1972729</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. employer identification no.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM180_57d3d07c-2725-4785-8120-efd6ca26e509">700 US Highway 202/206</ix:nonNumeric> <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" xsi:nil="true" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM183_1944ae70-d221-478e-beb2-a3627ecc6c0b"></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xMA_d08248b4-e581-4ba4-a6ac-ba22a60f2e73">Bridgewater</ix:nonNumeric>, <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xNA_75af9bf5-500d-4ae3-a70d-26c5df1541fc">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xNw_afc0fb9f-a797-42d1-978a-2c542add8385">08807</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTItMS0xLTAvdGV4dHJlZ2lvbjo0YjU5NzliNzI4Nzg0ZDJlYTFmYjZiNGFhMTBhOTljZV81_7ceaaf98-9c34-4229-a188-d40b2b896b59">908</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTItMS0xLTAvdGV4dHJlZ2lvbjo0YjU5NzliNzI4Nzg0ZDJlYTFmYjZiNGFhMTBhOTljZV85_3d363022-89ae-417e-9464-3f6bdeb2d7c0">977-9900</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Registrant's telephone number including area code)</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.250%"><tr><td style="width:1.0%"></td><td style="width:38.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading symbols</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTAtMS0xLTA_11bd971e-441d-47f2-9ba7-4b2586f200c3">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTEtMS0xLTA_712444e0-c81e-4950-8497-e5b33649a8aa">INSM</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTItMS0xLTA_e1ad073a-8ff6-467a-b23e-4ee283618721">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180MzA_fba14937-b349-4335-894e-a8618356c859">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY181NzE_9c1a0a79-1a1b-442b-9325-8b47addfeea2">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY185MjE_05110bac-e927-48a6-91fd-3322e8f125f7">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMjQx_ea867c7b-16c0-4bb2-a8d8-592ef0c11b2e">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company (See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act). <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNTk5_3a11d4d0-fc0e-4a67-8c25-5805cb4b2480">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNjc0_c7817f94-c2bd-4ea3-a86e-30a2cb5adbb5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNzAx_ce660dee-392f-4d98-85c5-c8524982021e">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180Mzk4MDQ2NTE0ODA5_4a3b154a-8be7-480b-8988-5db979632ac6">&#9746;</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a Shell Company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18yMDcz_7a9cc94c-a80b-461d-9423-55f3a0f8bd29">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant on June&#160;30, 2020, was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630" decimals="-8" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18yMjE0_6c83f278-44b7-4070-99ed-d990f687ab6d">2.8</ix:nonFraction> billion (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">based on the closing price for shares of the registrant's common stock as reported on the Nasdaq Global Select Market on that date). In determining this figure, the registrant has assumed solely for this purpose that all of its directors, executive officers, persons beneficially owning 10% or more of the registrant's outstanding common stock and certain other stockholders of the registrant may be considered to be affiliates. This assumption shall not be deemed conclusive as to affiliate status for this or any other purpose.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">On February&#160;22, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i568098e806134d1ebaedc445a945607c_I20210222" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180Mzk4MDQ2NTE0ODQw_28a24025-4b59-448f-b1f4-5d522c964195">103,043,347</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"> of the registrant's common stock, $0.01 par value, outstanding.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">____________________________________________________________________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:51.75pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18zMzEz_f740f737-155d-4d72-a715-c56456cb6eb8" continuedAt="i7225f58411034134af7b4c18f00a1d46" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Portions of the registrant's definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission no later </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">than April 30, 2021 an</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:continuation id="i7225f58411034134af7b4c18f00a1d46">d to be delivered to shareholders in connection with the 2021 Annual Meeting of Shareholders, are herein incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K</ix:continuation>.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:10.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_10">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_10">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_13">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_16">ITEM 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_22">ITEM 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_22">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_22">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_25">ITEM 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_25">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_25">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_28">ITEM 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_28">PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_28">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_31">ITEM 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_31">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_31">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_34">ITEM 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_34">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_34">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_37">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_37">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_40">ITEM 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_40">MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_40">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_43">ITEM 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">[RESERVED]</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_43">59</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_58">ITEM 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_58">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_46">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_67">ITEM 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_67">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_67">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_70">ITEM 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_70">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_70">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_73">ITEM 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_73">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_73">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_76">ITEM 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_76">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_76">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_79">ITEM 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_79">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_79">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_82">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_82">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_85">ITEM 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_85">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_85">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_88">ITEM 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_88">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_88">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_91">ITEM 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_91">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_91">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_94">ITEM 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_94">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_94">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_97">ITEM 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_97">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_97">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_100">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_100">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_103">ITEM 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_103">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_103">72</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_109">ITEM 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_109">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_109">76</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_115">REPORTS OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_115">79</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_118">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_118">82</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, references in this Annual Report on Form&#160;10-K to &#8220;Insmed Incorporated&#8221; refers to Insmed Incorporated, a Virginia corporation, and the &#8220;Company,&#8221; &#8220;Insmed,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, ARIKARES and ARIKAYCE are trademarks of Insmed Incorporated. This Annual Report on Form&#160;10-K also contains trademarks of third parties. Each trademark of another company appearing in this Annual Report on Form&#160;10-K is the property of its owner.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Annual Report on Form&#160;10-K contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the Exchange Act)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">failure to successfully commercialize ARIKAYCE, our only approved product, in the United States (US) or Europe (amikacin liposome inhalation suspension and Liposomal 590 mg Nebuliser Dispersion, respectively), or to maintain US or European approval for ARIKAYCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to obtain full approval of ARIKAYCE from the US Food and Drug Administration (FDA), including the risk that we will not timely and successfully complete the study to validate a patient reported outcome (PRO) tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">inability of us, PARI Pharma GmbH (PARI) or our other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira&#174; Nebulizer System (Lamira);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">development of unexpected safety or efficacy concerns related to ARIKAYCE or our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">inaccuracies in our estimates of the size of the potential markets for ARIKAYCE or our product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">failure to obtain regulatory approval to expand ARIKAYCE&#8217;s indication to a broader patient population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">risk that brensocatib does not prove to be effective or safe for patients in ongoing and future clinical studies, including the ASPEN study;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">risk that treprostinil palmitil inhalation powder (TPIP) does not prove to be effective or safe for patients in ongoing and future clinical studies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and our other product candidates due to our limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">risks that our clinical studies will be delayed or that serious side effects will be identified during drug development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the US or Europe, or for our product candidates in the US, Europe, Japan or other markets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">failure of third parties on which we are dependent to manufacture sufficient quantities of ARIKAYCE or our product candidates for commercial or clinical needs, to conduct our clinical trials, or to comply with our agreements or laws and regulations that impact our business or agreements with us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to attract and retain key personnel or to effectively manage our growth;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to adapt to our highly competitive and changing environment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">impact of the novel coronavirus (COVID-19) pandemic and efforts to reduce its spread on our business, employees, including key personnel, patients, partners and suppliers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our inability to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">restrictions or other obligations imposed on us by agreements related to ARIKAYCE or our product candidates, including our license agreements with PARI and AstraZeneca AB (AstraZeneca), and failure to comply with our obligations under such agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">our limited experience operating internationally;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">changes in laws and regulations applicable to our business, including any pricing reform, and failure to comply with such laws and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%;padding-left:14.5pt">delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Any forward-looking statement is based on information current as of the date of this Annual Report on Form 10-K and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results, plans, intentions or expectations anticipated in these forward-looking statements as a result of a variety of factors, many of which are beyond our control. More information on factors that could cause actual results to differ materially from those anticipated is included from time to time in our reports filed with the Securities and Exchange Commission (SEC), including, but not limited to, those described in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in this Annual Report on Form 10-K. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_16"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_19"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, is approved in the US as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Liposomal 590 mg Nebuliser Dispersion. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. NTM lung disease caused by MAC (which we refer to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical-stage pipeline includes brensocat</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ib and TPIP. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which we are developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the current status and anticipated milestones for ARIKAYCE and our product candidates brensocatib and TPIP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Product/Product&#160;Candidate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next&#160;Expected&#160;Milestones</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARIKAYCE for&#160;MAC lung&#160;disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We continue to focus on the commercialization of ARIKAYCE in the US. The product was granted accelerated approval by the FDA for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options. We began commercial shipments of ARIKAYCE in October 2018.</span></div><div style="padding-left:13.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In March 2020, we submitted a new drug application (JNDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with MAC lung disease who did not sufficiently respond to prior treatment.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In June 2020, a Japanese Medical Device Notification (JMDN) was submitted to the MHLW for Lamira, the designated device for administration of ARIKAYCE. The JMDN was accepted and Lamira is authorized for use in Japan.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; The FDA has designated ARIKAYCE as an orphan drug and a qualified infectious disease product (QIDP) for NTM lung disease, and the EC has granted an orphan designation for ARIKAYCE for the treatment of NTM lung disease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In October 2020, the FDA approved a supplemental new drug application (sNDA) for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226; In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. In the fourth quarter of 2020, we launched ARIKAYCE in Germany. In February 2021, we launched ARIKAYCE in the Netherlands.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8226; In December 2020, we commenced the post-approval confirmatory frontline clinical trial program for ARIKAYCE in patients with MAC lung disease. The frontline clinical trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of the PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed MAC using the PRO tool validated in the ARISE trial. We are running these global studies in parallel and approximately 200 sites are expected to be initiated for these clinical trials.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We plan to commercialize ARIKAYCE in certain countries in Europe. In addition to our launches in Germany and the Netherlands, we plan to launch in other European countries, subject to local reimbursement processes.<br/><br/>&#8226; If our JNDA is approved by the relevant regulatory authorities, we expect ARIKAYCE would be the first inhaled therapy specifically indicated for the treatment of MAC lung disease in Japan, and we would anticipate launching ARIKAYCE in Japan in the middle of 2021.<br/><br/>&#8226; We will continue to advance the post-approval confirmatory, frontline clinical trial program for ARIKAYCE, through the ARISE trial and the ENCORE trial, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US, as well as to support the use of ARIKAYCE as a frontline treatment for patients with MAC lung disease in the US, Europe and Japan.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Product/Product&#160;Candidate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Next&#160;Expected&#160;Milestones</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brensocatib (oral reversible&#160;inhibitor of&#160;DPP1)&#160;for bronchiectasis and other neutrophil-mediated diseases</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In June 2020, we announced full results from our global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of brensocatib administered once daily in adults with non-cystic fibrosis bronchiectasis (NCFBE). Final results from the WILLOW study were published online in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;  Full results for the WILLOW study reflect that the study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). In addition, treatment with 10mg brensocatib resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint. Patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;  In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adult patients with bronchiectasis for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In November 2020, brensocatib received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for patients with NCFBE.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In December 2020, we commenced a Phase 3 trial (the ASPEN trial) through which we will seek to confirm the positive results seen in the WILLOW study. This trial is designed to investigate brensocatib in patients with</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the primary endpoint is the rate of pulmonary exacerbations over a 52-week treatment period. Patients with bronchiectasis due to cystic fibrosis (CF) may not be enrolled in the trial.</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We will continue to advance the ASPEN trial, to seek to confirm the positive results seen in the WILLOW trial and to support a new drug application (NDA) for brensocatib for the treatment of adult patients with bronchiectasis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We also plan to advance a clinical development program for brensocatib in CF and plan to initiate a pharmacokinetics study in CF patients in mid-2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We plan to explore the potential of brensocatib in additional neutrophil-mediated diseases in 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In April 2020, we announced that we would provide funding and clinical drug supply for the STOP-COVID19 (Superiority Trial of Protease inhibition in COVID-19) trial, a randomized, double-blind placebo-controlled investigator-initiated study of brensocatib in approximately 400 hospitalized patients with COVID-19 (SARS-CoV-2 infection) sponsored by the University of Dundee. The study, which has been prioritized and designated an Urgent Public Health trial by the UK&#8217;s National Institute for Health Research, has completed enrollment. </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TPIP (inhalation formulation of a treprostinil prodrug) for PAH and other rare pulmonary disorders</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In September 2020, we initiated dosing of the first subjects in a Phase 1 healthy volunteer trial of TPIP in the US to assess the pharmacokinetics and tolerability in TPIP.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We plan to present full data from the Phase 1 healthy volunteer trial of TPIP at an upcoming medical meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226; We plan to advance the development of TPIP with two studies in patients with PAH. The first is an open-label, proof-of-mechanism study to understand the impact of TPIP on pulmonary vascular resistance (PVR) over a 24-hour period. We anticipate sharing topline data from this study in the second half of 2021. The second will aim to investigate the effect of TPIP on PVR and 6-minute walk distance over a 16-week treatment period using an up-titration, once-daily dosing schedule. We plan to initiate this trial in the fourth quarter of 2021.</span></div><div><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earlier-stage pipeline includes preclinical compounds that we are evaluating in multiple rare diseases of unmet medical nee</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To complement our internal research and development, we actively evaluate in-licensing and acquisition opportunities for a broad range of rare diseases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy focuses on the needs of patients with rare diseases. We secured accelerated approval for ARIKAYCE from the FDA for the treatment of refractory MAC lung disease in patients with limited or no alternative treatment options, and currently are primarily focused on the successful commercialization of ARIKAYCE. In the EU, we recently secured EC approval of ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. We are also seeking regulatory approval of ARIKAYCE in Japan for the treatment of MAC lung disease in patients who did not sufficiently respond to prior treatment. We are not aware of any other approved inhaled therapies specifically indicated to treat MAC lung disease in North America, Europe or Japan. We believe that ARIKAYCE has the potential to prove beneficial in other patients with MAC. Our product candidates are brensocatib, our Phase 3 product candidate which we are developing for patients with bronchiectasis and potentially other neutrophil-mediated diseases, and TPIP, our product candidate that may offer a differentiated product profile for patients with PAH and other rare pulmonary disorders. We are also advancing earlier-stage programs in other rare pulmonary disorders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current priorities are as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue our efforts to ensure the successful commercialization of ARIKAYCE;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop and validate a PRO tool for NTM lung disease to be used in, among other trials, the ENCORE trial required for the full US approval of ARIKAYCE by the FDA in patients with MAC lung disease;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue our expansion efforts in</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Europe to support </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial activities for ARIKAYCE in the region;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue our expansion efforts in Japan to support pre-commercial activities in the country;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensure our product supply chain will support the global commercialization and potential future lifecycle management programs of ARIKAYCE;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop a core value dossier to support payor reimbursement for ARIKAYCE in Japan;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintain or obtain determinations of coverage and reimbursement in the US and Europe for ARIKAYCE from governmental and other third-party payors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Support further research and lifecycle management strategies for ARIKAYCE, including the potential use of ARIKAYCE as part of a frontline, multi-drug regimen;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Advance brensocatib, including in the Phase 3 ASPEN trial in patients with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance TPIP into Phase 2;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generate preclinical findings from our earlier-stage programs; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expand our pipeline through corporate development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARIKAYCE for Patients with MAC Lung Disease</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;ARIKAYCE is our first approved product. ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. In October 2020, ARIKAYCE received approval in the EU for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Amikacin solution for parenteral administration is an established drug that has activity against a variety of NTM; however, its use is limited by the need to administer it intravenously and by toxicity to hearing, balance, and kidney function. Unlike amikacin solution for intravenous administration, our propriet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ary Pulmovance&#8482; technology uses charge-neutral liposomes to deliver amikacin directly to the lungs where liposomal amikacin is taken up by the lung macrophages where the MAC infection resides. This technology also prolongs the release of amikacin in the lungs, while minimizing systemic exposure, thereby offering the potential for decreased systemic toxicities. ARIKAYCE's ability to deliver high levels of amikacin directly to the lung and sites of MAC infection via the use of our Pulmovance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">echnology, distinguishes it from intravenous amikacin. ARIKAYCE is administered once-daily, using Lamira, an inhalation device developed and manufactured by PARI. Lamira is a portable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nebulizer that enables aerosolization of liquid medications via a vibrating, perforated membrane, and was designed specifically for ARIKAYCE delivery.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has designated ARIKAYCE as an orphan drug and a QIDP for NTM lung disease. Orphan designated drugs are eligible for seven years of exclusivity for the orphan indication. QIDP designation features an additional five years of exclusivity for the designated indication. The FDA granted a total of 12 years of exclusivity in the indication for which ARIKAYCE was approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE also has been included in the international treatment guidelines for NTM lung disease. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA), now strongly recommend the use of ARIKAYCE for MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FDA approved an sNDA for ARIKAYCE, adding important efficacy data regarding the durability and sustainability of culture conversion to the ARIKAYCE label. The data, which are from the Phase 3 CONVERT study of ARIKAYCE, demonstrate that the addition of ARIKAYCE to GBT was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three months post-treatment compared with GBT alone.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we submitted an NDA for ARIKAYCE to the FDA to request accelerated approval. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. In September 2018, the FDA granted accelerated approval for ARIKAYCE under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options via the accelerated approval pathway. LPAD, which was enacted as part of the 21st Century Cures Act, serves to advance the development of new antibacterial drugs to treat serious or life-threatening infections in limited populations of patients with unmet needs. As required for drugs approved under the LPAD pathway, labeling for ARIKAYCE includes certain statements to convey that the drug has been shown to be safe and effective only for use in a limited population.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a condition of accelerated approval, we must conduct a post-approval confirmatory clinical trial. In December 2020, we commenced the post-approval confirmatory frontline clinical trial program for ARIKAYCE in patients with MAC lung disease. The frontline clinical trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed MAC lung disease using the PRO tool validated in the ARISE trial. We are running these global studies in parallel and approximately 200 sites are expected to be initiated for these clinical trials. The frontline clinical program is intended to fulfill the FDA&#8217;s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Pathway Outside of the US</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the EC granted marketing authorization for ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis.  We have launched in Germany and the Netherlands, and plan to launch in other European Union (EU) countries and the UK, subject to local reimbursement processes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, we submitted a JNDA to Japan's MHLW. The primary focus of the MHLW review is sputum culture conversion (defined as three consecutive sputum cultures) by Month 6, with durability of conversion at three months off treatment as a secondary consideration. In June 2020, a JMDN was submitted to the MHLW for Lamira, the designated device for administration of ARIKAYCE. The JMDN was accepted and Lamira is authorized for use in Japan. If our JNDA is approved, we anticipate launching ARIKAYCE in Japan in the middle of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The CONVERT Study</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated approval of ARIKAYCE was supported by preliminary data from the CONVERT study, a global Phase 3 study evaluating the safety and efficacy of ARIKAYCE in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. Patients who achieved sputum culture conversion by Month 6 continued in the CONVERT study for an additional 12 months of treatment following the first monthly negative sputum culture in order to assess the durability of culture conversion, as defined by patients that have completed treatment and continued in the CONVERT study off all therapy for three months. In May 2019, we presented at the American Thoracic Society meeting that 41/65 (63.1%) of patients on ARIKAYCE plus GBT who had achieved culture conversion by Month 6 had maintained durable culture conversion for three months off all therapy compared to 0/10 (0%) on GBT only (p&lt;0.0002). Safety data for these patients were consistent with safety data previously reported for patients by Month 6 of the CONVERT study.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who did not culture convert by Month 6 may have been eligible to enroll in the 312 study, an open-label extension study for these non-converting patients who completed six months of treatment in the CONVERT study. The primary objective of the 312 study was to evaluate the long-term safety and tolerability of ARIKAYCE in combination with a standard multi-drug regimen. The secondary objectives of the 312 study included evaluating the proportion of subjects achieving culture conversion (defined in the same way as the CONVERT study) by Month 6 and the proportion of subjects achieving culture conversion by Month 12, which was the end of treatment. We previously reported interim data as of December 2017 for patients in the 312 study, with 28.4% of patients who received GBT only in the CONVERT study (19/67) and 12.3% of patients who had received ARIKAYCE plus GBT in the CONVERT study (7/57) achieving culture conversion by Month 6 of the 312 study. The 312 study has concluded and final efficacy data regarding culture conversion were consistent with these interim data. We have analyzed the safety and efficacy data from the 312 study, and we did not observe any new safety signals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Further Research and Lifecycle Management</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently exploring and supporting research and lifecycle management programs for ARIKAYCE beyond treatment of refractory MAC lung disease as part of a combination antibacterial regimen for adult patients who have limited or no treatment options. As noted above, we will continue to advance the post-approval confirmatory, frontline clinical trial program for ARIKAYCE, through the ARISE trial and the ENCORE trial, which are intended to fulfill the FDA's post-marketing requirement to allow for the full approval of ARIKAYCE in the US, as well as to support the use of ARIKAYCE as a frontline treatment for patients with MAC lung disease in the US, Europe and Japan.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ARISE trial is a randomized, double-blind, placebo-controlled Phase 3b study in adult patients with newly diagnosed MAC lung disease that aims to generate evidence demonstrating the domain specification, reliability, validity, and responsiveness of PRO-based scores, including a respiratory symptom score. Patients will be randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for six months. Patients will then discontinue all study treatments and remain in the trial for one month for the continued assessment of PRO endpoints. The study is expected to enroll approximately 100 patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ENCORE trial is a randomized, double-blind, placebo-controlled Phase 3b study to evaluate the efficacy and safety of an ARIKAYCE-based regimen in patients with newly diagnosed MAC lung disease. Patients will be randomized 1:1 to receive ARIKAYCE plus background regimen or placebo plus background regimen once daily for 12 months. Patients will then discontinue all study treatments and remain in the trial for three months for the assessment of durability of culture conversion. The primary endpoint is change from baseline to Month 13 in respiratory symptom score. The key secondary endpoint is the proportion of subjects achieving durable culture conversion at Month 15. The study is expected to enroll approximately 250 patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We initiated the frontline clinical trial program of ARIKAYCE in December 2020 and are running the ARISE and ENCORE trials in parallel.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent lifecycle management studies could also potentially enable us to reach more patients. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These initiatives include investigator-initiated studies, which are clinical studies initiated and sponsored by physicians or research institutions with funding from us and may also include new clinical studies sponsored by us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Opportunity for ARIKAYCE in MAC Lung Disease</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung disease in the US, Europe and Japan. The prevalence of NTM lung disease has increased over the past two decades, and we believe it is an emerging public health concern worldwide. Based on an analysis conducted in 2017, using information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimated the potential patient population</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n the US, the European 5 (comprised of France, Germany, Italy, Spain and the United Kingdom) and Japan in 2019 were as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:80.263%"><tr><td style="width:1.0%"></td><td style="width:17.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.128%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Potential Market</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Number of Patients with Diagnosed NTM Lung Disease</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Number of Patients Treated for MAC Lung Disease</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Number of MAC lung disease Patients Refractory to Treatment**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,000-115,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,000-55,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,000-17,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000-145,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000-70,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000-18,000</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">** ARIKAYCE received accelerated approval for this population in the US in September 2018.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. Based on a burden of illness study that we conducted in the US with a major medical benefits provider, we previously concluded that patients with NTM lung disease are costly to healthcare plans, while a claims-based study in the US has shown that patients with NTM lung disease have higher resource utilization and costs than their age and gender-matched controls. Accordingly, we believe that a significant market opportunity for ARIKAYCE in NTM lung disease exists in the US and internationally.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2020, the EC approved ARIKAYCE for the treatment of NTM lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. The CONVERT study included a comprehensive pharmacokinetic sub-study in Japanese subjects in lieu of a separate local pharmacokinetic study in Japan, as agreed with the Pharmaceuticals and Medical Devices Agency (PMDA). We submitted regulatory filings in Japan in the first and second quarters of 2020. The JMDN was accepted and Lamira is authorized for use in Japan. We have established a Japanese subsidiary and, in 2018, began hiring local employees, including a general manager, to manage our regulatory and pre-commercial activities. If ARIKAYCE is approved by the relevant regulatory authorities in Japan, we anticipate launching ARIKAYCE in Japan in the middle of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Pipeline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brensocatib</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib is a small molecule, oral, reversible inhibitor of DPP1, which we licensed from AstraZeneca in October 2016. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs) in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Neutrophils contain the NSPs (including neutrophil elastase, proteinase 3, and cathepsin G) that have been implicated in a variety of inflammatory diseases. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by inhibiting DPP1 and its activation of NSPs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a severe, chronic pulmonary disorder in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. B</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> affects approximately 340,000 to 520,000 patients in the US, and reports suggest that </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may affect approximately 350,000 to 500,000 patients in the European 5 and one to five million patients in the Asia-Pacific region. Today, there are no approved therapies in the US, Europe, or Japan for the treatment of patients with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the positive results of the WILLOW study discussed below, in December 2020 we commenced our Phase 3 trial, ASPEN, which will investigate brensocatib in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bronchiectasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASPEN is a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with bronchiectasis. Patients with bronchiectasis due to cystic fibrosis may not be enrolled in the study. Patients will be randomized to receive brensocatib 10 mg, brensocatib 25 mg, or placebo once daily for 52 weeks. The primary endpoint is the rate of pulmonary exacerbations over the 52-week treatment period. Secondary endpoints include time to first pulmonary exacerbation, percentage of subjects who remain pulmonary exacerbation-free, change from baseline in post-bronchodilator FEV1, rate of severe pulmonary exacerbations, change from baseline in the Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score, and incidence and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severity of treatment-emergent adverse events. The study is expected to enroll approximately 1,620 patients (540 in each arm) at approximately 480 sites in 40 countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, AstraZeneca exercised its first option pursuant to our October 2016 license agreement under which AstraZeneca can advance clinical development of brensocatib in the indications of chronic obstructive pulmonary disease (COPD) or asthma. Under the terms of the agreement, upon exercise of this option, AstraZeneca is solely responsible for all aspects of the development of brensocatib up to and including Phase 2b clinical trials in COPD or asthma. The agreement also includes a second and final option which, if exercised, would permit AstraZeneca to further develop brensocatib beyond Phase 2b clinical trials upon reaching agreement on commercial terms satisfactory to each party for the further development and commercialization of brensocatib in COPD or asthma. We retain full development and commercialization rights for brensocatib in all other indications and geographies.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the FDA granted breakthrough therapy designation for brensocatib for the treatment of adult patients with NCFBE</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">for reducing exacerbations. The FDA's breakthrough therapy designation is designed to expedite the development and review of therapies that are intended to treat serious or life-threatening diseases and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy. The benefits of breakthrough therapy designation include more frequent communication and meetings with FDA, eligibility for rolling and priority review, intensive guidance on an efficient drug development program, and organizational commitment from the FDA involving senior managers. In November 2020, brensocatib received PRIME designation from the EMA for patients with NCFBE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The WILLOW Study</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The WILLOW study was a randomized, double-blind, placebo-controlled, parallel-group, multi-center, multi-national, Phase 2 study to assess the efficacy, safety and tolerability, and pharmacokinetics of brensocatib administered once daily for 24 weeks in patients with NCFBE. The WILLOW study was conducted at 116 sites and enrolled 256 adult patients diagnosed with NCFBE who had at least two documented pulmonary exacerbations in the 12 months prior to screening. Patients were randomized 1:1:1 to receive either 10 mg or 25 mg of brensocatib or matching placebo. The primary efficacy endpoint was the time to first pulmonary exacerbation over the 24-week treatment period in the brensocatib arms compared to the placebo arm. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Efficacy Data</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We announced top-line data for the WILLOW study in February 2020 and full data for the WILLOW study in June 2020. In September 2020, final results from the WILLOW study were published online in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The data demonstrate that the WILLOW study met its primary endpoint of time to first pulmonary exacerbation over the 24-week treatment period for both the 10 mg and 25 mg dosage groups of brensocatib compared to placebo (p=0.027, p=0.044, respectively). The risk of exacerbation at any time during the trial was reduced by 42% for the 10 mg group versus placebo (HR 0.58, p=0.029) and by 38% for the 25 mg group versus placebo (HR 0.62, p=0.046). In addition, treatment with brensocatib 10 mg also resulted in a significant reduction in the rate of pulmonary exacerbations, a key secondary endpoint, versus placebo. Specifically, patients treated with brensocatib experienced a 36% reduction in the 10 mg arm (p=0.041) and a 25% reduction in the 25 mg arm (p=0.167) versus placebo. Change in concentration of active NE in sputum versus placebo from baseline to the end of the treatment period was also statistically significant (p=0.034 for 10 mg, p=0.021 for 25 mg).</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WILLOW Safety and Tolerability Data</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brensocatib was generally well-tolerated in the study. Rates of adverse events (AEs) leading to discontinuation in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg were 10.6%, 7.4%, and 6.7%, respectively. The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, fatigue, and upper respiratory tract infection. Rates of adverse events of special interest (AESIs) in patients treated with placebo, brensocatib 10 mg, and brensocatib 25 mg, respectively, were as follows: rates of skin events (including hyperkeratosis) were 11.8%, 14.8%, and 23.6%; rates of dental events were 3.5%, 16.0%, and 10.1%; and rates of infections that were considered AESIs were 17.6%, 13.6%, and 16.9%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Further Research and Development</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we received notice from the FDA that we were awarded a development grant of $1.8 million for specific work to be performed on a PRO tool over the next two years. The grant funding is for the development of a novel PRO tool for use in clinical trials to measure symptoms in patients with NCFBE with and without NTM lung infection.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to advance a clinical development program for brensocatib in cystic fibrosis and plan to initiate a pharmacokinetics study in CF patients in mid-2021. We are also exploring the potential of brensocatib in various neutrophil-driven inflammatory conditions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigator-Initiated Study in Patients with Severe COVID-19</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced we would provide funding and clinical drug supply for the STOP-COVID19 trial, an investigator-initiated study of brensocatib in hospitalized patients in the UK with COVID-19 sponsored by the University of Dundee. The study, which has been prioritized and designated an Urgent Public Health trial by the UK&#8217;s National Institute for Health Research. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The STOP-COVID19 trial is a prospective, randomized, double-blind, placebo-controlled trial of brensocatib in patients with severe COVID-19.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The multicenter study has enrolled approximately 400 patients at 10 sites in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the UK who present to the hospital with confirmed COVID-19 and are at risk of needing increased levels of supplemental oxygen and/or ventilation. Patients were randomized 1:1 to receive either brensocatib 25 mg once daily or matching placebo on top of standard of care. The primary endpoint is clinical improvement on a seven-point ordinal scale as defined by the World Health Organization. Patients were treated for up to 28 days. Enrollment of the STOP-COVID19 trial has been completed and results are expected to be shared by early in the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treprostinil Palmitil Inhalation Powder</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TPIP is an investigational inhaled formulation of treprostinil prodrug that has the potential to address certain of the current limitations of existing prostanoid therapies. We believe that TPIP prolongs duration of effect and may provide PAH patients with greater consistency in pulmonary arterial pressure reduction over time. Current inhaled prostanoid therapies must be dosed four to nine times per day for the treatment of PAH. Reducing dose frequency has the potential to ease patient burden and improve compliance. Additionally, we believe that TPIP may be associated with fewer side effects, including elevated heart rate, low blood pressure, and severity and/or frequency of cough, associated with high initial drug levels and local upper airway exposure when using current inhaled prostanoid therapies. We believe TPIP may offer a differentiated product profile for PAH and other rare pulmonary disorders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we announced topline results from the Phase 1 study of TPIP in healthy volunteers. The objective of this first-in-human single ascending dose and multiple ascending dose study was to assess the pharmacokinetics and tolerability profile of TPIP. Data from the study demonstrated that TPIP was generally well tolerated, with a pharmacokinetic profile that supports continued development with once-daily dosing. The most common adverse events (AEs) across all cohorts in the study were cough, dizziness, headache, and nausea. Most AEs were mild in severity and consistent in nature with those typically seen with other inhaled prostanoid therapies. There were few moderate AEs and no severe or serious AEs. Subjects in the multiple dose panel that incorporated an up-titration approach beginning at 112.5 &#181;g once-daily and progressing to 225 &#181;g once-daily reported fewer AEs compared to the panel dosed with 225 &#181;g once-daily from the first dose.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Overall pharmacokinetic results demonstrated that treprostinil exposure (AUC and C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:1.69pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) was dose-proportional, with low to moderate inter-subject variability. Treprostinil was detected in the plasma at 24 hours at all doses and throughout the 48-hour sampling period for the two highest doses. Compared with currently available inhaled treprostinil therapy, TPIP showed substantially lower C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:1.69pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and longer half-life. We plan to present full data from this study at an upcoming medical meeting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to advance the development of TPIP with two studies in patients with PAH. The first is an open-label, proof-of-mechanism study to understand the impact of TPIP on PVR over a 24-hour period. We anticipate sharing topline data from this study in the second half of 2021. The second will aim to investigate the effect of TPIP on PVR and 6-minute walk distance over a 16-week treatment period using an up-titration, once-daily dosing schedule. We plan to initiate this trial in the fourth quarter of 2021. Beyond PAH, we continue to explore potential development pathways for TPIP in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and idiopathic pulmonary fibrosis (IPF), and plan to initiate a study in patients with PH-ILD using an up-titration, once-daily dosing schedule.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Development</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to develop, acquire, in license or co-promote other products, product candidates and technologies, including those that address rare diseases. We are focused broadly on rare disease therapeutics and prioritizing those areas that best align with our core competencies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any in-house manufacturing capability other than for small-scale preclinical development programs, and depend completely on a small number of third-party manufacturers and suppliers for the manufacture of our product candidates for use in clinical trials. We plan to rely on third-party manufacturers and suppliers for the commercial manufacture and supply of any product candidates that we commercialize. ARIKAYCE is manufactured currently by Resilience Biotechnologies&#160;Inc. (Resilience) (formerly Therapure Biopharma Inc.) in Canada at a 200 kilogram (kg) scale and by Ajinimoto Althea,&#160;Inc. (Althea) in the US at a 50 kg scale. For additional information about our agreements with Resilience and Althea, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Other Agreements&#8212;ARIKAYCE-related Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into certain agreements with Patheon UK Limited (Patheon) related to increasing our long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our long-term anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;The aggregate investment to increase the long-term production capacity, including under these agreements, and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million. In addition, we have a commercialization agreement with PARI, the manufacturer of our drug delivery nebulizer for ARIKAYCE, to address our commercial supply needs (the Commercialization Agreement).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our future requirements for brensocatib and TPIP will be manufactured by a contract manufacturing organization (CMO).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license rights to more than 450 issued patents and pending patent applications in the US and in foreign countries, including more than 250 issued patents and pending patent applications related to ARIKAYCE. Our success depends in large part on our ability to maintain proprietary protection surrounding our product candidates, technology and know-how; to operate without infringing the proprietary rights of others; and to prevent others from infringing our proprietary rights. We actively seek patent protection by filing patent applications, including on inventions that are important to the development of our business in the US, Europe, Japan, Canada, and selected other foreign markets that we consider key for our product candidates. These international markets generally include Australia, China, India, Israel and Mexico.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent strategy includes obtaining patent protection, where possible, on compositions of matter, methods of manufacture, methods of use, dosing and administration regimens and formulations. We also rely on trade secrets, know-how, continuing technological innovation, in-licensing and partnership opportunities to develop and maintain our proprietary position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to create blocks to our products or otherwise interfere with the development of our business. We are aware, for example, of US patents, and corresponding international counterparts, owned by third parties that contain claims related to treating lung infections using inhaled antibiotics. If any of these patents were to be asserted against us, we do not believe that our marketed product or development candidates would be found to infringe any valid claim of these patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reflecting our commitment to safeguarding proprietary information, we require our employees, consultants, advisors, collaborators and other third-party partners to sign confidentiality agreements to protect the exchange of proprietary materials and information. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARIKAYCE Patents and Trade Secrets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the patents and applications related to ARIKAYCE, there are 10 issued US patents that cover the ARIKAYCE composition and its use in treating NTM. These patents are listed in the FDA Orange Book. These patents and their expiration dates are as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;7,718,189 (expires June&#160;6, 2025)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;8,226,975 (expires August&#160;15, 2028)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;8,632,804 (expires December&#160;5, 2026)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;8,802,137 (expires April&#160;8, 2024)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;8,679,532 (expires December&#160;5, 2026)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;8,642,075 (expires December&#160;5, 2026)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;9,566,234 (expires January&#160;18, 2034)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No.&#160;9,827,317 (expires April&#160;8, 2024)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No. 9,895,385 (expires May 15, 2035)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">US Patent No. 10,251,900 (expires May 15, 2035)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">US Patent No. 10,751,355 (expires May 15, 2035)</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we own five pending US patent applications that cover the ARIKAYCE composition and/or its use in treating NTM, including MAC lung infections. We also own a pending US application that covers methods for making ARIKAYCE. One or more of these patent applications, if issued as patents in their current form, may be eligible for listing in the FDA Orange Book for ARIKAYCE. We anticipate that in the US, we will have patent coverage for ARIKAYCE and its use in treating NTM lung disease, including NTM lung disease caused by MAC, through May 15, 2035.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Eight patents have been granted by the European Patent Office (EPO) (European Patent Nos.&#160;1581236, 1909759, 1962805, 2823820, 3067046, 3142643, 3427742 and 3466432) that relate to ARIKAYCE and its use in treating NTM, including MAC lung infections. In addition, we have four patent applications pending before the EPO that relate to ARIKAYCE and its use in treating NTM lung disease. We also have a pending European application that describes certain methods of making ARIKAYCE. European Patent No. 2363114 was opposed by Generics (UK) Ltd, a wholly-owned subsidiary of Mylan NV, and was revoked in November 2020. European Patent No.&#160;1909759 (the '759 patent), owned by us, was previously opposed by Generics (UK)&#160;Ltd. A hearing was held on October&#160;19, 2015, during which we submitted amended claims. The European Patent Office Opposition Division (EPOOD) maintained the patent as amended and Generics (UK) Ltd appealed the decision. The EPO Technical Board of Appeals heard arguments related to the appeal on January 8, 2019 and the product claims of the patent were held invalid. The method of manufacture claims was remitted to the EPOOD for further consideration, and remain enforceable. Oral proceedings related to the method of manufacture claims were scheduled to take place via videoconference on January 19, 2021, but the EPO has since indicated that the proceeding would instead continue based on written submissions. European Patent Nos. 1962805 and 3067046, both of which expire approximately five months after the &#8216;759 patent (December 5, 2026 vs. July 19, 2026), also include claims related to ARIKAYCE and its use in treating NTM lung disease.&#160;European Patent Nos. 3142643 and 3466432 each expire May 15, 2035 and include claims related to ARIKAYCE and its use for treating MAC lung infections.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More than 60 patents have also been issued in other major foreign markets, e.g.,&#160;Japan, China, Korea, Australia, and India, that relate to ARIKAYCE and/or methods of using ARIKAYCE for treating various pulmonary disorders, including NTM lung disease. More than 30&#160;foreign patent applications are pending that relate to the ARIKAYCE composition and/or its use in treating various pulmonary disorders, including NTM lung disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our agreements with PARI, we have license rights to US and foreign patents and applications that cover the Lamira Nebulizer System medical device through January 18, 2034. We have entered into a commercial supply agreement with PARI and we also have rights to use the nebulizers in expanded access programs and clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brensocatib Patents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our agreement with AstraZeneca, we have licensed US Patent Nos.&#160;9,522,894, 9,815,805, 10,287,258 and 10,669,245, which have claims related to brensocatib and methods for using brensocatib. Each of these patents expires January&#160;21, 2035 (not taking into account any potential patent term extension). Counterpart patent applications are pending in the US and throughout the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TPIP Patents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own US Patent Nos.&#160;9,255,064, 9,469,600 and 10,010,518, each expiring October&#160;24, 2034 (not taking into account any potential patent term extensions or adjustments), each with claims covering hexadecyl-treprostinil, the treprostinil prodrug component of TPIP, or its use. US Patent No. 9,255,064 has claims reciting hexadecyl-treprostinil, and other treprostinil prodrugs. US Patent No.&#160;9,469,600 has claims directed to TPIP and other treprostinil prodrug formulations. US Patent No. 10,010,518 has claims directed to methods of treating pulmonary hypertension, including PAH, with TPIP and other treprostinil prodrug formulations and expires October&#160;24, 2034. Counterpart patent applications to these US Patents have issued in Europe, Japan and other foreign jurisdictions. Counterpart patent applications to these US Patents are also pending in select jurisdictions, including the US, Europe and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own pending patent applications that relate to methods for using treprostinil prodrugs and formulations comprising the same, including TPIP in treating patients with PAH and other diseases, as well as methods for manufacturing such treprostinil prodrugs and formulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basic terms of utility patents issued in the US are the longer of 17&#160;years from the issue date or 20&#160;years from the earliest effective filing date, if the patent was in force on or was issued from a patent application that was filed prior to June&#160;8, 1995; or 20&#160;years from the earliest effective filing date, if the patent application was filed on or after June&#160;8, 1995. All ARIKAYCE, brensocatib and TPIP patents and patent applications have earliest effective filing dates falling after June&#160;8, 1995. The basic term of foreign utility patents may vary in accordance with provisions of applicable local law, but is typically 20&#160;years from the earliest effective filing date.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patents and trade secrets, we have filed applications to register certain trademarks in the US and/or abroad, including INSMED and ARIKAYCE. At present, we have received two registrations for the INSMED mark and one registration for the ARIKAYCE mark from the US Patent and Trademark Office (USPTO). We have also received notices of allowance or registrations in a number of countries abroad for the INSMED and ARIKAYCE marks, among others. The EMA has authorized the use of the name ARIKAYCE liposomal, and the FDA has approved our use of the name ARIKAYCE, as the trade name for amikacin liposome inhalation suspension. Our ability to obtain and maintain trademark registrations will in certain geographical locations depend on making use of the mark in commerce on or in connection with our products and approval of the trademarks for our products by regulatory authorities in each country.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Other Agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARIKAYCE-related Agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and will continue to rely, on agreements with a number of third parties in connection with the development and manufacture of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PARI</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a licensing agreement with PARI for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, we have rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit the system with ARIKAYCE for the treatment of such indications, but we cannot manufacture the nebulizers except as permitted under our Commercialization Agreement with PARI, which is described in further detail below. Lamira has been approved for use in the US (in combination with ARIKAYCE) and EU and is authorized for use in Japan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also currently have rights to use the nebulizers in expanded access programs and clinical trials. Lamira is labeled as investigational for use in our clinical trials in Japan, Canada and Australia and must receive regulatory approval before we can market ARIKAYCE outside the US and EU.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have certain obligations under this licensing agreement in relation to specified licensed indications. With respect to NTM, we met all obligations to achieve certain commercial, developmental and regulatory milestones by the required deadlines. With respect to bronchiectasis, we have an obligation to use commercially reasonable efforts to initiate a Phase 3 trial for bronchiectasis by a set deadline. With respect to CF, we are obligated to use commercially reasonable efforts to develop, obtain regulatory and reimbursement approval, market and sell ARIKAYCE in two or more major European countries, as well as to achieve certain milestones specified in the licensing agreement. Termination of the licensing agreement or loss of exclusive rights may occur if we fail to meet our obligations, including payment of royalties to PARI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the licensing agreement, we paid PARI an upfront license fee and milestone payments. Upon FDA acceptance of our NDA and the subsequent FDA and EMA approvals of ARIKAYCE, we made additional milestone payments of &#8364;1.0 million, &#8364;1.5&#160;million and &#8364;0.5&#160;million, respectively, to PARI. In October 2017, we exercised an option to buy-down the royalties payable to PARI. PARI is entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE pursuant to the licensing agreement, subject to certain specified annual minimum royalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This licensing agreement will remain in effect on a country-by-country basis until the final royalty payments have been made with respect to the last country in which ARIKAYCE is sold, or until the agreement is otherwise terminated by either party. We have the right to terminate this licensing agreement upon written notice for PARI's uncured material breach, if PARI is the subject of specified bankruptcy or liquidation events, or if PARI fails to reach certain specified obligations. PARI has the right to terminate this licensing agreement upon written notice for our uncured material breach, if we are the subject of specified bankruptcy or liquidation events, if we assign or otherwise transfer the agreement to a third-party that does not agree to assume all of our rights and obligations set forth in the agreement, or if we fail to reach certain specified milestones.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira nebulizer systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when we will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of 15 years that began to run in October 2018 (the Initial Term). The term of the Commercialization Agreement may be extended by us for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resilience</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we entered into a contract manufacturing agreement with Therapure Biopharma Inc., which has been assumed by Resilience, for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, we collaborated with Resilience to construct a production area for the manufacture of ARIKAYCE in Resilience's </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing manufacturing facility in Mississauga, Ontario, Canada. The agreement has an initial term of five years, which began in October 2018, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years' prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, we are obligated to pay a minimum of $6 million for commercial ARIKAYCE batches produced and certain manufacturing activities each calendar year. The agreement allows for termination by either party upon the occurrence of certain events, including (i)&#160;the material breach by the other party of any provision of the agreement or the quality agreement expected to be entered into between the parties, and (ii)&#160;the default or bankruptcy of the other party. In addition, we may terminate the agreement for any reason upon no fewer than 180&#160;days' advance notice.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Althea</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. We are obligated to pay a minimum of $2.7&#160;million for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and, following an extension in 2018, will remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional two-year periods upon mutual written agreement of the Company and Althea at least one year prior to the expiration of its then-current term. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either we or Althea may terminate the Fill/Finish Agreement upon the occurrence of certain events, including (i)&#160;material breach of the Fill/Finish Agreement by either party, provided such breach is not cured within 30&#160;days after receipt by the breaching party of written notice of the breach or (ii)&#160;insolvency or bankruptcy of the other party. In addition, we may terminate the Fill/Finish Agreement without cause with 12&#160;months' prior written notice to Althea, and Althea may terminate the Agreement without cause with 24&#160;months' prior written notice to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patheon and related agreements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into certain agreements with Patheon related to the increase of our long-term production capacity for ARIKAYCE. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. Our manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either we or Patheon have given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The aggregate investment to increase our long-term production capacity, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT)</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2004 and 2009, we entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby we received $1.7 million and $2.2 million in research funding for the development of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, we owe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone payments to CFFT of $13.4 million in the aggregate, of which $1.0 million has been paid through December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are payable through 2025. Furthermore, if certain global sales milestones are met within five years of the commercialization of ARIKAYCE, we would owe up to an additional $3.9 million. We have determined the likelihood of meeting such global sales milestones and have accrued for these contingent obligations proportionally based on net sales of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PPD Development, L.P.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which we retained PPD to perform clinical development services in connection with certain of our clinical research programs. The master services agreement has an initial term of five years. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days&#8217; written notice, (ii) any project addendum in the event of the other party&#8217;s breach of the master services agreement or such project addendum upon 30 days&#8217; written notice, provided that such breach is not cured within such 30-day period, (iii) the master services agreement or any project addendum immediately upon the occurrence of an insolvency event with respect to the other party or (iv) any project addendum upon 30 days&#8217; written notice if (a) the continuation of the services under such project addendum would post material ethical or safety risks to study participants, (b) any approval from a regulatory authority necessary to perform the applicable study is revoked, suspended or expires without renewal or (c) in the reasonable opinion of such party, continuation of the services provided under such project addendum would be in violation of applicable law. We have entered into project addenda with PPD to perform clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development services over several years for, but not limited to, our ARISE, ENCORE and ASPEN studies. We currently expect to incur approximately $200 million of costs related to these project addenda.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brensocatib-related Agreements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into a license agreement with AstraZeneca (the AZ License Agreement), pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed brensocatib). In consideration of the licenses and other rights granted by AstraZeneca, we made an upfront payment of $30.0&#160;million in late October 2016. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we incurred a $12.5 million milestone payment obligation upon the first dosing in a Phase 3 clinical trial of brensocatib. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make a series of additional contingent milestone payments to AstraZeneca totaling up to $72.5&#160;million upon the achievement of clinical development and regulatory filing milestones.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> elect to develop brensocatib for a second indication, we will be obligated to make an additional series of contingent milestone payments totaling up to $42.5 million, the first of which occurs at the initiation of a Phase 3 trial in the additional indication. We are not obligated to make any additional milestone payments for additional indications. In addition, we have agreed to pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on brensocatib and one additional payment of $35.0&#160;million upon the first achievement of $1&#160;billion in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with us for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma. If we fail to comply with our obligations under our agreements with AstraZeneca (including, among other things, if we fail to use commercially reasonable efforts to develop and commercialize a product based on brensocatib, or we are subject to a bankruptcy or insolvency), AstraZeneca would have the right to terminate the license.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive. We face potential competitors from many different areas including commercial pharmaceutical, biotechnology and device companies, academic institutions and scientists, other smaller or earlier stage companies and non-profit organizations developing anti-infective drugs and drugs for respiratory, inflammatory, immunology, oncology, and rare diseases. Many of these companies have greater human and financial resources and may have product candidates in more advanced stages of development and may reach the market before our product candidates. Competitors may develop products that are more effective, safer or less expensive or that have better tolerability or convenience. We also may face generic competitors where third-party payors will encourage use of the generic products. Although we believe that our formulation delivery technology, respiratory and anti-infective expertise, experience and knowledge in our specific areas of focus provide us with competitive advantages, these potential competitors could reduce our commercial opportunity. Additionally, there currently are, and in the future there may be, already-approved products for certain of the indications for which we are developing, or in the future may choose to develop, product candidates. For instance, PAH is a competitive indication with established products, including other formulations of treprostinil.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the lung disease market, our major competitors include pharmaceutical and biotechnology companies that have approved therapies or therapies in development for the treatment of chronic lung infections. There are other companies that are currently conducting early stage clinical trials for the treatment of lung disease. We are not aware of any approved inhaled therapies specifically indicated for refractory NTM lung infections in North America, Europe or Japan, but, there is recommended treatment regimen that is utilized. The international treatment guidelines, which are issued by the ATS, ERS, ESCMID and IDSA, strongly recommend the use of ARIKAYCE for the treatment of patients with refractory NTM lung disease caused by MAC as a part of a combination antibacterial drug regiment for adult patients with limited or no alternative treatment options who have failed to convert to a negative sputum culture after at least six months of treatment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, defined as a disease or condition for which the drug is intended affects fewer than 200,000 people in the US, if it meets certain criteria specified by the ODA and FDA. After the FDA grants orphan drug designation, the drug and the specific intended use(s) for which it has obtained designation are listed by the FDA in a publicly accessible database. The FDA has designated ARIKAYCE as an orphan drug for treatment of (i)&#160;infections caused by NTM, (ii)&#160;bronchiectasis in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> aeruginosa or other susceptible microbial pathogens and (iii)&#160;bronchopulmonary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> aeruginosa infections in CF patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies the sponsor for various development incentives of the ODA, including tax credits for qualified clinical testing, and a waiver of the PDUFA application fee (unless the application seeks approval for an indication </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not included in the orphan drug designation). Orphan drug designation also affords the company a period of exclusivity for the orphan indication upon approval of the drug. Specifically, the first NDA applicant with an FDA orphan drug designation for a particular active moiety to receive FDA approval of the drug for an indication covered by the orphan designation is entitled to a seven-year exclusive marketing period, often referred to as orphan drug exclusivity, in the US for that drug in that indication. A product that has several separate orphan designations may have several separate exclusivities for separate orphan indications. During the orphan drug exclusivity period, the FDA may not approve any other applications to market the same drug for the same indication for use, except in limited circumstances, such as a showing of clinical superiority to the product that has orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition or the same drug for a different disease or condition, and it does not alter the timing or scope of the regulatory review and approval process; the sponsor must still submit evidence from clinical and non-clinical studies sufficient to demonstrate the safety and effectiveness of the drug.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission grants orphan drug designation to promote the development of drugs or biologics (1)&#160;for life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU, or (2)&#160;for life threatening, seriously debilitating or serious and chronic condition in the EU where, without incentives, sales of the drug in the European Economic Area (the EU plus Iceland, Lichtenstein and Norway) (EEA) are unlikely to be sufficient to justify its development. Orphan drug designation is available either if no other satisfactory method of diagnosing, preventing or treating the condition is approved in the EEA or if such a method does exist but the proposed orphan drug will be of significant benefit to patients. The European Commission has granted an orphan designation for ARIKAYCE for the treatment of NTM lung disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a drug with an orphan drug designation subsequently receives a marketing authorization for a therapeutic indication which is covered by such designation, the drug is entitled to orphan exclusivity. Orphan exclusivity means that the EMA or a national medicines agency may not accept another application for authorization, or grant an authorization, for a same or similar drug for the same therapeutic indication. Competitors may receive such a marketing authorization despite orphan exclusivity, provided that they demonstrate that the existing orphan product is not supplied in sufficient quantities or that the 'second' drug or biologic is clinically superior to the existing orphan product. The 'second' drug may but need not have an orphan designation as well. The period of orphan exclusivity is 10 years, which can be extended by two years where an agreed pediatric investigation plan has been implemented. The exclusivity period may also be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Each orphan designation carries the potential for one market exclusivity for all the therapeutic indications that are covered by the designation. A product that has several separate orphan designations may have several separate market exclusivities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation also provides opportunities for free protocol assistance and fee reductions for access to the centralized regulatory procedure or fee exemptions for companies with a small and medium enterprises status. In addition, EU Member States may provide national benefits to orphan drugs, such as early access to the reimbursement procedure or exemption from any turnover tax imposed on pharmaceutical companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The orphan designation may be applied for at any time during the development of the drug but before the application for marketing authorization. At the time of marketing authorization, the criteria for orphan designation are examined again, and the European Commission decides on the maintenance of the orphan designation. The non-maintenance of the orphan designation means that the drug loses its orphan status and thus no longer benefits from orphan exclusivity, fee reductions or exemptions, and national benefits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MHLW may, after hearing the opinion of the Pharmaceutical Affairs and Food Sanitation Council, grant orphan drug designation to a drug intended to treat a rare disease or condition if the drug meets the following conditions: (i) the number of target patients is less than 50,000 in Japan, (ii) the necessity of orphan drug designation is high from a medical point of view, (iii) there are sufficient theoretical grounds to use the drug for the target disease, and (iv) the plan for development of the drug is appropriate. Even if a drug is granted orphan drug designation, however, it does not always receive the manufacturing and marketing approval that is necessary for the drug to be sold or marketed in Japan. ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients in Japan exceeding 50,000.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Approval</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the US, pharmaceutical products are subject to extensive regulation by the FDA and other government bodies. The US Federal Food, Drug, and Cosmetic Act (FDCA) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable US requirements at any time during product development, approval, or after approval may subject a company to a variety of administrative or judicial sanctions, such as imposition of clinical holds, FDA refusal to file or approve new drug applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, civil penalties, and criminal prosecution. The description below summarizes the current approval process in the US for our product and product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Studies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, and pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including the FDA's good laboratory practice (GLP) regulations and the US Department of Agriculture's regulations implementing the Animal Welfare Act. An Investigational New Drug application (IND) sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND. Certain non-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND is submitted. An IND automatically becomes effective 30&#160;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted (i)&#160;in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice (GCP) standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors as well as (ii)&#160;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the US (whether in patients or healthy volunteers) must be included as a submission to the IND, and the FDA must be notified of subsequent protocol amendments, including new protocols. In addition, the protocol must be reviewed and approved by an institutional review board (IRB), and all study subjects must provide informed consent. Typically, before any clinical trial, each institution participating in the trial will require review of the protocol before the trial commences at that institution. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for certain adverse events.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with the FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB also may require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential pre-approval phases, but the phases may overlap or be combined. In Phase&#160;1, short term (typically less than a few months) testing is conducted in a small group of subjects (typically 20-100), who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase&#160;2, the drug is given to a larger group of subjects (typically up to several hundred) with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase&#160;3 studies typically last between several months and two years. In Phase&#160;3, the drug is given to a large group of subjects with the target disease or condition (typically several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. Only a small percentage of investigational drugs complete all three phases of development and obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">NDA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA can be prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the US. The NDA is a large submission that must include, among other things, the results of all preclinical, clinical and other testing and a compilation of data relating to the product's pharmacology, chemistry, manufacture, and controls. The application also includes representative samples, copies of the proposed product labeling, patent information, and a financial certification or disclosure statement. The cost of preparing and submitting an NDA is substantial. Additionally, under federal law (as amended by the most recent reauthorization of the Prescription Drug User Fee Act (PDUFA VI) in the FDA Reauthorization Act of 2017), most NDAs are subject to a substantial application fee and, upon approval, the applicant will be assessed an annual prescription drug program fee, both of which are adjusted annually. NDAs for orphan drugs are not subject to an application fee, unless the application includes an indication </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other than the orphan-designated indication. FDA also has the authority to grant waivers of certain user fees, pursuant to the FDCA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60&#160;days from its receipt of an NDA to determine whether the application is accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with current good manufacturing practice (cGMP) is satisfactory and the NDA contains data that provide substantial evidence of effectiveness for the proposed indication, generally consisting of adequate and well-controlled clinical investigations, and that the drug is safe for use under the conditions of use in the proposed labeling. The FDA also reviews the proposed labeling submitted with the NDA and typically requires changes in the labeling text.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After the FDA evaluates the NDA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. An approval letter, which may specify post approval requirements, authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. The FDA sets a goal date by which the FDA expects to issue either an approval letter or a complete response letter, unless the review period is adjusted by mutual agreement between the FDA and the applicant or as a result of the applicant submitting a major amendment. The FDA's current performance goals call for the FDA to complete review of 90&#160;percent of standard (non-priority) NDAs within 10&#160;months and priority NDAs within six months of NDA filing (in the case of new molecular entity (NME) NDA submissions) or receipt (in the case of non-NME original NDA submissions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of NDA approval, the FDA may require substantial post-approval testing, known as Phase&#160;4 studies, to be conducted in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Beyond routine post marketing safety surveillance, the FDA may require specific additional surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the drug. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy (REMS) or a REMS with elements to assure safe use to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. Further post-approval requirements are discussed below.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expedited Review and Approval of Eligible Drugs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDA's accelerated approval program, the FDA may approve certain drugs for serious or life-threatening conditions on the basis of a surrogate or intermediate endpoint that is reasonably likely to predict clinical benefit, which can substantially reduce time to approval. A surrogate endpoint used for accelerated approval is a marker&#8212;a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than irreversible morbidity and mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA bases its decision on whether to accept the proposed surrogate or intermediate clinical endpoint on the scientific support for that endpoint.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of accelerated approval, the FDA typically requires certain post-marketing clinical studies to verify and describe clinical benefit of the product, and may impose restrictions on distribution to assure safe use. Post marketing studies would usually be required to be studies already underway at the time of the accelerated approval. In addition, promotional materials for an accelerated approval drug to be used in the first 120&#160;days post-approval must be submitted to the FDA prior to approval, and materials to be used after that 120-day period must be submitted 30&#160;days prior to first use. If the required post-marketing studies fail to verify the clinical benefit of the drug, or if the applicant fails to perform the required post-marketing studies with due diligence, the FDA may withdraw approval of the drug under streamlined procedures in accordance with the agency's regulations. The agency may also withdraw approval of a drug if, among other things, the promotional materials for the product are false or misleading, or other evidence demonstrates that the drug product is not shown to be safe or effective under its conditions of use.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also has various programs&#8212;fast track designation, priority review and breakthrough designation&#8212;that are intended to expedite or streamline the process for the development and FDA review of drugs that meet certain qualifications. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures. The programs each have different eligibility criteria and provide different benefits, and can be applied either alone or in combination depending on an applicant's circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fast track designation applies to a drug that is intended to treat a serious condition and for which nonclinical or clinical data demonstrate the potential to address unmet medical need. It should be requested at the time of IND submission or ideally no later than the pre-NDA meeting. The FDA must respond to requests for fast track designation within 60&#160;days of receipt of the request. If granted, the applicant is eligible for actions to expedite development and review, such as frequent interaction with the review team, as well as for rolling review, meaning that the applicant may submit sections of the application as they are available. The timing of FDA's review of these sections depends on a number of factors, and the review clock does not start running until the agency has received a complete NDA submission. The FDA may withdraw fast track designation if the agency determines that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Priority review applies to an application (both original and efficacy supplement) for a drug that treats a serious condition and that, if approved, would provide a significant improvement in safety or effectiveness. It also applies to any supplement that proposes a labeling change pursuant to a report on a pediatric study. A request for priority review is submitted at the time of NDA or supplemental NDA submission. The FDA must respond within 60&#160;days of receipt of the request. If granted, the review time is shortened from the standard 10&#160;months to 6&#160;months, beginning either at the 60 day filing date (in the case of NME NDA submissions) or the date of receipt (in the case of non-NME original NDA submissions).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough therapy designation applies to a drug that is intended to treat a serious condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. It can be requested with the IND submission and ideally no later than the end-of-Phase&#160;2 meeting. The FDA must respond within 60&#160;days of receipt of the request. If granted, the applicant receives intensive guidance on efficient drug development, intensive involvement of senior managers and experienced review and regulatory health project management staff in a proactive, collaborative, cross-disciplinary review, rolling review, and other actions to expedite review. Designation may be rescinded if the product no longer meets the criteria for breakthrough therapy designation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs that are designated as QIDPs may be eligible for priority review and will receive fast track designation upon the request of the sponsor, and also may be eligible for market exclusivity. A product is eligible for QIDP designation if it is an antibacterial or anti-fungal drug for human use that is intended to treat serious or life-threatening infections, including: those caused by an anti-bacterial or anti-fungal resistant pathogen, including novel or emerging infectious pathogens; or caused by qualifying pathogens listed by the FDA. A drug sponsor may request that the FDA designate its product as a QIDP at any time prior to NDA submission. The FDA must make a QIDP determination within 60&#160;days of receiving the designation request. ARIKAYCE has been designated as a QIDP for NTM lung disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA may approve eligible drugs under the LPAD. A product is eligible if it is intended to treat a serious or life-threatening infection in a limited population of patients with unmet needs, the drug otherwise meets the standards of approval, and the FDA receives a written request from the sponsor to approve the drug under this pathway. An antibacterial or anti-fungal drug approved through this pathway may follow a streamlined clinical development program involving smaller, shorter, or fewer clinical trials. Approval is based on a benefit-risk assessment in the intended limited population, taking into account the severity, rarity, or prevalence of the infection the drug is intended to treat and the availability or lack of alternative treatment for the patient population. Such drugs may not have favorable benefit-risk profiles in a broader population. Drugs approved under LPAD are subject to additional regulatory requirements, including labeling and advertising statements regarding the limited population and submission of promotional materials to the FDA at least 30 days prior to dissemination.&#160;The FDA may remove these additional requirements if the agency approves the drug for a broader population.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusivities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">After NDA approval, owners of relevant drug patents may obtain up to a five-year patent term extension on a single patent. The allowable patent term extension is calculated as half of the drug's testing phase (the time between IND application and NDA submission) and all of the review phase (the time between NDA submission and approval) up to a maximum of five years, to the extent such testing phase and approval phase occur after the issue date of the patent. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total post-NDA approval patent term including the extension may not exceed 14 years. For patents that might expire while a patent term extension application is pending, the patent owner may request an interim patent term extension. The Director of the USPTO shall extend, until a final determination is made, the term of the patent for periods of up to one year if the Director determines that the patent is eligible for extension. An interim patent term extension may be renewed up to four times until a final determination is made, and up to the amount of time for which the patent might be eligible for extension. For each interim patent term extension granted, the final patent term extension is reduced by a corresponding amount. Interim patent extensions may also be available for a patent that will expire before a drug is expected to be approved, but the NDA for the drug must have been submitted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of non-patent exclusivity periods are available under the FDCA that can delay the submission or approval of certain applications for competing products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A five-year period of non-patent exclusivity within the US is granted to the first applicant to gain approval of an NDA for a new chemical entity (NCE). An NCE is a drug that contains no active moiety (the molecule or ion responsible for the action of the drug substance) that has been approved by the FDA in any other application submitted under section&#160;505(b) of the FDCA. During the exclusivity period for an NCE, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company that references (i.e.,&#160;relies on the FDA's prior approval of) the NCE drug. However, an ANDA or 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity or non-infringement with respect to a patent listed with the FDA for the NCE drug.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A three-year period of non-patent exclusivity is granted for a drug product that contains an active moiety that has been previously approved, when the application contains reports of new clinical investigations (other than bioavailability studies) conducted or sponsored by the sponsor that were essential to approval of the application, for example, for new indications, dosages, strengths or dosage forms of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations, which means that the FDA may approve applications for other versions of the original, unmodified drug product. Where this form of exclusivity applies, it prevents FDA approval of an ANDA or 505(b)(2) NDA that is subject to the exclusivity for the three-year period; however, the FDA may accept and review ANDAs or 505(b)(2) NDAs during the three-year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusivities also do not preclude FDA approval of a 505(b)(1) NDA for a duplicate version of the drug during the period of exclusivity, provided that the applicant conducts or obtains a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products with QIDP designation may receive a five-year extension of other non-patent exclusivities for which the drug is also eligible, subject to certain limitations. Depending upon the scope of the non-patent exclusivity that is extended, the five-year extension might not prevent the FDA from approving a subsequent application for a change to the QIDP-designated drug that results in a new indication, route of administration, dosing, schedule, dosage form, delivery system, delivery device, or strength. A drug that has been designated as both an orphan drug and a QIDP for the same indication, like ARIKAYCE, might be eligible for a combined 12 years of exclusivity for that indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Device Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices, such as Lamira, may receive marketing authorization from the FDA as stand-alone devices, or in some cases, may receive marketing authorization as part of a combination product. In either case, the ultimate product will need to satisfy FDA requirements. The primary pathways for marketing authorization for devices in the US are 510(k) clearance or premarket approval (PMA).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices are also subject to certain post-clearance, post-approval requirements. Those requirements include continuing Quality System Regulation compliance, Medical Device Reporting, Correction and Removal, and requirements governing labeling and promotional advertising.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA permits medical devices intended for investigational use to be shipped to clinical sites if such devices comply with prescribed procedures and conditions. Devices intended for investigational use may be exempted from premarket notification and premarket approval requirements when shipped for use in clinical trials, but they must bear a label indicating that they are for investigational use. This labeling may not represent that the device is safe or effective for the purposes for which it is being investigated.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Combination Products</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A combination product is a product comprising two or more regulated components (e.g.,&#160;a drug and device) that are combined into a single product, co-packaged, or sold separately but intended for co-administration, as evidenced by the labeling for the products. Drugs that are administered using a nebulizer or another device, such as ARIKAYCE or TPIP, are examples of combination drug/device products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is divided into various Centers, which each have authority over a specific type of product. NDAs are reviewed by personnel within the Center for Drug Evaluation and Research, while device applications and premarket notifications are reviewed by the Center for Devices and Radiological Health. Combination products, such as drug/device combinations, generally will be reviewed by the Center that regulates the product's primary mode of action (PMOA), which is the single mode of a combination product that provides the most important therapeutic action of the combination product. If the PMOA is unclear or in dispute, a sponsor may file a Request for Designation with FDA&#8217;s Office of Combination Products (OCP), which will render a determination and assign a lead Center. OCP generally assigns jurisdiction based on PMOA. If there are two independent modes of action, neither of which is subordinate to the other, the FDA makes a determination as to which Center to assign the product based on consistency with other combination products raising similar types of safety and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness questions or to the Center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an application for a combination product, a lead Center may consult other Centers and apply the standards that would be applicable but still retain reviewing authority, or it may assign review of a specific section of the application to another Center, delegating its review authority for that section. Depending on the type of combination product, approval or clearance could be obtained through submission of a single marketing application or through separate applications for the individual constituent parts (e.g.,&#160;an NDA for the drug and a premarket notification for the device). The FDCA directs the FDA to conduct a review of a combination product under a single marketing application whenever appropriate. The agency has the discretion to require the submission of separate applications to more than one Center, and applicants may choose to submit separate applications for constituent parts of a combination (unless the FDA determines one application is necessary). One reason to submit multiple applications is if the applicant wishes to receive some benefit that accrues only from approval under a particular type of application, like new drug product exclusivity. If multiple applications are submitted, each application is generally reviewed by the Center with authority over each application type. For combination products that contain an approved constituent part (such as a drug-device combination product in which the device has previously received clearance), the FDA may require that the application(s) include only such information as is necessary to meet the standard for clearance or approval, taking into account any prior finding of safety or effectiveness for the approved constituent part.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like their constituent products&#8212;e.g.,&#160;drugs and devices&#8212;combination products are highly regulated and subject to a broad range of post marketing requirements including cGMP, adverse event reporting, periodic reports, labeling and advertising and promotion requirements and restrictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disclosure of Clinical Trial Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under US and certain foreign laws intended to improve clinical trial transparency, sponsors of clinical trials may be required to register and disclose certain information about their clinical trials. This can include information related to the investigational drug, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial. This information is then made publicly available. Under US regulations, sponsors are obligated to disclose the results of these trials after completion. In the US, disclosure of the results of these trials can be delayed for up to two years if the sponsor is seeking initial approval of the product or approval of a new indication. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Post-approval Regulatory Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMP, as well as registration, listing, and inspection. There also are continuing, annual user fee requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of an NDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All aspects of pharmaceutical manufacture must conform to cGMP after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMP. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement, in some cases before the change may be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously mentioned, the FDA also may require Phase&#160;4 studies and may require a REMS, which could restrict the distribution or use of the product.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MAA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain approval of a drug under the EU regulatory system, an application for a marketing authorization may be submitted under a centralized, a decentralized or a national procedure. The centralized procedure, which is compulsory for medicines produced by certain biotechnological processes or for orphan drugs, provides for the grant of a single marketing authorization that is valid for all EU member states, which grants the same rights and obligations in each member state as a national marketing authorization. As a general rule, only one marketing authorization may be granted for drugs approved through the centralized procedure and the marketing authorization is also relevant for the EEA countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the Committee for Medicinal Products for Human Use (CHMP) is required to adopt an opinion on a valid application within 210&#160;days, excluding clock stops when additional information is to be provided by the applicant in response to questions. More specifically, on day 120 of the procedure, once the CHMP has received the preliminary assessment reports and opinions from the Rapporteur and Co-Rapporteur designated by the CHMP, it adopts a list of questions, which are sent to the applicant together with the CHMP's overall conclusions. Applicants then have three months to respond to the CHMP (and can request a three-month extension). The Rapporteur and Co-Rapporteur assess the applicant's replies, revise the assessment report as necessary and may prepare a list of outstanding issues. The revised assessment report and list of outstanding issues are sent to the applicant together with the CHMP's recommendation by day 180 of the procedure. Applicants then have one month to respond to the CHMP (and can request a one or two-month extension). The Rapporteur and Co-Rapporteur assess the applicant's replies, submit them for discussion to the CHMP and prepare a final assessment report. Once its scientific evaluation is completed, the CHMP gives a favorable or unfavorable opinion as to whether to grant the marketing authorization. After the adoption of the CHMP opinion, a decision must be adopted by the European Commission, after consulting the Standing Committee of the Member States. The European Commission prepares a draft decision and circulates it to the member states; if the draft decision differs from the CHMP opinion, the Commission must provide detailed explanations. The European Commission adopts a decision within 15&#160;days of the end of the consultation procedure.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accelerated Procedure, Conditional Approval and Approval Under Exceptional Circumstances</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various programs, including accelerated procedure, conditional approval and approval under exceptional circumstances, are intended to expedite or simplify the approval of drugs that meet certain qualifications. The purpose of these programs is to provide important new drugs to patients earlier than under standard approval procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For drugs which are of major interest from the point of view of public health, in particular from the viewpoint of therapeutic innovation, applicants may submit a substantiated request for accelerated assessment. If the CHMP accepts the request, the review time is reduced from 210 to 150&#160;days.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, for certain categories of medicinal products, marketing authorizations may be granted on the basis of less complete data than is normally required in order to meet unmet medical needs of patients or in the interest of public health. In such cases, the company may request, or the CHMP may recommend, the granting of a marketing authorization, subject to certain specific obligations; such marketing authorization may be conditional or under exceptional circumstances. The timelines for the centralized procedure described above also apply with respect to applications for a conditional marketing authorization or marketing authorization under exceptional circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations may be granted for products designated as orphan medicinal products, if all of the following conditions are met: (1)&#160;the risk-benefit balance of the product is positive, (2)&#160;the applicant will likely be in a position to provide the required comprehensive clinical trial data, (3)&#160;the product fulfills unmet medical needs, and (4)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditional marketing authorizations are valid for one year, on a renewable basis until the holder provides a comprehensive data package. The granting of conditional marketing authorization depends on the applicant's ability to fulfill the conditions imposed within the agreed upon deadline. They are subject to "conditions", i.e.&#160;the holder is required to complete ongoing studies or to conduct new studies with a view to confirming that the benefit-risk balance is positive or to fulfill specific obligations in relation to pharmacovigilance. Once the holder has provided a comprehensive data package, the conditional marketing authorization is replaced by a 'regular' marketing authorization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorizations under exceptional circumstances may be granted where the applicant demonstrates that, for objective and verifiable reasons, they are unable to provide comprehensive data on the efficacy and safety of the drug under normal conditions of use. Such marketing authorizations are subject to certain conditions, in particular relating to safety of the drug, notification of incidents relating to its use or actions to be taken. They are valid for an indefinite period of time, but the conditions upon which they are based are subject to an annual reassessment in order to ensure that the risk-benefit balance remains positive.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusivities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an approved drug contains a new active substance, it is protected by data exclusivity for eight years from the notification of the Commission decision granting the marketing authorization and then by marketing protection for an additional two or three years. Overall, the drug is protected for ten or eleven years against generic competition, and no additional exclusivity protection is granted for any new development of the active substance it contains.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the eight-year period of data exclusivity, competitors may not refer to the marketing authorization dossier of the approved drug for regulatory purposes. During the period of marketing protection, competitors may not market their generic drugs. The period of marketing protection is normally two years but may become three years if, during the eight-year data exclusivity period, a new therapeutic indication is approved that is considered as bringing a significant clinical benefit over existing therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Devices Regulations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the marketing of medical devices is not subject to a prior approval by a health authority, but, depending on the class of device, may require prior review by a Notified Body. Notified Bodies are technical review bodies that are accredited and supervised by national health authorities. They conduct conformity assessment procedures of, among others, medical devices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices are generally governed by Directive 93/42/EEC on Medical Devices (Directive 93/42) that harmonizes the conditions for placing medical devices on the European market. This Directive however does not regulate certain important marketing aspects, such as advertising or pricing and reimbursement, which remain governed by national law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directive 93/42 requires medical devices to meet the essential requirements which are enumerated in the annexes to the Directive. Compliance with those requirements is demonstrated by the CE mark as the manufacturer may only affix the CE mark if it may declare conformity with the essential requirement for each medical device that is marketed. Directive 93/42 provides recourse to harmonized European standards in order to facilitate compliance with the essential requirements. Harmonized standards provide a presumption of conformity with the essential requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directive 93/42 institutes several conformity assessment procedures. The relevant conformity assessment procedure depends on the type of medical device and the risks involved. Devices are divided in four groups: Class&#160;I, Class&#160;IIa, Class&#160;IIb, and Class&#160;III. Class&#160;I devices present the lowest level of risk so that, for most of these devices the manufacturer can self-certify the product and need not rely on certification by a Notified Body. For the other classes, a Notified Body must review the manufacturer's procedures and/or the product. Every device is initially classified by the manufacturer. However, the Notified Body may dispute the classification and assert that the device should be included in a class requiring stricter conformity assessment procedures. Specific rules apply to custom-made medical devices, medical devices that are used in clinical trials, and medical devices that incorporate a medicinal ingredient.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For classes of devices other than Class&#160;I, a manufacturer must have a Notified Body test and certify conformity of its design and production procedures or its products with the essential requirements of Directive 93/42. Certification takes the form of a certificate of conformity issued by the Notified Body, which is valid throughout the EU. Upon certification by the Notified Body, the manufacturer affixes the CE mark to the medical device, which allows the product to move freely within the EU and thus prevents EU Member States from restricting sales and marketing of the devices, unless such measure is justified on the basis of evidence of non-compliance. Ultimately, the manufacturer is responsible for the conformity of the device with the essential requirements and for the affixing of the CE mark. Lamira is CE marked by PARI in the EU.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of medical devices are subject to materiovigilance obligations that require reporting of incidents or near incidents related to the use of a medical device, which incidents may demonstrate the need for corrective action by the manufacturer. In addition, Notified Bodies regularly reassess the conformity of a medical device to the essential requirements of Directive 93/42 and may from time to time audit the manufacturer and may, where needed, suspend or withdraw the manufacturer's certificate of conformity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the EU adopted a new Medical Devices Regulation (EU) 2017/745 (MDR), which will repeal and replace Directive 93/42 with effect from May 26, 2021. The MDR envisages, among other things, stricter controls of medical devices, including strengthening of the conformity assessment procedures, increased expectations as regards clinical data for devices and pre-market regulatory review of high-risk devices. Under transitional provisions, medical devices with notified </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">body certificates issued under Directive 93/42 prior to May 26, 2021 may continue to be placed on the market for the remaining validity of the certificate, until May 27, 2024 at the latest. After the expiry of any applicable transitional period, only devices that have been CE marked under the MDR may be placed on the market in the EU.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Japanese regulatory system administered by the MHLW and the PMDA (which is responsible for product review and evaluations under the supervision of the MHLW), pre-marketing approval and clinical studies are required for all pharmaceutical products. The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (Act No. 145 of 1960) requires a license for marketing authorization when importing to Japan and selling pharmaceutical products manufactured in other countries. It also requires a foreign manufacturer to get each of its manufacturing sites certified as a manufacturing site of pharmaceutical products to be marketed in Japan. To receive a license for marketing authorization, the manufacturer or seller must, at the very least, employ certain manufacturing marketing, quality and safety personnel. A license for marketing authorization may not be granted if the quality management methods and post marketing safety management methods applied with respect to the pharmaceutical product fail to conform to the standards stipulated in the ordinances promulgated by the MHLW. To obtain manufacturing/marketing approval for a new product, a Company must submit an application for approval to the MHLW with results of nonclinical and clinical studies to show the quality, efficacy and safety of the product candidate. A data compliance review, on-site inspection for good clinical practice, audit and detailed data review for compliance with current good manufacturing practices are undertaken by the PMDA. The application is then discussed by the committees of the Pharmaceutical Affairs and Food Sanitation Council. Based on the results of these reviews, the final decision on approval is made by the MHLW. The time required for the approval process varies depending on the product, but it can take years. The product also needs approval for pricing to be applied for redemption of health insurance. The medical products which once are approved and marketed are also subject to regular post-marketing vigilance of safety and quality under the standards of Good Manufacturing Practice. In Japan, the National Health Insurance system maintains a Drug Price List specifying which pharmaceutical products are eligible for reimbursement, and the MHLW sets the prices of the products on this list. After receipt of marketing approval, negotiations regarding the reimbursement price with the MHLW would begin. Price would be determined within 60 to 90 days unless the applicant disagrees, which may result in extended pricing negotiations. The government generally introduces price cut rounds every other year and also mandates price decreases for specific products. New products judged innovative or useful, that are indicated for pediatric use, or that target orphan or small population diseases, however, may be eligible for a pricing premium. The government has also promoted the use of generics, where available.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003 (PREA), certain NDAs and supplements must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may, on its own initiative or at the request of an applicant, grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, and subject to an exception for certain oncology drugs, PREA does not apply to any drug for an indication for which orphan designation has been granted. Under the Best Pharmaceuticals for Children Act (BPCA), pediatric research is incentivized by the possibility of six months of pediatric exclusivity, which if granted, is added to existing exclusivity periods and patent-based exclusivity listed for the applicable drug in the FDA's Orange Book at the time the sponsor satisfies the FDA's "written request" for pediatric research. Sponsors may seek to negotiate the terms of a written request during drug development. While the sponsor of an orphan-designated drug may not be required to perform pediatric studies under PREA unless one of the above exceptions applies, they are eligible to participate in the incentives under the BPCA if the FDA issues a written request.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Union</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, new drugs (i.e.&#160;drugs containing a new active substance) for adults must also be tested in children. This mandatory pediatric testing is carried out through the implementation of a pediatric investigation plan (PIP), which is proposed by the applicant and approved by the EMA. A PIP contains all the studies to be conducted and measures to be taken in order to support the approval of the new drug, including pediatric pharmaceutical forms, in all subsets of the pediatric population. Validation of the MAA for adults is subject to the implementation of the PIP, subject to one or more waivers or deferrals. On the one hand, the PIP may allow a deferral for one or more of the studies or measures included therein in order not to delay the approval of the drug in adults, and, on another hand, the EMA may grant either a product-specific waiver for the (adult) disease/condition or one or more pediatric subsets or a class waiver for the disease/condition. PIPs are subject to modifications from time to time, when they no longer are workable. Prior to obtaining the validation of a MAA for adults, the applicant has to demonstrate compliance with the PIP at the time of submission of the application. In the case of orphan medicinal products, completion of an approved PIP can result in an extension of the market exclusivity period from ten to twelve years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Japan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, there is no statutory rule which imposes any obligation on pharmaceutical manufacturers engaging in pediatric drug development. However, the guidelines of the MHLW (Handling of Pharmaceuticals during the Reexamination Interval Period (Issue No. 107, February 1, 1999 and No. 1324, December 27, 2000)) state as follows: (i) since information on pediatric patients obtained in clinical trials may be limited, the MHLW recommends that pharmaceutical manufacturers conduct adequate post-marketing surveillance during the reexamination interval period and collect as much information as possible for proper use of drugs for pediatric patients; and (ii) if a pharmaceutical manufacturer plans to conduct a clinical trial to set the dose of a pediatric drug to prepare application for manufacturing/marketing approval or after receiving the same approval, the reexamination interval period may be extended up to 10 years. In addition, since 2010 the MHLW has been promoting the development of children&#8217;s drugs that have been approved for use in Europe and the US but are not yet approved in Japan, so that they can be used as early as possible in Japan as well. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside the US, Europe and Japan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the US, Europe and Japan, we will be subject to a variety of regulations in other jurisdictions governing clinical studies of our candidate products, including medical devices. Regardless of whether we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of countries outside the US before we can commence clinical studies or marketing of the product candidate in those countries. The requirements for approval and the approval process vary from country to country, and the time may be longer or shorter than that required for FDA approval. Under certain harmonized medical device approval/clearance regulations outside the US, reference to US clearance permits fast-tracking of market clearance. Other regions are harmonized with EU standards, and therefore recognize the CE mark as a declaration of conformity to applicable standards. Furthermore, we must obtain any required pricing approvals in addition to regulatory approval prior to launching a product candidate in the approving country. The discussion of EU government regulations also applies to the United Kingdom.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Early Access Programs (EAPs)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain countries allow the supply or use of non-authorized medicinal products within strictly regulated EAPs. Some may also provide reimbursement for drugs provided in the context of EAPs. Under EU law, member states are authorized to adopt national legal regimes for the supply or use of non-authorized drugs in case of therapeutic needs. The most common national legal regimes are compassionate use programs and named patient sales, but other national regimes for early access may be available, depending on the member state. For drugs that must be approved through the centralized procedure, such as orphan drugs, compassionate use programs are also regulated at the European level. ARIKAYCE is available in certain countries under these early access programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special programs can be set up to make available to patients with an unmet medical need a promising drug which has not yet been authorized for their condition (compassionate use). As a general rule, compassionate use programs can only be put in place for drugs or biologics that are expected to help patients with life-threatening, long-lasting or seriously disabling illnesses who currently cannot be treated satisfactorily with authorized medicines, or who have a disease for which no medicine has yet been authorized. The compassionate use route may be a way for patients who cannot enroll in an ongoing clinical trial to obtain treatment with a potentially life-saving medicine. Compassionate use programs are coordinated and implemented by the EU member states, which decide independently how and when to open such programs according to national rules and legislation. Generally, doctors who wish to obtain a promising drug for their seriously ill patients will need to contact the relevant national authority in their respective country and follow the procedure that has been set up. Typically, the national authority keeps a register of the patients treated with the drug within the compassionate use program, and a system is in place to record any side effects reported by the patients or their doctors. Orphan drugs very often are subject to compassionate use programs due to their very nature (rare diseases are life-threatening, long-lasting or seriously disabling diseases) and the long time required for both their approval and effective marketing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Doctors can also obtain certain drugs for their patients by requesting a supply of a drug from the manufacturer or a pharmacist located in another country, to be used for an individual patient under their direct responsibility. This is often called treatment on a 'named-patient basis' and is distinct from compassionate use programs. In this case, the doctor responsible for the treatment will either contact the manufacturer directly or issue a prescription to be fulfilled by a pharmacist. While manufacturers or pharmacists do record what they supply, there is no central register of the patients that are being treated in this way.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement of Pharmaceutical Products</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the US, many independent third-party payors, as well as the Medicare and state Medicaid programs, reimburse dispensers of pharmaceutical products. Medicare is the federal program that provides healthcare benefits to senior citizens and certain disabled and chronically ill persons. Medicaid is the need-based federal and state program administered by the states to provide healthcare benefits to certain persons.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As one of the conditions for obtaining Medicaid and, if applicable, Medicare Part&#160;B coverage for our marketed pharmaceutical products, we will need to agree to pay a rebate to state Medicaid agencies that provide reimbursement for those products. We will also have to agree to sell our commercial products under contracts with the Department of Veterans Affairs, Department of Defense, Public Health Service, and numerous other federal agencies as well as certain hospitals that are designated by federal statutes to receive drugs at prices that are significantly below the price we charge to commercial pharmaceutical distributors. These programs and contracts are highly regulated and will impose restrictions on our business. Failure to comply with these regulations and restrictions could result in adverse consequences such as civil money penalties, imposition of a Corporate Integrity Agreement and/or a loss of Medicare and Medicaid reimbursement for our drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private healthcare payors also attempt to control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of Congress have indicated an interest in legislative measures designed to lower drug costs.&#160;The Biden Administration has also indicated that lowering prescription drug prices is a priority. Drug pricing is an active area for regulatory reform at both the federal and state levels, and significant changes to current drug pricing and reimbursement structures in the US could be forthcoming</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of drugs through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to patients. Some jurisdictions operate positive and negative list systems under which drugs may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for drugs, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new drugs. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drugs will allow favorable reimbursement and pricing arrangements for any of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, drugs can be sold on the market if they undergo the PMDA&#8217;s review of safety, effectiveness and quality and receive manufacturing/marketing approval. However, in order for drugs to be covered by the National Health Insurance, they must be included in a Drug Price List. The "Drug Pricing Organization," which is a division of the Central Social Insurance Medical Council (CSIMC), calculates the price of drugs, the general meeting of the CSIMC approves the calculated price, and the MHLW includes the drugs and the calculated price in the Drug Price List. After receiving manufacturing/marketing approval, drugs are included in the Drug Price List within 60 to 90 days unless the applicant disagrees, which may result in extended pricing negotiations. The MHLW updates the Drug Price List biennially after taking into account the survey result of the actual sales price of drugs and hearing the opinion of the CSIMC.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fraud and Abuse and Other Laws</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians and other healthcare providers and third-party payors (government or private) often play a primary role in the recommendation and prescription of healthcare products. In the US and most other jurisdictions, numerous detailed requirements apply to government and private healthcare programs, and a broad range of fraud and abuse laws, transparency laws, and other laws are relevant to pharmaceutical companies. US federal and state healthcare laws and regulations in these areas include the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal anti-kickback statute;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil False Claims Act;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal criminal false statements statute;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price reporting requirements under the Medicaid Drug Rebate Program and the Veterans Health Care Act of 1992;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous and similar state laws and regulations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar restrictions apply in the member states of the EU and Japan, which have been set out by laws or industry codes of conduct. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had a total of 521 employees: 213 in research, clinical, regulatory, medical affairs and quality assurance; 41 in technical operations, manufacturing and quality control; 99 in general and administrative functions; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168 in commercial activities. We had 403 employees in the US, 74 employees in Europe and 44 employees in Japan. We anticipate increasing our headcount in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees are represented by a labor union and we believe that our relations with our employees are generally good. Generally, our employees are at-will employees; however, we have entered into employment agreements with certain of our executive officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Attraction, Retention and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dedicated to attracting and retaining the best possible talent. Our compensation program, including short- and long-term incentives and benefits, is designed to allow us to attract and retain individuals whose skills are critical to our current and long-term success. Total compensation is generally positioned within a competitive range of the peer market median, with differentiation based on tenure, skills, proficiency, and performance to attract and retain key talent. With our compensation program, we also aim to align the interests of our employees with those of our stockholders.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that continued growth and development are essential to the professional well-being of our team. We seek to develop our employee talent within the organization through access to training, continuous learning programs and other development initiatives. As our organization and capabilities grow, we aim to ensure we have provided our team members with the guidance and resources they need to develop as professionals and to support our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Core Values</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five core values&#8212;collaboration, accountability, passion, respect, and integrity&#8212;set the tone for our culture and guide the actions we take each day. We strive to ensure that these values drive all of our human capital endeavors, including our annual employee feedback process, our Leadership Competencies, our Recognition Program, and our new employee onboarding initiatives.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on maintaining a diverse and inclusive atmosphere. Among other factors in hiring, we consider geographic, gender, age, racial and ethnic diversity. Currently, women represent 50% of our executive team, and 30% of our board of directors. We expect to continue implementing initiatives to enhance our workforce diversity, advance the development of diverse talent and ensure diverse succession plans both in our employee workforce and our board of directors. These initiatives include the establishment of a series of focus groups centered around diversity and inclusivity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are committed to the safety and well-being of our workforce. During the COVID-19 pandemic, our employees are provided the ability to work virtually in order to flexibly manage business and home responsibilities during the global pandemic. We have enhanced our internal communications and touch points to ensure connectivity to our workforce. With the exception of our laboratory personnel, who returned to the laboratories during the summer as other regions opened, our employees are able to use their own discretion to use our facilities. Returning to the office has not been required for the majority of our workforce. For those who do choose to work from the office, all of our facilities have been appropriately evaluated and maintained for social distancing and sanitation on a daily basis in line with state and CDC guidelines. We will continue to manage this situation with a focus towards the safety of our employees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file electronically with the SEC our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (Exchange Act). We make available on our website at http://www.insmed.com, free of charge, copies of these reports as soon as reasonably practicable after filing, or furnishing them to, the SEC. The public can also obtain materials that we file with the SEC through the SEC's website at http://www.sec.gov.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also available through our website's "Investors-Corporate Governance" page are charters for the Audit, Compensation, Nominations and Governance and Science and Technology Committees of our board of directors, our Corporate Governance Guidelines, and our Code of Business Conduct and Ethics. We intend to satisfy the disclosure requirements regarding any amendment to, or waiver from, a provision of the Code of Business Conduct and Ethics by making disclosures concerning such matters available on our website.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The references to our website and the SEC's website are intended to be inactive textual references only. Neither the information in or that can be accessed through our website, nor the contents of the SEC's website, are incorporated by reference in this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information required under this Item&#160;1 is incorporated herein by reference to Item&#160;8 of this Annual Report on Form&#160;10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-bottom:7.5pt;margin-top:7.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to substantial risks and uncertainties. Any of the risks and uncertainties described below, either alone or taken together, could materially and adversely affect our business, financial condition, results of operations, prospects for growth, and the value of an investment in our common stock. In addition, these risks and uncertainties could cause actual results to differ materially from those expressed or implied by forward-looking statements contained in this Annual Report on Form 10-K (please read the Cautionary Note Regarding Forward-Looking Statements appearing at the beginning of this Annual Report on Form 10-K). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities is subject to various risks, the most significant of which are summarized below. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our prospects are highly dependent on the success of our only approved product, ARIKAYCE. If we are unable to successfully commercialize or maintain approval for ARIKAYCE, our business, financial condition, results of operations and prospects and the value of our common stock will be materially adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The commercial success of ARIKAYCE will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the healthcare community.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We obtained regulatory approval of ARIKAYCE in the United States (US) through an accelerated approval process, and full approval will be contingent on successful completion of a confirmatory post-marketing study. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We remain subject to substantial, ongoing regulatory requirements in the US related to ARIKAYCE, and failure to comply with these requirements could lead to enforcement action or otherwise materially harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or if we are unable to obtain acceptable prices for ARIKAYCE, our prospects for generating revenue and achieving profitability will be materially adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ARIKAYCE could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If estimates of the size of the potential markets for ARIKAYCE, brensocatib, treprostinil palmitil inhalation powder (TPIP) and our other product candidates are overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to successfully market and sell ARIKAYCE, our ability to generate revenue will be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may not be successful in clinical trials or in obtaining regulatory approvals required to expand the indications for which ARIKAYCE was approved, which may materially adversely affect our prospects and the value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The novel coronavirus (COVID-19) pandemic and efforts to reduce its spread have negatively impacted, and could continue to negatively impact, our business and operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may not be able to obtain regulatory approvals for ARIKAYCE outside of the US or European Union (EU) or for our product candidates in the US, Europe, Japan or other markets, which may materially adversely affect us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will not be able to commercialize ARIKAYCE if the Lamira Nebulizer System is not approved or cleared for use as a delivery system for ARIKAYCE by regulators in additional markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our clinical studies do not produce positive results or our clinical trials are delayed, or if serious side effects are identified during drug development, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates in the US, Europe, Japan or other markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may not be able to enroll enough patients to conduct and complete our clinical trials or retain a sufficient number of patients in our clinical trials to generate the data necessary for regulatory approval of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to form and sustain relationships with third party service providers that are critical to our business, or if any third-party arrangements that we may enter into are unsuccessful, our ability to develop and commercialize our products may be materially adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, the Lamira Nebulizer System or our product candidates to meet our required supply for commercialization or clinical studies, which would materially harm our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Adverse consequences to our business could result if we and our manufacturing partners fail to comply with applicable regulations or maintain required approvals.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any acquisitions we make, or collaborative relationships we enter into, may not be clinically or commercially successful, and may require financing or a significant amount of our available cash, which could adversely affect our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business and operations, including our drug development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or our clinical research organizations (CROs) or other contractors or consultants.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have limited experience operating internationally, are subject to a number of risks associated with our international activities and operations and may not be successful in our efforts to expand internationally.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to protect our intellectual property rights adequately, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to comply with obligations in our third party agreements, our business could be adversely affected, including as a result of the loss of license rights that are important to our business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Government healthcare reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to comply with applicable laws, including "fraud and abuse" laws, anti-corruption laws and trade control laws, we could be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If another party obtains orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our use of hazardous materials could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have a history of operating losses, expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may need to raise additional funds to continue our operations, but we face uncertainties with respect to our ability to access capital.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have outstanding indebtedness in the form of convertible senior notes, and may incur additional indebtedness in the future, which could adversely affect our financial position, prevent us from implementing our strategy, and dilute the ownership interest of our existing shareholders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The accounting method for the Convertible Notes may have an adverse effect on our reported financial results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may be unable to use certain of our net operating losses and other tax assets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The market price of our stock has been and may continue to be highly volatile, which could lead to shareholder litigation against us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements between us and our employees could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of us.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization and Continued Approval of ARIKAYCE</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our prospects are highly dependent on the success of our only approved product, ARIKAYCE, which was approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE&#174; Liposomal 590 mg Nebuliser Dispersion. If we are unable to successfully commercialize or maintain approval for ARIKAYCE, our business, financial condition, results of operations and prospects and the value of our common stock will be materially adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term viability and growth depend on the successful commercialization of ARIKAYCE, our only approved product. ARIKAYCE was approved in the US for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting, as defined by patients who do not achieve negative sputum cultures after a minimum of six consecutive months of a multidrug background regimen therapy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, ARIKAYCE was approved in the EU for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. We refer to NTM lung disease caused by MAC as MAC lung disease.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have invested</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and continue to invest significant efforts and financial resources in the commercialization of ARIKAYCE, and our ability to generate revenue from ARIKAYCE will depend heavily on successfully commercializing and obtaining full regulatory approval for ARIKAYCE by conducting an appropriate confirmatory post-marketing study. ARIKAYCE was our first commercial launch, and its successful commercialization and our receipt of full regulatory approval for ARIKAYCE in the US are subject to many risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of ARIKAYCE will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the healthcare community.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite receiving US Food and Drug Administration (FDA) and European Commission (EC) approval of ARIKAYCE, market acceptance may vary among physicians, patients, third-party payors or others in the healthcare community. ARIKAYCE was the first product approved in the US via the LPAD pathway, and there is limited information on how this approval may impact market acceptance of the product. If ARIKAYCE does not achieve and maintain an adequate level of acceptance, it is not likely that we will continue to generate significant revenue or become profitable. The degree of market acceptance of ARIKAYCE, which we launched in the US early in the fourth quarter of 2018 and in the EU in the fourth quarter of 2020, is also dependent on a number of additional factors, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The willingness of the target patient population to use, and of physicians to prescribe, ARIKAYCE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The efficacy and potential advantages of ARIKAYCE over alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk and safety profile of ARIKAYCE, including, among other things, physician and patient concern regarding the US boxed warning and other safety precautions resulting from its association with an increased risk of respiratory adverse reactions, and any adverse safety information that becomes available as a result of longer-term use of ARIKAYCE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Relative convenience and ease of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability of the patient to tolerate ARIKAYCE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The pricing of ARIKAYCE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability and willingness of the patient to pay out of pocket costs for ARIKAYCE, for example, co-payments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sufficient third-party insurance coverage and reimbursement; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The strength of marketing and distribution support and timing of market introduction of competitive products and treatments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Publicity concerning ARIKAYCE or any potential competitive products and treatments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to educate physicians, patients, third-party payors and others in the healthcare community on the benefits of ARIKAYCE has required and will continue to require significant resources, which may be greater than those required to commercialize more established technologies and these efforts may never be successful.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We obtained regulatory approval of ARIKAYCE in the US through an accelerated approval process, and full approval will be contingent on successful completion of a confirmatory post-marketing study. Failure to obtain full approval or otherwise meet our post-marketing requirements and commitments would have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA approved ARIKAYCE under the LPAD and accelerated approval pathways, and full approval will be based on results from a post-approval confirmatory clinical trial. Accelerated approval allows drugs that (i) are being developed to treat a serious or life-threatening disease or condition and (ii) provide a meaningful therapeutic benefit over existing treatments to be approved substantially based on an intermediate endpoint or a surrogate endpoint that is reasonably likely to predict clinical benefit, rather than a clinical endpoint such as survival or irreversible morbidity. Accelerated approval of ARIKAYCE was supported by preliminary data from the Phase 3 CONVERT study, which evaluated the safety and efficacy of ARIKAYCE </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in adult patients with refractory MAC lung disease, using achievement of sputum culture conversion (defined as three consecutive negative monthly sputum cultures) by Month 6 as the primary endpoint. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of accelerated approval, we must conduct a post-approval confirmatory clinical trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we commenced the post-approval confirmatory frontline clinical trial program for ARIKAYCE in patients with MAC lung disease. The front-line clinical trial program consists of the ARISE trial, an interventional study designed to validate cross-sectional and longitudinal characteristics of a PRO tool in MAC lung disease, and the ENCORE trial, designed to establish the clinical benefits and evaluate the safety of ARIKAYCE in patients with newly diagnosed MAC using the PRO tool validated in the ARISE trial. We are running these global studies in parallel and approximately 200 sites are expected to be initiated for these clinical trials. The frontline clinical program is intended to fulfill the FDA&#8217;s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE. Pursuant to the timetable agreed upon with the FDA when the approval letter of ARIKAYCE was received, confirmatory trial results are to be reported by 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is little precedent for clinic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al development and regulatory expectations for agents to treat MAC lung disease. If our PRO tool is not validated in the ARISE trial, we would need to develop a new clinical endpoint for the ENCORE trial. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also encounter substantial delays in enrolling and conducting these trials, and we may not be able to enroll and conduct the trials in a manner satisfactory to the FDA or within the time period required by the FDA. If the ENCORE trial is not successful, the FDA could, among other things, withdraw its approval of ARIKAYCE. Separate from the confirmatory trial, additional results from ongoing and recently completed studies may affect the FDA&#8217;s benefit-risk analysis for the product. Additionally, ARIKAYCE is subject to post-marketing commitments consisting of implementation of a healthcare provider communication plan, conducting a drug utilization assessment, and conducting further studies to identify an optimal quality control in vitro drug release method. Failure to meet post-marketing commitments may raise additional regulatory challenges.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We remain subject to substantial, ongoing regulatory requirements in the US related to ARIKAYCE, and failure to comply with these requirements could lead to enforcement action or otherwise materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE is subject to a variety of manufacturing, packaging, storage, labeling, advertising, promotion, and record-keeping requirements, including requirements to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conduct sales, marketing and promotion, scientific exchange, speaker programs, charitable donations and educational grant programs in compliance with federal and state laws; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disclose clinical trial information and payments to healthcare professionals and healthcare organizations on publicly available databases; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monitor and report complaints, adverse events and instances of failure to meet product specifications; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comply with current good manufacturing practices (cGMP) and certain quality systems requirements for device components. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these ongoing regulatory obligations could have significant negative consequences, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of warning letters or untitled letters by FDA asserting that we are in violation of the law;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of injunctions or civil monetary penalties or pursuit by regulators of civil or criminal prosecutions and fines against us or our responsible officers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or withdrawal of regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seizure of products, required product recalls or refusal to allow us to enter into supply contracts, including government contracts, or to import or export products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Enforcement actions, such as a product recalls, or product shortages due to failure to meet certain manufacturing or regulatory requirements, including the successful completion and results of quality control or release testing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative publicity, including communications issued by regulatory authorities, which could negatively impact the perception of us or ARIKAYCE by patients, physicians, third-party payors or the healthcare community.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide financial assistance with out-of-pocket costs to patients enrolled in commercial health insurance plans. In addition, independent foundations may assist with out-of-pocket financial obligations. The ability of these organizations to provide assistance to patients is dependent on funding from external sources, and we cannot guarantee that such funding will be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available at adequate levels, if at all. Patient assistance programs, whether provided directly by manufacturers or charitable foundations, have come under recent government scrutiny. If we are deemed to fail to comply with relevant laws, regulations or government guidance with respect to these programs, we could be subject to significant fines or penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could reduce market acceptance of ARIKAYCE, substantially reduce our revenue, increase the costs of operating our business, and cause us significant reputational damage, among other consequences. We are subject to similar ongoing regulatory oversight in the EU and, if we ultimately receive approval for ARIKAYCE in other jurisdictions, we expect to be subject to similar ongoing regulatory oversight by the relevant foreign regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or if we are unable to obtain acceptable prices for ARIKAYCE, our prospects for generating revenue and achieving profitability will be materially adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prospects for generating revenue and achieving profitability depend heavily upon the availability of adequate reimbursement for the use of ARIKAYCE from governmental and other third-party payors, both in the US and in other markets. We expect a substantial majority of ARIKAYCE revenue will come from Medicare reimbursement. Reimbursement by a third-party payor depends upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A covered benefit under its health plan;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safe, effective and medically necessary;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Appropriate for the specific patient;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost-effective; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Neither experimental nor investigational.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a determination of coverage and reimbursement for a product from each governmental or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each payor. Since commercializing ARIKAYCE, payors have evaluated ARIKAYCE for inclusion on formularies. Going forward, we may not be able to provide data sufficient to gain positive coverage and reimbursement determinations or we might need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of ARIKAYCE to such payors&#8217; satisfaction. Such studies might require us to commit a significant amount of management time and financial and other resources. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when a payor determines that a product is eligible for reimbursement, the payor may impose coverage limitations that preclude payment for some uses that are approved by the FDA or non-US regulatory authorities and/or may set a reimbursement rate that is too low to support a profitable sales price for the product. In the US, payors have restricted and may also continue to restrict coverage of ARIKAYCE by using a variable co-payment structure that imposes higher costs on patients for drugs that are not preferred by the payor and by imposing requirements for prior authorization or step edits. Subsequent approvals of competitive products could result in a detrimental change to the reimbursement of our products. The occurrence of any of these events likely would adversely impact market acceptance and demand for ARIKAYCE, which, in turn, could affect our ability to successfully commercialize ARIKAYCE and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a significant focus in the US healthcare industry and elsewhere on drug prices and value, and public and private payors are taking increasingly aggressive steps to control their expenditures for pharmaceuticals by, inter alia, negotiating manufacturer discounts and placing restrictions on reimbursement, and patient access to, medications. These pressures could negatively affect our business. We expect changes in the Medicare program and state Medicaid programs, as well as managed care organizations and other third-party payors, to continue to put pressure on pharmaceutical product pricing. For instance, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) expanded Medicare outpatient prescription drug coverage for the elderly through Part D prescription drug plans sponsored by private entities and authorized such plans to use formularies where they can limit the number of drugs that will be covered in any therapeutic class. The plans generally negotiate significant price concessions as a condition of formulary placement. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs, which is generally believed to have resulted in lower Medicare reimbursement for physician-administered drugs. These cost reduction initiatives and other provisions of this legislation provide additional pressure to contain and reduce drug prices and could decrease the coverage and price that we receive for any approved products and could seriously harm our business. Although the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations when setting their own reimbursement rates, and any reimbursement reduction resulting from the MMA may result in a similar reduction in payments from private payors. Additionally, the Patient Protection and Affordable Care Act (ACA) revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes and increased the minimum percentage for Medicaid drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rebates to states, required drug manufacturers to provide a significant discount (70% as of January 1, 2019) on prescriptions for branded drugs filled while the beneficiary is in the Medicare Part D coverage gap (also known as the donut hole), and imposed a significant annual fee on companies that manufacture or import branded prescription drug products. We believe it is likely that the ACA, or any legislation enacted to amend or replace it, will continue the pressure on pharmaceutical pricing, especially under the Medicare program, and also may increase our regulatory burdens and operating costs. Such changes may have a significant impact on our ability to set a product price we believe is fair and may adversely affect our ability to generate revenue and achieve or maintain profitability. For instance, we have observed an increase in the time to fill prescriptions, particularly for patients that are insured through Medicare, in the first quarter of the year as a result of the donut hole, and, while we do not expect this situation to extend through the entire year, this situation may recur in the first quarter of subsequent years. We expect further federal and state proposals and healthcare reforms to continue to be proposed, which could limit the prices that can be charged for the products we develop or may otherwise limit our commercial opportunity. See Reimbursement of Pharmaceutical Products in Item 1 of Part I of this Annual Report on Form 10-K for more information. In addition, in connection with various government programs, we are required to report certain pricing information to the government, and the failure to do so may subject us to penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In markets outside the US, including countries in Europe, Japan and Canada, pricing of pharmaceutical products is subject to governmental control. Evaluation criteria used by many government agencies in European countries for the purposes of pricing and reimbursement typically focus on a product&#8217;s degree of innovation and its ability to meet a clinical need unfulfilled by currently available therapies. The ACA created a similar entity, the Patient-Centered Outcomes Research Institute, designed to review the effectiveness of treatments and medications in federally-funded healthcare programs. An adverse result could lead to a treatment or product being removed from Medicare or Medicare coverage. The decisions of such governmental agencies could affect our ability to sell our products profitably.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had discussions with third-party payors regarding our price for ARIKAYCE, but our pricing may meet resistance from them and the public generally. If we are unable to obtain adequate reimbursement of ARIKAYCE, the adoption of ARIKAYCE by physicians and patients may be limited. This, in turn, could affect our ability to successfully commercialize ARIKAYCE and adversely impact our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARIKAYCE could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE was granted accelerated approval from the FDA based on Month 6 data from the CONVERT study. In the US, ARIKAYCE is now being used by larger numbers of patients, potentially for longer periods of time, and we and others (including regulatory agencies and private payors) will collect extensive information on the efficacy and safety of ARIKAYCE by monitoring its use in the marketplace. In addition, we are conducting a confirmatory trial to assess and describe the clinical benefit of ARIKAYCE in patients with MAC lung disease and may conduct additional trials in connection with lifecycle management programs for ARIKAYCE in the US. New safety or efficacy data from both market surveillance and our clinical trials may result in negative consequences including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Modification to product labeling or promotional statements, such as additional boxed or other warnings or contraindications, or the issuance of additional &#8220;Dear Doctor Letters&#8221; or similar communications to healthcare professionals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Required changes in the administration of ARIKAYCE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Imposition of additional post-marketing surveillance, post-marketing clinical trial requirements, distribution restrictions or other risk management measures, such as a risk evaluation and mitigation strategy (REMS) or a REMS with elements to assure safe use;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or withdrawal of regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or termination of ongoing clinical trials or refusal by regulators to approve pending marketing applications or supplements to approved applications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension of, or imposition of restrictions on, our operations, including costly new manufacturing requirements with respect to ARIKAYCE; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Voluntary or mandatory product recalls or withdrawals from the market and costly product liability claims.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these circumstances could reduce ARIKAYCE&#8217;s market acceptance and would be likely to materially adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If estimates of the size of the potential markets for ARIKAYCE, brensocatib, treprostinil palmitil inhalation powder (TPIP) and our other product candidates are overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied on external sources, including market research funded by us and third parties, and internal analyses and calculations to estimate the potential market opportunities for ARIKAYCE, brensocatib, TPIP and our other product candidates. The externally sourced information used to develop these estimates has been obtained from sources we believe to be reliable, but we have not verified the data from such sources, and their accuracy and completeness cannot be assured. With respect to ARIKAYCE, our internal analyses and calculations are based upon management&#8217;s understanding and assessment of numerous inputs and market conditions, including, but not limited to, the projected increase in prevalence of MAC lung disease, Medicare patient population growth and ongoing population shifts to geographies with increased rates of MAC lung disease. These understandings and assessments necessarily require assumptions subject to significant judgment and may prove to be inaccurate. As a result, our estimates of the size of these potential markets for ARIKAYCE could prove to be overstated, perhaps materially. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are relying on third-party data to identify the physicians who treat the majority of MAC lung disease patients in the US and to determine how to deploy our resources to market to those physicians; however, we may not be marketing to the appropriate physicians and may therefore be limiting our market opportunity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may develop estimates with respect to market opportunities for other product candidates in the future, and such estimates would be subject to similar risks. In addition, a potential market opportunity could be reduced if a regulator limits the proposed treatment population for one of our product candidates, similar to the limited population for which ARIKAYCE was approved. In either circumstance, even if we obtain regulatory approval, we may be unable to commercialize the product on a scale sufficient to generate significant revenue from such product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We continue to build our global marketing and sales organization, and we have limited experience in marketing drug products. If we are unable to successfully market and sell ARIKAYCE, our ability to generate revenue will be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to commercialize ARIKAYCE, we must develop marketing, market access, sales and distribution capabilities on our own or make arrangements with third parties for its marketing, sale and distribution. We have commenced commercialization of ARIKAYCE in the US and Europe using our sales force, but we may not</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> continue to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be successful in these efforts. If approved, we also plan to commercialize ARIKAYCE in Japan using our own sales force. The establishment, development and maintenance of our own sales force is and will continue to be expensive and time-consuming. As a result, we may seek one or more partners to handle some or all of the sales and marketing of ARIKAYCE in certain markets outside the US following approval by the relevant regulatory authority in those markets. However, we may not be able to enter into arrangements with third parties to sell ARIKAYCE on favorable terms or at all. In the event that either our own marketing, market access, and sales force or third-party marketing, market access, and sales organizations are not effective, we would not be able to successfully commercialize ARIKAYCE, which would adversely affect our ability to generate revenue and materially harm us. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARIKAYCE was approved for treatment in a limited population of patients with refractory MAC lung disease, and additional clinical studies and regulatory applications will be required to expand its indication. We may not be successful in these trials or in obtaining such regulatory approval, which may materially adversely affect our prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA granted accelerated approval of ARIKAYCE for the treatment of refractory MAC lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting, as defined by patients who do not achieve negative sputum culture after a minimum of six consecutive months of a multidrug background regimen therapy. Our CONVERT study and 312 study focused on this refractory population, and we do not anticipate obtaining an indication for a broader population of patients with MAC lung disease or any other illnesses or infections without additional clinical data. Additional clinical trials will require additional time and expense. We are conducting our confirmatory clinical trial program for full approval of ARIKAYCE, through the ARISE trial and the ENCORE trial, in the broader population of patients with MAC lung disease, but this trial program, along with any other clinical trials of ARIKAYCE may not be successful. Additional results from ongoing and recently completed studies may affect the FDA&#8217;s benefit-risk analysis for the product. If we are unable to expand the indication for use of ARIKAYCE, our prospects and the value of our common stock may be materially adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The novel coronavirus (COVID-19) pandemic and efforts to reduce its spread have negatively impacted, and could continue to negatively impact, our business and operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations expose us to risks associated with public health crises and pandemics, including COVID-19, particularly as the patients we seek to treat suffer from serious and rare diseases that may make them especially vulnerable. The degree to which COVID-19 affects us will depend on developments that are highly uncertain and beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, and the speed with which and the extent to which normal economic and operating conditions resume.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We modified our business practices in March 2020 in an effort to allow infectious disease specialists and pulmonologists to focus on critical COVID-19 relief efforts and to aid in the global containment effort, including through implementation of a remote working policy for all employees. The remote working policy included all of our field-based therapeutic specialists and employees who support ARIKAYCE prescribers. Beginning on June 1, 2020, certain of our field-based employees who support ARIKAYCE prescribers were permitted to return to the field. To date, access to prescribers has been limited with significant regional variability. In the event of further increases in the number of COVID-19 cases nationwide, we may once again impose our remote working policy on all field-based employees. If our remote working policy continues and the focus of pulmonologists and infectious disease specialists remains on COVID-19, we expect that our business and results of operations in future periods could be negatively impacted. We also may take further actions as required by government authorities or that we determine are in the best interests of our employees, patients, partners, and suppliers in the future that harm our ability to promote ARIKAYCE or support patients beginning treatment with ARIKAYCE, which could negatively impact our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 may also have an adverse impact on our operations and supply chain as a result of (i) our or our third-party manufacturers&#8217; employees or other key personnel becoming infected, (ii) preventive and precautionary measures that governments and we and other businesses, including our third-party manufacturers, are taking, such as border closures, prolonged quarantines and other travel restrictions, (iii) shortages of supplies necessary for the manufacture of ARIKAYCE, including as a result of government orders providing for the requisition of personal protective equipment and other medical supplies and equipment, and (iv) cold-chain storage and shipping limitations resulting from the need to prioritize delivery of one or more COVID-19 vaccines, which could cause disruptions or delays in our ability to distribute ARIKAYCE due to lack of sufficient cold-chain storage and shipping capacity. Any of these circumstances could impact the ability of third parties on which we rely to manufacture ARIKAYCE or its components and our ability to perform critical functions, which could significantly hamper our ability to supply ARIKAYCE to patients. While we have experienced no disruption to date in our supply chain, if we encounter delays or difficulties in the manufacturing process that disrupt our ability to supply ARIKAYCE, we may not be able to satisfy patient demand or we may experience a product stock-out, which would likely have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could also require us to delay the start of new clinical trials or otherwise impair our ability to complete those trials. For instance, our ability to enroll patients and retain principal investigators and site staff could be impaired due to an outbreak in their geography or prioritization of hospital resources toward the outbreak, or as a result of quarantines and other travel restrictions that interrupt healthcare services. Furthermore, patients, investigators, or site staff may be unwilling or unable to comply with clinical trial protocols due to COVID-19 illness, concerns about the pandemic, or quarantines or other travel restrictions that impede their movement. Additionally, any interruption in the supply of the study drug might delay our ability to start or complete clinical trials. Significant delays in the timing and completion of our clinical trials are costly and could adversely affect our ability to satisfy our post-marketing requirements for ARIKAYCE and to obtain regulatory approval for and to commercialize our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Development and Regulatory Approval of Our Product Candidates Generally</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development in the pharmaceutical industry is an expensive, high-risk, lengthy, complicated, resource intensive process. In order to develop a product successfully, we must, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identify potential product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submit for and receive regulatory approval to perform clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Design and conduct appropriate preclinical and clinical trials, including confirmatory clinical trials, according to good laboratory practices and good clinical practices and disease-specific expectations of the FDA and other regulatory bodies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Select and recruit clinical investigators and subjects for our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtain and correctly interpret data establishing adequate safety of our product candidates and demonstrating with statistical significance that our product candidates are effective for their proposed indications, as indicated by satisfaction of pre-established endpoints;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submit for and receive regulatory approvals for marketing; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacture the product candidates and device components according to cGMP and other applicable standards and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons. Importantly, positive results from preclinical studies of a product candidate may not be predictive of similar results in human clinical trials, and promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving positive results in earlier stages of development and have abandoned development efforts or sought partnerships in order to continue development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are many other difficulties and uncertainties inherent in pharmaceutical research and development that could significantly delay or otherwise materially impair our ability to develop future product candidates, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Conditions imposed by regulators, ethics committees or institutional review boards for preclinical testing and clinical trials relating to the scope or design of our clinical trials, including selection of endpoints and number of required patients or clinical sites; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges in designing our clinical trials to support potential claims of superiority over current standard of care or future competitive therapies; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions placed upon, or other difficulties with respect to, clinical trials and clinical trial sites, including with respect to potential clinical holds or suspension or termination of clinical trials due to, among other things, potential safety or ethical concerns or noncompliance with regulatory requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delayed or reduced enrollment in clinical trials, or high discontinuation rates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure by third-party contractors, contract research organizations (CROs), clinical investigators, clinical laboratories, or suppliers to comply with regulatory requirements or meet their contractual obligations in a timely manner;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Greater than anticipated cost of our clinical trials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Insufficient product supply or inadequate product quality.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop future product candidates for any of these reasons may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain regulatory approvals for ARIKAYCE outside of the US or the EU or for our product candidates in the US, Europe, Japan or other markets. Any such failure to obtain regulatory approvals may materially adversely affect us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to obtain various regulatory approvals prior to studying our products in humans and then again before we market and distribute our products, and the failure to obtain such approvals will prevent us from commercializing our products, which would materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. While we have obtained accelerated approval for ARIKAYCE in the US and approval in the EU, seeking approval for ARIKAYCE in other jurisdictions as well as approval for our product candidates in the US and foreign markets presents significant obstacles. Approval processes in the US, Europe and Japan require the submission of extensive preclinical and clinical data, manufacturing and quality information regarding the process and facility, scientific data characterizing our product and other supporting data in order to establish safety and effectiveness. These processes are complex, lengthy, expensive, resource intensive and uncertain. Regulators will also conduct a rigorous review of any trade name we intend to use for our products. Even after they approve a trade name, these regulators may request that we adopt an alternative name for the product if adverse event reports indicate a potential for confusion with other trade names and medication error. If we are required to adopt an alternative name, potential commercialization of ARIKAYCE or our product candidates could be delayed or interrupted. We have limited experience in submitting and pursuing applications necessary to obtain these regulatory approvals. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data submitted to regulators are subject to varying interpretations that could delay, limit or prevent regulatory agency approval. Even if we believe our clinical trial results are promising, regulators may disagree with our interpretation of data, study design or execution and may refuse to accept our application for review or decline to grant approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the grant of a designation by the FDA or European Medicines Agency (EMA) or approval by the FDA or EC does not ensure a similar decision by the regulatory authorities of other countries, and a decision by one foreign regulatory authority does not ensure regulatory authorities in other foreign countries or the FDA will agree with the decision. For instance, although ARIKAYCE received orphan drug designation in the US, ARIKAYCE did not qualify for orphan drug designation in Japan due to the estimated number of NTM patients in Japan exceeding 50,000. Similarly, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries. Approval procedures vary among countries and can involve additional product testing, including additional preclinical studies or clinical trials, and administrative review periods. The time required to obtain approval in these other territories might differ from that required to obtain FDA approval. We may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">never obtain approval for ARIKAYCE outside of the US and Europe or for our product candidates in the US or other jurisdictions, which would limit our market opportunities and materially adversely affect our business. Even if ARIKAYCE is approved outside of the US and Europe or if another product candidate is approved, regulators may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely assess regulatory strategies which could expedite the development and regulatory review of our product candidates in the US and other markets, but we may be unsuccessful in pursuing such strategies. The FDA has denied our request for orphan drug designation for brensocatib for the treatment of bronchiectasis. In addition, although we believe that TPIP could be eligible for approval under Section 505(b)(2), and thus could rely at least in part on studies not conducted by or for us and for which we do not have a right of reference, we may not obtain approval from the FDA to use this pathway.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also encounter delays or rejections based on changes in regulatory agency policies during the period in which we develop a product and the period required for review of any application for regulatory agency approval of a particular product. Resolving such delays could force us or third parties to incur significant costs, limit our allowed activities or the allowed activities of third parties, diminish any competitive advantages that we or our third parties may attain or adversely affect our ability to receive royalties, any of which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will not be able to commercialize ARIKAYCE if the Lamira Nebulizer System is not approved or cleared for use as a delivery system for ARIKAYCE by regulators in additional markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARIKAYCE is administered using the Lamira Nebulizer System, and the Lamira Nebulizer System must receive regulatory approval or clearance on its own or in conjunction with ARIKAYCE as a combination product in order for us to develop and commercialize ARIKAYCE in a given market. The FDA granted accelerated approval of the Lamira Nebulizer System with ARIKAYCE as part of the approval of the drug/device combination product, and the Lamira Nebulizer System is CE marked by PARI in Europe. However, outside the US and Europe, the Lamira Nebulizer System is labeled as investigational for use in our clinical trials, including in Japan, Canada and Australia, and is not approved for commercial use in Canada or certain other markets in which we may seek to commercialize ARIKAYCE in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek regulatory approval in markets in which the Lamira Nebulizer System is not approved and we and PARI are not successful in obtaining approval for the Lamira Nebulizer System, our ability to commercialize ARIKAYCE in those markets would be materially impaired. In addition, failure to maintain regulatory approval or clearance of the Lamira Nebulizer System could result in increased development costs, withdrawal of regulatory approval, and delays in ARIKAYCE reaching the market. Failure to obtain or maintain regulatory approval or clearance of the Lamira Nebulizer System could result in potential loss of regulatory approval or otherwise materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our clinical studies do not produce positive results or our clinical trials are delayed, or if serious side effects are identified during drug development, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates in the US, Europe, Japan or other markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of our product candidates, we must conduct, at our own expense, extensive preclinical tests to demonstrate the safety of our product candidates in animals, and clinical trials to demonstrate the safety and efficacy of our product candidates in humans. If we experience delays in our clinical trials or other testing or the results of these trials or tests are not positive or are only modestly positive, including with respect to safety, we may:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Experience increased product development costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Be delayed in obtaining, or be unable to obtain, regulatory approval for one or more of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obtain approval for indications or patient populations that are not as broad as intended or entirely different than those indications for which we sought approval or with labeling with boxed warnings or other warnings or contraindications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Need to change the way the product is administered; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Have regulatory authorities withdraw, or suspend, their approval of the product or impose risk mitigation strategies such as restrictions on distribution or other REMS;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Face a shortened patent protection period during which we may have the exclusive right to commercialize our products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Have competitors that are able to bring similar products to market before us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Be sued for alleged injuries caused to patients using our products&#894; or</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suffer reputational damage.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such circumstances would impair our ability to commercialize our products and harm our business and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enroll enough patients to conduct and complete our clinical trials or retain a sufficient number of patients in our clinical trials to generate the data necessary for regulatory approval of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion rate of our clinical trials is dependent on, among other factors, the patient enrollment rate. Patient enrollment is a function of many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Investigator identification and recruitment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approvals to initiate study sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient population size;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The nature of the protocol to be used in the trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient proximity to clinical sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eligibility criteria for the trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patient willingness to participate in the trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Discontinuation rates; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition from other companies&#8217; potential clinical trials for the same patient population.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment for our clinical trials, including in the confirmatory clinical trial for ARIKAYCE, like those we encountered in enrolling the CONVERT study, could increase costs and delay commercialization and sales, if any, of our products. Once enrolled, patients may elect to discontinue participation in a clinical trial at any time. If patients elect to discontinue participation in our clinical trials at a higher rate than expected, we may be unable to generate the data required by regulators for approval of our product candidates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties including collaborators, CROs, clinical and analytical laboratories, contract manufacturing organizations (CMOs) and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products may be materially adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties for significant research, analytical services, preclinical development, clinical development and manufacturing of our product candidates and commercial scale manufacturing of ARIKAYCE and the Lamira Nebulizer System. For example, we do not own facilities for clinical-scale or commercial manufacturing of our product candidates. We currently rely on Resilience Biotechnologies Inc. (Resilience) (formerly Therapure Biopharma Inc.) and Ajinimoto Althea, Inc. (Althea) to provide our clinical and commercial supply of ARIKAYCE, and intend to rely on Patheon in the future. Additionally, almost all of our clinical trial work is done by CROs, such as PPD Development, L.P., our CRO for the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARISE, ENCORE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ASPEN</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> trials,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clinical laboratories. Reliance on these third parties poses a number of risks, including the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The diversion of management time and cost of third-party advisers associated with the negotiation, documentation and implementation of agreements with third parties in the pharmaceutical industry;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to control whether third parties devote sufficient resources to our programs or products, including with respect to meeting contractual deadlines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to control the regulatory and contractual compliance of third parties, including their quality systems, processes and procedures, systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to establish and implement collaborations or other alternative arrangements on favorable terms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes with third parties, including CROs, leading to loss of intellectual property rights, delay or termination of research, development, or commercialization of product candidates or litigation or arbitration; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contracts with our collaborators fail to provide sufficient protection of our intellectual property; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty enforcing our contractual rights if one of these third parties fails to perform.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our product candidates, and the failure of these third parties to appropriately carry out such evaluation and selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity could delay or otherwise adversely affect approval of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, the Lamira Nebulizer System or our product candidates to meet our required supply for commercialization or clinical studies, which would materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any in-house manufacturing capability other than for small-scale preclinical development programs and depend completely on a small number of third-party manufacturers and suppliers for the manufacture of our product candidates on a clinical or commercial scale. For instance, we are and expect to remain dependent upon Resilience, Althea and eventually Patheon to supply ARIKAYCE both for our clinical trials and commercial sale. Althea manufactures ARIKAYCE at a relatively small scale; Resilience, operates at a larger scale than Althea. We may not be able to maintain adequate quantities to meet future demand. As additional supporting data become available, we believe the current approved shelf life for product manufactured at our CMOs will increase. If we encounter delays or difficulties in the manufacturing process that disrupt our ability to supply our distributors with ARIKAYCE, we may experience a product stock-out, which would likely have a material adverse effect on our business and reputation. In addition, we have entered into certain agreements with Patheon related to increasing our long-term production capacity for ARIKAYCE commercial inventory, although Patheon&#8217;s supply obligations will commence only after certain technology transfer and construction services are completed. Any delay in the commencement of Patheon&#8217;s supply obligations, whether due to delays in technology transfer and construction or from adding Patheon to our NDA as a CMO, would increase the risks associated with either Resilience or Althea being unable to provide us with an adequate supply of ARIKAYCE. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also dependent upon PARI being able to provide an adequate supply of nebulizers both for commercial sale of ARIKAYCE and any ongoing clinical trials, as PARI is the sole manufacturer of the Lamira Nebulizer System. We have no alternative supplier for the nebulizer, and because significant effort and time were expended in the optimization of the nebulizer for use with ARIKAYCE, we do not intend to seek an alternative or secondary supplier. In the event PARI cannot provide us with sufficient quantities of the nebulizer, replication of the optimized device by another party would likely require considerable time and additional regulatory approval. In the case of certain specified supply failures, we have the right under our commercialization agreement with PARI to make the nebulizer and have it made by certain third parties, but not those deemed under the commercialization agreement to compete with PARI.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate suppliers or enter into favorable agreements with them. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inadequate supply of ARIKAYCE or the Lamira Nebulizer System would likely harm our commercial efforts or delay or impair clinical trials of ARIKAYCE or our product candidates and adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacturing facilities of our third-party manufacturers are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we and our manufacturing partners fail to comply with the regulations or maintain the approvals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of ARIKAYCE, the Lamira Nebulizer System and our product candidates are subject to cGMP, Quality System Regulations and similar standards. While we have policies and procedures in place to select third-party manufacturers for our product and product candidates that adhere, and monitor their adherence to, such standards, they may nonetheless fail to do so. Similarly, while we have entered into a Commercialization Agreement with PARI for the manufacture of the Lamira Nebulizer System for use with ARIKAYCE, PARI may fail to adhere to applicable standards. These manufacturers and their facilities will be subject to periodic review and inspections by the FDA and other regulatory authorities following regulatory approval of our products, as with ARIKAYCE. For instance, to monitor compliance with applicable regulations, the FDA routinely conducts inspections of facilities and may identify potential deficiencies. The FDA issues what are referred to as &#8220;Form 483s&#8221; that set forth observations and concerns identified during its inspections. Failure to satisfactorily address the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerns or potential deficiencies identified in a Form 483 could result in the issuance of a warning letter, which is a notice of the issues that the FDA believes to be significant regulatory violations requiring prompt corrective actions. Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements could result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one of these manufacturers fails to maintain compliance with regulatory requirements or experiences supply problems, including in the scale-up of commercial production, the production of ARIKAYCE, the Lamira Nebulizer System and our product candidates could be interrupted, resulting in delays, additional costs or restrictions on the marketing or sale of our products. An alternative manufacturer would need to be qualified, through regulatory filings, which could result in further delay. The regulatory authorities may also require additional testing if a new manufacturer is relied upon for commercial production. In addition, with respect to our product candidates, our manufacturers and their facilities are subject to pre-approval cGMP inspection by the FDA and other regulatory authorities, and the findings of the cGMP inspection could result in a failure to obtain, or a delay in obtaining, regulatory approval for future product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Operation of our Business</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend heavily on our management team and our principal clinical and commercial personnel, the loss of whose services might significantly delay or prevent the achievement of our research, development or commercialization objectives. Our success depends, in large part, on our ability to attract and retain qualified management, clinical and commercial personnel, and on our ability to develop and maintain important relationships with commercial partners, leading research institutions and key distributors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel in our industry and market is intense because of the numerous pharmaceutical and biotechnology companies that seek similar personnel. These companies may have greater financial and other resources, offer a greater opportunity for career advancement and have a longer history in the industry than we do. We also experience competition for the hiring of our clinical and commercial personnel from universities, research institutions, and other third parties. We cannot assure that we will attract and retain such persons or maintain such relationships. Our inability to retain and attract qualified employees would materially harm our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our commercialization of ARIKAYCE in the US and Europe, and our continued international expansion efforts, we expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, quality, commercial compliance, medical affairs, and sales and marketing. For example, we plan to continue to hire additional personnel to support ARIKAYCE and the advancement of our pipeline programs. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to the limited experience of our management team in managing a company with this anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, which could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any acquisitions we make, or collaborative relationships we enter into, may not be clinically or commercially successful, and may require financing or a significant amount of our available cash, which could adversely affect our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may effect acquisitions to obtain additional businesses, products, technologies, capabilities and personnel. Acquisitions involve a number of operational risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to achieve expected synergies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulty and expense of assimilating the operations, technology and personnel of any acquired business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to retain the management, key personnel and other employees of any acquired business;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability to maintain any acquired company&#8217;s relationship with key third parties, such as alliance partners;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Exposure to legal claims or other liabilities for activities of any acquired business prior to acquisition;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diversion of our management&#8217;s attention from our core business; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential impairment of intangible assets, adversely affecting our reported results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may enter into collaborative relationships that would involve our collaborators conducting proprietary development programs. Disagreements with collaborators may develop over the rights to our intellectual property, and any conflict with our collaborators could limit our ability to obtain future collaboration agreements and negatively influence our relationship with existing collaborators. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we make one or more significant acquisitions or enter into a significant collaboration in which the consideration includes cash, we may be required to use a substantial portion of our available cash and/or need to raise additional capital, which could adversely affect our financial condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to product liability claims, and we have only limited product liability insurance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture and sale of human therapeutic products involve an inherent risk of product liability claims, particularly as we now commercialize ARIKAYCE in the US and Europe. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased demand for ARIKAYCE and any other products that we may commercialize, and a corresponding loss of revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Substantial monetary awards to patients or trial participants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant time and costs to defend the related litigation&#894;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawal or reduced enrollment of clinical trial participants; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reputational harm and significant negative media attention.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only limited product liability insurance for our products. We do not know if we will be able to maintain existing, or obtain additional, product liability insurance on acceptable terms or with adequate coverage against potential liabilities. This type of insurance is expensive and may not be available on acceptable terms. If we are unable to obtain or maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to commercialize our products. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts and may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations, including our drug development programs, could be materially disrupted in the event of system failures, security breaches, violations of data protection laws or data loss or damage by us or our CROs or other contractors or consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary business information and that of our suppliers, as well as personally identifiable information of clinical trial participants and employees. Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such an event could have a material adverse effect on our business operations, including a material disruption of our drug development and commercialization programs. Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. In addition, the loss of clinical trial data for our product candidates could result in delays in our regulatory submission and approval efforts and significantly increase our costs to recover or reproduce the data, if possible. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have general liability insurance coverage, including coverage for errors and omissions, our insurance may not cover all claims, continue to be available on reasonable terms or be sufficient in amount to cover one or more large claims; additionally, the insurer may disclaim coverage as to any claim. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience operating internationally, are subject to a number of risks associated with our international activities and operations and may not be successful in our efforts to expand internationally.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited operations outside of the US. As of December&#160;31, 2020, we had 74 employees located in Europe and 44 employees located in Japan, although we have clinical trial sites and suppliers located around the world. In order to meet our long-term goals, we expect to grow our international operations over the next several years, including in Europe and Japan, and continue to source material used in the manufacture of our product candidates from abroad. Consequently, we are and will continue to be subject to risks related to operating in foreign countries, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limited experience with international regulatory requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An inability to achieve optimal pricing and reimbursement for ARIKAYCE, if approved in another jurisdiction, or subsequent changes in reimbursement, pricing and other regulatory requirements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any implementation of, or changes to, tariffs, trade barriers and other import-export regulations in the US or other countries in which we, or our third-party partners, operate;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unexpected adverse events related to ARIKAYCE or our product candidates occurring in foreign markets that we have not experienced in the US;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Economic and political conditions, including geopolitical events, such as war and terrorism, foreign currency fluctuations and inflation, which could result in reduced revenue, increased or unpredictable operating expenses and other obligations incident to doing business in, or with a company located in, another country;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes resulting from the UK's exit from the EU, including: (i) the uncertainty and instability in economic and market conditions; (ii) the uncertainty regarding the UK&#8217;s access to the EU Single Market and the impact on the wider trading, legal, regulatory and labor environments; and (iii) the uncertainty in the European regulatory framework, including the relocation of the EMA from the UK to the Netherlands, and the subsequent potential disruption and delay of EMA regulatory actions and, following the transition period, UK regulatory actions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with foreign or US laws, rules and regulations, including data privacy requirements, labor relations laws, tax laws, anti-competition regulations, import, export and trade restrictions, anti-bribery/anti-corruption laws, regulations or rules, which could lead to actions by us or our distributors, manufacturers, other third parties who act on our behalf or with whom we do business in foreign countries or our employees who are working abroad that could subject us to investigation or prosecution under such foreign or US laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other risks associated with our international operations may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. Our future success will depend in large part on our ability to maintain a competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Compounds, products or processes that we develop may become obsolete before we recover any expenses incurred in connection with their development. We face substantial competition from pharmaceutical, biotechnology and other companies, universities and research institutions with respect to NTM lung disease, bronchiectasis, and pulmonary arterial hypertension (PAH). Relative to us, most of these entities have substantially greater capital resources, research and development staffs, facilities and experience in conducting clinical studies, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. Many of our competitors may achieve product commercialization or obtain patent protection earlier than us. Furthermore, we believe that our competitors have used, and may continue to use, litigation to gain a competitive advantage. Our competitors may also use different technologies or approaches to develop products similar to ARIKAYCE and our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that competing successfully will depend, among other things, on the relative speed with which we can develop products, complete the clinical testing and regulatory approval processes and supply commercial quantities of the product to the market, as well as product efficacy, safety, reliability, availability, timing and scope of regulatory approval and price. We expect competition to increase as technological advances are made and commercial applications broaden. There are potential competitive products, both approved and in development, which include oral, systemic, or inhaled antibiotic products to treat chronic respiratory infections. For instance, certain entities have expressed interest in studying their products for lung disease and are seeking to advance studies in lung disease, including NTM lung disease caused by mycobacterial species other than MAC. We are not aware of any entities currently conducting clinical trials for the treatment of refractory MAC lung disease or of any other approved inhaled therapies specifically indicated for NTM lung disease in North America, Europe or Japan. If any of our competitors develops a product that is more effective, safe, tolerable or, convenient or less expensive than ARIKAYCE or our product candidates, it would likely materially adversely affect our ability to generate revenue. We also may face lower priced generic competitors if third-party payors encourage use of generic or lower-priced versions of our product or if competing products are imported into the US or other countries where we may sell ARIKAYCE. In addition, in an effort to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">put downward pressure on drug pricing, Congress and the FDA are working to facilitate generic competition, which could result in our experiencing competition earlier than otherwise would be the case.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also other amikacin products that have been approved by the FDA, MHLW and other regulatory agencies for use in other indications, and physicians may elect to prescribe those products rather than ARIKAYCE to treat the indications for which ARIKAYCE has received approval, which is commonly referred to as off-label use. Although regulations prohibit a drug company from promoting off-label use of its product, the FDA and other regulatory agencies do not regulate the practice of medicine and cannot direct physicians as to what product to prescribe to their patients. As a result, we would have limited ability to prevent any off-label use of a competitor&#8217;s product to treat diseases for which we have received FDA or other regulatory agency approval, even if this use violates our patents or any statutory exclusivities that the FDA may grant for the use of amikacin to treat such diseases. If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property rights adequately, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical, scientific and factual questions, and our success depends in large part on our ability to protect our proprietary technology and to obtain and maintain patent protection for our products, prevent third parties from infringing our patents, both domestically and internationally. We have sought to protect our proprietary position by filing patent applications in the US and abroad related to our novel technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies or from developing competing products and technologies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection or otherwise provide us with any competitive advantage. Any conclusions we may reach regarding non-infringement, inapplicability or invalidity of a third-party&#8217;s intellectual property vis-&#224;-vis our proprietary rights, or those of a licensor, are based in significant part on a review of publicly available databases and other information. There may be information not available to us or otherwise not reviewed by us that could render these conclusions inaccurate. Our competitors may also be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, patents issued to us or our licensors may be challenged, narrowed, invalidated, held to be unenforceable or circumvented through litigation, which could limit our ability to stop competitors from marketing similar products or reduce the term of patent protection for amikacin liposome inhalation suspension or our product candidates. US patents and patent applications may also be subject to interference or derivation proceedings, and US patents may be subject to re-examination proceedings, reissue, post-grant review and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review in the USPTO. Our foreign patents have been and may be in the future subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property-ARIKAYCE Patents and Trade Secrets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1 of Part I of this Annual Report on Form 10-K for more information on our European patents that have been previously opposed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either patent laws or in interpretations of patent laws in the US and other countries may also diminish the value of our intellectual property or narrow the scope of our patent protection, including making it easier for competitors to challenge our patents. For example, the America Invents Act included a number of changes to established practices, including the transition to a first-inventor-to-file system and new procedures for challenging patents and implementation of different methods for invalidating patents.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of ARIKAYCE and our product candidates could be materially diminished.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, advisors, collaborators, and other third parties and partners to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information or may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, third parties may independently develop or discover our trade secrets and proprietary information. Regulators also may disclose information we consider to be proprietary to third parties under certain circumstances, including in response to third-party requests for such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure under the Freedom of Information Act or comparable laws. Additionally, the FDA, as part of its Transparency Initiative, continues to consider whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time whether and how the FDA&#8217;s disclosure policies may change in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world, which could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal systems of some foreign countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. Many companies have encountered significant problems in protecting and defending intellectual property rights in such foreign jurisdictions. For example, certain foreign countries have compulsory licensing laws under which a patent owner may be required to grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. This legal environment could make it difficult for us to stop the infringement of our patents or in-licensed patents or the misappropriation of our other intellectual property rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, and our efforts to protect our intellectual property rights in such countries may be inadequate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The drug research and development industry has a history of intellectual property litigation, and we could become involved in costly intellectual property disputes, which could delay or impair our product development efforts or prevent us from, or increase the cost of, commercializing ARIKAYCE or any other approved product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may claim that we have infringed upon or misappropriated their proprietary rights. Any existing third-party patents, or patents that may later issue to third parties, could negatively affect our commercialization of ARIKAYCE, brensocatib, TPIP or any other product candidate that receives regulatory approval. For instance, PAH is a competitive indication with established products, including other formulations of treprostinil. Our supply of the active pharmaceutical ingredient for TPIP is dependent upon a single supplier. The supplier owns patents on its manufacturing process, and we have filed patent applications for TPIP; however, a competitor in the PAH indication may claim that we or our supplier have infringed upon or misappropriated its proprietary rights. Moreover, in the event that we pursue approval of TPIP, or any other product candidate, via the 505(b)(2) regulatory pathway, we will be required to file a certification against any unexpired patents listed in the Orange Book for the third-party drug we rely upon as part of our regulatory submission. This certification process may lead to litigation and could also delay launch of a product candidate, if approved by regulators.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of successful litigation or settlement of claims against us for infringement or misappropriation of a third-party&#8217;s proprietary rights, we may be required to take actions including but not limited to the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Paying damages, including up to treble damages, royalties, and the other party&#8217;s attorneys&#8217; fees, which may be substantial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ceasing development, manufacture, marketing and sale of products or use of processes that infringe the proprietary rights of others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expending significant resources to redesign our products or our processes so that they do not infringe the proprietary rights of others, which may not be possible, or may result in significant regulatory delays associated with conducting additional clinical trials or other steps to obtain regulatory approval; and/or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquiring one or more licenses from third parties, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also have to undertake costly litigation or engage in other proceedings, such as interference or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, to enforce or defend the validity of any patents issued or licensed to us, to confirm the scope and validity of our or a licensor&#8217;s proprietary rights or to defend against allegations that we have infringed a third-party&#8217;s intellectual property rights. Any proceedings regarding our intellectual property rights are likely to be time consuming and may divert management attention from operation of our business, and could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain of the agreements to which we are, or may become, a party relating to ARIKAYCE and our product candidates impose, or may in the future impose, restrictions on our business or other material obligations on us. If we fail to comply with these obligations, our business could be adversely affected, including as a result of the loss of license rights that are important to our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various agreements related to ARIKAYCE and our product candidates, including licensing agreements with PARI and AstraZeneca, which we view as material to our business. For additional information regarding the terms of these agreements, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business-License and Other Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1 of Part I of this Annual Report on Form 10-K. These agreements impose a number of obligations on us and our business, including restrictions on our ability to freely develop or commercialize our product candidates and requirements to make milestone and royalty payments to our counterparties upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain events. Under our license agreement with AstraZeneca, AstraZeneca retains a right of first negotiation pursuant to which it may exclusively negotiate with us before we can negotiate with a third-party regarding any transaction to develop or commercialize brensocatib, subject to certain exceptions. While this right of first negotiation is not triggered by a change of control, it may impede or delay our ability to consummate certain other transactions involving brensocatib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with our obligations under these agreements, our counterparties may have the right to take action against us, up to and including termination of a relevant license. For instance, under our licensing agreement with PARI, with respect to NTM lung disease and bronchiectasis, we have specific obligations to use commercially reasonable efforts to achieve certain developmental and regulatory milestones by set deadlines. Additionally, for NTM lung disease, we are obligated to use commercially reasonable efforts to achieve certain commercial milestones in Europe. The consequences of our failing to use commercially reasonable efforts to achieve certain commercial milestones are context-specific, but include ending PARI&#8217;s non-compete obligation, making the license non-exclusive and terminating the license, in each case with respect to the applicable indication. Similarly, under our license agreement with AstraZeneca, AstraZeneca may terminate our license to brensocatib if we fail to use commercially reasonable efforts to develop and commercialize a product based on brensocatib, or we are subject to a bankruptcy or insolvency. Reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms and may materially harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, if we do not proceed with the development of our ARIKAYCE program in the NTM lung disease or CF indications, certain of our contract counterparties may elect to proceed with the development of these indications.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government healthcare reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration and the then-majority party in the Senate indicated their desire to repeal the ACA and, in December 2017, Congress repealed the ACA's individual mandate, i.e., the penalty imposed on individuals who do not obtain healthcare coverage. It is unclear what the effect of this partial repeal will be and whether, when and how repeal of other sections of the law may be effectuated and what the effect on the healthcare sector will be. In December 2018, a federal district court judge in Texas found the ACA to be unconstitutional, although the ruling was stayed while the case is appealed. In December 2019, the US Court of Appeals for the Fifth Circuit found the individual mandate to be unconstitutional and remanded the case to the district court to determine whether the individual mandate provision is severable from the rest of the law. The district court&#8217;s ruling remains stayed pending appeal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The case is currently under consideration by the U.S. Supreme Court, and a decision is expected by mid-2021. It is unclear what the outcome of this litigation and other pending challenges to the ACA's constitutionality, as well as the effect of these matters on the healthcare sector, will be. President Trump had indicated an interest in taking steps to lower drug prices, such as having the federal government negotiate drug prices with pharmaceutical manufacturers and/or in indexing certain federally reimbursement payments to international drug prices. The incoming Biden Administration has also indicated that lowering prescription drug prices is a priority. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reimbursement of Pharmaceutical Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1 of Part I of this Annual Report on Form 10-K for more information. Changes to the ACA, to the Medicare or Medicaid programs, or to the ability of the federal government to negotiate or otherwise affect drug prices, or other federal legislation regarding healthcare access, financing or legislation in individual states, could affect our business, financial condition, results of operations and prospects and the value of our common stock. It remains unclear how any new legislation or regulation might affect the prices we may obtain for ARIKAYCE or any of our product candidates for which regulatory approval is obtained. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found in violation of federal or state &#8220;fraud and abuse&#8221; laws, we may be required to pay a penalty or may be suspended from participation in federal or state healthcare programs, which may adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the US, we are subject to various federal and state healthcare &#8220;fraud and abuse&#8221; laws, including anti-kickback laws, false claims laws and other laws intended to reduce fraud and abuse in federal and state healthcare programs. Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the US government, and our business, financial condition, results of operations and prospects and the value of our common stock may be adversely affected. Our reputation could also suffer. In addition, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several states.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ACA, we are required to report information on payments or transfers of value to US physicians and teaching hospitals, which is posted in searchable form on a public website. Failure to submit required information may result in civil monetary penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. In addition to the federal government, some states, as well as other countries, including France, require the disclosure of certain payments to healthcare professionals. The federal privacy regulations under HIPAA, state, and foreign medical record privacy laws may limit access to information identifying those individuals who may be prospective users. There are ambiguities as to what is required to comply with these requirements, and we could be subject to penalties if it is determined that we have failed to comply with an applicable legal requirement. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws and trade control laws, as well as other laws governing our operations. If we fail to comply with these laws, we could be subject to negative publicity, civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the US Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and other anti-corruption laws that apply in countries where we do business. The FCPA, UK Bribery Act and these other laws generally prohibit us, our employees and our intermediaries from making prohibited payments to government officials or other persons to obtain or retain business or gain some other </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantage. We have conducted various studies at a broad range of trial sites around the world. Certain of these jurisdictions pose a risk of potential FCPA violations, and we have relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the US Department of Commerce&#8217;s Bureau of Industry and Security, the US Department of Treasury&#8217;s Office of Foreign Assets Control, and various non-US government entities, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, currency exchange regulations and transfer pricing regulations (collectively, Trade Control laws).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and prospects and the value of our common stock. Likewise, even an investigation by US or foreign authorities of potential violations of the FCPA other anti-corruption laws or Trade Control laws could have an adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If another party obtains orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition. The company that obtains the first regulatory approval from the FDA for a designated orphan drug for a rare disease generally receives marketing exclusivity for use of that drug for the designated condition for a period of seven years. Similar laws exist in the EU with a term of 10 years. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business-Government Regulation-Orphan Drug Designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1 of Part I of this Annual Report on Form 10-K for additional information. If a competitor obtains approval of the same drug for the same indication or disease before us, and the FDA grants such orphan drug exclusivity, we would be prohibited from obtaining approval for our product for seven or more years, unless our product can be shown to be clinically superior. In addition, even if we obtain orphan exclusivity, the FDA may approve another product during our orphan exclusivity period for the same indication under certain circumstances.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our research, development and manufacturing activities used in the production of ARIKAYCE and our product candidates involve the use of hazardous materials, which could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development program and manufacturing activities for ARIKAYCE and our product candidates involve the controlled use of hazardous materials and chemicals. We generally contract with third parties for the disposal of these materials and wastes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we strive to comply with all pertinent regulations, the risk of environmental contamination, damage to facilities or injury to personnel from the accidental or improper use or control of these materials remains. In addition to any liability we could have for any misuse by us of hazardous materials and chemicals, we could also potentially be liable for activities of our CMOs or other third parties. Any such liability, or even allegations of such liability, could materially adversely affect our results of operations and financial condition. We also could incur significant costs as a result of civil or criminal fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Condition and Need for Additional Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of operating losses, expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses each previous year of our operation, except in 2009, when we sold our manufacturing facility and certain other assets to Merck &amp; Co, Inc. As of December&#160;31, 2020, our accumulated deficit was $1.8 billion. For the years ended December&#160;31, 2020, 2019 and 2018, our consolidated net loss was $294.1 million, $254.3 million and $324.3 million, respectively. Our ability to generate revenue will depend on the success of commercial sales of ARIKAYCE; however, we do not anticipate our revenue from the sale of ARIKAYCE will be sufficient for us to become profitable without reductions in our operating expenses. Despite our commercialization of ARIKAYCE in the US and Europe, we expect to continue to incur substantial operating expenses, and resulting operating losses, for the foreseeable future as we:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initiate or continue clinical studies of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Complete a post-marketing clinical trial of ARIKAYCE, as required by the FDA&#894;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seek to discover or in-license additional product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Seek regulatory approvals for ARIKAYCE in additional foreign markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Scale-up manufacturing capabilities for future ARIKAYCE production, including the increase of production capacity at Patheon and process improvements in order to manufacture at a larger commercial scale&#894; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Enhance operational, compliance, financial, quality and information management systems and hire more personnel, including personnel to support our commercialization efforts and development of our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional funds to continue our operations, but we face uncertainties with respect to our ability to access capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. We expect to expend substantial financial resources to commercialize, fund the confirmatory post-marketing ARISE study and, where applicable, seek regulatory approval for ARIKAYCE as well as continue research and development of our product candidates, brensocatib and TPIP. We may need to raise additional capital to fund these activities, including due to changes in our product development plans or misjudgment of expected costs, to fund corporate development, to maintain our intellectual property portfolio or for other purposes, including to resolve litigation. As of December&#160;31, 2020, we had $532.8 million of cash and cash equivalents on hand. Our operating expenses and long-term investments were significantly higher in 2020 than in 2019, reflecting our continued investment in the build-out of our commercial organization to support global expansion activities for ARIKAYCE and manufacture of commercial inventory, which includes capital and long-term investments, and continued investment in research and development as well as selling, general and administrative expenses. We do not know whether additional financing will be available when needed, or, if available, whether the terms will be favorable. If adequate funds are not available to us when needed, we may be forced to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have outstanding indebtedness in the form of convertible senior notes, and may incur additional indebtedness in the future, which could adversely affect our financial position, prevent us from implementing our strategy, and dilute the ownership interest of our existing shareholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we completed an underwritten public offering of 1.75% convertible senior notes due 2025 (the Convertible Notes). The Convertible Notes may be convertible into common stock at an initial conversion rate of 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes. We sold $450.0 million aggregate principal amount of the Convertible Notes, including the exercise in full of the underwriters&#8217; option to purchase additional Convertible Notes, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in net proceeds of approximately $435.8 million. Holders of the Convertible Notes may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. On or after October 15, 2024 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their Convertible Notes at any time. Upon conversion of the Convertible Notes, we may deliver cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree to which we are leveraged could have negative consequences, such as the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be more vulnerable to economic downturns, less able to withstand competitive pressures, and less flexible in responding to changing economic conditions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to obtain financing in the future may be limited;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A substantial portion of our cash flows from operations in the future may be required for the payment of the principal amount of the Convertible Notes when they or any additional indebtedness become due&#894; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may elect to make cash payments upon conversion of the Convertible Notes, which would reduce our available cash.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to pay principal or interest on or, if desired, to refinance our indebtedness, including the Convertible Notes, depends on our future performance, which is subject to economic, financial, competitive and other factors, some of which are beyond our control. Our business may not generate cash flow from operations in the future sufficient to satisfy any obligations under the Convertible Notes to make cash payments to noteholders or our obligations under any future indebtedness we may incur. If we are unable to generate such cash flow, we may be required to delay, restrict or eliminate all or a portion of our development programs or commercialization efforts or refinance or obtain additional equity capital on terms that may be onerous or highly dilutive. If we do not meet our debt obligations, it could materially adversely affect our results of operations, financial condition and the value of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion of some or all of the Convertible Notes will dilute the ownership interests of our existing shareholders to the extent we deliver shares upon their conversion. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock could depress the price of our common stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The accounting method for the Convertible Notes may have an adverse effect on our reported financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance requires that we separately account for the liability and equity components of the Convertible Notes because they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. As a result, the equity component of the Convertible Notes is required to be included in the additional paid-in capital section of shareholders&#8217; equity on our consolidated balance sheet, and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the Convertible Notes. We may report greater net loss (or lower net income) in our financial results because this guidance requires interest to include both the current period&#8217;s amortization of the debt discount and the instrument&#8217;s coupon interest, which could adversely affect our reported or future financial results, the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding October 15, 2024 only under certain circumstances. For example, after the quarter ending March 31, 2018, holders may convert their Convertible Notes at their option during any quarter (and only during such quarter) if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding quarter is greater than or equal to 130% of the conversion price on each applicable trading day. If the Convertible Notes become convertible prior to October 15, 2024, we may be required to reclassify our Convertible Notes and the related debt issuance costs as current liabilities and certain portions of our equity outside of equity to mezzanine equity, which would have an adverse impact on our reported financial results for such quarter, and could have an adverse impact on the market price of our common stock and the trading price of the Convertible Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to use certain of our net operating losses and other tax assets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial tax loss carry forwards for US federal income tax and state income tax purposes, and beginning in 2015, we had tax loss carry forwards in Ireland as well. In general, our net operating losses and tax credits have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. In particular, our ability to fully use certain US tax loss carry forwards and general business tax credit carry forwards recorded prior to December 2010 to offset future income or tax liability is limited under section 382 of the Internal Revenue Code of 1986, as amended (the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Code). Changes in the ownership of our stock, including those resulting from the issuance of shares of our common stock offerings or upon exercise of outstanding options, may limit or eliminate our ability to use certain net operating losses and tax credit carry forwards in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our stock has been and may continue to be highly volatile, which could lead to shareholder litigation against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol &#8220;INSM&#8221;. The market price of our stock has been and may continue to be highly volatile and could be subject to wide fluctuations in price in response to various factors, including those discussed herein, many of which are beyond our control. In addition, the stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for emerging biotechnology and pharmaceutical companies like us, and which have often been unrelated to their operating performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, when the market price of a stock has been volatile, shareholders are more likely to institute securities and derivative class action litigation against the issuer of such stock. We previously faced a shareholder suit following a decline in our stock price. If any of our shareholders bring a lawsuit against us in the future, it could have a material adverse effect on our business. We have insurance policies related to some of the risks associated with our business, including directors&#8217; and officers&#8217; liability insurance policies; however, our insurance coverage may not be sufficient and our insurance carriers may not cover all claims in a given litigation. If we are not successful in our defense of claims asserted in shareholder litigation, those claims are not covered by insurance or they exceed our insurance coverage, we may have to pay damage awards, indemnify our executive officers, directors and third parties from damage awards that may be entered against them and pay our and their costs and expenses incurred in defense of, or in any settlement of, such claims. In addition, such shareholder suits could divert the time and attention of management from our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements between us and our employees could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements with our employees could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The requirement that shareholders provide advance notice when nominating director candidates to serve on our board of directors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The inability of shareholders to convene a shareholders&#8217; meeting without the chairman of the board, the president or a majority of the board of directors first calling the meeting.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition to severance agreements with our officers and provisions in our incentive plans that permit acceleration of equity awards upon a change in control, a severance plan for eligible full-time employees that provides such employees with severance equal to six months of their then-current base salaries in connection with a termination of employment without cause upon, or within 18 months following, a change in control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously had a shareholder rights plan, or &#8220;poison pill,&#8221; which expired in May 2011. Under Virginia law, our board of directors may implement a new shareholders&#8217; rights plan without shareholder approval. Our board of directors intends to regularly consider this matter, even in the absence of specific circumstances or takeover proposals, to facilitate its future ability to quickly and effectively protect shareholder value.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease 117,022 square feet of office space for our corporate headquarters in Bridgewater, New Jersey. The initial lease, which commenced in the fourth quarter of 2019, provides us a one-time option to expand the leased premises by up to 50,000 square feet prior to the fifth anniversary of the initial lease commencement. The initial term of this lease will expire in 2030.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease laboratory space located in Bridgewater for which the initial lease term expires in December 2021. In October 2018, we expanded this lease to a total of 28,002 square feet. In addition, we lease office space in France, Ireland, the Netherlands, Switzerland and Japan.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_31"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trading symbol is "INSM." Our common stock currently trades on the Nasdaq Global Select Market. As of February&#160;22, 2021, there were approximately 132 holders of record of our common stock.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We anticipate that we will retain all earnings, if any, to support operations and to finance the growth and development of our business for the foreseeable future. Any future determination as to the payment of dividends will be dependent upon these and any contractual or other restrictions to which we may be subject and, to the extent permissible thereunder, will be at the sole discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors our board of directors deems relevant at that time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among Insmed Incorporated, the NASDAQ Composite Index,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the S&amp;P 500 Index, the NASDAQ Pharmaceutical Index and the NASDAQ Biotechnology Index</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><img src="insm-20201231_g1.jpg" alt="insm-20201231_g1.jpg" style="height:408px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;$100 invested on 12/31/15 in stock or index, including reinvestment of dividends.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal year ending December&#160;31.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copyright&#169; 2021 Standard&#160;&amp; Poor's, a division of S&amp;P Global. All rights reserved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion also should be read in conjunction with our consolidated financial statements and the notes thereto contained elsewhere in this Annual Report on Form&#160;10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled Risk Factors, Cautionary Note Regarding Forward-Looking Statements and elsewhere herein, our actual results may differ materially from those anticipated in these forward-looking statements.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_49"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Our first commercial product, ARIKAYCE, was approved in the US in September 2018 and in the EU in October 2020. Our clinical-stage pipeline includes brensocatib and TPIP. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which we are developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders. We have legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK) and Japan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Part I, Item 1. "Business" for a summary of our ongoing commercial and clinical programs for ARIKAYCE and our ongoing clinical programs for brensocatib and TPIP.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2019, we had not generated significant revenue and through December&#160;31, 2020, we had an accumulated deficit of $1.8 billion. We have financed our operations primarily through the public offerings of our equity securities and debt financings. Although it is difficult to predict our future funding requirements, based upon our current operating plan, we anticipate that our cash and cash equivalents as of December&#160;31, 2020 will enable us to fund our operations for at least the next 12&#160;months.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to reduce our operating loss and begin to generate positive cash flow from operations depends on the continued success in commercializing ARIKAYCE, including expanding the commercial sale of ARIKAYCE to additional territories, as well as achieving positive results from the ARIKAYCE frontline clinical trial program in order to potentially reach more patients. Additionally, our continued success also depends on bringing additional clinical stage products to market, such as brensocatib and TPIP. We expect to continue to incur substantial expenses related to our research and development activities as we continue the ARIKAYCE frontline clinical program, conduct the Phase 3 ASPEN trial for brensocatib, and continue the required trials for TPIP. We also expect to continue to incur significant costs related to the commercialization of ARIKAYCE, especially as we anticipate launching in new markets. Our financial results may fluctuate from quarter to quarter and will depend on, among other factors, the net sales of ARIKAYCE; the scope and progress of our research and development efforts; and the timing of certain expenses. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such products and whether or when they may become profitable.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_55"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEY COMPONENTS OF OUR RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product revenues, net, consist primarily of net sales of ARIKAYCE in the US and Europe. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors.&#160;In December 2020, we began commercial sales of ARIKAYCE in Germany</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recognize revenue for product received by our customers net of allowances for customer credits, including prompt pay discounts, service fees, estimated rebates, including government rebates, such as Medicaid rebates and Medicare Part D coverage gap reimbursements in the US, chargebacks and returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (Excluding Amortization of Intangible Assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. We began capitalizing inventory upon FDA approval of ARIKAYCE. All costs related to inventory for ARIKAYCE prior to FDA approval were expensed as incurred and therefore not included in cost of product revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in our research and development functions, including medical affairs and program management. R&amp;D </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense also includes other internal operating expenses, the cost of manufacturing product candidates, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. Our R&amp;D expenses related to manufacturing our product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations (CMOs) that manufacture brensocatib and TPIP. Our R&amp;D expenses related to clinical trials are primarily related to activities at contract research organizations (CROs) that conduct and manage clinical trials on our behalf. These contracts with CROs set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts with CROs primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative (SG&amp;A) Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for our non-employee directors and personnel serving in our executive, finance and accounting, legal and compliance, commercial and pre-commercial, corporate development, field sales, information technology and human resource functions. SG&amp;A expenses also include professional fees for legal services, consulting services, including commercial activities, insurance, board of director fees, tax and accounting services and certain milestones related to ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ARIKAYCE, our intangible assets began to be amortized over their estimated useful lives. The fair values assigned to our intangible assets are based on estimates and assumptions we believe are reasonable based on available facts and circumstances. Unanticipated events or circumstances may occur that require us to review the assets for impairment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investment Income and Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income consists of interest and dividend income earned on our cash and cash equivalents. Interest expense consists primarily of the accretion of debt discount, contractual interest costs and the amortization of debt issuance costs related to our accretion of debt. Debt discount is accreted, and debt issuance costs are amortized, to interest expense using the effective interest rate method over the term of the debt. Our balance sheet reflects debt, net of the debt discount, debt issuance costs paid to the lender, and other third-party costs. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are committed to the safety and well-being of our workforce. In March 2020, we implemented a number of corporate initiatives in response to the novel coronavirus (SARS-CoV-2) global pandemic which manifests as COVID-19. These initiatives included a remote working policy for all employees in order to aid the global containment effort and allow infectious disease specialists and pulmonologists to focus exclusively on treating patients and containing the virus. The policy included all of the field-based therapeutic specialists and employees who support ARIKAYCE prescribers. Beginning on June 1, 2020, certain of our field-based employees who support ARIKAYCE prescribers were permitted to return to the field. To date, access to prescribers has been limited with significant regional variability. Our Arikares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> trainers are continuing to offer remote training for patients who initiate treatment with ARIKAYCE. While we continue to see use of ARIKAYCE, including new patient adds and continued prescription renewals, there remains a general uncertainty regarding the impact of COVID-19 on the ARIKAYCE patient population and physicians. Patients suffering from refractory NTM lung disease are typically older individuals with underlying lung conditions, and are often treated by infectious disease specialists and pulmonologists. These treating physicians are on the front lines in addressing this global pandemic and must now, understandably, focus their attention on COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many uncertainties regarding the COVID-19 pandemic, and we are closely monitoring the impact of the pandemic on all aspects of our business, including how it will impact our patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect our financial results and business operations through the year ended December 31, 2020, we are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to numerous uncertainties. We will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to our operations as necessary.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_58"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2020 and 2019 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview - Operating Results</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the year ended December&#160;31, 2020, included the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product revenues, net, increased $27.9 million, or 20.5%, as compared to the prior year as a result of the growth in ARIKAYCE net sales;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of product revenues (excluding amortization of intangibles) increased $15.7 million, or 64.7%, as compared to the prior year as a result of the increase in net sales of ARIKAYCE and the decrease in the benefit from the sale of inventory for which the cost was incurred prior to FDA approval of ARIKAYCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">R&amp;D expenses increased $49.4 million, or 37.5%, as compared to the prior year primarily resulting from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases in clinical development and research expenses related to our new clinical trials, achievement of a patient dosing milestone (resulting in a milestone payment obligation) in our agreement with AstraZeneca in December 2020, and an increase in compensation and benefit related expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">SG&amp;A expenses decreased $7.2 million, or 3.4%, as compared to the prior year resulting from decreases in professional fees and other external expenses related to ARIKAYCE; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amortization of intangible assets was consistent with the prior year; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense increased $1.9 million as compared to the prior year related primarily to finance lease interest expense for our corporate headquarters.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year ended December&#160;31, 2020 was $294.1 million, or $3.01 per share&#8212;basic and diluted, compared with a net loss of $254.3 million, or $3.01 per share&#8212;basic and diluted, for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Revenues, Net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consists of net sales of ARIKAYCE. The following table summarizes the sources of revenue for the years ended December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.350%"><tr><td style="width:1.0%"></td><td style="width:33.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, for the year ended December&#160;31, 2020 increased to $164.4 million as compared to $136.5 million in 2019 as a result of the growth in net sales of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Revenues (Excluding Amortization of Intangibles)</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangibles) for the years ended December&#160;31, 2020 and 2019 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:37.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangibles)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Cost of product revenues, as % of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangibles) increased by $15.7 million, or 64.7%, to $39.9 million for the year ended December&#160;31, 2020 as compared to $24.2 million in 2019. The increase in cost of product revenues (excluding amortization of intangibles) in the year ended December 31, 2020 was directly attributable to the increase in total revenues discussed above and a decrease in the benefit from the sale of inventory for which the cost was incurred prior to FDA approval of ARIKAYCE. All product costs incurred prior to FDA approval of ARIKAYCE in September 2018 were expensed as R&amp;D expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the years ended December&#160;31, 2020 and 2019 were comprised of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:42.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.331%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.390%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">External Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical development and research</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone payment to AstraZeneca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.4%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory, quality assurance, and medical affairs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;external expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,498&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,535&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.6%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other internal operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal&#8212;internal expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,157&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">R&amp;D expenses increased to $181.2 million during the year ended December&#160;31, 2020 from $131.7 million in 2019. The $49.4 million increase was primarily due to a $13.6 million increase in compensation and benefit related expenses and stock-based compensation due to an increase in headcount, a $13.3 million increase in clinical development and research costs related to the initiation of the ARIKAYCE frontline clinical trial program and the Phase 3 ASPEN trial of brensocatib, and the $12.5 million milestone payment obligation due to AstraZeneca upon the first dosing in our Phase 3 ASPEN trial.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">External R&amp;D expenses by product for the years ended December&#160;31, 2020 and 2019 were comprised of the following (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:37.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARIKAYCE external R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brensocatib external R&amp;D expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other external R&amp;D expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,678&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expect R&amp;D expenses to increase in 2021 relative to 2020 primarily due to our clinical trial activities and related spend including our Phase 3 ASPEN trial of brensocatib, our confirmatory clinical trial of ARIKAYCE in a front-line treatment setting for patients with MAC lung disease, and our TPIP clinical trials.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SG&amp;A Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the years ended December&#160;31, 2020 and 2019 were comprised of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:41.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.710%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease)</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and benefit related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and other external expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility related and other internal expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,698)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total SG&amp;A expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,796&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,183)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SG&amp;A expenses decreased to $203.6 million during the year ended December&#160;31, 2020 from $210.8 million in 2019. The $7.2 million decrease was primarily due to a $14.0 million decrease in professional fees and other external expenses resulting from a $10.2 million milestone related to agreements with CFFT in the prior year and the reduction of certain commercial activities in the current year due to COVID-19 restrictions. In addition, there was a $2.7 million decrease in facility related and other internal expenses due to decreases in travel and other office related expenses. These decreases were partially </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">offset by a $5.6 million increase in stock-based compensation and a $3.9 million increase in compensation and benefit related expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets for the years ended December&#160;31, 2020 and 2019 was $5.0 million and $5.0 million, respectively. Amortization of intangible assets is comprised of amortization of acquired ARIKAYCE R&amp;D and amortization of the milestones paid to PARI for the FDA and EMA approvals of ARIKAYCE.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $29.6 million for the year ended December&#160;31, 2020 as compared to $27.7 million for 2019. The $1.9 million increase in interest expense in the year ended December&#160;31, 2020 as compared to the prior year period relates to finance lease interest expense for our corporate headquarters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision was $1.4 million and $0.8 million for the years ended December&#160;31, 2020 and 2019, respectively. The income tax provision for the year ended December&#160;31, 2020 and December&#160;31, 2019 reflects the current income tax expense recorded as a result of taxable income in certain of our subsidiaries in Europe and Japan as well as a liability for certain state income taxes. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2019 and 2018</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please refer to the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019 for a comparative discussion of our fiscal years ended December&#160;31, 2019 and December&#160;31, 2018.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_61"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is considerable time and cost associated with developing potential pharmaceutical products to the point of regulatory approval and commercialization. We commenced commercial shipments of ARIKAYCE in October 2018. We expect to continue to incur operating losses at our US and certain international entities, as we plan to fund R&amp;D for ARIKAYCE, brensocatib, TPIP and our other pipeline programs, continue commercialization activities for ARIKAYCE in the US and Europe, continue to invest in pre-commercial and regulatory activities for ARIKAYCE in Japan, and other general and administrative activities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 2020, we completed an underwritten public offering of 11,155,000 shares of our common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares, a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t a public offering price of $23.25 per share. Our net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $13.5 million, were $245.9 million. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, we comple</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ted an underwritten public offering of 10,657,692 shares of common stock, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,042,307 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares at a public offering price of $26.00. Our net proceeds from the sale of the shares, after deducting underwriting discounts and commissions and other offering expenses of $16.0 million, were $261.1 million. The offering also included the sale of 400,000 shares from our Chair and Chief Executive Officer</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from which we received no proceed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we completed an underwritten public offering of $450.0 million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were $435.8 million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital to fund our operations, including continued commercialization of ARIKAYCE and future clinical trials related to ARIKAYCE, to design and conduct ongoing and future clinical trials for brensocatib and TPIP, and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. We believe we currently have sufficient funds to meet our financial needs for at least the next 12 months. We expect to opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise. We expect such additional funding, if any, would be used to continue to commercialize ARIKAYCE, to conduct further trials of ARIKAYCE, to develop brensocatib, TPIP and our other product candidates, or to pursue the license </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or purchase of other technologies or products and product candidates. During 2021, we plan to continue to support the commercialization of ARIKAYCE in the US and Europe, to continue to fund further clinical development of ARIKAYCE, brensocatib and TPIP, and to fund our global expansion efforts to support commercial launch activities in additional countries in Europe and pre-commercial activities in Japan including obtaining regulatory approvals for ARIKAYCE in Japan. Our cash requirements for the next 12 months will be impacted by a number of factors, the most significant of which we expect to be </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses related to our commercialization efforts and our ARISE and ENCORE clinical trials for ARIKAYCE, expenses related to the ASPEN trial and other development activities for brensocatib, and to a lesser extent, expenses related to the clinical development of TPIP.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had cash and cash equivalents of $532.8 million, as compared with $487.4 million as of December&#160;31, 2019. The $45.3 million increase was due to cash received from the underwritten public offering of our common stock in the second quarter of 2020, partially offset by cash used in operating activities and, to a lesser extent, cash used in investing activities. Our working capital was $504.1 million as of December&#160;31, 2020 as compared with $470.0 million as of December&#160;31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $219.3 million and $250.6 million for the years ended December&#160;31, 2020 and 2019, respectively. The net cash used in operating activities during the years ended December&#160;31, 2020 and 2019 was primarily for the commercial, clinical and manufacturing activities related to ARIKAYCE, as well as other SG&amp;A expenses and clinical trial expenses related to brensocatib. The decrease in cash used in operating </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities for the year ended December&#160;31, 2020 compared to 2019 was primarily due to increased cash collections from the sale of ARIKAYCE and the net change in working capital, driven by an in increase in accounts payable and accrued compensation and, to a lesser extent, a decrease in accounts receivable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $6.8 million and $42.3 million for the years ended December&#160;31, 2020 and 2019, respectively. The net cash used in investing activities during the years ended December&#160;31, 2020 and 2019 was primarily related to the investment in our long-term production capacity at Patheon.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $271.0 million and $285.3 million for the years ended December&#160;31, 2020 and 2019, respectively. Net cash provided by financing activities for the year ended December&#160;31, 2020 included net cash proceeds of $245.9 million from our underwritten public offering of 11,155,000 shares of common stock in the second quarter of 2020 and cash proceeds from stock option exercises. Net cash provided by financing activities during 2019 primarily included net cash proceeds of $261.1 million from our underwritten public offering of 10,657,692 shares of common stock in the second quarter of 2019 and cash proceeds from stock option exercises.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, we completed an underwritten public offering of $450.0 million aggregate principal amount of Convertible Notes pursuant to an indenture between the Company and Wells Fargo Bank, National Association, as trustee. Our net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. The Convertible Notes are convertible into common stock of the Company under certain circumstances described in the indenture. For more information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8 - Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our notes to the consolidated financial statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we entered into an agreement (the Lease) with Exeter 700 Route 202/206, LLC to lease 117,022 square feet of office space located in Bridgewater, New Jersey for our corporate headquarters. Subject to certain conditions, we have the one-time option to expand the leased premises by up to 50,000 rentable square feet, exercisable prior to the fifth anniversary of the Commencement Date, which was October 1, 2019. The initial Lease term runs 130 months from the Commencement Date and we have the option to extend that term for up to three additional five-year periods. In addition, we are responsible for operating expenses and taxes pursuant to the Lease. Future minimum payments under the Lease during the initial Lease Term are approximately $23.8 million. The Lease contains customary default provisions, including those relating to payment defaults, performance defaults and events of bankruptcy.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In February 2014, we entered into a contract manufacturing agreement with Therapure Biopharma Inc., which has been assumed by Resilience, for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, we collaborated with Resilience to construct a production area for the manufacture of ARIKAYCE in Resilience's existing manufacturing facility in Canada. The agreement has an initial term of five years, which began in October 2018, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">two years' prior written notice to the other party. Under the agreement, we are obligated to pay certain minimum amounts for the batches of ARIKAYCE produced each calendar year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Althea, for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, we are obligated to pay a minimum of $2.7&#160;million for the batches of ARIKAYCE produced each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, the agreement remains in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional two-year periods upon mutual written agreement of the Company and Althea at least one year prior to the expiration of its then-current term.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have a licensing agreement with PARI for the use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, we have rights under several US and foreign issued patents, and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit the system with ARIKAYCE for the treatment of such indications, but we cannot manufacture the nebulizers except as permitted under our Commercialization Agreement with PARI, as described below. The Lamira Nebulizer System has been approved for use in the US (in combination with ARIKAYCE) and the EU. Under the licensing agreement, we made an upfront license fee and milestone payments to PARI. Upon FDA acceptance of our NDA and the subsequent FDA and EMA approvals of ARIKAYCE, we made additional milestone payments of &#8364;1.0 million, &#8364;1.5&#160;million, and &#8364;0.5&#160;million, respectively, to PARI. In October 2017, we exercised an option to buy-down the royalties payable to PARI, which was included within selling, general and administrative expenses in the fourth quarter of 2017. PARI is entitled to receive royalty payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of the Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of 15 years that began in October 2018 (the Initial Term). The term of the Commercialization Agreement may be extended by us for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, we entered into certain agreements with Patheon related to the increase of our long-term production capacity for ARIKAYCE. The agreements provide for Patheon to manufacture and supply ARIKAYCE for our anticipated commercial needs.&#160;Under these agreements, we are required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. Our manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either we or Patheon have given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties. The aggregate investment to increase our long-term production capacity, including under the Patheon agreements and related agreements or purchase orders with third parties for raw materials and fixed assets, is estimated to be approximately $60 million.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2004 and 2009, we entered into research funding agreements with CFFT whereby we received $1.7 million and $2.2 million in research funding for the development of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, we owe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone payments to CFFT of $13.4 million in the aggregate, of which $1.0 million has been paid through December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are payable through 2025. Furthermore, if certain global sales milestones are met within five years of the commercialization of ARIKAYCE, we would owe up to an additional $3.9 million. We have determined the likelihood of meeting such global sales milestones and have accrued for these contingent obligations proportionally based on net sales of ARIKAYCE.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2020, we entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which we retained PPD to perform clinical development services in connection with certain of our clinical research programs. The master services agreement has an initial term of five years. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days&#8217; written notice, (ii) any project addendum in the event of the other party&#8217;s breach of the master services agreement or such project addendum upon 30 days&#8217; written notice, provided that such breach is not cured within such 30-day period, (iii) the master services agreement or any project addendum immediately upon the occurrence of an insolvency event with respect to the other party or (iv) any project addendum upon 30 days&#8217; written notice if (a) the continuation of the services under such project addendum would post material ethical or safety risks to study participants, (b) any approval from a regulatory authority necessary to perform the applicable study is revoked, suspended or expires without renewal or (c) in the reasonable opinion of such party, continuation of the services provided under such project addendum would be in violation of applicable law. We have entered into project addenda with PPD to perform clinical development services over several years for, but not limited to, our ARISE, ENCORE and ASPEN studies. We currently expect to incur approximately $200 million of costs related to these project addenda.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into the AZ License Agreement, pursuant to which AstraZeneca granted us exclusive global rights for the purpose of developing and commercializing AZD7986 (which we renamed brensocatib). In consideration of the licenses and other rights granted by AstraZeneca, we made an upfront payment of $30.0&#160;million, which was included as research and development expense in the fourth quarter of 2016. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we incurred a $12.5 million milestone payment obligation upon first dosing in a Phase 3 clinical trial of brensocatib. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make a series of additional contingent milestone payments to AstraZeneca totaling up to an additional $72.5&#160;million upon the achievement of clinical development and regulatory filing milestones. If we elect to develop brensocatib for a second indication, we will be obligated to make an additional series of contingent milestone payments totaling up to $42.5&#160;million, the first of which occurs at the initiation of a Phase 3 trial in the additional indication. We are not obligated to make any additional milestone payments for any additional indications. In addition, we have agreed to pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on brensocatib and one additional payment of $35.0&#160;million upon the first achievement of $1&#160;billion in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with us for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional capital to fund our operations, including the continued commercialization of ARIKAYCE, current and future clinical trials related to ARIKAYCE, development of brensocatib and TPIP, and the potential development, acquisition, in-license or co-promotion of other products or product candidates, including those that address orphan or rare diseases. We expect that our future capital requirements may be substantial and will depend on many factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing and cost of our current and future clinical trials of ARIKAYCE for the treatment of patients with NTM lung infections, including the ARISE and ENCORE trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The decisions of the MHLW and PMDA with respect to our applications for marketing approval of ARIKAYCE in Japan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs of activities related to the regulatory approval process and the timing of approvals, if received;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of supporting the sales and marketing efforts necessary to support the continued commercial efforts of ARIKAYCE;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of filing, prosecuting, defending, and enforcing patent claims;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The timing and cost of our ongoing and anticipated clinica</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">l trials for our product candidates, including our brensocatib Phase 3 ASPEN trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs of our manufacturing-related activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The costs associated with commercializing ARIKAYCE in Japan, if approved; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The levels, timing and collection of revenue earned from sales of ARIKAYCE and other products approved in the future, if any.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have raised $943&#160;million in net proceeds from securities offerings since 2018. We believe we currently have sufficient funds to meet our financial needs for at least the next 12&#160;months. However, our business strategy may require us to raise additional capital at any time through equity or debt financing(s), strategic transactions or otherwise.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. We do not have any interest in special purpose entities, structured finance entities or other variable interest entities.</span></div><div style="text-indent:42.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of financial statements in accordance with generally accepted accounting principles in the US requires us to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues and expenses and the disclosures of contingent assets and liabilities. We use our historical experience and other relevant factors when developing our estimates and assumptions and we regularly evaluate these estimates and assumptions. The amounts of assets and liabilities reported in our consolidated balance sheets and the amounts reported in our consolidated statements of comprehensive loss are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue recognition, research and development, stock-based compensation, inventory, finite-lived intangible assets, and accrued expenses. The accounting estimates discussed below involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Actual results could differ materially from our estimates. For additional accounting policies, see Note&#160;2 to our Consolidated Financial Statements&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, consist primarily of net sales of ARIKAYCE in the US and Europe. In October 2018, we began shipping ARIKAYCE to our customers in the US, which include specialty pharmacies and specialty distributors.&#160;In December 2020, we began commercial sales of ARIKAYCE in Germany, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plan to launch in other EU countries and the UK, subject to local reimbursement processes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net, are recognized for arrangements within the scope of ASC 606, once we perform the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer payments, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (customer fees and rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which the relevant third party is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer payments:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and fees for services are based on contractual rates agreed with the respective specialty pharmacies. We anticipate that our customers will earn these discounts and fees and, therefore, we deduct the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. We estimate the rebates we will provide to third-party payors and deduct these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheets. We estimate the rebates that will be provided to third-party payors based upon (i) our contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from our specialty pharmacies. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from our specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to us the difference between the price they initially paid and the discounted price paid by the contracted customers. We estimate the chargebacks provided to the specialty distributor and deduct these estimated amounts from gross product revenues at the time revenues are recognized.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-payment assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and our historical experience with copay redemptions, we estimate the average co-pay mitigation amounts and the percentage of patients that we expect to participate in the program in order to establish our accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. We adjust our accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of our actual experience vary from the estimates above, we may need to adjust prior period accruals, affecting revenue in the period of adjustment. For additional information regarding our estimates of variable consideration, including quantitative impacts on our financial results, see Note&#160;2 to our Consolidated Financial Statements&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have recognized revenue related to early access programs (EAPs) in Europe, primarily consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation or ATU) and from the named patient program in Germany, both compassionate use programs. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_67"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our cash and cash equivalents were in cash accounts or were invested in money market funds. Our investments in money market funds are not insured by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $450.0&#160;million of Convertible Notes outstanding which bear interest at a coupon rate of 1.75%. If a 10% change in interest rates had occurred on December&#160;31, 2020, it would not have had a material effect on the fair value of our debt as of that date, nor would it have had a material effect on our future earnings or cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our business is conducted in US dollars. However, we do conduct certain transactions in other currencies, including Euros, British Pounds and Japanese Yen. Historically, fluctuations in foreign currency exchange rates have not materially affected our results of operations. During the years ended December&#160;31, 2020, 2019 and 2018, our results of operations were not materially affected by fluctuations in foreign currency exchange rates.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;8 is included in our Financial Statements and Supplementary Data set forth in Item&#160;15 of Part&#160;IV of this Annual Report on Form 10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_73"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_76"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020. The term "disclosure controls and procedures," as defined in Rules&#160;13a-15(e) and 15d- 15(e) under the Exchange Act means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit with the SEC is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on that evaluation our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December&#160;31, 2020 at the reasonable assurance level.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) and 15d-15(f) under the Exchange Act, as a process designed by, or under the supervision of, our principal executive and principal financial and accounting officers and effected by our board of directors and management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US generally accepted accounting principles, and that receipts and expenditures of our company are being made only in accordance with authorizations of our management and board of directors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2020, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework. Based on management's assessment, management concluded that the Company's internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young&#160;LLP, our independent registered public accounting firm, issued an attestation report on our internal control over financial reporting. The report of Ernst&#160;&amp; Young&#160;LLP is contained in Item&#160;15 of Part&#160;IV of this Annual Report on Form&#160;10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_79"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_85"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;10 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Election of Class II Directors, Corporate Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Delinquent Section&#160;16(a) Reports</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive proxy statement for our 2021 annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_88"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;11 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive proxy statement for our 2021 annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;12 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Directors and Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive proxy statement for our 2021 annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_94"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;13 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the captions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certain Relationships and Related Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive proxy statement for our 2021 annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_97"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;14 of Form&#160;10-K is incorporated by reference from the discussion responsive thereto under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ratification of the Appointment of Independent Registered Public Accounting Firm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our definitive proxy statement for our 2021 annual meeting of shareholders to be filed with the SEC no later than 120&#160;days after the close of the fiscal year covered by this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_103"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Documents filed as part of this report.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following consolidated financial statements of the Company are set forth herein, beginning on </span><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_115">page&#160;76</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt"> Reports of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.8pt"> Consolidated Balance Sheets as of December&#160;31, 2020 and 2019</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.03pt"> Consolidated Statements of Comprehensive Loss for the Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt"> Consolidated Statements of Shareholders' Equity for the Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"> Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.57pt"> Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;FINANCIAL STATEMENT SCHEDULES.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None required.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;EXHIBITS.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits that are required to be filed or incorporated by reference herein are listed in the Exhibit Index.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_106"></div><div style="-sec-extract:summary;margin-bottom:15pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036113012797/ex3_1.htm">3.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Articles of Incorporation of Insmed Incorporated, as amended through June&#160;14, 2012 (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on March&#160;18, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465920040374/tm2014206d1_ex3-1.htm">3.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws of Insmed Incorporated (incorporated by reference from Exhibit&#160;3.1 to Insmed Incorporated's Current Report on Form&#160;8-K filed on March 30, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000091664100000328/0000916641-00-000328.txt">4.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen stock certificate representing common stock, $0.01 par value per share, of the Registrant (incorporated by reference from Exhibit&#160;4.2 to Insmed Incorporated's Registration Statement on Form&#160;S-4/A (Registration No.&#160;333-30098) filed on March&#160;24, 2000).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d1.htm">4.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated as of January 26, 2018, by and between the Company and Wells Fargo Bank, National Association (incorporated by reference from Exhibit 4.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on January 26, 2018).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d2.htm">4.3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Supplemental Indenture, dated as of January 26, 2018, by and between the Company and Wells Fargo Bank, National Association (incorporated by reference from Exhibit 4.2 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on January 26, 2018).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918004153/a18-3168_7ex4d2.htm">4.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 1.75% Convertible Senior Note due 2025 (included in Exhibit 4.3).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex45.htm">4.5</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913037892/a13-10493_1ex10d3.htm">10.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Incorporated Amended and Restated 2000 Stock Incentive Plan (incorporated by reference from Exhibit&#160;10.3 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed on May&#160;8, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913044678/a13-12881_1ex99d1.htm">10.2**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit&#160;99.1 to Insmed Incorporated's Registration Statement on Form&#160;S-8 filed on May&#160;24, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_5.htm">10.2.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Incentive Stock Options pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit 10.5 to Insmed Incorporated's Annual Report on Form 10-K filed on March 6, 2014).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746914001864/a2218603zex-10_6.htm">10.2.2**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated 2013 Incentive Plan (incorporated by reference from Exhibit 10.6 to Insmed Incorporated's Annual Report on Form 10-K filed on March 6, 2014).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915041594/a15-12882_1ex99d1.htm">10.3**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Incorporated 2015 Incentive Plan (incorporated by reference from Exhibit&#160;99.1 to Insmed Incorporated's Registration Statement on Form&#160;S-8 filed on May&#160;28, 2015).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917029170/a17-8848_1ex10d2.htm">10.3.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated 2015 Incentive Plan (incorporated by reference from Exhibit 10.2 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed May 3, 2017).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d3.htm">10.4**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.3 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 3, 2017).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d4.htm">10.4.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d3.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreements for Restricted Stock Units pursuant to the Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.4 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 3, 2017).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d5.htm">10.4.2**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated 2017 Incentive Plan (incorporated by reference from Exhibit 10.5 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 3, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex101.htm">10.5**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insmed Incorporated 2019 Incentive Plan (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 1, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746920001933/a2241179zdef14a.htm#la13801_appendix_a">10.5.1**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment No. 1 to the Insmed Incorporated 2019 Incentive Plan (incorporated by reference from Appendix A to Insmed Incorporated&#8217;s Proxy Statement on Schedule 14A filed March 31, 2020).</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1052.htm">10.5.2**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Restricted Stock Units pursuant to the Insmed Incorporated 2019 Incentive Plan (filed herewith).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1053.htm">10.5.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1053.htm">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1053.htm">**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Non-Qualified Stock Options pursuant to the Insmed Incorporated 2019 Incentive Plan (filed herewith). </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1054.htm">10.5.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1054.htm">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex1054.htm">**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Award Agreement for Restricted Stock Units issued to directors pursuant to the Insmed Incorporated 2019 Incentive Plan (filed herewith).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex106.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex106.htm">6</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex106.htm">**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Omnibus Amendment to Insmed Incorporated Incentive Plans, dated December 10, 2020 (filed herewith).</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d2.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d2.htm">7</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d2.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Insmed Incorporated Senior Executive Bonus Plan (incorporated by reference from Exhibit 10.2 to Insmed Incorporated's Quarterly Report on Form 10-Q filed on November 5, 2013).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d6.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d6.htm">8</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465917049121/a17-13313_1ex10d6.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Non-Qualified Stock Option Inducement Award Agreement (incorporated by reference from Exhibit 10.6 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 3, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914002807/a14-3554_1ex10d1.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914002807/a14-3554_1ex10d1.htm">9</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914002807/a14-3554_1ex10d1.htm">**</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form of Indemnification Agreement entered into with each of the Company's directors and officers (incorporated by reference from Exhibit 10.1 to Insmed Incorporated's Current Report on Form 8-K filed on January 16, 2014).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036112040054/ex10_1.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036112040054/ex10_1.htm">10</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000114036112040054/ex10_1.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, effective as of September 10, 2012, between Insmed Incorporated and William Lewis (incorporated by reference from Exhibit 10.1 to Insmed Incorporated's Current Report on Form 8-K filed on September 11, 2012).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex105.htm">10.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex105.htm">10</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex105.htm">.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment to Employment Agreement, effective as of July 31, 2019, between Insmed Incorporated and William Lewis (incorporated by reference from Exhibit 10.5 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed on August 1, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d1.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d1.htm">1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465913080816/a13-19824_1ex10d1.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, effective as of July 29, 2013, between Insmed Incorporated and Christine Pellizzari (incorporated by reference from Exhibit 10.1 to Insmed Incorporated's Quarterly Report on Form 10-Q filed on November 5, 2013).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_31.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_31.htm">1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_31.htm">.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment to Employment Agreement, effective as of September 26, 2016, between Insmed Incorporated and Christine Pellizzari (incorporated by reference from Exhibit 10.31 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed February 23, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex107.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex107.htm">1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex107.htm">.2**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Second Amendment to Employment Agreement, effective as of July 31, 2019, between Insmed Incorporated and Christine Pellizzari (incorporated by reference from Exhibit 10.7 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed on August 1, 2019).</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915035191/a15-7891_1ex10d2.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915035191/a15-7891_1ex10d2.htm">2</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915035191/a15-7891_1ex10d2.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, effective as of January 2, 2013, between Insmed Incorporated and S. Nicole Schaeffer (incorporated by reference from Exhibit 10.2 to Insmed Incorporated's Quarterly Report on Form 10-Q filed on May 7, 2015).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_32.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_32.htm">2</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_32.htm">.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment to Employment Agreement, effective as of September 26, 2016, between Insmed Incorporated and S. Nicole Schaeffer (incorporated by reference from Exhibit 10.32 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed February 23, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000011/insm20200331ex101.htm">10.12.</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000011/insm20200331ex101.htm">2</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000011/insm20200331ex101.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Second Amendment to Employment Agreement, effective as of July 31, 2019, between Insmed Incorporated and S. Nicole Schaeffer (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed April 30, 2020).</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916154364/a16-17150_1ex10d2.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916154364/a16-17150_1ex10d2.htm">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916154364/a16-17150_1ex10d2.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, effective as of September 27, 2016, between Insmed Incorporated and Roger Adsett (incorporated by reference from Exhibit 10.2 to Insmed Incorporated's Quarterly Report on Form 10-Q filed November 3, 2016).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex106.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex106.htm">3</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000020/insm20190630ex106.htm">.1**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment to Employment Agreement, effective as of July 31, 2019, between Insmed Incorporated and Roger Adsett (incorporated by reference from Exhibit 10.6 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed August 1, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000007/insm20191231ex1013.htm">10.1</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000007/insm20191231ex1013.htm">4</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000007/insm20191231ex1013.htm">**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, effective as of January 28, 2020, between Insmed Incorporated and Sara Bonstein (incorporated by reference from Exhibit 10.13 to Insmed Incorporated's Annual Report on Form 10-K filed February 25, 2020).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000007/insm20191231ex1014.htm">10.15**</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, effective as of March 17, 2014, between Insmed Incorporated and John Goll (incorporated by reference from Exhibit 10.14 to Insmed Incorporated's Annual Report on Form 10-K filed February 25, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000019/insm20200930ex101.htm">10.16*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License Agreement, dated April 25, 2008, between Transave, Inc. and PARI Pharma GmbH, and Amendments No. 1-4 thereto (incorporated by reference from Exhibit 10.1 to Insmed Incorporated's Quarterly Report on Form 10-Q filed on October 29, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_141.htm">10.16.1*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment No. 5 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of October 5, 2015 (incorporated by reference from Exhibit 10.14.1 to Insmed Incorporated's Annual Report on Form 10-K filed on February 25, 2016).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746916010395/a2227323zex-10_142.htm">10.16.2*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amendment No. 6 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of October 9, 2015 (incorporated by reference from Exhibit 10.14.2 to Insmed Incorporated's Annual Report on Form 10-K filed on February 25, 2016).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450617000005/insm-20170930xex101.htm">10.16.3*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 7 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017 (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed on November 2, 2017).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000009/insm-20181231xex10154.htm">10.16.4*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 8 to License Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of December 19, 2018 (incorporated by reference from Exhibit 10.15.4 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed on February 22, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000019/insm20200930ex1021.htm">10.17*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing Agreement, dated February&#160;7, 2014, between Insmed Incorporated and Resilience Biotechnologies Inc. (successor to Therapure Biopharma&#160;Inc.) (incorporated by reference from Exhibit&#160;10.2.1 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed on October 29, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450620000019/insm20200930ex1022.htm">10.17.1*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amending Agreement, dated March&#160;13, 2014, between Insmed Incorporated and Resilience Biotechnologies Inc. (successor to Therapure Biopharma&#160;Inc.) (incorporated by reference from Exhibit&#160;10.2.2 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed on October 29, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465914077304/a14-19864_1ex10d1.htm">10.18*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization Agreement dated July&#160;8, 2014 between Insmed Incorporated and PARI Pharma&#160;GmbH (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed on November&#160;6, 2014).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450617000005/insm-20170930xex102.htm">10.18.1*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 1 to Commercialization Agreement between Insmed Incorporated and PARI Pharma GmbH, effective as of July 21, 2017 (incorporated by reference from Exhibit 10.2 to Insmed Incorporated&#8217;s Quarterly Report on Form 10-Q filed on November 2, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746915001346/a2222985zex-10_29.htm">10.19*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Master Agreement for Services, dated as of August&#160;27, 2014, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.29 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;27, 2015).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746915001346/a2222985zex-10_30.htm">10.19.1*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work Order 1, dated as of December&#160;30, 2014, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.30 to Insmed Incorporated's Annual Report on Form&#160;10-K filed on February&#160;27, 2015).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916136806/a16-11538_1ex10d2.htm">10.19.2*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Scope 1 to Work Order 1, dated as of May&#160;27, 2016, by and between Insmed Incorporated and SynteractHCR,&#160;Inc. (incorporated by reference from Exhibit&#160;10.2 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed August&#160;4, 2016).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465915076446/a15-18005_1ex10d1.htm">10.20*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea,&#160;Inc., dated as of September&#160;15, 2015 (incorporated by reference from Exhibit&#160;10.1 to Insmed Incorporated's Quarterly Report on Form&#160;10-Q filed November&#160;6, 2015).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_30.htm">10.20.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extension of Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea,&#160;Inc., dated as of November&#160;30, 2016 (incorporated by reference from Exhibit 10.30 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed February 23, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450619000009/insm-20181231xex10292.htm">10.20.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Extension of Commercial Fill/Finish Services Agreement between Insmed Incorporated and Ajinomoto Althea, Inc., dated as of December 18, 2018 (incorporated by reference from Exhibit 10.29.2 to Insmed Incorporated's Annual Report on Form 10-K filed on February 22, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450618000002/insm-20171231xex1039.htm">10.21*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and Supply Agreement between Insmed Incorporated and Patheon UK Limited, dated as of October&#160;20, 2017 (incorporated by reference from Exhibit 10.39 to Insmed Incorporated's Annual Report on Form 10-K filed February 23, 2018).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110450618000002/insm-20171231xex1040.htm">10.22*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology Transfer Agreement between Insmed Incorporated and Patheon UK Limited, dated as of October&#160;20, 2017 (incorporated by reference from Exhibit 10.40 to Insmed Incorporated's Annual Report on Form 10-K filed February 23, 2018).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000104746917000856/a2230968zex-10_29.htm">10.23*</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License Agreement, dated October 4, 2016, between Insmed Incorporated and AstraZeneca AB (incorporated by reference from Exhibit 10.29 to Insmed Incorporated&#8217;s Annual Report on Form 10-K filed February 23, 2017).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465916136806/a16-11538_1ex10d1.htm">10.2</a>4</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease Agreement, effective as of July 1, 2016, by and between Insmed Incorporated and CIP II/AR Bridgewater Holdings, LLC (incorporated by reference from Exhibit 10.1 to Insmed Incorporated's Quarterly Report on Form 10-Q filed August 4, 2016).</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1104506/000110465918057228/a18-29057_1ex10d1.htm">10.</a>25</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Agreement, dated September 11, 2018, by and between Insmed Incorporated and Exeter 700 Route 202/206, LLC (incorporated by reference from Exhibit 10.1 to Insmed Incorporated&#8217;s Current Report on Form 8-K filed on September 17, 2018).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex211.htm">21.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of Insmed Incorporated (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex231.htm">23.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Ernst&#160;&amp; Young&#160;LLP (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex311.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex312.htm">31.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to Rules&#160;13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex321.htm">32.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of William H. Lewis, Chair and Chief Executive Officer (Principal Executive Officer) of Insmed Incorporated, pursuant to 18 USC Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:11.357%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="insm20201231ex322.htm">32.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Sara Bonstein, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of Insmed Incorporated, pursuant to 18 USC Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes Oxley Act of 2003 (filed herewith).</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Insmed Incorporated&#8217;s Annual Report on Form&#160;10-K for the year ended December 31, 2020 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i)&#160;Consolidated Balance Sheets as of December 31, 2020 and 2019, (ii)&#160;Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020, 2019 and 2018, (iii)&#160;Consolidated Statements of Shareholders' Equity for the years ended December 31, 2020, 2019 and 2018, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019, and 2018, and (v)&#160;Notes to the Consolidated Financial Statements, and (vi) Cover Page.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Annual Report on Form 10-K for the year ended December 31, 2020, formatted in iXBRL and contained in Exhibit 101.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">*</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain portions of this exhibit have been redacted.</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">**</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on February&#160;25, 2021.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INSMED INCORPORATED<br/>a Virginia corporation<br/>(Registrant)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;WILLIAM H. LEWIS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chair and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on February&#160;25, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;WILLIAM H. LEWIS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William H. Lewis</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;SARA BONSTEIN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAVID R. BRENNAN</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David R. Brennan</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;ALFRED F. ALTOMARI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alfred F. Altomari</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;CLARISSA DESJARDINS, PH.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clarissa Desjardins, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;STEINAR J. ENGELSEN, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steinar J. Engelsen, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;DAVID W.J. MCGIRR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David W.J. McGirr</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;ELIZABETH MCKEE ANDERSON</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth McKee Anderson</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MELVIN SHAROKY, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melvin Sharoky, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;LEO LEE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leo Lee</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;CAROL A. SCHAFER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carol A. Schafer</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Insmed Incorporated</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited the accompanying consolidated balance sheets of Insmed Incorporated (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of comprehensive loss, shareholders' equity and cash flows for each of the three years in the period ended December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February&#160;25, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Variable consideration in contracts with customers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 2 of the consolidated financial statements, the transaction price for product sales is typically adjusted for variable consideration, which includes rebates paid to government agencies. The Company estimates these reserves based upon a range of possible outcomes that are probability-weighted for the estimated payor mix.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing the Company's estimate of variable consideration for amounts to be paid to government agencies was complex and judgmental due to uncertainty about the ultimate third-party payor at the time of shipment to the specialty pharmacies and the amounts of rebates to be paid to those government agencies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The transaction price is sensitive to assumptions used in the rebate calculations.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified, evaluated and tested controls over management&#8217;s review of the calculated reductions to gross product prices related to government agencies including management&#8217;s review of the significant assumptions and the data utilized in its calculations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test the revenue adjustments related to government agencies our audit procedures included, among others, using internal specialists to assist with recalculating government rebates. We also tested the underlying data and inputs used by the Company in its determination of the estimated payor mix. We compared the inputs used by management to historical trends, evaluated the change in the estimated rebates amounts recorded throughout the year and assessed the historical accuracy of management&#8217;s estimates against actual results.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since at least 1999, but we are unable to determine the specific year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents </a></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:0.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Insmed Incorporated</span></div><div style="margin-top:1.1pt"><span><br/></span></div><div style="margin-top:1.1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:1.1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have audited Insmed Incorporated&#8217;s internal control over financial reporting as of December&#160;31, 2020, based on criteria established in Internal Control&#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2013 framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> (the COSO criteria). In our opinion, Insmed Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2020, based on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">.</span></div><div style="margin-top:0.35pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">balance sheets of the Company as of  December&#160;31, 2020 and 2019, and the related consolidated statements of comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2020, the related notes and our report dated February&#160;25, 2021 expressed an unqualified opinion thereon.</span></div><div style="margin-top:0.65pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:1.14pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.924%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Ernst&#160;&amp; Young&#160;LLP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Iselin, New Jersey</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_118"></div><hr style="page-break-after:always"/><div style="min-height:88.2pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value and share data)</span></div></div><div><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_121"></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:72.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQtMi0xLTEtMA_166eeb7e-35f9-4227-81b8-3083ad433e1d">532,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQtNC0xLTEtMA_5b70e533-34ab-4468-8008-8af808fdb359">487,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzUtMi0xLTEtMA_2bc8c2d9-6f83-4553-a252-28a145350a67">16,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzUtNC0xLTEtMA_6c06373d-df75-44df-8233-64da4fb1a2d3">19,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzYtMi0xLTEtMA_13496d5b-b880-4c1f-8243-07bc5f78e17a">49,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzYtNC0xLTEtMA_80864aee-f7a4-4f60-90f0-3f51861dc1dc">28,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzctMi0xLTEtMA_c15ae805-5118-4d33-adaa-a4fea7bb1511">23,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzctNC0xLTEtMA_eed08cab-395c-45f1-88fe-2a54d4c46fa4">20,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzgtMi0xLTEtMA_67063d9b-0f23-4922-98e0-e1238eafca16">622,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzgtNC0xLTEtMA_1d8a0396-0bc5-4448-b00e-1b792b92eee0">555,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEwLTItMS0xLTA_64305782-fe97-413d-aebc-e8b5471f9bde">49,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEwLTQtMS0xLTA_442177fe-5e81-478d-92a4-0472c6b57a9a">53,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzExLTItMS0xLTA_3097f106-3151-4bdf-8177-fab70788e75d">53,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzExLTQtMS0xLTA_f10008c0-6ea6-490e-9e3a-8228e3b94218">60,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEyLTItMS0xLTA_b0ba7d0c-68c9-422b-91bb-efb686804998">10,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEyLTQtMS0xLTA_59253814-438f-44bf-812a-8f6a51a4931a">15,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEzLTItMS0xLTA_799d6f73-5c4d-4c92-87c4-de7d1be6cc52">32,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEzLTQtMS0xLTA_9e3d312d-7b8e-4844-bf88-15fe5c0d0d76">37,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE0LTItMS0xLTA_ff917606-7bf3-4bd2-883a-b5a046459a2f">26,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE0LTQtMS0xLTA_666d6e18-d342-4cd1-ac6b-e1e87ee1e5bc">20,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE1LTItMS0xLTA_d3c808b6-0d3d-4982-8a6f-f8551f9b420e">796,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE1LTQtMS0xLTA_28b42c62-76a7-4fb4-a7a6-0e00ba3d1cf5">742,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE5LTItMS0xLTA_fa087dc4-3700-41ee-aad0-f9e6d75b8706">42,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE5LTQtMS0xLTA_54ec23e8-4cfc-401d-b864-722309e7ec7b">13,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIwLTItMS0xLTA_41caba6e-4cc2-4317-b065-ebb6b359591f">37,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIwLTQtMS0xLTA_8a45fd97-438c-4ba5-a515-130fe78a1289">40,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIxLTItMS0xLTA_086242f9-878d-4175-8b36-f1ec00c5a7ee">25,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIxLTQtMS0xLTA_80f16d6e-2a30-49cd-93f2-ed584e5f3105">19,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIyLTItMS0xLTA_437c87e2-14c4-4ab2-b714-a920de6c2d55">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIyLTQtMS0xLTA_6f3fea27-77f0-427f-8fdd-d35cb9dc5771">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIzLTItMS0xLTA_2d0f24cf-64e3-48ea-9183-fc76292fcc2e">11,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIzLTQtMS0xLTA_b4211992-d651-4ac4-bad1-c98f70762259">11,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI0LTItMS0xLTA_50d91c2a-8e73-4891-9690-72b1aafc1d22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI0LTQtMS0xLTA_7dc8d34c-8328-47a6-82e0-35b994a6737f">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI2LTItMS0xLTA_c77c0083-b099-4e10-93d8-187f0fcb391d">118,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI2LTQtMS0xLTA_acc8d3f7-e0b6-4eaa-95b7-272898c9165e">85,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI4LTItMS0xLTA_e279b66f-f4a8-4567-9876-3150f615e571">356,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI4LTQtMS0xLTA_9154ce19-4e66-4f1f-9f1c-d08d8fcaee71">335,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, long-term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI5LTItMS0xLTA_cbc4c30a-1604-4e51-9034-7d58083c1f2d">14,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI5LTQtMS0xLTA_01080c97-56f1-4fa7-8754-a542222b1361">19,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMwLTItMS0xLTA_bbb47761-9b3d-434b-815c-6bafa6ef6f64">21,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMwLTQtMS0xLTA_5236b00e-cfba-4cb5-8e61-504294af7c52">29,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMxLTItMS0xLTA_e9331885-3995-4099-8164-da02f400a56c">9,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMxLTQtMS0xLTA_98987142-b632-46e0-a639-386f81320502">10,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMyLTItMS0xLTA_d24f3334-5798-4ec0-9018-c38152febb98">520,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMyLTQtMS0xLTA_27ac71eb-8494-4ddc-abcf-83b9b16ac786">480,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18xOA_aefe51db-942b-4f61-a613-bf8bc67c66d3"><ix:nonFraction unitRef="usdPerShare" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18xOA_e3dc9531-539b-46fa-95fe-c189918ff3e9">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18zMg_521b19b7-a659-40fc-9754-5f1810d32468"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18zMg_e3b62ddc-0c04-4c9e-9c85-efc43009a55f">500,000,000</ix:nonFraction></ix:nonFraction> authorized shares, <ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N181NA_7295a523-cea2-4dc1-9085-bbc69e175700"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N181NA_8142df51-fd95-4da1-a969-38b77b6a8f3c">102,763,060</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N182MQ_8761f312-5587-4705-a46f-9c21586aef60"><ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N182MQ_a71738ef-eec6-44a4-bc1c-73513fb69de7">89,682,387</ix:nonFraction></ix:nonFraction> issued and outstanding shares at December&#160;31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTItMS0xLTA_9fb1c265-b9b5-4546-af5d-ee9221388d4b">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTQtMS0xLTA_87738537-138f-4d88-885b-227b7db9c44a">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM2LTItMS0xLTA_78b0e428-c6d0-4b00-93b4-9a038ce1d703">2,105,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM2LTQtMS0xLTA_dbf4dfc8-9594-4520-8717-379bb24c143c">1,797,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM3LTItMS0xLTA_a9fd4dda-f0bc-415a-b4e9-808cebaab213">1,830,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM3LTQtMS0xLTA_f4b51936-90c8-43e1-ab7e-e259cb0facd1">1,536,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM4LTItMS0xLTA_a6765807-eee5-4c63-8f44-8ab227dc8def">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM4LTQtMS0xLTA_64e0bde5-04ca-4abf-ae5f-62d9a615904f">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM5LTItMS0xLTA_c75d5ef0-0413-4f8f-bc78-974c856def4b">275,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM5LTQtMS0xLTA_9411fd47-7059-4b68-b90d-dcb94578fb91">261,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQwLTItMS0xLTA_ace92569-3723-4875-abea-c56eb5a1b722">796,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQwLTQtMS0xLTA_b2835073-09e8-451d-8f32-d98ae7ed5e83">742,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_124"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:62.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItMS0xLTEtMA_ba51d109-aa0e-4603-9b47-90a14f2325cf">164,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItMy0xLTEtMA_93e43428-8ede-40b3-bfa7-667f352bbba9">136,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItNS0xLTEtMA_2895bac6-7428-48dd-ba6d-3e79d735a48b">9,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (excluding amortization of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtMS0xLTEtOTE5_163d7fc2-04ba-47f0-a205-be4fd23fd329">39,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtMy0xLTEtOTE5_054590e0-0cf8-4f37-9288-7e30fb39ae65">24,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtNS0xLTEtOTE5_9cc1f981-5cfe-40b0-af5f-a1edaec593da">2,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctMS0xLTEtMA_edec2ac7-f386-4c81-b78b-46f377f57224">181,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctMy0xLTEtMA_a5f63573-c000-4855-aa55-d9288e07cd04">131,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctNS0xLTEtMA_057aa0d8-a04b-41d2-bfa7-c9447d7dfa43">145,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtMS0xLTEtMA_e81ad75f-5d07-402e-99e6-a72286062132">203,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtMy0xLTEtMA_1b2519de-7dd7-4cc2-90a7-72288fb37e38">210,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtNS0xLTEtMA_d716abca-a437-4a95-9e24-3857c91c89a2">168,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktMS0xLTEtMA_f3ecaf9f-49c7-47d0-89d5-d5dc383a301f">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktMy0xLTEtMA_dfba2681-3155-4cb1-9c20-e76e23168213">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktNS0xLTEtMA_27eb18a4-37cb-4a7d-9af8-60cf78adaa43">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTEtMS0xLTA_33005e8b-dfe8-4e93-9ecb-5ed15138caf3">429,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTMtMS0xLTA_035213a8-7399-46da-8103-df338909b1d5">371,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTUtMS0xLTA_7d065547-d428-43f5-9d68-28df0cb367ae">317,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTEtMS0xLTA_4a5c7bb9-9e1a-4e0f-a263-2d871e7449d8">265,232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTMtMS0xLTA_a283c85e-6bf6-41ab-a000-0903426c2fd6">235,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTUtMS0xLTA_371980da-f9c9-48d4-a916-56e6c4586662">307,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTEtMS0xLTA_ee429276-0fcf-4138-a966-44f479d71f87">1,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTMtMS0xLTA_53dd9502-16ad-496d-8d5b-782b7c650768">9,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTUtMS0xLTA_635f0a82-7801-49fd-9f59-003f8c659cab">10,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTEtMS0xLTA_fbea3cca-51ba-4054-acc3-1d7a632b7e8e">29,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTMtMS0xLTA_626f4e9c-26ea-4f71-be5d-7d6253afc07e">27,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTUtMS0xLTA_c01abbab-1416-4fde-b1c6-7044c417c41d">25,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTEtMS0xLTA_5ce36d1c-104e-4345-bf4f-82088d2f03b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTMtMS0xLTA_fad972bb-aa56-4de5-8101-28a02688552b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTUtMS0xLTA_fe791e8c-de3a-4078-a345-5f6889c2c5db">2,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTEtMS0xLTA_7afaa52f-13a8-40c3-b681-4f07a68a3b28">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTMtMS0xLTA_40354943-e29e-4eab-8fd5-a047b06ab21c">531</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTUtMS0xLTA_4ed38a21-086f-4f32-a52e-c598fa89ff73">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTEtMS0xLTA_0e3aa7cd-feaf-43dc-979e-400e4c997a5a">292,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTMtMS0xLTA_33912845-f60d-4e90-86b4-5db76bc2eeb1">253,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTUtMS0xLTA_3da93f0c-7829-46b9-a567-367b81d3d179">324,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTEtMS0xLTA_6dacfa34-2457-4f70-87bc-a5a687f43eb2">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTMtMS0xLTA_2681930c-cb74-4c81-a720-60cd95738d9c">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTUtMS0xLTA_ec73a251-7b29-4dbf-869d-4758f4fd243f">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTEtMS0xLTA_aaeae3aa-3f5e-4414-81bf-823610779104">294,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTMtMS0xLTA_1f76efb9-651e-4bae-88e6-675f95bf356a">254,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTUtMS0xLTA_5f3b5929-9df9-432a-8e54-f9218388275b">324,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTEtMS0xLTA_97d047cf-3622-4602-9fac-cbd9ecf7fa3a">3.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTMtMS0xLTA_4c63b2c6-cff3-4c3d-9d71-e681c84f3bf4">3.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTUtMS0xLTA_8791039f-e2af-4b30-8517-4039f9ce4422">4.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average basic and diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTEtMS0xLTA_f82e54a6-58fc-4122-a4b8-1f8f7cfe59b7">97,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTMtMS0xLTA_82e3da90-d5f0-43b8-8fed-f3137651ce40">84,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTUtMS0xLTA_5b37ff85-a722-4f15-8ea3-1f61e436e3b7">76,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTEtMS0xLTA_5ab1c462-c784-4669-92c2-ff37e6627eff">294,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTMtMS0xLTA_fb0eb673-87b7-4ae1-b7ab-06dd928c8f54">254,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTUtMS0xLTA_53a00337-6a65-42e3-9f14-8fa6d66a3dcf">324,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTEtMS0xLTA_1063bdbe-1e61-4711-913b-e7826e106e19">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTMtMS0xLTA_81dee487-7e43-43ea-b7af-3cf6d04b0ed2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTUtMS0xLTA_1ede8af7-b0b4-41df-ade8-b18f103338f9">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTEtMS0xLTA_d443bede-db10-41a6-9a35-eb72f03118bf">293,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTMtMS0xLTA_78d1e403-baa4-4ac5-9e0f-1f592918008c">254,338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTUtMS0xLTA_9b035fc5-cefe-4f0f-82ac-e4fbc696ed11">324,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to audited consolidated financial statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_127"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:31.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.860%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated <br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcf2af78768043e6a6d0f7f80a56687d_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMS0xLTEtMA_04b9600b-ee34-4076-9de8-85a1edf95cb6">76,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf2af78768043e6a6d0f7f80a56687d_I20171231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMy0xLTEtMA_b9396174-dd86-4e32-b780-0908a5760bee">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9883789f34af48faa49839a2c46e2971_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItNS0xLTEtMA_ceea1a79-1009-475b-9f08-817813fddcd7">1,318,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20647d4d256549fcb9f6d47074842d0c_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItNy0xLTEtMA_182c04db-36e1-49bc-91d5-401e406beee3">957,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if85fc514b5b74bbebdde290e2e17f393_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItOS0xLTEtMA_85facc48-7ba9-4102-a18a-be5504bb86a3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMTEtMS0xLTA_ec487e63-33df-43a2-9dbf-374fd8e801e6">361,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i253f9191270b47bbb377a3e554382848_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzQtNy0xLTEtMA_3c74105a-4e0d-4c34-9666-37c402f34c02">324,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzQtMTEtMS0xLTA_c888ab87-2026-491e-8ec6-40c3c87eacbb">324,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75a0bbd8f14f48d9891d78182180a475_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzUtOS0xLTEtMA_858c6f50-e083-4113-8a95-108148b0b978">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzUtMTEtMS0xLTA_7e0f0ca8-26b7-4ab4-8b67-33f61190f0e4">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMS0xLTEtMA_522ea3e1-996b-47ea-a4a2-8fd2526f58c1">645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMy0xLTEtMA_e38fadb2-2228-4102-a819-8e9b1dc3e7b4">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtNS0xLTEtMA_7086103d-0d7f-4a58-bf06-c40d5fa697db">8,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMTEtMS0xLTA_7ab5177e-365b-492b-9ad1-41478bd80843">8,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of convertible debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzctNS0xLTEtMA_6d869af3-dcd4-45b6-8cba-8d3cef14cd49">136,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzctMTEtMS0xLTA_20fae34a-0f3c-4999-b879-d7833e3c2754">136,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMS0xLTEtMA_643f28d1-a6a9-4cb9-8030-a6d5e7a67136">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMy0xLTEtMA_2f720909-60d4-43cd-835f-a9c9feebd09f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMTEtMS0xLTA_61e06c8c-7799-4592-a088-ce33442533b8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzktNS0xLTEtMA_55d5e9e8-3e6e-45cb-9fb3-ff6519117db9">26,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzktMTEtMS0xLTA_e9963a05-54d1-4c02-9579-5ed80a0ee1f3">26,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i546efb7b63d14554aa9bfdf739cebc90_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTEtMS0xLTA_737b556f-ee48-411e-b7f9-a8985229f7e7">77,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546efb7b63d14554aa9bfdf739cebc90_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTMtMS0xLTA_420c47bf-09fb-4add-8a16-8c11860e39dd">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib76325e7c3734939be7e498355efe724_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTUtMS0xLTA_168354fe-0cb1-459b-9602-5eb41a4ec22c">1,489,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a1515d5bd1d4ee4b52a34eebff6fa4b_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTctMS0xLTA_4576e3d7-7dc4-4ea7-907c-0d5f60236fb5">1,282,162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i872a79a3298a4fc0935733317644b8f7_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTktMS0xLTA_a9cf3a3a-c16d-405e-813b-6a05c73da2ba">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTExLTEtMS0w_e0fe3787-9f72-4364-af61-240ec8051353">208,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib081213375dc485f8d419cd32e77ad21_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEyLTctMS0xLTA_8b3ced79-6ac4-4634-b2c5-44fa14f86e21">254,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEyLTExLTEtMS0w_9794ca9b-6fb3-47d8-a90e-1bfe7317c7bd">254,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5326db554c74c3e8b3751c9d9d6fd9c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEzLTktMS0xLTA_38762d97-2983-4b01-94f0-f03e5fb5c109">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEzLTExLTEtMS0w_b0277558-935f-4946-95af-772c5b7594db">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTEtMS0xLTA_164d0dc3-8999-4b92-b553-883dadf45f94">1,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTMtMS0xLTA_e2d030c4-5f00-47ff-97df-bbb71b49651f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTUtMS0xLTA_342c50d0-462f-4e90-8a0a-c2f5bc7c03db">19,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTExLTEtMS0w_f5e5457a-9aa8-4b7c-944e-11666fb76a79">19,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTEtMS0xLTA_17a0ddd0-f79a-4917-b034-4142d6dc6163">10,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTMtMS0xLTA_9a600e36-5e0d-4ea7-b234-bc58df2a6395">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTUtMS0xLTA_064f7a89-02ea-48f0-8d05-47b955326fa4">260,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTExLTEtMS0w_296aae0f-9f1d-4d57-b36b-60b7f4522f56">261,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTEtMS0xLTA_564ddbde-2d5b-4d16-8911-69e24a08605a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTMtMS0xLTA_116b7882-31f0-443f-a2e5-3ef85030c19c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTExLTEtMS0w_d3d1b9d6-dc4c-40e8-87dc-dc97121e9fb3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE3LTUtMS0xLTA_ece9fe11-0189-4330-96f6-7c5a28a1c30b">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE3LTExLTEtMS0w_318a6cdf-d1e8-4601-b1d3-f41dd87ffb57">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i805a071174014bd59c6cd5891fc33d9d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTEtMS0xLTA_6d6a6331-02cb-4618-9d11-7dc14fec80fb">89,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805a071174014bd59c6cd5891fc33d9d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTMtMS0xLTA_3d435115-ab8a-4561-a69f-6fbfb9addb63">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b58797f08d4181a4d8d4f76c2b948e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTUtMS0xLTA_ebb65c72-0357-4de1-b8e5-98ea4d60015d">1,797,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie973139e8f3f474ba01ec72a33d057c2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTctMS0xLTA_bd48b754-7441-4361-8c24-142e6f44c854">1,536,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86609ec5e2274f059fdd63ee245fc9cb_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTktMS0xLTA_3564edb6-091e-4d98-a779-56ffb78921aa">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTExLTEtMS0w_14b13b69-31da-49cf-b151-07e92fdc2278">261,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44e12ab6a629456d98e9c2642ad51f4b_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIwLTctMS0xLTA_3c715e8d-173a-493a-93ae-d4b6877696ef">294,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIwLTExLTEtMS0w_34a77d3b-b44d-4b04-a59d-ef999e23a232">294,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b120d293904c698a3d259c3e643e2b_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIxLTktMS0xLTA_197f0415-07ca-48f2-9cab-8dfaa8eed83c">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIxLTExLTEtMS0w_d68316c1-6885-4b66-a02b-e8ce0967faff">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and ESPP shares issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTEtMS0xLTA_20fd1230-3b50-4337-bbc6-240bb3f04f53">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTMtMS0xLTA_9db957cb-19d9-42cd-97bd-40fc7b736b08">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTUtMS0xLTA_63ec51a5-7001-4ab7-a15b-812fc8815178">26,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTExLTEtMS0w_a192fb4d-a9c7-4aa8-8ae7-66807ac91c6c">26,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTEtMS0xLTA_10896ea0-e316-4fd0-86c1-e937f4168bbd">11,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTMtMS0xLTA_88fe6a75-36c2-42ef-bf6c-7f8bf4b9503b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTUtMS0xLTA_f75c3f90-7964-43a6-8901-78cb4a3fae8f">245,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTExLTEtMS0w_288a446d-c6e5-414f-83d9-68594833d13c">245,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock for vesting of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTEtMS0xLTA_836848ed-6dc4-48cc-9d1b-6fc4d30bbfac">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTMtMS0xLTA_e4057146-6aa0-48ac-9fec-553f72cf5574">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTExLTEtMS0w_40c34299-4b82-4a66-bcf1-3c384b1f046d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI1LTUtMS0xLTA_b28dceff-6c06-40b7-8e1b-2dcdf125af85">36,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI1LTExLTEtMS0w_192b2487-821f-4857-8208-bde810dd1c8e">36,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTEtMS0xLTA_57406579-e601-4ab4-8838-e9471d28a2e3">102,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTMtMS0xLTA_2b2a912f-4264-4b31-a363-4190a56c643c">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968e32794a5c4430ae11c1b0b3884003_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTUtMS0xLTA_8e71b037-15ab-4577-94f0-cdc14828bc4c">2,105,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0897592bf8bb4a21931904c230db9a43_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTctMS0xLTA_c23a5b95-1bff-4135-a149-3675aff89ab1">1,830,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia665daf63d884a34b3a03848ca8720da_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTktMS0xLTA_56df9408-ed81-49b8-a42d-f5e4623dada9">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTExLTEtMS0w_1a24dec4-2b72-41b0-bdfa-e4fdc13bc811">275,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to audited consolidated financial statements</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_130"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.473%"><tr><td style="width:1.0%"></td><td style="width:66.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.197%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtMS0xLTEtMA_15803e8a-3193-4ebc-8227-a8f6bcfc689c">294,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtMy0xLTEtMA_070a7bd0-dc49-4adf-ae2e-e9241c4fd3be">254,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtNS0xLTEtMA_91901945-317b-4eab-a368-7b4ecce6dc61">324,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtMS0xLTEtMA_be0c5467-3413-4f71-96e3-e9215d7ebdc7">9,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtMy0xLTEtMA_61347f08-531b-489c-b3ef-3e3453581cbf">5,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtNS0xLTEtMA_26a34e98-cc39-4916-834f-a27a732480ef">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtMS0xLTEtMA_dbe1784e-5fdf-471f-8b39-3239d5d2f9eb">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtMy0xLTEtMA_876a6152-6832-4942-83e0-90461564cfa2">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtNS0xLTEtMA_5dc98e6a-2761-42d4-b9cd-6f8392c5f374">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctMS0xLTEtMA_ec3b8b8b-12f1-48bb-ba34-858b0fff5f84">36,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctMy0xLTEtMA_1307c30a-8a8a-429f-848c-ed655de76eb1">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctNS0xLTEtMA_9bbb2f12-7425-4326-ab5c-8713fed4736a">26,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtMS0xLTEtMA_e66985e5-ad20-45ff-9a40-d8aeb5d709d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtMy0xLTEtMA_02b9a9d1-5031-4aed-9e8d-ec5070912e58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtNS0xLTEtMA_cd582e1a-8aef-4384-8daa-be343ce609ab">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktMS0xLTEtMA_16b17353-81c6-4646-8f27-d9b804bf6b2d">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktMy0xLTEtMA_717300e5-1efb-4ed1-b051-e20bb38c72d9">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktNS0xLTEtMA_5255b804-9d45-4442-b8c9-9842c4403c5f">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount and back-end fee on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTEtMS0xLTA_25dac9a1-b75d-4431-a51a-1ef59660e323">18,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTMtMS0xLTA_debf4d47-3714-43b2-a77c-5eba355f0f88">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTUtMS0xLTA_b806ef86-8ae9-4894-b20c-341d97f92d7f">15,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzExLTEtMS0xLTA_2a3cae55-30ec-44a5-aaca-9e2a05aacfd4">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzExLTMtMS0xLTA_00a82061-3f1c-4913-8029-071a271931d6">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:NoncashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEyLTEtMS0xLTA_2776d090-979e-4de0-96ef-8f8dd1ecc36e">5,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:NoncashOperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEyLTMtMS0xLTA_50fae4dd-0b19-41d4-8cf2-1159286f86d6">9,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTEtMS0xLTA_5056239c-b214-4fec-b31a-dd24bfb5e6d6">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTMtMS0xLTA_53052e68-24b2-4ec6-b1d0-eaa808fae67a">13,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTUtMS0xLTA_0aa9b741-eae4-4f14-8ea9-8c8d1b8a0d67">5,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTEtMS0xLTA_bd75082e-39a9-40e8-947f-705ffe79199f">21,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTMtMS0xLTA_1fe7cf9a-6648-44fe-b973-6d18391a413a">21,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTUtMS0xLTA_b38109e3-e7eb-4cf0-b015-40327b5365a5">7,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTEtMS0xLTA_89a00b77-bb24-426f-8481-435a6727f4ed">3,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTMtMS0xLTA_d501f346-2ee1-443b-b302-8de708bbfdda">8,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTUtMS0xLTA_0066b1e7-81cc-4ca5-acfd-8a61dd3801c8">5,514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTEtMS0xLTA_dcb3716d-0f80-4ac6-a47d-aa38f9530c1a">6,261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTMtMS0xLTA_4236d47c-98d9-4f7f-8a0d-1308b8ad58ad">16,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTUtMS0xLTA_4355aeb6-d374-45e2-9105-a3651a70c40f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTEtMS0xLTA_c925a045-11d3-423b-83d6-432e8436e26e">29,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTMtMS0xLTA_d49572bd-124e-45c3-9ff9-643414613b96">4,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTUtMS0xLTA_7c696857-2a6d-40b5-a0b4-b9e977a199f8">3,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTEtMS0xLTA_310e87cb-4ceb-472e-95db-8545a9f77df2">10,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTMtMS0xLTA_93caff61-6540-4702-8ce6-d5c350cbed57">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTUtMS0xLTA_a85fb088-1f6d-45a9-bbf4-55898430866e">19,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTEtMS0xLTA_270f4104-a71f-4a93-a9ef-29e381df4d07">5,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTMtMS0xLTA_0dcb5a6e-3926-4421-9328-d5150bd9a516">3,068</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTUtMS0xLTA_9616133b-3567-4ab7-8240-441176ce717f">10,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTEtMS0xLTA_d383a671-24f5-4c3d-8a22-16b97027552d">219,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTMtMS0xLTA_1f2b5665-d93f-47fa-83f8-246a482e4e42">250,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTUtMS0xLTA_c9487b51-f332-44e5-b67a-1932b1b9a87f">257,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTEtMS0xLTA_0863d9ff-e5e5-4252-9824-8eaead71f0a5">6,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTMtMS0xLTA_bc7ecd01-54ab-41ef-a182-2fa801e64936">42,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTUtMS0xLTA_59570b10-3fc8-4d36-87c2-2cfdf3c5565d">13,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestone upon regulatory approvals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTEtMS0xLTA_24a66f5e-29cb-4060-bcac-0e4e7fec3da6">582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTMtMS0xLTA_e908fa15-096c-4945-956d-3bfc7b0c841f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTUtMS0xLTA_cc8335ed-c253-4786-b17c-a7ab0dd5e686">1,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTEtMS0xLTA_6c5daca7-97db-4604-9676-fab76392d263">6,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTMtMS0xLTA_bcfeefeb-fc19-447f-9bb7-f6889a6c7169">42,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTUtMS0xLTA_1d08e902-11f7-4fd5-8db5-29c7e095d262">14,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of <ix:nonFraction unitRef="number" contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMjY0YzdhYjg4MzM0MjZmYjEzM2M5MzQ0ZmYwOTIzNl8zMA_75792b5a-e387-4dcd-88cf-0bb499afa6f1">1.75</ix:nonFraction>% convertible senior notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTEtMS0xLTA_e8a83747-c6d5-494c-8ab7-bccdfdb6fcae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTMtMS0xLTA_79037804-b9c4-422c-b405-736fb6e19b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTUtMS0xLTA_8f6922b3-0a66-46d9-96e6-4e7a3ffdceaf">450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt principal and extinguishment costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTEtMS0xLTA_6e2ad4ca-e18d-48b6-9190-9d890115205a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTMtMS0xLTA_75ecbe6f-bbb8-498f-8384-eca6a8ec07cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTUtMS0xLTA_b4361b74-c79a-4200-92ce-c449e735ba1a">57,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTEtMS0xLTA_29c89e58-5511-40fb-8881-e33e79fc7c0b">245,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTMtMS0xLTA_37f397f4-c4fe-460e-8331-dabef29b93c4">261,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTUtMS0xLTA_2ae80c3a-807b-4909-91f9-277a35deb40b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options, ESPP, and RSU vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTEtMS0xLTA_ab8798d1-748f-4d34-8a86-c82c6faf9ace">26,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTMtMS0xLTA_43212f5d-4fa9-4d56-92cf-60c86c2d7251">19,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTUtMS0xLTA_e60af15f-0463-49e4-b0d6-b53c6a2b8044">8,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTEtMS0xLTA_0fcdd7ba-3e14-4fd2-a635-68660daa239c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTMtMS0xLTA_00d18d09-4ef9-4ace-8c15-dfcda3051f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTUtMS0xLTA_66fb4dc5-79b8-4bf7-80fc-8c8a6be7f2d7">14,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of financing lease principal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM1LTEtMS0xLTA_9c907978-3118-42a1-91f7-bfcde17de613">936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM1LTMtMS0xLTA_98a3c1d2-7134-4edd-aac8-da5b719ba5f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from tenant improvement allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM2LTEtMS0xLTA_06074866-a977-4a3d-b739-2561e5fc7989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM2LTMtMS0xLTA_c4b2ad53-82b2-4af7-97b3-0b6cc2b42252">4,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTEtMS0xLTA_bb4e3133-5bff-4ab0-b541-788dd97863e7">271,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTMtMS0xLTA_ef4f00ca-c312-4a7e-9866-57148b9f3add">285,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTUtMS0xLTA_09325690-a89c-4ba7-8490-83530ef05310">386,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTEtMS0xLTA_43fc4527-bdb8-4c69-8dbf-5aceed52c6cc">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTMtMS0xLTA_6884ea46-ac70-486c-a64e-61f4aaf6a74c">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTUtMS0xLTA_967d703f-ea02-459b-9927-9010db7e49b5">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTEtMS0xLTA_ac9dab15-fc1f-48b0-81fb-be732392d8eb">45,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTMtMS0xLTA_135fcd04-598e-49f8-87cf-76a73dcc8eb9">7,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTUtMS0xLTA_798b2845-7a4f-4b7b-a16a-3da8f036b174">113,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTEtMS0xLTA_2103aeb3-57dd-4536-bdb0-bf8426014fd4">487,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTMtMS0xLTA_ba32f5fc-234e-40e6-8a73-bf1712ee1a95">495,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTUtMS0xLTA_89a2f3d4-d881-4629-a7ff-39a0cc39f904">381,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTEtMS0xLTA_01cae3e3-312e-4c8c-8f80-2a14cdf88347">532,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTMtMS0xLTA_cd896d58-88dc-4149-a584-7c37e649b21c">487,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTUtMS0xLTA_ca508a1d-1ec3-4ec5-a6ca-6c923b5de36b">495,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTEtMS0xLTA_f47b9009-ea48-4bec-bf69-717d9ab1693b">9,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTMtMS0xLTA_ba7ee751-4ed3-47ba-9074-520ad26a536a">7,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTUtMS0xLTA_5f7df7b1-ee74-4a8f-ba38-7051bb6ba62f">6,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTEtMS0xLTA_c993f29d-0ad4-4930-aa61-ea704b789c59">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTMtMS0xLTA_6399f1d8-1caa-4c90-8369-d4d9d25ab487">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTUtMS0xLTA_f58eabda-8230-4c2a-b24b-14948fa8bbca">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to audited consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ib70075c4f5c143bda8e7fff17e62c779_133"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_136"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzM4MDQ_6a68b9cd-5e87-4def-98e4-d9ef40c6bbee" continuedAt="ie4f7681175814bbfb1d0f5a38aa146c3" escape="true">Description of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ie4f7681175814bbfb1d0f5a38aa146c3"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE&#174; Liposomal 590 mg Nebuliser Dispersion. ARIKAYCE received accelerated approval in the United States (US) in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension and other rare pulmonary disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzE1MzM_6988e26b-155b-49d4-b568-a83dbb7f0c43">532.8</ix:nonFraction>&#160;million in cash and cash equivalents as of December&#160;31, 2020 and reported a net loss of $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzE2MDE_646e43a9-2946-4e48-9c34-eec776bedca3">294.1</ix:nonFraction> million for the year ended December&#160;31, 2020. Historically, the Company has funded its operations primarily through public offerings of equity securities and debt financings. The Company commenced commercial shipments of ARIKAYCE in October 2018. The Company expects to continue to incur operating losses both at its US and certain international entities while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing and commencing commercialization activities for ARIKAYCE in the US and Europe, respectively, continuing to invest in pre-commercial and regulatory activities for ARIKAYCE in Japan, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the continued commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop brensocatib and TPIP and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the year ended December 31, 2020, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzM4MDc_541b6eaa-6f18-43dc-ad63-ede9b2f09024" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, and Insmed Italy S.R.L.. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:nonNumeric></div></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg3_3e41be84-07f5-4e18-bcef-f6a01dab4861" continuedAt="i7223a8c693d84555bc44368dabdda9c5" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:continuation id="i7223a8c693d84555bc44368dabdda9c5" continuedAt="ia77fa8704b514e82b20d9e87914ffd30"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcz_6669fa68-d941-4fc8-b155-01591e537941" continuedAt="i635171dd7a8e44c8bcbaaafb486d68a6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and </span></ix:nonNumeric></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="ia77fa8704b514e82b20d9e87914ffd30" continuedAt="ib793682255ea47a0879a516c452f925b"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i635171dd7a8e44c8bcbaaafb486d68a6">judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="insm:InvestmentIncomeExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgx_f04b8c58-e87f-48e9-94ca-ef47feb6c697" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Income and Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTE2_1ed62c9a-d734-4bbd-af76-ef2f9881d123" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzQzOTgwNDY1NjM1NTI_960a1836-bb02-495b-b25c-e5f9bcc8267c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accounts receivable are recorded net of customer allowances for prompt pay discounts, chargebacks, and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, expected credit losses have not been material.</span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgz_4978c726-8e41-41d4-a81b-af636f5525d1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of <ix:nonNumeric contextRef="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE0NzA_dac2038e-d047-4139-a9f3-37e4d42a1171">three years</ix:nonNumeric> to <ix:nonNumeric contextRef="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE0NzY_bfff628a-deb6-4c5d-8afb-adaa3aa5fb07">five years</ix:nonNumeric> are used for computer equipment. Estimated useful lives of <ix:nonNumeric contextRef="i0ff79db52eb84c4598d7b7afcb119dfe_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE1Mzg_0111c14c-5568-4552-977c-7b3bbceb0825">seven years</ix:nonNumeric> are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDk5_bb935360-2972-4c56-8568-a2941ef36a54" continuedAt="ia1920f05eb0c4e429e0f40ecc3566a78" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. </span></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ia1920f05eb0c4e429e0f40ecc3566a78" continuedAt="i5861fabceb8b49ebbf3e57e416bb4de0">Impairment Assessment</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5861fabceb8b49ebbf3e57e416bb4de0">&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets.</ix:continuation> The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at December&#160;31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg4_62099d4b-8c57-41a1-b84c-9e70cad5420d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc0_3bd17a57-5fa9-40d4-a31d-480d42786751" continuedAt="i2e077ead83874f028b289c2ca0aedc25" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="ib793682255ea47a0879a516c452f925b" continuedAt="i5496109ec08147f890a3b0026b6a9bb8"><ix:continuation id="i2e077ead83874f028b289c2ca0aedc25"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's only financial assets and liabilities which were measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019 were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemptions and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc1_ce2bafad-eec3-4af8-bc60-1a9252969c4c" continuedAt="i94af7c099d3044be9525379572be42de" escape="true">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><ix:continuation id="i94af7c099d3044be9525379572be42de"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"><tr><td style="width:1.0%"></td><td style="width:32.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.339%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.939%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.939%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5f902b0ea148debdd39b7e096ed23b_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtMS0xLTEtMA_6c8b7a80-238d-4cd0-81f8-00536483d742">532.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad75b5ff0eb42f79faddf5ae9746ddb_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtMy0xLTEtMA_30799607-5de8-4d19-9e43-a7908ac65f53">532.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtNS0xLTEtMA_4f458322-c6a8-40e3-ac61-b7c6d02243c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0818f19ecc45e8bffe1b74c6ecc287_I20201231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtNy0xLTEtMA_4f88d25e-7c7a-48a0-aed2-0465035b73bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33069948ada4260b9525905a9028722_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktMS0xLTEtMA_ea395554-da12-4df0-a17e-c66a0704ea8f">487.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefdcf33de75d49cba0e70cc7853c3280_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktMy0xLTEtMA_32e5c7f3-f5d6-44e0-9a3d-d529bff881b6">487.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f8752f81b5546f6aac228d90c7b03d4_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktNS0xLTEtMA_5bba639b-5b39-4a20-b737-5e8a6df1f6f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c48b09e6691416abc16070aff6792d2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktNy0xLTEtMA_7f8a7aeb-fbb1-4fc0-885a-8da840d945a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were <ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="insm:FairValueLevel1Level2Level3TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYyNTI_07835b5c-6a37-4409-aec4-4f23b0f7b99f"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="insm:FairValueLevel1Level2Level3TransfersAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYyNTI_a6a27b27-d336-41e1-bc8d-6681290e31c1">no</ix:nonFraction></ix:nonFraction> transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during 2020 and 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company held <ix:nonFraction unitRef="security" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYzNjA_8a8f7f82-6fac-48e5-bfa5-d246400831c4"><ix:nonFraction unitRef="security" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYzNjA_8d6e7322-96e6-43e9-859d-f32bb83dc18e">no</ix:nonFraction></ix:nonFraction> securities that were in an unrealized loss or gain position.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the <ix:nonFraction unitRef="number" contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzY5NzY_105845b7-b422-4274-86bc-ed429c1bf987">1.75</ix:nonFraction>% convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzcxMjM_7fc8a09a-7842-4a3b-874e-3e4096524f92">516.4</ix:nonFraction> million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The $<ix:nonFraction unitRef="usd" contextRef="i9bd7a24933d64c00a17e23166ddcb249_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzcyNjM_2460631a-5186-4dd6-916f-cdeefecb3e94">356.3</ix:nonFraction> million carrying value of the Convertible Notes as of December&#160;31, 2020 excludes the $<ix:nonFraction unitRef="usd" contextRef="i93c687c71117495bbb85688c2e6da53f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzczMjk_d1e7c457-2d68-4149-a86d-358413d7f489">88.0</ix:nonFraction> million of the unamortized portion of the debt discount.</span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDY3_61b7dbd8-8e10-4f72-a167-e9b38488aacb" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="i5496109ec08147f890a3b0026b6a9bb8" continuedAt="i1f87df3640a54c77b72a775333cc1c2c"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTIw_f41b7774-3fe0-4f4d-87e4-dca2de99da03" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg1_c2a1be5f-04ab-47ec-b0a4-ec17effedb04" continuedAt="ie0829ff907d1405da66ffc7c7d119663" escape="true">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><ix:continuation id="ie0829ff907d1405da66ffc7c7d119663"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"><tr><td style="width:1.0%"></td><td style="width:51.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.933%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Gross Product Revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2557ec52f167465a9db110f78f63cea9_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzItMS0xLTEtMA_dd8a1741-8475-4e90-af9c-9e337bd090ca">28</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i017d5966090a4b0ab4fb5abb56c17d5c_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzItMy0xLTEtMA_a9bd5739-b537-4e4f-bb21-43a14707b29c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8b1b88435bd44aeb678f80443f3d14c_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzMtMS0xLTEtMA_7738044f-0cd4-4ab1-b355-469f7a433eae">27</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i84af194151234369a03dc3fdf9ff1c60_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzMtMy0xLTEtMA_dbc2a82e-db95-4bde-9741-46426aab016a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9ad5a7b26844352bc3de93a1fa02e5d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzQtMS0xLTEtMA_d2a76bf3-49dd-48cf-932f-794dc24347cb">23</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41b33cfe7496472887a9b46f5bb1a64e_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzQtMy0xLTEtMA_059fb3d2-392a-49ee-943e-da9256e2d29a">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</span></div></ix:nonNumeric><div style="text-indent:42.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc2_d2a7487d-b1e2-43fd-9986-5438018c654b" continuedAt="i8d2db307957149879b2e76191ca78d6d" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist primarily of net sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. The Company's customers in the US include specialty pharmacies and specialty distributors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="i1f87df3640a54c77b72a775333cc1c2c" continuedAt="i28715cf08e32410aaa2810a6ea34c9e8"><ix:continuation id="i8d2db307957149879b2e76191ca78d6d" continuedAt="ia342eae87f8c494881c883ebb7e993af"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees for services are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and fees and, therefore, deducts the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTA0_5b4030a5-f5ad-4572-b289-a62f644c03bb" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"><tr><td style="width:1.0%"></td><td style="width:37.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Credits, Fees and Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks and Co-pay Assistance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if411584126e147579c1290e85b019267_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtMS0xLTEtMA_7280d542-1cc2-4950-b389-38f120352ecf">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d80ecd614a347319af9d2f44019b7f0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtMy0xLTEtMA_f1501038-250d-44af-8290-663d504cc72e">5,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtNS0xLTEtMA_ded8514a-e745-4d62-a445-7086571773e3">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItMS0xLTEtMA_10c98090-cdde-4436-a20c-1c11338e268a">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItMy0xLTEtMA_9ca24adb-98fb-43b7-b191-04cde8578ffb">18,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItNS0xLTEtMA_b1d7f4fc-0b10-4934-b70a-e78faf5ef0ce">21,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtMS0xLTEtMA_689c76a6-fe62-4954-a9d7-58c2c94c498a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231" decimals="-3" sign="-" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtMy0xLTEtMA_e1acfa8f-fe73-4ffc-a9a4-d2d1d8ef3dd1">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtNS0xLTEtMA_027c1448-5250-463a-a0a6-7edf26c5d171">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtMS0xLTEtMA_0a2d045c-59ce-4365-94ff-cdde95d1cfec">3,742</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtMy0xLTEtMA_d4d94ad4-315e-431e-9e91-5dbb386b1caa">18,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtNS0xLTEtMA_3c891a3b-d63f-4989-8831-e6912804eefa">22,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84042da0fe82481489bbac6622c413bf_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtMS0xLTEtMA_f5ff148a-9d3f-49e8-a29c-fe6c6fa8f11a">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d6098b4cd2462ea2fe95fdcfff87a4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtMy0xLTEtMA_1e337e6d-40f5-48fa-9390-907e3302cd05">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtNS0xLTEtMA_b22b1de6-472c-4b31-adc9-384de13c21d2">4,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed9d4ebbe0c4a5c90652308ad3ede36_I20181231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctMS0xLTEtMA_94f08a0d-a447-4a1b-a0f8-353f1a8b0c3d">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if454ac4f869c4464a82f74996dd1dcae_I20181231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctMy0xLTEtMA_57132e75-c7d9-4130-a182-e224597602e7">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctNS0xLTEtMA_ddefdba9-4bc0-4dc1-bb8e-f2d7f9705ba1">922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtMS0xLTEtMA_8d5facbd-b7b2-41b9-bf41-033bd5d280b4">3,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtMy0xLTEtMA_8696173e-218d-4805-bb23-fb1c0b299d7f">12,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtNS0xLTEtMA_5955fbe2-5cb9-4f6c-b188-761d5bd7feba">15,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for prior period sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231" decimals="-3" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktMS0xLTEtMTYzOA_6bf0f53e-ec62-413e-abd2-2808ab68b9b6">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231" decimals="-3" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktMy0xLTEtMTYzOA_382d18ba-5039-4327-aee0-831b1d6c12e0">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktNS0xLTEtMA_90477c8d-5d0c-43d7-99a3-f4b8f3ec978f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTEtMS0xLTA_e392f8d6-a48b-4920-b10e-e5be8b9f3610">2,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTMtMS0xLTA_a2a84391-c27d-4180-9e32-c988aec3f751">7,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTUtMS0xLTA_b64fb7c3-f94e-4a47-917f-3f8de953641e">10,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if411584126e147579c1290e85b019267_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTEtMS0xLTA_756b87d6-59d5-4258-a2b0-7c3365090049">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d80ecd614a347319af9d2f44019b7f0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTMtMS0xLTA_4218223f-6147-4085-9c35-926b4e8c5091">5,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTUtMS0xLTA_3481350e-2217-4ea9-a58c-abab3c5efac7">5,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to certain early access programs (EAPs) in Europe, consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation, or ATU) and from the named patient program in Germany and </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="i28715cf08e32410aaa2810a6ea34c9e8" continuedAt="iace62f23e486416aa32add057ef37421"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia342eae87f8c494881c883ebb7e993af">other countries. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. In December 2020, the Company began recognizing product revenue from commercial sales to Germany subsequent to receiving approval by the EC.</ix:continuation></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDY4_254f20c6-7859-4fb2-bc4a-2c823a3e7c70" escape="true"><div style="margin-bottom:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first-out (FIFO) flow of goods.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTIz_cd86ac6b-c2a9-4d4a-bac4-0274815d84ce" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, including medical affairs. R&amp;D expense also includes other internal operating expenses, the cost of manufacturing a product candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. The Company's expenses related to manufacturing its product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture its clinical product supply of ARIKAYCE, brensocatib and TPIP. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</span></ix:nonNumeric></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTI0_800b3dbf-f5c1-4e49-b877-16905443335f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. The Company may also grant performance-based stock options to employees from time-to-time. The grant-date fair value of performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc4_ea8e8857-f8de-4fb8-982a-abbc1d73e74a" continuedAt="i60322c03752349fe9456ad7c0bde0c95" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="iace62f23e486416aa32add057ef37421" continuedAt="i1ed8ea2770e543e4ad7e126563adacc8"><ix:continuation id="i60322c03752349fe9456ad7c0bde0c95"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that is more likely than not to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision in the consolidated statements of comprehensive loss.</span></div></ix:continuation><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTA4_87a5f564-2365-4457-998b-7f417e60a1cc" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcx_88836ddd-5f3b-4767-8c5a-89612efb3ded" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtMS0xLTEtMA_28f0aaa4-20c7-43c8-a2db-45a08746d1c4">294,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtMy0xLTEtMA_9202749f-b0d5-4dc2-998b-576a32cbbe0e">254,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtNS0xLTEtMA_53318afb-a356-43dd-88c5-720fc475b83b">324,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtMS0xLTEtMA_2455caed-4e6a-4da6-9358-51617e2cd3b0">97,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtMy0xLTEtMA_f6d8e62e-e029-48d2-86f0-3920dd87fa28">84,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtNS0xLTEtMA_f76bbb0a-7716-424b-afab-94c6b27d242f">76,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e32e7ead80245768a4215e36f3d013e_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtMS0xLTEtMA_8f6367cf-b1d1-4fe0-ba62-0c11b501f02b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a17ed1cbdfb44299c8d6329a58ecd20_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtMy0xLTEtMA_b4b0096f-164c-4a7b-b3e4-4a6132109740">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b73eefc9dfc4da4b954ad4f37d36401_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtNS0xLTEtMA_3c14c9d2-2d32-4237-a07a-d081082e5575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktMS0xLTEtMA_040f6aec-a3b5-4891-b1e6-7cd3e1676535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktMy0xLTEtMA_d1b631f1-6da5-4568-905d-db4fa205969a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktNS0xLTEtMA_9f17db5e-beb8-4d24-b19f-8c031e57f501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaeb953793f734b5fa4ff72faaca69bed_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTEtMS0xLTA_042c3715-9abe-4193-a6c9-79775393f09c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b1e8f8d82d740f2a0b6f1636a4984fb_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTMtMS0xLTA_94525779-6aba-4d19-8960-28d4922a600b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e26a169ca6447e1bbd8420534209dd4_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTUtMS0xLTA_df175372-cfc7-453e-8b44-5f4456e7b345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTEtMS0xLTA_4900394e-650b-4b20-8a98-0b5d6893ad12">97,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTMtMS0xLTA_5df5a316-7fa4-4621-88bc-4007c9681a95">84,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTUtMS0xLTA_5c31e37b-bb80-47eb-b525-50fd7240737e">76,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTEtMS0xLTA_3e4e48ba-8784-4ec9-a00d-0fc73a20551b">3.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTMtMS0xLTA_b8f5044e-1b80-4beb-831c-b407a8bd9e26">3.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTUtMS0xLTA_17e9321b-2801-4a8c-80a2-d4a314c80e3c">4.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTE4_611e71d8-406b-40d9-86e3-31d7645406eb" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItMS0xLTEtMA_11a0c075-386c-4dd0-a9a7-6b5d93558998">12,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ff567a613c140aa9f850be249a8a85f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItMy0xLTEtMA_fd4e831e-a09c-420b-9c02-c86d74ff7ca4">10,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d1b35f80d7c4963a103aa9c2ed57381_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItNS0xLTEtMA_47b95f1a-2da8-45d5-ad11-d9e710e72c22">9,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f1f6e025d01493c8f016b27c71e8c6c_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtMS0xLTEtMA_51975850-0697-4c80-ba71-237c9e66a9ec">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97d0d45f93fd42eaa738fe0fc6f368ff_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtMy0xLTEtMA_f748dc22-8ea9-498a-8d8c-b2a8cd1c8c74">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8918052cbd746439e9093c317f861e3_D20180101-20181231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtNS0xLTEtMA_bb752289-03dd-41cc-889b-c3e60899c116">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib892164ea751411ca150501c187370ec_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtMS0xLTEtMA_480ccc08-e093-4330-97e9-ee5a61d39398">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida80845cbee243b2815d745facfea2d3_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtMy0xLTEtMA_e3210ea1-07c6-4c10-9c89-395f975a5f2c">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf9ed33bf5454a7d8711743ff01550c0_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtNS0xLTEtMA_ee0f868b-9db1-4d98-b168-a48bdbd24406">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgw_1da162a3-6b4c-4832-9312-6c982511d818" continuedAt="id092410b47d74ed3b44ef58480c66195" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term on the balance sheet. </span></ix:nonNumeric></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies (Continued)</span></div></div><ix:continuation id="i1ed8ea2770e543e4ad7e126563adacc8"><ix:continuation id="id092410b47d74ed3b44ef58480c66195"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of comprehensive income in the same line item as expenses arising from fixed lease payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 842, leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information presented prior to January 1, 2019 has not been adjusted and is presented in accordance with ASC 840. Refer to the Recently Adopted Accounting Pronouncements section within this note below and Note 7 - Leases for details about the Company's lease portfolio, including Topic 842 required disclosures.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcw_1309b760-881a-44e7-85b8-0f64b838ffa7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company currently operates in <ix:nonFraction unitRef="segment" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzI2ODAz_1dee9929-892d-4406-9f04-a6da3f24b4e4">one</ix:nonFraction> business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has <ix:nonFraction unitRef="segment" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzI3MTY4_e3fcff2d-5fbb-400f-8a69-1f0c4e5d97b0">one</ix:nonFraction> reportable segment.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTAx_a43868cf-518b-4356-89ae-e540b33d6a87" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8212; Credit Losses, which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. This ASU amends the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 effective January 1, 2020. Different aspects of the guidance required modified retrospective or prospective adoption. Adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Accounting for Convertible Instruments, to reduce the complexity associated with applying US GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company is currently evaluating the impact of adoption of ASU 2020-06 on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_142"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90ZXh0cmVnaW9uOjNmYWUzOWJjMTQzOTQ3MThiZTM1Yzk1MmFjN2RlNjAyXzU0OQ_2af3bc3a-c0bd-410a-9577-347d83dda0ee" continuedAt="ie87950e2876f4e8481a852e5f4d7a955" escape="true">Inventory</ix:nonNumeric></span></div><ix:continuation id="ie87950e2876f4e8481a852e5f4d7a955" continuedAt="i7ef0101d4c854880943f3700c30efcdb"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90ZXh0cmVnaW9uOjNmYWUzOWJjMTQzOTQ3MThiZTM1Yzk1MmFjN2RlNjAyXzU1MA_bc871508-569c-46e5-b361-af8ee8d0ba3a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands): </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"></td><td style="width:49.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzMtMS0xLTEtMA_c70bff4f-ec02-4465-b299-b5bb5fd08abd">21,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzMtMy0xLTEtMA_78c03c54-93ec-40bc-b0dd-6ffe08c34d29">16,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzQtMS0xLTEtMA_29a2addf-332e-4217-a6c8-545ee6432ef3">18,754</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzQtMy0xLTEtMA_15214fb3-7884-4895-81cf-e75a53a94f9b">6,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzUtMS0xLTEtMA_088c305f-7595-417a-9476-5f3287572700">9,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzUtMy0xLTEtMA_406d5361-6cff-41e8-ac2b-2085d8f12cec">5,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzYtMS0xLTEtMA_c520b181-e5c2-4c89-a734-10438f27383e">49,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzYtMy0xLTEtMA_2307f3e5-ce97-463a-9c97-3be022de3370">28,313</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ef0101d4c854880943f3700c30efcdb">Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzkzMA_319e6d3d-1a01-47d9-a74b-14bf23643ba4" continuedAt="i572153e913504d94a1035a8916f74b98" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="i572153e913504d94a1035a8916f74b98"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value as well as milestones paid to PARI for the license to use PARI's Lamira&#174; Nebulizer System for the delivery of ARIKAYCE to patients of $<ix:nonFraction unitRef="usd" contextRef="iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzMwMg_6e47313c-8db7-4c0a-9b4c-544282fcb2dd">1.7</ix:nonFraction> million as a result of the FDA approval of ARIKAYCE in September 2018 and $<ix:nonFraction unitRef="usd" contextRef="i1bd637936ab04afab59656afc255fd17_D20201001-20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzI3NDg3NzkwNzA3OTY_c0dcf7f8-b9be-4f73-b1fa-f91d1e3fed2c">0.6</ix:nonFraction> million as a result of the EMA approval of ARIKAYCE in October 2020. Total intangible assets, net was $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzUxOA_4c1aeb25-820c-4305-8ac9-ce702c1d0d9c">49.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzUyNQ_1d8c5734-fb40-426a-892e-29c1898becb5">53.7</ix:nonFraction> million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began amortizing its finite-lived intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzY5OA_b691fef5-8833-4d1d-84e7-70df2efd9b42">12</ix:nonNumeric> years. Amortization of these assets during each of the next five years is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_1a4e0df3-6239-4325-87d1-84d2b55885e0"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_c0bd14f2-c793-4994-a4d3-3f7bf47536b1"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_d7aa64f5-b32d-4884-9616-73b0b0a0703d"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_dd1c93f8-bb25-4002-bea0-e22e40022323"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_e32d5d38-24b0-499e-bdb8-a45926e1f977">5.1</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. </span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzkzNA_6e847003-c96b-4d14-ae6a-821c0011d93c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's finite-lived intangible assets for the years ended December&#160;31, 2020 and 2019 follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"><tr><td style="width:1.0%"></td><td style="width:30.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42ea68e2b42646b1959bc8837fbc4bcf_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtMi0xLTEtMA_90a8ebda-6db1-45f3-aa59-a90fc7df714e">52,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc7b7bc070a40c891c23f07c65ed05a_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtNC0xLTEtMA_72b90eb3-fcfa-4c7a-998c-163a26894849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24f4981464504148bd4aa06dc574e5ef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtNi0xLTEtMA_a89bf702-9408-41aa-af27-04d1cdad441d">4,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24f4981464504148bd4aa06dc574e5ef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtOC0xLTEtMA_118ac474-8684-4d37-bd58-47199e801bd0">47,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ded28353bf643aa99d3cb05cc110533_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtMi0xLTEtMA_5c7b92e0-6049-4e22-afd3-01cfa331c31f">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19cd90bf12b4d9eb4da95674aef4152_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtNC0xLTEtMA_95dbe50a-147b-4cbc-be14-a6d24fafb4e4">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0bd03488004153b5268b5e73764e14_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtNi0xLTEtMA_40b17cc0-b21c-4efc-876c-2b91ca7fbb1a">153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0bd03488004153b5268b5e73764e14_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtOC0xLTEtMA_5d919a8e-bc81-4cdd-acc4-cfddcfdaa662">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48973993a3149f79721dd24b81a822b_I20190101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtMi0xLTEtMA_093c836d-897c-4013-8457-e841fe8ef2c9">53,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtNC0xLTEtMA_492cf7b6-5be6-46f4-aaf0-5d6c192f78e6">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtNi0xLTEtMA_dedef5e6-1fe6-44fc-bfa3-68c9971cfc88">5,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtOC0xLTEtMA_a7c1c584-c816-4516-ad35-b21b9b183928">49,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief073ee95b334197863c0f30058817dc_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktMi0xLTEtMA_e1b5d7ef-3178-468c-837e-75a0adc39ea6">56,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb4c16988e4465da82e7f50e0573676_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktNC0xLTEtMA_d0d1af5e-e341-441a-bc97-bcaa978653fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia660e683387d45a2ac6386d394562fcc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktNi0xLTEtMA_20b65c60-757d-42a3-b2fb-1cca296314dc">4,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia660e683387d45a2ac6386d394562fcc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktOC0xLTEtMA_7ddac8a8-1ac6-42d1-a105-0bd35c1052eb">52,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfb89dc31514ee5a530da7763685f22_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTItMS0xLTA_66fefc7a-fbf1-4364-b7eb-39b020b6ac04">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83673d124194183900e1755392dbac3_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTQtMS0xLTA_ccdb3808-b61e-4794-8bdd-92c31e80480e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e98f2e617b543ad8b634db7a4621957_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTYtMS0xLTA_e9f6e7c2-13a9-467e-9ab5-c401a0c83a47">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e98f2e617b543ad8b634db7a4621957_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTgtMS0xLTA_6e523a54-0b88-4bba-a217-cbac118045f3">1,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a79104934c4503861efdd407cf050b_I20180101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTItMS0xLTA_a6e71f2c-d99b-4b01-bba5-085cfa4a896f">58,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTQtMS0xLTA_aeceac2d-54e3-4e70-873b-fc730fa7d137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTYtMS0xLTA_6ef23a55-9979-40ab-bfcf-3f6ece93a5ba">4,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTgtMS0xLTA_628a0b44-8129-45b8-8f8c-299e778cf4a2">53,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_151"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzYxMg_61cb9757-07c4-49db-92d6-21eb46509d50" continuedAt="i62a120df4e5847c3a300e4d457e8c2bd" escape="true">Fixed Assets, Net</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i62a120df4e5847c3a300e4d457e8c2bd" continuedAt="i5d59f2d76a054f90b79d7b3b10002f5a"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzYxNQ_083915da-0959-4e14-aa86-eb973dd4ea59" continuedAt="i61583d364e81490f9ba82b924eb493f9" escape="true">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span><br/></span></div></div><ix:continuation id="i5d59f2d76a054f90b79d7b3b10002f5a"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i61583d364e81490f9ba82b924eb493f9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.877%"><tr><td style="width:1.0%"></td><td style="width:40.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.663%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.666%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i74a83453ffc34b6295f8aff4ef7b27d1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItMi0xLTEtMA_fb806e90-6acf-4f9b-b951-e33197afcf51">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1633bbde7149ff91f24bafaf35316e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItNC0xLTEtMA_40310198-0a5d-4431-966f-c486d9f4401f">10,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cd0f2ffc22f44e4bddc73e49309d010_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItNi0xLTEtMA_2935ac67-1581-4eee-a4c2-33a471e5794b">9,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11fda285397a42e19d6a260af7e5f67d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtMi0xLTEtMA_09bc6183-533d-4c99-9d79-fe01161eeb9b">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e287d9cd08c41e0b6d0fd2c3d4b5fc8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtNC0xLTEtMA_5561e756-e1da-4c0a-8166-8a65e0cb0fea">5,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b08ca4050e48bf96bdaea7bcd7c871_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtNi0xLTEtMA_016c932f-b7c2-44aa-9aad-63a331f0ae0e">5,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtMi0xLTEtMC90ZXh0cmVnaW9uOmU1YmVkODRlZmVjYTQyMzFiMTdkMWY4NmVmYjhiNzMwXzQ_86b1b8d0-0bc1-418c-b821-fee0f9f84318">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtMi0xLTEtMC90ZXh0cmVnaW9uOmU1YmVkODRlZmVjYTQyMzFiMTdkMWY4NmVmYjhiNzMwXzk_83c3769f-1a5e-4a90-a245-8dbff32ef1d8">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i955be7a501ea48619d13734d6154f45e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtNC0xLTEtMA_cfef3eb6-9384-468c-8da9-0df4cbbd2b57">7,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i641fb1bda4d041b9b0710d36df07d468_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtNi0xLTEtMA_3a81c8b9-f4af-477a-83a4-3c3bcd491990">6,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibcda52d10cc646e78962f9e2486e8cbf_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtMi0xLTEtMA_73001041-6957-4407-939a-346a7d8a207f">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68616dc8974c4009a3f605818d4e3333_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtNC0xLTEtMA_6addb3e2-db5e-44d7-afae-f741d74d8dd2">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05db6e937b5d40acb4c6da58c96aed34_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtNi0xLTEtMA_9fc4dfd0-33c7-4493-a95b-4f519a47364c">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic3620656a3d74b50befaf129855bc9d8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtMi0xLTEtMA_9747b545-3418-4924-8396-1dd4026c11bc">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c99f6855754004b7860cc3f26ae215_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtNC0xLTEtMA_ab4a52bd-0e0f-4483-b9ef-d29a9687a710">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i829ced73ae454a818b994f29cf817fb7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtNi0xLTEtMA_b8564513-ceb0-4b58-88ff-4e0198a6d219">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17adbf61f3554994afc5c8d08ee421ac_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzctNC0xLTEtMA_41282420-620c-4c00-9ba4-0a0bb5cd457e">35,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336952f723a45f7aad277d34fd71fc0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzctNi0xLTEtMA_7dac485d-f746-4b1c-8759-0029ba839abe">33,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0653aae9e65348feaa6920fe60047862_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzgtNC0xLTEtMA_b6de4b3b-036d-4794-a917-86290b595024">21,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ad290bf1da9470cbb52bc0838395dc6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzgtNi0xLTEtMA_46af7322-4357-4dde-af42-f39308a9eea2">21,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzktNC0xLTEtMA_a6bdffee-c274-40fc-861c-7074053f536f">82,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzktNi0xLTEtMA_477ab144-9356-4b00-977a-83796c312aab">79,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzEwLTQtMS0xLTA_f3fede38-ce10-4f61-9f95-dc00780f239f">28,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzEwLTYtMS0xLTA_5ed41081-5faf-448a-bf17-00c9fc12c5e2">19,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzExLTQtMS0xLTA_a1856a8f-900b-4ec4-901c-8f3a79788a37">53,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzExLTYtMS0xLTA_d9fb7028-65c0-4f2a-a7dd-49d8aefa4c8d">60,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzI3NDg3NzkwNzAzNDg_edceb9c3-b296-4d0d-babc-d4e13b8b2f66">9.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzU1Mw_e9b9a3eb-47a0-4f72-b09c-5d446d4cc368">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzU2MA_7c0b7939-1ab6-4732-9122-3e5fc9e6a5af">3.6</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:38.25pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_145"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90ZXh0cmVnaW9uOjhmM2ZlMjFhZmEyNjQwOGFiZTEyZGJmYjBkYmUyZmFlXzky_f4d13e55-d646-463c-8884-d3821e92311f" continuedAt="i9e1c81ced0ff45009f9895484fd8a6a6" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i9e1c81ced0ff45009f9895484fd8a6a6"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90ZXh0cmVnaW9uOjhmM2ZlMjFhZmEyNjQwOGFiZTEyZGJmYjBkYmUyZmFlXzk0_bbe581fb-c362-4dc3-8dbd-b7cf6acdad0d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:71.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.104%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedClinicalTrialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzItMS0xLTEtMA_1d1d2667-cea2-46f6-893f-c6ca037f4859">6,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedClinicalTrialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzItMy0xLTEtMA_1cb91c31-cbf6-4054-8ae3-e188e4f81a7a">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzQtMS0xLTEtMA_db8e9ea3-0bd9-4f52-b751-d3398a0e5096">8,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzQtMy0xLTEtMA_87f234e4-cdff-4502-8bd7-585ac7685a0e">12,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedTechnicalOperationExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzUtMS0xLTEtMA_6f097170-fc6e-466c-b25f-92d026fcbf7c">9,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedTechnicalOperationExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzUtMy0xLTEtMA_358bb541-f4d3-48f5-981b-cf159d56d081">6,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzYtMS0xLTEtMA_8c41888b-43a2-4331-aab7-727b4ab55b2d">3,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzYtMy0xLTEtMA_2fd42250-efe5-45d2-bb7b-a6dc09fb7c5e">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzctMS0xLTEtMA_f7b91f4f-96bb-4d24-938e-7b206152226e">3,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzctMy0xLTEtMA_8f99db4d-3f51-4598-b205-a85272a2edce">3,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedSalesAllowancesandRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzgtMS0xLTEtMA_34bb2ed9-c886-4bde-9617-ea3d7edca5fc">5,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedSalesAllowancesandRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzgtMy0xLTEtMA_86211e06-dbdb-4508-8c73-581a7b028d2c">5,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" name="insm:AccruedConstructionLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzktMS0xLTEtMA_b0e3d520-06a1-4054-9c15-db9529022cea">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:AccruedConstructionLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzktMy0xLTEtMA_7cdb8e64-2973-4de2-b29e-03dcec6bca0f">2,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzEwLTEtMS0xLTA_8c0a5a61-2878-48fa-aca0-aec74e0bb37e">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzEwLTMtMS0xLTA_d827fd07-f3d6-4c84-a9f6-79ec4c9c8c7f">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzExLTEtMS0xLTA_3e42ebbb-81af-42d8-bc49-eb213d18e1db">37,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzExLTMtMS0xLTA_63de8253-3e2b-4df2-9995-5bd238c8b312">40,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODM_2e71e150-2d44-4ed2-af87-0fa270da2558" continuedAt="ic15b1524cc374c1faa3acda3e035a6b5" escape="true"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODM_52261b68-b4f2-4879-86c1-8387a9d57627" continuedAt="i198a1d9645f348e99fd38c964c20e0d7" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ic15b1524cc374c1faa3acda3e035a6b5" continuedAt="i4f399f5d625c426eac826992d13f28b2"><ix:continuation id="i198a1d9645f348e99fd38c964c20e0d7" continuedAt="i4f39411e640f49a78b9e845f4ab2f7ea"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office space, manufacturing facilities and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's corporate headquarters lease, which is classified as a finance lease. The terms of the Company's lease agreements that have commenced range from less than <ix:nonNumeric contextRef="i2f74877e573149a898ea49344d4209eb_D20200101-20201231" format="ixt-sec:durwordsen" name="insm:LeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI5NjI_fe598305-91cd-4908-a3b4-c662371981bc">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i13a7dcb8a06842e7ad8e6b069114005d_D20200101-20201231" format="ixt-sec:durwordsen" name="insm:LeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI5Njg_d4fb1fc9-4738-4f7a-906d-8fc32c7d2c6b">ten years, ten months</ix:nonNumeric>. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Leases (Continued)</span></div></div><ix:continuation id="i4f399f5d625c426eac826992d13f28b2" continuedAt="id1f2b022b7bc480faf55b53abe31f468"><ix:continuation id="i4f39411e640f49a78b9e845f4ab2f7ea" continuedAt="i468afd7e07d742ad9b150d082d23d8c3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODQ_dab1eb1a-3bfb-44e5-b691-9341ece469d6" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.807%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.423%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzQtMS0xLTEtMA_3635457e-e5c0-4e58-86b2-69e9fecc9049">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzQtMy0xLTEtMzA2_9673a01c-9dbd-495b-97a1-c6b3303b3220">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzUtMS0xLTEtMA_1458258d-0f87-4da5-b549-29fd05f73f81">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzUtMy0xLTEtMzA2_bfe13277-e59f-4859-863e-29980be85a5d">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzYtMi0xLTEtMA_18c7cf55-d92b-4617-a4d6-59a7d3aeef3a">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="insm:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzYtNC0xLTEtMzE1_a328c85b-f442-40cc-a9ae-23834e768e1d">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzctMi0xLTEtMA_a180a9e3-6870-4da1-bf4b-48acf41b9108">8,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzctNC0xLTEtMzE4_b097b62f-8f52-476f-89cf-17243aacddb0">12,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtMi0xLTEtMjE3NA_3507bf6f-6b48-4d44-b264-6df6b25eea39">9,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtNC0xLTEtMjE4Mw_490a9930-7ee4-4753-a166-6f121b1024a3">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtMi0xLTEtMA_916a0b5d-249e-4235-86b9-e33044e28bad">20,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtNC0xLTEtMzE4_a1fd2a29-97b2-41ac-a684-790d7b25e202">13,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEyLTItMS0xLTA_5c84a656-9633-4582-99cf-0df300e209e5">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEyLTQtMS0xLTMyMQ_0a890078-c279-48dd-ad44-9f8162958d70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEzLTItMS0xLTA_88320428-5f45-472c-9ed0-74ad881de473">8,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEzLTQtMS0xLTMyMQ_732e53e9-1d20-48cc-99d7-d8980a4ec4ce">10,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE0LTItMS0xLTA_fb0f2844-44da-4bd5-836a-36a1cf9f5aaa">936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE0LTQtMS0xLTMyMQ_10d9937e-c047-450d-9197-052e6f62ec42">4,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE1LTItMS0xLTA_497c3d97-b48c-4806-bd32-6de842efcfdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE1LTQtMS0xLTMyMQ_d6d6a5ed-6922-4d8f-bf29-82cc1f845248">20,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE2LTItMS0xLTA_6a13aebd-4bda-46e3-a1ee-712bbd50793e">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE2LTQtMS0xLTMyMQ_61acdcd7-bb18-4ee6-850b-36371cb79562">47,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE3LTItMS0xLTA_dac4043b-c8e6-48d6-837b-8c11d40befb4">9.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE3LTQtMS0xLTMyMQ_b4b806d8-68d7-49fe-832d-3a315d331d52">10.6</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE4LTItMS0xLTA_15ec43cc-35ee-4be5-bee3-5b2b875570d7">4.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE4LTQtMS0xLTMyMQ_cd02e1fa-191e-4a66-b840-57ea63e8df19">5.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE5LTItMS0xLTA_b0aa34d7-1bff-4609-84cc-6bc0bd6bc1ae">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE5LTQtMS0xLTMyMQ_d9a764e7-673b-45a4-af20-a40139a794fb">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzIwLTItMS0xLTA_d5e9b6bd-156f-4c19-a038-64c4acf3d8b9">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzIwLTQtMS0xLTMyMQ_20cb2196-a480-403c-a6a5-193d3c4bf6ff">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the operating lease costs disclosed above, the Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeasePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI3NDg3NzkwNzkwNTU_1dffa2e5-523b-4f07-b481-c1a617a89f95">9.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeasePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI3NDg3NzkwNzkwNjE_d6218d57-fc31-4056-95ea-009ebc40ac88">0.1</ix:nonFraction>&#160;million for the years ended December 31, 2020 and 2019, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODU_f479e907-8726-46ea-83ca-cf5c10c99254" continuedAt="if2cfdfeb4cf5466d9334a94ae7322f76" escape="true"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODU_f831d803-bf73-4674-b6c3-881d921bc073" continuedAt="i457539fa8e264529af250d96d8fabe94" escape="true">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).</ix:nonNumeric></ix:nonNumeric></span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Leases (Continued)</span></div></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="id1f2b022b7bc480faf55b53abe31f468" continuedAt="iad036b5fd93542e3937ed0d175fdf1a2"><ix:continuation id="i468afd7e07d742ad9b150d082d23d8c3" continuedAt="i7ebc4983656b49baaafad6515514722e"><ix:continuation id="if2cfdfeb4cf5466d9334a94ae7322f76"><ix:continuation id="i457539fa8e264529af250d96d8fabe94"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"><tr><td style="width:1.0%"></td><td style="width:53.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEtMS0xLTEtMA_ce5c13b7-d990-413b-a6de-490b575c1e36">2,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEtMy0xLTEtMA_a5bdb981-d56f-4638-abb1-00b4a13517fd">13,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzItMS0xLTEtMA_cda22e36-cd17-4317-9e11-7e2ce6988d9f">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzItMy0xLTEtMA_9fc313e8-5848-4452-8f96-c0b6c9c61852">6,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzMtMS0xLTEtMA_b9a6ec73-2f3e-4ebf-a0b2-d59cae53630b">1,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzMtMy0xLTEtMA_ff374de0-1f4a-432e-bb4e-d2412c32348e">6,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzQtMS0xLTEtMA_6508f2ff-6091-420f-8106-a22037079ba9">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzQtMy0xLTEtMA_8c7a1299-874c-4280-b496-f8a7fac2b94d">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzUtMS0xLTEtMA_bac47da8-51f2-4503-ae7c-ea76f32b090a">2,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzUtMy0xLTEtMA_3268b985-2a4b-4660-aa29-6b449c0d7427">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzYtMS0xLTEtMA_b319e275-7a09-40d0-bdc7-e54149ecfc6d">12,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzYtMy0xLTEtMA_333081e7-f7c5-4d3b-8127-b568a1863aff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzctMS0xLTEtMA_f3d27941-35fc-428e-b4e5-d9f60e92e3bc">23,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzctMy0xLTEtMA_739a084f-09b9-44b1-9397-cc3065c758f0">37,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzgtMS0xLTEtMA_dbf9bf78-b892-42ce-a7ca-8c0d1a22ea48">7,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzgtMy0xLTEtMA_feb0318d-effe-4d1a-aeec-4f7d08751291">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzktMS0xLTEtMA_b61ee198-5a0b-4679-9b29-ac9dd0a3155d">15,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzktMy0xLTEtMA_5f980216-823e-4475-a6d5-0d144ed6419d">32,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzExLTEtMS0xLTA_66122073-1423-4f1b-8e9b-66f1c7ebf319">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzExLTMtMS0xLTA_f2e28cd2-0e5b-4407-8dfe-ad8e2be19aec">11,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEyLTEtMS0xLTA_1cde5741-5e10-41a8-b4b9-14a6aadb41f5">14,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEyLTMtMS0xLTA_2f52bfb3-f0c4-40e1-bfe5-4030292ea933">21,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEzLTEtMS0xLTA_c45e7748-dbbe-408b-9f27-79f580d687d3">15,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEzLTMtMS0xLTA_d7884512-1c6f-4432-a0d1-daeec718ad06">32,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:continuation id="iad036b5fd93542e3937ed0d175fdf1a2" continuedAt="i7489dd73bde54ec281f36719e2444773"><ix:continuation id="i7ebc4983656b49baaafad6515514722e" continuedAt="ic892adad6abe4f83987245fd5a5b0b73"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU1NDY_90fb26ae-f5db-4ecd-835d-6d3210c5536b">25.1</ix:nonFraction> million incurred by the Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7489dd73bde54ec281f36719e2444773"><ix:continuation id="ic892adad6abe4f83987245fd5a5b0b73">other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</ix:continuation></ix:continuation> </span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_157"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzM_311ff473-dfe8-475a-813a-f31f499188da" continuedAt="i8932432116ac4ec79c44a2d569f4ed9e" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i8932432116ac4ec79c44a2d569f4ed9e" continuedAt="i012f6b7493564d6ba5fc3d24c7ebf09b"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold $<ix:nonFraction unitRef="usd" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE0Mw_f44d4bfb-1883-40fd-882f-5d1b46d517eb">450.0</ix:nonFraction> million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of $<ix:nonFraction unitRef="usd" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="INF" format="ixt:numdotdecimal" name="insm:DebtInstrumentOptionToPurchaseAdditionalDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI5OA_67330e03-678e-450e-b1ad-df95f9ccfe34">50.0</ix:nonFraction> million. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQzNA_db029b95-01e4-4429-aec0-2a4207da558e">14.2</ix:nonFraction> million, were approximately $<ix:nonFraction unitRef="usd" contextRef="i7789efc1fa15465a824da338e733666d_D20180101-20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ1Nw_8583e3c1-aa10-4b8a-9113-802f4a6ef317">435.8</ix:nonFraction> million. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzEyMzA_6f5c6f12-507e-47c2-9abe-ea0594eb5cc0">39.16</ix:nonFraction> per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the <ix:nonFraction unitRef="day" contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE4MzU_d05d3762-4191-44fa-b367-feccfa76eea1">five</ix:nonFraction> business day period immediately after any <ix:nonFraction unitRef="day" contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE4ODA_71ec0dd2-edce-4489-a638-de615b19c242">five</ix:nonFraction> consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzIxNDk_faed630a-96a4-49a3-b8e7-4630e80a1e09">98</ix:nonFraction>% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than <ix:nonFraction unitRef="day" contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI2MDg_f5c30f19-8966-43b6-91fe-8e18bb07821d">45</ix:nonFraction> days from </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt (Continued)</span></div><div style="margin-top:8pt"><span><br/></span></div></div><ix:continuation id="i012f6b7493564d6ba5fc3d24c7ebf09b" continuedAt="idd92cc640d4242b59d5b0318f0a166b1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the <ix:nonFraction unitRef="day" contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI4Mjk_f3136279-37d7-4469-9eef-7cb38178f46f">10</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding <ix:nonFraction unitRef="number" contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzMxNjk_b0f7f435-bf52-40ed-8355-aa3d26809dc8">10</ix:nonFraction>% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is <ix:nonFraction unitRef="day" contextRef="i9e454efc09a14c9f9b4641cc444070e4_D20180101-20180131" decimals="INF" name="insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQwNDY_7df9d567-a6dc-4eae-9380-ca1b33484132">30</ix:nonFraction> scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least <ix:nonFraction unitRef="day" contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQzMzQ_a7a60c8b-6b27-4a42-8540-6ea7579126b9">20</ix:nonFraction> trading days (whether or not consecutive) during the period of <ix:nonFraction unitRef="day" contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ0MDA_a4b71096-abc8-4f7f-aa9a-0934dd15db26">30</ix:nonFraction> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to <ix:nonFraction unitRef="number" contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ1MzM_71cf140c-da26-4b75-ab99-f3b6cbd76ad3">130</ix:nonFraction>% of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $<ix:nonFraction unitRef="usd" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY3MjA_85ced016-d526-4f0b-a573-a94c75b0b4af">309.1</ix:nonFraction> million using an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY3NTk_13de7359-6fe5-4723-9968-cddfdd247387">7.6</ix:nonFraction>%, and accordingly, the residual equity component on the date of issuance was $<ix:nonFraction unitRef="usd" contextRef="i3ca69534f44544678e6345d4061172bd_I20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY4Mzg_318feefe-e8b7-45d3-9990-5b0b58d52cf0">140.9</ix:nonFraction> million. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately <ix:nonNumeric contextRef="i7789efc1fa15465a824da338e733666d_D20180101-20180131" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY5Nzc_b3a9d658-7e03-476d-959d-97863b0b5605">4.04</ix:nonNumeric> years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2020, total interest expense related to the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i1f292dc67c894e10a48cb3e934955825_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzcwNTc_aaf372c2-3846-431c-b0f2-44dfc26e6bd3">28.3</ix:nonFraction> million, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzU_7e87f013-11f0-4161-9c10-b3be03ebf92a" continuedAt="i8080bca2ec6c4be3bf4289daef962d84" escape="true">The following table presents the carrying value of the Company&#8217;s debt balance as of December&#160;31, 2020 and 2019 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i8080bca2ec6c4be3bf4289daef962d84"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:48.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.660%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;<ix:nonFraction unitRef="number" contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmViNmJkMWQ4ZjE1MzQ0M2ViNzBmZDhlZTNiN2U4NmNjXzU_dd806a81-1e40-4ec2-ac2b-9ea942b14a6f">1.75</ix:nonFraction>% convertible senior notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzEtMS0xLTEtMA_763cf242-0b68-46b3-bc84-541dd590fd25">450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzItMy0xLTEtNDA1Ng_f0113270-03ff-44d1-930d-c854e32d3a7b">450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Debt issuance costs, unamortized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzItMS0xLTEtMA_78c16e63-4a53-46f8-987f-6110e22017a4">5,646</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzMtMy0xLTEtNDA2MA_bb129f12-2470-45e5-a2ff-622fc924866e">7,043</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzMtMS0xLTEtMA_17823d57-cde4-4c9f-a1af-cadd64ffcded">88,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzQtMy0xLTEtNDA2MA_d87927d1-306b-4837-942d-8a73d3035af1">107,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzQtMS0xLTEtMA_8167ef7e-b573-4638-85fb-aaacbf8f6582">356,318</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzUtMy0xLTEtNDA2NA_b4b15663-00b8-4389-be43-e65380d67608">335,940</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzY_e59eba6e-3174-4e57-a54e-150996abae7b" continuedAt="if3d4ec22080342c39e2ddbc4b0299bd0" escape="true">As of December&#160;31, 2020, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Debt (Continued)</span></div><div style="margin-top:8pt"><span><br/></span></div></div><ix:continuation id="idd92cc640d4242b59d5b0318f0a166b1"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="if3d4ec22080342c39e2ddbc4b0299bd0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.327%"><tr><td style="width:1.0%"></td><td style="width:61.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzEtMS0xLTEtMA_846d0d2f-c233-41a1-8d4a-6160f7f31e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzItMS0xLTEtMA_ef5dfb85-4f2a-47bf-abca-dcac7ba3ed12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzMtMS0xLTEtMA_2b52822f-57e2-4e62-8a7a-47d5ce8ee58a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzQtMS0xLTEtMA_ba010a06-9f57-4674-81fe-65df7351e2ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzUtMS0xLTEtMA_35c6a06b-4840-4e8f-a4e3-b9ffb5de3a0a">450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzgtMS0xLTEtMA_18493766-f2be-4e52-b0fd-053edf6b492c">450,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of $<ix:nonFraction unitRef="usd" contextRef="i207c67bfeb704bc880cce0755881858e_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc2ODk_5c5fa8ff-0875-44ac-b426-f19aeecd267f">55.0</ix:nonFraction> million for the principal amount and an additional $<ix:nonFraction unitRef="usd" contextRef="i207c67bfeb704bc880cce0755881858e_D20180201-20180228" decimals="-5" format="ixt:numdotdecimal" name="insm:RepaymentsOfDebtFeesAndOutstandingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc3MzU_13b13f93-bc65-4537-aa83-e08f583ef415">3.2</ix:nonFraction> million in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="i0ea99db509d54adeb7486a066eb4eb62_D20180101-20180331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc4Mjc_69834e78-6a34-48b8-8e2b-bbda1b2514c5">2.2</ix:nonFraction> million loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of December&#160;31, 2020 and 2019, the fair value of the Company's debt approximated the carrying amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1Mzc_859a6860-d906-4979-a66f-73beaf36afd7" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and the finance lease for the years ended December&#160;31, 2020, 2019, and 2018, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:58.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItMS0xLTEtMA_4b62a0da-c23b-41ac-a447-f1bd04a39459">7,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItMy0xLTEtMA_84a98f1b-0e0f-461c-a1a6-5dd7f59dc9ec">7,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItNS0xLTEtMA_1d262b20-15f0-41ca-90a8-d5fad87fdac0">8,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtMS0xLTEtMA_7dfc448d-9bfb-4fe2-a291-98c4e7f81799">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtMy0xLTEtMA_4ec6dcd4-151e-4090-a7cc-322f2def07d1">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtNS0xLTEtMA_a96ba089-1f46-4a7a-a217-89e4f1952294">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of back-end fee on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="insm:AmortizationOfBackendFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtMS0xLTEtMA_04c49378-910b-4920-a749-d6509d18a242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="insm:AmortizationOfBackendFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtMy0xLTEtMA_ea0080b1-6bf1-4e3a-954a-95d91858e208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="insm:AmortizationOfBackendFee" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtNS0xLTEtMA_fbe99177-40d7-465b-9c8e-e8f593a4b1d5">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtMS0xLTEtMA_5b15a491-f358-4a76-8e97-6ea966d4bcaf">18,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtMy0xLTEtMA_a4696e29-b9c1-49d7-ae63-99b99d3515d1">17,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtNS0xLTEtMA_07c7ecc9-c360-43f1-8c7a-063563a2dd60">15,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:ConvertibleDebtInterestExpenseTotal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtMS0xLTEtMA_59c9da53-dd13-4963-916b-57719e29ed44">28,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:ConvertibleDebtInterestExpenseTotal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtMy0xLTEtMA_993f334d-684d-4c35-a1e0-a7af129951ac">27,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="insm:ConvertibleDebtInterestExpenseTotal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtNS0xLTEtMA_c8e8b64b-15e7-4359-a542-ccb6d60920b1">25,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctMS0xLTEtMA_6ba57d72-3883-4435-b07c-c96d61a85fa1">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctMy0xLTEtMA_bf524723-16e6-4436-90d0-576fbeb11cc8">440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctNS0xLTEtMA_3943be6b-a320-4bed-b339-50dd082af647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtMS0xLTEtMA_d92fe7a0-e31e-4526-bd82-d16ee7b2cad4">29,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtMy0xLTEtMA_bc46dffc-b80c-41c1-8890-1c4e65c724f2">27,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtNS0xLTEtMA_916ec2c4-f16d-475d-8a5e-a7db53cdc874">25,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_163"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIxMzg_516484ce-9728-4070-911d-677e795677a7" continuedAt="i5e1e9ffd4a4b42a1b008c4a0caa7e029" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i5e1e9ffd4a4b42a1b008c4a0caa7e029" continuedAt="ic1f96eb2e538411d9a5936e4fde88e6a"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1ODI_f78419ef-380b-4732-a3b7-f48fd4de2676">500,000,000</ix:nonFraction> shares of common stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1ODY_5fcc9889-cb30-4c5b-913c-bb83f0b2a33e">0.01</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzOQ_91c69160-5b6f-4fde-9d44-357275ba465a"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzOQ_b9dc2df1-a23a-464c-a4d3-a097af147e9d">102,763,060</ix:nonFraction></ix:nonFraction> shares of common stock issued and outstanding. In addition, as of December&#160;31, 2020, the Company had reserved <ix:nonFraction unitRef="shares" contextRef="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIzNw_ec4de8a2-88a2-43b2-a3d3-d31279d78bbd">12,263,402</ix:nonFraction> shares of common stock for issuance upon the exercise of outstanding common stock options and <ix:nonFraction unitRef="shares" contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzMzNA_e0df9fa6-96b1-4037-b4e2-b0e4957a949f">844,391</ix:nonFraction> shares of common stock for issuance upon the vesting of restricted stock units.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i632484c618934954b43bf3c619cf75d9_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzI5OTI_b9449d35-3b80-4402-88b8-e441f3176092">11,155,000</ix:nonFraction> shares of the Company's common stock, including <ix:nonFraction unitRef="shares" contextRef="iff5a8670240445378f8c05d86d5621bb_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMDc_061839e4-974c-4253-9de7-74c8f1a9f666">1,455,000</ix:nonFraction> shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMTY_c22b4e7b-2625-407e-acc3-29c55e8c5be3">23.25</ix:nonFraction> per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i349a3db24a104296871f679b48d0727b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMzI_75947adc-84d5-4502-93d1-49a5629c1d8b">13.5</ix:nonFraction>&#160;million, were $<ix:nonFraction unitRef="usd" contextRef="i632484c618934954b43bf3c619cf75d9_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwODA_5c2abef2-c677-4fe0-971a-1c953a5d4c0e">245.9</ix:nonFraction>&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzUwNQ_ac225814-82e4-4be1-b208-d6e055607a0b">10,657,692</ix:nonFraction> shares of the Company's common stock, including <ix:nonFraction unitRef="shares" contextRef="id7d4ce336b0d4998950db423777b2a69_D20190524-20190524" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzYzMA_0a04ce63-acbd-4b18-a738-1e06eb93f648">1,042,307</ix:nonFraction> shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iefb0a77979724e36a4b8762928d10239_I20190524" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzY4NQ_e52a6717-06ec-4b29-84f1-bb540921392f">26.00</ix:nonFraction>. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i60e46a7dfb16496c852ec9544e1b781f_D20190524-20190524" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzg3NA_3372c38a-03a1-4270-ac18-b567b63bd5cb">16.0</ix:nonFraction>&#160;million, were $<ix:nonFraction unitRef="usd" contextRef="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzg4Mw_3f095b29-8e57-4033-b221-360ce5fb2c58">261.1</ix:nonFraction>&#160;million. The </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Shareholders' Equity (Continued)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic1f96eb2e538411d9a5936e4fde88e6a"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering also included the sale of <ix:nonFraction unitRef="shares" contextRef="i818541d9894e4786bafa4a7f073c56da_D20190524-20190524" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzkyNg_1e56d07d-b47e-4ad5-85a1-b59c0b2076d2">400,000</ix:nonFraction> shares from the Company's Chair and Chief Executive Officer, from which the Company received no proceeds.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of $<ix:nonFraction unitRef="usd" contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzExMTI_42d57f5d-04d1-4d3d-8994-be39fe6929d7">450.0</ix:nonFraction>&#160;million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $<ix:nonFraction unitRef="usd" contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzNzM_c7d1bedf-aeb8-4735-a6cb-4aad6849f77a">309.1</ix:nonFraction>&#160;million, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as $<ix:nonFraction unitRef="usd" contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzE0OTg_170e8f0f-6680-4a2b-a499-a704588d623b">140.9</ix:nonFraction>&#160;million using the residual method, as further described in Note 8 Debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of December&#160;31, 2020 and 2019, the Company had <ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTA_20a35900-085e-44ed-81c2-dda561c6ffbb"><ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTA_bedeb14e-164d-4eed-b66e-a0d7bf6f3af3">200,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock authorized with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTQ_24527175-e04a-4e85-8989-ddc8fa9ea41d"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTQ_755ab726-683d-468d-b201-4de36186dcba">0.01</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_161c85f3-ae91-4cb9-8cb5-eef71d3d6916"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_a825397d-23b9-413a-beca-50d0db2525d1"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_c1cf94a8-6f91-4cc8-a781-f3c861cf54ed"><ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_e83a0b9b-0df1-4abe-af2d-b142bd80aeb6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued and outstanding.</span></div></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_166"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTU_567d5050-c361-49df-b11b-e6ff121eb264" continuedAt="i9dade16b43954ae3a13cae490bdab5c7" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9dade16b43954ae3a13cae490bdab5c7" continuedAt="i4250e2072df64f8e8db7b261a9b0b4be"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current equity compensation plan, the 2019 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, <ix:nonFraction unitRef="shares" contextRef="ibb14027d5bff4fac80225d11be8c578f_I20190516" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzU4ODY_508d8f7a-0af4-4e4d-af11-9479e423a4c3">3,500,000</ix:nonFraction> shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional <ix:nonFraction unitRef="shares" contextRef="i7cb5fa6b23cb4fad903933f28e806e98_D20200512-20200512" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzU4OTg_f01a64ad-df66-4a7a-a6b0-11c7ca35e646">4,500,000</ix:nonFraction> shares under the plan. As of&#160;December&#160;31, 2020,&#160;<ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzEwNTY_bdecffd0-4cff-4dc4-9005-ba5be96fa540">5,200,879</ix:nonFraction>&#160;shares remained for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#8217; employment compensation in connection with the Company&#8217;s equity grant program. During the&#160;twelve months ended December&#160;31, 2020 and 2019, the Company granted inducement stock options covering <ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzE1OTM_3f28efb0-99a2-4d38-9519-5d9e4f82d272">996,830</ix:nonFraction>&#160;and <ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzE2MDA_1db5afd2-4245-4fd6-9e18-0adc7da40b69">305,180</ix:nonFraction>&#160;shares, respectively, of the Company's common stock to new employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMDQ_b0073202-be09-45db-bf07-09568c86e2dd" continuedAt="i353f524e09ee4422929e5f19ade4419e" escape="true">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended December&#160;31, 2020, 2019 and 2018.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i353f524e09ee4422929e5f19ade4419e"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:53.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMS0xLTEtMC90ZXh0cmVnaW9uOmZjMjU2ODQ1YTEwNTRlN2Y5MGI0OWVlY2E3NGVhNmMyXzQ_240f3221-0d2b-4f43-8596-cb8488ea84fc">66</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i24b05e9462b7490284e2dec768389895_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMS0xLTEtMC90ZXh0cmVnaW9uOmZjMjU2ODQ1YTEwNTRlN2Y5MGI0OWVlY2E3NGVhNmMyXzc_ea78ce1b-5c2f-4054-aabd-f84129653d09">71</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMy0xLTEtMC90ZXh0cmVnaW9uOjZmNDg0MzNhNmE2NjQ3MWM5NzVhZjY2MWJhM2Q4NDUzXzQ_aef44403-9218-46bf-9ebd-409612a55e24">67</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMy0xLTEtMC90ZXh0cmVnaW9uOjZmNDg0MzNhNmE2NjQ3MWM5NzVhZjY2MWJhM2Q4NDUzXzk_17d453ac-642f-4d6f-8519-4dad8d9fc2fd">70</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtNS0xLTEtMC90ZXh0cmVnaW9uOjQ1ZTRmMTU2ZWE4YjQ0YzVhZGNlZjAyZGNlMWE2OGM5XzQ_a80ad4de-7692-498d-a6b4-afc903bc545b">66</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtNS0xLTEtMC90ZXh0cmVnaW9uOjQ1ZTRmMTU2ZWE4YjQ0YzVhZGNlZjAyZGNlMWE2OGM5Xzk_d8b27466-fb70-4b71-baef-49f0f24a1538">68</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjBmZmRhZjczZDU3NDQ5MjY5ZGYxMTc2ZjhlN2RiZDY3XzQ_6138f5f9-bf16-4ade-b7d4-a48f71f3730d">0.22</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i24b05e9462b7490284e2dec768389895_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjBmZmRhZjczZDU3NDQ5MjY5ZGYxMTc2ZjhlN2RiZDY3Xzc_38c276bb-0f50-4f0a-9a7d-0c30e90ba7a4">1.67</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmJjNTk5N2IzYjBhOTRmZjA5OTFiYjE2ZjU4N2I4NjQ3XzQ_fe78f7ab-4e16-43ad-873f-879b97ea91d4">1.35</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmJjNTk5N2IzYjBhOTRmZjA5OTFiYjE2ZjU4N2I4NjQ3Xzk_c3bbb30c-4a76-455e-9e5d-ab40bb082c7d">2.56</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItNS0xLTEtMC90ZXh0cmVnaW9uOjgxNjgxMmIyYmMyOTQ5NDI5Y2JiZDI0ZDg2MDFmZjIwXzQ_fe99602f-52db-437e-a7df-c2babe0f6c5f">2.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItNS0xLTEtMC90ZXh0cmVnaW9uOjgxNjgxMmIyYmMyOTQ5NDI5Y2JiZDI0ZDg2MDFmZjIwXzk_8663de2d-0cf1-43cb-8dfa-b13db82cf30a">2.96</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtMS0xLTEtMA_6c7215c5-9697-44af-a464-af7a0bead63a">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtMy0xLTEtMA_cd3d4776-9c96-4c84-b9d2-aef3893ec5eb">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtNS0xLTEtMA_f51bff96-af1b-4aef-8e20-53b3f5db89e9">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtMS0xLTEtMA_39f0a3af-232b-4a01-8b6f-df7cad03e307">5.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtMy0xLTEtMA_07b12719-e69a-49b6-8567-70c12e848e3e">5.09</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtNS0xLTEtMA_f4bc4db9-9d71-42be-895b-644017942d8d">5.09</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtMS0xLTEtMA_083e0e7d-95ae-48a5-ac69-c5f10f0dfc56">13.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtMy0xLTEtMA_b4a7673e-2e31-433e-a762-281705d456fd">8.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtNS0xLTEtMA_1d0a7388-3b00-47d3-9cd7-ef8f938302e8">16.03</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;The company accounts for forfeitures as they occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). The Company had <ix:nonFraction unitRef="shares" contextRef="i1015f33ba83642e796387fad13fc1078_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_28be2604-38d9-4ba4-9e7f-38e2ff53aadb"><ix:nonFraction unitRef="shares" contextRef="i827d3608f7854deb81221457676b5339_I20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_5ca2d841-79cf-48e0-8fd0-508aac045e8b"><ix:nonFraction unitRef="shares" contextRef="id29981174a85438ab8f4063d1cd73795_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_afb03d17-bb73-4814-b953-489dfd26ab1c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> performance options outstanding as of December&#160;31, 2020, 2019 and 2018.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation (Continued)</span></div></div><ix:continuation id="i4250e2072df64f8e8db7b261a9b0b4be" continuedAt="i5db0cf6c00e2418087302d3566206cfb"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTc_e0c32194-8647-49d2-8b83-e09c2f58ab22" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for stock options granted for the years ended December&#160;31, 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in '000)</span></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE1LTEtMS0xLTA_67db53e8-1df5-4510-8127-52c0d54d74cc">8,608,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE1LTMtMS0xLTA_6d807f1d-c694-45a3-bf5f-66867c96c383">14.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE2LTEtMS0xLTA_f051c7b5-3f06-48ec-bf68-3c3df87b37d2">1,755,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE2LTMtMS0xLTA_29779572-a96a-4eac-906f-4325c601cbc6">27.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE3LTEtMS0xLTA_6b817412-a820-47c5-a3ec-e7e1097ba9d5">494,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE3LTMtMS0xLTA_3dba8d92-f85f-4892-aca1-62ad8cdecfed">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE4LTEtMS0xLTA_f9c0818f-43c6-40b8-a7e0-e4ed2b5b8a32">488,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE4LTMtMS0xLTA_55e327fd-dc75-4242-b9b7-5e21d1944e8a">19.79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE5LTEtMS0xLTA_bad37343-7f12-4e03-92ba-852e21faad37">9,381,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE5LTMtMS0xLTA_a3994758-812c-4d0c-ab08-f40be7ff8277">16.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIxLTEtMS0xLTA_4938be3a-2663-4ab4-9ed2-d0dad7ad593c">5,649,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIxLTMtMS0xLTA_9bdd24cd-d461-4fac-aea5-094f5cb4436a">13.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIzLTEtMS0xLTA_12f79fa0-c666-4eee-acc0-1e0ccd93a465">3,434,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIzLTMtMS0xLTA_195dd693-086f-49bf-ac52-eef4583cb5cd">15.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI0LTEtMS0xLTA_ad234bd1-66af-4edd-be32-605c8353e437">1,413,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI0LTMtMS0xLTA_c0f83277-4178-41ea-a981-d9c226b71679">11.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI1LTEtMS0xLTA_a5fcf023-3b62-4a31-bf6f-866dae3a7a98">909,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI1LTMtMS0xLTA_34a764e3-51fb-415c-a041-307a2d0b06b1">19.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI2LTEtMS0xLTA_49de1295-bd1a-4a07-9d62-e9fbf82d51ae">10,492,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI2LTMtMS0xLTA_8a195668-f04e-498b-9622-8af40c394c37">16.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI4LTEtMS0xLTA_fd437a7e-37fe-4d7d-8ae6-e975eefe6014">5,719,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI4LTMtMS0xLTA_59013183-3dc4-422e-a6f3-6794fbbb37ab">15.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI5LTEtMS0xLTA_e294a32b-6146-4ae0-ada4-bc57fad9dd28">3,990,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI5LTMtMS0xLTA_9441ac1b-f484-4183-b36c-030c100b39f0">24.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMwLTEtMS0xLTA_3fcf08aa-1773-40be-b09b-bb65d3b51e57">1,678,604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMwLTMtMS0xLTA_f6f2efe6-f35a-44c5-8b42-6d9db8a5b828">14.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMxLTEtMS0xLTA_23fa8d04-cf33-499f-8e3c-9f77bda5dfe3">541,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMxLTMtMS0xLTA_32bc20fe-a773-47c9-b86d-4b5d63af8b50">23.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTEtMS0xLTA_305f68d3-90ed-4995-b009-d7a17ba98b93">12,263,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTMtMS0xLTA_1809e7a6-90ea-411c-8c2b-41ee89f06a5d">18.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTUtMS0xLTA_55f66330-2244-479a-9618-1f83e292a83f">7.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTctMS0xLTA_1315c3f2-2569-4f81-9190-473b1809be8b">177,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTEtMS0xLTA_00e913a7-d50b-4d51-8bc3-0f429fa44f4f">6,028,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTMtMS0xLTA_abb4d532-97cd-47f0-929a-676967785c42">16.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTUtMS0xLTA_1bc11416-98c3-4947-9880-dbab73bca8b1">5.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTctMS0xLTA_20b58a34-0286-4cca-a2f2-4c1a67a3ff6a">103,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNTE_674bcfbd-1f98-4ca1-8d39-2765d828557c">24.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNTU_af371a92-466e-4c54-9808-ae2ffee15976">16.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNjI_23c1e792-b8c3-4f5a-a879-07fac1ceea85">5.6</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMzMDA_a0caf206-8a2b-4bdf-af2b-5fb18be6dbef">59.7</ix:nonFraction> million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzM0NDQ_5318582f-79c6-4403-b64c-b0ed72b97453">1.8</ix:nonNumeric> years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive <ix:nonFraction unitRef="shares" contextRef="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzM4MTQ_318c1c05-a8a1-4ba7-b80f-d9915988e691">one</ix:nonFraction> share of the Company's common stock upon the completion of a specific period of continued service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-Based Compensation (Continued)</span></div></div><ix:continuation id="i5db0cf6c00e2418087302d3566206cfb"><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMjA_3d0e0979-e4bf-410f-b7dc-7cd2ba9c4ae6" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU awards granted during the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:72.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzktMi0xLTEtMA_ad95b07a-959f-4066-b929-aa48e4a999b3">46,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzktNC0xLTEtMA_519266ed-4675-45ad-81d0-174e9630f205">17.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEwLTItMS0xLTA_02d35cca-13d2-48c5-9d67-5d021450c35d">253,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEwLTQtMS0xLTA_119a09fc-6b5c-44e6-955b-6de3255dec68">29.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzExLTItMS0xLTA_bdc2880b-2a6c-4adb-b817-d81a3f517cdb">51,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzExLTQtMS0xLTA_42daa81f-4312-490e-a018-6a8b2afb1f93">18.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEyLTItMS0xLTA_14e11006-3ac7-482a-ad60-297521bb7f6c">20,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEyLTQtMS0xLTA_6102e3a0-afed-4858-9774-7e29460166b0">29.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0be8cbb20b3e471da2e0aead19d7a176_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEzLTItMS0xLTA_d03618c6-8a53-4332-86cd-ce4297b25d76">227,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0be8cbb20b3e471da2e0aead19d7a176_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEzLTQtMS0xLTA_9d62395f-6647-4de5-a21b-cabb10a59eb6">29.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE0LTItMS0xLTA_e8d5ebb0-db49-4ecb-9e17-4fa1b929795b">407,655</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE0LTQtMS0xLTA_29e29f22-ac53-4f4a-a2a6-b1abd354378c">27.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE1LTItMS0xLTA_2c95f3fa-81a9-43f4-b0de-5f011d8e7c8e">92,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE1LTQtMS0xLTA_71f3500d-8291-46a7-88b4-28454802dd94">28.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE2LTItMS0xLTA_e39b51d3-021a-40b5-b39d-c385a36fcbcf">42,514</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE2LTQtMS0xLTA_d14ce06f-aed0-4ede-b369-f3aeb3f8a026">29.11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ce04f79cefd429f9fa32b6a5866706c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE3LTItMS0xLTA_239e74b0-8b7f-4c51-ab46-304dc834abee">500,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0ce04f79cefd429f9fa32b6a5866706c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE3LTQtMS0xLTA_b64feed8-ea5e-4eae-b47a-273aede654ae">28.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE4LTItMS0xLTA_452806d5-f90c-4b48-a5c0-db276c778abb">559,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE4LTQtMS0xLTA_f7c04c99-38f8-4e49-8d2c-c15315e9756b">23.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE5LTItMS0xLTA_98d361ec-aed8-4fc5-8dcd-be23f72af5b0">161,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE5LTQtMS0xLTA_91a4bf53-14c0-4ac6-a733-d9d409695cb4">28.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIwLTItMS0xLTA_12e15430-79c7-4533-b90d-f598f100d954">53,711</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIwLTQtMS0xLTA_711049e3-ba2d-4a88-8458-9a0dd322a2db">25.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIxLTItMS0xLTA_898510d8-bea2-4858-879e-165e1c1fc1b0">844,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIxLTQtMS0xLTA_d88da81f-626c-4e57-a0af-c5c5dccffdf8">25.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i96db1220ab75430ab3c6ae0bc9042f63_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzQzMDQ_89a6aa5a-0440-46e3-a557-1917bdef1d16">15.0</ix:nonFraction> million of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzQ0NDE_c9efb62c-c423-4dc4-880d-713661a9dd9d">2.3</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTA_2341873b-5a0d-4967-b798-c4eca08d51ec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended December&#160;31, 2020, 2019 and 2018 (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:54.763%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74916538d9974ba79e0b9d63850374aa_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItMi0xLTEtMA_e260ed04-6ea3-45a5-89ab-6d407d808f59">11.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364ee03e6c7541a69698fc45ca2ba4ce_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItNC0xLTEtMA_786f4269-e389-4812-a3f5-3ea89a3497f1">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38d1bbcd50f449aa39ec92d1409abba_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItNi0xLTEtMA_a2848d2d-d6ac-46f7-b3aa-042abc1318c6">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93060279fbe94fc7a1a08779106fc2f4_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtMi0xLTEtMA_db256fac-6fd2-4d31-9a0e-6b5fc30357cd">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba3be11a88b4bfca6f5772ebff95bcb_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtNC0xLTEtMA_d98e45df-8be3-496b-9dca-d3d839e824f2">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0e4ce89f3d4ea4bb96ff17f982a182_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtNi0xLTEtMA_5ca41a84-a1a6-4509-947f-e6ddd4698e8f">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic353257bd6e34e7dbe0b8636bd5d2538_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtMi0xLTEtMA_11f34448-c1d2-403d-81b1-fca51a2ac3a8">36.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa29866a032b4f66bcfd69a12e24036c_D20190101-20191231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtNC0xLTEtMA_64423a81-323d-40fb-b43e-4b693b7e0340">27.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b57931b8a04017a81e641841a99233_D20180101-20181231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtNi0xLTEtMA_55369888-2cae-4105-8baa-bc23b68b2c0e">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On May 15, 2018, the Company's shareholders approved the Company&#8217;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ifd1672f5e51546618f0cf07a08a28df1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUwNDg_2b14df25-9828-45b5-871d-8bb0737fda38">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i01f3c32373d84f8d8b6e8ad92ddfe7a5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUwNTU_4e444c0d-f657-442e-a7e4-31a57917dc72">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i21187a96ab01431487e85f22a31a8d4d_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzQ2MDM_7bfcbd78-5dce-4d3e-a2a1-57a020321ad9">0.9</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_169"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDA_d428cbce-4e1f-4ed7-bc37-ffa4a2b8ddd5" continuedAt="i635927db66b34efeb865a0c97966579c" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i635927db66b34efeb865a0c97966579c" continuedAt="i4e6cd86a3e274e6ca9faaccd4b96ef30"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision was $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzY4_9038aec1-641b-4c5d-a59b-126e62d9bd2a">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzcy_7c1835c1-eae8-4bb9-9bc3-16accf6e3874">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc5_83c28841-f641-42d4-bfd7-c53ee0eafda7">0.2</ix:nonFraction> million and the effective rates were approximately <ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyNQ_3856a811-32f5-4c39-ad2a-3203c0d77209">0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyOQ_da6f678c-1cfc-467f-ba7f-dad5cc13d68c">0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEzNg_2caa07e5-2107-48e1-a064-71307f49013f">0</ix:nonFraction>% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid alternative minimum tax. In addition, the income tax provision for the years ended December&#160;31, 2020, 2019 and 2018 reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries and certain state income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDc_af962fb1-9f6f-45f6-adc4-a6b9ff4917b5" continuedAt="i8a65df4829c44751b52fe3033faf95b8" escape="true">The Company's loss before income taxes in the US and globally was as follows (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><ix:continuation id="i4e6cd86a3e274e6ca9faaccd4b96ef30" continuedAt="iafd0ae6a0ec94f728e1d46df54c725c8"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i8a65df4829c44751b52fe3033faf95b8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItMS0xLTEtMA_15856f29-30fa-4143-98ec-207039b6754d">207,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItMy0xLTEtMA_d02c6c34-3877-4e31-b6e0-a3a67163657d">201,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItNS0xLTEtMA_641a92e7-f5c8-40cd-96d9-bebf1228c8aa">286,211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtMS0xLTEtMA_f6de1fa4-f273-4484-92de-4ee8f75dfc42">85,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtMy0xLTEtMA_3a81c2dc-b619-4acf-982e-ab2271d789e3">52,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtNS0xLTEtMA_0fe619c6-0be4-4d63-a2da-07b933784f07">37,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtMS0xLTEtMA_e19ed881-3ffa-42b6-8b2a-cf72d4cc5c77">292,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtMy0xLTEtMA_4681d248-a577-4911-97bc-5a91588ac3f9">253,560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtNS0xLTEtMA_5d7c81bb-a9be-4852-954c-a4f4d1c52bcb">324,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDg_f1ff357c-64b8-4100-ba09-3b6a53e13dac" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's income tax provision consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtMS0xLTEtMA_94ab2df3-351f-45ce-bec3-5e2350c7a5d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtMy0xLTEtMA_3cab68ca-bb6d-4d2e-8d21-ee22bcd5e8e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtNS0xLTEtMA_ee7da077-df48-4335-8e18-fd853203c9ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtMS0xLTEtMA_2e1707fe-f6ed-4a17-8bef-510a9d8a4d9d">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtMy0xLTEtMA_4d25af89-b88d-4e37-856d-fa4cf8b15afd">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtNS0xLTEtMA_3dda620a-b3f4-42a4-8a6a-f6037500dffe">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtMS0xLTEtMA_8daaa11c-adff-4c20-ac04-8d9e5e005b8c">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtMy0xLTEtMA_4055c37f-d4d1-4b4c-8584-b0c9eb5ea5c2">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtNS0xLTEtMA_66180fb1-46fc-442f-b448-39103f661739">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtMS0xLTEtMA_4967481a-044e-4634-adc7-cbe5adec42bb">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtMy0xLTEtMA_4b278b7f-9080-42c7-a714-1e3465aa2c4f">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtNS0xLTEtMA_772f990a-64bb-4410-aebe-47012fca4bc7">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtMS0xLTEtMA_246f640b-5711-4d51-aa2b-2c648cdaa805">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtMy0xLTEtMA_672db627-5d82-41a8-bf2b-4e97e0617212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtNS0xLTEtMA_e52ec066-edee-4e77-95fa-056efbb4b5a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktMS0xLTEtMA_cf733e0e-8b3d-4b29-80ba-069f4d2170a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktMy0xLTEtMA_9021f720-75e9-490b-840f-036be5e48775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktNS0xLTEtMA_361526cb-a7d2-42f4-bbb7-3d64265b4ff2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTEtMS0xLTA_ca49010b-e4a1-4aa5-87a6-d97df6caa2c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTMtMS0xLTA_5be8bfad-3ef4-4b63-b2ad-23d4f789209a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTUtMS0xLTA_7332d19a-3a4e-4df7-a54e-0e1d45e6fb85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTEtMS0xLTA_c6a82685-8c19-4919-ae12-bcc11f4bcd78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTMtMS0xLTA_38335aba-d158-4e23-9c98-630512b84683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTUtMS0xLTA_81e2942c-bcc9-47c4-908b-b55842a3e027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTEtMS0xLTA_8ccd7a08-fc1c-48a6-a149-2caefe3cf69e">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTMtMS0xLTA_628f0781-0329-4f52-a354-400cac5f05bb">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTUtMS0xLTA_32bc878f-047a-4cc1-a789-57b7d6a33fef">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc1OTU_0abfb3b7-ebc8-4d4a-ac1d-33300aa09b84" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItMS0xLTEtMA_3300a629-25cc-44a8-959b-41f7c34abb9e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItMy0xLTEtMA_25e3642b-8760-40da-92aa-7f469af6e88b">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItNS0xLTEtMA_826911dc-8906-437e-b85a-b77b0ccfc4fe">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" format="ixt:zerodash" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtMS0xLTEtMA_81942cae-079d-46d5-b6da-be1507e09a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" sign="-" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtMy0xLTEtMA_fe6ad75f-f2fa-42d3-8f39-928f71ac9d2d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" format="ixt:zerodash" name="insm:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtNS0xLTEtMA_22e26d5a-2bd3-4d49-a05b-8177fc1b01a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtMS0xLTEtMA_37dbd4d5-746b-428e-8342-ab8d4aa4ccca">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtMy0xLTEtMA_439acaa9-e220-42c2-8b27-6af769044103">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtNS0xLTEtMA_efea428a-9f99-4057-8ecd-e53d87a6e2fd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtMS0xLTEtMA_7106e7f1-1864-4ac8-9ca5-e593af173601">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtMy0xLTEtMA_4c9976c5-24aa-4c5f-8ac6-95226c94a5e3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtNS0xLTEtMA_12b6e247-7f4b-4a47-94f3-d0437dbabdc4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtMS0xLTEtMA_8147e122-edc0-4f10-abdb-9a5dbb606ca8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtMy0xLTEtMA_ea9c4627-e9c2-4d30-9d42-af0999e5b8fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtNS0xLTEtMA_f84315b4-fb94-4ebd-9585-6fd4fe737f47">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtMS0xLTEtMA_3998c644-d34c-401b-ab6b-74f00e1aef21">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtMy0xLTEtMA_f46962e3-0dbc-43f3-ab6e-58b5d301b4aa">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtNS0xLTEtMA_f758bd4b-ca49-453e-a2ee-19b13f893d1e">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Irish trading status</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" name="insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktMS0xLTEtMA_4b7622c5-ecea-4579-859a-844f8d7fb926">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" name="insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktMy0xLTEtMA_fe4cac83-3fbb-4a58-a387-ec4cf30d509c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" format="ixt:zerodash" name="insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktNS0xLTEtMA_ee5624b0-0ac4-4e7c-be13-6ed6d5f0a50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTEtMS0xLTA_f1f38629-09fb-4659-b3de-b50300f09e95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTMtMS0xLTA_a4c84582-0e6f-4b78-aeff-0c034370b939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTUtMS0xLTA_dd8123cc-e412-4229-a109-0e3c1f48f70f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading income tax rate for an Irish company is <ix:nonFraction unitRef="number" contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231" decimals="3" name="insm:EffectiveIncomeTaxRateReconciliationTradingIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyOTI_1eaccf3b-dc5f-45ae-9656-5cb77fc144f6">12.5</ix:nonFraction>% and the non-trading income tax rate is <ix:nonFraction unitRef="number" contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231" decimals="2" name="insm:EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEzMzQ_8b2a69de-6fc3-404c-a7ec-0e80edfb5ba5">25</ix:nonFraction>%. During 2019, the Company determined that it qualifies as a non-trading company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As such, the Company&#8217;s Irish NOLs were revalued to the higher rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, not all expenses incurred will result in a non-trading company loss carryforward.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These changes had no impact to income tax expense as a result of the valuation allowance.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="iafd0ae6a0ec94f728e1d46df54c725c8" continuedAt="id0bd638179074dbb9a109034941c5353"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc1OTc_bfc59180-d1fb-447c-acd9-4269170a9b91" continuedAt="ib9bc5788612a424496b13e3fb8a3511b" escape="true">The components of the deferred tax assets and liabilities consist of the following:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="ib9bc5788612a424496b13e3fb8a3511b"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzMtMS0xLTEtMA_085fd5d9-6bee-42f7-b2b6-4e324866b6ff">377,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzMtMy0xLTEtMA_07c77d1d-d0f1-4f36-aa92-2b13103d874e">304,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzQtMS0xLTEtMA_bc79120b-146c-48f1-bb5e-8a7ee438db55">123,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzQtMy0xLTEtMA_bca0398d-154a-4b01-bd9f-9c019e452d9f">114,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLicensePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzUtMS0xLTEtMA_66b38d67-83a1-43de-b5c6-7c2203e529e6">5,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLicensePayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzUtMy0xLTEtMA_993ecdc8-1190-448d-9011-45fd01b5a6b6">6,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzYtMS0xLTEtMA_6eb6de45-b753-4d2e-9ce1-0141a697fc30">3,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzYtMy0xLTEtMA_302d6b1f-9f54-40d0-ad40-d4c843ea5b2d">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzctMS0xLTEtMA_6e3f76e8-a662-4670-b0fe-8d47e53d283f">12,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzctMy0xLTEtMA_1002f620-b8f8-44f5-8031-9f3ddd3f4e3d">16,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMS0xLTEtMzU2MA_d59a8681-aa95-45eb-9765-3e0b55b76da5">21,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMy0xLTEtMzU1Ng_c98c3a01-e7fd-4b12-8b46-5244ac5d280d">20,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMS0xLTEtMA_04ae7698-c402-4c93-813a-021a3a3fd94c">8,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMy0xLTEtMA_51a4bd29-e1ff-41d8-b0d7-6d5e06b932c8">6,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzktMS0xLTEtMA_6ba090fc-42e6-4085-902b-864acf01895e">552,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzktMy0xLTEtMA_143bc455-874e-476b-8000-742493971a88">471,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzExLTEtMS0xLTA_3811026f-5625-41a7-ac9b-77f42d5ab6e1">9,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzExLTMtMS0xLTA_b73b6ebe-449e-4292-b660-df8bf7df37e3">14,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTEtMS0xLTM2MjI_b874a7c3-139c-4811-9b11-6a10a0eb6c6d">11,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTMtMS0xLTM2MzA_51c8e7b5-c006-4dfb-87e8-e4ff062382c1">15,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxLiabilitiesConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEyLTEtMS0xLTA_7bd0b9c7-4ad7-4f17-8b79-d4c75966c212">22,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxLiabilitiesConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEyLTMtMS0xLTA_221a1080-2aec-45b4-aa5a-9cfc49739260">28,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTEtMS0xLTA_e87b71b6-38f8-46de-bcc9-a1a5aca0c83a">42,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTMtMS0xLTA_c4080626-6b09-4342-a477-38eb57e7b740">58,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE0LTEtMS0xLTA_3b4174a1-8c7c-448b-ae58-7fb602253816">509,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE0LTMtMS0xLTA_9747cffa-9bdf-4454-b45a-a640188e10df">413,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE1LTEtMS0xLTA_9784c0ab-7415-4034-a880-1522c5a12c15">509,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE1LTMtMS0xLTA_ac441fc6-d625-420b-a1e6-985df5fd8a16">413,477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE2LTEtMS0xLTA_16366fba-2aae-4449-a08d-919a387af434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE2LTMtMS0xLTA_8635de2b-12ec-4438-bcfa-9a055771b7e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax assets (prior to applying the valuation allowance) of $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIwNDQ_87120dd5-f9c2-4f60-92d7-72d2abc9ddb2">509.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIwNTE_1026c0a1-5098-4d34-9598-6fb400695491">413.5</ix:nonFraction> million at December&#160;31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a valuation allowance on its net deferred tax assets by increasing the valuation allowance by $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIzMjY_5b515c3e-21ad-4f9d-bd49-37d515894989">96.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIzMzM_aa774fa3-873f-48b6-899a-82a185d47d97">80.9</ix:nonFraction> million in 2020 and 2019, respectively, as it was more likely than not that such tax benefits will not be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had federal net operating loss carryforwards for income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i60c1a8f856324526bc222644c67d2afb_I20201231" decimals="-8" format="ixt:numdotdecimal" name="insm:OperatingLossCarryforwardsTotal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI1NDY_6ae43444-fd1b-4516-b94b-f4e54ab3a4d6">1.2</ix:nonFraction> billion. Due to the limitation on NOLs as more fully discussed below, $<ix:nonFraction unitRef="usd" contextRef="i60c1a8f856324526bc222644c67d2afb_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI2MTE_2c450fbd-54f0-47d4-bdec-6410e6cd6307">1.0</ix:nonFraction> billion of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="i5509be6b4fb84159b9c6b41efd84a675_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI4MzA_882b74a5-9eaa-4dd9-8abe-8ca0427c7f43">456.7</ix:nonFraction> million of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below). The Company has $<ix:nonFraction unitRef="usd" contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="insm:OperatingLossCarryforwardsNonTradingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzQzOTgwNDY1MjEzNTg_2d5f06c6-b80d-4857-9d74-f137e6cbec4d">202.8</ix:nonFraction>&#160;million of non-trading loss carryforwards for Irish tax purposes. The Company has disallowed interest expense carryover of $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="insm:OperatingLossCarryforwardsDisallowedInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzQzOTgwNDY1MjEzNzU_2718f5e8-b6e3-497e-ab09-eb61ac11ecc7">6.1</ix:nonFraction>&#160;million which carryforward indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually 3 years). Since the Company's formation in 1999, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes (Continued)</span></div></div><ix:continuation id="id0bd638179074dbb9a109034941c5353"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Changes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains numerous income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#8217;s income taxes for 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, the Company would recognize a tax benefit of $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzYzOTc_0de8f878-9971-4ddc-bfbb-db4c712e503f">5.6</ix:nonFraction> million. <ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDY_b1547f05-7c2d-4f59-954a-cb0357ee5422" continuedAt="i432bb2be49e74138a40cb8cd16d64169" escape="true">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i432bb2be49e74138a40cb8cd16d64169"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:62.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzEtMS0xLTEtMA_b7de3836-2ce0-4938-ac41-45634192fd72">4,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6225cad52544c692427c26bd334021_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzEtMy0xLTEtMA_fcb24436-f9a0-47f7-a45e-718591e4ccfe">4,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzItMS0xLTEtMA_e5f12668-903e-4f65-9731-36e699483d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzItMy0xLTEtMA_573a6939-8b7a-4b87-be1f-af80be3c18a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzMtMS0xLTEtMA_2e690bba-e134-44f9-9741-afd9f8f5f036">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzMtMy0xLTEtMA_4f97d7eb-31d0-4461-9bb6-9804d7d81caa">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzQtMS0xLTEtMA_4a84a617-63eb-4606-a4f0-3c339b0f7036">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzQtMy0xLTEtMA_6a6e4dde-19bf-4229-955c-79994573c809">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzYtMS0xLTEtMA_9dd1ac78-8317-46cd-8d40-437b166437bb">5,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzYtMy0xLTEtMA_0ba9d151-aa67-4cfb-8dd4-d556e44b45da">4,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2016 and later, and is generally open for certain states for the years 2015 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded <ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcxNDY_2945edc9-aede-49f6-a268-b2fed46a38d3"><ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcxNDY_366fc08a-a3f7-44b7-9ba2-e582a89b67a3">no</ix:nonFraction></ix:nonFraction> such expense. As of December&#160;31, 2020 and 2019, the Company has recorded reserves for unrecognized income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcyNTQ_ac64cc14-6ca0-4c58-abcb-e72e7029efdb">5.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcyNjE_25cd8cb1-4938-4b43-8ca7-fd00c000942c">4.8</ix:nonFraction> million, respectively. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib70075c4f5c143bda8e7fff17e62c779_172"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="insm:LicenseAndOtherAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzg1MjM_78bdf785-eb3e-4219-ae40-d65f7a8c5a93" continuedAt="ib7804ddfd5f04e99bb933aeef7190259" escape="true">License and Other Agreements</ix:nonNumeric></span></div><ix:continuation id="ib7804ddfd5f04e99bb933aeef7190259" continuedAt="i325847346ee14d778ba2103e4f7c7031"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-License Agreements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">PARI Pharma&#160;GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit the system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture the nebulizers except as permitted under the commercialization agreement with PARI, which is described in further detail below. The Lamira Nebulizer System has been approved for use in the US (in combination with ARIKAYCE) and the EU. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA and EMA approval of ARIKAYCE, the Company paid PARI additional milestone payments of &#8364;<ix:nonFraction unitRef="eur" contextRef="i6cf490c2bd404047bb4076dfbe4a9035_D20080401-20080430" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzExMTU_4c803688-59e9-4ed0-b886-8ef566989105">1.0</ix:nonFraction> million, &#8364;<ix:nonFraction unitRef="eur" contextRef="if80ed6a320744417ad76e4542ce13f86_D20080401-20080430" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzExMjI_4d089764-04a9-4e33-a075-5bdf3f58668f">1.5</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="i7e1cd387ddb44953ad773aa9410675d5_D20080401-20080430" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzEwOTk1MTE2MzY4MjM_92a75e8d-3fcd-4704-9f1b-00c3aec78118">0.5</ix:nonFraction> million, respectively. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. As a result, PARI is entitled to receive royalty </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;License and Other Agreements (Continued)</span></div></div><ix:continuation id="i325847346ee14d778ba2103e4f7c7031" continuedAt="i8838d810e9d941e3b5fb0cb1e54fc2ea"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. See below for information related to the commercialization agreement with PARI. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation Therapeutics,&#160;Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received $<ix:nonFraction unitRef="usd" contextRef="i579a8c2c42bf45ff98f87f2c584c06ea_D20040101-20041231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIwNjY_8a10b967-27e6-44da-9453-bfbd8151b090">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iea44e908cf7e4040bb2902ceff09e1f2_D20090101-20091231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIwNzM_c268d5d0-e8c6-439e-8911-fab6c77fc63c">2.2</ix:nonFraction> million in research funding for the development of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owes milestone payments to CFFT of $<ix:nonFraction unitRef="usd" contextRef="ibad33e6bc291434cbfb0f351cbf0d854_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzEwOTk1MTE2NDQ3MjM_db29853e-dae5-4e0b-b375-87a0cd32906c">13.4</ix:nonFraction> million in the aggregate, of which $<ix:nonFraction unitRef="usd" contextRef="i2cfcedfa9eec4b33b05c236c449b48a7_D20040101-20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI3NDg3NzkwODY0MDE_6a2fed12-abe2-4b8f-b057-14a91593e372">1.0</ix:nonFraction> million has been paid through December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are payable through 2025. Furthermore, if certain global sales milestones are met within <ix:nonNumeric contextRef="ifb4bec08f1b8439f95f590be3ffee05d_D20200101-20201231" format="ixt-sec:durwordsen" name="insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIzNzY_58253b5c-881c-46e9-ad10-1147b97c21f1">five years</ix:nonNumeric> of the commercialization of ARIKAYCE, the Company would owe up to an additional $<ix:nonFraction unitRef="usd" contextRef="ibad33e6bc291434cbfb0f351cbf0d854_I20201231" decimals="-5" format="ixt:numdotdecimal" name="insm:AdditionalRoyaltyGuaranteesCommitmentsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI0NTg_ab33c764-7c28-4f5e-8bc6-92160b8c3c47">3.9</ix:nonFraction> million. The Company has determined the likelihood of meeting such global sales milestones and have accrued for these contingent obligations proportionally based on net sales of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resilience Biotechnologies Inc. (successor to Therapure Biopharma&#160;Inc.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma Inc., which was assumed by Resilience Biotechnologies&#160;Inc. (Resilience) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Resilience collaborated to construct a production area for the manufacture of ARIKAYCE in Resilience's existing manufacturing facility in Canada. The agreement has an initial term of <ix:nonNumeric contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228" format="ixt-sec:durwordsen" name="insm:InitialTermOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMwODg_3ec8518c-edc4-43f9-a433-6e8709b318b9">five years</ix:nonNumeric>, which began in October 2018, and will renew automatically for successive periods of <ix:nonNumeric contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228" format="ixt-sec:durwordsen" name="insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMxNzY_cbcd4ca4-b0e4-4883-bbaa-3f0e7c1c0d2f">two years</ix:nonNumeric> each, unless terminated by either party by providing the required <ix:nonNumeric contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228" format="ixt-sec:durwordsen" name="insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMyNDU_c2a8f993-0099-4910-9ce1-ed0c00000990">two years</ix:nonNumeric> prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay a minimum of $<ix:nonFraction unitRef="usd" contextRef="i49b84c0ce9224662b5305154df7099d8_I20140228" decimals="-6" format="ixt:numdotdecimal" name="insm:CommercialServicesAgreementMinimumObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzM0OTM_333e3313-13ee-4916-8353-58c8e3b981d7">6</ix:nonFraction> million for commercial ARIKAYCE batches produced and certain manufacturing activities each calendar year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PARI Pharma&#160;GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In July 2014, the Company entered into a commercialization agreement with PARI (the Commercialization Agreement) for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of <ix:nonNumeric contextRef="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731" format="ixt-sec:durwordsen" name="insm:InitialTermOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQyMjM_b3326826-79f0-4ed3-a6cf-1d168b1c8072">fifteen years</ix:nonNumeric> from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional <ix:nonNumeric contextRef="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731" format="ixt-sec:durwordsen" name="insm:AdditionalTermOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzODA_aa207c41-7e56-4d4c-93f2-b0dd682bf977">five years</ix:nonNumeric> by providing written notice to PARI at least <ix:nonNumeric contextRef="id633afd47e954538a26c547411ecfe02_D20140701-20140731" format="ixt-sec:durwordsen" name="insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQ0Mjg_04abc7b8-7002-4ad2-be2a-776563e4a3bd">one year</ix:nonNumeric> prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ajinomoto Althea,&#160;Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of $<ix:nonFraction unitRef="usd" contextRef="ib05c0670068f485e8afcc6417da49edf_I20150930" decimals="-5" format="ixt:numdotdecimal" name="insm:CommercialServicesAgreementMinimumObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzUwMDI_9eea10da-1475-4376-93a4-0a93a0ad922b">2.7</ix:nonFraction> million for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional <ix:nonNumeric contextRef="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231" format="ixt-sec:durwordsen" name="insm:CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjAwNTQ_4c114796-da57-45ca-a5ab-ee9646e75d3e">two-year</ix:nonNumeric> periods upon mutual written agreement of the Company and Althea at least <ix:nonNumeric contextRef="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231" format="ixt-sec:durwordsen" name="insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzU0MTY_71827d98-79af-4c0b-bf79-aaa69162d92b">one year</ix:nonNumeric> prior to the expiration of its then-current term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed brensocatib). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzYwMTA_48e5efa2-766e-431f-805d-1a8824e61c92">30.0</ix:nonFraction> million, which was included as research and development expense in the fourth quarter of 2016. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company incurred a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementPhase3StudyPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI3NDg3NzkwNzk2MzE_bb3ed7be-5ee6-4905-9029-f5e1b959fd0f">12.5</ix:nonFraction> million milestone payment obligation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the first dosing in a Phase 3 clinical trial of brensocatib. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also obligated to make a series of additional contingent milestone payments totaling up to an additional $<ix:nonFraction unitRef="usd" contextRef="i13e3ed8648004855b71e7b4adb845d68_I20161031" decimals="-5" format="ixt:numdotdecimal" name="insm:PaymentsUponAchievementOfClinicalMilestonesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzYyMDk_cab75c06-9373-416a-944c-b20d0e47fd65">72.5</ix:nonFraction> million upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop brensocatib for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to $<ix:nonFraction unitRef="usd" contextRef="i13e3ed8648004855b71e7b4adb845d68_I20161031" decimals="-5" format="ixt:numdotdecimal" name="insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY0Nzk_5e384465-82e3-4db2-8a56-44e4752d5109">42.5</ix:nonFraction> million, the first of which occurs at the initiation of a Phase 3 trial in the additional indication. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on brensocatib and one additional payment of $<ix:nonFraction unitRef="usd" contextRef="if28faba5eb55435f9579cbc04ed74d86_D20161001-20161031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY3NzU_9e13a91f-6166-4af5-9d3f-295154a96822">35.0</ix:nonFraction> million upon the first achievement of $<ix:nonFraction unitRef="usd" contextRef="i1957ada0d9cd42738836fe4ca797ec73_D20161001-20161031" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY4MDg_cec21dc1-33fc-47e5-bc13-21f359058f0d">1.0</ix:nonFraction> billion </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;License and Other Agreements (Continued)</span></div></div><ix:continuation id="i8838d810e9d941e3b5fb0cb1e54fc2ea"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patheon UK Limited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PPD Development, L.P.&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which it retained PPD to perform clinical development services in connection with certain of its clinical research programs. The master services agreement has an initial term of <ix:nonNumeric contextRef="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430" format="ixt-sec:durwordsen" name="insm:InitialTermOfClinicalDevelopmentServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjcxMzM_cfed4bbb-22f2-44f2-9d47-43909dac86a2">five years</ix:nonNumeric>. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon <ix:nonNumeric contextRef="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430" format="ixt-sec:durday" name="insm:WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjcxNTA_f601be2e-cbce-457e-892b-abfed2b64301">30</ix:nonNumeric> days&#8217; written notice, (ii) any project addendum in the event of the other party&#8217;s breach of the master services agreement or such project addendum upon 30 days&#8217; written notice, provided that such breach is not cured within such 30-day period, (iii) the master services agreement or any project addendum immediately upon the occurrence of an insolvency event with respect to the other party or (iv) any project addendum upon 30 days&#8217; written notice if (a) the continuation of the services under such project addendum would post material ethical or safety risks to study participants, (b) any approval from a regulatory authority necessary to perform the applicable study is revoked, suspended or expires without renewal or (c) in the reasonable opinion of such party, continuation of the services provided under such project addendum would be in violation of applicable law. The Company entered into project addenda with PPD to perform clinical development services over several years for, but not limited to, its ARISE, ENCORE and ASPEN studies.</span></div></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_175"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzE5MDc_47e9eaad-cefd-4b0c-a55d-77d39a642e11" continuedAt="i24efe86a6cb74962ac3853b2084f4172" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i24efe86a6cb74962ac3853b2084f4172"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company entered into a lease for its new corporate headquarters in Bridgewater, New Jersey. The initial lease term commenced in October 2019 and expires in September 2030. In July 2016, the Company signed an operating lease for laboratory space, also located in Bridgewater, for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for laboratory space located in Bridgewater, which commenced in January 2019. Future minimum rental payments under the Bridgewater leases are $<ix:nonFraction unitRef="usd" contextRef="i667f6be698f043288e59286e0ec72ad8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzYwNg_48961223-404d-4bff-acd5-4ebad4ed4e19">24.9</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY0OQ_0e99cbc0-33f6-445a-a569-249f9264171f">3.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY1Mw_1b10b8b3-c5c8-43c6-8a9a-e8a9cdcc2559">3.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY2MQ_9713e7ab-6e61-4e63-8478-6a8bb4c85cd4">2.1</ix:nonFraction> million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total $<ix:nonFraction unitRef="usd" contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzEwODQ_c9dea49c-f1d1-4be7-9de5-69e8f9d32000">83.1</ix:nonFraction> million. These amounts do not represent the Company's entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend amounts or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></div></ix:continuation><div id="ib70075c4f5c143bda8e7fff17e62c779_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzU2OA_96b7e9a5-b0b8-467c-a0ac-fe936ce8736d" continuedAt="idb6bd79ecf984bdc8432d893c3fbd549" escape="true">Retirement Plan</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib70075c4f5c143bda8e7fff17e62c779_7">Table of Contents</a></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSMED INCORPORATED</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Retirement Plan (Continued)</span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idb6bd79ecf984bdc8432d893c3fbd549">The Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched <ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzI1Mg_0e826234-304c-4675-9129-377f238a47e0">100</ix:nonFraction>% of eligible employee contributions on the first <ix:nonFraction unitRef="number" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzMwMw_dbcadda5-0ad9-433b-89cb-2c82f5cb3527">4</ix:nonFraction>% of employee salary (up to the IRS maximum). Employer contributions for the year ended December&#160;31, 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usd" contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzQxMQ_2b6b59bd-07b8-44b0-a2a2-d5955c72e4b7">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzQxNQ_cd2b76e1-e496-47ba-94bf-9bebc7d438f4">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzI3NDg3NzkwNzAxNjA_daf6455b-b145-4e1b-af3e-7207d2f564e0">2.2</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>insm20201231ex45.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i258a3bf430fa4284b04fafed289c4c0f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.5 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">DESCRIPTION OF SECURITIES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REGISTERED UNDER SECTION 12 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following information is a summary of the material terms of the common stock of Insmed Incorporated (&#8220;we&#8221;, &#8220;our&#8221; and &#8220;us,&#8221;), which is based upon, and is qualified in its entirety by reference to, our Articles of Incorporation, as amended (the &#8220;Articles of Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and applicable provisions of the Virginia Stock Corporation Act (&#8220;VSCA&#8221;). This summary may not contain all of the information that is important to you&#59; you can obtain additional information regarding our Articles of Incorporation and Bylaws by referring to such documents, copies of which are included as exhibits to the Annual Report on Form 10-K of which this Exhibit 4.5 is a part.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under our Articles of Incorporation, we have authority to issue 500,000,000 shares of common stock, par value $0.01 per share. All of our issued and outstanding shares of common stock are fully paid and nonassessable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Dividend Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the rights of the holders of any of our preferred stock then outstanding, the holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this Annual Report on Form 10-K, we have not declared or paid any dividends on our shares of common stock, and there were no shares of preferred stock outstanding, although our board of directors is authorized to issue preferred stock with rights senior to those of the common stock without any further vote or action by the holders of our common stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rights Upon Liquidation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and liabilities, each holder of common stock will receive distributions pro rata out of assets that we can legally use to pay distributions, subject to the rights of the holders of any of our preferred stock then outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Voting Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock are entitled to one vote per share and will have the exclusive power to vote on all matters presented to our shareholders, including the election of directors, except as otherwise provided by the VSCA and subject to the rights of the holders of any of our preferred stock then outstanding. An election of directors by our shareholders will be determined by a plurality of the votes cast by the shareholders entitled to vote on the election, although we have a director resignation policy applicable to director nominees in uncontested elections. Our Articles of Incorporation do not provide for cumulative voting. In accordance with our Articles of Incorporation, our board is divided into three classes serving staggered three-year terms, with one class being elected each year at our annual meeting of shareholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to certain exceptions set forth in the VSCA, matters other than the election of directors generally will be approved if the votes cast by our shareholders favoring the action exceed the votes cast opposing the action. Subject to the rights of the holders of any of our preferred stock then outstanding, however, the affirmative vote of at least 75% of the voting power of the outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single group, will be required to take the following actions&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">remove a director, which may only be done for cause&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">alter, amend, repeal, or adopt any provision inconsistent with, the provisions of (1) our Articles of Incorporation that provide for a classified board, director removal only for cause, filling of newly created or vacant directorships, or bylaw amendments or (2) our Bylaws.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Other Rights</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock will have no preference, appraisal or exchange rights, except for any appraisal rights provided by the VSCA. Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Potential Anti-Takeover Effects of Certain Provisions of Virginia Law and Our Organizational Documents </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain provisions of the VSCA, our Articles of Incorporation and our Bylaws could hamper a third-party&#8217;s acquisition of, or discourage a third-party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock. These provisions or arrangements include&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus expanding the time required to change the composition of a majority of directors.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The requirement that shareholders provide advance notice when nominating director candidates to serve on our board of directors.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The inability of shareholders to convene a shareholders&#8217; meeting without the chairman of the board, the president or a majority of the board of directors first calling the meeting.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The prohibition against entering into a business combination with the beneficial owner of 10% or more of our</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">outstanding voting stock for a period of three years after the 10% or greater owner first reached that level of</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">stock ownership, unless certain criteria are met.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>3
<FILENAME>insm20201231ex106.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i56c04aa3e23b4c2abd12c101642f87e3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OMNIBUS AMENDMENT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INCENTIVE PLANS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December 10, 2020</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Insmed Incorporated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) sponsors and maintains the Insmed Incorporated Amended and Restated 2000 Stock Incentive Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2000 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Insmed Incorporated 2013 Incentive Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2013 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Insmed Incorporated 2015 Incentive Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2015 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Insmed Incorporated 2017 Incentive Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2017 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Insmed Incorporated 2019 Incentive Plan (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">2019 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, together with the 2000 Plan, the 2013 Plan, the 2015 Plan and the 2017 Plan, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to amend each Plan to permit the transfer of certain awards made thereunder for estate-planning purposes&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, each Plan authorizes the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to amend such Plan and provides that, subject to certain exceptions, the Board may exercise any power of the Administrator under such Plan, which in each case is the Compensation Committee of the Board&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Administrator under each Plan, subject to certain exceptions, may amend or alter any agreement or other document evidencing an award made under such Plan. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, the Plans are amended as follows, effective as of the date hereof&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Article XIII of the 2000 Plan (&#8220;General Provisions&#8221;) is hereby amended by adding the following as a new Section 13.05&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in Section 6.04, Section 7.05 and Section 8.05 of the Plan, a Participant may, with the prior approval of the Company&#8217;s Chief Legal Officer or Chief Financial Officer or any designee of the Company&#8217;s Chief Legal Officer or Chief Financial Officer (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no such person may approve a transfer under this Section 13.05 by such person) and subject to applicable laws, rules and regulations and such terms and conditions as the Company&#8217;s Chief Legal Officer or Chief Financial Officer or such designee, as applicable, shall specify, transfer an award granted under the Plan (other than an incentive stock option), for no consideration, to a family member (as defined in the General Instructions to Form S-8 under the Securities Act of 1933) of the Participant, in each case, with respect to whom such award or the exercise thereof (as applicable) is covered by an effective registration statement under the Securities Act of 1933 (collectively, the &#8220;Permitted Transferees&#8221;). Any award transferred to a Permitted Transferee shall be further transferable only by will or the laws of descent and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">distribution or, for no consideration, to another Permitted Transferee of the Participant. Notwithstanding anything to the contrary in Section 6.04 of the Plan, during the Participant&#8217;s lifetime, each Option shall be exercisable only by the Participant or by his or her Permitted Transferee to whom such Option has been transferred in accordance with this paragraph&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that outstanding Options may be exercised following the Participant&#8217;s death by the Participant&#8217;s beneficiaries, any such Permitted Transferee or as permitted by the Administrator.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Section 16 of the 2013 Plan, the 2015 Plan and the 2017 Plan, and Section 15 of the 2019 Plan (&#8220;Transferability&#8221;) are, in each case, hereby amended and restated in their entirety as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Award may be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that a Participant may, with the prior approval of the Company&#8217;s Chief Legal Officer or Chief Financial Officer or any designee of the Company&#8217;s Chief Legal Officer or Chief Financial Officer (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that no such person may approve a transfer under this Section by such person) and subject to applicable laws, rules and regulations and such terms and conditions as the Company&#8217;s Chief Legal Officer or Chief Financial Officer or such designee, as applicable, shall specify, transfer an Award, other than an Incentive Stock Option, for no consideration, to a family member (as defined in the General Instructions to Form S-8 under the Securities Act of 1933) of the Participant, in each case, with respect to whom such Award or the exercise thereof (as applicable) is covered by an effective registration statement under the Securities Act of 1933 (collectively, the &#8220;Permitted Transferees&#8221;). Any Award transferred to a Permitted Transferee shall be further transferable only by will or the laws of descent and distribution or, for no consideration, to another Permitted Transferee of the Participant. During the Participant&#8217;s lifetime, each Option or Stock Appreciation Right shall be exercisable only by the Participant or by his or her Permitted Transferee to whom such Option or Stock Appreciation Right has been transferred in accordance with this paragraph&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that outstanding Options may be exercised following the Participant&#8217;s death by the Participant&#8217;s beneficiaries, any such Permitted Transferee or as permitted by the Administrator.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;This Amendment shall be and is hereby incorporated in, and forms a part of, each applicable Plan as set forth above. All other terms and provisions of the Plans shall remain unchanged except as specifically modified by this Amendment. Each Plan, as amended by this Amendment, is hereby ratified and confirmed.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#91;Signature page follows&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><div id="i56c04aa3e23b4c2abd12c101642f87e3_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned officer hereby certifies that the foregoing amendment to the Plans was duly adopted by the Board.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INSMED INCORPORATED</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.2
<SEQUENCE>4
<FILENAME>insm20201231ex1052.htm
<DESCRIPTION>EX-10.5.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i07915144c72a4152831076fa00b12a7f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE 2019 INCENTIVE PLAN FOR U.S. EMPLOYEES</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee Name&#58; &#91;_____&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of RSUs&#58; &#91;_____&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;_____&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Insmed Incorporated 2019 Incentive Plan (the &#8220;Plan&#8221;) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this &#8220;Agreement&#8221;), Insmed Incorporated (the &#8220;Company&#8221;) hereby grants an award of &#91;_____&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;RSU Award&#8221;) to the individual named above (the &#8220;Grantee&#8221;). The RSU Award shall be referred to herein as the &#8220;Award.&#8221; Subject to the restrictions and conditions set forth herein and in the Plan, the Grantee shall receive the number of Restricted Stock Units specified above. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between the Grantee and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Award Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the shares of Common Stock subject to the Award in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator and permitted under the Plan and applicable law.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Execution of this Agreement by the Grantee or receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Award, and the Company shall administer this Agreement accordingly.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictions and Conditions on Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Restricted Stock Units granted herein shall be subject to all the terms, conditions and restrictions set forth herein and in the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Timing and Form of Payout of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. As soon as practicable (but in no event later than 30 days) following the applicable Vesting Date (as defined below) or, if earlier, the date the Award vests in accordance with Section 5 or Section 6 of this Agreement, the vested Restricted Stock Units shall be settled in shares of Common Stock (except as provided in Section 5 of this Agreement). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Vesting of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as set forth in Section 5 of this Agreement, the restrictions and conditions in Section 2 of this Agreement shall lapse with respect to 25% of the RSU Award on each anniversary of the Grant Date (each a &#8220;Vesting Date&#8221;) through the fourth anniversary of the Grant Date, so long as the Grantee remains an employee of the Company or its Affiliates on the applicable Vesting Date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary herein or in the Plan, the Administrator may at any time accelerate the vesting schedule specified in this Section 4.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of a Change in Control, vesting of the RSU Award may be accelerated in accordance with the provisions of the Plan and&#47;or Service Agreement. If, in connection with a Change in Control, the RSU Award is not assumed and no award is substituted for the RSU Award, then the vested Restricted Stock Units shall be settled in cash in an amount equal to the Fair Market Value of the shares of Common Stock underlying such vested Restricted Stock Units determined as of the date of the Change in Control. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as otherwise provided in this Agreement or the Plan and&#47;or Service Agreement, any unvested portion of the RSU Award shall be forfeited without payment of consideration upon the termination of the Grantee&#8217;s employment with the Company or its Affiliates for any reason.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Voting Rights and Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Until such time as Restricted Stock Units are paid out in shares of Common Stock (if at all), the Grantee shall not have any voting, dividend or other shareholder rights with respect to any shares of Common Stock underlying this RSU Award (&#8220;Underlying Shares&#8221;). No dividend equivalents shall accrue or be paid to the Grantee with respect to the Underlying Shares. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon certain unusual or nonrecurring events, or other events, the terms of these Restricted Stock Units shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, this Award and this Agreement shall be subject to and governed by all the terms and conditions of the Plan. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Taxes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee shall, not later than the date as of which this RSU Award gives rise to a taxable event for Federal income or employment tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, local or other taxes required by law to be withheld on account of such taxable event. The Company shall have no obligation to deliver shares of Common Stock until such withholding requirements have been fully satisfied by the Grantee. The Company makes no representation or undertaking regarding the tax treatment of the grant, vesting, or settlement of this RSU Award or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">subsequent sale of any of the Underlying Shares. The Company does not commit and is under no obligation to structure this RSU Award to reduce or eliminate Grantee&#8217;s tax liability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Award is intended to comply with the requirements of Section 409A of the Code or an exemption thereto, and this Agreement shall be interpreted in a manner consistent with this intent in order to avoid the imposition of any additional tax, interest or penalties under Section 409A of the Code. In no event shall the Company be liable for any additional tax, interest or penalties that may be imposed on the Grantee pursuant to Section 409A of the Code or any damages for failing to comply with Section 409A of the Code or an exemption thereto.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Right to Continued Employment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable Service Agreement, nor shall any terms of the Plan or this Agreement confer upon Grantee any right to continue his or her employment for any specified period of time. Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract with the Company, any Subsidiary and&#47;or its Affiliates. If Grantee is a non-employee consultant or advisor, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Grantee&#8217;s service in accordance with the terms of the contract with such consultant or advisor. In no event shall any of the terms of the Plan or this Agreement itself confer upon Grantee any right to continue his or her service for any specified period of time. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to the Grantee at the address on the Company&#8217;s records or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to the Grantee, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:234pt"><font><br></font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; Sara Bonstein</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; &#91;_____&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.3
<SEQUENCE>5
<FILENAME>insm20201231ex1053.htm
<DESCRIPTION>EX-10.5.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7326152337364412bec93ad39eb2fdec_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NON-QUALIFIED STOCK OPTION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE 2019 INCENTIVE PLAN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">No. of shares subject to Option&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;_____&#93;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS AGREEMENT dated this &#91;_____&#93;, between INSMED INCORPORATED, a Virginia corporation (the &#34;Company&#34;), and &#91;_____&#93; (&#34;Participant&#34;), is made pursuant and subject to the provisions of the Insmed Incorporated 2019 Incentive Plan, as amended (the &#34;Plan&#34;), a copy of which has been made available to the Participant. All terms used herein that are defined in the Plan have the same meaning given them in the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If and to the extent that this Agreement conflicts or is inconsistent with the terms, conditions and provisions of any employment, consulting or similar services agreement between the Participant and the Company (or any of its Affiliates, as applicable) as may be in effect (the &#8220;Service Agreement&#8221;), the Service Agreement shall control, and this Award Agreement shall be deemed to be modified accordingly so long as such modification is not expressly prohibited by the Plan.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to the Plan, the Company, on &#91;_____&#93; (the &#34;Date of Grant&#34;), granted to Participant, subject to the terms and conditions of the Plan and subject further to the terms and conditions herein set forth, the right and Option to purchase from the Company all or any part of an aggregate of &#91;_____&#93; shares of Common Stock at the Option price of &#91;_____&#93; per share, being not less than the Fair Market Value of such shares on the Date of Grant. This Option is intended to be a nonqualified stock option and not an &#34;incentive stock option&#34; within the meaning of Section 422 of the Code. This Option is exercisable as hereinafter provided.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Option is subject to the following terms and conditions&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Option shall expire ten years from the Date of Grant (the &#34;Expiration Date&#34;).</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Except as provided in paragraphs 3, 4 and 5, this Option shall be exercisable with respect to twenty-five percent (25%) of the shares of Common Stock subject to this Option on the first annual anniversary of the Date of Grant (the &#8220;First Anniversary Date&#8221;) and with respect to an additional twelve and a half percent (12.5%) of the shares of Common Stock subject to this Option on the six-month anniversary of the First Anniversary Date and each six-month anniversary date thereafter through the fourth annual anniversary of the Date of Grant. If the foregoing schedule would produce fractional shares, the number of shares for which the Option becomes exercisable shall be rounded down to the nearest whole share. Once this Option has become exercisable in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">accordance with the preceding sentence it shall continue to be exercisable until the termination of Participant's rights hereunder pursuant to paragraph 3, 4 or 5 or until the Option has expired pursuant to subparagraph 2(a). A partial exercise of this Option shall not affect Participant's right to exercise this Option with respect to the remaining shares, subject to the conditions of the Plan and this Agreement.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Method of Exercising Option and Payment for Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Option shall be exercised by written notice delivered to the attention of the Company's Chief Financial Officer at the Company's principal office in New Jersey. The exercise date shall be (i) in the case of notice by mail, the date of postmark, or (ii) if delivered in person, the date of delivery. Such notice shall be accompanied by payment of the Option price in full, in cash or cash equivalent acceptable to the Committee, or such other method as determined by the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under the Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock deliverable upon exercise which, together with any cash or cash equivalent paid, is not less than the Option price for the number of shares for which this Option is being exercised.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement with Terms. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Execution of this Agreement by Participant or receipt of any benefits under this Agreement by Participant shall constitute Participant&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Option, and the Company shall administer this Agreement accordingly.</font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of Participant&#8217;s termination of employment, any vested portion of this Option that is not exercised during the period specified in paragraph 3, paragraph 4 or paragraph 5 of this Agreement, as applicable, shall be forfeited upon the expiration of such period. Any portion of this Option that is unvested as of the date of Participant&#8217;s termination of employment shall be forfeited on such date. </font></div><div style="text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant dies before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date of Participant&#8217;s death. In that event, this Option may be exercised, to the extent exercisable under subparagraph 2(b), by Participant's estate or by the person or persons to whom his rights under this Option shall pass by will or the laws of descent and distribution. Participant's estate or such persons may exercise this Option within one (1) year </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">after Participant's death or during the remainder of the period preceding the Expiration Date, whichever is shorter. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise in the Event of Permanent and Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Participant becomes permanently and totally disabled within the meaning of Section 22(e)(3) of the Code (&#34;Permanently and Totally Disabled&#34;) before the expiration of this Option pursuant to subparagraph 2(a), this Option shall be exercisable with respect to all or part of the shares of Common Stock that Participant was entitled to purchase under subparagraph 2(b) on the date he ceases to be employed by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled. In that event, Participant may exercise this Option, to the extent exercisable under subparagraph 2(b), within one (1) year after the date he ceases to be employed by the Company and its Affiliates as a result of his becoming Permanently and Totally Disabled or during the period preceding the Expiration Date, whichever is shorter. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Exercise After Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Except as provided in paragraphs 3 and 4 hereof, if the Participant ceases to be employed by the Company and its Affiliates prior to the Expiration Date, this Option shall be exercisable for all or part of the number of shares that the Participant was entitled to purchase under subparagraph 2(b), as well as set forth under any Service Agreement, on the date of Participant&#8217;s termination of employment. In that event, Participant may exercise this Option, to the extent exercisable under subparagraph 2(b) and&#47;or under any Service Agreement, during the remainder of the period preceding the Expiration Date or until the date that is three (3) months (or such other period of time provided under any Service Agreement) after the date he ceases to be employed by the Company and its Affiliates, whichever is shorter. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to the Participant at the address on the payroll records of the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. Additionally, if such notice or communication is by the Company to the Participant, the Company may provide such notice electronically (including via email). Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Fractional shares shall not be issuable hereunder, and when any provision hereof may entitle Participant to a fractional share such fraction shall be disregarded.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.68pt">Withholding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, local or other taxes </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">required by law to be withheld on account of such taxable event. The Company shall have no obligation to deliver shares of Common Stock until such withholding requirements have been fully satisfied by the Participant. </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Tax Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nothing in the Plan or in this Agreement shall be interpreted or construed to transfer any liability for any tax (including, without limitation, a tax or penalty due as a result of a failure to comply with Section 409A of the Code) due by the Participant to the Company, any Subsidiary or Affiliate, or to any other individual or entity, and the Company shall have no liability to the Participant, or any other party, thereto.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Participant acknowledges that the Company and its Subsidiaries and Affiliates&#58; (a) make no representations or undertakings regarding the tax treatment in connection with any aspect of the Option&#59; and (b) do not commit to structure the terms of the grant or any other aspect of the Option to reduce or eliminate the Participant&#8217;s tax liabilities.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">No Right to Continued Employment or Other Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate the Participant&#8217;s employment at any time or for any reason in accordance with the Company&#8217;s Bylaws, governing law and any applicable Service Agreement, nor shall any terms of the Plan or this Agreement confer upon Participant any right to continue his or her employment for any specified period of time. Neither this Agreement nor any benefits arising under the Plan or this Agreement shall constitute an employment contract with the Company, any Subsidiary and&#47;or its Affiliates. If Participant is not an employee, nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate Participant&#8217;s service, (i) if a member of the Board, on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, or (ii) if a non-employee consultant or advisor, in accordance with the terms of the contract with such consultant or advisor. In no event shall any of the terms of the Plan or this Agreement itself confer upon Participant any right to continue his or her service for any specified period of time. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon certain unusual or nonrecurring events, or other events, the terms of this Option shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be governed by the laws of the Commonwealth of Virginia.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of any conflict between the provisions of the Plan as in effect on the date hereof and the provisions of this Agreement, the provisions of the Plan shall govern. All references herein to the Plan shall mean the Plan as in effect on the date hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Award and Participant Bound by Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, this Option and this Agreement shall be subject to and governed by all the terms and conditions of the Plan. Participant hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the limitations stated above and in the Plan, this Agreement shall be binding upon and inure to the benefit of the legatees, distributees, and personal representatives of Participant and the successors of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Company has caused this Agreement to be signed by a duly authorized officer, and Participant has affixed his signature hereto.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________________________By&#58; &#47;s&#47; Sara Bonstein</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________________</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47; &#91;_____&#93;</font></div><div style="padding-left:216pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5.4
<SEQUENCE>6
<FILENAME>insm20201231ex1054.htm
<DESCRIPTION>EX-10.5.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3c6f92d131cf4b1bbb695c9438223821_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED UNIT AWARD AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNDER THE 2019 INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR MEMBERS OF THE BOARD OF DIRECTORS</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;NAME&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Number of RSUs&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;AMOUNT&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> &#91;DATE&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Insmed Incorporated 2019 Incentive Plan (the &#8220;Plan&#8221;) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this &#8220;Agreement&#8221;), Insmed Incorporated (the &#8220;Company&#8221;) hereby grants an award of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#91;AMOUNT&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> restricted stock units (the &#8220;Restricted Stock Units&#8221; or the &#8220;RSU Award&#8221;) to the individual named above (the &#8220;Grantee&#8221;).&#160;&#160;The RSU Award shall be referred to herein as the &#8220;Award.&#8221;  Subject to the restrictions and conditions set forth herein and in the Plan, the Grantee shall receive the number of Restricted Stock Units specified above.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the shares of Common Stock subject to the Award in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator and permitted under the Plan and applicable law.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Agreement with Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Execution of this Agreement by the Grantee or receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee&#8217;s acknowledgement of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Award, and the Company shall administer this Agreement accordingly.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Restrictions and Conditions on Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Restricted Stock Units granted herein shall be subject to all the terms, conditions and restrictions set forth herein and in the Plan.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Timing and Form of Payout of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as practicable (but in no event later than 30 days) following the Vesting Date (as defined below) or, if earlier, the date the Award vests in accordance with Section 5 or Section 6 of this Agreement, the vested Restricted Stock Units shall be settled in shares of Common Stock.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Vesting of Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as set forth in Sections 5 or 6 of this Agreement, the restrictions and conditions in Section 2 of this Agreement shall lapse, with respect to 100% of the RSU Award, on the first anniversary of the Grant Date (the &#8220;Vesting Date&#8221;) so long as (a) the Grantee remains a member of the Board on such Vesting Date and (b) the Grantee attends at least seventy-five percent (75%) of the Board meetings that take place during the period of time commencing from the Grant Date and ending on the first anniversary of the Grant Date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise provided in Sections 5 and 6 of this Agreement, the Grantee shall forfeit any unvested portion of the RSU Award if either the following shall occur&#58; (i) in the event the Grantee&#8217;s service as a member of the Board is terminated for any reason prior to the Vesting Date&#59; or (ii) in the event that the Grantee fails to attend at least seventy-five percent (75%) of the Board meetings that take place during the period of time commencing from the Grant Date and ending on the first anniversary of the Grant Date.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary herein or in the Plan, the Administrator may at any time accelerate the vesting schedule specified in this Section 4.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a Change in Control of the Company, the unvested portion of the RSU Award, to the extent not previously forfeited or cancelled, shall immediately vest as of the date of such Change in Control.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided herein, any unvested portion of the RSU Award shall be forfeited without payment of consideration upon the termination of the Grantee&#8217;s service with the Company or its Affiliates for any reason, except as otherwise provided in this Section 6.  Notwithstanding the foregoing, upon the Grantee&#8217;s death (while an active member of the Board) or upon the termination of the Grantee&#8217;s service due to Disability (as defined below), the RSU Award to extent not previously forfeited or cancelled, shall immediately vest as of the date of the Grantee&#8217;s death or Disability.  For purposes of this Agreement, the Grantee will be considered &#8220;Disabled&#8221; if, as a result of the Grantee&#8217;s incapacity due to physical or mental illness, the Grantee shall have been absent from his duties to the Company or its Affiliates on a full-time basis for 180 calendar days in the aggregate in any 12-month period.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Voting Rights and Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If and until such time as Restricted Stock Units are paid out in shares of Common Stock (if at all), the Grantee shall not have any voting rights with respect to any shares of Common Stock underlying this RSU Award (&#8220;Underlying Shares&#8221;).  However, bookkeeping equivalents of all dividends and other distributions paid with respect to the Common Stock shall accrue with respect to the Underlying Shares and shall be converted to additional Restricted Stock Units (rounded to the nearest whole share of Common Stock) based on the closing price of the Common Stock on the dividend distribution date.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Adjustments Upon Certain Unusual or Nonrecurring Events or Other Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Upon certain unusual or nonrecurring events, or other events, the terms of these Restricted Stock Units shall be adjusted by the Administrator pursuant to Section 14 of the Plan.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything herein to the contrary, this Award and this Agreement shall be subject to and governed by all the terms and conditions of the Plan.  To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Grantee is ultimately liable and responsible for all taxes owed by Grantee in connection with this RSU Award. The Company makes no representation or undertaking regarding the tax treatment of the grant, vesting, or settlement of this RSU Award or the subsequent sale of any of the Underlying Shares.  The Company does not commit and is under no obligation to structure this RSU Award to reduce or eliminate Grantee&#8217;s tax liability. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Section 409A of the Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Award is intended to comply with the requirements of Section 409A of the Code or an exemption thereto, and this Agreement shall be interpreted in a manner consistent with this intent in order to avoid the imposition of any additional tax, interest or penalties under Section 409A of the Code. In no event shall the Company be liable for any additional tax, interest or penalties that may be imposed on the Grantee pursuant to Section 409A of the Code or any damages for failing to comply with Section 409A of the Code or an exemption thereto. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">No Right to Re-Election or Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in the Plan or this Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and&#47;or its Affiliates to terminate the Grantee&#8217;s service on the Board at any time or for any reason in accordance with the Company&#8217;s Bylaws and governing law, nor shall any terms of the Plan or this Agreement confer upon Grantee any right to continue his or her service for any specified period of time.  Neither this Agreement nor any benefits arising under the Plan shall constitute an employment contract with the Company, any Subsidiary and&#47;or its Affiliates.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice or other communication given pursuant to this Agreement shall be in writing and shall be personally delivered or mailed by United States registered or certified mail, postage prepaid, return receipt requested, to the Company at its principal place of business or to the Grantee at the address on the Company&#8217;s records or, in either case, at such other address as one party may subsequently furnish to the other party in writing.&#160;&#160;Additionally, if such notice or communication is by the Company to the Grantee, the Company may provide such notice electronically (including via email).  Any such notice shall be deemed to have been given (a) on the date of postmark, in the case of notice by mail, or (b) on the date of delivery, if delivered in person or electronically.</font></div><div style="padding-left:36pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSMED INCORPORATED</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;By&#58; ___________________________________&#160;&#160;&#160;&#160;      </font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#91;NAME&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>insm20201231ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1773719380624973b904c7000e553823_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:72.435%"><tr><td style="width:1.0%"></td><td style="width:74.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Celtrix Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Ireland Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed France SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Netherlands B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Godo Kaisha</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Italy S.R.L</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insmed Switzerland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>insm20201231ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5ac369fd3e3f41b5b43d8ac8483e475f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)       Registration Statement on Form S-3 No. 333-238560 of Insmed Incorporated, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)       Registration Statements on Form S-8 Nos. 333-39200, 333-87878, 333-129479, 333-175532, 333-188852, 333-204503, 33-218668, 333-225323, 333-233407, and 333-238558 of Insmed Incorporated&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our reports dated February 25, 2021, with respect to the consolidated financial statements of Insmed Incorporated and the effectiveness of internal control over financial reporting of Insmed Incorporated included in this Annual Report (Form 10-K) of Insmed Incorporated for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Iselin, New Jersey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 25, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>insm20201231ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i146485f91bfd4774a8d8dfc00df8960a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1&#160;</font></div><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William H. Lewis, Chairman and Chief Executive Officer of Insmed Incorporated, certify that&#58;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this annual report on Form&#160;10-K of Insmed Incorporated&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021</font></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:53.654%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>insm20201231ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if5b3e501ddb04f5292f489747e3bcca4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 31.2&#160;</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 Certification&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sara Bonstein, Chief Financial Officer of Insmed Incorporated, certify that&#58;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) I have reviewed this annual report on Form&#160;10-K of Insmed Incorporated&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>insm20201231ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic88b9e95ae5a4d10a2ca4c28d27f4689_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 32.1&#160;</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 USC. SECTION&#160;1350,&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2003&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Annual Report on Form&#160;10-K of Insmed Incorporated (the &#34;Company&#34;) for the period ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, William H. Lewis, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 USC. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:55.116%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; William H. Lewis</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">William H. Lewis</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>insm20201231ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6fb10b60aa1b4b8292a82f1755c81850_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXHIBIT 32.2&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">18 USC. SECTION&#160;1350,&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2003&#160;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> connection with this Annual Report on Form&#160;10-K of Insmed Incorporated (the &#34;Company&#34;) for the period ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Sara Bonstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2003, that&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:54.239%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sara Bonstein</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sara Bonstein</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;25, 2021</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Insmed Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>insm-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:insm="http://www.insmed.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.insmed.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="insm-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.insmed.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>1004005 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1106101 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentation" roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation">
        <link:definition>2101102 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails">
        <link:definition>2402401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103103 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.insmed.com/role/Inventory">
        <link:definition>2113104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.insmed.com/role/InventoryTables">
        <link:definition>2314302 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleofInventoryCurrentDetails" roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails">
        <link:definition>2415409 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.insmed.com/role/IntangibleAssetsNet">
        <link:definition>2116105 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.insmed.com/role/IntangibleAssetsNetTables">
        <link:definition>2317303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetDetails" roleURI="http://www.insmed.com/role/IntangibleAssetsNetDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsnet" roleURI="http://www.insmed.com/role/FixedAssetsnet">
        <link:definition>2119106 - Disclosure - Fixed Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsnetTables" roleURI="http://www.insmed.com/role/FixedAssetsnetTables">
        <link:definition>2320304 - Disclosure - Fixed Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsnetDetails" roleURI="http://www.insmed.com/role/FixedAssetsnetDetails">
        <link:definition>2421411 - Disclosure - Fixed Assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.insmed.com/role/AccruedExpenses">
        <link:definition>2122107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.insmed.com/role/AccruedExpensesTables">
        <link:definition>2323305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.insmed.com/role/AccruedExpensesDetails">
        <link:definition>2424412 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.insmed.com/role/Leases">
        <link:definition>2125108 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.insmed.com/role/LeasesTables">
        <link:definition>2326306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.insmed.com/role/LeasesNarrativeDetails">
        <link:definition>2427413 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostDetails" roleURI="http://www.insmed.com/role/LeasesLeaseCostDetails">
        <link:definition>2428414 - Disclosure - Leases - Lease, Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>2429415 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>2429415 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.insmed.com/role/Debt">
        <link:definition>2130109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.insmed.com/role/DebtTables">
        <link:definition>2331307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDetails" roleURI="http://www.insmed.com/role/DebtDetails">
        <link:definition>2432416 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsofDebtDetails" roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails">
        <link:definition>2433417 - Disclosure - Debt - Components of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturePrincipalRepaymentsofDebtDetails" roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails">
        <link:definition>2434418 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails">
        <link:definition>2435419 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.insmed.com/role/ShareholdersEquity">
        <link:definition>2136110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.insmed.com/role/ShareholdersEquityDetails">
        <link:definition>2437420 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.insmed.com/role/StockBasedCompensation">
        <link:definition>2138111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.insmed.com/role/StockBasedCompensationTables">
        <link:definition>2339308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.insmed.com/role/IncomeTaxes">
        <link:definition>2143112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.insmed.com/role/IncomeTaxesTables">
        <link:definition>2344309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2445424 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails">
        <link:definition>2446425 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitProvisionDetails" roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails">
        <link:definition>2447426 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails">
        <link:definition>2448427 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2449428 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>2450429 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandOtherAgreements" roleURI="http://www.insmed.com/role/LicenseandOtherAgreements">
        <link:definition>2151113 - Disclosure - License and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandOtherAgreementsDetails" roleURI="http://www.insmed.com/role/LicenseandOtherAgreementsDetails">
        <link:definition>2452430 - Disclosure - License and Other Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.insmed.com/role/CommitmentsandContingencies">
        <link:definition>2153114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2454431 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.insmed.com/role/RetirementPlan">
        <link:definition>2155115 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanDetails" roleURI="http://www.insmed.com/role/RetirementPlanDetails">
        <link:definition>2456432 - Disclosure - Retirement Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="insm_RepaymentsOfDebtFeesAndOutstandingInterest" abstract="false" name="RepaymentsOfDebtFeesAndOutstandingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" abstract="false" name="ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_NoncashOperatingLeaseExpense" abstract="false" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_OperatingLossCarryforwardsDisallowedInterestExpense" abstract="false" name="OperatingLossCarryforwardsDisallowedInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" abstract="false" name="WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PaymentsUponAchievementOfClinicalMilestonesAmount" abstract="false" name="PaymentsUponAchievementOfClinicalMilestonesAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AdditionalTermOfContractManufacturingAgreement" abstract="false" name="AdditionalTermOfContractManufacturingAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_ConversionTermivMember" abstract="true" name="ConversionTermivMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_WeightedAverageRemainingContractualLifeInYearsAbstract" abstract="true" name="WeightedAverageRemainingContractualLifeInYearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_AmortizationOfBackendFee" abstract="false" name="AmortizationOfBackendFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DeferredTaxLiabilitiesConvertibleDebt" abstract="false" name="DeferredTaxLiabilitiesConvertibleDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AccruedSalesAllowancesandRelatedCosts" abstract="false" name="AccruedSalesAllowancesandRelatedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" abstract="false" name="PaymentsForProceedsFromFinancingLeaseTenantAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" abstract="false" name="ContractWithCustomerAssetAllowanceForPriorPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" abstract="true" name="CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedTable" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_DebtInstrumentOptionToPurchaseAdditionalDebt" abstract="false" name="DebtInstrumentOptionToPurchaseAdditionalDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MilestoneEMAApprovalMember" abstract="true" name="MilestoneEMAApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_DeferredTaxAssetsLicensePayment" abstract="false" name="DeferredTaxAssetsLicensePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_InitialTermOfContractManufacturingAgreement" abstract="false" name="InitialTermOfContractManufacturingAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_CollaborativeArrangementPhase3StudyPayment" abstract="false" name="CollaborativeArrangementPhase3StudyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" abstract="false" name="DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_CustomerFeesDiscountsandOtherMember" abstract="true" name="CustomerFeesDiscountsandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_LicenseAndOtherAgreementsTextBlock" abstract="false" name="LicenseAndOtherAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="insm_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_OperatingLossCarryforwardsTotal" abstract="false" name="OperatingLossCarryforwardsTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" abstract="true" name="OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" abstract="false" name="CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CollaborativeArrangementMilestonePayment" abstract="false" name="CollaborativeArrangementMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_A2019IncentivePlanMember" abstract="true" name="A2019IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" abstract="true" name="ContractwithCustomerAssetAllowanceforCreditLossLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_MilestonePaymentDomain" abstract="true" name="MilestonePaymentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CollaborativeArrangementUpfrontPayment" abstract="false" name="CollaborativeArrangementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" abstract="false" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" abstract="false" name="ContractWithCustomerAssetAllowanceForCurrentPeriodSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" abstract="false" name="IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" abstract="false" name="CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" abstract="false" name="AmortizationOfDebtDiscountPremiumAndAccretionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="insm_PRIPharmaGmbhCommercializationAgreementMember" abstract="true" name="PRIPharmaGmbhCommercializationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="insm_FairValueLevel1Level2Level3TransfersAmount" abstract="false" name="FairValueLevel1Level2Level3TransfersAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_InitialTermOfClinicalDevelopmentServicesAgreement" abstract="false" name="InitialTermOfClinicalDevelopmentServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" abstract="false" name="WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_InvestmentIncomeExpensePolicyTextBlock" abstract="false" name="InvestmentIncomeExpensePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="insm_AccruedTechnicalOperationExpenses" abstract="false" name="AccruedTechnicalOperationExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermDomain" abstract="true" name="DebtInstrumentConversionTermDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ConversionTermiiMember" abstract="true" name="ConversionTermiiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" abstract="true" name="ResilienceBiotechnologiesIncContractManufacturingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_EquipmentFurnitureAndFixturesMember" abstract="true" name="EquipmentFurnitureAndFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CustomerCMember" abstract="true" name="CustomerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" abstract="false" name="AdditionalRoyaltyGuaranteesCommitmentsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_DebtInstrumentConversionTermAxis" abstract="true" name="DebtInstrumentConversionTermAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_ContractwithCustomerAssetAllowanceforCreditLossTable" abstract="true" name="ContractwithCustomerAssetAllowanceforCreditLossTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_RebatesChargebacksandCoPayAssistanceMember" abstract="true" name="RebatesChargebacksandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_BridgewaterNewJerseyFacilityMember" abstract="true" name="BridgewaterNewJerseyFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" abstract="false" name="AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="insm_MilestoneNewDrugApplicationMember" abstract="true" name="MilestoneNewDrugApplicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_LeaseRemainingLeaseTerm" abstract="false" name="LeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_LicenseAndOtherAgreementsAbstract" abstract="true" name="LicenseAndOtherAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_LicenseAgreementWithAstrazenecaMember" abstract="true" name="LicenseAgreementWithAstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_IrelandTaxMember" abstract="true" name="IrelandTaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" abstract="true" name="PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_MilestonePaymentAxis" abstract="true" name="MilestonePaymentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="insm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" abstract="false" name="PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTradingIncomePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" abstract="true" name="ScheduleofEarningsPerShareBasicandDilutedLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="insm_ConversionTermiiiMember" abstract="true" name="ConversionTermiiiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" abstract="false" name="NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="insm_CommercialServicesAgreementMinimumObligation" abstract="false" name="CommercialServicesAgreementMinimumObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_MilestoneFDAApprovalMember" abstract="true" name="MilestoneFDAApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_EffectiveIncomeTaxRateReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="insm_ConvertibleDebtInterestExpenseTotal" abstract="false" name="ConvertibleDebtInterestExpenseTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_RestrictedStockAndRestrictedStockUnitsMember" abstract="true" name="RestrictedStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CommercialFilVFinishServicesAgreementMember" abstract="true" name="CommercialFilVFinishServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_AccruedConstructionLiabilitiesCurrent" abstract="false" name="AccruedConstructionLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PPDDevelopmentLPAgreementMember" abstract="true" name="PPDDevelopmentLPAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" abstract="false" name="CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" abstract="false" name="PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" abstract="false" name="InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="insm_OperatingLossCarryforwardsNonTradingLoss" abstract="false" name="OperatingLossCarryforwardsNonTradingLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="insm_ConversionTermiMember" abstract="true" name="ConversionTermiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_ComputerHardwareAndSoftwareMember" abstract="true" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="insm_EmployeeAndDirectorsStockOptionsMember" abstract="true" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>insm-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/CoverPage" xlink:type="simple" xlink:href="insm-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4520fda7-8ede-4738-b1ae-466e8e096c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:to="loc_us-gaap_LiabilitiesCurrent_4520fda7-8ede-4738-b1ae-466e8e096c1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aae8cdf5-10e8-40c2-896f-8efc02ea761a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aae8cdf5-10e8-40c2-896f-8efc02ea761a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_96be8d04-2c63-4c2b-9a5e-8c9d95a54d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_96be8d04-2c63-4c2b-9a5e-8c9d95a54d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32478ae8-91c8-48de-ab7a-a886f4d7f101" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32478ae8-91c8-48de-ab7a-a886f4d7f101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9b3aef26-5072-4b30-8439-9701191bf0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bfd04dff-84e2-4a35-ac1f-feccd798dedb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9b3aef26-5072-4b30-8439-9701191bf0e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fa747908-51f4-4b09-b7a6-1a3bd8b076e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfed9799-a686-4604-9931-08ce159f1268" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa747908-51f4-4b09-b7a6-1a3bd8b076e2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dfed9799-a686-4604-9931-08ce159f1268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_27f1ce9c-ff75-4b7b-a983-20a89834873d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa747908-51f4-4b09-b7a6-1a3bd8b076e2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_27f1ce9c-ff75-4b7b-a983-20a89834873d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_23b4df72-62b7-43a1-9c82-15d6512e7b36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa747908-51f4-4b09-b7a6-1a3bd8b076e2" xlink:to="loc_us-gaap_InventoryNet_23b4df72-62b7-43a1-9c82-15d6512e7b36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fa8d31ae-5fb1-479c-a570-0a9b0ea50db7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_fa747908-51f4-4b09-b7a6-1a3bd8b076e2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fa8d31ae-5fb1-479c-a570-0a9b0ea50db7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_506ddd66-9c2a-42a3-b38d-aee775d175ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_10b8f301-2b8e-4dff-8a5d-04f59b17a400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_506ddd66-9c2a-42a3-b38d-aee775d175ca" xlink:to="loc_us-gaap_CommonStockValue_10b8f301-2b8e-4dff-8a5d-04f59b17a400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_14bca5ef-438d-4d37-91f2-d58acd7812c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_506ddd66-9c2a-42a3-b38d-aee775d175ca" xlink:to="loc_us-gaap_AdditionalPaidInCapital_14bca5ef-438d-4d37-91f2-d58acd7812c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7be12fb7-f880-46eb-81de-df8606f55848" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_506ddd66-9c2a-42a3-b38d-aee775d175ca" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7be12fb7-f880-46eb-81de-df8606f55848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba7c0d1c-9176-42f2-8ba6-ea51092edc78" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_506ddd66-9c2a-42a3-b38d-aee775d175ca" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ba7c0d1c-9176-42f2-8ba6-ea51092edc78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7fbf1da3-c4ae-4caf-b519-8a7e36203cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_AccountsPayableCurrent_7fbf1da3-c4ae-4caf-b519-8a7e36203cc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_efa63488-a114-497c-b393-e36184a05fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_efa63488-a114-497c-b393-e36184a05fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52d1095e-0668-455f-9fff-ad7634293e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_52d1095e-0668-455f-9fff-ad7634293e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f8e155f5-a24f-446c-9e36-3607e4278fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f8e155f5-a24f-446c-9e36-3607e4278fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27e6b7c7-007d-47ad-8cb2-cb917449f838" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27e6b7c7-007d-47ad-8cb2-cb917449f838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd8fe019-9565-4430-b92f-b8200c75933d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_da9ef116-a500-460c-ac32-0468d1616f0e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fd8fe019-9565-4430-b92f-b8200c75933d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1642eb-3e9e-4707-b7f1-e6e9d6c9a828" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70978cd9-20d2-4c95-8f42-12a75f68aece" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1642eb-3e9e-4707-b7f1-e6e9d6c9a828" xlink:to="loc_us-gaap_Liabilities_70978cd9-20d2-4c95-8f42-12a75f68aece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac72a13f-350a-41bd-b72c-ddb60dde02cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1642eb-3e9e-4707-b7f1-e6e9d6c9a828" xlink:to="loc_us-gaap_StockholdersEquity_ac72a13f-350a-41bd-b72c-ddb60dde02cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_56d68537-dcc8-4679-8230-6b32c09dce6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_AssetsCurrent_56d68537-dcc8-4679-8230-6b32c09dce6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2604fbb-fc93-4148-83a6-3e1204aa5b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2604fbb-fc93-4148-83a6-3e1204aa5b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_007bfacd-ea7a-4f1f-a664-171795c1cd0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_OtherAssets_007bfacd-ea7a-4f1f-a664-171795c1cd0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c1d801e-9952-4cb4-864c-3a803b7cc514" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7c1d801e-9952-4cb4-864c-3a803b7cc514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_174afaf6-0065-4e4a-b536-6f2f90831599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_174afaf6-0065-4e4a-b536-6f2f90831599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3cd0fe75-310f-43bc-892f-04f4ec4fc76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2475cafa-dd4d-4491-989a-2bbf5e0d3b96" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3cd0fe75-310f-43bc-892f-04f4ec4fc76c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_458a7ad8-7e9c-4dc4-9656-f7afc270f3ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a7a4436b-87e5-46e5-b412-b8c827ad28de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_458a7ad8-7e9c-4dc4-9656-f7afc270f3ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a7a4436b-87e5-46e5-b412-b8c827ad28de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cbc3a1a7-f0a5-4378-8b77-84a00d479b71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_458a7ad8-7e9c-4dc4-9656-f7afc270f3ea" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cbc3a1a7-f0a5-4378-8b77-84a00d479b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_a21a8ab8-fd26-4611-b6b0-a7b1d289a58a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_458a7ad8-7e9c-4dc4-9656-f7afc270f3ea" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_a21a8ab8-fd26-4611-b6b0-a7b1d289a58a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_60e18055-71a8-4025-9f9f-b1795ba46edd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_458a7ad8-7e9c-4dc4-9656-f7afc270f3ea" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_60e18055-71a8-4025-9f9f-b1795ba46edd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73b91362-c20d-46f2-91a8-da1b3199f262" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5863941c-7e10-4e42-b763-dcd857bfd86a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_73b91362-c20d-46f2-91a8-da1b3199f262" xlink:to="loc_us-gaap_CostsAndExpenses_5863941c-7e10-4e42-b763-dcd857bfd86a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f8c95c8-22c9-46b0-874c-20a94d8298c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_73b91362-c20d-46f2-91a8-da1b3199f262" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f8c95c8-22c9-46b0-874c-20a94d8298c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d66222f4-2931-4f18-8fb0-561998e25849" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:to="loc_us-gaap_OperatingIncomeLoss_d66222f4-2931-4f18-8fb0-561998e25849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_7d2a6b47-18c3-45a8-8ecf-c353a8bc7a52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_7d2a6b47-18c3-45a8-8ecf-c353a8bc7a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f112fa08-a60f-4ebc-a14b-c419e6b3d628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:to="loc_us-gaap_InterestExpense_f112fa08-a60f-4ebc-a14b-c419e6b3d628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_214c666c-bb31-46bd-9ca1-53804cfd0c90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_214c666c-bb31-46bd-9ca1-53804cfd0c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ec864a74-0e44-46c3-827a-6c0f90cd97c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_818c0b29-da0a-452b-8576-6684807c72fc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ec864a74-0e44-46c3-827a-6c0f90cd97c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f38278d5-a745-4817-a3f2-771e132e6174" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d194c4ef-7f9a-4cbb-a56d-f66f19d419cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f38278d5-a745-4817-a3f2-771e132e6174" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d194c4ef-7f9a-4cbb-a56d-f66f19d419cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d14d5ccd-43f3-4d0f-bafb-43d8cc8ae764" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_f38278d5-a745-4817-a3f2-771e132e6174" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d14d5ccd-43f3-4d0f-bafb-43d8cc8ae764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46be4c86-38c7-4e02-a8ec-fe8e018fac1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb7ca26f-62be-4c9e-9d72-e8770ab2b2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46be4c86-38c7-4e02-a8ec-fe8e018fac1d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb7ca26f-62be-4c9e-9d72-e8770ab2b2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_802cc3e6-3535-4059-b487-874f510d2775" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_46be4c86-38c7-4e02-a8ec-fe8e018fac1d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_802cc3e6-3535-4059-b487-874f510d2775" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34185e0b-8bf7-49b5-8103-44491b855de5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d070e310-485c-45ee-9563-639d6ace49f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34185e0b-8bf7-49b5-8103-44491b855de5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d070e310-485c-45ee-9563-639d6ace49f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29caa56b-9794-48e9-ae33-64ef328cfeea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34185e0b-8bf7-49b5-8103-44491b855de5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29caa56b-9794-48e9-ae33-64ef328cfeea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_42f09e9f-2341-4082-85c1-cfc46f7d687c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34185e0b-8bf7-49b5-8103-44491b855de5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_42f09e9f-2341-4082-85c1-cfc46f7d687c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfaffcbd-2085-4b3a-93aa-0dd3be796cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34185e0b-8bf7-49b5-8103-44491b855de5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dfaffcbd-2085-4b3a-93aa-0dd3be796cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_323ff843-75b5-4bbb-b5f9-697eb6fd2c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_323ff843-75b5-4bbb-b5f9-697eb6fd2c5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_361b837b-fa7d-4f92-aaca-241719106f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_RepaymentsOfDebt_361b837b-fa7d-4f92-aaca-241719106f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf32c7-ad3e-43b0-be9b-d96dd0cef6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e1bf32c7-ad3e-43b0-be9b-d96dd0cef6d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ece1df8a-2b6c-454a-b3fe-337bb472a64a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ece1df8a-2b6c-454a-b3fe-337bb472a64a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_97e46d7f-b45c-47d5-9d53-00688a3a0d9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_97e46d7f-b45c-47d5-9d53-00688a3a0d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_8aabba3e-df6c-4b24-91f7-19fbba24f1c4" xlink:href="insm-20201231.xsd#insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_8aabba3e-df6c-4b24-91f7-19fbba24f1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7ff7570a-eefd-4aeb-85de-4a631fcb9a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_88ed2f79-6aa5-4329-8012-d6382bf75890" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7ff7570a-eefd-4aeb-85de-4a631fcb9a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11752afa-73fe-44ac-8832-28ff483d5d69" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_NetIncomeLoss_11752afa-73fe-44ac-8832-28ff483d5d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c7738be7-2e90-4957-b41b-5578629a348a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_Depreciation_c7738be7-2e90-4957-b41b-5578629a348a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3df2b541-7bd0-4acd-8706-6e58b8d6573f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3df2b541-7bd0-4acd-8706-6e58b8d6573f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58d94245-ae0f-4ec5-a124-e3c80e5bcc4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_ShareBasedCompensation_58d94245-ae0f-4ec5-a124-e3c80e5bcc4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cb011eb7-044e-474d-b270-4521896efe36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cb011eb7-044e-474d-b270-4521896efe36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6a4d6f34-038b-4d3b-bce8-6e12cd608da0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6a4d6f34-038b-4d3b-bce8-6e12cd608da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_481325de-6dd9-43ed-817a-02a363c70da1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_481325de-6dd9-43ed-817a-02a363c70da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bc8abf81-a3ae-43ad-afb8-007bee293fad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bc8abf81-a3ae-43ad-afb8-007bee293fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f86cfed0-bee8-4ceb-8ea0-4271020598fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f86cfed0-bee8-4ceb-8ea0-4271020598fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_50c49a28-1c11-42c1-9f98-ab31b7a36d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_50c49a28-1c11-42c1-9f98-ab31b7a36d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_f5db7c02-e248-44df-937e-ead8e0ffaaf5" xlink:href="insm-20201231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_f5db7c02-e248-44df-937e-ead8e0ffaaf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3def0437-cfa1-4a12-a920-efbb87f8f134" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3def0437-cfa1-4a12-a920-efbb87f8f134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c6987436-54d3-44fd-acd8-dd3397020911" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c6987436-54d3-44fd-acd8-dd3397020911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f8ed5696-a7ed-41fe-b942-dfd10cefce0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f8ed5696-a7ed-41fe-b942-dfd10cefce0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_a8e71e68-931a-4f63-901e-17d5289a2567" xlink:href="insm-20201231.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_insm_NoncashOperatingLeaseExpense_a8e71e68-931a-4f63-901e-17d5289a2567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_e5b0b44c-5f8c-4892-9bf8-f7c75e729dac" xlink:href="insm-20201231.xsd#insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53194d78-b385-4aeb-9bb6-55a45fa9b8bb" xlink:to="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_e5b0b44c-5f8c-4892-9bf8-f7c75e729dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e58a2b1-341d-472f-8186-534d6165ad84" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba4392ab-7a01-4c1b-908a-0fa30b25f9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e58a2b1-341d-472f-8186-534d6165ad84" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba4392ab-7a01-4c1b-908a-0fa30b25f9aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e7a521ec-d685-44ca-ba94-0cc68cfae424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e58a2b1-341d-472f-8186-534d6165ad84" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e7a521ec-d685-44ca-ba94-0cc68cfae424" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_869626b6-68a8-47e0-87c4-7863fd7f5a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c4b20b82-80e4-4c4a-89e1-d419237bf395" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_869626b6-68a8-47e0-87c4-7863fd7f5a1e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c4b20b82-80e4-4c4a-89e1-d419237bf395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1feba65b-082d-49b0-9d96-1be2aa6664d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_869626b6-68a8-47e0-87c4-7863fd7f5a1e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1feba65b-082d-49b0-9d96-1be2aa6664d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:type="simple" xlink:href="insm-20201231.xsd#Inventory"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e847c28b-f0d9-409d-831d-60a33be4d18e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b275fd43-e586-477f-9ce5-9417fa1e7155" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e847c28b-f0d9-409d-831d-60a33be4d18e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_b275fd43-e586-477f-9ce5-9417fa1e7155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f5875ac8-43ba-4972-aeed-6c6ea330abe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e847c28b-f0d9-409d-831d-60a33be4d18e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f5875ac8-43ba-4972-aeed-6c6ea330abe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_973e0659-ee74-4cc7-8dee-7fdda06c4ebe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e847c28b-f0d9-409d-831d-60a33be4d18e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_973e0659-ee74-4cc7-8dee-7fdda06c4ebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNet"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnet" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnet"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsnet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db69a11b-b7b7-4d34-9f19-78f65c4708eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1343a6c2-d8f5-4b7d-a802-2c094555a552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db69a11b-b7b7-4d34-9f19-78f65c4708eb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1343a6c2-d8f5-4b7d-a802-2c094555a552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e7f6aa72-4f3a-4eb3-a019-d47734e4e17d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_db69a11b-b7b7-4d34-9f19-78f65c4708eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e7f6aa72-4f3a-4eb3-a019-d47734e4e17d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_d36f427d-e8c4-49dd-9bd1-16cd588dec28" xlink:href="insm-20201231.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_insm_AccruedClinicalTrialExpenses_d36f427d-e8c4-49dd-9bd1-16cd588dec28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a7278826-0c5c-416e-b236-b4c73c82305c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a7278826-0c5c-416e-b236-b4c73c82305c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_41ac5bde-a040-497b-acb2-dfdf7d07282f" xlink:href="insm-20201231.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_41ac5bde-a040-497b-acb2-dfdf7d07282f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_2c71b989-9100-462f-8d60-f32be00cea1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_us-gaap_InterestPayableCurrent_2c71b989-9100-462f-8d60-f32be00cea1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts_9840dab4-cd84-4a12-9ac8-0868e8d67f88" xlink:href="insm-20201231.xsd#insm_AccruedSalesAllowancesandRelatedCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_insm_AccruedSalesAllowancesandRelatedCosts_9840dab4-cd84-4a12-9ac8-0868e8d67f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_dc48274b-3c3f-42fa-a073-236b025e4c9a" xlink:href="insm-20201231.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_dc48274b-3c3f-42fa-a073-236b025e4c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6275347d-a0ac-4078-b60d-bb905ce9b07a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6275347d-a0ac-4078-b60d-bb905ce9b07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_50ff79d2-fe96-4a93-a61a-b2fb1c7c3924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_43b73630-be16-4c5d-8377-263629f2e399" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_50ff79d2-fe96-4a93-a61a-b2fb1c7c3924" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Leases" xlink:type="simple" xlink:href="insm-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7d722822-6dc3-47d1-9140-e110f495e2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bc240fdb-24c0-4ab8-bc55-52190c7bdefb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d722822-6dc3-47d1-9140-e110f495e2b6" xlink:to="loc_us-gaap_OperatingLeaseCost_bc240fdb-24c0-4ab8-bc55-52190c7bdefb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FinanceLeaseCost_cd2d8a99-e5c0-487c-a014-5a819bf1c0f7" xlink:href="insm-20201231.xsd#insm_FinanceLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d722822-6dc3-47d1-9140-e110f495e2b6" xlink:to="loc_insm_FinanceLeaseCost_cd2d8a99-e5c0-487c-a014-5a819bf1c0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_70c24d4a-1ebf-4bcf-9a29-4d4575548af6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_7d722822-6dc3-47d1-9140-e110f495e2b6" xlink:to="loc_us-gaap_VariableLeaseCost_70c24d4a-1ebf-4bcf-9a29-4d4575548af6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0cf621c1-d828-4d30-af2e-75dde5d3038c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_bced75e2-f967-4edb-a91c-eea2ce3f9ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0cf621c1-d828-4d30-af2e-75dde5d3038c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_bced75e2-f967-4edb-a91c-eea2ce3f9ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a82ca31f-9a36-4704-ac83-a841c05a35ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0cf621c1-d828-4d30-af2e-75dde5d3038c" xlink:to="loc_us-gaap_FinanceLeaseLiability_a82ca31f-9a36-4704-ac83-a841c05a35ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a913ecac-d752-4803-ae48-ebd8f7e094e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a913ecac-d752-4803-ae48-ebd8f7e094e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c5006e27-faeb-4cb7-a88c-1d0fe7da2a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c5006e27-faeb-4cb7-a88c-1d0fe7da2a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa9de5a1-0423-4260-9d63-373f39795f51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa9de5a1-0423-4260-9d63-373f39795f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f74cb98a-7b68-4f4c-a6d9-91b3ae95e90c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f74cb98a-7b68-4f4c-a6d9-91b3ae95e90c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1066a29f-a05f-4fbf-a25e-2c1e92deb237" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1066a29f-a05f-4fbf-a25e-2c1e92deb237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_03305708-023c-49e6-8b55-67dcc1e25b26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b2af7ff6-7534-4129-ad50-537c71883689" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_03305708-023c-49e6-8b55-67dcc1e25b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8ff9df34-7179-4f2e-89f3-781fdb6b0e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab25ff3f-51ac-48ae-babd-7c25f43d247c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8ff9df34-7179-4f2e-89f3-781fdb6b0e6d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ab25ff3f-51ac-48ae-babd-7c25f43d247c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_01923a6d-1d67-4609-88d5-afc2aac63a66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_8ff9df34-7179-4f2e-89f3-781fdb6b0e6d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_01923a6d-1d67-4609-88d5-afc2aac63a66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_fd028dab-ed31-490c-8ec9-c9adee841323" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_237a6f60-b1c0-4fd0-bcba-45788432ae33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_fd028dab-ed31-490c-8ec9-c9adee841323" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_237a6f60-b1c0-4fd0-bcba-45788432ae33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_179482ed-b346-4604-b256-294dbfdacebb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_fd028dab-ed31-490c-8ec9-c9adee841323" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_179482ed-b346-4604-b256-294dbfdacebb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_471c9cb5-5131-4b30-bb3c-2f723fef2a59" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_471c9cb5-5131-4b30-bb3c-2f723fef2a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3a515019-6c4c-4d00-9c3d-ab20f6675281" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3a515019-6c4c-4d00-9c3d-ab20f6675281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9785bc7-8ff5-4f2e-a64a-1251ebd3adec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_f9785bc7-8ff5-4f2e-a64a-1251ebd3adec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_44d604a9-a2d7-408a-8b89-51983a2ab70f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_44d604a9-a2d7-408a-8b89-51983a2ab70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_14486ffa-a3fc-4ca2-ac20-dc908d5a86d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_14486ffa-a3fc-4ca2-ac20-dc908d5a86d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3d71bb11-45aa-4ee3-a7ae-3f5f7fe187e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f26bdb45-a046-4965-a28a-817c34e88e66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_3d71bb11-45aa-4ee3-a7ae-3f5f7fe187e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3390e680-a18d-4c34-ae2f-4916973dcee8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eeb0cb90-37ad-494a-958e-d4c20bdb6703" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3390e680-a18d-4c34-ae2f-4916973dcee8" xlink:to="loc_us-gaap_OperatingLeaseLiability_eeb0cb90-37ad-494a-958e-d4c20bdb6703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_771e7467-3fc0-4f2d-949f-08528e311502" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3390e680-a18d-4c34-ae2f-4916973dcee8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_771e7467-3fc0-4f2d-949f-08528e311502" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:type="simple" xlink:href="insm-20201231.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtComponentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9b19a4a4-fa71-488f-b31c-428df1dbb6a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_62bbfac6-eee5-4bfa-b7e2-fb0358691eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9b19a4a4-fa71-488f-b31c-428df1dbb6a4" xlink:to="loc_us-gaap_SecuredDebt_62bbfac6-eee5-4bfa-b7e2-fb0358691eb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_76165e05-75d4-426b-b434-6748b421636e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9b19a4a4-fa71-488f-b31c-428df1dbb6a4" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_76165e05-75d4-426b-b434-6748b421636e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f2a67a5c-b268-4606-ac47-f372f272a3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_9b19a4a4-fa71-488f-b31c-428df1dbb6a4" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f2a67a5c-b268-4606-ac47-f372f272a3f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e188b999-cf96-49ab-9ce6-9970ecfe5072" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e188b999-cf96-49ab-9ce6-9970ecfe5072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4e1c9190-47aa-4b76-ad2e-f984c0f240d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4e1c9190-47aa-4b76-ad2e-f984c0f240d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb5a5205-81f2-48ae-b660-729fec5edf26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_cb5a5205-81f2-48ae-b660-729fec5edf26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f6760458-abff-4af5-842f-f2264d06a424" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f6760458-abff-4af5-842f-f2264d06a424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3dd9386d-36e0-4c58-914b-73ad2c39ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cfea0fee-edd7-4ad1-8ac3-15d3c6a839a8" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3dd9386d-36e0-4c58-914b-73ad2c39ecd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_0bacaa02-ec1a-488b-9480-bb8027c93a43" xlink:href="insm-20201231.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_3926e9f4-8056-472b-aac5-222975174a11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_0bacaa02-ec1a-488b-9480-bb8027c93a43" xlink:to="loc_us-gaap_InterestExpenseDebt_3926e9f4-8056-472b-aac5-222975174a11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfBackendFee_2cb65938-0e57-4037-affb-04b131175d89" xlink:href="insm-20201231.xsd#insm_AmortizationOfBackendFee"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_0bacaa02-ec1a-488b-9480-bb8027c93a43" xlink:to="loc_insm_AmortizationOfBackendFee_2cb65938-0e57-4037-affb-04b131175d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a869dec4-6653-4d96-955c-81848578c08c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_0bacaa02-ec1a-488b-9480-bb8027c93a43" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a869dec4-6653-4d96-955c-81848578c08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_3ec5ab81-6241-4e8b-925d-f56e43ebc36d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal_0bacaa02-ec1a-488b-9480-bb8027c93a43" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_3ec5ab81-6241-4e8b-925d-f56e43ebc36d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_23319d68-0e6f-4606-abdc-4767014a4e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_352a23fe-5750-4e2f-aae6-2fed6aa10564" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_23319d68-0e6f-4606-abdc-4767014a4e0b" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_352a23fe-5750-4e2f-aae6-2fed6aa10564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_5018576c-575e-406e-a335-86afc9b35a83" xlink:href="insm-20201231.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpense_23319d68-0e6f-4606-abdc-4767014a4e0b" xlink:to="loc_insm_ConvertibleDebtInterestExpenseTotal_5018576c-575e-406e-a335-86afc9b35a83" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e99f9eb3-b2ad-47c0-9f3c-cbe2d091ce28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4e9e476b-6738-4f60-856e-dafb60a4ea5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e99f9eb3-b2ad-47c0-9f3c-cbe2d091ce28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4e9e476b-6738-4f60-856e-dafb60a4ea5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_917e2f9c-c750-434e-8729-979da85f143a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e99f9eb3-b2ad-47c0-9f3c-cbe2d091ce28" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_917e2f9c-c750-434e-8729-979da85f143a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dca09e1d-4737-4040-a0c6-e9e34bf9ecaf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1f96a187-ffbb-45df-8078-0b9d1857d19f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dca09e1d-4737-4040-a0c6-e9e34bf9ecaf" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1f96a187-ffbb-45df-8078-0b9d1857d19f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5da59b03-8c47-4b2d-9c9e-e23a8efeb647" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dca09e1d-4737-4040-a0c6-e9e34bf9ecaf" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5da59b03-8c47-4b2d-9c9e-e23a8efeb647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8ceeed56-b9b6-408a-85fc-0270af5df95d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_dca09e1d-4737-4040-a0c6-e9e34bf9ecaf" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8ceeed56-b9b6-408a-85fc-0270af5df95d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_709c8be1-0919-4eeb-9a99-5091279e71fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_34553db6-609c-4679-b4a6-b7bf8a4da5ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_709c8be1-0919-4eeb-9a99-5091279e71fc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_34553db6-609c-4679-b4a6-b7bf8a4da5ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f1d64064-fa1f-4d1d-a827-9068444de6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_709c8be1-0919-4eeb-9a99-5091279e71fc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f1d64064-fa1f-4d1d-a827-9068444de6c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7f363731-f558-4448-865d-dd25768d5442" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_709c8be1-0919-4eeb-9a99-5091279e71fc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7f363731-f558-4448-865d-dd25768d5442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4c293d9-bc5b-458e-8704-9cdae251f902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_41ae593f-bbca-41ef-a19e-6c0c590e15cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b4c293d9-bc5b-458e-8704-9cdae251f902" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_41ae593f-bbca-41ef-a19e-6c0c590e15cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cc6e7904-549b-486e-aebd-3d53e50fce99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b4c293d9-bc5b-458e-8704-9cdae251f902" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cc6e7904-549b-486e-aebd-3d53e50fce99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cb8fa27d-84eb-44b2-94c0-77027969fe7e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cb8fa27d-84eb-44b2-94c0-77027969fe7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_0b08ed06-7356-47d0-83d4-05455113bfba" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_0b08ed06-7356-47d0-83d4-05455113bfba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ec777539-b070-44a1-bdb6-ebf02a95aa77" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ec777539-b070-44a1-bdb6-ebf02a95aa77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_ff03126c-6d55-4c7d-9c9d-4400c67bf64e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_ff03126c-6d55-4c7d-9c9d-4400c67bf64e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2744d58c-5a3c-4d4d-96c5-b0119972cfd9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2744d58c-5a3c-4d4d-96c5-b0119972cfd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d8883bb-01fc-4017-97f4-9713e2de4b24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d8883bb-01fc-4017-97f4-9713e2de4b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_cb06eb63-c1ca-49d1-a4b0-5c361300ff7d" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2d277cdf-76f1-467f-97b8-ec858a1c8e36" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_cb06eb63-c1ca-49d1-a4b0-5c361300ff7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_775eedb7-5372-48e9-99ca-8969a7119f83" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_20a31fb0-4c47-4d0d-8218-a59c6315ef65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_775eedb7-5372-48e9-99ca-8969a7119f83" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_20a31fb0-4c47-4d0d-8218-a59c6315ef65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0026cd0b-334c-4557-9dbb-c1894d75cec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_775eedb7-5372-48e9-99ca-8969a7119f83" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0026cd0b-334c-4557-9dbb-c1894d75cec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3121b08e-ef46-468b-891a-4fdf93b3dbcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_e820a0ca-81bd-48e8-bf24-8297512e930a" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3121b08e-ef46-468b-891a-4fdf93b3dbcb" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_e820a0ca-81bd-48e8-bf24-8297512e930a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6c06e8a1-f561-4fd2-b92f-4712227cc41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_3121b08e-ef46-468b-891a-4fdf93b3dbcb" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6c06e8a1-f561-4fd2-b92f-4712227cc41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_904ac18d-d246-4d45-9141-ed8fd0836844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_904ac18d-d246-4d45-9141-ed8fd0836844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_72338996-7fc9-4b2f-8550-2a7876bd99a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_72338996-7fc9-4b2f-8550-2a7876bd99a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment_6736821a-0977-4828-bfde-2afe217aa00b" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLicensePayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_insm_DeferredTaxAssetsLicensePayment_6736821a-0977-4828-bfde-2afe217aa00b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_237ae3ec-ead3-498c-b5db-eb6936418ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_237ae3ec-ead3-498c-b5db-eb6936418ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_cd37e4fb-c8b3-4068-995d-ffa81b79c17c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_cd37e4fb-c8b3-4068-995d-ffa81b79c17c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_61d3110a-4106-403f-86da-cd7c8fd0da80" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_61d3110a-4106-403f-86da-cd7c8fd0da80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLeaseLiabilities_c77768ab-5abe-4f87-b236-a46f3ce029bc" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1da8afe9-5684-4ba8-954f-2c5471e75ca3" xlink:to="loc_insm_DeferredTaxAssetsLeaseLiabilities_c77768ab-5abe-4f87-b236-a46f3ce029bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_342df5d5-2e6f-4d5a-9033-2fa141e33e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b0d6e6c2-cc87-4dcb-96e8-d16349ede517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_342df5d5-2e6f-4d5a-9033-2fa141e33e7a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b0d6e6c2-cc87-4dcb-96e8-d16349ede517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_030c9215-3678-45a3-aaa1-2a13e8857488" xlink:href="insm-20201231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_342df5d5-2e6f-4d5a-9033-2fa141e33e7a" xlink:to="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_030c9215-3678-45a3-aaa1-2a13e8857488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ba9b6ef4-a208-430f-8656-f037f954cd2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_342df5d5-2e6f-4d5a-9033-2fa141e33e7a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_ba9b6ef4-a208-430f-8656-f037f954cd2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreements"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlan"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlanDetails"/>
  <link:calculationLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>insm-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.insmed.com/role/CoverPage" xlink:type="simple" xlink:href="insm-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/CoverPage" xlink:type="extended" id="i3c6210167c2d4e658f2e3442d37cb730_CoverPage"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i733763f06b4342289c13a08ab27ae2ef_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ib05f98a75bba4e22ab87ab64cedd18d0_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i23a74fcfcca447fabe27977f294478d4_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="i7f3d82714c5c480f92d90fcb6359d440_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76b46482-aacd-4d99-9673-d827ec7aaf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockholdersEquity_76b46482-aacd-4d99-9673-d827ec7aaf5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_70588478-190e-436c-b6ed-5a30c1646416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_SharesOutstanding_70588478-190e-436c-b6ed-5a30c1646416" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1391041-e272-4479-ac64-867d48ce4409" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:to="loc_us-gaap_NetIncomeLoss_f1391041-e272-4479-ac64-867d48ce4409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2b41ca9-cac1-4471-8949-3eb5210cde09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2b41ca9-cac1-4471-8949-3eb5210cde09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f372cb3f-b1ee-4085-bd3a-3bd0c1c19661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f372cb3f-b1ee-4085-bd3a-3bd0c1c19661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18b20520-7cb9-44d5-9825-2f9fa0b54a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18b20520-7cb9-44d5-9825-2f9fa0b54a0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_62270631-f45c-460c-95e3-3bcf6546f84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_62270631-f45c-460c-95e3-3bcf6546f84e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e2d4efc-fba9-48a0-a1d5-369a4976cf86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e2d4efc-fba9-48a0-a1d5-369a4976cf86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bde22b69-7c1a-412e-92e0-c3bd94c2278a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bde22b69-7c1a-412e-92e0-c3bd94c2278a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a2fa9d2d-3b6b-4cec-b611-a03931b36fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a2fa9d2d-3b6b-4cec-b611-a03931b36fe6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_529c31e6-b914-4388-86a6-45acccc7a5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_529c31e6-b914-4388-86a6-45acccc7a5c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99296265-1b05-461a-aac0-6ea7524a40cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99296265-1b05-461a-aac0-6ea7524a40cd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df351d86-4f16-4c83-b749-d3d15d633928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5eea3a34-5139-4558-ad7a-12b64af7179b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:to="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a791abe1-1e15-4dbf-8186-a15d12b41942_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:to="loc_us-gaap_EquityComponentDomain_a791abe1-1e15-4dbf-8186-a15d12b41942_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:to="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_195b5568-8f78-46d2-a542-ba16a37a16ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_CommonStockMember_195b5568-8f78-46d2-a542-ba16a37a16ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d9ba057-39f8-41ad-a4c2-5503afbf31c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d9ba057-39f8-41ad-a4c2-5503afbf31c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9ddce04d-6b9b-42a3-ac9d-bc3c93a9859c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_RetainedEarningsMember_9ddce04d-6b9b-42a3-ac9d-bc3c93a9859c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3e5037c-f644-4d16-a8e9-232c37f2e961" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3e5037c-f644-4d16-a8e9-232c37f2e961" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i826bb959a41e4a21b5d04651abafb61f_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i25c085126d744f2fb68a5fc21a5812f7_ConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec07a7d2-3b9d-4aed-a16a-b725f161be9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec07a7d2-3b9d-4aed-a16a-b725f161be9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:to="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_52a1e559-1df7-4e14-b7a7-01d0c19d20d3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_52a1e559-1df7-4e14-b7a7-01d0c19d20d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_77fcd605-aa04-4f41-9f84-8cb5da9aff9f" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_77fcd605-aa04-4f41-9f84-8cb5da9aff9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_011c6f53-882f-4e09-b1f0-aabd49ac5be9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_011c6f53-882f-4e09-b1f0-aabd49ac5be9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b64dc268-c91e-4056-a779-7c72394f4768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b64dc268-c91e-4056-a779-7c72394f4768" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended" id="ic596029f6b7c4850a1350e68280b9fef_DescriptionofBusinessandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="extended" id="i2a52427027034b428496ba69c1e0b1ca_DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i6ce644c9e1b04450ba02db4a331fd721_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i334cc0cdcdbe42ba82b9483fa0b050c3_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i6f8e3584d3294b51814e7d2f288317b6_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended" id="ic82eea5f9fc046779783b9f972ec830b_SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6356c473-47bc-4099-9955-14462e75d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6356c473-47bc-4099-9955-14462e75d81d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f491538e-2e23-4dda-8c07-3463e6355594_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f491538e-2e23-4dda-8c07-3463e6355594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_fd6f896c-1e1e-4336-be7c-557372a83e17" xlink:href="insm-20201231.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_fd6f896c-1e1e-4336-be7c-557372a83e17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember_09ccc04a-82c8-41b1-ba02-ce3bb42cce3e" xlink:href="insm-20201231.xsd#insm_EquipmentFurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:to="loc_insm_EquipmentFurnitureAndFixturesMember_09ccc04a-82c8-41b1-ba02-ce3bb42cce3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:to="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d73465e-30b6-4796-88cf-aa99f73a2b81_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:to="loc_srt_RangeMember_3d73465e-30b6-4796-88cf-aa99f73a2b81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:to="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_190390c5-3f6c-41e8-9827-fd8260bfffda" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:to="loc_srt_MinimumMember_190390c5-3f6c-41e8-9827-fd8260bfffda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a94a526e-fb47-4806-9831-8979db9201db" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:to="loc_srt_MaximumMember_a94a526e-fb47-4806-9831-8979db9201db" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended" id="i2d0faa5d6e63488b9ecd7a09910dd9fb_SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a79b2d3a-e1dc-4edb-8827-671eba3346bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a79b2d3a-e1dc-4edb-8827-671eba3346bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_aca76a8c-faf3-442a-8f91-c3dac2609bda" xlink:href="insm-20201231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_aca76a8c-faf3-442a-8f91-c3dac2609bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_8e803e96-9bf6-4169-8af2-1bd406baef58" xlink:href="insm-20201231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_8e803e96-9bf6-4169-8af2-1bd406baef58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4170d414-166a-4878-8960-c6f0b954d5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4170d414-166a-4878-8960-c6f0b954d5c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_053608bb-0151-4bcf-8d6e-3debafc6af3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_053608bb-0151-4bcf-8d6e-3debafc6af3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5860dfa7-f8b9-4096-921a-3b3356c78422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5860dfa7-f8b9-4096-921a-3b3356c78422" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23536386-864c-4a50-92c1-907445410171_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_23536386-864c-4a50-92c1-907445410171_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4fabbc92-a63e-4ca0-8c2b-0f0f02689632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4fabbc92-a63e-4ca0-8c2b-0f0f02689632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_31c754c9-e2d6-46bc-aa3e-567c9f6917cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_31c754c9-e2d6-46bc-aa3e-567c9f6917cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d074c40-e071-498c-8c95-b2ca34880de6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6d074c40-e071-498c-8c95-b2ca34880de6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7408d27-f426-48c1-adf0-1df137350e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7408d27-f426-48c1-adf0-1df137350e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f0c31b1-c995-46ef-950b-e72c2baa7b9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3f0c31b1-c995-46ef-950b-e72c2baa7b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d4d77b69-48d2-4c68-81fb-7dbba5199378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d4d77b69-48d2-4c68-81fb-7dbba5199378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_34b4dd2f-0ad6-4f5a-9def-06b43d204518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_34b4dd2f-0ad6-4f5a-9def-06b43d204518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7fbe0e63-10d3-4a84-9019-d9e8c668889c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7fbe0e63-10d3-4a84-9019-d9e8c668889c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6dd01ed3-fb3a-4b81-bde0-9a4718587d60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6dd01ed3-fb3a-4b81-bde0-9a4718587d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bb564527-e262-4efa-abd9-bae467b9d199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bb564527-e262-4efa-abd9-bae467b9d199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_de5465cc-c66b-440f-8e9b-a2e1aec504ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_de5465cc-c66b-440f-8e9b-a2e1aec504ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_d64f5a15-b773-4c5f-83ae-bf2b030a0f24" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_d64f5a15-b773-4c5f-83ae-bf2b030a0f24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended" id="i7db40ed6568440aaaaa0a236a780d501_SummaryofSignificantAccountingPoliciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1e2bdd95-0b05-4398-81b4-2abe40c65800" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1e2bdd95-0b05-4398-81b4-2abe40c65800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:to="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_76634457-85da-4e03-bb8b-60a527ac9b9f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_76634457-85da-4e03-bb8b-60a527ac9b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_df5f721f-4a7d-4546-90ae-b9a16febdba1" xlink:href="insm-20201231.xsd#insm_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerAMember_df5f721f-4a7d-4546-90ae-b9a16febdba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_e2114744-540a-4e9e-a7af-eb7f59b6cf4f" xlink:href="insm-20201231.xsd#insm_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerBMember_e2114744-540a-4e9e-a7af-eb7f59b6cf4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_c3ea633a-c5a3-473e-bffa-0f527ca78d60" xlink:href="insm-20201231.xsd#insm_CustomerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerCMember_c3ea633a-c5a3-473e-bffa-0f527ca78d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56c8aa31-4316-436b-93c5-6ca4d4237083_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56c8aa31-4316-436b-93c5-6ca4d4237083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_a775f99e-94f4-44b6-af12-3a0e70645569" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_a775f99e-94f4-44b6-af12-3a0e70645569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8e0256c3-66a9-4ace-927c-25f45410b924_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8e0256c3-66a9-4ace-927c-25f45410b924_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6a6279b8-4de4-463c-9c6a-1fbada044faf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6a6279b8-4de4-463c-9c6a-1fbada044faf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="extended" id="ia53a9b95e7574ad99c0995285593baf7_SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:to="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_1e2ee06a-4e72-431b-9744-ef75d76495e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_1e2ee06a-4e72-431b-9744-ef75d76495e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_63e6edbd-e3c2-41df-a1c5-9a124ccc119f" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_63e6edbd-e3c2-41df-a1c5-9a124ccc119f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_fd2c6b51-d1d3-4131-a0cc-784899bb1263" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_fd2c6b51-d1d3-4131-a0cc-784899bb1263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_07093811-537d-46e6-befc-a72b5f505bec" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_07093811-537d-46e6-befc-a72b5f505bec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_e7cea0c1-f827-4d7e-98e2-f4e474c6d11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:to="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_80c49ad6-59b6-416d-90ca-b78e808863bb_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_80c49ad6-59b6-416d-90ca-b78e808863bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember_603b09dc-c12b-4cf3-a6ce-2eff64088b2f" xlink:href="insm-20201231.xsd#insm_CustomerFeesDiscountsandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:to="loc_insm_CustomerFeesDiscountsandOtherMember_603b09dc-c12b-4cf3-a6ce-2eff64088b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember_77b9d447-6748-4bfc-aa15-f03493701ab5" xlink:href="insm-20201231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:to="loc_insm_RebatesChargebacksandCoPayAssistanceMember_77b9d447-6748-4bfc-aa15-f03493701ab5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended" id="i8d57233a239e4a6db000cac8bc16b3d9_SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_567631c8-c215-4823-b945-2ca8b1270041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:to="loc_us-gaap_NetIncomeLoss_567631c8-c215-4823-b945-2ca8b1270041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e0527f-6e87-43ad-a613-80fdfb3eb381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e0527f-6e87-43ad-a613-80fdfb3eb381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1cbfb5f8-25ad-4db5-a165-9722402ed327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1cbfb5f8-25ad-4db5-a165-9722402ed327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0755a812-1bad-4283-920b-8af7232711f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0755a812-1bad-4283-920b-8af7232711f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_46e5deca-cb94-4dc4-9763-3f7861c8962e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_46e5deca-cb94-4dc4-9763-3f7861c8962e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:to="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f561baf3-7f05-4e1f-bf14-65abe4d13a9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f561baf3-7f05-4e1f-bf14-65abe4d13a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5fed6bc5-7a4d-4856-8a32-e91086548811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5fed6bc5-7a4d-4856-8a32-e91086548811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da72ffd9-9236-43b4-812c-a9ebb233bc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da72ffd9-9236-43b4-812c-a9ebb233bc6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_5b3e89ab-1050-49d4-b425-e1d3aa142c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_5b3e89ab-1050-49d4-b425-e1d3aa142c71" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i4c7d951102f44e5c94866fdc047c429f_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f018afef-4e1a-410f-a0f6-a008c201e48c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f018afef-4e1a-410f-a0f6-a008c201e48c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01ff5abd-8163-4875-8013-9ca562b10ac2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_01ff5abd-8163-4875-8013-9ca562b10ac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_3de7f4bb-6988-4492-b228-c43ff45c363e" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_3de7f4bb-6988-4492-b228-c43ff45c363e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4457ffef-ceae-403d-afae-c67e470b1c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_us-gaap_RestrictedStockMember_4457ffef-ceae-403d-afae-c67e470b1c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_777b167b-7547-4da9-be50-b7f5e557296b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_777b167b-7547-4da9-be50-b7f5e557296b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended" id="i8f32a3e259ec494298f5a836f73611a6_SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:type="simple" xlink:href="insm-20201231.xsd#Inventory"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended" id="ieae5b357cc6e4e28a6fe6d20782002c0_Inventory"/>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended" id="i85b1551ac2c647bbad633cd3c7d25ca0_InventoryTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended" id="if46166c4b1f043a4bddf3da61305c9d3_InventoryScheduleofInventoryCurrentDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNet"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="extended" id="ie3182230a8b4411588571bb7d0ef9ad5_IntangibleAssetsNet"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="extended" id="i7b391bf93bfd4be2ba585ecfce26a0a3_IntangibleAssetsNetTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="extended" id="if3dedec536344742a14e4c8b7c181601_IntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b28cdca1-8b36-4cfe-98ac-f48526d201e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b28cdca1-8b36-4cfe-98ac-f48526d201e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_14cc71ce-1ce5-45be-a7e9-377fa31be602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_14cc71ce-1ce5-45be-a7e9-377fa31be602" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_74c9a645-7d15-40d3-b567-bd7f8475be45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_74c9a645-7d15-40d3-b567-bd7f8475be45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14bb5c78-cd49-4ce2-ab55-2f9758cc73d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14bb5c78-cd49-4ce2-ab55-2f9758cc73d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9521984-2e0d-4669-ab8b-b25c7570234e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a9521984-2e0d-4669-ab8b-b25c7570234e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_071d6e96-4d7a-4dc4-8db1-85b2508663ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_071d6e96-4d7a-4dc4-8db1-85b2508663ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_c1038122-b821-49c8-b3b6-932d1db39bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:to="loc_us-gaap_LicensingAgreementsMember_c1038122-b821-49c8-b3b6-932d1db39bbc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnet" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnet"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsnet" xlink:type="extended" id="i6d72aa8dd958442c985b1c2576f9a89c_FixedAssetsnet"/>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="extended" id="i633479a1d3934b2f832b309697cddbe4_FixedAssetsnetTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="extended" id="ia6ef2da384124c10965f564cd300c21b_FixedAssetsnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2b589f8d-ab25-4c54-8459-336804c9de28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2b589f8d-ab25-4c54-8459-336804c9de28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_020a31f7-dec9-4a4d-8bda-b219ca4e962e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_020a31f7-dec9-4a4d-8bda-b219ca4e962e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de4eac50-d659-452e-aa41-0e35496c8f43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de4eac50-d659-452e-aa41-0e35496c8f43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_60f2589a-dc99-4124-bdd5-984445cfed1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_60f2589a-dc99-4124-bdd5-984445cfed1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1b0c6faf-17a2-4160-98bd-00d7426310a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1b0c6faf-17a2-4160-98bd-00d7426310a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20956ee3-7513-40a8-9c1c-6607894c8e40_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_20956ee3-7513-40a8-9c1c-6607894c8e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_36a2c2f7-17e0-4bc5-bc2c-bfa1eda25efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_EquipmentMember_36a2c2f7-17e0-4bc5-bc2c-bfa1eda25efc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f60953ee-f5b1-420f-8bb4-e8ecf1d82437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f60953ee-f5b1-420f-8bb4-e8ecf1d82437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_51823428-9aa7-497f-a795-1310631e189f" xlink:href="insm-20201231.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_51823428-9aa7-497f-a795-1310631e189f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_38715604-17d0-4669-ac16-d1828a4474da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_OfficeEquipmentMember_38715604-17d0-4669-ac16-d1828a4474da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_e1d05d89-5acc-440b-bd0b-007fe6998bbd" xlink:href="insm-20201231.xsd#insm_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_insm_ManufacturingEquipmentMember_e1d05d89-5acc-440b-bd0b-007fe6998bbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c3a07009-db33-466e-91d2-857ca4c2b56a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c3a07009-db33-466e-91d2-857ca4c2b56a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8eaa4537-caae-408e-ad47-ffd4d0884342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_ConstructionInProgressMember_8eaa4537-caae-408e-ad47-ffd4d0884342" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:to="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6790e144-8316-4e37-aad9-c535a52ae734_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:to="loc_srt_RangeMember_6790e144-8316-4e37-aad9-c535a52ae734_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:to="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb37028c-73c6-47db-99d7-f0aebe640e7a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:to="loc_srt_MinimumMember_bb37028c-73c6-47db-99d7-f0aebe640e7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7573e54b-4ac3-447c-831c-51766481f09b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:to="loc_srt_MaximumMember_7573e54b-4ac3-447c-831c-51766481f09b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended" id="i6a5ceb0f09d94a8b88c015cd88877533_AccruedExpenses"/>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended" id="i342a525887de437fb9843dff6ff85f18_AccruedExpensesTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended" id="i84b8991d0f7d4248be6dfe3cb7e1fabf_AccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/Leases" xlink:type="simple" xlink:href="insm-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/Leases" xlink:type="extended" id="if63a1f488f37417a97107815aa0deab5_Leases"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesTables" xlink:type="extended" id="i66a6a7edcc004b1a99edbd1b00b1b91e_LeasesTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ib079c580315d48fdab1379076d265414_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_561b91bc-84f3-43da-aae2-33891bae2a07" xlink:href="insm-20201231.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_insm_LeaseRemainingLeaseTerm_561b91bc-84f3-43da-aae2-33891bae2a07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment_96deab42-f535-4671-958d-d216d1da30b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_us-gaap_VariableLeasePayment_96deab42-f535-4671-958d-d216d1da30b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_b68057a4-fb99-4bc2-81e1-82fac4c808a9" xlink:href="insm-20201231.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_b68057a4-fb99-4bc2-81e1-82fac4c808a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:to="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_42943675-c00f-4c36-a427-2d15c40492c1_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:to="loc_srt_RangeMember_42943675-c00f-4c36-a427-2d15c40492c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:to="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44d74e98-bfaa-4de7-b915-fd4baf59f23d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:to="loc_srt_MinimumMember_44d74e98-bfaa-4de7-b915-fd4baf59f23d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c8e815f-97de-473c-aa8e-571530bb557c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:to="loc_srt_MaximumMember_6c8e815f-97de-473c-aa8e-571530bb557c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="extended" id="i07e9465d65f14fdd996d52538a40c9f9_LeasesLeaseCostDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended" id="i6eb8682d4b064e3787aff5f5f88a11e7_LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:type="simple" xlink:href="insm-20201231.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended" id="ib83e18f8ea2048fbaa84f3a51a95c738_Debt"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended" id="id718d4704a2c4739b836c681f94d3f2d_DebtTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended" id="i3074b9d865b1487ab9fd1b9b7335d336_DebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_047ea6b1-ae42-45ae-8c80-3d9fcd2b306f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_047ea6b1-ae42-45ae-8c80-3d9fcd2b306f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_31b48f50-cf28-47f0-b126-592865d9dff0" xlink:href="insm-20201231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_31b48f50-cf28-47f0-b126-592865d9dff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_08d16175-4519-47ef-a4b1-9fa6731c037f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_08d16175-4519-47ef-a4b1-9fa6731c037f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_2c7df19d-16be-4188-95f9-8dd3d4b6f793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_2c7df19d-16be-4188-95f9-8dd3d4b6f793" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d7643e30-d042-4607-884a-fa0a32b74789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d7643e30-d042-4607-884a-fa0a32b74789" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_60fb5d84-ea99-48c4-80b1-fad4519c13fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_60fb5d84-ea99-48c4-80b1-fad4519c13fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1549f470-dc14-462e-b368-db5b4a0ac2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1549f470-dc14-462e-b368-db5b4a0ac2f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_62faa4b6-d575-4b3e-b280-fc7d290c2a94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_62faa4b6-d575-4b3e-b280-fc7d290c2a94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0451a65-60e3-4f9f-91bd-6a969a4e4572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0451a65-60e3-4f9f-91bd-6a969a4e4572" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_e3beab66-07e8-4c15-aa01-c607924a50c5" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_e3beab66-07e8-4c15-aa01-c607924a50c5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e703f10-d962-4b12-b4dc-eea5bb7e3607" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e703f10-d962-4b12-b4dc-eea5bb7e3607" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ced6eed1-2b14-4bfa-ac5b-f6c88f95b5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ced6eed1-2b14-4bfa-ac5b-f6c88f95b5e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_cda39fba-fbac-4092-80e3-bc6a081bfc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_cda39fba-fbac-4092-80e3-bc6a081bfc25" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_16bb7d2f-35f2-4c48-870f-a936045ac257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_16bb7d2f-35f2-4c48-870f-a936045ac257" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d692963d-57bc-4910-866d-79db45a8b5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_InterestExpense_d692963d-57bc-4910-866d-79db45a8b5d5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c254171e-c002-4181-8502-002f490638d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_RepaymentsOfDebt_c254171e-c002-4181-8502-002f490638d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_0504f2b9-24db-4053-9609-97d4980e8b37" xlink:href="insm-20201231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_0504f2b9-24db-4053-9609-97d4980e8b37" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4aaec062-0844-499f-b052-c4d3b1324d83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4aaec062-0844-499f-b052-c4d3b1324d83" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_d99a837a-d744-4c6b-b7fa-92f8cb9a765b_default" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_d99a837a-d744-4c6b-b7fa-92f8cb9a765b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiMember_5a5f7f60-170e-4057-86ec-0d9506c8f558" xlink:href="insm-20201231.xsd#insm_ConversionTermiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiMember_5a5f7f60-170e-4057-86ec-0d9506c8f558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiMember_de72259a-f15a-40c3-a17d-1473d01ea37d" xlink:href="insm-20201231.xsd#insm_ConversionTermiiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiiMember_de72259a-f15a-40c3-a17d-1473d01ea37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiiMember_ebd59739-eb9a-4111-a8ba-14cde3066108" xlink:href="insm-20201231.xsd#insm_ConversionTermiiiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiiiMember_ebd59739-eb9a-4111-a8ba-14cde3066108" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermivMember_d2f88c9f-1e3d-4fad-8041-d3090468fae0" xlink:href="insm-20201231.xsd#insm_ConversionTermivMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermivMember_d2f88c9f-1e3d-4fad-8041-d3090468fae0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3b43b534-522f-4919-afaf-0352fefecc9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3b43b534-522f-4919-afaf-0352fefecc9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8d67b71b-f78a-471c-b8fa-e3e1331b9788" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8d67b71b-f78a-471c-b8fa-e3e1331b9788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8352793-8deb-4b31-8e47-8f418fad7027_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8352793-8deb-4b31-8e47-8f418fad7027_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e84cc1e5-1cee-414c-bde7-85e0f87bc0f0" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e84cc1e5-1cee-414c-bde7-85e0f87bc0f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2be679ce-26a3-49f0-b5ad-bd66e324cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:to="loc_us-gaap_LineOfCreditMember_2be679ce-26a3-49f0-b5ad-bd66e324cbac" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtComponentsofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="extended" id="i2a68db23f2ff4952a0a674a6ecac5483_DebtComponentsofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_b952f535-e744-4036-ac82-bb1436840cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_SecuredDebt_b952f535-e744-4036-ac82-bb1436840cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71128a79-9772-4591-bb1f-cc6e1037e4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71128a79-9772-4591-bb1f-cc6e1037e4cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0cb2c906-f040-4ca9-bdd6-b1aea5ff3d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0cb2c906-f040-4ca9-bdd6-b1aea5ff3d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ad75840-8f05-4f90-a77b-01ef3b2bcde9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ad75840-8f05-4f90-a77b-01ef3b2bcde9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_28f33fb1-506b-4dbd-97a8-42a84fca601b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_28f33fb1-506b-4dbd-97a8-42a84fca601b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f36bb747-d7fd-4519-b88e-914409e58ac0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f36bb747-d7fd-4519-b88e-914409e58ac0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8887ef05-13b5-4fce-9424-f2bebf938ace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8887ef05-13b5-4fce-9424-f2bebf938ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ddb3ab8-a52d-4bde-8c49-9103909bcf52_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ddb3ab8-a52d-4bde-8c49-9103909bcf52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_7185d5a6-50b2-49cc-9af0-e4fcdcfc73a1" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_7185d5a6-50b2-49cc-9af0-e4fcdcfc73a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended" id="i5dda0488db0441d582fc1086f0d907e5_DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="i4fa5230925254d42b13bc1a03f5814a8_DebtInterestExpenseDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended" id="i2fd44fbd7448453c9c1a9082b65a72d8_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended" id="i301a560f460f4062af4c49a6e94aedaa_ShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_323ec5e9-2614-45a6-842a-2cccd6a25ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_323ec5e9-2614-45a6-842a-2cccd6a25ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69a734ba-5f0b-4c82-8e1b-ce2da814c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69a734ba-5f0b-4c82-8e1b-ce2da814c1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_06e8f35e-4455-4258-a823-508831782aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesIssued_06e8f35e-4455-4258-a823-508831782aef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30b22763-b169-4576-9ca7-9067700c470b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30b22763-b169-4576-9ca7-9067700c470b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e86626c8-fbb9-4c7d-96c3-eee264a2ff47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e86626c8-fbb9-4c7d-96c3-eee264a2ff47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5ec05fbc-abf4-4533-9033-fc1e664b8b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5ec05fbc-abf4-4533-9033-fc1e664b8b70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_abf845fe-a5a7-4a18-9d6e-ba82bd0bbe09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_abf845fe-a5a7-4a18-9d6e-ba82bd0bbe09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b94729d-a965-4598-af02-ee0fc2783302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b94729d-a965-4598-af02-ee0fc2783302" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3962eb3c-7ac4-4723-a8cf-ecee9e5d02e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3962eb3c-7ac4-4723-a8cf-ecee9e5d02e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2ee6ebda-603e-4319-acec-8838f7a52213" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2ee6ebda-603e-4319-acec-8838f7a52213" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0c81a236-5ff2-42ff-a414-6d5cb708097e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0c81a236-5ff2-42ff-a414-6d5cb708097e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9e79e018-7d0b-43d9-bf5a-91a3789ec0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9e79e018-7d0b-43d9-bf5a-91a3789ec0bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d07c1f1f-6271-4104-86bc-c9437afba04e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d07c1f1f-6271-4104-86bc-c9437afba04e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0cd07806-aa06-44cb-96ef-d392912114f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0cd07806-aa06-44cb-96ef-d392912114f5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b43f68b7-b6fa-450d-acb0-f119245db260" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b43f68b7-b6fa-450d-acb0-f119245db260" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a8fb47ae-7a3f-4e45-b566-4c5327a8c653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a8fb47ae-7a3f-4e45-b566-4c5327a8c653" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d0f1b569-4f65-414b-83cd-cd62a5851b21_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d0f1b569-4f65-414b-83cd-cd62a5851b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_034b8705-3d9b-49fb-afd0-1d00e1860819" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_034b8705-3d9b-49fb-afd0-1d00e1860819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9ee73e83-fb0f-4b9b-94c7-999d3c44e816_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9ee73e83-fb0f-4b9b-94c7-999d3c44e816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_f82c26e6-a952-45c4-a336-792f0c24d6e6" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_f82c26e6-a952-45c4-a336-792f0c24d6e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_c48ad840-0cb6-4ad1-ae27-ecae2f050851" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_c48ad840-0cb6-4ad1-ae27-ecae2f050851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c11e333-e028-4fb0-90d6-5e81c6737d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c11e333-e028-4fb0-90d6-5e81c6737d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3f77e514-9ab6-4598-8c67-3bd365bfbb63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3f77e514-9ab6-4598-8c67-3bd365bfbb63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_6c612c51-2edb-4d42-8f42-de3db3295018" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_insm_PublicStockOfferingMember_6c612c51-2edb-4d42-8f42-de3db3295018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7698fd11-04cf-4c36-a79b-cbccd369361b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7698fd11-04cf-4c36-a79b-cbccd369361b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_f4ddf810-edc1-4d89-a1e0-265709b1bf2b" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_f4ddf810-edc1-4d89-a1e0-265709b1bf2b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended" id="i515acb1651834b1384b3e746cd5372d5_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended" id="iecf69ee500524f80a5218737636918bd_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i48fbd5794c734acda4e3d7c4ef546d3c_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20fddb07-803b-4ddc-8c5d-d7a99e7eaa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20fddb07-803b-4ddc-8c5d-d7a99e7eaa6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fbc56060-e1fe-47fe-8c03-d63d8ee3751b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fbc56060-e1fe-47fe-8c03-d63d8ee3751b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_df76e3c2-85c5-4737-b807-78b76032832b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_df76e3c2-85c5-4737-b807-78b76032832b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_98791d1f-5103-43fb-8d6a-549dec2e6142" xlink:href="insm-20201231.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_98791d1f-5103-43fb-8d6a-549dec2e6142" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_14418166-e9f8-4562-b49d-fe41cd1af172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_14418166-e9f8-4562-b49d-fe41cd1af172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9cd095d1-1d1a-4c04-93d1-e6bdbd0fefa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9cd095d1-1d1a-4c04-93d1-e6bdbd0fefa5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6660aa0-9ff3-4d09-add0-c722dd5f1f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6660aa0-9ff3-4d09-add0-c722dd5f1f7b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:to="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_195832c1-aeea-48e4-977b-7706072b7088_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_195832c1-aeea-48e4-977b-7706072b7088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_a1299315-c414-49ea-a9a6-bfbf0b3bd3a0" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_a1299315-c414-49ea-a9a6-bfbf0b3bd3a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:to="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_433417d4-45be-41a6-a0a5-85947ce676a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:to="loc_us-gaap_PlanNameDomain_433417d4-45be-41a6-a0a5-85947ce676a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:to="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember_241c4a61-8db3-4ee3-a3a9-f80e23f6f681" xlink:href="insm-20201231.xsd#insm_A2019IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:to="loc_insm_A2019IncentivePlanMember_241c4a61-8db3-4ee3-a3a9-f80e23f6f681" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended" id="i71ae58a5e80141ceacc2cd938842d941_StockBasedCompensationStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_186cafdd-ce20-4d7f-b2cc-4a0c0de3f674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_186cafdd-ce20-4d7f-b2cc-4a0c0de3f674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81ef8a39-5aa9-48c8-84cd-7c6aa71cd419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81ef8a39-5aa9-48c8-84cd-7c6aa71cd419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_735efc18-6a22-4f3c-93d3-bb9bda4e5931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_735efc18-6a22-4f3c-93d3-bb9bda4e5931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4dcf6d7-e220-4657-b79f-87c44d5f5a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4dcf6d7-e220-4657-b79f-87c44d5f5a62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec32b462-d499-4aea-b9fa-f158f6fbe3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec32b462-d499-4aea-b9fa-f158f6fbe3f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f69172b4-f8bf-4e72-8029-211681ac0a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f69172b4-f8bf-4e72-8029-211681ac0a64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8962acd-4dca-4536-9a78-c9db7ea0a8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8962acd-4dca-4536-9a78-c9db7ea0a8a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_931edf2a-1ac2-4edd-af1f-6f504bc8aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_931edf2a-1ac2-4edd-af1f-6f504bc8aefe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_01d0e5d0-2d28-45dd-923a-c6bfad76d938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_01d0e5d0-2d28-45dd-923a-c6bfad76d938" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_951fb8cf-1c84-4c20-beb9-d1df09d6775c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8593f961-bddf-47ae-9cbd-505bfcb5ed86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8593f961-bddf-47ae-9cbd-505bfcb5ed86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fdd6700-b917-4b9e-beec-426a58b4d0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fdd6700-b917-4b9e-beec-426a58b4d0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ec6b2130-6fd8-4d31-9e8f-945d8cc57568" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ec6b2130-6fd8-4d31-9e8f-945d8cc57568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54fb2e9b-77cd-49f9-bc80-726fa8651246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54fb2e9b-77cd-49f9-bc80-726fa8651246" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd336393-094f-4fd8-aa60-2ab298523816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd336393-094f-4fd8-aa60-2ab298523816" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0508a1ec-ff74-4e07-8091-05cb502d7a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_278e1527-baeb-43e8-8fa2-c63f8d2a9a75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_278e1527-baeb-43e8-8fa2-c63f8d2a9a75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:href="insm-20201231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bf9ff16f-7312-4dbb-9c0d-cacf7fa4fb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bf9ff16f-7312-4dbb-9c0d-cacf7fa4fb6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_da6ffa06-52b0-462e-b391-54eb3fd46a99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_da6ffa06-52b0-462e-b391-54eb3fd46a99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dea66e63-fc28-4b69-9c25-945881c3a793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dea66e63-fc28-4b69-9c25-945881c3a793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb0227d7-979a-4bbf-9b47-56e562188acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb0227d7-979a-4bbf-9b47-56e562188acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:to="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0715e25f-c803-4978-8be8-334d68089290_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0715e25f-c803-4978-8be8-334d68089290_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_4bb3279d-d868-4e86-82c0-5651e9ea455a" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_4bb3279d-d868-4e86-82c0-5651e9ea455a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6523d362-83e6-40cd-bada-a006197c3a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:to="loc_us-gaap_PerformanceSharesMember_6523d362-83e6-40cd-bada-a006197c3a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:to="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df1593c3-7f3a-48da-becf-a0ff97ef806f_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:to="loc_srt_RangeMember_df1593c3-7f3a-48da-becf-a0ff97ef806f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:to="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_edd67538-26c2-4508-a975-ec783f62666e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:to="loc_srt_MinimumMember_edd67538-26c2-4508-a975-ec783f62666e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7bca1428-8c01-4cac-9551-3a52e74ff7e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:to="loc_srt_MaximumMember_7bca1428-8c01-4cac-9551-3a52e74ff7e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="ia511f7d8d6b6462ab31a80f3809377a3_StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_e1264320-c36d-4287-a322-6335fd097f2b" xlink:href="insm-20201231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_e1264320-c36d-4287-a322-6335fd097f2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_35ffad60-157a-4934-86d8-1de40aeda326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_35ffad60-157a-4934-86d8-1de40aeda326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a96a54d8-423f-49af-ba6c-fe936c3d6bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a96a54d8-423f-49af-ba6c-fe936c3d6bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d23ec0b-a94b-474f-9366-57e6238f55bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d23ec0b-a94b-474f-9366-57e6238f55bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_728074cb-b339-4336-bde6-517ceff7016c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_728074cb-b339-4336-bde6-517ceff7016c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_12a2d5d6-5fda-4f75-a40b-93b9192a34b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_12a2d5d6-5fda-4f75-a40b-93b9192a34b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f9063afa-d04d-484a-b77e-15000789509b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f9063afa-d04d-484a-b77e-15000789509b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2a048d89-352e-4aa1-b1aa-1319f4d8f38c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b17dab9f-0310-4293-9958-42d12de94592" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b17dab9f-0310-4293-9958-42d12de94592" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a68e9433-fd60-4322-b267-9e7633212625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a68e9433-fd60-4322-b267-9e7633212625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_246aeeb6-0a80-4491-908b-da5bc26723f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_246aeeb6-0a80-4491-908b-da5bc26723f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bbea043c-abcf-44f2-9782-a519d4db32b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bbea043c-abcf-44f2-9782-a519d4db32b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7a60c9d2-8b23-40ae-ade6-7b10127996a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8f17cfff-8174-4d19-b63c-38c6ba21266f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8f17cfff-8174-4d19-b63c-38c6ba21266f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:to="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da2199fe-5eb4-4a60-8224-8a7d98ef869f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da2199fe-5eb4-4a60-8224-8a7d98ef869f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0a797b34-a1cc-4c4b-9ffc-813c7649de48" xlink:href="insm-20201231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0a797b34-a1cc-4c4b-9ffc-813c7649de48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c080df4e-605a-4893-a4bb-6c6bb85d158c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c080df4e-605a-4893-a4bb-6c6bb85d158c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_98375ead-f961-4e26-a56a-a57a23f49a94" xlink:href="insm-20201231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_98375ead-f961-4e26-a56a-a57a23f49a94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_82ea389f-6650-4f5c-ba86-9c1b2963cbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_us-gaap_EmployeeStockMember_82ea389f-6650-4f5c-ba86-9c1b2963cbe4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73691ee5-a4a1-4152-8ad8-54fdc4256400_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73691ee5-a4a1-4152-8ad8-54fdc4256400_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ed06afc3-08eb-436e-9574-555e470e7a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ed06afc3-08eb-436e-9574-555e470e7a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_baea2355-ee39-4244-9107-acabfdbc837b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_baea2355-ee39-4244-9107-acabfdbc837b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended" id="i797d3e659003403bac1444f6d09a2802_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended" id="i94e63dcde12846e78c99200bae7e1d10_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="ie7134aa560634adb99b3672ea44a697e_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_966d45a1-ff18-404f-84c6-df67e124e879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_966d45a1-ff18-404f-84c6-df67e124e879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68b2afe3-3795-441f-aafa-191c16f7b91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68b2afe3-3795-441f-aafa-191c16f7b91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_383971fd-199a-4a64-882e-e2d7030d90bb" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_383971fd-199a-4a64-882e-e2d7030d90bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_fb8e3c09-fd65-4478-998a-319f7d2bde53" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_fb8e3c09-fd65-4478-998a-319f7d2bde53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_44df7fcb-30b3-4e6a-8d4f-4604ac1a9b9f" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_44df7fcb-30b3-4e6a-8d4f-4604ac1a9b9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0feb922a-8b99-44aa-a284-3f2c91fa800a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0feb922a-8b99-44aa-a284-3f2c91fa800a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsTotal_b0615b76-bd66-438a-8a13-006e394974be" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsTotal_b0615b76-bd66-438a-8a13-006e394974be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0303aec4-de37-4745-bf53-157655a736a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0303aec4-de37-4745-bf53-157655a736a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsNonTradingLoss_2940d945-0738-4f2a-9c03-b8dc45fa51b2" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsNonTradingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsNonTradingLoss_2940d945-0738-4f2a-9c03-b8dc45fa51b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense_6df9698e-f14e-44a9-a037-c77eacdfd497" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsDisallowedInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense_6df9698e-f14e-44a9-a037-c77eacdfd497" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5a7b664b-2875-417e-8acf-5b3deedc1bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5a7b664b-2875-417e-8acf-5b3deedc1bde" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3a66a195-dc0f-4dc4-bffe-d4ea7b753675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3a66a195-dc0f-4dc4-bffe-d4ea7b753675" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_08ad30f3-099a-47ff-b274-51f1b21e2d5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_08ad30f3-099a-47ff-b274-51f1b21e2d5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_7a8fa2fd-79a8-4f68-8d9d-6f8a18640183" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_7a8fa2fd-79a8-4f68-8d9d-6f8a18640183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IrelandTaxMember_fd34569b-dcfe-4bdf-8b33-81362bc5574a" xlink:href="insm-20201231.xsd#insm_IrelandTaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:to="loc_insm_IrelandTaxMember_fd34569b-dcfe-4bdf-8b33-81362bc5574a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_359485ac-26eb-48c6-a5ea-fb5946b01861_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_359485ac-26eb-48c6-a5ea-fb5946b01861_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3c2859a8-49ff-49a7-a883-9dc93d97e988" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:to="loc_us-gaap_DomesticCountryMember_3c2859a8-49ff-49a7-a883-9dc93d97e988" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="extended" id="ic25d92c871a74d0faddc8bf48a6378a3_IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended" id="i47c4241bba9f450b92234eb0b22c21c4_IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="extended" id="i4ad27a2d2e654c37b181fac9819af642_IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="i9d40b99d706c4418a50c2e9ac1cc7d00_IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended" id="ia81d30c18b894e09abd8001c0c543334_IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreements"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="extended" id="ibb98ea5f5b274e33bbd169e916dbb366_LicenseandOtherAgreements"/>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="extended" id="id2c19d1d1c964bc9a31cf7bf0acbea4f_LicenseandOtherAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment_557082a3-6659-40e1-bae4-09fdc9b2eaca" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementMilestonePayment_557082a3-6659-40e1-bae4-09fdc9b2eaca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_15970081-4472-4bca-bd89-cf388535086a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_15970081-4472-4bca-bd89-cf388535086a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_a105214c-61b8-4cc4-9504-06e033009f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_a105214c-61b8-4cc4-9504-06e033009f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_a29d9729-324c-4bf0-9a47-6343e55645f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RoyaltyExpense_a29d9729-324c-4bf0-9a47-6343e55645f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_0406c155-7a0e-426d-94ef-0f0e28b35dc3" xlink:href="insm-20201231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_0406c155-7a0e-426d-94ef-0f0e28b35dc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_df81d224-ee9a-42f8-8f8a-d4870453da38" xlink:href="insm-20201231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_df81d224-ee9a-42f8-8f8a-d4870453da38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement_8599eaed-e1e7-4c8b-b8b3-0c1f58166ad3" xlink:href="insm-20201231.xsd#insm_InitialTermOfContractManufacturingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_InitialTermOfContractManufacturingAgreement_8599eaed-e1e7-4c8b-b8b3-0c1f58166ad3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_e93f7c7e-6d2f-420d-b519-e3d78c534545" xlink:href="insm-20201231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_e93f7c7e-6d2f-420d-b519-e3d78c534545" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_6fa0b52d-dfe3-493a-8cb6-c0fe70c9c5a0" xlink:href="insm-20201231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_6fa0b52d-dfe3-493a-8cb6-c0fe70c9c5a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation_e045cd8c-7346-48f0-a0cd-ba3fb6946666" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementMinimumObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementMinimumObligation_e045cd8c-7346-48f0-a0cd-ba3fb6946666" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement_235a5d62-407a-44b9-8029-b1ee6bab59bb" xlink:href="insm-20201231.xsd#insm_AdditionalTermOfContractManufacturingAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_AdditionalTermOfContractManufacturingAgreement_235a5d62-407a-44b9-8029-b1ee6bab59bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_ae035350-9eed-4fd2-baa6-2de75f2e37a2" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_ae035350-9eed-4fd2-baa6-2de75f2e37a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_980b50d9-623e-4907-8b6e-d8322f8806e6" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_980b50d9-623e-4907-8b6e-d8322f8806e6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment_7b727b38-1250-4464-94be-10133be7c2d1" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementUpfrontPayment_7b727b38-1250-4464-94be-10133be7c2d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementPhase3StudyPayment_d08a284c-25c4-4122-a898-1db3556ef8e3" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementPhase3StudyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementPhase3StudyPayment_d08a284c-25c4-4122-a898-1db3556ef8e3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_9e38f16e-86a1-4f00-85c5-bd61a177a3df" xlink:href="insm-20201231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_9e38f16e-86a1-4f00-85c5-bd61a177a3df" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_9ac327ba-721e-4007-acd9-8de5aab838b0" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_9ac327ba-721e-4007-acd9-8de5aab838b0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_5928d420-eb02-4c35-83cd-5561f82c70d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_PaymentsForRoyalties_5928d420-eb02-4c35-83cd-5561f82c70d1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_56132862-8552-4142-8ff2-5e4153193ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_56132862-8552-4142-8ff2-5e4153193ffd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement_337604aa-2630-4163-862f-ba6025dfa3b4" xlink:href="insm-20201231.xsd#insm_InitialTermOfClinicalDevelopmentServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement_337604aa-2630-4163-862f-ba6025dfa3b4" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_ba776dee-1547-4715-88cc-971a8b712dca" xlink:href="insm-20201231.xsd#insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_ba776dee-1547-4715-88cc-971a8b712dca" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:href="insm-20201231.xsd#insm_MilestonePaymentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentDomain_6ac9826d-ec5b-49b0-9d19-25b999ebbf84_default" xlink:href="insm-20201231.xsd#insm_MilestonePaymentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:to="loc_insm_MilestonePaymentDomain_6ac9826d-ec5b-49b0-9d19-25b999ebbf84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:href="insm-20201231.xsd#insm_MilestonePaymentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:to="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneNewDrugApplicationMember_19e0ab53-7cab-423e-86be-f4e0851764bc" xlink:href="insm-20201231.xsd#insm_MilestoneNewDrugApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneNewDrugApplicationMember_19e0ab53-7cab-423e-86be-f4e0851764bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneFDAApprovalMember_f3cdae57-996d-40a8-9b9f-b219fecff2fe" xlink:href="insm-20201231.xsd#insm_MilestoneFDAApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneFDAApprovalMember_f3cdae57-996d-40a8-9b9f-b219fecff2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEMAApprovalMember_225bf1eb-a5f7-4464-82cd-502917eccf7b" xlink:href="insm-20201231.xsd#insm_MilestoneEMAApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneEMAApprovalMember_225bf1eb-a5f7-4464-82cd-502917eccf7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3f774d0-154c-4510-a6d6-f3e86c1b4da8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:to="loc_srt_ProductsAndServicesDomain_e3f774d0-154c-4510-a6d6-f3e86c1b4da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:to="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_27504523-5efd-4a40-8878-3b7f3adc276f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:to="loc_us-gaap_LicenseAndServiceMember_27504523-5efd-4a40-8878-3b7f3adc276f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f5e5592-cbdd-4263-bcf9-671f4258424d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f5e5592-cbdd-4263-bcf9-671f4258424d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_5ad8d184-f614-46e9-b34f-4a110959e818" xlink:href="insm-20201231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_5ad8d184-f614-46e9-b34f-4a110959e818" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_c219d584-94b6-4d81-963f-ce1615aa969a" xlink:href="insm-20201231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_c219d584-94b6-4d81-963f-ce1615aa969a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_4463963e-8ce8-44e8-b13d-22c2ba45823d" xlink:href="insm-20201231.xsd#insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_4463963e-8ce8-44e8-b13d-22c2ba45823d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember_5d66299a-0d4a-4fae-8184-dec65b974147" xlink:href="insm-20201231.xsd#insm_CommercialFilVFinishServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_CommercialFilVFinishServicesAgreementMember_5d66299a-0d4a-4fae-8184-dec65b974147" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember_12c2b642-88d8-4c0d-82ce-f7d1cc3d6f76" xlink:href="insm-20201231.xsd#insm_LicenseAgreementWithAstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_LicenseAgreementWithAstrazenecaMember_12c2b642-88d8-4c0d-82ce-f7d1cc3d6f76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PPDDevelopmentLPAgreementMember_67cea324-a961-4ea4-ab35-bf4a0c592410" xlink:href="insm-20201231.xsd#insm_PPDDevelopmentLPAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_PPDDevelopmentLPAgreementMember_67cea324-a961-4ea4-ab35-bf4a0c592410" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0dfb01f4-7f87-4b2a-8b6b-027a419255b8_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:to="loc_srt_RangeMember_0dfb01f4-7f87-4b2a-8b6b-027a419255b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:to="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4b30a1c-d04c-4af8-a806-6cd2dbf3c54d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:to="loc_srt_MaximumMember_b4b30a1c-d04c-4af8-a806-6cd2dbf3c54d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2032e7c4-2a70-46f8-9607-fb6d780b7521" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:to="loc_srt_MinimumMember_2032e7c4-2a70-46f8-9607-fb6d780b7521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ac1b3936-6be6-4d46-99b7-37eede75dfcc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ac1b3936-6be6-4d46-99b7-37eede75dfcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16885895-4fbd-4255-a3b8-70238b46d3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16885895-4fbd-4255-a3b8-70238b46d3d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="extended" id="i8ea888d406a04082981e2cabfecee827_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ic86eb7e8f06c4912a08fe8160818b142_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b845c9ff-0a4c-4366-b9a0-bdc2946c36c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b845c9ff-0a4c-4366-b9a0-bdc2946c36c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f3bf2b94-4796-4a03-ae37-750443e0cd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_OperatingLeaseExpense_f3bf2b94-4796-4a03-ae37-750443e0cd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_e1422015-5223-44e0-9d48-994591531da9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_e1422015-5223-44e0-9d48-994591531da9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_fcdc8904-0126-4e3b-875e-ae2d20ce2c92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_PurchaseObligation_fcdc8904-0126-4e3b-875e-ae2d20ce2c92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:to="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d008fb69-9c0e-4f1a-991c-c24f5da3886a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:to="loc_srt_SegmentGeographicalDomain_d008fb69-9c0e-4f1a-991c-c24f5da3886a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:to="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_c0507d23-64c5-4d05-ae25-2bdb3bc7c3bb" xlink:href="insm-20201231.xsd#insm_BridgewaterNewJerseyFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_c0507d23-64c5-4d05-ae25-2bdb3bc7c3bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlan"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended" id="ia7f3823d9f03483993a0a202f1b0442d_RetirementPlan"/>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlanDetails"/>
  <link:definitionLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended" id="i3cadd73bff274ae0870990a8c79676ef_RetirementPlanDetails"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>insm-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_055cf2cd-4871-499f-85e2-6fb999fa3621_terseLabel_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash operating lease expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_label_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:label id="lab_insm_NoncashOperatingLeaseExpense_documentation_en-US" xlink:label="lab_insm_NoncashOperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Operating Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense" xlink:href="insm-20201231.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NoncashOperatingLeaseExpense" xlink:to="lab_insm_NoncashOperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_e08d3677-493c-42d0-81c1-584a716baf36_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7014a091-59df-4301-9d80-518ce9f0488e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3067aeb6-137a-4a62-985b-42aafd440604_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4ff3ca08-fb80-439d-ad9b-c81ccee3673a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_072e6e1e-9590-4ed2-a65d-5fbd5d7dcb1a_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_10fd1c1f-8a0b-405f-8617-41d65c2fd4e5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f17a8e5e-ba6e-4ad4-abea-088bebdd33fb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ceb24e5b-3e3b-42fa-aa1b-2a397aadcaac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_5d24ee41-c6ef-4b03-8555-cfbfebd67a0b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_dc089a65-23f3-4a6e-ac95-5c64ca84a034_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9c9fd5f9-57d9-4da0-b208-f74f074eef9e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6080a589-51a9-44bc-8a59-99f43c2e5246_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerAMember_852f5377-87a7-4767-b651-7c9cbcce2075_terseLabel_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_insm_CustomerAMember_label_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_insm_CustomerAMember_documentation_en-US" xlink:label="lab_insm_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember" xlink:href="insm-20201231.xsd#insm_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerAMember" xlink:to="lab_insm_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_40937c57-e483-4b42-bba3-c6e7466ca070_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2a70e869-bb01-490f-8776-007dd275560f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_dc53cd32-7799-4772-8790-c7363dd22efb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3f50de9c-4ffa-471a-a318-6e8ee485619c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_42401306-4e90-4e37-9d0d-39bcc296999b_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_4522cce5-54a3-4ab5-80d2-5bba3cc4a7f1_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermAxis_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermAxis" xlink:to="lab_insm_DebtInstrumentConversionTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_62671947-72c0-4f81-873c-551a644120f4_terseLabel_en-US" xlink:label="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount and back-end fee on debt</link:label>
    <link:label id="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_label_en-US" xlink:label="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount Premium And Accretion Expense</link:label>
    <link:label id="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_documentation_en-US" xlink:label="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount Premium And Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:href="insm-20201231.xsd#insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:to="lab_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1d7eae8e-ed0b-4612-aa9c-6f5439f9eccf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d0dafe3a-523c-4bfd-8f02-d6346371e277_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets as of January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b1eb29e1-aa31-43ca-8f75-b02cfba25a52_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets as of December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d744fc0-3859-4bd5-8227-109b9b9d1fff_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c43859a4-5de5-4516-bf4f-ee5b317b1523_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_eefc3c25-98a2-4b08-9bfd-c0e2fb66010a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9c0c83c6-c790-4d55-8df8-27b6faf6e649_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_b37bd295-aaf0-438f-924b-6c4304d8ae12_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5f99603e-87cb-4e06-82ba-9ba4a6819202_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7282be59-d6fa-4e72-bffc-d227a25e7cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_5111a90e-ea5d-4ca9-ae39-0f10bc60305e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ce5cc421-def5-4f13-b45d-7e9275d2ef2e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c19b9a93-ab26-437f-b2f2-7a6e1225eee4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and (Not Yet Adopted)</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1bba246c-3643-4045-a5a1-8a39dd79295e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_faeb66a6-f42d-41e8-8934-791b7a171cdc_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e2af0ef1-0e0f-466a-9e46-da5dc9cfe71a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_88d5b12f-f1bc-4009-9963-42e2de6b5f11_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_feda8ac5-3f83-46ac-b4ba-1f415397a8fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_d5d994ea-8192-4780-afed-9915248edf13_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_label_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Conversion Term [Domain]</link:label>
    <link:label id="lab_insm_DebtInstrumentConversionTermDomain_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConversionTermDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Debt Instrument Conversion Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConversionTermDomain" xlink:to="lab_insm_DebtInstrumentConversionTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_145bdc6e-56ea-4cce-909c-83c21636e04d_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a84bc1aa-5331-4205-a3b1-a353896a3f33_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_479dd4a4-9757-4892-a963-46627e5d1e90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vesting of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9c57eb8d-aedd-4c17-be46-f37aac41ecaa_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_a844975d-5f48-48b5-b92b-b42db1cb20a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_69bc0a92-6011-4652-9def-269d40e57c4d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_972fe70e-a5ba-40c4-8573-d8fd3303d888_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3d98e53c-9b71-4843-bac4-d123779635cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_282a8098-9839-41e2-a5fa-6e26fb521f29_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_deb66761-fe5c-4153-ac24-5795724109d6_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConversionTermivMember_a15995c2-5a2e-473b-9790-fd8ad7e887b7_terseLabel_en-US" xlink:label="lab_insm_ConversionTermivMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iv)</link:label>
    <link:label id="lab_insm_ConversionTermivMember_label_en-US" xlink:label="lab_insm_ConversionTermivMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iv) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermivMember_documentation_en-US" xlink:label="lab_insm_ConversionTermivMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iv) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermivMember" xlink:href="insm-20201231.xsd#insm_ConversionTermivMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermivMember" xlink:to="lab_insm_ConversionTermivMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a6808601-85de-47e9-b66e-0f1f53d9028e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value discount</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4feb1edf-7fbf-448a-881e-4fe85adf2d6e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d20e43de-a867-4349-abe2-30ac8eb62ee9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_fe095354-4833-401b-ba73-8fc7d1d940aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes ($450.0 face value)</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PPDDevelopmentLPAgreementMember_b66d9e89-9195-4f83-9749-fab121cdfdcb_terseLabel_en-US" xlink:label="lab_insm_PPDDevelopmentLPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPD Development, L.P. Agreement</link:label>
    <link:label id="lab_insm_PPDDevelopmentLPAgreementMember_label_en-US" xlink:label="lab_insm_PPDDevelopmentLPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPD Development, L.P. Agreement [Member]</link:label>
    <link:label id="lab_insm_PPDDevelopmentLPAgreementMember_documentation_en-US" xlink:label="lab_insm_PPDDevelopmentLPAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPD Development, L.P. Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PPDDevelopmentLPAgreementMember" xlink:href="insm-20201231.xsd#insm_PPDDevelopmentLPAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PPDDevelopmentLPAgreementMember" xlink:to="lab_insm_PPDDevelopmentLPAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1d294a57-19a3-4945-86b9-918ca2222d07_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1d356b71-ed14-4a69-ae60-d26fcff84046_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_03f11391-fd55-484e-9dd4-dc85db086855_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7487288a-c792-4a48-8d68-d1e6a8fbb4f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2f07640a-5919-49d5-8e6f-4c00892ef7ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_5ec9b1cf-9fc9-4ba6-9de6-e17812d7fb08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_19688a80-832c-4036-bd93-fa1d1d0618dd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_913fc3bc-46d7-4201-8c7d-9d816b2c0fa0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_42d7441c-7f26-4b37-a931-a1bc18a92ae8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ccc2dae7-a3cf-43e1-8ca6-74b12d69a135_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress (CIP)</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ef0cba22-7ce3-4b6a-bb2e-fc304ed7e3db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a1762f67-9f9c-44f9-b043-96bff37a7342_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_988327b7-20e9-477c-860b-e6fbbad13a27_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock and restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7675d671-ac41-4c4a-9334-98614e5ff225_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_8eab33de-4a2f-4b07-90b6-dbb6cf450cba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_048b4a77-cacd-4d1c-a4d2-df2abbc30f8e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5e8b8fc0-8032-4f89-947c-90a0088962d7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_60fc65a5-9c16-4fd2-8d63-5fccab33de8c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_b9ac11f1-e027-419b-918f-8c1adea7d260_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_2d84bda7-696d-4d1b-99d2-90c221b673e2_verboseLabel_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in an unrealized gain or loss position</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_label_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:label id="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_documentation_en-US" xlink:label="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:href="insm-20201231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:to="lab_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AmortizationOfBackendFee_e3c21731-4bb5-4d3c-a262-7bb76c416c27_terseLabel_en-US" xlink:label="lab_insm_AmortizationOfBackendFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of back-end fee on debt</link:label>
    <link:label id="lab_insm_AmortizationOfBackendFee_label_en-US" xlink:label="lab_insm_AmortizationOfBackendFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Backend Fee</link:label>
    <link:label id="lab_insm_AmortizationOfBackendFee_documentation_en-US" xlink:label="lab_insm_AmortizationOfBackendFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Backend Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfBackendFee" xlink:href="insm-20201231.xsd#insm_AmortizationOfBackendFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AmortizationOfBackendFee" xlink:to="lab_insm_AmortizationOfBackendFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_01dc987e-abed-4e9a-a82b-1f59b6f04b26_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_52cfe75e-2809-48a2-9384-be1c1967b292_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of 1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_4888a4aa-166a-414c-a3d4-6a23bd6c2a87_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f25c94c3-2c02-47b4-9d62-a196056d1b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_31797567-0bab-4a6d-b7ab-1f2d911e24ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_74d3d026-6cef-4061-851b-e708331a9e1c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a20113f6-3c11-48e2-9cc2-43a81223abeb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a18bebd1-1ac8-4e91-a666-94802a203780_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_aca2ae48-736f-4636-9b82-ef720b8a241a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f621b13-a980-48fa-be57-2bcaac162223_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a615fac-1e0b-46d6-a58a-17294cc431a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_d03c0aa8-329a-4b41-94cd-a359659ec833_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b61f6279-a8a9-4529-929b-96befc65fcd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_3f16a983-e358-4c9a-846f-5f4af4090373_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_347a1456-bd2d-4bb6-8a0b-b4896f10a12f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_bcee7ea9-16be-4587-a542-467ef4043611_terseLabel_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement stock option granted to new employees (in shares)</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross</link:label>
    <link:label id="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_documentation_en-US" xlink:label="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross number of inducement share options (or share units) granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:href="insm-20201231.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:to="lab_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5881e525-7007-452e-b913-4717ecf99324_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average basic and diluted common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_321321c8-7001-4d68-bbe2-e58eeb154690_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_d0bf6eb1-5863-4e8d-af6e-66bf4cfcd49d_terseLabel_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares each award holder is entitled to receive (in shares)</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_label_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit</link:label>
    <link:label id="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_documentation_en-US" xlink:label="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:href="insm-20201231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:to="lab_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e305b7ea-a39a-4e08-a010-55f955cbd921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_146c78fe-5d67-4ee4-a186-66ec80cfea70_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_356ff362-f0ee-4073-986d-684e2ba1ecc2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_78c911d3-9677-4a65-a8c0-11a083a15dec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_7f6a97b7-548a-4d7d-9ff4-852276bf970e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense_d0b412cc-9375-4399-8d3f-c281655685be_terseLabel_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disallowed interest expense</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense_label_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Disallowed Interest Expense</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense_documentation_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Disallowed Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsDisallowedInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:to="lab_insm_OperatingLossCarryforwardsDisallowedInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_fb39d0ca-3053-42e7-88db-f3dc3f6421bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_ecc1b51b-de0b-4473-b862-228d0ac29b5c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_338dbd55-9ee0-4835-aba8-e82ab3aa8fd7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a2ebb45d-3788-48a2-9d6a-32f744b3d302_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_00e83722-9338-4c08-997b-ca0d6d2274c4_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CashFlowLesseeAbstract_1c4adb51-76bc-4aa2-9442-af2efc3df6b4_terseLabel_en-US" xlink:label="lab_insm_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_insm_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_insm_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_insm_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_insm_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CashFlowLesseeAbstract" xlink:href="insm-20201231.xsd#insm_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CashFlowLesseeAbstract" xlink:to="lab_insm_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9599cc7c-e60e-4271-970c-ca3aeeba95b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9b69dfc9-fca6-4cef-b535-0e470ee0f6a8_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement_0ddcf366-b86c-48a9-a305-9a9836125966_terseLabel_en-US" xlink:label="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of clinical development services agreement</link:label>
    <link:label id="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement_label_en-US" xlink:label="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term of Clinical Development Services Agreement</link:label>
    <link:label id="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement_documentation_en-US" xlink:label="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term of Clinical Development Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:href="insm-20201231.xsd#insm_InitialTermOfClinicalDevelopmentServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:to="lab_insm_InitialTermOfClinicalDevelopmentServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LicenseAndOtherAgreementsAbstract_bb342fe7-2059-4bba-baad-b67b8ddd274c_terseLabel_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Other Agreements</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsAbstract_label_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Other Agreements</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsAbstract_documentation_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract" xlink:href="insm-20201231.xsd#insm_LicenseAndOtherAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract" xlink:to="lab_insm_LicenseAndOtherAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_075be8d8-09ee-4839-887a-3ccc36ed1dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_403e3911-6681-432e-92bc-c45eddcbf197_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0b82108e-9b89-4952-9c3b-488cfb33114b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d9cf9f3e-9cd8-4a6a-b4e9-d8cc9e00963c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_28e2c518-f754-4ae6-960b-e71fd29e5c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_4e7280d7-69ea-4d68-8707-58266a090d68_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_26593580-79d5-4e1f-a1f9-b0c0f4b97adb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d07f623d-83a4-469d-98a5-e49d2994a475_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_34ce60ad-4edc-44eb-978d-ba51987d6847_negatedTerseLabel_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_label_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Convertible Debt</link:label>
    <link:label id="lab_insm_DeferredTaxLiabilitiesConvertibleDebt_documentation_en-US" xlink:label="lab_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:href="insm-20201231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:to="lab_insm_DeferredTaxLiabilitiesConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_A2019IncentivePlanMember_73aafc19-f16e-486a-9d0e-1df750fe454b_terseLabel_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_insm_A2019IncentivePlanMember_label_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan [Member]</link:label>
    <link:label id="lab_insm_A2019IncentivePlanMember_documentation_en-US" xlink:label="lab_insm_A2019IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember" xlink:href="insm-20201231.xsd#insm_A2019IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_A2019IncentivePlanMember" xlink:to="lab_insm_A2019IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_52c9526d-f7be-4bf0-a27a-9a4d767f0f67_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_4b9b13d4-a67e-494e-92a3-76f64166e460_terseLabel_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for current period sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_label_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Allowance For Current Period Sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_documentation_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Allowance For Current Period Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:to="lab_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_07757432-e2d2-4121-be5d-9f26121bcc59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_388bff80-1af6-4e15-9327-0d7d9f6680fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_89c9613c-113f-49c1-be83-9bb5f1a8cf7b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues, net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ff1a3367-7ee4-41b8-9de5-7e783f3d0a3e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_36abb536-9f7c-498c-a5b2-72ce08c765e4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_82e48338-4f01-4bc4-b724-b190b9e8ac9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised during the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_476cb458-bafa-436c-a5f4-deb43c729c19_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2f8c4398-5ca6-48bb-8658-f1942b2c2f72_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_afc050ec-ad6c-4b6c-b0a6-16af0c4afaf4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_da832b14-ee13-4438-96d3-a9f521bb3aa7_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (prior to applying the valuation allowance)</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_0ab07f88-c0ff-4af9-8886-f38608d54480_totalLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities) Net before Valuation Allowances</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:to="lab_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7e025c5a-31a5-403e-9d4f-a365d985547e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_51d89989-01a4-4759-b647-cab77b76204a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4b22d4be-5c6f-4501-b35d-a4ca6a238ca2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b3aca75c-c431-4668-bab0-2631d645c596_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_0d58a2b8-458c-422e-b012-0e4bbc26744d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_49a00161-386b-438c-bc09-0e39154f159a_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_de69aa8a-fb81-4002-bf97-3a5c08f33f31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ba2d40d4-f402-448b-8bb8-e1f8b30b3d32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2a37ebd1-0d0c-4667-a7ea-95519ccf8843_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_233e06ff-9511-4a5f-99c5-e2d7adc17ad0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_2ec38a1b-3a8f-42cb-8289-3337b663f36b_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_a9ce6a9e-8613-4f06-bfaa-0ea04fad5575_terseLabel_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="insm-20201231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_insm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_630e2c78-cfbd-4f8c-9345-09de582db449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e09e469c-6e3e-4d67-8465-00361ccc1bef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d5f91e38-9379-45cd-8589-1f24c4a943b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_IrelandTaxMember_a5733663-7749-4551-b66d-1598e49639dd_terseLabel_en-US" xlink:label="lab_insm_IrelandTaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland Tax</link:label>
    <link:label id="lab_insm_IrelandTaxMember_label_en-US" xlink:label="lab_insm_IrelandTaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland Tax [Member]</link:label>
    <link:label id="lab_insm_IrelandTaxMember_documentation_en-US" xlink:label="lab_insm_IrelandTaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IrelandTaxMember" xlink:href="insm-20201231.xsd#insm_IrelandTaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_IrelandTaxMember" xlink:to="lab_insm_IrelandTaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_77458a3b-5c42-4707-8ff8-0f5d6cdf7296_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4f17f423-6bba-4905-a240-caa00ba833e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_90dba6f6-7cec-4075-b099-32c61f8d6668_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_bca12dd9-f735-4b52-b138-10595885ed4a_terseLabel_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate payment upon the achievement of certain clinical milestones</link:label>
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_label_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Upon Achievement Of Clinical Milestones Amount</link:label>
    <link:label id="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_documentation_en-US" xlink:label="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate payment upon the achievement of certain clinical milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:href="insm-20201231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:to="lab_insm_PaymentsUponAchievementOfClinicalMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b0a3f80a-8864-49a0-b2b7-d3f642ee120c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_0cc4422b-ab7a-4901-8441-da861dc5e403_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_97d3fea2-84d1-43ac-aeb7-348e7d72cff2_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fc6da768-92fa-4a32-bb82-ff9cd414be7a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_650d0a28-c0b8-4604-9f6d-5c544cffd02d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d61f0f9b-d53d-45f7-a020-21dc2b7b8afb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_f972afe9-864f-4eeb-a45b-2088ffc56f77_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional contingent payments upon second indication to develop INS1007</link:label>
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_label_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Additional Contingent Payments Upon Second Indication</link:label>
    <link:label id="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional series of contingent milestone payments if selects to develop for second indication.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:to="lab_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e4e617e9-ff8f-4656-b3cf-9341880dac03_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_68fcffe8-bd94-4ba7-9417-df2977425bab_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_a0a7dea8-a114-41bc-9802-a817e77f5aae_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9a4ce9ce-f2a8-4bfb-b817-389c8aeddccb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0ce9c93d-fac4-4ced-895b-853b2bdf9a9a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d10daf18-8a67-40f1-8ca7-e36e798d72f1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14e936e5-a949-4167-869a-993c38a9ad7b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_98945f7f-ac72-44be-bbcb-30b4013d8479_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum rental payments under Bridgewater</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_97f08be4-df54-4ff7-a4f2-268c2c752c18_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_d80d7c0f-3417-4c28-866f-fce89de96bdd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_3976bfaa-1c68-4ce8-b201-9ee5903f64dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_085f17b9-d605-4248-9200-7ce65804f308_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7cb8949e-ccac-44d0-9ed5-b271ce34684d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1b60a2ca-bd67-4084-b056-e60fc4b4e099_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_6cb63354-9a41-45b3-9831-276e4583f0a7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_bf1bc7d0-abf5-4f3c-8632-e4c347078229_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_57f64cb4-f41f-42c9-b8bd-0a9555c7ab52_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_90eaa68a-2d66-4ea0-8761-a4f6630e461a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_07a7398f-c45c-45fa-9da8-4eaf70f2ee1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Allocation of Employee Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_669d1cc9-5536-46aa-aefa-ea10dd7587bd_terseLabel_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost, future right-of-use asset</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:label id="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="insm-20201231.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fac49b34-4d2a-43a7-948c-ce477c0d32ec_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dea6eda5-12ad-47ab-8880-946bc280d495_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0402756b-898c-45b7-99fa-7e4367eb6c53_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_806e59fc-bdb2-4095-a5e9-b782e9ff9b59_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP shares issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0f8cde9f-cd8d-443d-9388-8ed1c2c2b1f7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConversionTermiiiMember_bad0e6a8-4782-4baf-876c-efb42d3625bf_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiiiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iii)</link:label>
    <link:label id="lab_insm_ConversionTermiiiMember_label_en-US" xlink:label="lab_insm_ConversionTermiiiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iii) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiiiMember_documentation_en-US" xlink:label="lab_insm_ConversionTermiiiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (iii) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiiMember" xlink:href="insm-20201231.xsd#insm_ConversionTermiiiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiiiMember" xlink:to="lab_insm_ConversionTermiiiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8a648220-4032-4c0b-a2a1-9068126c665f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ManufacturingEquipmentMember_512ed40e-242f-4173-8960-c834cdc02f59_terseLabel_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_insm_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_insm_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents manufacturing equipment used to produce goods and services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember" xlink:href="insm-20201231.xsd#insm_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ManufacturingEquipmentMember" xlink:to="lab_insm_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_674ed18f-060d-49f3-bb28-a99dbee51282_terseLabel_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_label_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Line Items]</link:label>
    <link:label id="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_documentation_en-US" xlink:label="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:to="lab_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_71d15670-7feb-4645-ae2f-cb8c8b9eee75_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_25113d62-b0db-4368-acdb-81fd86634abd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6c196ef8-319f-4f94-b41c-9e047f3100d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_cd51dab7-aa35-4c42-8ac1-0745c191ca5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of convertible debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9a614b8e-000f-428e-8fbc-a43f717342f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_48b6850c-1442-4782-b299-0719dbe248e8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_14ac3c95-3adc-4393-a47f-646909235b84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options, ESPP, and RSU vesting</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_32bec85b-a035-4590-9644-6dca81c3fd3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_2de49d0d-a259-4f04-b8e9-971e6086b0af_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_707466e6-9ddf-473a-8360-56b00c8df323_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_abefeba7-9bdd-4989-969d-31906b5aef6a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_504e9971-0f55-483b-8f1b-a1d379a05ebc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d7d2a82b-2a50-4e4f-869d-8179df687a7b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47f74dcd-647c-414d-b473-3e9e8f836a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5bb245a-454e-4f49-932e-40a9b199e919_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_0b3e4d5f-56ea-4c81-a5d7-54ec43e82a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_3069ca90-21e4-4106-9bb5-80ad74d0e52a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_10579c9b-9749-40c7-bff0-dabcfd8094a8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f7330220-5f6a-475b-bbd0-59e91c859013_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_e7a831aa-98ed-4cf1-be31-0f6f74731c6c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_439db100-a5a2-4762-9745-546dca035d96_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerCMember_ed4e1a52-3118-42e2-a3bc-4c7059ba468b_terseLabel_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C</link:label>
    <link:label id="lab_insm_CustomerCMember_label_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:label id="lab_insm_CustomerCMember_documentation_en-US" xlink:label="lab_insm_CustomerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember" xlink:href="insm-20201231.xsd#insm_CustomerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerCMember" xlink:to="lab_insm_CustomerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_9e83ec60-eb5d-4e28-aaf8-69c6352bb17b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_fe9bae14-0b98-4317-b565-aa4f9cba6769_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8555cee6-cde8-4a51-9001-379b96c80981_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_c1f993ec-2e4a-405c-914e-720abc32c114_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_274847b2-abac-4f28-b11f-c248149c2f9a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_371e7a1c-e88b-4905-bb56-80ed01649f6c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_f01dc262-731e-430d-8a37-effece62630d_terseLabel_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued technical operation expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_label_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Technical Operation Expenses</link:label>
    <link:label id="lab_insm_AccruedTechnicalOperationExpenses_documentation_en-US" xlink:label="lab_insm_AccruedTechnicalOperationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses" xlink:href="insm-20201231.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedTechnicalOperationExpenses" xlink:to="lab_insm_AccruedTechnicalOperationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9e1a7238-435d-48e2-af9b-3d1223191351_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_261226dc-e691-4f8d-bb5d-d449fe88dddf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_8547ef25-4821-4e0f-80cb-f6d31b55e12f_terseLabel_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_label_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_insm_EmployeeAndDirectorsStockOptionsMember_documentation_en-US" xlink:label="lab_insm_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EmployeeAndDirectorsStockOptionsMember" xlink:to="lab_insm_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_66da06f2-64bc-459c-8248-302dd47450de_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e4bacf58-6828-4706-9848-6f1369169a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_edf41274-4556-4af2-b03f-0164cb20e8df_terseLabel_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater, NJ Facility</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_label_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridgewater New Jersey Facility [Member]</link:label>
    <link:label id="lab_insm_BridgewaterNewJerseyFacilityMember_documentation_en-US" xlink:label="lab_insm_BridgewaterNewJerseyFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember" xlink:href="insm-20201231.xsd#insm_BridgewaterNewJerseyFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_BridgewaterNewJerseyFacilityMember" xlink:to="lab_insm_BridgewaterNewJerseyFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_ac759151-24fe-4f93-a695-1f9bcf545ce9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0d18861a-1d95-4f5e-bed8-18e835d593aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b798b717-286e-48d8-9071-7ca052454ce8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_33c9990d-8a21-453a-bb7d-cf9c47517c69_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6fcaa4b1-fa5f-4c5a-ad28-724ee0dc71a7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_b7aba41c-da48-4028-8114-86d26e9c0be4_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_48bd9557-a7ec-4391-a754-e950035c82c3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0af061b2-ff91-46f5-82cc-427e2bbc82e3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_221d2aff-f414-47ff-a72f-acabd7a33a95_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6ab13278-9503-4298-a2a3-37669b7019a5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_fc465d86-3c70-4f11-a84d-a64225d0d2ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_14bb2b19-bd08-4846-8eb2-9a495be372ac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d062407b-7c89-4cef-af09-921a70f5fc01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d28bb902-17f6-4049-899b-9b8c42517531_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_01a751cf-b101-42e6-abf8-d2e46b0f8bb7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_99ddbd5a-f6b3-41d0-913d-ee7d63a776c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Debt Balance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_48407141-b499-4896-ab7d-6807e0808ddb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_ea00659e-3b0b-4da6-b7fb-547dcdaa95b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_f19fe005-0477-41fc-a38d-a6eca2c9357a_negatedTerseLabel_en-US" xlink:label="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from tenant improvement allowance</link:label>
    <link:label id="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_4dfa4e68-fdcd-4e36-8581-a347308a759d_terseLabel_en-US" xlink:label="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from tenant improvement allowance</link:label>
    <link:label id="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_label_en-US" xlink:label="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Financing Lease Tenant Allowance</link:label>
    <link:label id="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_documentation_en-US" xlink:label="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Financing Lease Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:href="insm-20201231.xsd#insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:to="lab_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bdac1817-cb25-4e72-be8f-9976ecd2ae88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6057d48e-f8f2-4ba3-90ce-a3a460a1cf14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_246187fb-c902-46bd-aa88-95d44c8b6a5a_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8ec80930-e552-472c-88ba-f2f80ec45a3d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_aa612f4b-4d79-4502-883a-3aa2fa3057dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards available to offset future taxable income</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_94d1ebfd-b820-4bbc-ae28-acb418d458cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_09b661de-368d-4130-a9e4-e88aa585bf6a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_fd274036-3645-481b-a4a8-73e44187cf3e_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Line Items]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_88d1c352-dbf6-4487-bfa5-d18046420164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8f2319b8-7ed3-4a81-964a-c76e9163beae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_f41f2ea0-72c4-4e4b-bc7f-97b108f52bd1_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PARI milestone upon FDA approval</link:label>
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_label_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementMilestonePayment_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementMilestonePayment" xlink:to="lab_insm_CollaborativeArrangementMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_1afd83d6-0b03-4e6b-84c9-798200fea112_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_64987476-9858-4ccd-a88d-147090479527_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_52a9df08-b892-4025-84ea-c60fe4523a06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_21b2404e-9079-47d8-80cb-aa315429da03_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate, trading income of Irish company</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Trading Income, Percent</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Trading Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_02353eb2-9512-42b0-b3e4-bd99199076d2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_f8392b33-435f-4acb-9d78-6972d08395d4_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Irish trading status</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Trading Status, Percent</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Foreign Trading Status, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_30921886-2e04-47d1-b057-5dc5864fb58e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3bebc32f-d150-41d8-8467-72af40470ea8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_1e74961e-9cc4-404c-b0af-414017131c1f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_f5857062-1150-4936-9c2c-ac0c0b051e4c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9f370fa2-6933-4d74-b8b1-7e524f9080ff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerBMember_6b387792-d788-4bfd-b2de-3cf0042deb96_terseLabel_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_insm_CustomerBMember_label_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_insm_CustomerBMember_documentation_en-US" xlink:label="lab_insm_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember" xlink:href="insm-20201231.xsd#insm_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerBMember" xlink:to="lab_insm_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_589a6ecb-45c0-4904-95a9-49bb3a0be402_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_3d5a9bef-da4b-4d35-a3b8-d723ce9407c5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2f858ed6-faf7-4507-8323-d755fd8c4516_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_ad961f14-dff2-40cd-93f3-8b513e8881c5_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3198b5c9-b79c-4d0c-87ad-9d60a9dba321_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful live of fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a87e7621-36c2-4812-aaa1-77e8f2ba899a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_37b22e47-8229-423c-b727-e3e71f6f2465_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8b7e670b-0721-42a2-a2a4-ced916bfc3ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Value and Fair Value of Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_436c86fb-20b4-491e-a553-02005e146792_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d6ff89f3-19a6-4528-966d-7e8012043a35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock, maximum authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_fa01da8f-5585-4e2d-b5cc-b7d80d760cbc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7b3e5c40-7131-447a-96b9-234150e240f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_256a70ed-4acc-4658-b9fa-c23c1715b029_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_224f7cc6-27ff-4c6d-9fac-c1a38f163cdc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestonePaymentDomain_e6359eba-b933-475a-b1a3-fcd2734c7a67_terseLabel_en-US" xlink:label="lab_insm_MilestonePaymentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Domain]</link:label>
    <link:label id="lab_insm_MilestonePaymentDomain_label_en-US" xlink:label="lab_insm_MilestonePaymentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Domain]</link:label>
    <link:label id="lab_insm_MilestonePaymentDomain_documentation_en-US" xlink:label="lab_insm_MilestonePaymentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone Payment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentDomain" xlink:href="insm-20201231.xsd#insm_MilestonePaymentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestonePaymentDomain" xlink:to="lab_insm_MilestonePaymentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a2cfe673-a909-45d1-bb81-e861771e257b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1efa5e57-e758-475a-b8a6-7e022e00c4f7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_02c8af30-900a-4373-b5a6-288cb3bde431_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option to purchase additional debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_label_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:label id="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_documentation_en-US" xlink:label="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Option To Purchase Additional Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:href="insm-20201231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:to="lab_insm_DebtInstrumentOptionToPurchaseAdditionalDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_7ff73375-b28c-4736-a098-03646f066e91_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods upon written extension agreement</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Services Agreement, Extension Period, Period Upon Written Extension Agreement</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Services Agreement, Extension Period, Period Upon Written Extension Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:to="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9240837c-c62f-4a61-8152-3efa5ba24d92_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_776a74cf-229c-4dd2-8c1d-af44eaf856fc_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebt_13a00c90-4ca0-475b-a7b1-1257f2288fdc_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.75% convertible senior notes due 2025</link:label>
    <link:label id="lab_us-gaap_SecuredDebt_label_en-US" xlink:label="lab_us-gaap_SecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebt" xlink:to="lab_us-gaap_SecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d841f501-a73d-41e8-870a-a4fde1669f97_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_d3149079-29bb-4407-886d-d4eaa4afbcfb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_52fb8be9-85ca-4a98-bfde-bbcc62db676d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_78958ae3-97b5-4ff7-aee3-737a65209f56_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_600518b6-1353-47a9-8f9c-513c9d978016_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_d6e49a97-2c2c-4a99-8786-378d3ccb2228_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bbfbfcc3-ca96-417f-8ffc-f6d5c3b3fee7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_df3270ef-4590-4323-a2d4-eceb049dee80_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_35d60873-bba9-4750-b761-dc5ea89fccde_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_c4193a93-aca4-4080-8a87-3f231ea8a304_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeasePayment_dcd3b076-5b3e-4558-a29a-f8964a79e256_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease payments</link:label>
    <link:label id="lab_us-gaap_VariableLeasePayment_label_en-US" xlink:label="lab_us-gaap_VariableLeasePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment" xlink:to="lab_us-gaap_VariableLeasePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OperatingLossCarryforwardsNonTradingLoss_8d9ccbd3-7b2e-4dcc-ac37-bcf0561cd16f_terseLabel_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards, non-trading loss</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsNonTradingLoss_label_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Non-Trading Loss</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsNonTradingLoss_documentation_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Non-Trading Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsNonTradingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:to="lab_insm_OperatingLossCarryforwardsNonTradingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5751b192-5c58-49cc-a9ad-5c88c8331ab8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_c9ca5362-2abb-42b5-9e1e-3f4c6f532e1e_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_7b767178-03a6-4b75-ad36-e834de104801_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation earned under research funding agreements with CFFT</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_40cd26db-d34f-47c4-aadf-45e9432870ea_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_333890c5-d4fd-4911-8a74-415c2a1ee534_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_71306b0a-997f-49cb-8648-b447091a001a_terseLabel_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards for income tax purposes</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_label_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Total</link:label>
    <link:label id="lab_insm_OperatingLossCarryforwardsTotal_documentation_en-US" xlink:label="lab_insm_OperatingLossCarryforwardsTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, for income tax purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsTotal" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OperatingLossCarryforwardsTotal" xlink:to="lab_insm_OperatingLossCarryforwardsTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_5abeac42-7417-4eeb-bdb7-7cb444ffb45d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_4da6815e-24e3-4450-8aba-4ae09cbeff73_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_21a9f422-6389-4660-a1a3-d1638420031e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a4c670f3-3e23-46f0-9f97-4bc3173af703_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_f9802e2e-6899-4235-b891-b772e0b4c56a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, long-term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_9f17fc1e-59da-4e18-96ee-dbe96fd038cb_totalLabel_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total convertible debt interest expense</link:label>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_label_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Interest Expense, Total</link:label>
    <link:label id="lab_insm_ConvertibleDebtInterestExpenseTotal_documentation_en-US" xlink:label="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Interest Expense, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal" xlink:href="insm-20201231.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConvertibleDebtInterestExpenseTotal" xlink:to="lab_insm_ConvertibleDebtInterestExpenseTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cb3eb3ce-a3a6-4da3-b3ad-e4e17fbd955a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0b1ab07a-47d4-4003-aa36-797f3461abcb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5cbe4a1c-3694-4faf-a146-e34b0a432b22_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8842149-97ef-4eeb-b271-624deef17266_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8dd869be-3cd2-4a74-93bb-ead3b4122135_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8962c448-c9e6-466f-982a-6f7b2cdf2b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_a476bc75-5ad7-46be-b670-eb12411c81af_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3bd28e36-669d-4ebb-b40e-dffb5d9905aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_938cda5f-dd8c-49c4-849e-6e6e8a77b546_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0a2a5906-76b4-4493-8a22-f72060b5f5ec_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8806a1b5-3e19-4eac-9c88-f1a3ddd9357c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0b613734-a722-45c0-a6ef-6f4211bdd3af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_36cfcdc4-4c78-400b-bf6e-e1bbf3d7935a_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_label_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Upfront Payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementUpfrontPayment_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of upfront payment paid during the period under collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementUpfrontPayment" xlink:to="lab_insm_CollaborativeArrangementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_06cd25a3-5adf-4bbf-a707-b57abbd71531_terseLabel_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CFFT</link:label>
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_label_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]</link:label>
    <link:label id="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_documentation_en-US" xlink:label="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:href="insm-20201231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:to="lab_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8ae37535-69c6-468b-aa8c-05f63568bc48_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_20c4c173-2cde-4dbc-aa02-eff428b6af79_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_af0bbe16-21b2-4a20-9240-389b894f5664_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_14adb2d6-a172-4c3a-9d49-52ef19e645d4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_c574f987-25c0-4445-8e2f-469c76cf404e_terseLabel_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Credits, Fees and Discounts</link:label>
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_label_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Fees, Discounts and Other [Member]</link:label>
    <link:label id="lab_insm_CustomerFeesDiscountsandOtherMember_documentation_en-US" xlink:label="lab_insm_CustomerFeesDiscountsandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Fees, Discounts and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember" xlink:href="insm-20201231.xsd#insm_CustomerFeesDiscountsandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CustomerFeesDiscountsandOtherMember" xlink:to="lab_insm_CustomerFeesDiscountsandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_e05991ca-b42e-42b2-b6bb-900a49e0c74a_negatedTerseLabel_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_label_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_documentation_en-US" xlink:label="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:to="lab_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_3db635ac-359d-4df8-8515-f41b5bb62275_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D and other tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_29a11e20-5d12-4579-84e0-97f73e85f603_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b80f6be3-1f99-4cc3-909d-72833629cf50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_e645b1bf-780f-4683-80d3-e43bed15f91a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_382ff1db-465e-449e-9bcd-d2c554d6880c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_fb7cc4aa-939d-4619-8a66-f1a054dde355_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e4d678be-3f30-4b50-8c4d-f589f32425ba_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_8260b545-69fa-4dc3-bcf1-7a9a5a0c2baa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9e33c7f3-9fde-4865-acc6-0bdffd1e320f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_86b12d40-8b08-4376-8f3d-8f743c41e30f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_96a205bf-907e-4459-a2a8-457883b41339_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_77f695b2-d76a-4ed3-939d-43c310dbfba6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_e94350fd-65cd-4545-afa6-5c537d73dfaf_terseLabel_en-US" xlink:label="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resilience Biotechnologies</link:label>
    <link:label id="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_label_en-US" xlink:label="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resilience Biotechnologies Inc. Contract Manufacturing Agreement [Member]</link:label>
    <link:label id="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_documentation_en-US" xlink:label="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the agreement with Resilience Biotechnologies Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:href="insm-20201231.xsd#insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:to="lab_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9375189-876d-4a63-acd3-975ca03d2702_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_6e04345b-226a-400b-b2fa-b0bcff767269_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_67f0b780-7bac-47cb-a55e-ede94997d544_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_40b0a6b8-e2a3-406a-ab40-b6c3ca700440_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_aecc6c12-7097-4f85-85bc-4daa10792f41_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense charged to operations</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_bc0ca2cb-b152-449f-b6d9-29f1444d5152_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_10abb4ac-46b2-485f-8503-a872ae7d3c58_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_dad0c0fe-c651-4850-bdb0-ace6dade2401_terseLabel_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement with AstraZeneca</link:label>
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_label_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement With Astrazeneca [Member]</link:label>
    <link:label id="lab_insm_LicenseAgreementWithAstrazenecaMember_documentation_en-US" xlink:label="lab_insm_LicenseAgreementWithAstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to license agreement with AstraZeneca AB, a Swedish corporation (AstraZeneca).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember" xlink:href="insm-20201231.xsd#insm_LicenseAgreementWithAstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAgreementWithAstrazenecaMember" xlink:to="lab_insm_LicenseAgreementWithAstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7b725b79-2b4e-4558-a058-2d92f339174f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1a91d47f-1c1c-48b3-a76f-80667d14d94a_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bde4dc19-d20c-4616-9cec-d374bff65fc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7c8d1ec6-4338-4881-963f-b614cf79a16f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_8691ce1d-15f6-44d5-82ae-335c9ed41e18_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_43bf9785-a9ec-4ea7-af7b-ccd59d4cc13d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_b69882c3-1cfb-4b28-b538-553073538011_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_432bc8d4-3ee0-4e10-87a9-47cfdcbd245e_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_d1395a11-7359-4096-99ac-6009c669b8d0_terseLabel_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for prior period sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_label_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Allowance For Prior Period Sales</link:label>
    <link:label id="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_documentation_en-US" xlink:label="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Allowance For Prior Period Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:to="lab_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_12e9938c-1e4a-427e-9aea-58f8f890794a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a8135332-cc36-4efc-b344-7a9ebd898465_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_2451636c-1a1b-469c-9464-19dc1e60ef98_terseLabel_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Chargebacks and Co-pay Assistance</link:label>
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_label_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Chargebacks, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_insm_RebatesChargebacksandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Chargebacks, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:href="insm-20201231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:to="lab_insm_RebatesChargebacksandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_44c82fc5-ae08-41f1-a0bf-547af9438fd1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e06598d6-b3ad-4ddb-a950-8e9ed3c01196_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-condition options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_6d10351c-6f5d-4a92-b863-a4847b97c0f6_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_99cf2c3a-c232-445d-b588-52de5aefb0a7_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product license</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, License Payment</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLicensePayment_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLicensePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLicensePayment" xlink:to="lab_insm_DeferredTaxAssetsLicensePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_73f07cf9-b28b-4766-b848-1a78f5f59bf6_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period prior to expiration for extension</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Services Agreement, Extension Period, Period Prior To Expiration For Extension Agreement</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:to="lab_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_ebf47d2c-474f-47e5-9c38-7f83f53f0f57_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_2bd2b636-9b40-45ad-9bae-eb23f6d51af6_terseLabel_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional term of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_label_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Term Of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_AdditionalTermOfContractManufacturingAgreement_documentation_en-US" xlink:label="lab_insm_AdditionalTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the additional extension period of contract manufacturing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement" xlink:href="insm-20201231.xsd#insm_AdditionalTermOfContractManufacturingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalTermOfContractManufacturingAgreement" xlink:to="lab_insm_AdditionalTermOfContractManufacturingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PublicStockOfferingMember_cc8ea78d-787e-4a9c-89a3-922b60edac6a_terseLabel_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_label_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_insm_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_insm_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PublicStockOfferingMember" xlink:to="lab_insm_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0f4e8ec8-d6f0-4253-a158-5f6b67fea7bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_e35ab8f3-cead-4f4c-ae25-79679b59d682_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_93b7233f-a226-45ee-8fd2-5c3aa7ae3151_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_94d94751-e488-4e23-8a23-6ea34c10254a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt principal and extinguishment costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_57cdb7f0-e1b7-47d4-b03b-745a9713d03e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5b3f8942-0ee1-4643-b12d-b716d62e4dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value and assumptions used in determining fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_93329953-4f63-4e39-90b0-7de76de879a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and ESPP shares issuance</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_62207f37-755a-4e91-9b62-2e35fe652111_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7888aa17-0bd8-41a4-a076-6ac638078215_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b61f050d-e65b-4c6c-b4d1-b833d4f462bb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9c7af305-9d67-4c6d-82e1-c1e8601c6860_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_09356f10-dace-4267-a624-2daef74236bb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_4bfb7395-f437-4853-b28a-d209907e594c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_cc48f482-fd53-469a-898d-5609bc443b80_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_c950bd3a-a6aa-486a-b208-e7d4decdc037_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:to="lab_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_11d67c97-478c-4a8e-9169-3698ca7dd793_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba62b9ea-fbe7-44c7-a297-bed5b4aa57e8_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_17188fb7-46ae-4219-aca9-e3e8a5bebe34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Principal Repayments of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9df5e1ec-4b60-4a21-988c-53b545db4025_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_658f7058-22ff-4c3a-bf22-227b6c059e51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c7334a5a-c17e-4759-9a9a-cdebae12fd61_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1d31c844-c842-4fe1-86a4-9ed73b089dd4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_eb398c43-4eea-4aea-a877-637dd2c06ea7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_742a17b3-0661-4439-9f4d-f9d4a8a42123_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_ecb60408-1a7b-464f-8ee4-b734b34f22c1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum commitments due for firm purchase</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_83dd0a66-30c4-449c-84de-11c6e047ab89_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate - operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_48b3b2b3-dc67-4c53-9fd5-e7267661de9a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual net sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_7a9c42b6-0f36-420a-90ee-05bded832763_terseLabel_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written notice period required for termination of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_label_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Notice Period for Termination of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_documentation_en-US" xlink:label="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the written notice period required for termination of contract manufacturing agreement by either party.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:href="insm-20201231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:to="lab_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0b6e0e8d-5c64-4a08-9264-2411f35aed7c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9de4e774-d25f-473b-b3dc-6df3fcb478ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_67e8decc-b55c-490f-9cae-325d51765ad1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_da2b5bbb-5e65-4bb7-9c95-0b4323cbfac9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_10718030-6168-4a69-b756-eeb1ffed027f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_43128f2e-c8a0-4187-a5af-19409eba3800_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_667c8c16-bdbe-4b48-9788-ea1ad78df0a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_86b0e488-f58d-4344-a25b-836aeec90159_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d655c36c-b1f5-48ca-90cb-7db18dae5a7c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_11712b10-2996-4b06-88fb-5106ce7f49e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_0d4c90f7-3c3a-400d-8405-4b9e7a25a63e_terseLabel_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fill/Finish Agreement</link:label>
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_label_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Fil V Finish Services Agreement [Member]</link:label>
    <link:label id="lab_insm_CommercialFilVFinishServicesAgreementMember_documentation_en-US" xlink:label="lab_insm_CommercialFilVFinishServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to the Commercial Fill/Finish Services Agreement (the "Fill/Finish Agreement") with Ajinomoto Althea, Inc., a Delaware corporation ("Althea"), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember" xlink:href="insm-20201231.xsd#insm_CommercialFilVFinishServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialFilVFinishServicesAgreementMember" xlink:to="lab_insm_CommercialFilVFinishServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_715a7efb-ea9e-44fd-be08-edbc04d80f25_terseLabel_en-US" xlink:label="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written notice termination term of clinical development services agreement</link:label>
    <link:label id="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_label_en-US" xlink:label="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Notice Termination Term Of Clinical Development Services Agreement</link:label>
    <link:label id="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_documentation_en-US" xlink:label="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Notice Termination Term Of Clinical Development Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:href="insm-20201231.xsd#insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:to="lab_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_59cff06c-0182-4416-9c1e-481166dfe86a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_93230cc2-9da4-4fc7-8222-66ce41c9dec3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e0574810-5b67-4b95-b29f-f308a1e6e7b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_c627551f-c497-41f2-863c-5b88526e66d0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_f2e59e5a-6e1e-46a3-8d14-dcb567f8f1de_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate - finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_69272215-68af-462a-aa21-931d6b24d69e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_86647cf8-c04a-4e99-a781-e8b85ccfdd2a_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense paid for ARIKAYCE approval</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d8a0fe15-8197-4ebf-90fa-98e90c17cc66_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_08f54b65-3726-4113-ad0e-55558e97ccfb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4417944e-ef54-4464-b858-a447feacdda8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_d4c8d46f-f977-43a7-8537-4cd4093961d5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_7f55f8c6-f251-4eec-89c7-c80e6547902b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:to="lab_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_0bcf5b99-9cf6-4533-b87b-7a581df1f69a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_47c4d5be-ca41-4359-82cc-25467035eb4c_terseLabel_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial term of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_label_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_InitialTermOfContractManufacturingAgreement_documentation_en-US" xlink:label="lab_insm_InitialTermOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the initial period of contract manufacturing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement" xlink:href="insm-20201231.xsd#insm_InitialTermOfContractManufacturingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InitialTermOfContractManufacturingAgreement" xlink:to="lab_insm_InitialTermOfContractManufacturingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b07d1ea9-5609-4003-8721-d378ffa112d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6687bce4-635d-4a43-9e05-03ca21bcda96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_fb9843d4-475d-4803-9d9b-a2f6fb5f17ab_terseLabel_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Other Agreements</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_label_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Other Agreements [Text Block]</link:label>
    <link:label id="lab_insm_LicenseAndOtherAgreementsTextBlock_documentation_en-US" xlink:label="lab_insm_LicenseAndOtherAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This entire text block refers to License and Other Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAndOtherAgreementsTextBlock" xlink:href="insm-20201231.xsd#insm_LicenseAndOtherAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LicenseAndOtherAgreementsTextBlock" xlink:to="lab_insm_LicenseAndOtherAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f7d18bf4-aab7-4d93-8eb9-a51762d729c4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_444fcec1-c0db-4829-b6f0-cdc77b8fab4a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestoneFDAApprovalMember_c9a2f89a-07c9-47c8-bdc0-9ae0ca6d0a0d_terseLabel_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, FDA Approval</link:label>
    <link:label id="lab_insm_MilestoneFDAApprovalMember_label_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, FDA Approval [Member]</link:label>
    <link:label id="lab_insm_MilestoneFDAApprovalMember_documentation_en-US" xlink:label="lab_insm_MilestoneFDAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, FDA Approval [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneFDAApprovalMember" xlink:href="insm-20201231.xsd#insm_MilestoneFDAApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneFDAApprovalMember" xlink:to="lab_insm_MilestoneFDAApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_ade5102c-b39a-44e0-b76b-4982d41a640f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f4b035cd-ee57-461d-871e-25bbb9027964_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_285ad93b-4c3a-4882-96d3-464f8da1b994_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6f8f8b75-ee2a-420e-8215-8b4725f8952f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_6bd6b0f6-0a3b-44d1-8b16-8a14e3579862_terseLabel_en-US" xlink:label="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer</link:label>
    <link:label id="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer [Member]</link:label>
    <link:label id="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:to="lab_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_73f8c091-1cc1-410e-a098-4303d0fa34f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, long-term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8580122b-6924-4d20-b39a-949bea5bc83e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_156361c7-4122-4bfe-a286-91f933ace429_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd81f492-db3b-4b3d-b42f-9cd22cb00d8e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_15f1badf-9ab4-40fc-b4ba-f5d12e254312_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c5416692-cd95-480c-9c76-224cd7dac055_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_98d64010-435b-4ac0-9679-7a4cf77e1348_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_817853a2-3ffa-4a8b-88eb-ccd53662aa60_terseLabel_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum obligation</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_label_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Services Agreement, Minimum Obligation</link:label>
    <link:label id="lab_insm_CommercialServicesAgreementMinimumObligation_documentation_en-US" xlink:label="lab_insm_CommercialServicesAgreementMinimumObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum obligation due under the terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementMinimumObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CommercialServicesAgreementMinimumObligation" xlink:to="lab_insm_CommercialServicesAgreementMinimumObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_76ec45cb-3259-4adc-a9ef-9811f72dea86_terseLabel_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income and Interest Expense</link:label>
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_label_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income (Expense) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InvestmentIncomeExpensePolicyTextBlock_documentation_en-US" xlink:label="lab_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for components of investment income and interest expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:href="insm-20201231.xsd#insm_InvestmentIncomeExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:to="lab_insm_InvestmentIncomeExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3715e914-7274-42eb-907f-13c66ec4b5b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_3b1b0b1e-e08a-471a-9677-9ef4d3436413_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable on approval of ARIKAYCE as commercialized drug</link:label>
    <link:label id="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9d9ef08c-8c3d-4080-83c3-a6dc8024f9bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c296fffa-a775-463c-b470-1177b3204ccb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_32afb9ca-7325-4d51-8815-6dcbbf9465de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PARI milestone upon regulatory approvals</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f90af3fd-b48e-4d13-8fd7-c507711359a3_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New drug milestone payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_ad90fc4b-fa5e-4fe1-a17f-7bdf555becf7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_284faaed-c2f3-4141-8d26-f5ec02a40b8d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_89c37566-5e6a-4b8d-a163-34a118cdb1b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_543d38ad-af16-4c16-8ab1-2d4d3417bb76_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_bb1c1c06-f6e0-4c93-87e9-3b2f0998061c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_890cc9d1-109f-4ba1-b855-33579baaea09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_493ed8e1-24bc-491d-97a2-238e95464b45_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConversionTermiiMember_11d8c77e-9934-42fd-84d9-5933bb12aa5a_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (ii)</link:label>
    <link:label id="lab_insm_ConversionTermiiMember_label_en-US" xlink:label="lab_insm_ConversionTermiiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (ii) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiiMember_documentation_en-US" xlink:label="lab_insm_ConversionTermiiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (ii) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiMember" xlink:href="insm-20201231.xsd#insm_ConversionTermiiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiiMember" xlink:to="lab_insm_ConversionTermiiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_981792de-c914-4479-9102-1edebc4cbfa9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f0eedf39-689a-4f5b-8153-fb0aaab7f857_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f4b60f45-86a5-40e2-bf56-952b8313d44a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd734d27-b865-4ee5-ae54-384adddf0820_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_d72a6f9d-263d-4ce4-847d-07271b2f57f6_terseLabel_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_insm_RestrictedStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:href="insm-20201231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:to="lab_insm_RestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_7fc69dd5-7c81-40fb-8fe5-6f5c7f653702_terseLabel_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued construction costs</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_label_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:label id="lab_insm_AccruedConstructionLiabilitiesCurrent_documentation_en-US" xlink:label="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Construction Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent" xlink:href="insm-20201231.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedConstructionLiabilitiesCurrent" xlink:to="lab_insm_AccruedConstructionLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_5d9c85ed-00e1-4314-8f66-a7c317968f89_terseLabel_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Current Liabilities</link:label>
    <link:label id="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:href="insm-20201231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="lab_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3b20785a-1fa2-4dde-86ab-b7e856d57786_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_33d290e9-4bc5-4047-85cc-4bd4ed82d42a_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c1fdfb59-10a0-4bf8-9bb2-3d8f6ec3226b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_c85a5a30-0baf-4616-a09e-241f70e8ebe5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Product Line</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_b9e42aed-f87e-4374-a45c-8035bf9bf3a6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_08b4ddbb-1eca-4247-9bb6-3c396339b22e_terseLabel_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:label id="lab_insm_LeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_insm_LeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm" xlink:href="insm-20201231.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_LeaseRemainingLeaseTerm" xlink:to="lab_insm_LeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_efc5e19c-ce35-4620-b155-87a382316d22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe630dea-0a25-4700-b3a5-c4f4dbdd6b5c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_cf266140-a60a-4bc7-9668-8c41f5bdb186_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_29e6d041-c492-4b15-850f-be28c2433764_terseLabel_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of each automatic renewal of contract manufacturing agreement</link:label>
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_label_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Each Automatic Renewal of Contract Manufacturing Agreement</link:label>
    <link:label id="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_documentation_en-US" xlink:label="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the period of each automatic renewal of contract manufacturing agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:href="insm-20201231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:to="lab_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cda3d669-2fbd-43ac-a42f-0e9a028e4738_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_94299cf3-9dcd-4d0e-8bbd-b43fb3e6bd71_terseLabel_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_label_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:label id="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_documentation_en-US" xlink:label="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Allowance for Credit Loss [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:to="lab_insm_ContractwithCustomerAssetAllowanceforCreditLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_CollaborativeArrangementPhase3StudyPayment_809c4e08-7094-458d-a8a7-6bcd4528740e_terseLabel_en-US" xlink:label="lab_insm_CollaborativeArrangementPhase3StudyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 study payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementPhase3StudyPayment_label_en-US" xlink:label="lab_insm_CollaborativeArrangementPhase3StudyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Phase 3 Study Payment</link:label>
    <link:label id="lab_insm_CollaborativeArrangementPhase3StudyPayment_documentation_en-US" xlink:label="lab_insm_CollaborativeArrangementPhase3StudyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Phase 3 Study Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementPhase3StudyPayment" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementPhase3StudyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_CollaborativeArrangementPhase3StudyPayment" xlink:to="lab_insm_CollaborativeArrangementPhase3StudyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_cc87f401-e622-430e-abe4-9b478aaee3fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e5d66df7-12df-429b-98b9-53c81e49435a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_09608352-caa4-46a2-ac53-d5119c5d2280_terseLabel_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_label_en-US" xlink:label="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:href="insm-20201231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:to="lab_insm_WeightedAverageRemainingContractualLifeInYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_64cec58f-bfab-4413-b4b4-d2117ee6150c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted average period for recognizing unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b16d4340-c904-4a6d-8a90-8ad1106b1973_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted average period for recognized and unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9ca08a35-68ef-4f74-a6df-4925c5e5b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5d3d30fe-dfdb-4531-a936-2ec18993856c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_5fc37a8b-7540-400d-ab03-c0a6f64407d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4854be9e-b8b3-4c85-9a88-51834a02925b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term - finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestoneEMAApprovalMember_91b01ac7-398d-4c2f-b286-74014a396061_terseLabel_en-US" xlink:label="lab_insm_MilestoneEMAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, EMA Approval</link:label>
    <link:label id="lab_insm_MilestoneEMAApprovalMember_label_en-US" xlink:label="lab_insm_MilestoneEMAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, EMA Approval [Member]</link:label>
    <link:label id="lab_insm_MilestoneEMAApprovalMember_documentation_en-US" xlink:label="lab_insm_MilestoneEMAApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, EMA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEMAApprovalMember" xlink:href="insm-20201231.xsd#insm_MilestoneEMAApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneEMAApprovalMember" xlink:to="lab_insm_MilestoneEMAApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_82d46c24-f06a-4b1f-bef3-055a7c4ceeb2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_22b5835b-b125-4fd0-92ab-5e8dd5bbc73e_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_36cc793b-71a4-42fa-a9c4-e27483d0891e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_78760a41-de51-4161-92f1-c3a5ed620af4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_d3475faa-467e-40f6-965f-92cba0c413f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3699f9f5-6428-488d-ac62-759ddacd9dc5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_085780f5-ed84-45fe-adea-9c76971053f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_547e5547-01a4-4072-8b09-7ea019079146_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_07ac6842-1448-4f9b-90e2-c46eb6f35430_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eaef7438-d77c-4cb7-b756-ec98281abc3b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c38a85b8-736f-4104-b54c-3a948083c971_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ea0019a0-734d-4154-9e7e-85d4fd7e3e61_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_24f6acdf-22e5-4af3-8934-2e35bc2c9dff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Before Income Taxes in the US and Globally</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_29ff4d9d-9810-4ee8-966d-27649f33b2fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_65ff7e3d-e3a2-41af-b436-4f7a0644a092_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3c21049c-e0b7-4bd1-9487-c0f571ab8e5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ConversionTermiMember_53380694-529c-41c1-a69b-42966a7cb07e_terseLabel_en-US" xlink:label="lab_insm_ConversionTermiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (i)</link:label>
    <link:label id="lab_insm_ConversionTermiMember_label_en-US" xlink:label="lab_insm_ConversionTermiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (i) [Member]</link:label>
    <link:label id="lab_insm_ConversionTermiMember_documentation_en-US" xlink:label="lab_insm_ConversionTermiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Term (i) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiMember" xlink:href="insm-20201231.xsd#insm_ConversionTermiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ConversionTermiMember" xlink:to="lab_insm_ConversionTermiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_03b6f384-7a4d-412f-989e-4c4c6cfd47da_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5dd0d585-b3cf-4a12-a629-b2da558b5b99_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9cca71e2-b880-4a63-bdb1-7edb43eff13b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f15f1e6e-6d05-4960-9df5-0783c6a1444c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_b888565f-102e-48b0-8398-413242cd26de_terseLabel_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PARI Agreement</link:label>
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_label_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">P R I Pharma Gmbh Commercialization Agreement [Member]</link:label>
    <link:label id="lab_insm_PRIPharmaGmbhCommercializationAgreementMember_documentation_en-US" xlink:label="lab_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the agreement with PARI Pharma GmbH, for the manufacture and supply of eFlow nebulizer systems and related accessories, liposomal amikacin for inhalation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:href="insm-20201231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:to="lab_insm_PRIPharmaGmbhCommercializationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f5a4b7d5-e20b-47bc-9408-e5438845517e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_01af2eef-ee49-4469-9c13-3c45b54e5198_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1aab0d80-b526-4f5d-986f-ed3407e559a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_93117fb4-fc54-40cd-8044-30b01d74b6b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_25830933-ae80-496f-b9a5-6934266ee3a7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4c1a4759-1894-4505-a2c7-48e01614397d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_08deded4-7d29-4fe3-bb03-98c300e380f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_36e71004-f609-4aae-a10c-c5bf7de22285_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_0606a3e7-d2a5-468a-b73b-8ddf7fadcc5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3904a01b-28be-4a6a-8633-c13a335bade1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e1fb115b-bc9e-45fc-a032-cc91d03a8a54_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d11512f2-2fab-41d0-a3b4-34ddb20a9ff9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1a8fa427-9b61-4c91-94cf-ef604ecbad17_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_03575bda-24af-49b6-94d0-65f9af00662a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_7beb5c2e-58d8-411e-83b9-30d0c2763ca5_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_67ce8c6f-db60-425d-aab0-c869cf4e4538_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_4b824c6d-6414-474c-a2a4-7beed7d5ceae_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_af6a703b-7b49-4ae0-9585-cc7b954ee4ce_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2e0b2b3b-7df5-4555-8c0b-d2feda087cb8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Weighted Average Grant Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_63aea949-bc11-4e13-afac-53df541c3ae0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c49aab18-e14e-4b56-bb62-7a6f082080a1_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_75ee98f0-bb33-48ce-ad84-bc22009913ac_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b89fa12a-44e7-456b-b804-b19dafb447f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4a16aeb9-f177-4a7a-81cf-15ba98384a5f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_564a3ef8-7217-4430-ae44-e151323f50fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_e3896e43-8380-47e9-a968-53e62d5a33b6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_33e6e500-72de-4ccc-8849-9d413e0bf3ca_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2d0d36fc-4b64-457a-8648-a187e82b6877_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash operating lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b28e5988-618f-451c-85e5-98a698db0f1a_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70f91b1f-62a6-4d2d-a619-3f971c2d70d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c4e7a3ef-2954-44f1-a812-60a912123ef7_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c5042f91-4bb8-4987-b2e4-356ec746ceef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_7416d442-7bd8-401b-8900-1c79314fe922_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_8d3419cc-e9b4-43cc-8ecd-b751bad26e4b_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_f466dbad-9b14-485b-afd7-41a460526320_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net and Impairment Assessment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4f84fee5-457a-4a17-a6b4-8ad55af9daed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_ad836e04-5ffa-4dd5-9a67-0b4fb8e3c3c0_terseLabel_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_insm_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_insm_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses" xlink:href="insm-20201231.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedClinicalTrialExpenses" xlink:to="lab_insm_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_120876d5-dcce-4f81-a7c5-cc36cef5085c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_4d39cdac-e4fd-42e6-8012-802954d69e3f_terseLabel_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures</link:label>
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_label_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Furniture And Fixtures [Member]</link:label>
    <link:label id="lab_insm_EquipmentFurnitureAndFixturesMember_documentation_en-US" xlink:label="lab_insm_EquipmentFurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to equipment, furniture and fixtures.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember" xlink:href="insm-20201231.xsd#insm_EquipmentFurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EquipmentFurnitureAndFixturesMember" xlink:to="lab_insm_EquipmentFurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_59acff17-abc6-4af8-968e-e99907cf7047_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_69877ad3-34fe-4c43-8121-9b1f5330645b_verboseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_3784325f-c7cd-4756-b572-607b1cc49653_terseLabel_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_label_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware And Software [Member]</link:label>
    <link:label id="lab_insm_ComputerHardwareAndSoftwareMember_documentation_en-US" xlink:label="lab_insm_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased computer hardware and software applications.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember" xlink:href="insm-20201231.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_ComputerHardwareAndSoftwareMember" xlink:to="lab_insm_ComputerHardwareAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d526ea6d-9429-4e91-839e-e3649f7615d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_4c1d62ea-a97a-4442-bd64-63ac092ac0e1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_7d37c269-aa9e-496b-b592-66274dbcccc1_terseLabel_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payable on meeting certain sales milestones</link:label>
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_label_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Royalty Guarantees Commitments Amount</link:label>
    <link:label id="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_documentation_en-US" xlink:label="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of royalty payments if entity meets certain milestones under a research and development agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:href="insm-20201231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:to="lab_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_64a0c5ad-a7ed-4a06-a256-218395d08ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8c8182b9-c778-4516-8a3d-dd5a78bb2ead_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f0e0f7a0-7831-4e9f-bba4-744047c23406_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_cd310e5e-6ede-4d50-97f5-0e05ac80fbb3_terseLabel_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for meeting sales milestones for additional royalty payments</link:label>
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_label_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for Meeting Sales Milestones for Additional Royalty Payments</link:label>
    <link:label id="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_documentation_en-US" xlink:label="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for meeting sales milestones for additional royalty payments after the drug is commercialized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:href="insm-20201231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:to="lab_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3086c829-db2a-4a74-b8b5-15d2b8711dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components Income Tax (Benefit) Provision</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_effe318b-02c4-46bb-85d1-0cf9c0e5d950_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_95805a19-f048-4d11-9db3-f48500098454_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_bca87745-fb9e-429d-85ac-090f49c22b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6f8a3d31-a3c2-4e1d-8260-1289c4dfcb25_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 500,000,000 authorized shares, 102,763,060 and 89,682,387 issued and outstanding shares at December&#160;31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_263607fd-6013-47f1-858c-e47540fec587_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_71e7491d-e63f-48c4-8d6a-140094e6642a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b48eda13-43a8-4001-aaff-e5f236d45e6e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_803a7bf0-b079-429b-9261-ac52d74e3b5a_terseLabel_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, New Drug Application</link:label>
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_label_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, New Drug Application [Member]</link:label>
    <link:label id="lab_insm_MilestoneNewDrugApplicationMember_documentation_en-US" xlink:label="lab_insm_MilestoneNewDrugApplicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone, New Drug Application [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneNewDrugApplicationMember" xlink:href="insm-20201231.xsd#insm_MilestoneNewDrugApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestoneNewDrugApplicationMember" xlink:to="lab_insm_MilestoneNewDrugApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_bd24278c-924d-4969-a0a1-976e75c6ed0b_terseLabel_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and cost of product revenues (excluding amortization of intangible assets)</link:label>
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</link:label>
    <link:label id="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:href="insm-20201231.xsd#insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:to="lab_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0afd4565-8abf-463b-bba3-6816c40d61a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited and expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b3c22dc8-dfc6-41b4-b4dd-54f636e0db6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_80626e76-d45f-4dad-851f-656a5e9e0e95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0c4345d-e0f9-4b74-9737-da3d25e6f80b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3915644c-1940-4faa-8b8c-d4dd23e6fb3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f3eec8bf-e0ac-43ce-901c-4295494ced09_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_MilestonePaymentAxis_514235e1-4661-4e6a-bf9d-d914465926e4_terseLabel_en-US" xlink:label="lab_insm_MilestonePaymentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:label id="lab_insm_MilestonePaymentAxis_label_en-US" xlink:label="lab_insm_MilestonePaymentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:label id="lab_insm_MilestonePaymentAxis_documentation_en-US" xlink:label="lab_insm_MilestonePaymentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentAxis" xlink:href="insm-20201231.xsd#insm_MilestonePaymentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_MilestonePaymentAxis" xlink:to="lab_insm_MilestonePaymentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a42fe92-3e1a-4520-9b50-a9b3afa5ad6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a905bb2e-0f82-4070-b058-b4f3e525ddb4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares used in calculation of basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_15d4fac9-5cda-4cbd-8726-b31c8b37989b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4d54e049-dddf-4a4b-88a0-951241dd74cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_eec0e2f0-921a-4e30-a0b6-15b1b40a4311_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f7760ae5-03c1-42ab-ab28-1a98c266012f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff6bcd52-d7c3-4574-b4f8-f76c7a68b59f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_06d3d42a-b169-444c-bd59-5fbe979e6415_terseLabel_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.75% convertible senior note due 2025</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_label_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:label id="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_documentation_en-US" xlink:label="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:to="lab_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_391841de-ac7c-4584-9588-3c02d0a0c9b9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_cd20bfa3-5e31-4503-8f85-4b8bd170d536_terseLabel_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value transfers in or out of Level 1, Level 2 or Level 3</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_label_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:label id="lab_insm_FairValueLevel1Level2Level3TransfersAmount_documentation_en-US" xlink:label="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Level 1, Level 2, Level 3 Transfers, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:href="insm-20201231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:to="lab_insm_FairValueLevel1Level2Level3TransfersAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5e12b249-3232-4de3-a186-8c3edcfc73ef_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_462a1415-b1c8-479b-be6d-23fb85f32db6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63f10d01-a7d5-45aa-9255-a9367c434b2f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_97d77dd6-e958-4fb9-9512-66bdc3b512ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_19530c7c-a26e-4218-804e-aee65abed26e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_63cb9cf3-2ea4-4077-af86-26fcbef3b4cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_1ebc9c59-1492-4e07-bfb7-fc743c09717d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fd1cee0b-f1dd-4363-833b-1276a73201c1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_105f75a7-4037-4fb5-82a1-71a7a6538f6a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_11379d81-1906-45da-b35a-2a3cbecb3e26_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_59ed9e39-f718-408e-8ed0-ec7ef81824ca_terseLabel_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days following fundamental change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_label_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:label id="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_documentation_en-US" xlink:label="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:to="lab_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5ff95d72-69d7-428b-a843-68dd6ad1e954_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab481975-cbd7-42cf-8854-0fcb640bbb65_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7476984f-45c5-4f55-b328-0b0cb6869876_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_a1f5df35-aad8-435a-b8b0-ef345d7c2274_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d3528fe3-c3a2-4963-b65f-f05226dc42ea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f058ca87-bb96-4f3b-9f5a-f47305008263_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d3b26d5a-4873-4eae-ae5e-2309cee73730_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_FinanceLeaseCost_90e29ec0-c766-44d0-bd6d-256901e7b5a2_terseLabel_en-US" xlink:label="lab_insm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_insm_FinanceLeaseCost_label_en-US" xlink:label="lab_insm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_insm_FinanceLeaseCost_documentation_en-US" xlink:label="lab_insm_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FinanceLeaseCost" xlink:href="insm-20201231.xsd#insm_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_FinanceLeaseCost" xlink:to="lab_insm_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0d018760-c78c-4eb5-9f68-cef7dfc03bc1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_62b6ec31-b9ba-493b-8f9b-6a9620ed73d6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_08c3b4fb-be29-4a1d-90b0-e5d3369fd854_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_7bc81b45-32a1-4ea7-9969-a37be97d9ab8_terseLabel_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_label_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Debt Fees And Outstanding Interest</link:label>
    <link:label id="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest_documentation_en-US" xlink:label="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Debt Fees And Outstanding Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:href="insm-20201231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:to="lab_insm_RepaymentsOfDebtFeesAndOutstandingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cb4a1406-4a82-4e97-95f7-90a2bb75a7d9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3b7f1782-0e67-4a12-ac0c-3e1226a21a0e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_dff985f8-684d-4d74-8b1f-f45e4e04eea4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_1cd6ccb5-92ea-4d90-a8c1-41d5f6eb8705_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3153eaef-5163-48e6-a596-fbced3f6038a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_298591ca-9327-4dcb-a478-dc6408178e0a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_13ec65af-5c60-4dcf-912a-e767066ec23d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_179227b4-5812-4b06-b779-cf983f1ee4a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_7cb65576-7ed1-4832-a5a7-e9e8222370b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining discount amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_94bd7ee6-61df-4a3a-8bfc-bfe9ce43efa1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48d6cddf-7aaa-4eb7-9216-3929cfa334c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_84222683-3893-48b9-8598-d11868d41513_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_a3379fc7-903f-4f8c-ad45-02e0cfdbde68_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_61aefa60-bc8b-46f0-900d-aaf608d793f1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3410bad1-c293-4236-aeff-8f3fc8cf6384_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_1aab712a-7be3-48a1-91cf-84e6479457cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_a79f7c8e-5d20-4897-8591-aeef1e123a21_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, unamortized</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_145fabb3-9237-458c-8a62-f9fc41895014_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_35b6e989-a366-492b-9604-2761c95c4ef2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_57145876-3366-4d39-8beb-76cc0cf6d401_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows for finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_cd22cc36-1cb4-42d4-838a-765b1b152666_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_dd50a590-e82c-4024-abf0-bcc3deb595e2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A&amp;R Loan Agreement with Hercules</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_120a2876-2b66-43ee-ada2-f99b9ab7b6b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_2fc68200-1779-4986-a0ee-9e394649b4fd_terseLabel_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate, non-trading income of Irish company</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_label_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-trading Income, Percent</link:label>
    <link:label id="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_documentation_en-US" xlink:label="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Non-trading Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:to="lab_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_0a20413d-1eba-4596-899d-2ec1e44be2c5_terseLabel_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales allowances and related costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_label_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Allowances and Related Costs</link:label>
    <link:label id="lab_insm_AccruedSalesAllowancesandRelatedCosts_documentation_en-US" xlink:label="lab_insm_AccruedSalesAllowancesandRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Allowances and Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts" xlink:href="insm-20201231.xsd#insm_AccruedSalesAllowancesandRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_AccruedSalesAllowancesandRelatedCosts" xlink:to="lab_insm_AccruedSalesAllowancesandRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_630dd3a7-d81b-47fc-8582-b5a955c4e652_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_insm_DeferredTaxAssetsLeaseLiabilities_99f4ff2b-6835-468c-bb45-4487df4f6b12_terseLabel_en-US" xlink:label="lab_insm_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_insm_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_insm_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_insm_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLeaseLiabilities" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_insm_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_insm_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_9fef99cc-8cc4-4309-9eb2-60b74d719d16_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>insm-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46a863e0-f198-4bed-a191-64348fbc6e88,g:08a4823a-edd9-4c00-b0ab-698527766cad-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.insmed.com/role/CoverPage" xlink:type="simple" xlink:href="insm-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b547a68a-3946-4b66-98d5-7de38b317b36" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentType_b547a68a-3946-4b66-98d5-7de38b317b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4b42c0c4-553d-4849-8ce3-18b263983b46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentAnnualReport_4b42c0c4-553d-4849-8ce3-18b263983b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0c97f772-9b45-41e2-9406-9e85403b2a1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentPeriodEndDate_0c97f772-9b45-41e2-9406-9e85403b2a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a972ba24-5975-4137-a123-d05bfd4fe709" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_CurrentFiscalYearEndDate_a972ba24-5975-4137-a123-d05bfd4fe709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_90dd68d4-df5d-4757-a0ec-a0d11dd11214" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentTransitionReport_90dd68d4-df5d-4757-a0ec-a0d11dd11214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_69675be4-ec7f-4f45-8976-87fc898870b7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityFileNumber_69675be4-ec7f-4f45-8976-87fc898870b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_dfe1df2e-2ae1-4a21-8b7d-4e6ef15487c9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityRegistrantName_dfe1df2e-2ae1-4a21-8b7d-4e6ef15487c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9420c463-8989-4d9e-a1a1-8d0e77acb8a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9420c463-8989-4d9e-a1a1-8d0e77acb8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d88cfe7f-7fe1-4efb-9378-4a06a15e06bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityTaxIdentificationNumber_d88cfe7f-7fe1-4efb-9378-4a06a15e06bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a22f7425-d450-4e5f-afb5-6997db1a0fca" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityAddressAddressLine1_a22f7425-d450-4e5f-afb5-6997db1a0fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_cd4d6405-4a08-4938-8dc2-ee1cb77b91e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityAddressAddressLine2_cd4d6405-4a08-4938-8dc2-ee1cb77b91e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_478cc22a-c6d9-4c1a-8ff0-bdf95a5c1c43" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityAddressCityOrTown_478cc22a-c6d9-4c1a-8ff0-bdf95a5c1c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_56bed276-1289-4944-a9c1-f2fde13e6f50" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityAddressStateOrProvince_56bed276-1289-4944-a9c1-f2fde13e6f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_73f4d615-2ef6-4ebe-bc04-bb7eb1e8d2fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityAddressPostalZipCode_73f4d615-2ef6-4ebe-bc04-bb7eb1e8d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_49dd662b-2a7e-4dff-8240-4a5fa89c0c74" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_CityAreaCode_49dd662b-2a7e-4dff-8240-4a5fa89c0c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_11a175c8-086f-4358-827c-0edf4a0d68a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_LocalPhoneNumber_11a175c8-086f-4358-827c-0edf4a0d68a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_46bdea4a-1103-4a16-a96b-cb3af2b2a0c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_Security12bTitle_46bdea4a-1103-4a16-a96b-cb3af2b2a0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_68672845-b144-4c58-8da0-67bd3ce94c1a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_TradingSymbol_68672845-b144-4c58-8da0-67bd3ce94c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d699f0c9-3f68-4d11-8ac9-e6fb75db047a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_SecurityExchangeName_d699f0c9-3f68-4d11-8ac9-e6fb75db047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_84c5f5c1-2fb7-459c-bd5f-8d57186fa203" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_84c5f5c1-2fb7-459c-bd5f-8d57186fa203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_ea5e6c14-42d5-458c-b24a-4a698413d228" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityVoluntaryFilers_ea5e6c14-42d5-458c-b24a-4a698413d228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e730d961-dd03-4685-ab1a-a262f4f17495" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityCurrentReportingStatus_e730d961-dd03-4685-ab1a-a262f4f17495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_edf7f6d9-c25a-4804-8273-7b923e95a10d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityInteractiveDataCurrent_edf7f6d9-c25a-4804-8273-7b923e95a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_30bbb9a3-a311-47e1-8e42-f3be2f76f8bd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityFilerCategory_30bbb9a3-a311-47e1-8e42-f3be2f76f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ff226a84-1a0c-4c78-8baf-89e9ca419885" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntitySmallBusiness_ff226a84-1a0c-4c78-8baf-89e9ca419885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e1fce928-556d-491d-b23f-4e4352ecc67f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityEmergingGrowthCompany_e1fce928-556d-491d-b23f-4e4352ecc67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_378e89c1-4977-4fe7-a925-ecf731aa168b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_IcfrAuditorAttestationFlag_378e89c1-4977-4fe7-a925-ecf731aa168b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0f35f41b-e53c-4f48-ae9f-39d35a65fb10" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityShellCompany_0f35f41b-e53c-4f48-ae9f-39d35a65fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_8dfe6d95-c044-4f01-baa5-cec9646a57a7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityPublicFloat_8dfe6d95-c044-4f01-baa5-cec9646a57a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f4539038-5b55-4fae-9a73-1c97f1139c93" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f4539038-5b55-4fae-9a73-1c97f1139c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0260b7d5-ae11-4e05-a92b-2cc7f383ba70" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_0260b7d5-ae11-4e05-a92b-2cc7f383ba70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f2a81284-b28b-44a3-989d-18ad5771c5cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_AmendmentFlag_f2a81284-b28b-44a3-989d-18ad5771c5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_66e82fe4-1a4b-4fa2-a971-343837965729" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentFiscalYearFocus_66e82fe4-1a4b-4fa2-a971-343837965729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_01856ab9-5a53-426b-8301-16bec6b43cf7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_01856ab9-5a53-426b-8301-16bec6b43cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_84688631-13d5-4b2d-ac7f-93e9a291448b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a5ef9b89-bc6e-461e-bf7c-2828cdf8601b" xlink:to="loc_dei_EntityCentralIndexKey_84688631-13d5-4b2d-ac7f-93e9a291448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e8318992-5d71-4ed5-976b-9e405c1d7c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e8318992-5d71-4ed5-976b-9e405c1d7c5c" xlink:to="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8cefaa0-3aa8-4ed5-bf7e-7f3955e91826" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8cefaa0-3aa8-4ed5-bf7e-7f3955e91826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c4b85a7a-6319-470d-9331-a2ee93004345" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c4b85a7a-6319-470d-9331-a2ee93004345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bb63fbce-ce37-4d61-95a5-06ad4c696844" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:to="loc_us-gaap_InventoryNet_bb63fbce-ce37-4d61-95a5-06ad4c696844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6402c898-3635-4f58-88b1-f6f9a627ecd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6402c898-3635-4f58-88b1-f6f9a627ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f90faefd-53be-4caa-b5ba-0b6b3fa10edb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9a0c49ac-5e6b-4750-9316-8fe15a9f8c6d" xlink:to="loc_us-gaap_AssetsCurrent_f90faefd-53be-4caa-b5ba-0b6b3fa10edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b792c898-f482-4c17-a97b-4126b4d56dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b792c898-f482-4c17-a97b-4126b4d56dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c3c7eb15-5164-4b35-a4ce-ecdbc07eeec5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c3c7eb15-5164-4b35-a4ce-ecdbc07eeec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_38b855f2-6f1c-44f9-b935-44f6f4de4208" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_38b855f2-6f1c-44f9-b935-44f6f4de4208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_50694b72-48de-4fa3-915e-bce11c3f4a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_50694b72-48de-4fa3-915e-bce11c3f4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_7e8af098-90e2-4b51-b6a8-3ee325878c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_OtherAssets_7e8af098-90e2-4b51-b6a8-3ee325878c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b81df433-79a8-4e6e-ae72-d7faf8d91bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a71e9766-fab6-454e-a361-a84a90308cc1" xlink:to="loc_us-gaap_Assets_b81df433-79a8-4e6e-ae72-d7faf8d91bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e8318992-5d71-4ed5-976b-9e405c1d7c5c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_39c4ac12-e079-45de-ab57-55f61547d45b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_AccountsPayableCurrent_39c4ac12-e079-45de-ab57-55f61547d45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ffb1b3ba-0e15-4652-af21-5622b0c1f227" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ffb1b3ba-0e15-4652-af21-5622b0c1f227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2a6067f-6250-4fd7-b773-942d6cd98f3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f2a6067f-6250-4fd7-b773-942d6cd98f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7bbc67f-cf8b-4a1d-b0ad-e42526aeeae3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7bbc67f-cf8b-4a1d-b0ad-e42526aeeae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_07745e4c-d52d-42e2-8b11-19e6a6c1c576" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_07745e4c-d52d-42e2-8b11-19e6a6c1c576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_cde9506b-e5cc-4bdd-969d-92bf9947ba6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_cde9506b-e5cc-4bdd-969d-92bf9947ba6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1f5306ba-c6c5-481a-a929-92a3457a4d37" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bedffcde-399d-4d6f-b20c-9352efab0ceb" xlink:to="loc_us-gaap_LiabilitiesCurrent_1f5306ba-c6c5-481a-a929-92a3457a4d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_264f1a43-e04a-4e39-abc4-a41563574d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_264f1a43-e04a-4e39-abc4-a41563574d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4bc640ce-a8db-4307-ba2d-2e4f56b6446d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_4bc640ce-a8db-4307-ba2d-2e4f56b6446d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65c1a93f-83d3-44df-8ac0-339988809a95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65c1a93f-83d3-44df-8ac0-339988809a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dba0401c-a169-497a-88ed-869b429d2c07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dba0401c-a169-497a-88ed-869b429d2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9cba695f-6b95-47aa-a3aa-c19044d7cd56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_Liabilities_9cba695f-6b95-47aa-a3aa-c19044d7cd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_06db41a1-b3c2-4e4d-a0e5-ce5cb745f974" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_65b04f04-8363-4fe1-bc6a-5a448f8a4ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_CommonStockValue_65b04f04-8363-4fe1-bc6a-5a448f8a4ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b3be595b-5365-4935-84b5-6718f5f68042" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b3be595b-5365-4935-84b5-6718f5f68042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89aef74-5e24-4973-82a8-a9fb8e3d317d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d89aef74-5e24-4973-82a8-a9fb8e3d317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f0f129c3-7e1f-4402-af25-2f45c13847c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f0f129c3-7e1f-4402-af25-2f45c13847c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_aeaa9fcc-0b07-4e0b-8833-f2776ba9e119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_StockholdersEquity_aeaa9fcc-0b07-4e0b-8833-f2776ba9e119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3383b93-426b-4581-bcb8-2843fbec4628" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d040d271-50a2-470c-87a9-77c883034525" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a3383b93-426b-4581-bcb8-2843fbec4628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e2284-7723-42cd-90f9-d9dc6c741b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_abb2a527-7d8d-466a-861b-350a91acc7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e2284-7723-42cd-90f9-d9dc6c741b0f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_abb2a527-7d8d-466a-861b-350a91acc7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dc0b7fd0-a625-49a6-a341-de76d8c9e992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e2284-7723-42cd-90f9-d9dc6c741b0f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dc0b7fd0-a625-49a6-a341-de76d8c9e992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c74b567b-3458-4673-868b-3ab7e7dd1531" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e2284-7723-42cd-90f9-d9dc6c741b0f" xlink:to="loc_us-gaap_CommonStockSharesIssued_c74b567b-3458-4673-868b-3ab7e7dd1531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_279f7bf3-f8cf-4c1e-b12f-e6539c7625a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ce3e2284-7723-42cd-90f9-d9dc6c741b0f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_279f7bf3-f8cf-4c1e-b12f-e6539c7625a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73e581ea-d54d-47a4-b111-de84bc471533" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73e581ea-d54d-47a4-b111-de84bc471533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_97fdb2e3-ebb3-495d-bc6b-6bbdccc6a962" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_97fdb2e3-ebb3-495d-bc6b-6bbdccc6a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_51659909-1ad2-4558-b134-64653212bf34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_51659909-1ad2-4558-b134-64653212bf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3e0ef68b-62f1-40ed-920b-8d8977071e54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3e0ef68b-62f1-40ed-920b-8d8977071e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_db38c55e-f2ca-45af-b016-a339c3db3107" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_db38c55e-f2ca-45af-b016-a339c3db3107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_9d50dbbc-1c54-4cf1-8538-db23f318dbef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c1f8d3dd-d656-4ab6-81f8-e4e3b997af38" xlink:to="loc_us-gaap_CostsAndExpenses_9d50dbbc-1c54-4cf1-8538-db23f318dbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c959dddb-d2bc-495d-9c64-47ef813af274" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_OperatingIncomeLoss_c959dddb-d2bc-495d-9c64-47ef813af274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_0bef3118-2943-4947-ae9a-3ad85d1c48ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_0bef3118-2943-4947-ae9a-3ad85d1c48ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ab3fdf99-a3c6-4fa8-82e1-8ac630c1acae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_InterestExpense_ab3fdf99-a3c6-4fa8-82e1-8ac630c1acae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5468470d-da36-4bc3-a876-3226121bccd3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5468470d-da36-4bc3-a876-3226121bccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0b95c357-4700-495c-b8ae-2e4156ec6cc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0b95c357-4700-495c-b8ae-2e4156ec6cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ea15c9a9-9482-45a6-b3eb-9ab4a1beb11c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ea15c9a9-9482-45a6-b3eb-9ab4a1beb11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f5a1244a-bb4e-493c-890a-421fdea6b8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f5a1244a-bb4e-493c-890a-421fdea6b8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_02d237b8-ab6e-4698-96a8-bff50899e2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_NetIncomeLoss_02d237b8-ab6e-4698-96a8-bff50899e2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_02da59d7-7352-484c-acdb-54b76a967fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_02da59d7-7352-484c-acdb-54b76a967fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18678d2c-18ab-4657-b14e-735771c7e66f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_18678d2c-18ab-4657-b14e-735771c7e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a5f9d4ad-cda0-4877-98a3-b5f50f1c43fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a5f9d4ad-cda0-4877-98a3-b5f50f1c43fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_515a969c-2ef0-4b7f-b1fe-3954e02c43dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_515a969c-2ef0-4b7f-b1fe-3954e02c43dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_aef98d35-6073-4108-914a-8ac73ce0df21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_515a969c-2ef0-4b7f-b1fe-3954e02c43dd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_aef98d35-6073-4108-914a-8ac73ce0df21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_42f67a1e-e9e4-411d-b96d-ca7898e78259" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6ddf21e5-f5dd-4b37-b37d-e75120477840" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_42f67a1e-e9e4-411d-b96d-ca7898e78259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_faa330b0-3796-4d81-81d5-2541481dcab7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_faa330b0-3796-4d81-81d5-2541481dcab7" xlink:to="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a791abe1-1e15-4dbf-8186-a15d12b41942" xlink:to="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_195b5568-8f78-46d2-a542-ba16a37a16ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_CommonStockMember_195b5568-8f78-46d2-a542-ba16a37a16ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d9ba057-39f8-41ad-a4c2-5503afbf31c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d9ba057-39f8-41ad-a4c2-5503afbf31c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9ddce04d-6b9b-42a3-ac9d-bc3c93a9859c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_RetainedEarningsMember_9ddce04d-6b9b-42a3-ac9d-bc3c93a9859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3e5037c-f644-4d16-a8e9-232c37f2e961" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0d65c8b9-b4bc-409f-8862-0d3ec73beac9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a3e5037c-f644-4d16-a8e9-232c37f2e961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22ab2357-bc6f-41e6-a1d7-63d8cbd310e4" xlink:to="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2169ecb5-a9d6-4d2b-bf6a-8743e4bb81c5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76b46482-aacd-4d99-9673-d827ec7aaf5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockholdersEquity_76b46482-aacd-4d99-9673-d827ec7aaf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_70588478-190e-436c-b6ed-5a30c1646416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_SharesOutstanding_70588478-190e-436c-b6ed-5a30c1646416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1391041-e272-4479-ac64-867d48ce4409" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:to="loc_us-gaap_NetIncomeLoss_f1391041-e272-4479-ac64-867d48ce4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2b41ca9-cac1-4471-8949-3eb5210cde09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_d6805a16-4f26-47bc-bf06-66a6da4ee466" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e2b41ca9-cac1-4471-8949-3eb5210cde09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f372cb3f-b1ee-4085-bd3a-3bd0c1c19661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f372cb3f-b1ee-4085-bd3a-3bd0c1c19661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18b20520-7cb9-44d5-9825-2f9fa0b54a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18b20520-7cb9-44d5-9825-2f9fa0b54a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_62270631-f45c-460c-95e3-3bcf6546f84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_62270631-f45c-460c-95e3-3bcf6546f84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e2d4efc-fba9-48a0-a1d5-369a4976cf86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e2d4efc-fba9-48a0-a1d5-369a4976cf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bde22b69-7c1a-412e-92e0-c3bd94c2278a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_bde22b69-7c1a-412e-92e0-c3bd94c2278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a2fa9d2d-3b6b-4cec-b611-a03931b36fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_a2fa9d2d-3b6b-4cec-b611-a03931b36fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_529c31e6-b914-4388-86a6-45acccc7a5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_529c31e6-b914-4388-86a6-45acccc7a5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99296265-1b05-461a-aac0-6ea7524a40cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_99296265-1b05-461a-aac0-6ea7524a40cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df351d86-4f16-4c83-b749-d3d15d633928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_StockholdersEquity_df351d86-4f16-4c83-b749-d3d15d633928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5eea3a34-5139-4558-ad7a-12b64af7179b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c3bcf816-f5df-47a7-b6ae-6f297b8deb85" xlink:to="loc_us-gaap_SharesOutstanding_5eea3a34-5139-4558-ad7a-12b64af7179b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28f185e0-ceb3-485f-9cf2-bb2c3fa973da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28f185e0-ceb3-485f-9cf2-bb2c3fa973da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b03ff9ad-7742-464d-a91c-fb77eaf93414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28f185e0-ceb3-485f-9cf2-bb2c3fa973da" xlink:to="loc_us-gaap_NetIncomeLoss_b03ff9ad-7742-464d-a91c-fb77eaf93414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28f185e0-ceb3-485f-9cf2-bb2c3fa973da" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9ec6cc2f-153e-4dbe-b293-efc7b55da326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_Depreciation_9ec6cc2f-153e-4dbe-b293-efc7b55da326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2e774b43-c8b9-4280-83b5-fdf85cae8784" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2e774b43-c8b9-4280-83b5-fdf85cae8784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_efd4bacd-378c-4c76-ba93-72c9d70c9d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_ShareBasedCompensation_efd4bacd-378c-4c76-ba93-72c9d70c9d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6a43e7b5-d126-4222-a14e-f053414ec780" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6a43e7b5-d126-4222-a14e-f053414ec780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_21707a41-360b-4304-a39c-78e75fb5f4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_21707a41-360b-4304-a39c-78e75fb5f4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_1a8679eb-1257-4439-901d-46a51e79e900" xlink:href="insm-20201231.xsd#insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense_1a8679eb-1257-4439-901d-46a51e79e900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_360e4354-f6cf-4019-aa9b-c156c4e13849" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_360e4354-f6cf-4019-aa9b-c156c4e13849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NoncashOperatingLeaseExpense_56b008b1-c128-42a4-8bf1-b8eb426e33a7" xlink:href="insm-20201231.xsd#insm_NoncashOperatingLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_insm_NoncashOperatingLeaseExpense_56b008b1-c128-42a4-8bf1-b8eb426e33a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4a93a93e-efc0-4b78-9ba6-0f0152b932bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37389237-1d4e-4354-b184-b858ff3ca98b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_37389237-1d4e-4354-b184-b858ff3ca98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f5bfeb51-9b4d-45f2-9c61-e3a3345d0374" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f5bfeb51-9b4d-45f2-9c61-e3a3345d0374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af42001e-5f05-43ad-bf66-b7b60c7e8524" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_af42001e-5f05-43ad-bf66-b7b60c7e8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d5777a4e-d572-4f8c-a9e4-177bb0789e41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d5777a4e-d572-4f8c-a9e4-177bb0789e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d645a3a6-5e1b-4be4-8c5e-fe7438cc0246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d645a3a6-5e1b-4be4-8c5e-fe7438cc0246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_5bb15783-4737-4803-af7b-82e6b55f0183" xlink:href="insm-20201231.xsd#insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities_5bb15783-4737-4803-af7b-82e6b55f0183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c6088685-a2dc-463b-a269-05c41a73e248" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c6088685-a2dc-463b-a269-05c41a73e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13e9e926-57ed-4180-8966-a340d933f286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_adb80073-b4b6-46e0-928f-25bc1d49846a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13e9e926-57ed-4180-8966-a340d933f286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca852e17-7b6a-4447-8131-55111f83fffa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca852e17-7b6a-4447-8131-55111f83fffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1fa6c9d-6145-4bb7-86ff-f08db3fbeef3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca852e17-7b6a-4447-8131-55111f83fffa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f1fa6c9d-6145-4bb7-86ff-f08db3fbeef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_97e919bc-e13b-48ee-aa45-77af6e12b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca852e17-7b6a-4447-8131-55111f83fffa" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_97e919bc-e13b-48ee-aa45-77af6e12b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bce4c0f-71df-44a8-a326-cad9962cf15e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca852e17-7b6a-4447-8131-55111f83fffa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bce4c0f-71df-44a8-a326-cad9962cf15e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4ed007c4-b42f-4eff-8cbc-31d3bb4380f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4ed007c4-b42f-4eff-8cbc-31d3bb4380f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_e0179ee1-9c03-48d2-b4e2-72c3cd928364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_RepaymentsOfDebt_e0179ee1-9c03-48d2-b4e2-72c3cd928364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1db800c-0ec3-4e03-811d-0aea8f796f01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1db800c-0ec3-4e03-811d-0aea8f796f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4dc1b7e3-52e3-46c7-be8e-11ba28d43b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4dc1b7e3-52e3-46c7-be8e-11ba28d43b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_03136a56-98ba-43d2-b33e-10a673a152c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_03136a56-98ba-43d2-b33e-10a673a152c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f0530445-e20a-4088-92a4-c9a697fc9fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f0530445-e20a-4088-92a4-c9a697fc9fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_5aaeb3a0-ea65-4c65-9e60-8b2a4d8b0152" xlink:href="insm-20201231.xsd#insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_5aaeb3a0-ea65-4c65-9e60-8b2a4d8b0152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13596471-994d-48f9-82a0-3cd990812536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cde74bc4-c352-4755-9968-a79b5c016cc2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_13596471-994d-48f9-82a0-3cd990812536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_497b9eef-4952-4b83-b80d-18cd5b7e91ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_497b9eef-4952-4b83-b80d-18cd5b7e91ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5258e219-5c5b-4150-b44a-0b060f8b2e82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5258e219-5c5b-4150-b44a-0b060f8b2e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3cdd21ce-5536-4f38-98cf-112ae4b70792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3cdd21ce-5536-4f38-98cf-112ae4b70792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd3d0a2-8518-416b-87b3-d8f0779738f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1bd3d0a2-8518-416b-87b3-d8f0779738f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7b25209b-70de-4233-ba12-199f73ff7c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ee2fccaf-9ee2-429f-9e9f-fad109a5111f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7b25209b-70de-4233-ba12-199f73ff7c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8fb711ed-28f6-48bb-b175-3661e84e1f00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7b25209b-70de-4233-ba12-199f73ff7c86" xlink:to="loc_us-gaap_InterestPaidNet_8fb711ed-28f6-48bb-b175-3661e84e1f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_e61ed73d-dd94-4fdb-8357-73825d390729" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7b25209b-70de-4233-ba12-199f73ff7c86" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_e61ed73d-dd94-4fdb-8357-73825d390729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="insm-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_75623bcd-2980-4d66-b2e3-9c96d662a0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_75623bcd-2980-4d66-b2e3-9c96d662a0e3" xlink:to="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:to="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_52a1e559-1df7-4e14-b7a7-01d0c19d20d3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_77fcd605-aa04-4f41-9f84-8cb5da9aff9f" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_86fc4047-e5f5-44a2-859a-03e34e53eb03" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_77fcd605-aa04-4f41-9f84-8cb5da9aff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_011c6f53-882f-4e09-b1f0-aabd49ac5be9" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b64dc268-c91e-4056-a779-7c72394f4768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66b52785-07e9-437c-8388-4555222a1291" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b64dc268-c91e-4056-a779-7c72394f4768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_aa94e71a-4597-465e-8285-3f3104a810d3" xlink:to="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec07a7d2-3b9d-4aed-a16a-b725f161be9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d2383264-35ab-4ad0-afea-569bff933a36" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ec07a7d2-3b9d-4aed-a16a-b725f161be9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a5f1d91-89ce-42db-b21c-6c74d8a63ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9ad63efe-a072-4d82-b570-9b16297959a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5a5f1d91-89ce-42db-b21c-6c74d8a63ed4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9ad63efe-a072-4d82-b570-9b16297959a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4611dcc1-12f7-4730-be9b-ce68a5275a16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54fd41d3-e194-4b81-b90b-aa5245d3e5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4611dcc1-12f7-4730-be9b-ce68a5275a16" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54fd41d3-e194-4b81-b90b-aa5245d3e5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ec53d923-9b22-4179-a6d1-ee7c6029c854" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4611dcc1-12f7-4730-be9b-ce68a5275a16" xlink:to="loc_us-gaap_NetIncomeLoss_ec53d923-9b22-4179-a6d1-ee7c6029c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b5bf7ade-cd1d-49d8-bf88-ae7694e7d68e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4599e8a8-a3ee-46c5-a88e-6f1e982b12a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b5bf7ade-cd1d-49d8-bf88-ae7694e7d68e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4599e8a8-a3ee-46c5-a88e-6f1e982b12a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f8274d40-0823-4db6-9254-553bc79b9ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f8274d40-0823-4db6-9254-553bc79b9ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_9918a4df-363d-4d0e-a97e-9b9494903d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_UseOfEstimates_9918a4df-363d-4d0e-a97e-9b9494903d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InvestmentIncomeExpensePolicyTextBlock_4ee60383-9c67-402d-ab3d-49978db30fc9" xlink:href="insm-20201231.xsd#insm_InvestmentIncomeExpensePolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_insm_InvestmentIncomeExpensePolicyTextBlock_4ee60383-9c67-402d-ab3d-49978db30fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6232bbee-3c77-40a9-b66c-b2b08a2ddec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_6232bbee-3c77-40a9-b66c-b2b08a2ddec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7e7c041d-c62a-48b8-ba00-fabd626b0571" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_7e7c041d-c62a-48b8-ba00-fabd626b0571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_57df528a-fc66-4bc2-b940-5d719ea666ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_57df528a-fc66-4bc2-b940-5d719ea666ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_22de39aa-ff1c-411f-a0d6-ba0eced4c6d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_22de39aa-ff1c-411f-a0d6-ba0eced4c6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_8317b848-d50b-4d0c-8a0c-5c78b50f992d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_DebtPolicyTextBlock_8317b848-d50b-4d0c-8a0c-5c78b50f992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3841d36e-7561-4fc7-a7ac-b59fc1af27e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3841d36e-7561-4fc7-a7ac-b59fc1af27e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_48ba9635-3f60-44e1-a3a9-45e5b7e22e88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_48ba9635-3f60-44e1-a3a9-45e5b7e22e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_667b2daf-a0fb-4886-a93f-23cee2ae89ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_667b2daf-a0fb-4886-a93f-23cee2ae89ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c44f72ac-f87e-4996-817f-c6b70dfc1dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c44f72ac-f87e-4996-817f-c6b70dfc1dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_c8125a96-a194-4675-a4d6-83379750a666" xlink:href="insm-20201231.xsd#insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock_c8125a96-a194-4675-a4d6-83379750a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_24ba72c1-cae5-427c-b185-4feff8ea52af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_24ba72c1-cae5-427c-b185-4feff8ea52af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f017a8e4-0eb8-4cd1-ae3e-e0d66b73079a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f017a8e4-0eb8-4cd1-ae3e-e0d66b73079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2fab54a2-ceaa-4bde-a5a3-e0d8c7d0d41e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2fab54a2-ceaa-4bde-a5a3-e0d8c7d0d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_404c6a82-4c6a-4db3-b622-5ec8df5b344a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_404c6a82-4c6a-4db3-b622-5ec8df5b344a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_882cbdc1-7ef0-4cf1-8e5c-53c2331c41bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_882cbdc1-7ef0-4cf1-8e5c-53c2331c41bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d6373392-26b1-4c3b-b4b0-5b337928e7db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_d6373392-26b1-4c3b-b4b0-5b337928e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_07a53ac0-8697-4db6-9f6c-78e39f11f706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a0960f73-43d1-4b67-8ded-2b4fcc1a023f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_07a53ac0-8697-4db6-9f6c-78e39f11f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9aff015a-b4f0-4dec-a5fd-0967c0e50076" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9aff015a-b4f0-4dec-a5fd-0967c0e50076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_186e3f09-6180-4d61-af7d-fb5ce12659f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_186e3f09-6180-4d61-af7d-fb5ce12659f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_61ee23af-da73-4b84-8af3-859af6bb1779" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:to="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_61ee23af-da73-4b84-8af3-859af6bb1779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_445e1f35-796e-4b04-b9c1-f61f1ec4e748" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_445e1f35-796e-4b04-b9c1-f61f1ec4e748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a63c85ae-a533-4f24-a40b-f565d96dcc0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_db11aa7b-7fbd-4642-82be-4762f2632780" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a63c85ae-a533-4f24-a40b-f565d96dcc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12c8317a-5689-4452-aea3-324230177ede" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12c8317a-5689-4452-aea3-324230177ede" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f491538e-2e23-4dda-8c07-3463e6355594" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_fd6f896c-1e1e-4336-be7c-557372a83e17" xlink:href="insm-20201231.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_fd6f896c-1e1e-4336-be7c-557372a83e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EquipmentFurnitureAndFixturesMember_09ccc04a-82c8-41b1-ba02-ce3bb42cce3e" xlink:href="insm-20201231.xsd#insm_EquipmentFurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2d11b9fd-1f36-41a2-89cb-2dc7523a262f" xlink:to="loc_insm_EquipmentFurnitureAndFixturesMember_09ccc04a-82c8-41b1-ba02-ce3bb42cce3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:to="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3d73465e-30b6-4796-88cf-aa99f73a2b81" xlink:to="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_190390c5-3f6c-41e8-9827-fd8260bfffda" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:to="loc_srt_MinimumMember_190390c5-3f6c-41e8-9827-fd8260bfffda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a94a526e-fb47-4806-9831-8979db9201db" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0982f36e-e22d-4d49-8f0a-a2cd1e5554ec" xlink:to="loc_srt_MaximumMember_a94a526e-fb47-4806-9831-8979db9201db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7e793c17-8290-4303-acfd-919e4b5fd9a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6356c473-47bc-4099-9955-14462e75d81d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b25258f-2b37-47fa-a5c1-dc5806e8b435" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6356c473-47bc-4099-9955-14462e75d81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bfccdc42-944e-4464-8b54-f4f9e0e9d92b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bfccdc42-944e-4464-8b54-f4f9e0e9d92b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_23536386-864c-4a50-92c1-907445410171" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1d2fdb87-e244-4f91-969c-f8b2a8975aa8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4fabbc92-a63e-4ca0-8c2b-0f0f02689632" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_4fabbc92-a63e-4ca0-8c2b-0f0f02689632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_31c754c9-e2d6-46bc-aa3e-567c9f6917cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_cb6e6b57-b018-4497-ac09-11c7f80dc2b5" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_31c754c9-e2d6-46bc-aa3e-567c9f6917cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6d074c40-e071-498c-8c95-b2ca34880de6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a7408d27-f426-48c1-adf0-1df137350e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a5570d33-a78c-4637-b2f4-16cbee456cef" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a7408d27-f426-48c1-adf0-1df137350e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3f0c31b1-c995-46ef-950b-e72c2baa7b9e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d4d77b69-48d2-4c68-81fb-7dbba5199378" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d4d77b69-48d2-4c68-81fb-7dbba5199378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_34b4dd2f-0ad6-4f5a-9def-06b43d204518" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_34b4dd2f-0ad6-4f5a-9def-06b43d204518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7fbe0e63-10d3-4a84-9019-d9e8c668889c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f3569db9-813f-446a-8f78-93183bcb4916" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7fbe0e63-10d3-4a84-9019-d9e8c668889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6dd01ed3-fb3a-4b81-bde0-9a4718587d60" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_bb564527-e262-4efa-abd9-bae467b9d199" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f5c699a5-e30c-4265-948b-eae9b42d348b" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_bb564527-e262-4efa-abd9-bae467b9d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_de5465cc-c66b-440f-8e9b-a2e1aec504ab" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_d64f5a15-b773-4c5f-83ae-bf2b030a0f24" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ac605544-2ac9-424d-8888-058aa89a3336" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_d64f5a15-b773-4c5f-83ae-bf2b030a0f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a286a5ac-3a70-4b78-a507-e858f5524946" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a79b2d3a-e1dc-4edb-8827-671eba3346bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a79b2d3a-e1dc-4edb-8827-671eba3346bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FairValueLevel1Level2Level3TransfersAmount_aca76a8c-faf3-442a-8f91-c3dac2609bda" xlink:href="insm-20201231.xsd#insm_FairValueLevel1Level2Level3TransfersAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_insm_FairValueLevel1Level2Level3TransfersAmount_aca76a8c-faf3-442a-8f91-c3dac2609bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_8e803e96-9bf6-4169-8af2-1bd406baef58" xlink:href="insm-20201231.xsd#insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities_8e803e96-9bf6-4169-8af2-1bd406baef58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4170d414-166a-4878-8960-c6f0b954d5c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4170d414-166a-4878-8960-c6f0b954d5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_053608bb-0151-4bcf-8d6e-3debafc6af3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_053608bb-0151-4bcf-8d6e-3debafc6af3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5860dfa7-f8b9-4096-921a-3b3356c78422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2c203f77-5206-472d-b334-92ab4871b928" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5860dfa7-f8b9-4096-921a-3b3356c78422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b78b54f5-71d4-435a-9be2-c09eb11fac4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b78b54f5-71d4-435a-9be2-c09eb11fac4e" xlink:to="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_76634457-85da-4e03-bb8b-60a527ac9b9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerAMember_df5f721f-4a7d-4546-90ae-b9a16febdba1" xlink:href="insm-20201231.xsd#insm_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerAMember_df5f721f-4a7d-4546-90ae-b9a16febdba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerBMember_e2114744-540a-4e9e-a7af-eb7f59b6cf4f" xlink:href="insm-20201231.xsd#insm_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerBMember_e2114744-540a-4e9e-a7af-eb7f59b6cf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerCMember_c3ea633a-c5a3-473e-bffa-0f527ca78d60" xlink:href="insm-20201231.xsd#insm_CustomerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b295a95-d928-4d33-bbf7-2d850548c18d" xlink:to="loc_insm_CustomerCMember_c3ea633a-c5a3-473e-bffa-0f527ca78d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56c8aa31-4316-436b-93c5-6ca4d4237083" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_a775f99e-94f4-44b6-af12-3a0e70645569" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3959d4ea-93de-475f-9b48-6bd554d240d2" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_a775f99e-94f4-44b6-af12-3a0e70645569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_8e0256c3-66a9-4ace-927c-25f45410b924" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_6a6279b8-4de4-463c-9c6a-1fbada044faf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_29b9a1a6-8e16-4744-ad65-702b1268a2a3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_6a6279b8-4de4-463c-9c6a-1fbada044faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a0e6e6e9-d361-41b7-a7ce-6af589f4cbc5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1e2bdd95-0b05-4398-81b4-2abe40c65800" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_21b32ba9-7771-4845-be74-019c9bbed5b4" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1e2bdd95-0b05-4398-81b4-2abe40c65800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c8feb9a0-fbd7-40f6-ac70-8ec2ec3b6801" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8feb9a0-fbd7-40f6-ac70-8ec2ec3b6801" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:to="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_80c49ad6-59b6-416d-90ca-b78e808863bb" xlink:to="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CustomerFeesDiscountsandOtherMember_603b09dc-c12b-4cf3-a6ce-2eff64088b2f" xlink:href="insm-20201231.xsd#insm_CustomerFeesDiscountsandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:to="loc_insm_CustomerFeesDiscountsandOtherMember_603b09dc-c12b-4cf3-a6ce-2eff64088b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RebatesChargebacksandCoPayAssistanceMember_77b9d447-6748-4bfc-aa15-f03493701ab5" xlink:href="insm-20201231.xsd#insm_RebatesChargebacksandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d391c7a5-5393-4ef2-9549-5d318d3adadf" xlink:to="loc_insm_RebatesChargebacksandCoPayAssistanceMember_77b9d447-6748-4bfc-aa15-f03493701ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:href="insm-20201231.xsd#insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossTable_1634a312-458a-43e9-8cc8-968d28ce637b" xlink:to="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems_ff153030-100f-437d-b32b-6e1235ff8fdd" xlink:to="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_1e2ee06a-4e72-431b-9744-ef75d76495e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_1e2ee06a-4e72-431b-9744-ef75d76495e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_63e6edbd-e3c2-41df-a1c5-9a124ccc119f" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales_63e6edbd-e3c2-41df-a1c5-9a124ccc119f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_fd2c6b51-d1d3-4131-a0cc-784899bb1263" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales_fd2c6b51-d1d3-4131-a0cc-784899bb1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_07093811-537d-46e6-befc-a72b5f505bec" xlink:href="insm-20201231.xsd#insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits_07093811-537d-46e6-befc-a72b5f505bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_e7cea0c1-f827-4d7e-98e2-f4e474c6d11b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward_3c65b13e-ad54-47c7-982f-2b4cc8fc0820" xlink:to="loc_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_e7cea0c1-f827-4d7e-98e2-f4e474c6d11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_03396d00-a017-472b-9fe7-cf8e6a9bea42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03396d00-a017-472b-9fe7-cf8e6a9bea42" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:to="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f561baf3-7f05-4e1f-bf14-65abe4d13a9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5fed6bc5-7a4d-4856-8a32-e91086548811" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5fed6bc5-7a4d-4856-8a32-e91086548811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_da72ffd9-9236-43b4-812c-a9ebb233bc6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_da72ffd9-9236-43b4-812c-a9ebb233bc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_5b3e89ab-1050-49d4-b425-e1d3aa142c71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b221152-11d6-462f-8930-c5f55c1477ab" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_5b3e89ab-1050-49d4-b425-e1d3aa142c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:href="insm-20201231.xsd#insm_ScheduleofEarningsPerShareBasicandDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedTable_55905ecb-ffac-4d46-9367-bc6ae5f5c027" xlink:to="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_567631c8-c215-4823-b945-2ca8b1270041" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_633a76a7-6985-4447-aa16-a7817b615877" xlink:to="loc_us-gaap_NetIncomeLoss_567631c8-c215-4823-b945-2ca8b1270041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e0527f-6e87-43ad-a613-80fdfb3eb381" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d4e0527f-6e87-43ad-a613-80fdfb3eb381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1cbfb5f8-25ad-4db5-a165-9722402ed327" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_b0bf9aec-8d34-41e5-83ae-77f57816b599" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1cbfb5f8-25ad-4db5-a165-9722402ed327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0755a812-1bad-4283-920b-8af7232711f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_622a0eed-621d-4376-9d26-f8070105a222" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0755a812-1bad-4283-920b-8af7232711f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_ScheduleofEarningsPerShareBasicandDilutedLineItems_5a67c520-55b9-4073-9568-69a8bc80a898" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_46e5deca-cb94-4dc4-9763-3f7861c8962e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_969dce15-d353-4bf3-90e5-12f9f919d1f9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_46e5deca-cb94-4dc4-9763-3f7861c8962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7fadec37-225d-42a8-97d4-bb00f525f51f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7fadec37-225d-42a8-97d4-bb00f525f51f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_01ff5abd-8163-4875-8013-9ca562b10ac2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_3de7f4bb-6988-4492-b228-c43ff45c363e" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_3de7f4bb-6988-4492-b228-c43ff45c363e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_4457ffef-ceae-403d-afae-c67e470b1c20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_us-gaap_RestrictedStockMember_4457ffef-ceae-403d-afae-c67e470b1c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_777b167b-7547-4da9-be50-b7f5e557296b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f67912ff-dee2-40e2-98ae-52d8b51c61b3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_777b167b-7547-4da9-be50-b7f5e557296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_57fcc380-d3a0-4113-89dd-59b0b20bdaac" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f018afef-4e1a-410f-a0f6-a008c201e48c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f86c2698-0b92-4c02-9b06-6274042ed3f9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f018afef-4e1a-410f-a0f6-a008c201e48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91cdf50a-c056-431a-bd6a-a4f998dbcd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e2c669c3-3601-4314-84a6-ac6ad1edec3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91cdf50a-c056-431a-bd6a-a4f998dbcd9b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e2c669c3-3601-4314-84a6-ac6ad1edec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7216df79-54c3-4d53-8640-fb8c9bf39749" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91cdf50a-c056-431a-bd6a-a4f998dbcd9b" xlink:to="loc_us-gaap_NumberOfReportableSegments_7216df79-54c3-4d53-8640-fb8c9bf39749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Inventory" xlink:type="simple" xlink:href="insm-20201231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4687b278-6a6d-4cce-b529-6c39bf454046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_a77e34e2-aa0b-42ba-84a6-ce5ab5487977" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4687b278-6a6d-4cce-b529-6c39bf454046" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_a77e34e2-aa0b-42ba-84a6-ce5ab5487977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryTables" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d8f7ef41-90c5-4554-8cf2-46accf3d0dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_40a587eb-63f1-4732-81c4-f04571ec921d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d8f7ef41-90c5-4554-8cf2-46accf3d0dc5" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_40a587eb-63f1-4732-81c4-f04571ec921d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#InventoryScheduleofInventoryCurrentDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_945a1e37-0cc1-49ca-a74f-be5efd95ca32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a4b383bb-9e36-4fdf-bfa2-433762de15a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_945a1e37-0cc1-49ca-a74f-be5efd95ca32" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a4b383bb-9e36-4fdf-bfa2-433762de15a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f3b3268a-7678-4710-aca6-be51e7a5b047" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_945a1e37-0cc1-49ca-a74f-be5efd95ca32" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f3b3268a-7678-4710-aca6-be51e7a5b047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d8eb05bd-24b3-4b14-a7b7-96b6fe84cd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_945a1e37-0cc1-49ca-a74f-be5efd95ca32" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_d8eb05bd-24b3-4b14-a7b7-96b6fe84cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c06e8b2a-3a15-47aa-9de5-14940a6f7e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_945a1e37-0cc1-49ca-a74f-be5efd95ca32" xlink:to="loc_us-gaap_InventoryNet_c06e8b2a-3a15-47aa-9de5-14940a6f7e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2526800d-a979-40b4-b23c-25a44d045447" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b175e170-1bf4-40a1-b0ff-cc8e306b7df7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2526800d-a979-40b4-b23c-25a44d045447" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b175e170-1bf4-40a1-b0ff-cc8e306b7df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b63078ae-0e0e-4c21-8335-dc1e9144505c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5349a711-e8ee-421c-bb00-49e74f31e207" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b63078ae-0e0e-4c21-8335-dc1e9144505c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5349a711-e8ee-421c-bb00-49e74f31e207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba79230c-c6c0-412c-b5d4-651984ea5ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_ba79230c-c6c0-412c-b5d4-651984ea5ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77272851-72a4-4d24-b6c6-5ce66da46b97" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77272851-72a4-4d24-b6c6-5ce66da46b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ab7b96c0-30c5-4260-a335-ad58bcba080b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ab7b96c0-30c5-4260-a335-ad58bcba080b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a8c8364c-5411-4dad-baac-23493ccf51fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a8c8364c-5411-4dad-baac-23493ccf51fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d386625b-37ea-418a-924f-226dbe956913" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d386625b-37ea-418a-924f-226dbe956913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f5fcce57-21f2-4eb2-93af-a067db70349d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f5fcce57-21f2-4eb2-93af-a067db70349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bb3b40fd-6d99-4b39-81a7-707dfad8e507" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bb3b40fd-6d99-4b39-81a7-707dfad8e507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_156c756a-ec19-433d-9f42-bb9ac489d980" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_156c756a-ec19-433d-9f42-bb9ac489d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_91640da4-8c60-4ed9-8f39-8f8e354fc653" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9521984-2e0d-4669-ab8b-b25c7570234e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_071d6e96-4d7a-4dc4-8db1-85b2508663ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_071d6e96-4d7a-4dc4-8db1-85b2508663ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_c1038122-b821-49c8-b3b6-932d1db39bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_25348495-30dc-45df-bac7-5f11affe23c0" xlink:to="loc_us-gaap_LicensingAgreementsMember_c1038122-b821-49c8-b3b6-932d1db39bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d5619166-160c-446e-969c-12c8431425cc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_32af53e5-5526-45d6-9da6-02454cc7e33e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b28cdca1-8b36-4cfe-98ac-f48526d201e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b28cdca1-8b36-4cfe-98ac-f48526d201e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_14cc71ce-1ce5-45be-a7e9-377fa31be602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_14cc71ce-1ce5-45be-a7e9-377fa31be602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_74c9a645-7d15-40d3-b567-bd7f8475be45" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_74c9a645-7d15-40d3-b567-bd7f8475be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14bb5c78-cd49-4ce2-ab55-2f9758cc73d4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_940f5170-fa72-40e5-a7af-1243c7476700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_14bb5c78-cd49-4ce2-ab55-2f9758cc73d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnet" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnet"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3b101b10-4fab-43dd-a284-9cb27a6d3bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bc680d46-a0eb-49de-a169-08943252b517" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3b101b10-4fab-43dd-a284-9cb27a6d3bd5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_bc680d46-a0eb-49de-a169-08943252b517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5881e133-a0db-4583-bb63-3c6296624558" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df755225-bccf-4c83-98b2-6c593b78ec33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5881e133-a0db-4583-bb63-3c6296624558" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_df755225-bccf-4c83-98b2-6c593b78ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#FixedAssetsnetDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/FixedAssetsnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f1a011c3-e640-4580-8593-bb9725060d67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f1a011c3-e640-4580-8593-bb9725060d67" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_20956ee3-7513-40a8-9c1c-6607894c8e40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_36a2c2f7-17e0-4bc5-bc2c-bfa1eda25efc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_EquipmentMember_36a2c2f7-17e0-4bc5-bc2c-bfa1eda25efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f60953ee-f5b1-420f-8bb4-e8ecf1d82437" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f60953ee-f5b1-420f-8bb4-e8ecf1d82437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ComputerHardwareAndSoftwareMember_51823428-9aa7-497f-a795-1310631e189f" xlink:href="insm-20201231.xsd#insm_ComputerHardwareAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_insm_ComputerHardwareAndSoftwareMember_51823428-9aa7-497f-a795-1310631e189f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_38715604-17d0-4669-ac16-d1828a4474da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_OfficeEquipmentMember_38715604-17d0-4669-ac16-d1828a4474da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ManufacturingEquipmentMember_e1d05d89-5acc-440b-bd0b-007fe6998bbd" xlink:href="insm-20201231.xsd#insm_ManufacturingEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_insm_ManufacturingEquipmentMember_e1d05d89-5acc-440b-bd0b-007fe6998bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c3a07009-db33-466e-91d2-857ca4c2b56a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c3a07009-db33-466e-91d2-857ca4c2b56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_8eaa4537-caae-408e-ad47-ffd4d0884342" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f83e5fc-f4f0-4bc7-a406-186b45c1c84e" xlink:to="loc_us-gaap_ConstructionInProgressMember_8eaa4537-caae-408e-ad47-ffd4d0884342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:to="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6790e144-8316-4e37-aad9-c535a52ae734" xlink:to="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb37028c-73c6-47db-99d7-f0aebe640e7a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:to="loc_srt_MinimumMember_bb37028c-73c6-47db-99d7-f0aebe640e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7573e54b-4ac3-447c-831c-51766481f09b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c4ab67b3-7372-4f48-9a5b-266eb0df3306" xlink:to="loc_srt_MaximumMember_7573e54b-4ac3-447c-831c-51766481f09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2815986d-5017-451c-a3d6-daf6d10cfee6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2b589f8d-ab25-4c54-8459-336804c9de28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2b589f8d-ab25-4c54-8459-336804c9de28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_020a31f7-dec9-4a4d-8bda-b219ca4e962e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_020a31f7-dec9-4a4d-8bda-b219ca4e962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de4eac50-d659-452e-aa41-0e35496c8f43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_de4eac50-d659-452e-aa41-0e35496c8f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_60f2589a-dc99-4124-bdd5-984445cfed1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_60f2589a-dc99-4124-bdd5-984445cfed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1b0c6faf-17a2-4160-98bd-00d7426310a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1fa24370-87b2-4161-abe9-1aaaecad6697" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1b0c6faf-17a2-4160-98bd-00d7426310a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpenses" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_25d7a229-316f-4522-82ca-df6d1cd33047" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8529b17a-af87-4e40-b956-533813042acf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_25d7a229-316f-4522-82ca-df6d1cd33047" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8529b17a-af87-4e40-b956-533813042acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5579fdf0-ce87-4c23-81bc-a5dd0acd031d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e354d699-e946-4e43-887b-287809de8197" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5579fdf0-ce87-4c23-81bc-a5dd0acd031d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e354d699-e946-4e43-887b-287809de8197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedClinicalTrialExpenses_c2dc876d-c068-448a-810b-a1c3e44afda1" xlink:href="insm-20201231.xsd#insm_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_insm_AccruedClinicalTrialExpenses_c2dc876d-c068-448a-810b-a1c3e44afda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a1e9af28-5ca6-475d-9520-1cf322a7be13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a1e9af28-5ca6-475d-9520-1cf322a7be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedTechnicalOperationExpenses_4203753c-b73d-4638-afcd-f95682462f33" xlink:href="insm-20201231.xsd#insm_AccruedTechnicalOperationExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_insm_AccruedTechnicalOperationExpenses_4203753c-b73d-4638-afcd-f95682462f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_c9529d5d-e9f7-4b32-9455-950d263cabd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_c9529d5d-e9f7-4b32-9455-950d263cabd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_407c5d38-1c8f-4aa0-a062-852ea54c2f58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_us-gaap_InterestPayableCurrent_407c5d38-1c8f-4aa0-a062-852ea54c2f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedSalesAllowancesandRelatedCosts_33829c20-1685-4035-a699-f486aaf3295e" xlink:href="insm-20201231.xsd#insm_AccruedSalesAllowancesandRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_insm_AccruedSalesAllowancesandRelatedCosts_33829c20-1685-4035-a699-f486aaf3295e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AccruedConstructionLiabilitiesCurrent_508ebb9b-5fd7-4e23-9c8e-10632680382b" xlink:href="insm-20201231.xsd#insm_AccruedConstructionLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_insm_AccruedConstructionLiabilitiesCurrent_508ebb9b-5fd7-4e23-9c8e-10632680382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4f44460c-7dcd-4ba6-9433-35ac6df59822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4f44460c-7dcd-4ba6-9433-35ac6df59822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e63e7430-0c92-49df-be29-55e25c1ac68d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4545220c-98e2-4bd4-90eb-3ec6dc14eb4c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e63e7430-0c92-49df-be29-55e25c1ac68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/Leases" xlink:type="simple" xlink:href="insm-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b7759ad5-bd32-493b-907e-87d285be4203" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_545f9cd3-f13a-4493-b560-89f2487e2038" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7759ad5-bd32-493b-907e-87d285be4203" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_545f9cd3-f13a-4493-b560-89f2487e2038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_38f38f69-97c3-4473-bba4-19efaf66afb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b7759ad5-bd32-493b-907e-87d285be4203" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_38f38f69-97c3-4473-bba4-19efaf66afb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b32c00c0-4f78-4011-9347-db67cee631f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6c2bfaf8-f949-4ceb-861f-1f6a77e217e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b32c00c0-4f78-4011-9347-db67cee631f4" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6c2bfaf8-f949-4ceb-861f-1f6a77e217e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_16c91bd9-b650-4aff-b35f-a647a383b43d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b32c00c0-4f78-4011-9347-db67cee631f4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_16c91bd9-b650-4aff-b35f-a647a383b43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1a82a19d-b113-499d-8f7a-92cda5535046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b32c00c0-4f78-4011-9347-db67cee631f4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1a82a19d-b113-499d-8f7a-92cda5535046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0a637e88-2479-4428-886f-1f4cfa7208a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0a637e88-2479-4428-886f-1f4cfa7208a3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:to="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_42943675-c00f-4c36-a427-2d15c40492c1" xlink:to="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44d74e98-bfaa-4de7-b915-fd4baf59f23d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:to="loc_srt_MinimumMember_44d74e98-bfaa-4de7-b915-fd4baf59f23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c8e815f-97de-473c-aa8e-571530bb557c" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35383b09-9837-4fe7-8520-892dc90b8fdd" xlink:to="loc_srt_MaximumMember_6c8e815f-97de-473c-aa8e-571530bb557c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_61d0e354-eaa1-4fad-9602-ddedd138e269" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LeaseRemainingLeaseTerm_561b91bc-84f3-43da-aae2-33891bae2a07" xlink:href="insm-20201231.xsd#insm_LeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_insm_LeaseRemainingLeaseTerm_561b91bc-84f3-43da-aae2-33891bae2a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeasePayment_96deab42-f535-4671-958d-d216d1da30b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeasePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_us-gaap_VariableLeasePayment_96deab42-f535-4671-958d-d216d1da30b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_b68057a4-fb99-4bc2-81e1-82fac4c808a9" xlink:href="insm-20201231.xsd#insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8937c5ed-652e-4445-8e86-b4f6287eaa70" xlink:to="loc_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount_b68057a4-fb99-4bc2-81e1-82fac4c808a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1e66d475-524d-4869-b23c-3576bea9c86b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1e66d475-524d-4869-b23c-3576bea9c86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8a11e96e-f76d-443e-b744-b07450887e56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8a11e96e-f76d-443e-b744-b07450887e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_FinanceLeaseCost_8c212288-70b8-48ab-aee9-10c5d8612c61" xlink:href="insm-20201231.xsd#insm_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_insm_FinanceLeaseCost_8c212288-70b8-48ab-aee9-10c5d8612c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_86b127e4-1fb1-45b4-a5d5-d61d559b495f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_us-gaap_OperatingLeaseCost_86b127e4-1fb1-45b4-a5d5-d61d559b495f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b0aa03ef-9885-475c-82e6-20bc7ecc46b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_us-gaap_VariableLeaseCost_b0aa03ef-9885-475c-82e6-20bc7ecc46b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_94765b4d-aa55-44a3-98ff-ea634dbf445d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_120016c4-a188-4829-a94c-f928f0c9841a" xlink:to="loc_us-gaap_LeaseCost_94765b4d-aa55-44a3-98ff-ea634dbf445d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:href="insm-20201231.xsd#insm_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_19d29c82-afbb-4cad-9dd2-e03f4bfa831a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_19d29c82-afbb-4cad-9dd2-e03f4bfa831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_a6a32691-c992-4fb1-92cc-6c59362add3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:to="loc_us-gaap_OperatingLeasePayments_a6a32691-c992-4fb1-92cc-6c59362add3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d258cd01-4074-4da6-a566-e938bed85f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d258cd01-4074-4da6-a566-e938bed85f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_3c0ca5de-17ed-4dea-8b53-d8db28eef174" xlink:href="insm-20201231.xsd#insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_CashFlowLesseeAbstract_3b2cdefd-a9a7-4651-8029-db51779f0799" xlink:to="loc_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance_3c0ca5de-17ed-4dea-8b53-d8db28eef174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5e0c4451-c26e-44d6-a6cb-bc93f5aa0753" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5e0c4451-c26e-44d6-a6cb-bc93f5aa0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d266a34-0fa2-4a48-bb72-7082a6c4d13a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d266a34-0fa2-4a48-bb72-7082a6c4d13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4afa9db3-2555-48cc-bbba-3209a47fbc67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4afa9db3-2555-48cc-bbba-3209a47fbc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_abb79855-bc45-45d2-bb37-a688d0fc376c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_abb79855-bc45-45d2-bb37-a688d0fc376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_77aa2422-9759-4e37-aa4d-a144864c3dd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_77aa2422-9759-4e37-aa4d-a144864c3dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_deb2c0a5-6727-4b15-b6e9-bb2303dcb5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9dd8a2c1-ac44-438d-8b66-aec04011dbf5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_deb2c0a5-6727-4b15-b6e9-bb2303dcb5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_59ee4804-0bfe-4be5-83ef-f72257d9f4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_59ee4804-0bfe-4be5-83ef-f72257d9f4a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bb43c6a0-648d-4ce7-a423-e8385ffc70ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bb43c6a0-648d-4ce7-a423-e8385ffc70ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9a58c698-3a97-4ea1-a102-ea1cadab2117" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9a58c698-3a97-4ea1-a102-ea1cadab2117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_06064e1c-615b-4fac-bf0b-171d8a20d57a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_06064e1c-615b-4fac-bf0b-171d8a20d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8914bac3-588e-48b6-913c-14acbea7b001" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8914bac3-588e-48b6-913c-14acbea7b001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2c2bc8d2-44ea-4e72-ab43-ba13039174e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2c2bc8d2-44ea-4e72-ab43-ba13039174e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9d04b370-8800-452a-805e-a52727f7a6ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9d04b370-8800-452a-805e-a52727f7a6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_60bf441e-33b9-42a2-bd7d-a6af67fb8df6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_60bf441e-33b9-42a2-bd7d-a6af67fb8df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a3de7475-fccf-4cfd-91d4-04407d63eb52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a3de7475-fccf-4cfd-91d4-04407d63eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_eb8bd56f-933d-458a-803d-1731eb35405d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiability_eb8bd56f-933d-458a-803d-1731eb35405d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d7e29cb3-583e-4011-b844-149046b9e151" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d7e29cb3-583e-4011-b844-149046b9e151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0347a316-b6f1-4c6d-a9c5-9b52f7878d26" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0347a316-b6f1-4c6d-a9c5-9b52f7878d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_b2bff0c3-776e-479b-9e53-6b3a44285b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_5de7c978-cded-4920-b8a7-92fe396f4f7c" xlink:to="loc_us-gaap_FinanceLeaseLiability_b2bff0c3-776e-479b-9e53-6b3a44285b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_59ee4804-0bfe-4be5-83ef-f72257d9f4a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4f9770cf-648c-4f1c-b59c-72e0132f7165" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4f9770cf-648c-4f1c-b59c-72e0132f7165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52565224-f6b8-4a55-a885-24eef0f40694" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52565224-f6b8-4a55-a885-24eef0f40694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f67806b6-1721-4b6f-8533-80b895d535a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f67806b6-1721-4b6f-8533-80b895d535a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_acd5fcad-fadc-4546-80e5-47018671e093" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_acd5fcad-fadc-4546-80e5-47018671e093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_471509ac-f04e-4084-8828-6f501f28b464" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_471509ac-f04e-4084-8828-6f501f28b464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d10c91ec-f9eb-4c31-b11d-f1d5931c4469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d10c91ec-f9eb-4c31-b11d-f1d5931c4469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a297b9f0-3fef-41fd-b9dc-8e78a5ca7b2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a297b9f0-3fef-41fd-b9dc-8e78a5ca7b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e1e03e5-cc5f-4b37-8b54-987dca85410c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e1e03e5-cc5f-4b37-8b54-987dca85410c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_417f857b-9c8d-4bb2-8d1d-c05ef8d93f62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_OperatingLeaseLiability_417f857b-9c8d-4bb2-8d1d-c05ef8d93f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b7c75fd-c058-4ea0-9455-e09b9239ddb2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0b7c75fd-c058-4ea0-9455-e09b9239ddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26cdc0fe-7a10-4c4f-9f17-1ed6c0d6cb50" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26cdc0fe-7a10-4c4f-9f17-1ed6c0d6cb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_18ab0d40-b86a-440a-97c1-3e4d38b2e194" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5b57eab0-c5cb-4fbe-8661-261bfadefc2b" xlink:to="loc_us-gaap_OperatingLeaseLiability_18ab0d40-b86a-440a-97c1-3e4d38b2e194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="insm-20201231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.insmed.com/role/Debt" xlink:type="simple" xlink:href="insm-20201231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7d44c226-e890-4a64-ade8-20beca96e4e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_560b2675-5599-47b3-a14f-e1d73eae7d25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7d44c226-e890-4a64-ade8-20beca96e4e5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_560b2675-5599-47b3-a14f-e1d73eae7d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtTables" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ec5f7cc5-3636-43a5-bcb6-4ef711687e03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0f230fd9-686f-4c4f-b9cf-40e9ab0d967d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec5f7cc5-3636-43a5-bcb6-4ef711687e03" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0f230fd9-686f-4c4f-b9cf-40e9ab0d967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_04ddfc05-f883-4e32-9963-a22c4fd5a36b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec5f7cc5-3636-43a5-bcb6-4ef711687e03" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_04ddfc05-f883-4e32-9963-a22c4fd5a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_34c4107f-cfc2-4cfa-ab43-0bc1403a96c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec5f7cc5-3636-43a5-bcb6-4ef711687e03" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_34c4107f-cfc2-4cfa-ab43-0bc1403a96c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_496d3a36-89fd-4769-951f-fb55135e10ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_496d3a36-89fd-4769-951f-fb55135e10ad" xlink:to="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConversionTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermAxis_d99a837a-d744-4c6b-b7fa-92f8cb9a765b" xlink:to="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiMember_5a5f7f60-170e-4057-86ec-0d9506c8f558" xlink:href="insm-20201231.xsd#insm_ConversionTermiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiMember_5a5f7f60-170e-4057-86ec-0d9506c8f558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiMember_de72259a-f15a-40c3-a17d-1473d01ea37d" xlink:href="insm-20201231.xsd#insm_ConversionTermiiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiiMember_de72259a-f15a-40c3-a17d-1473d01ea37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermiiiMember_ebd59739-eb9a-4111-a8ba-14cde3066108" xlink:href="insm-20201231.xsd#insm_ConversionTermiiiMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermiiiMember_ebd59739-eb9a-4111-a8ba-14cde3066108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConversionTermivMember_d2f88c9f-1e3d-4fad-8041-d3090468fae0" xlink:href="insm-20201231.xsd#insm_ConversionTermivMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_DebtInstrumentConversionTermDomain_e7264830-cd4a-4b50-87d8-610804664a5e" xlink:to="loc_insm_ConversionTermivMember_d2f88c9f-1e3d-4fad-8041-d3090468fae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3b43b534-522f-4919-afaf-0352fefecc9e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8d67b71b-f78a-471c-b8fa-e3e1331b9788" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_57e24980-14f6-4e8e-9fb1-de2728890335" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8d67b71b-f78a-471c-b8fa-e3e1331b9788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8352793-8deb-4b31-8e47-8f418fad7027" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e84cc1e5-1cee-414c-bde7-85e0f87bc0f0" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_e84cc1e5-1cee-414c-bde7-85e0f87bc0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_2be679ce-26a3-49f0-b5ad-bd66e324cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b47e8d65-b086-4505-8d54-0659a0aba0e6" xlink:to="loc_us-gaap_LineOfCreditMember_2be679ce-26a3-49f0-b5ad-bd66e324cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_216caeba-64eb-4edc-a813-3dd57d3e45d9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_047ea6b1-ae42-45ae-8c80-3d9fcd2b306f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_047ea6b1-ae42-45ae-8c80-3d9fcd2b306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_31b48f50-cf28-47f0-b126-592865d9dff0" xlink:href="insm-20201231.xsd#insm_DebtInstrumentOptionToPurchaseAdditionalDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_DebtInstrumentOptionToPurchaseAdditionalDebt_31b48f50-cf28-47f0-b126-592865d9dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_08d16175-4519-47ef-a4b1-9fa6731c037f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_08d16175-4519-47ef-a4b1-9fa6731c037f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_2c7df19d-16be-4188-95f9-8dd3d4b6f793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_2c7df19d-16be-4188-95f9-8dd3d4b6f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d7643e30-d042-4607-884a-fa0a32b74789" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_d7643e30-d042-4607-884a-fa0a32b74789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_60fb5d84-ea99-48c4-80b1-fad4519c13fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_60fb5d84-ea99-48c4-80b1-fad4519c13fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1549f470-dc14-462e-b368-db5b4a0ac2f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1549f470-dc14-462e-b368-db5b4a0ac2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_62faa4b6-d575-4b3e-b280-fc7d290c2a94" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_62faa4b6-d575-4b3e-b280-fc7d290c2a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0451a65-60e3-4f9f-91bd-6a969a4e4572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_c0451a65-60e3-4f9f-91bd-6a969a4e4572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_e3beab66-07e8-4c15-aa01-c607924a50c5" xlink:href="insm-20201231.xsd#insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange_e3beab66-07e8-4c15-aa01-c607924a50c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e703f10-d962-4b12-b4dc-eea5bb7e3607" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_4e703f10-d962-4b12-b4dc-eea5bb7e3607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ced6eed1-2b14-4bfa-ac5b-f6c88f95b5e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ced6eed1-2b14-4bfa-ac5b-f6c88f95b5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_cda39fba-fbac-4092-80e3-bc6a081bfc25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_cda39fba-fbac-4092-80e3-bc6a081bfc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_16bb7d2f-35f2-4c48-870f-a936045ac257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_16bb7d2f-35f2-4c48-870f-a936045ac257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d692963d-57bc-4910-866d-79db45a8b5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_InterestExpense_d692963d-57bc-4910-866d-79db45a8b5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_c254171e-c002-4181-8502-002f490638d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_RepaymentsOfDebt_c254171e-c002-4181-8502-002f490638d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_0504f2b9-24db-4053-9609-97d4980e8b37" xlink:href="insm-20201231.xsd#insm_RepaymentsOfDebtFeesAndOutstandingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_insm_RepaymentsOfDebtFeesAndOutstandingInterest_0504f2b9-24db-4053-9609-97d4980e8b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4aaec062-0844-499f-b052-c4d3b1324d83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8a5b14f2-9f71-42bf-a41e-dac84b34dad3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4aaec062-0844-499f-b052-c4d3b1324d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtComponentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtComponentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_37e4b347-b6d0-459a-8297-778a77d8b6dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_37e4b347-b6d0-459a-8297-778a77d8b6dd" xlink:to="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f36bb747-d7fd-4519-b88e-914409e58ac0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_8887ef05-13b5-4fce-9424-f2bebf938ace" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6327dc3e-3858-4026-9ba6-5f56fae1b7cd" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_8887ef05-13b5-4fce-9424-f2bebf938ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ddb3ab8-a52d-4bde-8c49-9103909bcf52" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_7185d5a6-50b2-49cc-9af0-e4fcdcfc73a1" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90108558-ee40-4364-9ce7-df539ea9b4e8" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_7185d5a6-50b2-49cc-9af0-e4fcdcfc73a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_01dadf07-9c03-4a72-bcfe-7165ecf1ab66" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebt_b952f535-e744-4036-ac82-bb1436840cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_SecuredDebt_b952f535-e744-4036-ac82-bb1436840cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71128a79-9772-4591-bb1f-cc6e1037e4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71128a79-9772-4591-bb1f-cc6e1037e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0cb2c906-f040-4ca9-bdd6-b1aea5ff3d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0cb2c906-f040-4ca9-bdd6-b1aea5ff3d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ad75840-8f05-4f90-a77b-01ef3b2bcde9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1ad75840-8f05-4f90-a77b-01ef3b2bcde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_28f33fb1-506b-4dbd-97a8-42a84fca601b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1f6bd505-a1b8-4ce4-bb52-71888ed2c655" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_28f33fb1-506b-4dbd-97a8-42a84fca601b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtFuturePrincipalRepaymentsofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7bb181d5-aac4-406e-8bdb-5b7293ab848c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7bb181d5-aac4-406e-8bdb-5b7293ab848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ceada2e9-1324-4a02-bedc-d74d4cff67cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ceada2e9-1324-4a02-bedc-d74d4cff67cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3affa2fa-f849-419f-895c-50cecd48c0da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3affa2fa-f849-419f-895c-50cecd48c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6452a92b-284a-46f4-8bdf-f97443f6184d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6452a92b-284a-46f4-8bdf-f97443f6184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3f95d958-79a5-4f7b-b152-2ca03219c661" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3f95d958-79a5-4f7b-b152-2ca03219c661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9455d8ea-f5e8-42cb-b5d4-02789c66ad35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc01aa6b-63b8-4b11-944c-cefbb68075dd" xlink:to="loc_us-gaap_LongTermDebt_9455d8ea-f5e8-42cb-b5d4-02789c66ad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_787ba1b2-93ef-48b4-8b4e-524fb76d5cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_us-gaap_InterestExpenseDebt_787ba1b2-93ef-48b4-8b4e-524fb76d5cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_14929af7-e4ce-44bd-85ca-07aad1fd0878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_14929af7-e4ce-44bd-85ca-07aad1fd0878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AmortizationOfBackendFee_9d714874-5302-49c5-a000-b377d8c38dfd" xlink:href="insm-20201231.xsd#insm_AmortizationOfBackendFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_insm_AmortizationOfBackendFee_9d714874-5302-49c5-a000-b377d8c38dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_31bcd775-20c3-462e-91b2-ae611a22b0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_31bcd775-20c3-462e-91b2-ae611a22b0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ConvertibleDebtInterestExpenseTotal_c5e0add2-59b8-4982-8595-09e7a1682894" xlink:href="insm-20201231.xsd#insm_ConvertibleDebtInterestExpenseTotal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_insm_ConvertibleDebtInterestExpenseTotal_c5e0add2-59b8-4982-8595-09e7a1682894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_8366e321-4125-4eb2-830a-4598cddb220c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_8366e321-4125-4eb2-830a-4598cddb220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_28be4582-710e-4f34-b2a0-7f7d35e767af" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66cf05bd-f405-4644-8edc-9bdf490d66b3" xlink:to="loc_us-gaap_InterestExpense_28be4582-710e-4f34-b2a0-7f7d35e767af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1d1f9eb7-61a6-4706-a1b1-ae57a9c8ab4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b941974a-acc7-4556-bb17-15424777896d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1d1f9eb7-61a6-4706-a1b1-ae57a9c8ab4a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b941974a-acc7-4556-bb17-15424777896d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_458230ec-c190-45f9-8498-6dbf9fb372c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_458230ec-c190-45f9-8498-6dbf9fb372c0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d0f1b569-4f65-414b-83cd-cd62a5851b21" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_034b8705-3d9b-49fb-afd0-1d00e1860819" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8df983db-998e-4387-8cac-c180fcb70bc6" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_034b8705-3d9b-49fb-afd0-1d00e1860819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9ee73e83-fb0f-4b9b-94c7-999d3c44e816" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_f82c26e6-a952-45c4-a336-792f0c24d6e6" xlink:href="insm-20201231.xsd#insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_22df71a8-70b1-472e-8cab-2db818474939" xlink:to="loc_insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member_f82c26e6-a952-45c4-a336-792f0c24d6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76ba6b7a-4f28-4cae-9e51-92ac3e1391cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_c48ad840-0cb6-4ad1-ae27-ecae2f050851" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_c48ad840-0cb6-4ad1-ae27-ecae2f050851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c11e333-e028-4fb0-90d6-5e81c6737d2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_91f8a267-c289-474b-82bd-ae9726e9b046" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c11e333-e028-4fb0-90d6-5e81c6737d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3f77e514-9ab6-4598-8c67-3bd365bfbb63" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingMember_6c612c51-2edb-4d42-8f42-de3db3295018" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_insm_PublicStockOfferingMember_6c612c51-2edb-4d42-8f42-de3db3295018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7698fd11-04cf-4c36-a79b-cbccd369361b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7698fd11-04cf-4c36-a79b-cbccd369361b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_f4ddf810-edc1-4d89-a1e0-265709b1bf2b" xlink:href="insm-20201231.xsd#insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_30cd8b2b-1bbd-4b9c-9de0-828067462392" xlink:to="loc_insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember_f4ddf810-edc1-4d89-a1e0-265709b1bf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a1a033cb-b0c6-49a9-8453-bfcc4bcab6cd" xlink:to="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_323ec5e9-2614-45a6-842a-2cccd6a25ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_323ec5e9-2614-45a6-842a-2cccd6a25ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_69a734ba-5f0b-4c82-8e1b-ce2da814c1bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_69a734ba-5f0b-4c82-8e1b-ce2da814c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_06e8f35e-4455-4258-a823-508831782aef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesIssued_06e8f35e-4455-4258-a823-508831782aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_30b22763-b169-4576-9ca7-9067700c470b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_30b22763-b169-4576-9ca7-9067700c470b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e86626c8-fbb9-4c7d-96c3-eee264a2ff47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_e86626c8-fbb9-4c7d-96c3-eee264a2ff47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5ec05fbc-abf4-4533-9033-fc1e664b8b70" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5ec05fbc-abf4-4533-9033-fc1e664b8b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_abf845fe-a5a7-4a18-9d6e-ba82bd0bbe09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_abf845fe-a5a7-4a18-9d6e-ba82bd0bbe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b94729d-a965-4598-af02-ee0fc2783302" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3b94729d-a965-4598-af02-ee0fc2783302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3962eb3c-7ac4-4723-a8cf-ecee9e5d02e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3962eb3c-7ac4-4723-a8cf-ecee9e5d02e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2ee6ebda-603e-4319-acec-8838f7a52213" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2ee6ebda-603e-4319-acec-8838f7a52213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0c81a236-5ff2-42ff-a414-6d5cb708097e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_0c81a236-5ff2-42ff-a414-6d5cb708097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9e79e018-7d0b-43d9-bf5a-91a3789ec0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_9e79e018-7d0b-43d9-bf5a-91a3789ec0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d07c1f1f-6271-4104-86bc-c9437afba04e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d07c1f1f-6271-4104-86bc-c9437afba04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0cd07806-aa06-44cb-96ef-d392912114f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0cd07806-aa06-44cb-96ef-d392912114f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b43f68b7-b6fa-450d-acb0-f119245db260" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b43f68b7-b6fa-450d-acb0-f119245db260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a8fb47ae-7a3f-4e45-b566-4c5327a8c653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1267841f-53a6-4721-8f62-b4b703347536" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a8fb47ae-7a3f-4e45-b566-4c5327a8c653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_ea99640c-d6cc-4366-a23d-d6250f62efec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_24044dce-d88a-4a9b-a1d5-e95de4c2813f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_ea99640c-d6cc-4366-a23d-d6250f62efec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_24044dce-d88a-4a9b-a1d5-e95de4c2813f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_68f50b10-25ac-44f4-a805-1ee24dd47cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6e75282-af02-4f14-9e6b-2f315ef3f454" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_68f50b10-25ac-44f4-a805-1ee24dd47cd5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6e75282-af02-4f14-9e6b-2f315ef3f454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16ec8a02-0f95-42a9-a1ef-cb08daa710cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_68f50b10-25ac-44f4-a805-1ee24dd47cd5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_16ec8a02-0f95-42a9-a1ef-cb08daa710cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_33bb4363-e1f6-48da-b9de-334b829d3949" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_68f50b10-25ac-44f4-a805-1ee24dd47cd5" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_33bb4363-e1f6-48da-b9de-334b829d3949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2dcee47e-ea27-465d-a5b0-f242b263c210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_68f50b10-25ac-44f4-a805-1ee24dd47cd5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2dcee47e-ea27-465d-a5b0-f242b263c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_227abb31-e933-4f2a-ab1d-cda908f39620" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_227abb31-e933-4f2a-ab1d-cda908f39620" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:to="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_195832c1-aeea-48e4-977b-7706072b7088" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_a1299315-c414-49ea-a9a6-bfbf0b3bd3a0" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33dcb24b-b5cf-46d4-9900-5eb2245ce4e2" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_a1299315-c414-49ea-a9a6-bfbf0b3bd3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:to="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_433417d4-45be-41a6-a0a5-85947ce676a1" xlink:to="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_A2019IncentivePlanMember_241c4a61-8db3-4ee3-a3a9-f80e23f6f681" xlink:href="insm-20201231.xsd#insm_A2019IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_41efab20-76a6-4a10-9aa6-5d92e250485d" xlink:to="loc_insm_A2019IncentivePlanMember_241c4a61-8db3-4ee3-a3a9-f80e23f6f681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_31dc74a9-76b0-4f77-a68e-48720c334dfc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20fddb07-803b-4ddc-8c5d-d7a99e7eaa6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20fddb07-803b-4ddc-8c5d-d7a99e7eaa6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fbc56060-e1fe-47fe-8c03-d63d8ee3751b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fbc56060-e1fe-47fe-8c03-d63d8ee3751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_df76e3c2-85c5-4737-b807-78b76032832b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_df76e3c2-85c5-4737-b807-78b76032832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_98791d1f-5103-43fb-8d6a-549dec2e6142" xlink:href="insm-20201231.xsd#insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross_98791d1f-5103-43fb-8d6a-549dec2e6142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_14418166-e9f8-4562-b49d-fe41cd1af172" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_14418166-e9f8-4562-b49d-fe41cd1af172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9cd095d1-1d1a-4c04-93d1-e6bdbd0fefa5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_9cd095d1-1d1a-4c04-93d1-e6bdbd0fefa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6660aa0-9ff3-4d09-add0-c722dd5f1f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_82724fe7-dfc0-4800-b954-614b7910e10c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6660aa0-9ff3-4d09-add0-c722dd5f1f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_3e76ce6a-fa06-410e-ab07-e50651924a19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_3e76ce6a-fa06-410e-ab07-e50651924a19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:to="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0715e25f-c803-4978-8be8-334d68089290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EmployeeAndDirectorsStockOptionsMember_4bb3279d-d868-4e86-82c0-5651e9ea455a" xlink:href="insm-20201231.xsd#insm_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:to="loc_insm_EmployeeAndDirectorsStockOptionsMember_4bb3279d-d868-4e86-82c0-5651e9ea455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6523d362-83e6-40cd-bada-a006197c3a7d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef3bfe0d-ac9b-4de6-92f2-f69b2def482e" xlink:to="loc_us-gaap_PerformanceSharesMember_6523d362-83e6-40cd-bada-a006197c3a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:to="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df1593c3-7f3a-48da-becf-a0ff97ef806f" xlink:to="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_edd67538-26c2-4508-a975-ec783f62666e" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:to="loc_srt_MinimumMember_edd67538-26c2-4508-a975-ec783f62666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7bca1428-8c01-4cac-9551-3a52e74ff7e3" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f87e1061-3d6a-47fd-9833-a94102db2542" xlink:to="loc_srt_MaximumMember_7bca1428-8c01-4cac-9551-3a52e74ff7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_09c9d357-0981-44c8-9414-b8f07bf77460" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_186cafdd-ce20-4d7f-b2cc-4a0c0de3f674" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_186cafdd-ce20-4d7f-b2cc-4a0c0de3f674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81ef8a39-5aa9-48c8-84cd-7c6aa71cd419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_81ef8a39-5aa9-48c8-84cd-7c6aa71cd419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_735efc18-6a22-4f3c-93d3-bb9bda4e5931" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_735efc18-6a22-4f3c-93d3-bb9bda4e5931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4dcf6d7-e220-4657-b79f-87c44d5f5a62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b4dcf6d7-e220-4657-b79f-87c44d5f5a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec32b462-d499-4aea-b9fa-f158f6fbe3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_3a74443b-cec2-40b2-92a6-18e1328c49e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ec32b462-d499-4aea-b9fa-f158f6fbe3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f69172b4-f8bf-4e72-8029-211681ac0a64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f69172b4-f8bf-4e72-8029-211681ac0a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8962acd-4dca-4536-9a78-c9db7ea0a8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a8962acd-4dca-4536-9a78-c9db7ea0a8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_931edf2a-1ac2-4edd-af1f-6f504bc8aefe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_931edf2a-1ac2-4edd-af1f-6f504bc8aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_01d0e5d0-2d28-45dd-923a-c6bfad76d938" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_01d0e5d0-2d28-45dd-923a-c6bfad76d938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_951fb8cf-1c84-4c20-beb9-d1df09d6775c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c65882bf-a8ff-47ec-8bea-b08c7cad1efa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_951fb8cf-1c84-4c20-beb9-d1df09d6775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8593f961-bddf-47ae-9cbd-505bfcb5ed86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8593f961-bddf-47ae-9cbd-505bfcb5ed86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fdd6700-b917-4b9e-beec-426a58b4d0c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1fdd6700-b917-4b9e-beec-426a58b4d0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ec6b2130-6fd8-4d31-9e8f-945d8cc57568" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ec6b2130-6fd8-4d31-9e8f-945d8cc57568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54fb2e9b-77cd-49f9-bc80-726fa8651246" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_54fb2e9b-77cd-49f9-bc80-726fa8651246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd336393-094f-4fd8-aa60-2ab298523816" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_bd336393-094f-4fd8-aa60-2ab298523816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0508a1ec-ff74-4e07-8091-05cb502d7a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8298dd57-a0cc-41c4-81e2-d61394552b0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0508a1ec-ff74-4e07-8091-05cb502d7a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_278e1527-baeb-43e8-8fa2-c63f8d2a9a75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_278e1527-baeb-43e8-8fa2-c63f8d2a9a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:href="insm-20201231.xsd#insm_WeightedAverageRemainingContractualLifeInYearsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bf9ff16f-7312-4dbb-9c0d-cacf7fa4fb6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_bf9ff16f-7312-4dbb-9c0d-cacf7fa4fb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_da6ffa06-52b0-462e-b391-54eb3fd46a99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_WeightedAverageRemainingContractualLifeInYearsAbstract_33f27c7d-56da-4ee4-aadc-434e72d54422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_da6ffa06-52b0-462e-b391-54eb3fd46a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f87034ac-0a38-49aa-951a-a946d3b05e2c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dea66e63-fc28-4b69-9c25-945881c3a793" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_dea66e63-fc28-4b69-9c25-945881c3a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb0227d7-979a-4bbf-9b47-56e562188acc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_01606b10-7000-4620-ace7-c6d71bc9ddae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bb0227d7-979a-4bbf-9b47-56e562188acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_4e687c79-04ee-4c0c-ae8f-b3755a016c52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4e687c79-04ee-4c0c-ae8f-b3755a016c52" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:to="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da2199fe-5eb4-4a60-8224-8a7d98ef869f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0a797b34-a1cc-4c4b-9ffc-813c7649de48" xlink:href="insm-20201231.xsd#insm_RestrictedStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_insm_RestrictedStockAndRestrictedStockUnitsMember_0a797b34-a1cc-4c4b-9ffc-813c7649de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c080df4e-605a-4893-a4bb-6c6bb85d158c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c080df4e-605a-4893-a4bb-6c6bb85d158c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_StockOptionsAndRestrictedStockUnitsMember_98375ead-f961-4e26-a56a-a57a23f49a94" xlink:href="insm-20201231.xsd#insm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_insm_StockOptionsAndRestrictedStockUnitsMember_98375ead-f961-4e26-a56a-a57a23f49a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_82ea389f-6650-4f5c-ba86-9c1b2963cbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_39ba2754-0805-4bfc-a2cc-d00641aba686" xlink:to="loc_us-gaap_EmployeeStockMember_82ea389f-6650-4f5c-ba86-9c1b2963cbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_73691ee5-a4a1-4152-8ad8-54fdc4256400" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ed06afc3-08eb-436e-9574-555e470e7a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ed06afc3-08eb-436e-9574-555e470e7a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_baea2355-ee39-4244-9107-acabfdbc837b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0a619781-d0f2-4c1b-98d2-e6db358d2495" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_baea2355-ee39-4244-9107-acabfdbc837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_571b6e1f-eb5d-40a2-8a8e-9ce8c4dd4d99" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_e1264320-c36d-4287-a322-6335fd097f2b" xlink:href="insm-20201231.xsd#insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit_e1264320-c36d-4287-a322-6335fd097f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_35ffad60-157a-4934-86d8-1de40aeda326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_35ffad60-157a-4934-86d8-1de40aeda326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a96a54d8-423f-49af-ba6c-fe936c3d6bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a96a54d8-423f-49af-ba6c-fe936c3d6bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d23ec0b-a94b-474f-9366-57e6238f55bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d23ec0b-a94b-474f-9366-57e6238f55bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_728074cb-b339-4336-bde6-517ceff7016c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_728074cb-b339-4336-bde6-517ceff7016c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_12a2d5d6-5fda-4f75-a40b-93b9192a34b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_12a2d5d6-5fda-4f75-a40b-93b9192a34b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f9063afa-d04d-484a-b77e-15000789509b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f9063afa-d04d-484a-b77e-15000789509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2a048d89-352e-4aa1-b1aa-1319f4d8f38c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4c7ad7c1-a8fb-4f28-8785-c45d945d1039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2a048d89-352e-4aa1-b1aa-1319f4d8f38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b17dab9f-0310-4293-9958-42d12de94592" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b17dab9f-0310-4293-9958-42d12de94592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a68e9433-fd60-4322-b267-9e7633212625" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a68e9433-fd60-4322-b267-9e7633212625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_246aeeb6-0a80-4491-908b-da5bc26723f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_246aeeb6-0a80-4491-908b-da5bc26723f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bbea043c-abcf-44f2-9782-a519d4db32b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bbea043c-abcf-44f2-9782-a519d4db32b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7a60c9d2-8b23-40ae-ade6-7b10127996a9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e813c2d-a10f-4ba0-8f38-ed7495f459db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7a60c9d2-8b23-40ae-ade6-7b10127996a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8f17cfff-8174-4d19-b63c-38c6ba21266f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_24da3659-c672-426d-9043-2f665c254c39" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8f17cfff-8174-4d19-b63c-38c6ba21266f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_42625db6-2bae-47ac-af30-b5600f33fe3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7969286a-6ed3-424a-9a7d-c3715f1de450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_42625db6-2bae-47ac-af30-b5600f33fe3a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7969286a-6ed3-424a-9a7d-c3715f1de450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_372950e2-35b4-4a9d-bd0b-aeb4a0fa5d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_372950e2-35b4-4a9d-bd0b-aeb4a0fa5d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d70b3b77-e753-4996-9776-084136f092c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d70b3b77-e753-4996-9776-084136f092c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16f647a5-9517-489f-b462-c586b20459d8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16f647a5-9517-489f-b462-c586b20459d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7d332b11-9e60-4c73-ad16-d05f41d8d68b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7d332b11-9e60-4c73-ad16-d05f41d8d68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_83c5c54b-c8d5-4398-aa8c-03b704e3b963" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ae6cc9a-77ce-4570-b863-ef1708796296" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_83c5c54b-c8d5-4398-aa8c-03b704e3b963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21d21792-22c9-4cba-af43-d53af9033d83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d21792-22c9-4cba-af43-d53af9033d83" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_08ad30f3-099a-47ff-b274-51f1b21e2d5d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_7a8fa2fd-79a8-4f68-8d9d-6f8a18640183" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_7a8fa2fd-79a8-4f68-8d9d-6f8a18640183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_IrelandTaxMember_fd34569b-dcfe-4bdf-8b33-81362bc5574a" xlink:href="insm-20201231.xsd#insm_IrelandTaxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_11966a6a-16f1-4f4f-8621-2aa2c3cc61d6" xlink:to="loc_insm_IrelandTaxMember_fd34569b-dcfe-4bdf-8b33-81362bc5574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_359485ac-26eb-48c6-a5ea-fb5946b01861" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_3c2859a8-49ff-49a7-a883-9dc93d97e988" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d24f3be3-472a-4883-80c5-c25b823fc493" xlink:to="loc_us-gaap_DomesticCountryMember_3c2859a8-49ff-49a7-a883-9dc93d97e988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_670c32d8-6c9f-457e-a54a-0156a655ae0f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_966d45a1-ff18-404f-84c6-df67e124e879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_966d45a1-ff18-404f-84c6-df67e124e879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68b2afe3-3795-441f-aafa-191c16f7b91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_68b2afe3-3795-441f-aafa-191c16f7b91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_383971fd-199a-4a64-882e-e2d7030d90bb" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent_383971fd-199a-4a64-882e-e2d7030d90bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_fb8e3c09-fd65-4478-998a-319f7d2bde53" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent_fb8e3c09-fd65-4478-998a-319f7d2bde53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_44df7fcb-30b3-4e6a-8d4f-4604ac1a9b9f" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_44df7fcb-30b3-4e6a-8d4f-4604ac1a9b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0feb922a-8b99-44aa-a284-3f2c91fa800a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0feb922a-8b99-44aa-a284-3f2c91fa800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsTotal_b0615b76-bd66-438a-8a13-006e394974be" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsTotal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsTotal_b0615b76-bd66-438a-8a13-006e394974be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0303aec4-de37-4745-bf53-157655a736a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0303aec4-de37-4745-bf53-157655a736a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsNonTradingLoss_2940d945-0738-4f2a-9c03-b8dc45fa51b2" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsNonTradingLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsNonTradingLoss_2940d945-0738-4f2a-9c03-b8dc45fa51b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense_6df9698e-f14e-44a9-a037-c77eacdfd497" xlink:href="insm-20201231.xsd#insm_OperatingLossCarryforwardsDisallowedInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_insm_OperatingLossCarryforwardsDisallowedInterestExpense_6df9698e-f14e-44a9-a037-c77eacdfd497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_5a7b664b-2875-417e-8acf-5b3deedc1bde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_5a7b664b-2875-417e-8acf-5b3deedc1bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3a66a195-dc0f-4dc4-bffe-d4ea7b753675" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_7c581461-89a6-404a-9f0d-f7b099dcaec9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3a66a195-dc0f-4dc4-bffe-d4ea7b753675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ebf402b-63fb-4506-b643-efc5b3ef1b76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6d7e7bbb-4b79-49c1-b53d-d703cfdde5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ebf402b-63fb-4506-b643-efc5b3ef1b76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6d7e7bbb-4b79-49c1-b53d-d703cfdde5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e299903d-46ca-4f49-852e-174b5dc47415" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ebf402b-63fb-4506-b643-efc5b3ef1b76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e299903d-46ca-4f49-852e-174b5dc47415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04084b67-5e35-4568-92c6-5de9cb160537" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ebf402b-63fb-4506-b643-efc5b3ef1b76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_04084b67-5e35-4568-92c6-5de9cb160537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesIncomeTaxBenefitProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8ca716-b810-4b7b-90fd-4c13c644be21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8ca716-b810-4b7b-90fd-4c13c644be21" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ddd5597d-66b3-44b0-8d03-d4821a94a902" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ddd5597d-66b3-44b0-8d03-d4821a94a902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c100214b-6c4b-4634-8184-21c0e2eac6fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c100214b-6c4b-4634-8184-21c0e2eac6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_353d756a-c647-436d-b903-529c3946276c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_353d756a-c647-436d-b903-529c3946276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_789e14ce-aac2-4e0a-aed9-9d395b9da633" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_62c35deb-6905-4607-9324-b86b8529c6b0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_789e14ce-aac2-4e0a-aed9-9d395b9da633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8ca716-b810-4b7b-90fd-4c13c644be21" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aada31a0-fbe1-4c98-9193-d5509e8ba887" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_aada31a0-fbe1-4c98-9193-d5509e8ba887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b6a7e600-318f-4fcd-a34f-218dddf84c52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b6a7e600-318f-4fcd-a34f-218dddf84c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc8dc2e4-ea87-4f85-9cf4-bd4d249ad8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_cc8dc2e4-ea87-4f85-9cf4-bd4d249ad8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_267e16c3-9b10-42f4-a368-d15cc6977c19" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b91eb275-e7cf-4b85-b7a4-b26256222e1d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_267e16c3-9b10-42f4-a368-d15cc6977c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f38d13d7-e373-4e64-866c-90fed3c1a5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fa8ca716-b810-4b7b-90fd-4c13c644be21" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f38d13d7-e373-4e64-866c-90fed3c1a5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a77b0bcd-4d71-490d-a17a-f0e82770e1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a77b0bcd-4d71-490d-a17a-f0e82770e1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_f4fc6c37-b76e-4fcf-b137-35a658c27e3a" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationPermanentItems_f4fc6c37-b76e-4fcf-b137-35a658c27e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fcf1f2c3-5047-4f1a-abb2-f8d6ba179db5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fcf1f2c3-5047-4f1a-abb2-f8d6ba179db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_df26957e-a93b-4fce-b843-75339ada62aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_df26957e-a93b-4fce-b843-75339ada62aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_500603c1-2ea1-4691-ad64-271a38baddaa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_500603c1-2ea1-4691-ad64-271a38baddaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_acc0d72b-21f4-4320-ac67-31484d622285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_acc0d72b-21f4-4320-ac67-31484d622285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_4db617f9-5a9d-4910-8e68-94e5c07d207b" xlink:href="insm-20201231.xsd#insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent_4db617f9-5a9d-4910-8e68-94e5c07d207b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5221e36c-9df9-4e6c-82ce-347c9db8756a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40ffca20-9b46-4f68-84b8-aefabad44205" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5221e36c-9df9-4e6c-82ce-347c9db8756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9fa90fa1-bc84-4c4e-9db3-68116214399a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9fa90fa1-bc84-4c4e-9db3-68116214399a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6dfd7e1c-bebb-4721-a83d-645f325894a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_6dfd7e1c-bebb-4721-a83d-645f325894a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLicensePayment_a7cadf71-69d4-4bcf-b35a-82fed825116a" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLicensePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_insm_DeferredTaxAssetsLicensePayment_a7cadf71-69d4-4bcf-b35a-82fed825116a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_3515e6d1-6b37-449a-b578-bbe118cfa0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_3515e6d1-6b37-449a-b578-bbe118cfa0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLeaseLiabilities_3195d0b0-7711-4db1-8f8f-0feada004d23" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_insm_DeferredTaxAssetsLeaseLiabilities_3195d0b0-7711-4db1-8f8f-0feada004d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c9cf7d95-a5d6-4cac-b044-84ed9c57167a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c9cf7d95-a5d6-4cac-b044-84ed9c57167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f2dc43dc-825b-4087-821a-8ca4973fd49f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f2dc43dc-825b-4087-821a-8ca4973fd49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_09efd93a-fdb0-4c87-9040-e35bab14760f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_5b1fee3a-f720-4a5b-bfd8-671d4f9aee06" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_09efd93a-fdb0-4c87-9040-e35bab14760f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b2705b5f-7854-4447-9608-9a9e644d588f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_b2705b5f-7854-4447-9608-9a9e644d588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c46e6fd2-4998-4ba4-810a-191e76d5cf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c46e6fd2-4998-4ba4-810a-191e76d5cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_909ef3e4-32ff-4b89-a736-20edc30b63ff" xlink:href="insm-20201231.xsd#insm_DeferredTaxLiabilitiesConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:to="loc_insm_DeferredTaxLiabilitiesConvertibleDebt_909ef3e4-32ff-4b89-a736-20edc30b63ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c923730f-7874-4fac-9b79-31e5eed02941" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_8d4d258b-e2ec-4e8f-b67d-869c15645e5a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c923730f-7874-4fac-9b79-31e5eed02941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_1782e0ac-cb47-4f60-8132-6fcf76f81ddb" xlink:href="insm-20201231.xsd#insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:to="loc_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances_1782e0ac-cb47-4f60-8132-6fcf76f81ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9026b934-932d-47e0-a71e-997a22e4eb21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9026b934-932d-47e0-a71e-997a22e4eb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_aa226a7e-3fa6-4248-97c9-1b8dfcc0639e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_27c8b6b4-7c2b-4f83-af84-3ce9d201eda4" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_aa226a7e-3fa6-4248-97c9-1b8dfcc0639e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef9dcb82-e8f9-4ad0-a424-308a171f9afb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef9dcb82-e8f9-4ad0-a424-308a171f9afb" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a0237bac-170b-441e-8554-160ea4419f46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a0237bac-170b-441e-8554-160ea4419f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b79acb87-215a-4f89-a462-801adeb49546" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_b79acb87-215a-4f89-a462-801adeb49546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1aeca0bb-fd30-412f-8e94-cc8860c233d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1aeca0bb-fd30-412f-8e94-cc8860c233d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d95b1791-2621-4eeb-97be-64a5c5f284a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d95b1791-2621-4eeb-97be-64a5c5f284a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a89dc6c8-731b-440e-ab28-cc1148fa2f91" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_af5bd4c5-9063-432f-a4fd-04b6c4d710b7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a89dc6c8-731b-440e-ab28-cc1148fa2f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreements"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract_877420ae-20dc-49a3-be4e-475fbef7bcdd" xlink:href="insm-20201231.xsd#insm_LicenseAndOtherAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAndOtherAgreementsTextBlock_23970a90-cd62-4251-853d-f33d815e0bb6" xlink:href="insm-20201231.xsd#insm_LicenseAndOtherAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract_877420ae-20dc-49a3-be4e-475fbef7bcdd" xlink:to="loc_insm_LicenseAndOtherAgreementsTextBlock_23970a90-cd62-4251-853d-f33d815e0bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#LicenseandOtherAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/LicenseandOtherAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAndOtherAgreementsAbstract_8f4a6e08-ef76-42fe-86a7-3e852ed78cee" xlink:href="insm-20201231.xsd#insm_LicenseAndOtherAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_LicenseAndOtherAgreementsAbstract_8f4a6e08-ef76-42fe-86a7-3e852ed78cee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:href="insm-20201231.xsd#insm_MilestonePaymentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:href="insm-20201231.xsd#insm_MilestonePaymentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentAxis_6ac9826d-ec5b-49b0-9d19-25b999ebbf84" xlink:to="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneNewDrugApplicationMember_19e0ab53-7cab-423e-86be-f4e0851764bc" xlink:href="insm-20201231.xsd#insm_MilestoneNewDrugApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneNewDrugApplicationMember_19e0ab53-7cab-423e-86be-f4e0851764bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneFDAApprovalMember_f3cdae57-996d-40a8-9b9f-b219fecff2fe" xlink:href="insm-20201231.xsd#insm_MilestoneFDAApprovalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneFDAApprovalMember_f3cdae57-996d-40a8-9b9f-b219fecff2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_MilestoneEMAApprovalMember_225bf1eb-a5f7-4464-82cd-502917eccf7b" xlink:href="insm-20201231.xsd#insm_MilestoneEMAApprovalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_insm_MilestonePaymentDomain_a5718f3b-bf10-4e9a-8c43-e67cbd465489" xlink:to="loc_insm_MilestoneEMAApprovalMember_225bf1eb-a5f7-4464-82cd-502917eccf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3f774d0-154c-4510-a6d6-f3e86c1b4da8" xlink:to="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_27504523-5efd-4a40-8878-3b7f3adc276f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0b3c3bc-b329-4303-9cbc-4f51f49bf621" xlink:to="loc_us-gaap_LicenseAndServiceMember_27504523-5efd-4a40-8878-3b7f3adc276f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f5e5592-cbdd-4263-bcf9-671f4258424d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_5ad8d184-f614-46e9-b34f-4a110959e818" xlink:href="insm-20201231.xsd#insm_PRIPharmaGmbhCommercializationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_PRIPharmaGmbhCommercializationAgreementMember_5ad8d184-f614-46e9-b34f-4a110959e818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_c219d584-94b6-4d81-963f-ce1615aa969a" xlink:href="insm-20201231.xsd#insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember_c219d584-94b6-4d81-963f-ce1615aa969a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_4463963e-8ce8-44e8-b13d-22c2ba45823d" xlink:href="insm-20201231.xsd#insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember_4463963e-8ce8-44e8-b13d-22c2ba45823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialFilVFinishServicesAgreementMember_5d66299a-0d4a-4fae-8184-dec65b974147" xlink:href="insm-20201231.xsd#insm_CommercialFilVFinishServicesAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_CommercialFilVFinishServicesAgreementMember_5d66299a-0d4a-4fae-8184-dec65b974147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_LicenseAgreementWithAstrazenecaMember_12c2b642-88d8-4c0d-82ce-f7d1cc3d6f76" xlink:href="insm-20201231.xsd#insm_LicenseAgreementWithAstrazenecaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_LicenseAgreementWithAstrazenecaMember_12c2b642-88d8-4c0d-82ce-f7d1cc3d6f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PPDDevelopmentLPAgreementMember_67cea324-a961-4ea4-ab35-bf4a0c592410" xlink:href="insm-20201231.xsd#insm_PPDDevelopmentLPAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3445573-1460-4e2c-9cde-2719e888c357" xlink:to="loc_insm_PPDDevelopmentLPAgreementMember_67cea324-a961-4ea4-ab35-bf4a0c592410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0dfb01f4-7f87-4b2a-8b6b-027a419255b8" xlink:to="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b4b30a1c-d04c-4af8-a806-6cd2dbf3c54d" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:to="loc_srt_MaximumMember_b4b30a1c-d04c-4af8-a806-6cd2dbf3c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2032e7c4-2a70-46f8-9607-fb6d780b7521" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3d6a7581-94f4-4dfb-83be-54f94ec54a3a" xlink:to="loc_srt_MinimumMember_2032e7c4-2a70-46f8-9607-fb6d780b7521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ac1b3936-6be6-4d46-99b7-37eede75dfcc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16885895-4fbd-4255-a3b8-70238b46d3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c24456f3-cd3a-40a2-88ca-51b58a400aa7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_16885895-4fbd-4255-a3b8-70238b46d3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ee299bb3-57e6-4a4c-a617-dc632314cddb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementMilestonePayment_557082a3-6659-40e1-bae4-09fdc9b2eaca" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementMilestonePayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementMilestonePayment_557082a3-6659-40e1-bae4-09fdc9b2eaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_15970081-4472-4bca-bd89-cf388535086a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_15970081-4472-4bca-bd89-cf388535086a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_a105214c-61b8-4cc4-9504-06e033009f52" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RoyaltyGuaranteesCommitmentsAmount_a105214c-61b8-4cc4-9504-06e033009f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_a29d9729-324c-4bf0-9a47-6343e55645f2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RoyaltyExpense_a29d9729-324c-4bf0-9a47-6343e55645f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_0406c155-7a0e-426d-94ef-0f0e28b35dc3" xlink:href="insm-20201231.xsd#insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments_0406c155-7a0e-426d-94ef-0f0e28b35dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_df81d224-ee9a-42f8-8f8a-d4870453da38" xlink:href="insm-20201231.xsd#insm_AdditionalRoyaltyGuaranteesCommitmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount_df81d224-ee9a-42f8-8f8a-d4870453da38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfContractManufacturingAgreement_8599eaed-e1e7-4c8b-b8b3-0c1f58166ad3" xlink:href="insm-20201231.xsd#insm_InitialTermOfContractManufacturingAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_InitialTermOfContractManufacturingAgreement_8599eaed-e1e7-4c8b-b8b3-0c1f58166ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_e93f7c7e-6d2f-420d-b519-e3d78c534545" xlink:href="insm-20201231.xsd#insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement_e93f7c7e-6d2f-420d-b519-e3d78c534545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_6fa0b52d-dfe3-493a-8cb6-c0fe70c9c5a0" xlink:href="insm-20201231.xsd#insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement_6fa0b52d-dfe3-493a-8cb6-c0fe70c9c5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementMinimumObligation_e045cd8c-7346-48f0-a0cd-ba3fb6946666" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementMinimumObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementMinimumObligation_e045cd8c-7346-48f0-a0cd-ba3fb6946666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_AdditionalTermOfContractManufacturingAgreement_235a5d62-407a-44b9-8029-b1ee6bab59bb" xlink:href="insm-20201231.xsd#insm_AdditionalTermOfContractManufacturingAgreement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_AdditionalTermOfContractManufacturingAgreement_235a5d62-407a-44b9-8029-b1ee6bab59bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_ae035350-9eed-4fd2-baa6-2de75f2e37a2" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement_ae035350-9eed-4fd2-baa6-2de75f2e37a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_980b50d9-623e-4907-8b6e-d8322f8806e6" xlink:href="insm-20201231.xsd#insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement_980b50d9-623e-4907-8b6e-d8322f8806e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementUpfrontPayment_7b727b38-1250-4464-94be-10133be7c2d1" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementUpfrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementUpfrontPayment_7b727b38-1250-4464-94be-10133be7c2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementPhase3StudyPayment_d08a284c-25c4-4122-a898-1db3556ef8e3" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementPhase3StudyPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementPhase3StudyPayment_d08a284c-25c4-4122-a898-1db3556ef8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_9e38f16e-86a1-4f00-85c5-bd61a177a3df" xlink:href="insm-20201231.xsd#insm_PaymentsUponAchievementOfClinicalMilestonesAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_PaymentsUponAchievementOfClinicalMilestonesAmount_9e38f16e-86a1-4f00-85c5-bd61a177a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_9ac327ba-721e-4007-acd9-8de5aab838b0" xlink:href="insm-20201231.xsd#insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication_9ac327ba-721e-4007-acd9-8de5aab838b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_5928d420-eb02-4c35-83cd-5561f82c70d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_PaymentsForRoyalties_5928d420-eb02-4c35-83cd-5561f82c70d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_56132862-8552-4142-8ff2-5e4153193ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_56132862-8552-4142-8ff2-5e4153193ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement_337604aa-2630-4163-862f-ba6025dfa3b4" xlink:href="insm-20201231.xsd#insm_InitialTermOfClinicalDevelopmentServicesAgreement"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_InitialTermOfClinicalDevelopmentServicesAgreement_337604aa-2630-4163-862f-ba6025dfa3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_ba776dee-1547-4715-88cc-971a8b712dca" xlink:href="insm-20201231.xsd#insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c7cb801f-341c-4375-a1e2-d1ebc504a9fe" xlink:to="loc_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement_ba776dee-1547-4715-88cc-971a8b712dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1cbfc242-eb24-4047-b05d-c0e79b8caadb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_17d4f07e-85c2-4ad3-b93c-0ce7bf9c34ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1cbfc242-eb24-4047-b05d-c0e79b8caadb" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_17d4f07e-85c2-4ad3-b93c-0ce7bf9c34ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_657ab782-eb0a-421c-a650-05acfb2e1bae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_657ab782-eb0a-421c-a650-05acfb2e1bae" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:to="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d008fb69-9c0e-4f1a-991c-c24f5da3886a" xlink:to="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_insm_BridgewaterNewJerseyFacilityMember_c0507d23-64c5-4d05-ae25-2bdb3bc7c3bb" xlink:href="insm-20201231.xsd#insm_BridgewaterNewJerseyFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c2114df5-1fa7-4efa-82c5-6571c138f025" xlink:to="loc_insm_BridgewaterNewJerseyFacilityMember_c0507d23-64c5-4d05-ae25-2bdb3bc7c3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_02340d17-030c-4b1d-87ad-1e884da7d532" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b845c9ff-0a4c-4366-b9a0-bdc2946c36c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b845c9ff-0a4c-4366-b9a0-bdc2946c36c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f3bf2b94-4796-4a03-ae37-750443e0cd12" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_OperatingLeaseExpense_f3bf2b94-4796-4a03-ae37-750443e0cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_e1422015-5223-44e0-9d48-994591531da9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_LeaseAndRentalExpense_e1422015-5223-44e0-9d48-994591531da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_fcdc8904-0126-4e3b-875e-ae2d20ce2c92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9ef64e68-c5e6-485e-9e9d-d00b6b12299d" xlink:to="loc_us-gaap_PurchaseObligation_fcdc8904-0126-4e3b-875e-ae2d20ce2c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlan" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlan"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ad05efba-0fcf-49fd-92ee-fc17bab2e88d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76c03541-2313-4767-b954-432e04e1baf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ad05efba-0fcf-49fd-92ee-fc17bab2e88d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76c03541-2313-4767-b954-432e04e1baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="insm-20201231.xsd#RetirementPlanDetails"/>
  <link:presentationLink xlink:role="http://www.insmed.com/role/RetirementPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_990005a3-e5eb-4685-999e-7f27d9e9d850" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf722a15-cdf8-4f28-8181-22da4ae9d4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_990005a3-e5eb-4685-999e-7f27d9e9d850" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_cf722a15-cdf8-4f28-8181-22da4ae9d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_89bf9801-1d2a-48f3-b4e5-c2af009a8e36" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_990005a3-e5eb-4685-999e-7f27d9e9d850" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_89bf9801-1d2a-48f3-b4e5-c2af009a8e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3c106a7d-948d-49bb-8193-459f40ec14e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_990005a3-e5eb-4685-999e-7f27d9e9d850" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3c106a7d-948d-49bb-8193-459f40ec14e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>insm-20201231_g1.jpg
<TEXT>
begin 644 insm-20201231_g1.jpg
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MW-M%,"89GAD"R+%*%8QR[=DFUMK-@X[^@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7^UA_P EL^!_
M_8]R_P#I,U>Z5X7^UA_R6SX'_P#8]R_^DS5[I0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^
M!_\ V/<O_I,U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@_%/XF^"/@M\-
M/$'Q?^)>OPZ5X=\+:+<ZKKFI7!^2VM+>)I99#ZX16..IZ5^8'_!&G_@I-^UM
M\0_VQM8\+?MS:+<Z'X>_:LTNZ^)O[-EM?W!;['IUJQM'T<9X$ATZWLKT(GRE
M&>8_/<$#TW_@LIXFU#]LOX__  C_ .")_P /-<D@7XHWR^+/C?=V=QLDT_P1
MITPD>WW AD>]N8A"C#.#$0PVN:[_ /X++?L:^+/BE^QSH_Q1_9.T2'3OBM^S
MIJEKXU^#T6GVV!YFGJ/.TI43&Z&XM4:'R1A7=80>!0!]HT5Y=^Q7^U=\.OVX
MOV5/ O[5WPKG!T;QMH$5^EL90[V4_*7%HY'!DAG26%L<;HSCBO4: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_
MVL/^2V? _P#['N7_ -)FKW2O"_VL/^2V? __ +'N7_TF:O=* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWJ/A36_$=S)>^-RDHU?7I;I5"0EQM#GY3D<XZCBOKJ@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_)
M;/@?_P!CW+_Z3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 >%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U>Z4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M".*?4)$C:1T@C9@TK*BLY" D*I)X!- &K17SO^WC^UU^T[^S=)X8\'?LI?L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-7N
ME !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRLK%2#U!-?%G_!"SXS:%\#/B+\6?^".NI?$^P\31_!O57UOX.ZY::O'>#5O
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M? #]HGPW9H9M8\)_#UM1T#Q'Y:\L;(W.^WF(7)\L@R.0%0$FOJ']A/\ ;W^
M'_!0KX&K\</@7JE[ EG?2Z;XG\-Z]:_9=5\.:E#Q-8WT!),,R'W*L""I(- '
MM5%8&L_$?0K/X:ZE\4?"T,_BFQL-*N;ZWMO"YCNY]2\E'8PVP#A)96*%%7<
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MR@"1 6<C# #/%?0= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'A?[6'_ "6SX'_]CW+_ .DS5[I7A?[6'_);/@?_
M -CW+_Z3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\0?!S3OB;%)K'[->O>+D,,?CS1HV\H@EOEAO69#.D )WPSQ[=W[MYYOVA_\
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M7/V0?^">O_!.KQ5X]\9:']G36?B)X]?^Q/!.DF>!)T<7;'?J)5)%+PP;'&<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***_.K]NG]J_XZ_\
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MPEX@\">*--\4?#'Q9I=BDC^&M;T]]UI<) 2JRP@9CD@)4/$[*&0[74 ^//\
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M110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7^UA_R6SX'_\
M8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !117RI_P %//\ @I/!^Q-X<T'X/_!+P.?B%\?OB=<-IWPD
M^&-E)F2]N#PU_=D$>18P<O)(Q4-L*AE >2, Q?\ @I]_P4?\9?L\:QX?_8O_
M &+?"=MXX_:7^*$1C\$>%V^>U\/V9)637=4(_P!39P@.PW?ZQHR "JN1U_\
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M-X2_86^%%]\-O#GQ>^(/CR^UK7)-:\1^*_B5XJEU74=1OY(HHI)2[X6-2L*
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MN_&?Q+\;7_\ 8_PG^%^B@OJ/BC5G*JD:(N62!&=&EEQA%8 9=T5N%_X)A_\
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M4#FW\#>&9Q_PL+Q-9GM?79&W2$=>3$BF0 M'(CC#UR'@']A_]ES]@;_@N_\
MLX_!;]E+X2:?X5T0_ ;Q=<7YMR\MUJ5SYT*FYNKB0M+<2D #<['  5<* !ZQ
M_P 1('["G_1'OV@/_#):I_\ $UX_\(/VT/ 7_!0?_@O7\&?C!\#?A?\ $C3_
M  ]X3^"_B?3-8U'QGX#O-)C2YFDCDC16F4!LJ#WZT ?J]1110 4444 %%%%
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M?#[PO?\ CCQYXHT_1-%TJU>ZU35]6O4M[:S@09>6660A8T &2S$ 5^>7B_\
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MZ?[;W[2T/]H?\%7/^"R_Q7\:6UTG^G^!?AQK$UAI6>Z[YP8G4\ @6<9P.O3
M!]\?M-_\%0?^">7[&\=XG[2G[8O@+PQ?6 !NM!FUZ.YU50>F-/MS)=/_ ,!B
M-?"GQ+_X.I_AW\1M2NO!?_!,+]@+XR?M#:S%*88]2TSPU<V>F%CT<&.&>Y(
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M 55 P  .@ H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'C'[>G["?P+_ ."B'[/.H_L]_'33)E@EE6\\/^(-.?R]
M0\/:G&#Y&H6<O6.:,D^S*61@58@_.7_!.']NWXY_#3XVS?\ !)__ (*<:G#%
M\:O#U@9_A[X_VF.Q^*FA1@[+Z!FX^W1HA^T0YW$J[C)63;]Z5\^?\%'?^"=W
MPL_X**_!*'P#XKUB[\,^,/#=^NL?#3XC:(2FI^$]9C(:&[MW4JQ7<JB2+< Z
M@<JZQN@!]!T5\3_\$Q_^"B'Q5\>^/-9_X)U_\%"M'M/"_P"TI\.[)9+T0#R]
M/\?:0,K%KVEL0HD5PN98U V/N(5 'CA^V* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKG?BQ\7/A=\"/A]J?Q8^-'Q!T?PMX
M9T6W,^JZ[KNH1VUK;)TRTCD $D@ =6)  )(% '15\M?M[?\ !6K]G']AK6;#
MX.VVGZO\2_C+XB 3PA\%OA];_;=<U*1ERCRH@86<&/F,LN/E5V19-A%?/>H_
MMS?M]_\ !7K4)_ /_!*30+KX2_!5YFMM9_:B\=Z&ZW6JQ E7'AS39=K2G@@7
M,NT#YA^YD12?I_\ 8)_X)>?LJ_\ !//1K^\^$?AZ^UOQMX@)E\9_%'QC>G4?
M$7B*=CN>2YO)!N"EOF\I-L>1DJ6RQ /FOPC_ ,$QOVN_^"E_BBP^.7_!;#QQ
M!:>$K6[2]\+?LJ^ M5=-!TYE.8WUJ[C;=JERO&55O*5@=K;':(?H;X0\'^$O
MA]X7L/ _@/POI^B:+I5JEKI>D:39);VUG @PD4448"QH ,!5  K1K*\9>._!
M'PZT23Q+\0?&6E:%IL7^MU#6=1BM8$^LDC*H_.@#5HKY"^-?_!>W_@C_ / 6
M=[#QE^WEX(U*\1MBV/@RXE\03/)G C TR.?#9XP2,'KBO.#_ ,%Y=8^+">3^
MQ3_P2G_:;^*?F?\ 'IKEWX&7P]H=QGIB^O7XS[QC P>] 'WOXCU_3O"N@7OB
M;6!<?9-/M9+BY^R64MS+Y:*6;9%"K22-@'"HK,>@!-?#WQ"_X.5/^"-'@CPQ
MK>K6'[9>E:MJ>D6-S+!H5KH.J+/>7$2,5MD+6@57=E" L0 3R<5E'XU?\'('
MQY<+\/OV+OV?/@/8S??E^*'Q"NO$U]"A[HND*L1DQ@X<;>QK^0:@#]T?^#;?
M_@OK\%/@7JWQV\)_\%&/CS%X9@\>>.'\>:)K%_9W=S%+JMZ[KJ4($$4C)NVV
MSJ#@?+)WZ_J!J_\ P<M?\$2]*M7GA_;>L=0F7 BLM+\':W<3SN<!41$LCN8D
M@>GJ1S7\=U?K;_P:P?MN:-^QSJWQMBT7]C#XF?&?QSXH3PW'X0TKX:^$$OY+
M)8/[5^T/=7;L!80MYT&7.=VP\$)D '[%_P##\[XE_&3]Q^PQ_P $B/VC_B:)
M,_9-=\2>'8?">AW7H4OKYVX]28Q@$<54UWXC?\'&GQ>T>X\07G@;]F3]F?PW
M%$9;Z^\7^([OQ-JU@G][?;[; @=R^!TP:D_X2'_@XL_;&XT#P9\(/V1?"]U_
MR]:W=?\ ";>*X4/1TBC"Z?TR2DFU@<#L:MZ'_P &]G[/_P 4-8M_&G_!1C]I
MSXO?M,:W#*)A9_$'QC/::#;2C/S6VEV+1I"N3GRR[J?3&00#XF^.7QT^#FI>
M*6^'/[37_!PS^T/^T1XQG9MOPO\ V,O"UOIAO".#;[M*26WD4'"%7G1SGG!R
M1!\)?^"3GQE^-6L?\)'^S+_P0]^'_P .K>]8&;XG_MK^/+[Q7K%ZN>93H:2R
M+!,!C"3(4)ZG&<?M5\#OV;/V>OV9?"P\$_L[? _PGX'TD ;K#PIH%O81R$?Q
M.(47>WJS9))R37;4 ?FI\./^#>"7QIH:Z/\ MV?MY>//'&C2X-U\,OA=I]KX
M!\'NN/\ 52:?I*J9PHRHDWHQ!.<$FOL/]EK_ ()U?L,?L46,=K^RS^ROX,\&
MSI%Y;:KINCH^HRKC&)+V7?<2\9^_(W4^M>T44 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !15'Q-XG\->"O#M[XO\9>(;'2-)TRU>YU+5-3NTM[>TA0%GEDD<A8T4 D
MLQ  &37B_P %/^"E_P"PW^T#X\N?AE\-?VCO#-QKJ:P^G:9IMUJL4$FM2+#%
M*9+ .P^VQ[9D^:+=W.,8) /=J*Y[XI_%KX7? [P+?_$_XS?$71/"GAS2XO,U
M'7/$.IQ6=I;KZO+*RJ,] ,Y)X'-:7A;Q/H'C;PQIOC/PIJL5]I>KV$-[IM]
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M +;'_!;#QSIVGS_Z_P *?L^>%[3PI' I^]&FHXDN)0>F73./K0!]*:?\-?\
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M_I]N?.\S[=_L;?*_BW?* ??]%%% !1110 4444 %%%% !1110 4444 %%%%
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M>+(8;3X<:Y-*(8FD<JMA.QVJH)8X'  )/05_#4?A/\4U!9OAKX@ '4G1I_\
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M"DI&\H20QJQP"VQL9SM/2OY#S_P=&_\ !=<C'_#<W_F,_#'_ ,K*_2'XH?\
M!5?XW>(M2_X1[XU?\'&?PS\/WMR^W_A#/V4/@)<^*9;QN/W5OJ,\;F,]</NY
MP.N:_G?H ^DOV,_^"O/_  46_P""?=KXILOV2?VD[KPO%XTU./4?$RW'A[3-
M4^VW:!P)C_:%M/L<B1MQ3;OXW9VKC]V?^#5__@K)^WA_P42UOXW6W[<'QST_
MQ=I_A*V\.MH-Y=:5I>DRV$MRVI"1$BL;.$7"RBW0LTC_ +LP(%4^:Q'\RE?H
M/_P0C^#?[.?Q6'Q4O/VB/^"3GQ(_:@M-+_L/["_PXU&XCF\,>9_:'F>;%!=V
MYF^T^6FW);;]D;&-W(!_7J"& 92""."**_ $_ O_ (-Z/"[%OB5_P05_;1^&
M,@.)KS6?"OBR.-E[@/%K$H9,X.0HZ"IM+D_X-$+6\32]5^*_Q=^'-\3BUM-:
MU/QW9/".X5BLB*.2#N;H30!^_%%?BMX)^ 7_  ;%>-M@\!_\%8O$FAJS#RDN
M_P!I34-*$;_W_P#3I$VGIR>.*]>\$_\ !+#_ ()2_$39_P *>_X+(_&.^$IP
M1X6_:VCN?./;.QGSCG&/6@#]2Z*_/NR_X(%>"I[5+_PC_P %?/VY;*.1?W=U
MI/[1C8:/^Z";1@5R!_WR.:E_X<4>/-/_ .1>_P""W/[;\7E_ZC^TOC)%=X_W
M]UH-_?K[>E 'W_17P!_PY9_:@L1LT'_@NI^U3&OWA_:&OV5T=_KEH!E>GR_7
MUI?^'1O_  4)LO\ D"?\%\?CA'N_UOV_PKI-SG'3;N4;>^?7CTH ^_J*^ /^
M'7W_  5QL?FT'_@X.\;QL/E4ZA\#= NAL]"&<9;I\WU]:#_P3P_X+GZ=_P @
M;_@X9,T<?,5MJ7[*GAM]WJ'E$^X]^@]!0!]_T5\ ?\,4_P#!P!I_[NS_ ."V
MW@K41][S+_\ 9MTR%L_W<138V\=>O)]J7_AF;_@XKL.;3_@IU\$+\M]X7WP6
M:()]/+EYS[^E 'W]17P ?A#_ ,'*VF_-8_M@_LLZD4^4+J/P^U:$./[S>4YP
MW? XYH_X1K_@Z TSBQ^)?[$6IB/E#J6C>*H3-WP_E'Y1V^7L!WH Z?\ X*<?
M\$\/BMXZ\>:/_P %%?\ @GEK%IX8_:3^'EDR6BS$1Z?X_P!)7#2:#J@RHD5P
MN(96(\M]H+( DL/JO_!./_@HA\*O^"BWP1E^('A'2KKPUXN\.7[:1\2OASK1
M*:GX3UF/*S6EPC*K%=RMY<NT!U4\*ZNB>!_VK_P=%V'[N[\*_L)Z@3R)+&^\
M81*H_ND2#)/OTYKY5^.O[*?_  <.?#[]K9?^"H_P:_9J^ .E_$#3-!DM?'7A
MOX:>+=2DB^(6G1H-MM?6=T$6YN$5 (9(Y(Y<HBY<K&  ?M317Y3_ +%__!6G
M_@M5^W3\%X?CK^SS^PA\"?$NDQWLNG:M8)\5KG3]0TS4(B!-:W5O<Q;[:5"0
M2C]5964LK!CZR?VQO^#@O3>+W_@C3\.]3\OYG.G?M$6,(E'7:OFP_*>V3QGV
MH ^_Z*^ /^'@'_!>*P.R[_X-\[&_+<A[']J_P[$%]B)(,D_2J7B/_@I-_P %
ME+S0+W3&_P""!OC;1;BZM9(K/5=&^//AJ]GM)64A95CDA9"5/(WJRDC!!% '
MZ&$@#)-?'G_!(C_@JGX,_P""H&E?&2_\,RVP_P"%<_%S4=#TKR,9O-"+%M-O
MC@\><B3#ZPGKUK\6/^"@G_!4S_@Z-_95^'^II^U3I.L^"O!/BDW.BV^NW7P[
MT55'G1.OD_:K1)4AF,>\H=X8["R?=./@;_@F%^W[_P %!_V(OB_>>'_^"=_B
M"Z7Q3\2/LFCRZ!:^&H-5?5I5E)MTC@EC?,@:1PI49Q(PZ$T ?VQT5^6G[.7[
M./\ P=0?%7PC;:Q^T;_P4;^%/PL;5;-7>PTWX8Z=KNK:46P2KHL$5J91TPLT
MJ<]<]/1_^'%/COXMCS_VU?\ @KG^TS\2O,.;O1-#\71>&-%N<GD/8V49X[#$
M@P": /L7XS?M6_LO_LY6S7G[0/[1O@7P/&J;L^+?%EGIQ(QG@3R*3GL!R>U?
M*GCK_@X]_P""3OA[7)/!OPT^..M_%'Q$GW/#_P *_ ^IZU/-SCY)(X! V3QQ
M+72_!G_@@#_P1[^!UVNJ^'/V%O".MWX;?+J'CK[1XAEFDZF1AJ4DZ[B>>% S
MT KZK\"_#?X=_"[0U\,_#/P%HOAW34^YI^A:7#:0+](XE51^5 'PK_P]U_X*
M#?&I0G[''_!"OXS:A#/Q!JOQHU[3_!$2*>DIBN&E=U[[5(+#IUI1X:_X.4_C
MTY.L?$S]F?X!Z5-_J_[ T;4?%.M6^?[_ -I*V;D#IMP"0?:OT#IL\\%K ]S<
MS)''&A:221@%50,DDGH * /S]'_!$S]H[XPIO_;6_P""U7[1OC82<W>E?#^_
MM/!>F76>J26UDDFY/]D,/K77_"C_ (-X?^"/WPIU7_A)9?V.=)\8:S(^^[UC
MXC:M>^();I_[TB7TTD)/':,#VKN?VB?^"SG_  2Q_96:>U^-'[<O@"TOK8D3
MZ/HNK_VO?QL/X6M; 33*?0%!7R7^U+_P=._!;X*_#A_B?\)?V$OC/XHT*1S'
MI?BOQEI,?A+0]5DQD16ES>[Y;F3'S>7' S[3G&* /TJ^&/P5^#?P3T?_ (1[
MX,_"7PSX1T_ 'V'PQH-O80X'3Y($5?TKY'_:Z_X+)Z!X6^+5S^QA_P $Z_A+
M<?M!_'L QW?AWPY<A=#\*'.TW&M:EGRK94;K"&WEEV,8F92?E,6__!Q%_P %
MPO@^!=S^&/V-?A!KRX*(E]/XLUVSD'<922.# Z9LFD5^DL;<=[^R_P#\&K_P
M!^#7PVC^%WQ?_;;^,WB[07(?4_"7A?6U\*Z#JDF,&6YM+'=+<2$#;YDEPS[>
M-QXP 8I^#?[#OP6^*UK^U_\ \'!'_!2'X;?$WXQ:4YGT/X=WNO1#PUX(.=WE
M:;H2EIKJ1< &XFB9F*HQ3S%$A]B;_@X4^"GQ98Z;_P $_P#]BOX__M!.QVVN
ML^#/AQ<6&A9'_/6^OQ%Y*^A,1%>X?LZ?\$<_^"77[*)@N/@?^PY\/M.O;;'V
M?6-3T4:IJ$?NMW?&:=?P?FOI2...&-8HHU5%4!548  Z "@#\^O^%L?\''/[
M2V!X!_9:^ _[-^CW'W[GXB^,)_%>M0QGH\4>FJMMOZ'9*,#D'F@?\$9?VN?C
MV#<?M]_\%H?C?XOAFYN?#7PICM/!&E2*>L$L=FLC3QCIDE6. 20:_0:B@#Y#
M^ O_  0:_P""2?[.]\NN^$_V*/"FN:QYGFS:YX]27Q%=RS9R9BVI/,$?/.4"
MX/3%?66B:%HGAG2H-!\-Z-:Z?8VJ!+:RL;=8HHE_NJB@!1[ 5:HH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LT,5
MQ$T$\2NCJ5='7(8'@@@]17*?##X$_"#X+7OB#4/A7\/M.T.;Q3K!U77GL(BO
MVJ[,4<1<@DA1LB0!%P@() RS$];10 4444 4I?#GAZ;78O%$V@V3ZG# 8(=1
M:U0SQQ$Y*+)C<%)Y(!Q5T@$8(HHH IZ%X<\/>%['^R_#.A6>G6QD:0V]A:I#
M'O8Y9MJ #)/)/>KE%% !1110!X7^UA_R6SX'_P#8]R_^DS5[I7A?[6'_ "6S
MX'_]CW+_ .DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 5-<T'0
M_$^D7'A_Q+HUIJ-A=Q&.[L;ZW6:&9#U5T<%6'L1BOCKXZ_\ !O\ _P#!+KXS
M^)?^%B>&?@')\+/&,;,]IXR^#.L3>&;ZU<]9$2T*VY<GG<\+'/U.?M"B@#\@
M_P!H7_@W;_:I0S7_ ,-/VA?A/\?[ $F+P]^U5\+X)]59>X/B;2UCU)V8<<E!
MD GU'PS\?/\ @CC\%/A?-)=_M:?\$E/VC/@F;=MT?CS]FWQG#\0/#L9S_P ?
M,UK="2]M(5/.&GWC ]0*_IBHH _FK_9F^#O[5$MU!8_\$B_^#FG0_$DT+XM?
MAM\5=?U+PSJ <'!@CTO4_M<4TBG"DK&J''4#%?0UU^W]_P '<7[#R!/VB_V%
M-%^,>E0.?M&L:)X4CU":6$=95;P_< Q=#GS+7@9.VOU?_:B_X)L?L$_MIP3+
M^U#^R9X(\77<R;&UF^T5(M21<8PE]#LN8_\ @,@Z#TKYE;_@A?\ $7]G0_;_
M /@F)_P4_P#C/\%XX,FR\%>(]03Q?X7A Z1I8:@<Q@_=+F1V QP2.0#Y5^&?
M_!YM\,?#NM3>$?VR_P!@+QQX(U'3W":C_P ([K<%Y,">-PM-02QE4>JY8C'>
MOL'X+_\ !RU_P1U^,4EMINH?M0OX&U.Y0.NF?$3PW>Z244]";B2(VV/<3&O/
M/BSJ'_!9;P'H1\)_MU_\$Q/@/^V)X*MU*R:GX!N8;/4UAQS)+I>L1/'/*?\
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M5^K5% 'Y^?\ #C;XL?%C$_[9'_!8W]IOQ[OYNM(\*^*(/"FDW/J'L[*-LKZ
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M2Q7D)=A_L]>:_0"B@#\_S_P64_;)\'#_ (O%_P $'_VD[(K_ *S_ (0I-/\
M$6#WQY$J;OZTI_X.)OV:O#YQ\8?V)?VK_AYC_6?\)K\!KR#9ZY\B27IWK[_H
MH ^#_#W_  <P_P#!%?6[P:5JG[8;:#?#&^Q\2> ]=L73/JTED$]?XNU>K>"O
M^"T'_!)CX@;!X>_X*+_!Y&D("1ZKX[L[!V)Z +=/&<^V,U]%>(?"GA;Q=9_V
M?XK\-:?JEOS^XU&S2=.>ORN"*\I\;?\ !.;_ ()\_$G<WQ!_86^#VMLX.9-5
M^&FESOSW#/ 2#[@YH ZKP5^U-^S%\2=G_"NOVC? >O\ F'$?]B^+[*ZW'T'E
M2MFN[5E=0Z,"",@@\$5\>>-O^#?W_@C1X_W_ -N_\$^? D&\$-_8D5QIF/I]
MCEBQ^%<(_P#P;.?\$J]#<R?"'P=\1OAXW6-O!7Q=UR#RV_O+YUS+@_I0!F_M
MY?LC_';]A7]H?4O^"N7_  32\'RZMJ-XB']HCX(V&X0>/],CR6U&TC4$)JT"
MEG!49E^8X9FDCN/L?]D3]K?X%?MR?L_>'_VE_P!G/QE'K7ACQ%:^9!)@+/:3
M#B6UN(\DQ3Q-E'0]",@E2&/R3_PX2F\+-YWP;_X*^_MH>%]G^IL7^-'V^Q3_
M +83VQS^+5\9?M6?\$M?^"GW_!%KPOXF_;-_X)T?\%$?&^N^'-<UY-4^.&C#
MX<Z5J-_!:[OWVMP6$O\ HU[*BEVF"K;R$#>TA4.T8!^YM%?FA\ M/_X+N?&?
MX.^'_C[^R_\ \%5/V=OB]X2\2:>MYH>K^)_A)/IJ749)!$@T^0F*1&#(\9PR
M.C*P#*0.O7Q]_P '-7@8_P#%2? #]D'QU'&,#_A$O%6OZ7)*/7_3E*@^O;/3
MB@#\*O\ @MO_ ,'%/BO_ (+$?!CP=\#+']F7_A6>B>&O$LFMZE&/'!UC^U+D
M6[06_'V*V$0B66X_O[C*/N[?F^)OAK\>O#O[/_Q\^'/[0?[//A/7=&U;P'JN
ME:S*FN^)XK_[9JEI.DS21M#9VWD6\A0#R6$S*"P,KYKS&B@#^OW_ ((8_P#!
M<[_A]'_PM'_C%W_A6O\ PK7^Q/\ F=O[9_M'^T/M_P#TY6WD^7]A_P!O=YO\
M.WYOO+Q#XC\/>$M'G\1>*]>LM,T^U3?<WVH720PPK_>9W(51[DU_,7_P:H?L
MN_M=_M0_\+Y\/?LV_M_:U\"]#LO^$7_X37_A&O!UGJ&HZZ)/[7%LD-U<L&L/
M*"7!+Q@ES,N1\@K]B/#_ /P;D_L$>(-9@\7_ +77C+XN?M#:[!)YJ:G\9_B?
M?Z@J2>J06[01;.H",K #CG% '<?';_@O?_P22_9_U$^'M?\ VSO#7B36FD\J
MWT'X>+-XCNIYO^>0&G),BO[.RX/!YKSL?\%C?VT?CZ?L_P"P7_P17^-/B6WF
M(%OXF^,%W:>!]-93_P MX_M32/<1XYPNUFZ  U]@_ G]D3]E7]E_3AI?[./[
M-_@;P+#Y>Q_^$4\+6MB\H]7>&-6D)[EB2>Y->B4 ?GS_ ,*8_P"#C/\ :7&?
MB7^U]\#/V=-(N.EE\+_!,_B?5XXCU26;4V6!9,9&^$X&<@9%.3_@WF_9]^*<
MHUC]OO\ :^^/G[0DN[S+C2_'WQ,N;714(Y_<V-@81 G?:)"*^E/VY/\ @HK^
MR=_P3O\ AY%X\_:6^)$=C<ZB_D^&_"NF1?:]:\07.0%M[*S0^9,Q8JN[B-2R
M[W4'-?(*?L]_\%*?^"T,@UK]L^]US]FG]G"[.ZT^"OAS4/+\7^,+8\C^V[Q1
MFQ@D4_-:)AL%D=0RI-0!Q4?QS_8Q^$/Q3N_V/?\ @WL_X)S?#7XC?%S2W%OK
M_P 2;#088_#'@DY(\W4M;VF:\D7!(MX969B'4,74QGZ(_9 _X(V^&_!7Q:M_
MVSO^"@_Q9N_V@_CZ0)+?Q1XFM@NC>%CG=Y&BZ;CR;5$;I*5WY&]1$693]2?L
M\_LW? C]D[X5:;\$?V</A7H_@[PMI28L]'T6U$:;L -+(W+32M@%I9"SN>68
MGFNWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO]
MK#_DMGP/_P"Q[E_])FKW2O"_VL/^2V? _P#['N7_ -)FKW2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?B1\*_AA\9/"TW@;
MXO?#C0?%6B7/_'QH_B31X+ZUE[?-%.K(W4]16]10!\(_$3_@W<_X)]W7BB?X
ME_LL3>/_ -G;QA-R?$GP+\<76BEB#E5:U)DMO+SG*)&F02,^F(?@%_P<'_LD
M9D^"/[8WPL_:6\.6_P!SP_\ &+PN_A_7%A[10W^GL8IY?^FMQ@')XZ"OT)HH
M _/"_P#^"Y'B'X'6,WAW_@JE_P $O?C%\&;,HT>J^*M.T=/&/A-4QAC+?Z>#
M@$<[/*?C.3QS'X?_ &7O^#:__@K;;G4/AAX"^!OB[5KM?.D'@BX70->4XR))
M8;-K:\5AUS*O;GIBOT3(!&"*^8/VH/\ @C#_ ,$POVO[N37/C1^QWX2.N22>
M;_PD_ANU;1=4$P.5E-W8-#+(RGD>86&1T- 'S+\8/^#9SX<ZWIO]G? +]O#X
MK>'[.)-MEX5^)EOI_C_P[:#L(].U>(@#US(<X%?)GQ"_X-O_ -NOX-:X_C7X
M9_!SX%?$&ZA.8O$'PP\6:Y\-?%#X.?W<5O,VD0YZ_P"J."!CBON+_AT=^WU^
MS!B[_P""<_\ P6!^(EAIUOS;^ /CQ80^,-*=!TMX[F0)<6<0XQY89@.,\YH_
MX;[_ ."TO[* ^S_MK?\ !*>S^*>BVP_TKQS^R_XF^WNX']S1+[;=N2.<AU&1
MCOP ?G__ ,+<_P""O_[$0$?B[XH?MO?"NUM3^_D^('@;2/C-X?C4'[DVKVY@
MEA3'1HXF; P/6O5?@%_P<-_MOZE<)IVD?%#]CWX[JLFR'2K'Q]?_  W\0W#
MX,3P^)(XK?SLY&V$,OIGK7W1\!O^"_?_  2V^.'B/_A7VL_M#+\-/%\;B.\\
M&_&'2YO#-]:R'I&[7@6!G/3:DK'/'<9]P^,O[&G[#?[96B)K/QO_ &;?AO\
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M5N5!RJ1!DY1P)DW8QM+_ &$/V]_^"NFI6_Q#_P""LWB&X^%GP::9+G1/V6O
M>N.LVI1@[D;Q'J4.UYSPI^S1%5!VG]RZL&_0CX5_"?X9? [X?Z7\*?@YX!TC
MPOX:T6V%OI6A:%81VUK:QCG"1Q@ 9)))ZDDDY))H ^8/V&_^"/?P>_9@^(<W
M[4_[0'CW5OCC\?\ 54SK/Q>\?*)9[4D']SI=L2T>F6Z@LJK%\X5BN_9A!]?T
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M%_M8?\EL^!__ &/<O_I,U>Z5X7^UA_R6SX'_ /8]R_\ I,U>Z4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#PO]K#_ )+9\#_^Q[E_])FKW2O"_P!K#_DMGP/_
M .Q[E_\ 29J]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\
M:P_Y+9\#_P#L>Y?_ $F:O=*\+_:P_P"2V? __L>Y?_29J]TH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /"_P!K#_DMGP/_ .Q[E_\ 29J]
MTKPO]K#_ )+9\#_^Q[E_])FKW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \+_ &L/^2V? _\ ['N7_P!)FKW2O"_VL/\ DMGP/_['N7_T
MF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ :P_Y
M+9\#_P#L>Y?_ $F:O=*\+_:P_P"2V? __L>Y?_29J]TH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#@5;?_ !5'_#6'QL_Z,?\ '?\ X%6W_P 50![I17A?_#6'QL_Z,?\ '?\
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M6'QL_P"C'_'?_@5;?_%4 >Z45X7_ ,-8?&S_ *,?\=_^!5M_\51_PUA\;/\
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M_P 50![I17A?_#6'QL_Z,?\ '?\ X%6W_P 51_PUA\;/^C'_ !W_ .!5M_\
M%4 >Z45X7_PUA\;/^C'_ !W_ .!5M_\ %4?\-8?&S_HQ_P =_P#@5;?_ !5
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ME)KW2H-/TO3-(@-MI6G06L;2,[1V\*HI8G);  Y)ZF@">BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q
M[UG_ -*37NE0:?I>F:1 ;;2M.@M8VD9VCMX512Q.2V !R3U-3T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?_!/?_DB>K?\
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MA3^V;^TA\:?V;?A[\.O&6B:C\$+C1;;Q%=^+]&.G&]FU%+R2/R+>0^<L8CM
MVZ5(RPF4A<#)^B*_/#_@F7_RG&_X*,_]A#X7?^F"]H ]_P#VS?\ @H=<?LQ>
M+[?X1?!W]E#XD_&WQ[)I"ZO?^%_AUID;)H^GO))'%<7MU.RQ0><\,ZPQC?)(
M8),)A2U'_!-__@IW\"?^"EO@;Q)K/PS\->)?"?BGP+K7]C_$'X>^-M-%IK'A
MV]^<*D\09AM<QRA6SDF)U959&4>_0:+X5\+76K>*XK&SL9=0=;K6M08*AE,4
M*QAY'/98XU'/ "_6OC?_ ():? N/Q!^T_P#M*_\ !3FTTM].T3]H/Q7I$7@*
MQ:'R_M>@:+8_8H=7VD @7\IGN4W#)A,,G_+4B@#Z:U[XZC3_ -IKPY^S7HOA
MC[?<ZIX0U+Q'KFJ?;O+71[6WGM;:W5H]C>8]S+<2!!N0!;.=LG:%/F.A_P#!
M2_X1>)?^"BJ?\$V=+^'/C:W\6KX!N?%L^N:UH#Z?I[V45TEJOD?:-LUQNE\U
M?,6,1?N6VN_:[^QLB?%3XM_&+]K:?][#XD\7_P#"(>$YCVT/P\\]D0#W5]6D
MUN96'#1S1$9&"?G'QW_RM)^!O^S,+[_U(Y: /H_]O+_@H)X7_85T[PI;O^SY
M\3OBKXD\9ZC<6^B^"?A'X8&K:LUO;QA[F]:$R)MMHC) CR9^5KF+C!)'CWP'
M_P""VMC\9OVH? G[*?BS_@FW^TO\--:^(<M^N@:I\3/ EKI5B4LK5KFYD+M=
MEF5$"@[%8[I8QC+BOM@:-I U<^(!I5M]O-L+<WWD+YQA#;O+WXW;-Q)VYQDY
MKY.^!X'[2?\ P5F^+'QUDQ<>'_@3X0LOAGX6DSOB.MWXAUC7)4/19$A.C6Y(
MY!213CD$ ^NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "H[NYCLK66\F
M61DAC9W$,+2.0!D[54%F/H "3T J2B@#YW_9#_X*1?"G]LW]I#XT_LV_#WX=
M>,M$U'X(7&BVWB*[\7Z,=.-[-J*7DD?D6\A\Y8Q':!MTJ1EA,I"X&37_ &S?
M^"AUQ^S%XOM_A%\'?V4/B3\;?'LFD+J]_P"%_AUID;)H^GO))'%<7MU.RQ0>
M<\,ZPQC?)(8),)A2U> ?\$R_^4XW_!1G_L(?"[_TP7M??L&B^%?"UUJWBN*Q
ML[&74'6ZUK4&"H93%"L8>1SV6.-1SP OUH \!_X)O_\ !3OX$_\ !2WP-XDU
MGX9^&O$OA/Q3X%UK^Q_B#\/?&VFBTUCP[>_.%2>(,PVN8Y0K9R3$ZLJLC*/4
M->^.HT_]IKPY^S7HOAC[?<ZIX0U+Q'KFJ?;O+71[6WGM;:W5H]C>8]S+<2!!
MN0!;.=LG:%/S+_P2T^!<?B#]I_\ :5_X*<VFEOIVB?M!^*](B\!6+0^7]KT#
M1;'[%#J^T@$"_E,]RFX9,)AD_P"6I%>L_L;(GQ4^+?QB_:VG_>P^)/%__"(>
M$YCVT/P\\]D0#W5]6DUN96'#1S1$9&"0"EH?_!2_X1>)?^"BJ?\ !-G2_ASX
MVM_%J^ ;GQ;/KFM: ^GZ>]E%=):KY'VC;-<;I?-7S%C$7[EMKOV[G]J+]K7P
M3^S GA'0=1\-ZKXE\6_$+Q(N@^ _!N@>3]LUB]\IYY"&GDCBA@AABDFEFD<*
MB)_$S(C?(OCO_E:3\#?]F87W_J1RUTG_  7E^!6K^.?@/X"_:#^#OQO7P+\:
M/A3\0+;4?@G*]JUR/$6N7*&W701;J&:8WBG9PK!0C-)B$2L #WKP'^VE%-^T
MGI_[(GQW^%-]X#\=:]X;N=>\(QOJL&H:;X@L[9XTNUM;J+:WVB RQ-)#+%&=
MDBNAD4,5]QK\O?\ @EK^U7!^WQ_P4.USQ5^WQX:G^'7[3GP4\(S^'M%^"-Q8
MM;VFDV%S]G.HZY:3O(YU!KJ185# A(+<Q*HF#_:9/U"H **** "BBB@ HHHH
M **** "BBB@ HHHH **** ([NYCLK66\F61DAC9W$,+2.0!D[54%F/H "3T
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MDY$\;11M=,/*)^SB1;G<^'G[3_\ P5L^(?@WXA:EXZ_X)BV?P=/A[X>7?_"
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MM=,/*)^SB1;G[KHH ^,/AY^T_P#\%;/B'X-^(6I>.O\ @F+9_!T^'OAY=_\
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M*_B3PWX(^-UYX/D\&:_>>(=!N JZ/IES:S_:(;3499HO,>53'B-LC[VRI_\
M@I5\1/\ @I5XI^+VG_!3X#?\$N]9^*_P:MK9;CQC=1_&'P[X>'BVX(5DT]EN
MIWG&G)R)XVBC:Z8>43]G$BW/W710!\8?#S]J#_@K9\0O!OQ!U/QU_P $Q;/X
M.GP]\/;O_A -)E^*&E>)+KQ%XBEPEE&IL"([.U@VDRF126$J%<"-U;W?P]X)
MUS]C7]C;3/AU\"/A7JGQ$U3P%X-MM.T#PS9:K:65WK]S#$D89[F]FCAB:1\R
MRRR/GEV D?"MZQ10!^8OP5_:(_X+<_#;5-=^*?CK_@@M=>*OB+XH55UGQ-+^
MTQX5MH8K:,L;;3;2',AM;&'>Q6/>[,[R2R,\DC,?7/VTOV/?VEOC,_[,_P"W
MGH?@_3+WXY_ 77%U?Q!X-T>^C@AU?3]2MD@US2+.>:01^<J?\>\DT@C8Q$,R
M^:6'V]10!\5/^S/\3?VVO^"FOPR_;C^+7PEUGP1X"^ OA358/A_H?BQ[8:GK
M7B#50L5U>M!;S3+!:P6\4:)YC+*\WSA B*[_ &K110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<,['YQS0!^WU%? /_$2!^PI_P!$>_: _P##):I_\31_Q$@?L*?]$>_: _\
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MI:Y:6GB3Q#::'HSZ3X9O+Y);ZYD$<44DT,9AMRQ)(,SQA@K;=Q&*]@K\E/\
M@MUK_P"W/XK_ &#?A'\0_CC!\.+/1?$OQH\$7>L^#]"TF^CU'PS++?)-#$;^
M6[>+4MAQ#(5M;;+-O7Y5*G]:Z "BBB@ HHHH **** "BBB@ HHHH ***\_\
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M/#VI:S<&*QO!K,FDR/9Q(!]H5Y8F=5DN(O+5E!:3!- 'Z945^?GQ!_X*/_\
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MBBB@ HHHH **** /S]_X.2[NTL/V"?"=_?W,<$$'Q\\%2333.%2-!J:DLQ/
M  R2:^P_^&L/V6?^CE?A_P#^%E8__':?^T;^S%\ ?VNOAI+\'/VE/A9I?C'P
MO/>0W4NBZQ&S0M-$28W(4@Y4DXYKXH_:/_X)V?\ !M/^Q^MH/VH?@G\!_ <M
M^F^PL_$VKK:W%TF2"\<+S>9(H((+*I /!- 'VI_PUA^RS_T<K\/_ /PLK'_X
M[7QI_P $7_$.@>+/VTOV[/$?A;7+/4]/N_CY:26E_I]RDT,R?V9'\R.A*L/<
M&I/V>O\ @F3_ ,&X/[6FDSZU^S'\ O@7X]@M #>_\(IJZ7KVN3@>='%.7B)[
M!P,U]9?LL?L1_LG_ +$F@:KX6_90^!>A^!=/UR\2[U:TT.)D2ZF1-BNVYCR%
MXH ]4HHHH **** /@/\ X+?_ +/7[6?[3?B#]F_3?V:_V8];\9V?PS_:)\/^
M/?%FH6?B#1+)(]/T\R>9%$+^_@>29A,=J[=OR'+CC.Q^U9\%/VG_ (H?\%<O
MV3_VHO!?[,/B.Z\"_"W1/&,/C36FU[0XVLI=7TV.VMT$#Z@)9=CQ_O#&K !@
M5+\U]R44 ?GKX3^#7[=?PT_X*._MD_M9^ _V6M5BMO'_ ,)M&M?A%JNI:]HD
MD&I:WI.E7"1PS0QZ@TT22W+QHID101DN8QS7-_#C_@G^\?\ P44^$W[;O[(?
M['GBW]G?5E_M&3]HS0WO+&VT;6[62RD$=@MM:7,EM>W37CHZSP*L(56ED<2B
M-3^EU% 'Y_?\$^_@/^UG\";K]LK5_B?^R;XHT\_%/XQZ[XM\ 6T?B+P_-)JU
ME=P16\,8\O4F6";*%RLS1J%_CW?+7BG_  PA^W?_ ,0Q'_#M3_ADC7?^%O?V
M#_9'_"/_ /"5>'_)W?V_]N\_[5_:7D^5Y//W]^[C9WK];** /S:_:8^$W_!1
M7]F_]KGX8?\ !3K]D;]EVY^(,=Q\&K7X=_&7X*7OB.QL]6AMH+I[JWOK6=9I
M;:25)975@DD@V   ^8[Q:_[>7[+7[>W_  55_P""=OBNVUWX;V7PB\?6^OZ-
MXD^$?P\U77[>^FM+K2YFFWZC=VX\I)[L2.BQ*SQP"*!F?<TH7]#J* /RY_;'
MU+_@HQ^WMI/[+'B6#_@E]XX\*:_\*_VCO#GB_P"(NG:UXMT*.W"V,-U]I^P2
MK?.9[<;CB680DEXE19"SF/\ 3T7E\FC_ &^;29&N1;>8]A!*C,9-N3&K,54G
M/R@DJ/4@59HH _/O_@F'\"_VNO@-^W3^U_\ &KXT_LB^)]!\.?&#QY9:WX&O
MCXE\/W1N;:T@NXRDL=OJ3O#))NB*AEVCS/F9=I(\T_9R_8X_;A\"_P#!$W]H
MW]C_ ,6_LA>(K/XA_$+4O'7_  BNA?\ "4^'I%NH]:$QM9#.FIF&-4\P"0.Z
ML,':KCFOU/HH _*KX@?LA?\ !0WX!>'?V.OV\/V</V;IO$'Q#^!'PAMOA[\6
MO@OJ7B/3H;O6M*:PMH9FL[N&>6V+Q3Q2R+^\)?\ =':=K(WN/[0G[/O[6/\
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ML.HI>ZC-:*R6T3RVUO D,;.Z(9Y) Q:.-/OJB@#\F?VRHO\ @J1^W5_P3S\
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MH[6D=KX>\ ZIKMKJ>JW$FXO-?WDML#' N-D<-NC%@!,\O+QI'[C110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\(>+/^
M"2W[;OB'Q5J>OZ7_ ,%ROCQI5K?:A-<6VEVFEZ:8K.-W++"A*9*H"%&>< 4
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M/?$SQU_P6-^-'CS2-&U!;B_\'^(--T]++58P"/)F,:!@IR#QSQ7V?0!\5?\
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M;-M'%!=)!?O>VB744:I,ML&^8AG;X&^(GPK\9_\ !S5^Q-\9?C/HGC\:5=^
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MPTS3+.6[U&^NY0D5M!&A>21V/"JJJ6)/0 U^9_['G[1/[7G_  5)^*TGQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX'_#?1/A!\(_!]CX?\,^&]-BT_0]%TV+9#:6\:A411UZ#DG)))))))K\(?\
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MK7AV\BE$L4EO/@[D$BJQAD#Q,1DKN"L/?HQ((U$K*SA1N95P">^!DX_.EHH
M**** "BBB@#SS]HK]EKX,_M6>&+/P9\;M,UR^TRPU:SU.VM-(\9ZKI"_:[2Y
MCNK:9CI]S 9&BGABE3>3M>-6&" :[G3-(L])TF+1;=IY8(8O+4WMW)<2,O\
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M+JUU\0M6\*OX9U+6;[QMK$\%SHS2>:U@]E)=M:M;F3+^7Y6W<2<9.:\>MO\
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M0O"_ASXOW&CZ]H]HVB>'DBMDUF#_ $V^@::::".:U B# +.[[LHJOM_MG?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q<^#GPH^/OP^U
M'X4?&[X<:+XL\-:M%Y>I:%X@TV.[M;A>HW1R C(."&ZJ0""" :Z2B@#SS]G_
M /9M\(?LS^&X/A]\+?%GB=?"6GVHM]$\*ZUK3:C;Z5&,;4@GN0]V(U VI$\[
M1QK\J(H"@>AT44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RU\:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>insm-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:insm="http://www.insmed.com/20201231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="insm-20201231.xsd" xlink:type="simple"/>
    <context id="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i568098e806134d1ebaedc445a945607c_I20210222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="iebde4d2934ac45c684584d4c433bdde3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic2ee174a408b4a3e956206fe10d829f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c826cb488d548b29991ab78334baabf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibcf2af78768043e6a6d0f7f80a56687d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i9883789f34af48faa49839a2c46e2971_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i20647d4d256549fcb9f6d47074842d0c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if85fc514b5b74bbebdde290e2e17f393_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="if0573aa1bb72428a95e7d4716d768ca1_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i253f9191270b47bbb377a3e554382848_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i75a0bbd8f14f48d9891d78182180a475_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i546efb7b63d14554aa9bfdf739cebc90_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib76325e7c3734939be7e498355efe724_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i4a1515d5bd1d4ee4b52a34eebff6fa4b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i872a79a3298a4fc0935733317644b8f7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iff6225cad52544c692427c26bd334021_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib081213375dc485f8d419cd32e77ad21_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5326db554c74c3e8b3751c9d9d6fd9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i805a071174014bd59c6cd5891fc33d9d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6b58797f08d4181a4d8d4f76c2b948e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie973139e8f3f474ba01ec72a33d057c2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86609ec5e2274f059fdd63ee245fc9cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i44e12ab6a629456d98e9c2642ad51f4b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9b120d293904c698a3d259c3e643e2b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5e65405df6f448b786cddb256251701b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i968e32794a5c4430ae11c1b0b3884003_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0897592bf8bb4a21931904c230db9a43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia665daf63d884a34b3a03848ca8720da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b38925e110b406fb8d690af86e404ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ff79db52eb84c4598d7b7afcb119dfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:EquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifd5f902b0ea148debdd39b7e096ed23b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ad75b5ff0eb42f79faddf5ae9746ddb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e0818f19ecc45e8bffe1b74c6ecc287_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if33069948ada4260b9525905a9028722_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iefdcf33de75d49cba0e70cc7853c3280_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f8752f81b5546f6aac228d90c7b03d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c48b09e6691416abc16070aff6792d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9bd7a24933d64c00a17e23166ddcb249_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93c687c71117495bbb85688c2e6da53f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2557ec52f167465a9db110f78f63cea9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i017d5966090a4b0ab4fb5abb56c17d5c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8b1b88435bd44aeb678f80443f3d14c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84af194151234369a03dc3fdf9ff1c60_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9ad5a7b26844352bc3de93a1fa02e5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i41b33cfe7496472887a9b46f5bb1a64e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if411584126e147579c1290e85b019267_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d80ecd614a347319af9d2f44019b7f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i84042da0fe82481489bbac6622c413bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71d6098b4cd2462ea2fe95fdcfff87a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ed9d4ebbe0c4a5c90652308ad3ede36_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if454ac4f869c4464a82f74996dd1dcae_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7e7d083f6da0458181337d318c54b702_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:CustomerFeesDiscountsandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">insm:RebatesChargebacksandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e32e7ead80245768a4215e36f3d013e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a17ed1cbdfb44299c8d6329a58ecd20_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b73eefc9dfc4da4b954ad4f37d36401_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7daa5829bc564872bab33523184cce28_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaeb953793f734b5fa4ff72faaca69bed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b1e8f8d82d740f2a0b6f1636a4984fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e26a169ca6447e1bbd8420534209dd4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ff567a613c140aa9f850be249a8a85f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9d1b35f80d7c4963a103aa9c2ed57381_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5f1f6e025d01493c8f016b27c71e8c6c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i97d0d45f93fd42eaa738fe0fc6f368ff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia8918052cbd746439e9093c317f861e3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib892164ea751411ca150501c187370ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida80845cbee243b2815d745facfea2d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icf9ed33bf5454a7d8711743ff01550c0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-09-28</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="i1bd637936ab04afab59656afc255fd17_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i42ea68e2b42646b1959bc8837fbc4bcf_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i4bc7b7bc070a40c891c23f07c65ed05a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24f4981464504148bd4aa06dc574e5ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ded28353bf643aa99d3cb05cc110533_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ib19cd90bf12b4d9eb4da95674aef4152_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e0bd03488004153b5268b5e73764e14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia48973993a3149f79721dd24b81a822b_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="ief073ee95b334197863c0f30058817dc_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i1eb4c16988e4465da82e7f50e0573676_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia660e683387d45a2ac6386d394562fcc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2cfb89dc31514ee5a530da7763685f22_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ia83673d124194183900e1755392dbac3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e98f2e617b543ad8b634db7a4621957_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9a79104934c4503861efdd407cf050b_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="i74a83453ffc34b6295f8aff4ef7b27d1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a1633bbde7149ff91f24bafaf35316e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cd0f2ffc22f44e4bddc73e49309d010_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11fda285397a42e19d6a260af7e5f67d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e287d9cd08c41e0b6d0fd2c3d4b5fc8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23b08ca4050e48bf96bdaea7bcd7c871_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i955be7a501ea48619d13734d6154f45e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i641fb1bda4d041b9b0710d36df07d468_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibcda52d10cc646e78962f9e2486e8cbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68616dc8974c4009a3f605818d4e3333_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05db6e937b5d40acb4c6da58c96aed34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3620656a3d74b50befaf129855bc9d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85c99f6855754004b7860cc3f26ae215_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i829ced73ae454a818b994f29cf817fb7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">insm:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17adbf61f3554994afc5c8d08ee421ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie336952f723a45f7aad277d34fd71fc0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0653aae9e65348feaa6920fe60047862_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ad290bf1da9470cbb52bc0838395dc6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f74877e573149a898ea49344d4209eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13a7dcb8a06842e7ad8e6b069114005d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3ca69534f44544678e6345d4061172bd_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="i7789efc1fa15465a824da338e733666d_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i9e454efc09a14c9f9b4641cc444070e4_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermiiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="ia962faac0e554b0eade20b47d690b557_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:DebtInstrumentConversionTermAxis">insm:ConversionTermivMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i1f292dc67c894e10a48cb3e934955825_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i207c67bfeb704bc880cce0755881858e_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i0ea99db509d54adeb7486a066eb4eb62_D20180101-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="if478c817a20d48b1b85b1cda7a7158cd_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9654b342b1b943d1b4904dcb5401b4a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i632484c618934954b43bf3c619cf75d9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iff5a8670240445378f8c05d86d5621bb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i349a3db24a104296871f679b48d0727b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-24</startDate>
            <endDate>2019-05-24</endDate>
        </period>
    </context>
    <context id="id7d4ce336b0d4998950db423777b2a69_D20190524-20190524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-24</startDate>
            <endDate>2019-05-24</endDate>
        </period>
    </context>
    <context id="iefb0a77979724e36a4b8762928d10239_I20190524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <instant>2019-05-24</instant>
        </period>
    </context>
    <context id="i60e46a7dfb16496c852ec9544e1b781f_D20190524-20190524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
        </entity>
        <period>
            <startDate>2019-05-24</startDate>
            <endDate>2019-05-24</endDate>
        </period>
    </context>
    <context id="i818541d9894e4786bafa4a7f073c56da_D20190524-20190524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">insm:PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-24</startDate>
            <endDate>2019-05-24</endDate>
        </period>
    </context>
    <context id="i2ab005c49d7049b480307e85adfed0ea_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">insm:OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="ibb14027d5bff4fac80225d11be8c578f_I20190516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-16</instant>
        </period>
    </context>
    <context id="i7cb5fa6b23cb4fad903933f28e806e98_D20200512-20200512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">insm:A2019IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-12</startDate>
            <endDate>2020-05-12</endDate>
        </period>
    </context>
    <context id="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24b05e9462b7490284e2dec768389895_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d986e645bf145889f874249c82e4942_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1015f33ba83642e796387fad13fc1078_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i827d3608f7854deb81221457676b5339_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id29981174a85438ab8f4063d1cd73795_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0be8cbb20b3e471da2e0aead19d7a176_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0ce04f79cefd429f9fa32b6a5866706c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96db1220ab75430ab3c6ae0bc9042f63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:RestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74916538d9974ba79e0b9d63850374aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i364ee03e6c7541a69698fc45ca2ba4ce_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib38d1bbcd50f449aa39ec92d1409abba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i93060279fbe94fc7a1a08779106fc2f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifba3be11a88b4bfca6f5772ebff95bcb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3c0e4ce89f3d4ea4bb96ff17f982a182_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic353257bd6e34e7dbe0b8636bd5d2538_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa29866a032b4f66bcfd69a12e24036c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12b57931b8a04017a81e641841a99233_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">insm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifd1672f5e51546618f0cf07a08a28df1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01f3c32373d84f8d8b6e8ad92ddfe7a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21187a96ab01431487e85f22a31a8d4d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibc948d8df4a94b7eb93b753074d45f0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">insm:IrelandTaxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i60c1a8f856324526bc222644c67d2afb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5509be6b4fb84159b9c6b41efd84a675_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cf490c2bd404047bb4076dfbe4a9035_D20080401-20080430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneNewDrugApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="if80ed6a320744417ad76e4542ce13f86_D20080401-20080430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneFDAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="i7e1cd387ddb44953ad773aa9410675d5_D20080401-20080430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="insm:MilestonePaymentAxis">insm:MilestoneEMAApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2008-04-30</endDate>
        </period>
    </context>
    <context id="i579a8c2c42bf45ff98f87f2c584c06ea_D20040101-20041231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-01-01</startDate>
            <endDate>2004-12-31</endDate>
        </period>
    </context>
    <context id="iea44e908cf7e4040bb2902ceff09e1f2_D20090101-20091231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-01-01</startDate>
            <endDate>2009-12-31</endDate>
        </period>
    </context>
    <context id="ibad33e6bc291434cbfb0f351cbf0d854_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cfcedfa9eec4b33b05c236c449b48a7_D20040101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb4bec08f1b8439f95f590be3ffee05d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:ResilienceBiotechnologiesIncContractManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-02-01</startDate>
            <endDate>2014-02-28</endDate>
        </period>
    </context>
    <context id="i49b84c0ce9224662b5305154df7099d8_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:ResilienceBiotechnologiesIncContractManufacturingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="id633afd47e954538a26c547411ecfe02_D20140701-20140731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PRIPharmaGmbhCommercializationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-31</endDate>
        </period>
    </context>
    <context id="ib05c0670068f485e8afcc6417da49edf_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:CommercialFilVFinishServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i13e3ed8648004855b71e7b4adb845d68_I20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="if28faba5eb55435f9579cbc04ed74d86_D20161001-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i1957ada0d9cd42738836fe4ca797ec73_D20161001-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:LicenseAgreementWithAstrazenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">insm:PPDDevelopmentLPAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i667f6be698f043288e59286e0ec72ad8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001104506</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">insm:BridgewaterNewJerseyFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="security">
        <measure>insm:security</measure>
    </unit>
    <unit id="segment">
        <measure>insm:segment</measure>
    </unit>
    <unit id="day">
        <measure>insm:day</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF80LTEtMS0xLTA_a7d358ff-bf07-469a-8604-4bf6470e3ea0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF82LTEtMS0xLTA_72385ca4-8b52-48fe-a293-5c5307c58779">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGFibGU6YzA4NWM0MjEwNDA5NDIwNmFmOTI1ZDY1MmFmZmE1MjgvdGFibGVyYW5nZTpjMDg1YzQyMTA0MDk0MjA2YWY5MjVkNjUyYWZmYTUyOF83LTEtMS0xLTA_58dfc4b2-4db6-43e3-9283-2a29d4070239">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV80L2ZyYWc6OGQ0NTVmZWEwZDI5NDk1NGEyMmZhYWFlYTMxNzk5YjAvdGV4dHJlZ2lvbjo4ZDQ1NWZlYTBkMjk0OTU0YTIyZmFhYWVhMzE3OTliMF8yOQ_640f2eeb-3a5b-4dc4-87d1-3054937dc026">0001104506</dei:EntityCentralIndexKey>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="if478c817a20d48b1b85b1cda7a7158cd_D20180101-20180131"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjAvZnJhZzpjNDRiNWNmZjE3MGQ0NTMzOGVjYjllZDRiMDhmODUwNS90YWJsZTpjM2Y0ODllM2VkNWQ0Mzg3OGQ1ZmE3YzBkMjIzZjA4Yi90YWJsZXJhbmdlOmMzZjQ4OWUzZWQ1ZDQzODc4ZDVmYTdjMGQyMjNmMDhiXzItMS0xLTEtMA_8be4a2bc-5739-4307-8611-c7cf686365d6"
      unitRef="number">0.0255384</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY184Mg_33127434-6b58-43c2-adb7-1a8c8e646515">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8xLTAtMS0xLTA_2f8922a1-dbe9-4c1b-b7f8-10cd105d7762">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDBjZTVhNDdiNGU0OWI2ODQ0OGQ2MzU0MTgwOGUyOF8zMA_bd7968e0-23c5-47b5-87a6-61ff8c2bf082">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpiMDBjZTVhNDdiNGU0OWI2ODQ0OGQ2MzU0MTgwOGUyOF8zMA_3f226756-83ab-4981-a3ae-7a507774c5c5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6N2JlMTdkNTA1MWUyNGJhNDliNmQ4MTRmZTBlMWYwMDYvdGFibGVyYW5nZTo3YmUxN2Q1MDUxZTI0YmE0OWI2ZDgxNGZlMGUxZjAwNl80LTAtMS0xLTA_86fdccc1-836a-49a5-b015-873e05cc5b7b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMTE_afa3118f-0e71-4441-ba48-db33d7cbafc1">0-30739</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMTQ_ac843779-20e2-4463-84fb-b084ca62939a">INSMED INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8wLTAtMS0xLTAvdGV4dHJlZ2lvbjoyNTA2MDdkZjVkNmQ0YjVkYjliNGY5OWI5ZGYyOWU4Zl80_341f3111-695a-4606-853f-b986f86d69a0">VA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8wLTItMS0xLTAvdGV4dHJlZ2lvbjo1OTdmMDI5OWE1ODg0NGYwYTdmZGRmOTEwMzM5NTdiYV80_2eae7162-aa62-4491-9da8-c0bc1075ba36">54-1972729</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM180_57d3d07c-2725-4785-8120-efd6ca26e509">700 US Highway 202/206</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM183_1944ae70-d221-478e-beb2-a3627ecc6c0b"
      xsi:nil="true"/>
    <dei:EntityAddressCityOrTown
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xMA_d08248b4-e581-4ba4-a6ac-ba22a60f2e73">Bridgewater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xNA_75af9bf5-500d-4ae3-a70d-26c5df1541fc">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTAtMS0xLTAvdGV4dHJlZ2lvbjpkZjRjZDFiYmMyYWU0M2UwOWM2ZGY1NGVlNTgxMGNhM18xNw_afc0fb9f-a797-42d1-978a-2c542add8385">08807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTItMS0xLTAvdGV4dHJlZ2lvbjo0YjU5NzliNzI4Nzg0ZDJlYTFmYjZiNGFhMTBhOTljZV81_7ceaaf98-9c34-4229-a188-d40b2b896b59">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6ZjlhM2QzZGFlNWM1NDQ3YTljOWUzYWJhYWVhOTIzMzQvdGFibGVyYW5nZTpmOWEzZDNkYWU1YzU0NDdhOWM5ZTNhYmFhZWE5MjMzNF8yLTItMS0xLTAvdGV4dHJlZ2lvbjo0YjU5NzliNzI4Nzg0ZDJlYTFmYjZiNGFhMTBhOTljZV85_3d363022-89ae-417e-9464-3f6bdeb2d7c0">977-9900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTAtMS0xLTA_11bd971e-441d-47f2-9ba7-4b2586f200c3">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTEtMS0xLTA_712444e0-c81e-4950-8497-e5b33649a8aa">INSM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGFibGU6NTM2ZjNhNWE2NWQ2NDBjNTljMmQxZDc0NThjOWRhM2YvdGFibGVyYW5nZTo1MzZmM2E1YTY1ZDY0MGM1OWMyZDFkNzQ1OGM5ZGEzZl8xLTItMS0xLTA_e1ad073a-8ff6-467a-b23e-4ee283618721">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180MzA_fba14937-b349-4335-894e-a8618356c859">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY181NzE_9c1a0a79-1a1b-442b-9325-8b47addfeea2">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY185MjE_05110bac-e927-48a6-91fd-3322e8f125f7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xMjQx_ea867c7b-16c0-4bb2-a8d8-592ef0c11b2e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNTk5_3a11d4d0-fc0e-4a67-8c25-5805cb4b2480">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNjc0_c7817f94-c2bd-4ea3-a86e-30a2cb5adbb5">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18xNzAx_ce660dee-392f-4d98-85c5-c8524982021e">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180Mzk4MDQ2NTE0ODA5_4a3b154a-8be7-480b-8988-5db979632ac6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18yMDcz_7a9cc94c-a80b-461d-9423-55f3a0f8bd29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18yMjE0_6c83f278-44b7-4070-99ed-d990f687ab6d"
      unitRef="usd">2800000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i568098e806134d1ebaedc445a945607c_I20210222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY180Mzk4MDQ2NTE0ODQw_28a24025-4b59-448f-b1f4-5d522c964195"
      unitRef="shares">103043347</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xL2ZyYWc6NWIwNmVmZWYwNzcyNDc5OThjZmRiYWI5YjA3NjBmMWMvdGV4dHJlZ2lvbjo1YjA2ZWZlZjA3NzI0Nzk5OGNmZGJhYjliMDc2MGYxY18zMzEz_f740f737-155d-4d72-a715-c56456cb6eb8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Portions of the registrant's definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission no later &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;than April 30, 2021 an&lt;/span&gt;d to be delivered to shareholders in connection with the 2021 Annual Meeting of Shareholders, are herein incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQtMi0xLTEtMA_166eeb7e-35f9-4227-81b8-3083ad433e1d"
      unitRef="usd">532756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQtNC0xLTEtMA_5b70e533-34ab-4468-8008-8af808fdb359"
      unitRef="usd">487429000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzUtMi0xLTEtMA_2bc8c2d9-6f83-4553-a252-28a145350a67"
      unitRef="usd">16562000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzUtNC0xLTEtMA_6c06373d-df75-44df-8233-64da4fb1a2d3"
      unitRef="usd">19232000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzYtMi0xLTEtMA_13496d5b-b880-4c1f-8243-07bc5f78e17a"
      unitRef="usd">49592000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzYtNC0xLTEtMA_80864aee-f7a4-4f60-90f0-3f51861dc1dc"
      unitRef="usd">28313000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzctMi0xLTEtMA_c15ae805-5118-4d33-adaa-a4fea7bb1511"
      unitRef="usd">23982000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzctNC0xLTEtMA_eed08cab-395c-45f1-88fe-2a54d4c46fa4"
      unitRef="usd">20220000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzgtMi0xLTEtMA_67063d9b-0f23-4922-98e0-e1238eafca16"
      unitRef="usd">622892000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzgtNC0xLTEtMA_1d8a0396-0bc5-4448-b00e-1b792b92eee0"
      unitRef="usd">555194000</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEwLTItMS0xLTA_64305782-fe97-413d-aebc-e8b5471f9bde"
      unitRef="usd">49261000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEwLTQtMS0xLTA_442177fe-5e81-478d-92a4-0472c6b57a9a"
      unitRef="usd">53682000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzExLTItMS0xLTA_3097f106-3151-4bdf-8177-fab70788e75d"
      unitRef="usd">53953000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzExLTQtMS0xLTA_f10008c0-6ea6-490e-9e3a-8228e3b94218"
      unitRef="usd">60180000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEyLTItMS0xLTA_b0ba7d0c-68c9-422b-91bb-efb686804998"
      unitRef="usd">10334000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEyLTQtMS0xLTA_59253814-438f-44bf-812a-8f6a51a4931a"
      unitRef="usd">15256000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEzLTItMS0xLTA_799d6f73-5c4d-4c92-87c4-de7d1be6cc52"
      unitRef="usd">32946000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzEzLTQtMS0xLTA_9e3d312d-7b8e-4844-bf88-15fe5c0d0d76"
      unitRef="usd">37673000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE0LTItMS0xLTA_ff917606-7bf3-4bd2-883a-b5a046459a2f"
      unitRef="usd">26769000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE0LTQtMS0xLTA_666d6e18-d342-4cd1-ac6b-e1e87ee1e5bc"
      unitRef="usd">20314000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE1LTItMS0xLTA_d3c808b6-0d3d-4982-8a6f-f8551f9b420e"
      unitRef="usd">796155000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE1LTQtMS0xLTA_28b42c62-76a7-4fb4-a7a6-0e00ba3d1cf5"
      unitRef="usd">742299000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE5LTItMS0xLTA_fa087dc4-3700-41ee-aad0-f9e6d75b8706"
      unitRef="usd">42853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzE5LTQtMS0xLTA_54ec23e8-4cfc-401d-b864-722309e7ec7b"
      unitRef="usd">13184000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIwLTItMS0xLTA_41caba6e-4cc2-4317-b065-ebb6b359591f"
      unitRef="usd">37807000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIwLTQtMS0xLTA_8a45fd97-438c-4ba5-a515-130fe78a1289"
      unitRef="usd">40375000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIxLTItMS0xLTA_086242f9-878d-4175-8b36-f1ec00c5a7ee"
      unitRef="usd">25591000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIxLTQtMS0xLTA_80f16d6e-2a30-49cd-93f2-ed584e5f3105"
      unitRef="usd">19140000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIyLTItMS0xLTA_437c87e2-14c4-4ab2-b714-a920de6c2d55"
      unitRef="usd">1081000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIyLTQtMS0xLTA_6f3fea27-77f0-427f-8fdd-d35cb9dc5771"
      unitRef="usd">1221000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIzLTItMS0xLTA_2d0f24cf-64e3-48ea-9183-fc76292fcc2e"
      unitRef="usd">11475000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzIzLTQtMS0xLTA_b4211992-d651-4ac4-bad1-c98f70762259"
      unitRef="usd">11040000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI0LTItMS0xLTA_50d91c2a-8e73-4891-9690-72b1aafc1d22"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI0LTQtMS0xLTA_7dc8d34c-8328-47a6-82e0-35b994a6737f"
      unitRef="usd">280000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI2LTItMS0xLTA_c77c0083-b099-4e10-93d8-187f0fcb391d"
      unitRef="usd">118807000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI2LTQtMS0xLTA_acc8d3f7-e0b6-4eaa-95b7-272898c9165e"
      unitRef="usd">85240000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI4LTItMS0xLTA_e279b66f-f4a8-4567-9876-3150f615e571"
      unitRef="usd">356318000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI4LTQtMS0xLTA_9154ce19-4e66-4f1f-9f1c-d08d8fcaee71"
      unitRef="usd">335940000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI5LTItMS0xLTA_cbc4c30a-1604-4e51-9034-7d58083c1f2d"
      unitRef="usd">14713000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzI5LTQtMS0xLTA_01080c97-56f1-4fa7-8754-a542222b1361"
      unitRef="usd">19529000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMwLTItMS0xLTA_bbb47761-9b3d-434b-815c-6bafa6ef6f64"
      unitRef="usd">21255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMwLTQtMS0xLTA_5236b00e-cfba-4cb5-8e61-504294af7c52"
      unitRef="usd">29308000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMxLTItMS0xLTA_e9331885-3995-4099-8164-da02f400a56c"
      unitRef="usd">9178000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMxLTQtMS0xLTA_98987142-b632-46e0-a639-386f81320502"
      unitRef="usd">10608000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMyLTItMS0xLTA_d24f3334-5798-4ec0-9018-c38152febb98"
      unitRef="usd">520271000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzMyLTQtMS0xLTA_27ac71eb-8494-4ddc-abcf-83b9b16ac786"
      unitRef="usd">480625000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18xOA_aefe51db-942b-4f61-a613-bf8bc67c66d3"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18xOA_e3dc9531-539b-46fa-95fe-c189918ff3e9"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18zMg_521b19b7-a659-40fc-9754-5f1810d32468"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N18zMg_e3b62ddc-0c04-4c9e-9c85-efc43009a55f"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N181NA_7295a523-cea2-4dc1-9085-bbc69e175700"
      unitRef="shares">102763060</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N181NA_8142df51-fd95-4da1-a969-38b77b6a8f3c"
      unitRef="shares">102763060</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N182MQ_8761f312-5587-4705-a46f-9c21586aef60"
      unitRef="shares">89682387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTAtMS0xLTAvdGV4dHJlZ2lvbjpkYjRkNjcwMGNkMGQ0NGMyOWJkYWQzNjdkNTJiMjM1N182MQ_a71738ef-eec6-44a4-bc1c-73513fb69de7"
      unitRef="shares">89682387</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTItMS0xLTA_9fb1c265-b9b5-4546-af5d-ee9221388d4b"
      unitRef="usd">1028000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM1LTQtMS0xLTA_87738537-138f-4d88-885b-227b7db9c44a"
      unitRef="usd">897000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM2LTItMS0xLTA_78b0e428-c6d0-4b00-93b4-9a038ce1d703"
      unitRef="usd">2105252000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM2LTQtMS0xLTA_dbf4dfc8-9594-4520-8717-379bb24c143c"
      unitRef="usd">1797286000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM3LTItMS0xLTA_a9fd4dda-f0bc-415a-b4e9-808cebaab213"
      unitRef="usd">-1830589000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM3LTQtMS0xLTA_f4b51936-90c8-43e1-ab7e-e259cb0facd1"
      unitRef="usd">-1536499000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM4LTItMS0xLTA_a6765807-eee5-4c63-8f44-8ab227dc8def"
      unitRef="usd">193000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM4LTQtMS0xLTA_64e0bde5-04ca-4abf-ae5f-62d9a615904f"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM5LTItMS0xLTA_c75d5ef0-0413-4f8f-bc78-974c856def4b"
      unitRef="usd">275884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzM5LTQtMS0xLTA_9411fd47-7059-4b68-b90d-dcb94578fb91"
      unitRef="usd">261674000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQwLTItMS0xLTA_ace92569-3723-4875-abea-c56eb5a1b722"
      unitRef="usd">796155000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjEvZnJhZzo2NGNjMTYwMzA2ODA0YWM1ODc2MGEzNzMyODQzMjQ4NC90YWJsZTplMzdlOWM1YjE1ODk0MTE2YTNmNWI3ODk5ZWEyYjE0Ni90YWJsZXJhbmdlOmUzN2U5YzViMTU4OTQxMTZhM2Y1Yjc4OTllYTJiMTQ2XzQwLTQtMS0xLTA_b2835073-09e8-451d-8f32-d98ae7ed5e83"
      unitRef="usd">742299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItMS0xLTEtMA_ba51d109-aa0e-4603-9b47-90a14f2325cf"
      unitRef="usd">164413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItMy0xLTEtMA_93e43428-8ede-40b3-bfa7-667f352bbba9"
      unitRef="usd">136467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzItNS0xLTEtMA_2895bac6-7428-48dd-ba6d-3e79d735a48b"
      unitRef="usd">9835000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtMS0xLTEtOTE5_163d7fc2-04ba-47f0-a205-be4fd23fd329"
      unitRef="usd">39872000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtMy0xLTEtOTE5_054590e0-0cf8-4f37-9288-7e30fb39ae65"
      unitRef="usd">24212000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzYtNS0xLTEtOTE5_9cc1f981-5cfe-40b0-af5f-a1edaec593da"
      unitRef="usd">2423000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctMS0xLTEtMA_edec2ac7-f386-4c81-b78b-46f377f57224"
      unitRef="usd">181157000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctMy0xLTEtMA_a5f63573-c000-4855-aa55-d9288e07cd04"
      unitRef="usd">131711000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzctNS0xLTEtMA_057aa0d8-a04b-41d2-bfa7-c9447d7dfa43"
      unitRef="usd">145283000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtMS0xLTEtMA_e81ad75f-5d07-402e-99e6-a72286062132"
      unitRef="usd">203613000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtMy0xLTEtMA_1b2519de-7dd7-4cc2-90a7-72288fb37e38"
      unitRef="usd">210796000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzgtNS0xLTEtMA_d716abca-a437-4a95-9e24-3857c91c89a2"
      unitRef="usd">168218000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktMS0xLTEtMA_f3ecaf9f-49c7-47d0-89d5-d5dc383a301f"
      unitRef="usd">5003000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktMy0xLTEtMA_dfba2681-3155-4cb1-9c20-e76e23168213"
      unitRef="usd">4993000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzktNS0xLTEtMA_27eb18a4-37cb-4a7d-9af8-60cf78adaa43"
      unitRef="usd">1249000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTEtMS0xLTA_33005e8b-dfe8-4e93-9ecb-5ed15138caf3"
      unitRef="usd">429645000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTMtMS0xLTA_035213a8-7399-46da-8103-df338909b1d5"
      unitRef="usd">371712000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEwLTUtMS0xLTA_7d065547-d428-43f5-9d68-28df0cb367ae"
      unitRef="usd">317173000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTEtMS0xLTA_4a5c7bb9-9e1a-4e0f-a263-2d871e7449d8"
      unitRef="usd">-265232000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTMtMS0xLTA_a283c85e-6bf6-41ab-a000-0903426c2fd6"
      unitRef="usd">-235245000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzEyLTUtMS0xLTA_371980da-f9c9-48d4-a916-56e6c4586662"
      unitRef="usd">-307338000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTEtMS0xLTA_ee429276-0fcf-4138-a966-44f479d71f87"
      unitRef="usd">1703000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTMtMS0xLTA_53dd9502-16ad-496d-8d5b-782b7c650768"
      unitRef="usd">9921000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE0LTUtMS0xLTA_635f0a82-7801-49fd-9f59-003f8c659cab"
      unitRef="usd">10341000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTEtMS0xLTA_fbea3cca-51ba-4054-acc3-1d7a632b7e8e"
      unitRef="usd">29564000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTMtMS0xLTA_626f4e9c-26ea-4f71-be5d-7d6253afc07e"
      unitRef="usd">27705000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE1LTUtMS0xLTA_c01abbab-1416-4fde-b1c6-7044c417c41d"
      unitRef="usd">25472000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTEtMS0xLTA_5ce36d1c-104e-4345-bf4f-82088d2f03b4"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTMtMS0xLTA_fad972bb-aa56-4de5-8101-28a02688552b"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE2LTUtMS0xLTA_fe791e8c-de3a-4078-a345-5f6889c2c5db"
      unitRef="usd">-2209000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTEtMS0xLTA_7afaa52f-13a8-40c3-b681-4f07a68a3b28"
      unitRef="usd">405000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTMtMS0xLTA_40354943-e29e-4eab-8fd5-a047b06ab21c"
      unitRef="usd">-531000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE3LTUtMS0xLTA_4ed38a21-086f-4f32-a52e-c598fa89ff73"
      unitRef="usd">602000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTEtMS0xLTA_0e3aa7cd-feaf-43dc-979e-400e4c997a5a"
      unitRef="usd">-292688000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTMtMS0xLTA_33912845-f60d-4e90-86b4-5db76bc2eeb1"
      unitRef="usd">-253560000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzE4LTUtMS0xLTA_3da93f0c-7829-46b9-a567-367b81d3d179"
      unitRef="usd">-324076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTEtMS0xLTA_6dacfa34-2457-4f70-87bc-a5a687f43eb2"
      unitRef="usd">1402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTMtMS0xLTA_2681930c-cb74-4c81-a720-60cd95738d9c"
      unitRef="usd">777000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIwLTUtMS0xLTA_ec73a251-7b29-4dbf-869d-4758f4fd243f"
      unitRef="usd">201000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTEtMS0xLTA_aaeae3aa-3f5e-4414-81bf-823610779104"
      unitRef="usd">-294090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTMtMS0xLTA_1f76efb9-651e-4bae-88e6-675f95bf356a"
      unitRef="usd">-254337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzIyLTUtMS0xLTA_5f3b5929-9df9-432a-8e54-f9218388275b"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTEtMS0xLTA_97d047cf-3622-4602-9fac-cbd9ecf7fa3a"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTMtMS0xLTA_4c63b2c6-cff3-4c3d-9d71-e681c84f3bf4"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI0LTUtMS0xLTA_8791039f-e2af-4b30-8517-4039f9ce4422"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTEtMS0xLTA_f82e54a6-58fc-4122-a4b8-1f8f7cfe59b7"
      unitRef="shares">97605000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTMtMS0xLTA_82e3da90-d5f0-43b8-8fed-f3137651ce40"
      unitRef="shares">84560000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI2LTUtMS0xLTA_5b37ff85-a722-4f15-8ea3-1f61e436e3b7"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTEtMS0xLTA_5ab1c462-c784-4669-92c2-ff37e6627eff"
      unitRef="usd">-294090000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTMtMS0xLTA_fb0eb673-87b7-4ae1-b7ab-06dd928c8f54"
      unitRef="usd">-254337000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzI4LTUtMS0xLTA_53a00337-6a65-42e3-9f14-8fa6d66a3dcf"
      unitRef="usd">-324277000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTEtMS0xLTA_1063bdbe-1e61-4711-913b-e7826e106e19"
      unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTMtMS0xLTA_81dee487-7e43-43ea-b7af-3cf6d04b0ed2"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMxLTUtMS0xLTA_1ede8af7-b0b4-41df-ade8-b18f103338f9"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTEtMS0xLTA_d443bede-db10-41a6-9a35-eb72f03118bf"
      unitRef="usd">-293887000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTMtMS0xLTA_78d1e403-baa4-4ac5-9e0f-1f592918008c"
      unitRef="usd">-254338000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjQvZnJhZzo4M2ZiNTE0MjI3NWU0YjIxOGNmZTQ3NjM4YTg5MTQ1NC90YWJsZTpjZDIyZjlhYzA3Mzc0MmIyOWRjMTk3NWJjYzdhNDljZS90YWJsZXJhbmdlOmNkMjJmOWFjMDczNzQyYjI5ZGMxOTc1YmNjN2E0OWNlXzMyLTUtMS0xLTA_9b035fc5-cefe-4f0f-82ac-e4fbc696ed11"
      unitRef="usd">-324283000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ibcf2af78768043e6a6d0f7f80a56687d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMS0xLTEtMA_04b9600b-ee34-4076-9de8-85a1edf95cb6"
      unitRef="shares">76611000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibcf2af78768043e6a6d0f7f80a56687d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMy0xLTEtMA_b9396174-dd86-4e32-b780-0908a5760bee"
      unitRef="usd">766000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9883789f34af48faa49839a2c46e2971_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItNS0xLTEtMA_ceea1a79-1009-475b-9f08-817813fddcd7"
      unitRef="usd">1318181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i20647d4d256549fcb9f6d47074842d0c_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItNy0xLTEtMA_182c04db-36e1-49bc-91d5-401e406beee3"
      unitRef="usd">-957885000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if85fc514b5b74bbebdde290e2e17f393_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItOS0xLTEtMA_85facc48-7ba9-4102-a18a-be5504bb86a3"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzItMTEtMS0xLTA_ec487e63-33df-43a2-9dbf-374fd8e801e6"
      unitRef="usd">361059000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i253f9191270b47bbb377a3e554382848_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzQtNy0xLTEtMA_3c74105a-4e0d-4c34-9666-37c402f34c02"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzQtMTEtMS0xLTA_c888ab87-2026-491e-8ec6-40c3c87eacbb"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i75a0bbd8f14f48d9891d78182180a475_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzUtOS0xLTEtMA_858c6f50-e083-4113-8a95-108148b0b978"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzUtMTEtMS0xLTA_7e0f0ca8-26b7-4ab4-8b67-33f61190f0e4"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMS0xLTEtMA_522ea3e1-996b-47ea-a4a2-8fd2526f58c1"
      unitRef="shares">645000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMy0xLTEtMA_e38fadb2-2228-4102-a819-8e9b1dc3e7b4"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtNS0xLTEtMA_7086103d-0d7f-4a58-bf06-c40d5fa697db"
      unitRef="usd">8809000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzYtMTEtMS0xLTA_7ab5177e-365b-492b-9ad1-41478bd80843"
      unitRef="usd">8815000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzctNS0xLTEtMA_6d869af3-dcd4-45b6-8cba-8d3cef14cd49"
      unitRef="usd">136434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzctMTEtMS0xLTA_20fae34a-0f3c-4999-b879-d7833e3c2754"
      unitRef="usd">136434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMS0xLTEtMA_643f28d1-a6a9-4cb9-8030-a6d5e7a67136"
      unitRef="shares">52000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if01fe3f2137d4bc0991c350ef42b7a32_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMy0xLTEtMA_2f720909-60d4-43cd-835f-a9c9feebd09f"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzgtMTEtMS0xLTA_61e06c8c-7799-4592-a088-ce33442533b8"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1c3d6c84340943e2bd7c450a22bec997_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzktNS0xLTEtMA_55d5e9e8-3e6e-45cb-9fb3-ff6519117db9"
      unitRef="usd">26240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzktMTEtMS0xLTA_e9963a05-54d1-4c02-9579-5ed80a0ee1f3"
      unitRef="usd">26240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i546efb7b63d14554aa9bfdf739cebc90_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTEtMS0xLTA_737b556f-ee48-411e-b7f9-a8985229f7e7"
      unitRef="shares">77308000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i546efb7b63d14554aa9bfdf739cebc90_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTMtMS0xLTA_420c47bf-09fb-4add-8a16-8c11860e39dd"
      unitRef="usd">773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib76325e7c3734939be7e498355efe724_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTUtMS0xLTA_168354fe-0cb1-459b-9602-5eb41a4ec22c"
      unitRef="usd">1489664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a1515d5bd1d4ee4b52a34eebff6fa4b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTctMS0xLTA_4576e3d7-7dc4-4ea7-907c-0d5f60236fb5"
      unitRef="usd">-1282162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i872a79a3298a4fc0935733317644b8f7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTktMS0xLTA_a9cf3a3a-c16d-405e-813b-6a05c73da2ba"
      unitRef="usd">-9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEwLTExLTEtMS0w_e0fe3787-9f72-4364-af61-240ec8051353"
      unitRef="usd">208266000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib081213375dc485f8d419cd32e77ad21_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEyLTctMS0xLTA_8b3ced79-6ac4-4634-b2c5-44fa14f86e21"
      unitRef="usd">-254337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEyLTExLTEtMS0w_9794ca9b-6fb3-47d8-a90e-1bfe7317c7bd"
      unitRef="usd">-254337000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie5326db554c74c3e8b3751c9d9d6fd9c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEzLTktMS0xLTA_38762d97-2983-4b01-94f0-f03e5fb5c109"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzEzLTExLTEtMS0w_b0277558-935f-4946-95af-772c5b7594db"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTEtMS0xLTA_164d0dc3-8999-4b92-b553-883dadf45f94"
      unitRef="shares">1632000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTMtMS0xLTA_e2d030c4-5f00-47ff-97df-bbb71b49651f"
      unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTUtMS0xLTA_342c50d0-462f-4e90-8a0a-c2f5bc7c03db"
      unitRef="usd">19684000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE0LTExLTEtMS0w_f5e5457a-9aa8-4b7c-944e-11666fb76a79"
      unitRef="usd">19700000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTEtMS0xLTA_17a0ddd0-f79a-4917-b034-4142d6dc6163"
      unitRef="shares">10658000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTMtMS0xLTA_9a600e36-5e0d-4ea7-b234-bc58df2a6395"
      unitRef="usd">107000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTUtMS0xLTA_064f7a89-02ea-48f0-8d05-47b955326fa4"
      unitRef="usd">260967000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE1LTExLTEtMS0w_296aae0f-9f1d-4d57-b36b-60b7f4522f56"
      unitRef="usd">261074000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTEtMS0xLTA_564ddbde-2d5b-4d16-8911-69e24a08605a"
      unitRef="shares">84000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i21a0071493c44d0492e79fbbaf7a4868_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTMtMS0xLTA_116b7882-31f0-443f-a2e5-3ef85030c19c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE2LTExLTEtMS0w_d3d1b9d6-dc4c-40e8-87dc-dc97121e9fb3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i578aaa9fb2464951a67b31b7f16a3ce0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE3LTUtMS0xLTA_ece9fe11-0189-4330-96f6-7c5a28a1c30b"
      unitRef="usd">26971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE3LTExLTEtMS0w_318a6cdf-d1e8-4601-b1d3-f41dd87ffb57"
      unitRef="usd">26971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i805a071174014bd59c6cd5891fc33d9d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTEtMS0xLTA_6d6a6331-02cb-4618-9d11-7dc14fec80fb"
      unitRef="shares">89682000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i805a071174014bd59c6cd5891fc33d9d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTMtMS0xLTA_3d435115-ab8a-4561-a69f-6fbfb9addb63"
      unitRef="usd">897000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie6b58797f08d4181a4d8d4f76c2b948e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTUtMS0xLTA_ebb65c72-0357-4de1-b8e5-98ea4d60015d"
      unitRef="usd">1797286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie973139e8f3f474ba01ec72a33d057c2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTctMS0xLTA_bd48b754-7441-4361-8c24-142e6f44c854"
      unitRef="usd">-1536499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86609ec5e2274f059fdd63ee245fc9cb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTktMS0xLTA_3564edb6-091e-4d98-a779-56ffb78921aa"
      unitRef="usd">-10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzE4LTExLTEtMS0w_14b13b69-31da-49cf-b151-07e92fdc2278"
      unitRef="usd">261674000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i44e12ab6a629456d98e9c2642ad51f4b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIwLTctMS0xLTA_3c715e8d-173a-493a-93ae-d4b6877696ef"
      unitRef="usd">-294090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIwLTExLTEtMS0w_34a77d3b-b44d-4b04-a59d-ef999e23a232"
      unitRef="usd">-294090000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic9b120d293904c698a3d259c3e643e2b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIxLTktMS0xLTA_197f0415-07ca-48f2-9cab-8dfaa8eed83c"
      unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIxLTExLTEtMS0w_d68316c1-6885-4b66-a02b-e8ce0967faff"
      unitRef="usd">203000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTEtMS0xLTA_20fd1230-3b50-4337-bbc6-240bb3f04f53"
      unitRef="shares">1795000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTMtMS0xLTA_9db957cb-19d9-42cd-97bd-40fc7b736b08"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTUtMS0xLTA_63ec51a5-7001-4ab7-a15b-812fc8815178"
      unitRef="usd">26054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIyLTExLTEtMS0w_a192fb4d-a9c7-4aa8-8ae7-66807ac91c6c"
      unitRef="usd">26072000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTEtMS0xLTA_10896ea0-e316-4fd0-86c1-e937f4168bbd"
      unitRef="shares">11155000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTMtMS0xLTA_88fe6a75-36c2-42ef-bf6c-7f8bf4b9503b"
      unitRef="usd">112000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTUtMS0xLTA_f75c3f90-7964-43a6-8901-78cb4a3fae8f"
      unitRef="usd">245754000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzIzLTExLTEtMS0w_288a446d-c6e5-414f-83d9-68594833d13c"
      unitRef="usd">245866000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTEtMS0xLTA_836848ed-6dc4-48cc-9d1b-6fc4d30bbfac"
      unitRef="shares">131000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibff8e8a466f441c8909c8c2f85ebae45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTMtMS0xLTA_e4057146-6aa0-48ac-9fec-553f72cf5574"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI0LTExLTEtMS0w_40c34299-4b82-4a66-bcf1-3c384b1f046d"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e65405df6f448b786cddb256251701b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI1LTUtMS0xLTA_b28dceff-6c06-40b7-8e1b-2dcdf125af85"
      unitRef="usd">36158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI1LTExLTEtMS0w_192b2487-821f-4857-8208-bde810dd1c8e"
      unitRef="usd">36158000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTEtMS0xLTA_57406579-e601-4ab4-8838-e9471d28a2e3"
      unitRef="shares">102763000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8dc3fff7e5b84c4b9c04545ab8bc62e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTMtMS0xLTA_2b2a912f-4264-4b31-a363-4190a56c643c"
      unitRef="usd">1028000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i968e32794a5c4430ae11c1b0b3884003_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTUtMS0xLTA_8e71b037-15ab-4577-94f0-cdc14828bc4c"
      unitRef="usd">2105252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0897592bf8bb4a21931904c230db9a43_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTctMS0xLTA_c23a5b95-1bff-4135-a149-3675aff89ab1"
      unitRef="usd">-1830589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia665daf63d884a34b3a03848ca8720da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTktMS0xLTA_56df9408-ed81-49b8-a42d-f5e4623dada9"
      unitRef="usd">193000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMjcvZnJhZzphNDE4OTY1NjViYmU0ODEwOWJkZWFkY2Q2MjNlMGYzNy90YWJsZTphNTRlM2Y1MzdmMDA0NmJlYTBjMDFhMDRhZTY4NTMzMi90YWJsZXJhbmdlOmE1NGUzZjUzN2YwMDQ2YmVhMGMwMWEwNGFlNjg1MzMyXzI2LTExLTEtMS0w_1a24dec4-2b72-41b0-bdfa-e4fdc13bc811"
      unitRef="usd">275884000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtMS0xLTEtMA_15803e8a-3193-4ebc-8227-a8f6bcfc689c"
      unitRef="usd">-294090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtMy0xLTEtMA_070a7bd0-dc49-4adf-ae2e-e9241c4fd3be"
      unitRef="usd">-254337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMtNS0xLTEtMA_91901945-317b-4eab-a368-7b4ecce6dc61"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtMS0xLTEtMA_be0c5467-3413-4f71-96e3-e9215d7ebdc7"
      unitRef="usd">9147000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtMy0xLTEtMA_61347f08-531b-489c-b3ef-3e3453581cbf"
      unitRef="usd">5188000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzUtNS0xLTEtMA_26a34e98-cc39-4916-834f-a27a732480ef"
      unitRef="usd">3577000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtMS0xLTEtMA_dbe1784e-5fdf-471f-8b39-3239d5d2f9eb"
      unitRef="usd">5003000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtMy0xLTEtMA_876a6152-6832-4942-83e0-90461564cfa2"
      unitRef="usd">4993000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzYtNS0xLTEtMA_5dc98e6a-2761-42d4-b9cd-6f8392c5f374"
      unitRef="usd">1249000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctMS0xLTEtMA_ec3b8b8b-12f1-48bb-ba34-858b0fff5f84"
      unitRef="usd">36158000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctMy0xLTEtMA_1307c30a-8a8a-429f-848c-ed655de76eb1"
      unitRef="usd">26971000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzctNS0xLTEtMA_9bbb2f12-7425-4326-ab5c-8713fed4736a"
      unitRef="usd">26240000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtMS0xLTEtMA_e66985e5-ad20-45ff-9a40-d8aeb5d709d3"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtMy0xLTEtMA_02b9a9d1-5031-4aed-9e8d-ec5070912e58"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzgtNS0xLTEtMA_cd582e1a-8aef-4384-8daa-be343ce609ab"
      unitRef="usd">-2209000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktMS0xLTEtMA_16b17353-81c6-4646-8f27-d9b804bf6b2d"
      unitRef="usd">1397000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktMy0xLTEtMA_717300e5-1efb-4ed1-b051-e20bb38c72d9"
      unitRef="usd">1397000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzktNS0xLTEtMA_5255b804-9d45-4442-b8c9-9842c4403c5f"
      unitRef="usd">1350000</us-gaap:AmortizationOfFinancingCosts>
    <insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTEtMS0xLTA_25dac9a1-b75d-4431-a51a-1ef59660e323"
      unitRef="usd">18981000</insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense>
    <insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTMtMS0xLTA_debf4d47-3714-43b2-a77c-5eba355f0f88"
      unitRef="usd">17985000</insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense>
    <insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEwLTUtMS0xLTA_b806ef86-8ae9-4894-b20c-341d97f92d7f"
      unitRef="usd">15939000</insm:AmortizationOfDebtDiscountPremiumAndAccretionExpense>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzExLTEtMS0xLTA_2a3cae55-30ec-44a5-aaca-9e2a05aacfd4"
      unitRef="usd">1078000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzExLTMtMS0xLTA_00a82061-3f1c-4913-8029-071a271931d6"
      unitRef="usd">360000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <insm:NoncashOperatingLeaseExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEyLTEtMS0xLTA_2776d090-979e-4de0-96ef-8f8dd1ecc36e"
      unitRef="usd">5932000</insm:NoncashOperatingLeaseExpense>
    <insm:NoncashOperatingLeaseExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzEyLTMtMS0xLTA_50fae4dd-0b19-41d4-8cf2-1159286f86d6"
      unitRef="usd">9763000</insm:NoncashOperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTEtMS0xLTA_5056239c-b214-4fec-b31a-dd24bfb5e6d6"
      unitRef="usd">-2670000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTMtMS0xLTA_53052e68-24b2-4ec6-b1d0-eaa808fae67a"
      unitRef="usd">13717000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE0LTUtMS0xLTA_0aa9b741-eae4-4f14-8ea9-8c8d1b8a0d67"
      unitRef="usd">5515000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTEtMS0xLTA_bd75082e-39a9-40e8-947f-705ffe79199f"
      unitRef="usd">21180000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTMtMS0xLTA_1fe7cf9a-6648-44fe-b973-6d18391a413a"
      unitRef="usd">21281000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE1LTUtMS0xLTA_b38109e3-e7eb-4cf0-b015-40327b5365a5"
      unitRef="usd">7032000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTEtMS0xLTA_89a00b77-bb24-426f-8481-435a6727f4ed"
      unitRef="usd">3114000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTMtMS0xLTA_d501f346-2ee1-443b-b302-8de708bbfdda"
      unitRef="usd">8718000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE2LTUtMS0xLTA_0066b1e7-81cc-4ca5-acfd-8a61dd3801c8"
      unitRef="usd">5514000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTEtMS0xLTA_dcb3716d-0f80-4ac6-a47d-aa38f9530c1a"
      unitRef="usd">6261000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTMtMS0xLTA_4236d47c-98d9-4f7f-8a0d-1308b8ad58ad"
      unitRef="usd">16008000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE3LTUtMS0xLTA_4355aeb6-d374-45e2-9105-a3651a70c40f"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTEtMS0xLTA_c925a045-11d3-423b-83d6-432e8436e26e"
      unitRef="usd">29825000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTMtMS0xLTA_d49572bd-124e-45c3-9ff9-643414613b96"
      unitRef="usd">-4966000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE4LTUtMS0xLTA_7c696857-2a6d-40b5-a0b4-b9e977a199f8"
      unitRef="usd">3870000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTEtMS0xLTA_310e87cb-4ceb-472e-95db-8545a9f77df2"
      unitRef="usd">-10675000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTMtMS0xLTA_93caff61-6540-4702-8ce6-d5c350cbed57"
      unitRef="usd">4789000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzE5LTUtMS0xLTA_a85fb088-1f6d-45a9-bbf4-55898430866e"
      unitRef="usd">19916000</insm:IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTEtMS0xLTA_270f4104-a71f-4a93-a9ef-29e381df4d07"
      unitRef="usd">5781000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTMtMS0xLTA_0dcb5a6e-3926-4421-9328-d5150bd9a516"
      unitRef="usd">-3068000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIwLTUtMS0xLTA_9616133b-3567-4ab7-8240-441176ce717f"
      unitRef="usd">10011000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTEtMS0xLTA_d383a671-24f5-4c3d-8a22-16b97027552d"
      unitRef="usd">-219348000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTMtMS0xLTA_1f2b5665-d93f-47fa-83f8-246a482e4e42"
      unitRef="usd">-250649000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIxLTUtMS0xLTA_c9487b51-f332-44e5-b67a-1932b1b9a87f"
      unitRef="usd">-257977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTEtMS0xLTA_0863d9ff-e5e5-4252-9824-8eaead71f0a5"
      unitRef="usd">6240000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTMtMS0xLTA_bc7ecd01-54ab-41ef-a182-2fa801e64936"
      unitRef="usd">42268000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzIzLTUtMS0xLTA_59570b10-3fc8-4d36-87c2-2cfdf3c5565d"
      unitRef="usd">13090000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTEtMS0xLTA_24a66f5e-29cb-4060-bcac-0e4e7fec3da6"
      unitRef="usd">582000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTMtMS0xLTA_e908fa15-096c-4945-956d-3bfc7b0c841f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI1LTUtMS0xLTA_cc8335ed-c253-4786-b17c-a7ab0dd5e686"
      unitRef="usd">1724000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTEtMS0xLTA_6c5daca7-97db-4604-9676-fab76392d263"
      unitRef="usd">-6822000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTMtMS0xLTA_bcfeefeb-fc19-447f-9bb7-f6889a6c7169"
      unitRef="usd">-42268000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI2LTUtMS0xLTA_1d08e902-11f7-4fd5-8db5-29c7e095d262"
      unitRef="usd">-14814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxMjY0YzdhYjg4MzM0MjZmYjEzM2M5MzQ0ZmYwOTIzNl8zMA_75792b5a-e387-4dcd-88cf-0bb499afa6f1"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTEtMS0xLTA_e8a83747-c6d5-494c-8ab7-bccdfdb6fcae"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTMtMS0xLTA_79037804-b9c4-422c-b405-736fb6e19b39"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzI4LTUtMS0xLTA_8f6922b3-0a66-46d9-96e6-4e7a3ffdceaf"
      unitRef="usd">450000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTEtMS0xLTA_6e2ad4ca-e18d-48b6-9190-9d890115205a"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTMtMS0xLTA_75ecbe6f-bbb8-498f-8384-eca6a8ec07cf"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMwLTUtMS0xLTA_b4361b74-c79a-4200-92ce-c449e735ba1a"
      unitRef="usd">57835000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTEtMS0xLTA_29c89e58-5511-40fb-8881-e33e79fc7c0b"
      unitRef="usd">245866000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTMtMS0xLTA_37f397f4-c4fe-460e-8331-dabef29b93c4"
      unitRef="usd">261074000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMyLTUtMS0xLTA_2ae80c3a-807b-4909-91f9-277a35deb40b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTEtMS0xLTA_ab8798d1-748f-4d34-8a86-c82c6faf9ace"
      unitRef="usd">26073000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTMtMS0xLTA_43212f5d-4fa9-4d56-92cf-60c86c2d7251"
      unitRef="usd">19701000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzMzLTUtMS0xLTA_e60af15f-0463-49e4-b0d6-b53c6a2b8044"
      unitRef="usd">8815000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTEtMS0xLTA_0fcdd7ba-3e14-4fd2-a635-68660daa239c"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTMtMS0xLTA_00d18d09-4ef9-4ace-8c15-dfcda3051f64"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM0LTUtMS0xLTA_66fb4dc5-79b8-4bf7-80fc-8c8a6be7f2d7"
      unitRef="usd">14237000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM1LTEtMS0xLTA_9c907978-3118-42a1-91f7-bfcde17de613"
      unitRef="usd">936000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM1LTMtMS0xLTA_98a3c1d2-7134-4edd-aac8-da5b719ba5f2"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM2LTEtMS0xLTA_06074866-a977-4a3d-b739-2561e5fc7989"
      unitRef="usd">0</insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance>
    <insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM2LTMtMS0xLTA_c4b2ad53-82b2-4af7-97b3-0b6cc2b42252"
      unitRef="usd">-4503000</insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTEtMS0xLTA_bb4e3133-5bff-4ab0-b541-788dd97863e7"
      unitRef="usd">271003000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTMtMS0xLTA_ef4f00ca-c312-4a7e-9866-57148b9f3add"
      unitRef="usd">285278000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM3LTUtMS0xLTA_09325690-a89c-4ba7-8490-83530ef05310"
      unitRef="usd">386743000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTEtMS0xLTA_43fc4527-bdb8-4c69-8dbf-5aceed52c6cc"
      unitRef="usd">494000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTMtMS0xLTA_6884ea46-ac70-486c-a64e-61f4aaf6a74c"
      unitRef="usd">-4000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM4LTUtMS0xLTA_967d703f-ea02-459b-9927-9010db7e49b5"
      unitRef="usd">-45000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTEtMS0xLTA_ac9dab15-fc1f-48b0-81fb-be732392d8eb"
      unitRef="usd">45327000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTMtMS0xLTA_135fcd04-598e-49f8-87cf-76a73dcc8eb9"
      unitRef="usd">-7643000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzM5LTUtMS0xLTA_798b2845-7a4f-4b7b-a16a-3da8f036b174"
      unitRef="usd">113907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTEtMS0xLTA_2103aeb3-57dd-4536-bdb0-bf8426014fd4"
      unitRef="usd">487429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTMtMS0xLTA_ba32f5fc-234e-40e6-8a73-bf1712ee1a95"
      unitRef="usd">495072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQwLTUtMS0xLTA_89a2f3d4-d881-4629-a7ff-39a0cc39f904"
      unitRef="usd">381165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTEtMS0xLTA_01cae3e3-312e-4c8c-8f80-2a14cdf88347"
      unitRef="usd">532756000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTMtMS0xLTA_cd896d58-88dc-4149-a584-7c37e649b21c"
      unitRef="usd">487429000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQxLTUtMS0xLTA_ca508a1d-1ec3-4ec5-a6ca-6c923b5de36b"
      unitRef="usd">495072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTEtMS0xLTA_f47b9009-ea48-4bec-bf69-717d9ab1693b"
      unitRef="usd">9186000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTMtMS0xLTA_ba7ee751-4ed3-47ba-9074-520ad26a536a"
      unitRef="usd">7883000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQzLTUtMS0xLTA_5f7df7b1-ee74-4a8f-ba38-7051bb6ba62f"
      unitRef="usd">6289000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTEtMS0xLTA_c993f29d-0ad4-4930-aa61-ea704b789c59"
      unitRef="usd">814000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTMtMS0xLTA_6399f1d8-1caa-4c90-8369-d4d9d25ab487"
      unitRef="usd">339000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzAvZnJhZzpmMmE3MTU1ODVlOWQ0YTY3YmQ3MmMxMmFlMTQxNmFkOS90YWJsZTpmOTc2NzhiMWY4MDg0ODA2OGM4YjcyODBlODZlZjU1YS90YWJsZXJhbmdlOmY5NzY3OGIxZjgwODQ4MDY4YzhiNzI4MGU4NmVmNTVhXzQ0LTUtMS0xLTA_f58eabda-8230-4c2a-b24b-14948fa8bbca"
      unitRef="usd">154000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzM4MDQ_6a68b9cd-5e87-4def-98e4-d9ef40c6bbee">Description of Business and Basis of Presentation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE&#xae; Liposomal 590 mg Nebuliser Dispersion. ARIKAYCE received accelerated approval in the United States (US) in September 2018 for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mycobacterium avium complex&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension and other rare pulmonary disorders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $532.8&#160;million in cash and cash equivalents as of December&#160;31, 2020 and reported a net loss of $294.1 million for the year ended December&#160;31, 2020. Historically, the Company has funded its operations primarily through public offerings of equity securities and debt financings. The Company commenced commercial shipments of ARIKAYCE in October 2018. The Company expects to continue to incur operating losses both at its US and certain international entities while funding research and development (R&amp;amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing and commencing commercialization activities for ARIKAYCE in the US and Europe, respectively, continuing to invest in pre-commercial and regulatory activities for ARIKAYCE in Japan, and funding other general and administrative activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the continued commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop brensocatib and TPIP and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#x2019;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the year ended December 31, 2020, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, and Insmed Italy S.R.L.. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzE1MzM_6988e26b-155b-49d4-b568-a83dbb7f0c43"
      unitRef="usd">532800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzE2MDE_646e43a9-2946-4e48-9c34-eec776bedca3"
      unitRef="usd">-294100000</us-gaap:NetIncomeLoss>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzYvZnJhZzowMDZmMGI4YmQ4OWM0OGU2OGJhNGUxNWEyNmQ5NTU1OS90ZXh0cmVnaW9uOjAwNmYwYjhiZDg5YzQ4ZTY4YmE0ZTE1YTI2ZDk1NTU5XzM4MDc_541b6eaa-6f18-43dc-ad63-ede9b2f09024">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, and Insmed Italy S.R.L.. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg3_3e41be84-07f5-4e18-bcef-f6a01dab4861">Summary of Significant Accounting Policies&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and &lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Income and Interest Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Accounts receivable are recorded net of customer allowances for prompt pay discounts, chargebacks, and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, expected credit losses have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fixed Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of three years to five years are used for computer equipment. Estimated useful lives of seven years are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment Assessment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's only financial assets and liabilities which were measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019 were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemptions and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company held no securities that were in an unrealized loss or gain position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the liability component of the 1.75% convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of December&#160;31, 2020 was $516.4 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The $356.3 million carrying value of the Convertible Notes as of December&#160;31, 2020 excludes the $88.0 million of the unamortized portion of the debt discount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues, net consist primarily of net sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. The Company's customers in the US include specialty pharmacies and specialty distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer credits: The Company's customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fees for services are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and fees and, therefore, deducts the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Customer Credits, Fees and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Chargebacks and Co-pay Assistance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue related to certain early access programs (EAPs) in Europe, consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation, or ATU) and from the named patient program in Germany and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other countries. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. In December 2020, the Company began recognizing product revenue from commercial sales to Germany subsequent to receiving approval by the EC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first-out (FIFO) flow of goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred. Inventory used for clinical development purposes is expensed to research and development (R&amp;amp;D) expense when consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;R&amp;amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, including medical affairs. R&amp;amp;D expense also includes other internal operating expenses, the cost of manufacturing a product candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. The Company's expenses related to manufacturing its product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture its clinical product supply of ARIKAYCE, brensocatib and TPIP. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. The Company may also grant performance-based stock options to employees from time-to-time. The grant-date fair value of performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;amp;D and SG&amp;amp;A expenses in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that is more likely than not to be sustained upon ultimate settlement. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term on the balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of comprehensive income in the same line item as expenses arising from fixed lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 842, leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information presented prior to January 1, 2019 has not been adjusted and is presented in accordance with ASC 840. Refer to the Recently Adopted Accounting Pronouncements section within this note below and Note 7 - Leases for details about the Company's lease portfolio, including Topic 842 required disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company currently operates in one business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2014; Credit Losses, which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. This ASU amends the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 effective January 1, 2020. Different aspects of the guidance required modified retrospective or prospective adoption. Adoption of the standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In August 2020, the FASB issued ASU 2020-06, Debt &#x2014; Accounting for Convertible Instruments, to reduce the complexity associated with applying US GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company is currently evaluating the impact of adoption of ASU 2020-06 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcz_6669fa68-d941-4fc8-b155-01591e537941">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and &lt;/span&gt;judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <insm:InvestmentIncomeExpensePolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgx_f04b8c58-e87f-48e9-94ca-ef47feb6c697">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Income and Interest Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.&lt;/span&gt;</insm:InvestmentIncomeExpensePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTE2_1ed62c9a-d734-4bbd-af76-ef2f9881d123">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzQzOTgwNDY1NjM1NTI_960a1836-bb02-495b-b25c-e5f9bcc8267c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Accounts receivable are recorded net of customer allowances for prompt pay discounts, chargebacks, and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, expected credit losses have not been material.&lt;/span&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgz_4978c726-8e41-41d4-a81b-af636f5525d1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fixed Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of three years to five years are used for computer equipment. Estimated useful lives of seven years are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE0NzA_dac2038e-d047-4139-a9f3-37e4d42a1171">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE0NzY_bfff628a-deb6-4c5d-8afb-adaa3aa5fb07">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0ff79db52eb84c4598d7b7afcb119dfe_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzE1Mzg_0111c14c-5568-4552-977c-7b3bbceb0825">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDk5_bb935360-2972-4c56-8568-a2941ef36a54">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. &lt;/span&gt;Impairment Assessment&#x2014;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg4_62099d4b-8c57-41a1-b84c-9e70cad5420d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.&lt;/span&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc0_3bd17a57-5fa9-40d4-a31d-480d42786751">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#x2019;s anticipated life.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Inputs reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's only financial assets and liabilities which were measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019 were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemptions and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020 and 2019, the Company held no securities that were in an unrealized loss or gain position.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc1_ce2bafad-eec3-4af8-bc60-1a9252969c4c">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.339%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifd5f902b0ea148debdd39b7e096ed23b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtMS0xLTEtMA_6c8b7a80-238d-4cd0-81f8-00536483d742"
      unitRef="usd">532800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8ad75b5ff0eb42f79faddf5ae9746ddb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtMy0xLTEtMA_30799607-5de8-4d19-9e43-a7908ac65f53"
      unitRef="usd">532800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtNS0xLTEtMA_4f458322-c6a8-40e3-ac61-b7c6d02243c2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7e0818f19ecc45e8bffe1b74c6ecc287_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzQtNy0xLTEtMA_4f88d25e-7c7a-48a0-aed2-0465035b73bb"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if33069948ada4260b9525905a9028722_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktMS0xLTEtMA_ea395554-da12-4df0-a17e-c66a0704ea8f"
      unitRef="usd">487400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iefdcf33de75d49cba0e70cc7853c3280_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktMy0xLTEtMA_32e5c7f3-f5d6-44e0-9a3d-d529bff881b6"
      unitRef="usd">487400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4f8752f81b5546f6aac228d90c7b03d4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktNS0xLTEtMA_5bba639b-5b39-4a20-b737-5e8a6df1f6f6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8c48b09e6691416abc16070aff6792d2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjZDYxZmMxZDBjODM0ZjRjOGQxZTBhZGE0YjQ4ZWU3Ni90YWJsZXJhbmdlOmNkNjFmYzFkMGM4MzRmNGM4ZDFlMGFkYTRiNDhlZTc2XzktNy0xLTEtMA_7f8a7aeb-fbb1-4fc0-885a-8da840d945a4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYyNTI_07835b5c-6a37-4409-aec4-4f23b0f7b99f"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:FairValueLevel1Level2Level3TransfersAmount
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYyNTI_a6a27b27-d336-41e1-bc8d-6681290e31c1"
      unitRef="usd">0</insm:FairValueLevel1Level2Level3TransfersAmount>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYzNjA_8a8f7f82-6fac-48e5-bfa5-d246400831c4"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzYzNjA_8d6e7322-96e6-43e9-859d-f32bb83dc18e"
      unitRef="security">0</insm:AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzY5NzY_105845b7-b422-4274-86bc-ed429c1bf987"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="ida5a239cc3e440e4bff5e7ba4a08476d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzcxMjM_7fc8a09a-7842-4a3b-874e-3e4096524f92"
      unitRef="usd">516400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i9bd7a24933d64c00a17e23166ddcb249_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzcyNjM_2460631a-5186-4dd6-916f-cdeefecb3e94"
      unitRef="usd">356300000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i93c687c71117495bbb85688c2e6da53f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzczMjk_d1e7c457-2d68-4149-a86d-358413d7f489"
      unitRef="usd">88000000.0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDY3_61b7dbd8-8e10-4f72-a167-e9b38488aacb">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTIw_f41b7774-3fe0-4f4d-87e4-dca2de99da03">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDg1_c2a1be5f-04ab-47ec-b0a4-ec17effedb04">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Percentage of Total Gross Product Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2557ec52f167465a9db110f78f63cea9_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzItMS0xLTEtMA_dd8a1741-8475-4e90-af9c-9e337bd090ca"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i017d5966090a4b0ab4fb5abb56c17d5c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzItMy0xLTEtMA_a9bd5739-b537-4e4f-bb21-43a14707b29c"
      unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8b1b88435bd44aeb678f80443f3d14c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzMtMS0xLTEtMA_7738044f-0cd4-4ab1-b355-469f7a433eae"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i84af194151234369a03dc3fdf9ff1c60_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzMtMy0xLTEtMA_dbc2a82e-db95-4bde-9741-46426aab016a"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9ad5a7b26844352bc3de93a1fa02e5d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzQtMS0xLTEtMA_d2a76bf3-49dd-48cf-932f-794dc24347cb"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i41b33cfe7496472887a9b46f5bb1a64e_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo2N2I5ODQyZTAxMGU0YWJhOTBiM2FjYjNlYzJiZmQ2YS90YWJsZXJhbmdlOjY3Yjk4NDJlMDEwZTRhYmE5MGIzYWNiM2VjMmJmZDZhXzQtMy0xLTEtMA_059fb3d2-392a-49ee-943e-da9256e2d29a"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc2_d2a7487d-b1e2-43fd-9986-5438018c654b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenues, net consist primarily of net sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. The Company's customers in the US include specialty pharmacies and specialty distributors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer credits: The Company's customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fees for services are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and fees and, therefore, deducts the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Customer Credits, Fees and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Chargebacks and Co-pay Assistance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recognizes revenue related to certain early access programs (EAPs) in Europe, consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation, or ATU) and from the named patient program in Germany and &lt;/span&gt;&lt;/div&gt;other countries. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. In December 2020, the Company began recognizing product revenue from commercial sales to Germany subsequent to receiving approval by the EC.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTA0_5b4030a5-f5ad-4572-b289-a62f644c03bb">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Customer Credits, Fees and Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Chargebacks and Co-pay Assistance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for current period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Allowances for prior period sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="if411584126e147579c1290e85b019267_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtMS0xLTEtMA_7280d542-1cc2-4950-b389-38f120352ecf"
      unitRef="usd">464000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="i0d80ecd614a347319af9d2f44019b7f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtMy0xLTEtMA_f1501038-250d-44af-8290-663d504cc72e"
      unitRef="usd">5171000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEtNS0xLTEtMA_ded8514a-e745-4d62-a445-7086571773e3"
      unitRef="usd">5635000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItMS0xLTEtMA_10c98090-cdde-4436-a20c-1c11338e268a"
      unitRef="usd">3731000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItMy0xLTEtMA_9ca24adb-98fb-43b7-b191-04cde8578ffb"
      unitRef="usd">18244000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzItNS0xLTEtMA_b1d7f4fc-0b10-4934-b70a-e78faf5ef0ce"
      unitRef="usd">21975000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtMS0xLTEtMA_689c76a6-fe62-4954-a9d7-58c2c94c498a"
      unitRef="usd">0</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtMy0xLTEtMA_e1acfa8f-fe73-4ffc-a9a4-d2d1d8ef3dd1"
      unitRef="usd">-288000</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzMtNS0xLTEtMA_027c1448-5250-463a-a0a6-7edf26c5d171"
      unitRef="usd">-288000</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="i65de30489eb1405f9bf4561c3b4e721a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtMS0xLTEtMA_0a2d045c-59ce-4365-94ff-cdde95d1cfec"
      unitRef="usd">3742000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="i57e41ab20e3a4ef599dc7df9f39d245f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtMy0xLTEtMA_d4d94ad4-315e-431e-9e91-5dbb386b1caa"
      unitRef="usd">18609000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzQtNS0xLTEtMA_3c891a3b-d63f-4989-8831-e6912804eefa"
      unitRef="usd">22351000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="i84042da0fe82481489bbac6622c413bf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtMS0xLTEtMA_f5ff148a-9d3f-49e8-a29c-fe6c6fa8f11a"
      unitRef="usd">453000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="i71d6098b4cd2462ea2fe95fdcfff87a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtMy0xLTEtMA_1e337e6d-40f5-48fa-9390-907e3302cd05"
      unitRef="usd">4518000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzUtNS0xLTEtMA_b22b1de6-472c-4b31-adc9-384de13c21d2"
      unitRef="usd">4971000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="i3ed9d4ebbe0c4a5c90652308ad3ede36_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctMS0xLTEtMA_94f08a0d-a447-4a1b-a0f8-353f1a8b0c3d"
      unitRef="usd">234000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="if454ac4f869c4464a82f74996dd1dcae_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctMy0xLTEtMA_57132e75-c7d9-4130-a182-e224597602e7"
      unitRef="usd">688000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzctNS0xLTEtMA_ddefdba9-4bc0-4dc1-bb8e-f2d7f9705ba1"
      unitRef="usd">922000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtMS0xLTEtMA_8d5facbd-b7b2-41b9-bf41-033bd5d280b4"
      unitRef="usd">3151000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtMy0xLTEtMA_8696173e-218d-4805-bb23-fb1c0b299d7f"
      unitRef="usd">12059000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzgtNS0xLTEtMA_5955fbe2-5cb9-4f6c-b188-761d5bd7feba"
      unitRef="usd">15210000</insm:ContractWithCustomerAssetAllowanceForCurrentPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktMS0xLTEtMTYzOA_6bf0f53e-ec62-413e-abd2-2808ab68b9b6"
      unitRef="usd">14000</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktMy0xLTEtMTYzOA_382d18ba-5039-4327-aee0-831b1d6c12e0"
      unitRef="usd">26000</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzktNS0xLTEtMA_90477c8d-5d0c-43d7-99a3-f4b8f3ec978f"
      unitRef="usd">40000</insm:ContractWithCustomerAssetAllowanceForPriorPeriodSales>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="i7e7d083f6da0458181337d318c54b702_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTEtMS0xLTA_e392f8d6-a48b-4920-b10e-e5be8b9f3610"
      unitRef="usd">2935000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="id7fbf3a9d6234172a30844c77b7c56f3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTMtMS0xLTA_a2a84391-c27d-4180-9e32-c988aec3f751"
      unitRef="usd">7602000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzEwLTUtMS0xLTA_b64fb7c3-f94e-4a47-917f-3f8de953641e"
      unitRef="usd">10537000</insm:ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="if411584126e147579c1290e85b019267_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTEtMS0xLTA_756b87d6-59d5-4258-a2b0-7c3365090049"
      unitRef="usd">464000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="i0d80ecd614a347319af9d2f44019b7f0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTMtMS0xLTA_4218223f-6147-4085-9c35-926b4e8c5091"
      unitRef="usd">5171000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTo3MGQ2NDA3YzY0NTk0YzA0OGMzYjI0OWUxMjZjYmEyMi90YWJsZXJhbmdlOjcwZDY0MDdjNjQ1OTRjMDQ4YzNiMjQ5ZTEyNmNiYTIyXzExLTUtMS0xLTA_3481350e-2217-4ea9-a58c-abab3c5efac7"
      unitRef="usd">5635000</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDY4_254f20c6-7859-4fb2-bc4a-2c823a3e7c70">&lt;div style="margin-bottom:8pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory and Cost of Product Revenues (excluding amortization of intangible assets)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first-out (FIFO) flow of goods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred. Inventory used for clinical development purposes is expensed to research and development (R&amp;amp;D) expense when consumed.&lt;/span&gt;&lt;/div&gt;</insm:InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTIz_cd86ac6b-c2a9-4d4a-bac4-0274815d84ce">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;R&amp;amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, including medical affairs. R&amp;amp;D expense also includes other internal operating expenses, the cost of manufacturing a product candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. The Company's expenses related to manufacturing its product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture its clinical product supply of ARIKAYCE, brensocatib and TPIP. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTI0_800b3dbf-f5c1-4e49-b877-16905443335f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. The Company may also grant performance-based stock options to employees from time-to-time. The grant-date fair value of performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;amp;D and SG&amp;amp;A expenses in the consolidated statements of comprehensive loss.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDc4_ea8e8857-f8de-4fb8-982a-abbc1d73e74a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that is more likely than not to be sustained upon ultimate settlement. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTA4_87a5f564-2365-4457-998b-7f417e60a1cc">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcx_88836ddd-5f3b-4767-8c5a-89612efb3ded">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(294,090)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(254,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares used in calculation of basic net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding used in calculation of diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtMS0xLTEtMA_28f0aaa4-20c7-43c8-a2db-45a08746d1c4"
      unitRef="usd">-294090000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtMy0xLTEtMA_9202749f-b0d5-4dc2-998b-576a32cbbe0e"
      unitRef="usd">-254337000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzQtNS0xLTEtMA_53318afb-a356-43dd-88c5-720fc475b83b"
      unitRef="usd">-324277000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtMS0xLTEtMA_2455caed-4e6a-4da6-9358-51617e2cd3b0"
      unitRef="shares">97605000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtMy0xLTEtMA_f6d8e62e-e029-48d2-86f0-3920dd87fa28"
      unitRef="shares">84560000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzYtNS0xLTEtMA_f76bbb0a-7716-424b-afab-94c6b27d242f"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7e32e7ead80245768a4215e36f3d013e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtMS0xLTEtMA_8f6367cf-b1d1-4fe0-ba62-0c11b501f02b"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4a17ed1cbdfb44299c8d6329a58ecd20_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtMy0xLTEtMA_b4b0096f-164c-4a7b-b3e4-4a6132109740"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9b73eefc9dfc4da4b954ad4f37d36401_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzgtNS0xLTEtMA_3c14c9d2-2d32-4237-a07a-d081082e5575"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktMS0xLTEtMA_040f6aec-a3b5-4891-b1e6-7cd3e1676535"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktMy0xLTEtMA_d1b631f1-6da5-4568-905d-db4fa205969a"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzktNS0xLTEtMA_9f17db5e-beb8-4d24-b19f-8c031e57f501"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iaeb953793f734b5fa4ff72faaca69bed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTEtMS0xLTA_042c3715-9abe-4193-a6c9-79775393f09c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8b1e8f8d82d740f2a0b6f1636a4984fb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTMtMS0xLTA_94525779-6aba-4d19-8960-28d4922a600b"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8e26a169ca6447e1bbd8420534209dd4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEwLTUtMS0xLTA_df175372-cfc7-453e-8b44-5f4456e7b345"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTEtMS0xLTA_4900394e-650b-4b20-8a98-0b5d6893ad12"
      unitRef="shares">97605000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTMtMS0xLTA_5df5a316-7fa4-4621-88bc-4007c9681a95"
      unitRef="shares">84560000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzExLTUtMS0xLTA_5c31e37b-bb80-47eb-b525-50fd7240737e"
      unitRef="shares">76889000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTEtMS0xLTA_3e4e48ba-8784-4ec9-a00d-0fc73a20551b"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTMtMS0xLTA_b8f5044e-1b80-4beb-831c-b407a8bd9e26"
      unitRef="usdPerShare">-3.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpjODEyODBmNWJiZWI0NTQyOTcyM2FiYjcwOWZmNzZhMC90YWJsZXJhbmdlOmM4MTI4MGY1YmJlYjQ1NDI5NzIzYWJiNzA5ZmY3NmEwXzEzLTUtMS0xLTA_17e9321b-2801-4a8c-80a2-d4a314c80e3c"
      unitRef="usdPerShare">-4.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTE4_611e71d8-406b-40d9-86e3-31d7645406eb">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItMS0xLTEtMA_11a0c075-386c-4dd0-a9a7-6b5d93558998"
      unitRef="shares">12263000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ff567a613c140aa9f850be249a8a85f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItMy0xLTEtMA_fd4e831e-a09c-420b-9c02-c86d74ff7ca4"
      unitRef="shares">10493000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d1b35f80d7c4963a103aa9c2ed57381_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzItNS0xLTEtMA_47b95f1a-2da8-45d5-ad11-d9e710e72c22"
      unitRef="shares">9382000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f1f6e025d01493c8f016b27c71e8c6c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtMS0xLTEtMA_51975850-0697-4c80-ba71-237c9e66a9ec"
      unitRef="shares">844000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i97d0d45f93fd42eaa738fe0fc6f368ff_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtMy0xLTEtMA_f748dc22-8ea9-498a-8d8c-b2a8cd1c8c74"
      unitRef="shares">501000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia8918052cbd746439e9093c317f861e3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzMtNS0xLTEtMA_bb752289-03dd-41cc-889b-c3e60899c116"
      unitRef="shares">228000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib892164ea751411ca150501c187370ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtMS0xLTEtMA_480ccc08-e093-4330-97e9-ee5a61d39398"
      unitRef="shares">11492000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ida80845cbee243b2815d745facfea2d3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtMy0xLTEtMA_e3210ea1-07c6-4c10-9c89-395f975a5f2c"
      unitRef="shares">11492000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icf9ed33bf5454a7d8711743ff01550c0_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90YWJsZTpkZDZmOTIyNzljNzM0M2VjODdhNmVmZjNmZDg4YmQ1Ny90YWJsZXJhbmdlOmRkNmY5MjI3OWM3MzQzZWM4N2E2ZWZmM2ZkODhiZDU3XzQtNS0xLTEtMA_ee0f868b-9db1-4d98-b168-a48bdbd24406"
      unitRef="shares">11492000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDgw_1da162a3-6b4c-4832-9312-6c982511d818">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term on the balance sheet. &lt;/span&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of comprehensive income in the same line item as expenses arising from fixed lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Topic 842, leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information presented prior to January 1, 2019 has not been adjusted and is presented in accordance with ASC 840. Refer to the Recently Adopted Accounting Pronouncements section within this note below and Note 7 - Leases for details about the Company's lease portfolio, including Topic 842 required disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMDcw_1309b760-881a-44e7-85b8-0f64b838ffa7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company currently operates in one business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has one reportable segment.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzI2ODAz_1dee9929-892d-4406-9f04-a6da3f24b4e4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzI3MTY4_e3fcff2d-5fbb-400f-8a69-1f0c4e5d97b0"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xMzkvZnJhZzowMDA3YWI1NzNhMjQ0NjQwODg0ZTZmMzg0NzQzMmE1Ny90ZXh0cmVnaW9uOjAwMDdhYjU3M2EyNDQ2NDA4ODRlNmYzODQ3NDMyYTU3XzMwMTAx_a43868cf-518b-4356-89ae-e540b33d6a87">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2014; Credit Losses, which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. This ASU amends the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 effective January 1, 2020. Different aspects of the guidance required modified retrospective or prospective adoption. Adoption of the standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements (Not Yet Adopted)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In August 2020, the FASB issued ASU 2020-06, Debt &#x2014; Accounting for Convertible Instruments, to reduce the complexity associated with applying US GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company is currently evaluating the impact of adoption of ASU 2020-06 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90ZXh0cmVnaW9uOjNmYWUzOWJjMTQzOTQ3MThiZTM1Yzk1MmFjN2RlNjAyXzU0OQ_2af3bc3a-c0bd-410a-9577-347d83dda0ee">Inventory&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory balance consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90ZXh0cmVnaW9uOjNmYWUzOWJjMTQzOTQ3MThiZTM1Yzk1MmFjN2RlNjAyXzU1MA_bc871508-569c-46e5-b361-af8ee8d0ba3a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's inventory balance consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzMtMS0xLTEtMA_c70bff4f-ec02-4465-b299-b5bb5fd08abd"
      unitRef="usd">21601000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzMtMy0xLTEtMA_78c03c54-93ec-40bc-b0dd-6ffe08c34d29"
      unitRef="usd">16048000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzQtMS0xLTEtMA_29a2addf-332e-4217-a6c8-545ee6432ef3"
      unitRef="usd">18754000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzQtMy0xLTEtMA_15214fb3-7884-4895-81cf-e75a53a94f9b"
      unitRef="usd">6420000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzUtMS0xLTEtMA_088c305f-7595-417a-9476-5f3287572700"
      unitRef="usd">9237000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzUtMy0xLTEtMA_406d5361-6cff-41e8-ac2b-2085d8f12cec"
      unitRef="usd">5845000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzYtMS0xLTEtMA_c520b181-e5c2-4c89-a734-10438f27383e"
      unitRef="usd">49592000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDIvZnJhZzozZmFlMzliYzE0Mzk0NzE4YmUzNWM5NTJhYzdkZTYwMi90YWJsZTo2OWE4NWEwZmJkYjM0OTJjOTVkMzBhOTdjOTAyMzM3YS90YWJsZXJhbmdlOjY5YTg1YTBmYmRiMzQ5MmM5NWQzMGE5N2M5MDIzMzdhXzYtMy0xLTEtMA_2307f3e5-ce97-463a-9c97-3be022de3370"
      unitRef="usd">28313000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzkzMA_319e6d3d-1a01-47d9-a74b-14bf23643ba4">Intangible Assets, Net&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;amp;D, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value as well as milestones paid to PARI for the license to use PARI's Lamira&#xae; Nebulizer System for the delivery of ARIKAYCE to patients of $1.7 million as a result of the FDA approval of ARIKAYCE in September 2018 and $0.6 million as a result of the EMA approval of ARIKAYCE in October 2020. Total intangible assets, net was $49.3 million and $53.7 million as of December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company began amortizing its finite-lived intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's finite-lived intangible assets for the years ended December&#160;31, 2020 and 2019 follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzMwMg_6e47313c-8db7-4c0a-9b4c-544282fcb2dd"
      unitRef="usd">1700000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1bd637936ab04afab59656afc255fd17_D20201001-20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzI3NDg3NzkwNzA3OTY_c0dcf7f8-b9be-4f73-b1fa-f91d1e3fed2c"
      unitRef="usd">600000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzUxOA_4c1aeb25-820c-4305-8ac9-ce702c1d0d9c"
      unitRef="usd">49300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzUyNQ_1d8c5734-fb40-426a-892e-29c1898becb5"
      unitRef="usd">53700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzY5OA_b691fef5-8833-4d1d-84e7-70df2efd9b42">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_1a4e0df3-6239-4325-87d1-84d2b55885e0"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_c0bd14f2-c793-4994-a4d3-3f7bf47536b1"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_d7aa64f5-b32d-4884-9616-73b0b0a0703d"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_dd1c93f8-bb25-4002-bea0-e22e40022323"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4Xzc5OQ_e32d5d38-24b0-499e-bdb8-a45926e1f977"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90ZXh0cmVnaW9uOmNmNTE2OGEyZGFlMTQ1MTc4N2RjNjBmOTU2ZTI2NGY4XzkzNA_6e847003-c96b-4d14-ae6a-821c0011d93c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the Company's finite-lived intangible assets for the years ended December&#160;31, 2020 and 2019 follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired ARIKAYCE R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PARI milestone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i42ea68e2b42646b1959bc8837fbc4bcf_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtMi0xLTEtMA_90a8ebda-6db1-45f3-aa59-a90fc7df714e"
      unitRef="usd">52139000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i4bc7b7bc070a40c891c23f07c65ed05a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtNC0xLTEtMA_72b90eb3-fcfa-4c7a-998c-163a26894849"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i24f4981464504148bd4aa06dc574e5ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtNi0xLTEtMA_a89bf702-9408-41aa-af27-04d1cdad441d"
      unitRef="usd">4850000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i24f4981464504148bd4aa06dc574e5ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzMtOC0xLTEtMA_118ac474-8684-4d37-bd58-47199e801bd0"
      unitRef="usd">47289000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1ded28353bf643aa99d3cb05cc110533_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtMi0xLTEtMA_5c7b92e0-6049-4e22-afd3-01cfa331c31f"
      unitRef="usd">1543000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ib19cd90bf12b4d9eb4da95674aef4152_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtNC0xLTEtMA_95dbe50a-147b-4cbc-be14-a6d24fafb4e4"
      unitRef="usd">582000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3e0bd03488004153b5268b5e73764e14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtNi0xLTEtMA_40b17cc0-b21c-4efc-876c-2b91ca7fbb1a"
      unitRef="usd">153000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3e0bd03488004153b5268b5e73764e14_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzQtOC0xLTEtMA_5d919a8e-bc81-4cdd-acc4-cfddcfdaa662"
      unitRef="usd">1972000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia48973993a3149f79721dd24b81a822b_I20190101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtMi0xLTEtMA_093c836d-897c-4013-8457-e841fe8ef2c9"
      unitRef="usd">53682000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtNC0xLTEtMA_492cf7b6-5be6-46f4-aaf0-5d6c192f78e6"
      unitRef="usd">582000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtNi0xLTEtMA_dedef5e6-1fe6-44fc-bfa3-68c9971cfc88"
      unitRef="usd">5003000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzUtOC0xLTEtMA_a7c1c584-c816-4516-ad35-b21b9b183928"
      unitRef="usd">49261000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ief073ee95b334197863c0f30058817dc_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktMi0xLTEtMA_e1b5d7ef-3178-468c-837e-75a0adc39ea6"
      unitRef="usd">56988000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i1eb4c16988e4465da82e7f50e0573676_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktNC0xLTEtMA_d0d1af5e-e341-441a-bc97-bcaa978653fe"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia660e683387d45a2ac6386d394562fcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktNi0xLTEtMA_20b65c60-757d-42a3-b2fb-1cca296314dc"
      unitRef="usd">4849000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia660e683387d45a2ac6386d394562fcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzktOC0xLTEtMA_7ddac8a8-1ac6-42d1-a105-0bd35c1052eb"
      unitRef="usd">52139000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2cfb89dc31514ee5a530da7763685f22_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTItMS0xLTA_66fefc7a-fbf1-4364-b7eb-39b020b6ac04"
      unitRef="usd">1687000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ia83673d124194183900e1755392dbac3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTQtMS0xLTA_ccdb3808-b61e-4794-8bdd-92c31e80480e"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4e98f2e617b543ad8b634db7a4621957_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTYtMS0xLTA_e9f6e7c2-13a9-467e-9ab5-c401a0c83a47"
      unitRef="usd">144000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4e98f2e617b543ad8b634db7a4621957_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzEwLTgtMS0xLTA_6e523a54-0b88-4bba-a217-cbac118045f3"
      unitRef="usd">1543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id9a79104934c4503861efdd407cf050b_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTItMS0xLTA_a6e71f2c-d99b-4b01-bba5-085cfa4a896f"
      unitRef="usd">58675000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTQtMS0xLTA_aeceac2d-54e3-4e70-873b-fc730fa7d137"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTYtMS0xLTA_6ef23a55-9979-40ab-bfcf-3f6ece93a5ba"
      unitRef="usd">4993000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDgvZnJhZzpjZjUxNjhhMmRhZTE0NTE3ODdkYzYwZjk1NmUyNjRmOC90YWJsZToyMWE1OTZiZWIyOWI0ZDUyOWY1Mzc2YjliZmI0YTRhMi90YWJsZXJhbmdlOjIxYTU5NmJlYjI5YjRkNTI5ZjUzNzZiOWJmYjRhNGEyXzExLTgtMS0xLTA_628a0b44-8129-45b8-8f8c-299e778cf4a2"
      unitRef="usd">53682000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzYxMg_61cb9757-07c4-49db-92d6-21eb46509d50">Fixed Assets, NetFixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.877%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $9.1 million, $5.2 million and $3.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzYxNQ_083915da-0959-4e14-aa86-eb973dd4ea59">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.877%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.663%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress (CIP)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i74a83453ffc34b6295f8aff4ef7b27d1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItMi0xLTEtMA_fb806e90-6acf-4f9b-b951-e33197afcf51">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9a1633bbde7149ff91f24bafaf35316e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItNC0xLTEtMA_40310198-0a5d-4431-966f-c486d9f4401f"
      unitRef="usd">10352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9cd0f2ffc22f44e4bddc73e49309d010_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzItNi0xLTEtMA_2935ac67-1581-4eee-a4c2-33a471e5794b"
      unitRef="usd">9634000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i11fda285397a42e19d6a260af7e5f67d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtMi0xLTEtMA_09bc6183-533d-4c99-9d79-fe01161eeb9b">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9e287d9cd08c41e0b6d0fd2c3d4b5fc8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtNC0xLTEtMA_5561e756-e1da-4c0a-8166-8a65e0cb0fea"
      unitRef="usd">5917000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i23b08ca4050e48bf96bdaea7bcd7c871_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzMtNi0xLTEtMA_016c932f-b7c2-44aa-9aad-63a331f0ae0e"
      unitRef="usd">5908000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtMi0xLTEtMC90ZXh0cmVnaW9uOmU1YmVkODRlZmVjYTQyMzFiMTdkMWY4NmVmYjhiNzMwXzQ_86b1b8d0-0bc1-418c-b821-fee0f9f84318">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3ed8c1e53643455bb3211b3f89f119bb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtMi0xLTEtMC90ZXh0cmVnaW9uOmU1YmVkODRlZmVjYTQyMzFiMTdkMWY4NmVmYjhiNzMwXzk_83c3769f-1a5e-4a90-a245-8dbff32ef1d8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i955be7a501ea48619d13734d6154f45e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtNC0xLTEtMA_cfef3eb6-9384-468c-8da9-0df4cbbd2b57"
      unitRef="usd">7267000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i641fb1bda4d041b9b0710d36df07d468_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzQtNi0xLTEtMA_3a81c8b9-f4af-477a-83a4-3c3bcd491990"
      unitRef="usd">6806000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibcda52d10cc646e78962f9e2486e8cbf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtMi0xLTEtMA_73001041-6957-4407-939a-346a7d8a207f">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i68616dc8974c4009a3f605818d4e3333_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtNC0xLTEtMA_6addb3e2-db5e-44d7-afae-f741d74d8dd2"
      unitRef="usd">88000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i05db6e937b5d40acb4c6da58c96aed34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzUtNi0xLTEtMA_9fc4dfd0-33c7-4493-a95b-4f519a47364c"
      unitRef="usd">154000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic3620656a3d74b50befaf129855bc9d8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtMi0xLTEtMA_9747b545-3418-4924-8396-1dd4026c11bc">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i85c99f6855754004b7860cc3f26ae215_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtNC0xLTEtMA_ab4a52bd-0e0f-4483-b9ef-d29a9687a710"
      unitRef="usd">1567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i829ced73ae454a818b994f29cf817fb7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzYtNi0xLTEtMA_b8564513-ceb0-4b58-88ff-4e0198a6d219"
      unitRef="usd">1567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i17adbf61f3554994afc5c8d08ee421ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzctNC0xLTEtMA_41282420-620c-4c00-9ba4-0a0bb5cd457e"
      unitRef="usd">35289000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie336952f723a45f7aad277d34fd71fc0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzctNi0xLTEtMA_7dac485d-f746-4b1c-8759-0029ba839abe"
      unitRef="usd">33852000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0653aae9e65348feaa6920fe60047862_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzgtNC0xLTEtMA_b6de4b3b-036d-4794-a917-86290b595024"
      unitRef="usd">21823000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8ad290bf1da9470cbb52bc0838395dc6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzgtNi0xLTEtMA_46af7322-4357-4dde-af42-f39308a9eea2"
      unitRef="usd">21526000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzktNC0xLTEtMA_a6bdffee-c274-40fc-861c-7074053f536f"
      unitRef="usd">82303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzktNi0xLTEtMA_477ab144-9356-4b00-977a-83796c312aab"
      unitRef="usd">79447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzEwLTQtMS0xLTA_f3fede38-ce10-4f61-9f95-dc00780f239f"
      unitRef="usd">28350000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzEwLTYtMS0xLTA_5ed41081-5faf-448a-bf17-00c9fc12c5e2"
      unitRef="usd">19267000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzExLTQtMS0xLTA_a1856a8f-900b-4ec4-901c-8f3a79788a37"
      unitRef="usd">53953000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90YWJsZTpiNTQ0Y2IwOGM0YWE0NTcyYTViMjRkZTZlM2UwNTM3ZC90YWJsZXJhbmdlOmI1NDRjYjA4YzRhYTQ1NzJhNWIyNGRlNmUzZTA1MzdkXzExLTYtMS0xLTA_d9fb7028-65c0-4f2a-a7dd-49d8aefa4c8d"
      unitRef="usd">60180000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzI3NDg3NzkwNzAzNDg_edceb9c3-b296-4d0d-babc-d4e13b8b2f66"
      unitRef="usd">9100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzU1Mw_e9b9a3eb-47a0-4f72-b09c-5d446d4cc368"
      unitRef="usd">5200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTEvZnJhZzpjYjE5ZDFkOTQ4ZmE0ZjIzODJlOTg0ZjgxYjVkNzBhNC90ZXh0cmVnaW9uOmNiMTlkMWQ5NDhmYTRmMjM4MmU5ODRmODFiNWQ3MGE0XzU2MA_7c0b7939-1ab6-4732-9122-3e5fc9e6a5af"
      unitRef="usd">3600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90ZXh0cmVnaW9uOjhmM2ZlMjFhZmEyNjQwOGFiZTEyZGJmYjBkYmUyZmFlXzky_f4d13e55-d646-463c-8884-d3821e92311f">Accrued Expenses&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90ZXh0cmVnaW9uOjhmM2ZlMjFhZmEyNjQwOGFiZTEyZGJmYjBkYmUyZmFlXzk0_bbe581fb-c362-4dc3-8dbd-b7cf6acdad0d">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued technical operation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued sales allowances and related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued construction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <insm:AccruedClinicalTrialExpenses
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzItMS0xLTEtMA_1d1d2667-cea2-46f6-893f-c6ca037f4859"
      unitRef="usd">6733000</insm:AccruedClinicalTrialExpenses>
    <insm:AccruedClinicalTrialExpenses
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzItMy0xLTEtMA_1cb91c31-cbf6-4054-8ae3-e188e4f81a7a"
      unitRef="usd">5598000</insm:AccruedClinicalTrialExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzQtMS0xLTEtMA_db8e9ea3-0bd9-4f52-b751-d3398a0e5096"
      unitRef="usd">8594000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzQtMy0xLTEtMA_87f234e4-cdff-4502-8bd7-585ac7685a0e"
      unitRef="usd">12581000</us-gaap:AccruedProfessionalFeesCurrent>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzUtMS0xLTEtMA_6f097170-fc6e-466c-b25f-92d026fcbf7c"
      unitRef="usd">9164000</insm:AccruedTechnicalOperationExpenses>
    <insm:AccruedTechnicalOperationExpenses
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzUtMy0xLTEtMA_358bb541-f4d3-48f5-981b-cf159d56d081"
      unitRef="usd">6446000</insm:AccruedTechnicalOperationExpenses>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzYtMS0xLTEtMA_8c41888b-43a2-4331-aab7-727b4ab55b2d"
      unitRef="usd">3423000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzYtMy0xLTEtMA_2fd42250-efe5-45d2-bb7b-a6dc09fb7c5e"
      unitRef="usd">3117000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzctMS0xLTEtMA_f7b91f4f-96bb-4d24-938e-7b206152226e"
      unitRef="usd">3631000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzctMy0xLTEtMA_8f99db4d-3f51-4598-b205-a85272a2edce"
      unitRef="usd">3631000</us-gaap:InterestPayableCurrent>
    <insm:AccruedSalesAllowancesandRelatedCosts
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzgtMS0xLTEtMA_34bb2ed9-c886-4bde-9617-ea3d7edca5fc"
      unitRef="usd">5051000</insm:AccruedSalesAllowancesandRelatedCosts>
    <insm:AccruedSalesAllowancesandRelatedCosts
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzgtMy0xLTEtMA_86211e06-dbdb-4508-8c73-581a7b028d2c"
      unitRef="usd">5267000</insm:AccruedSalesAllowancesandRelatedCosts>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzktMS0xLTEtMA_b0e3d520-06a1-4054-9c15-db9529022cea"
      unitRef="usd">364000</insm:AccruedConstructionLiabilitiesCurrent>
    <insm:AccruedConstructionLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzktMy0xLTEtMA_7cdb8e64-2973-4de2-b29e-03dcec6bca0f"
      unitRef="usd">2689000</insm:AccruedConstructionLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzEwLTEtMS0xLTA_8c0a5a61-2878-48fa-aca0-aec74e0bb37e"
      unitRef="usd">847000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzEwLTMtMS0xLTA_d827fd07-f3d6-4c84-a9f6-79ec4c9c8c7f"
      unitRef="usd">1046000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzExLTEtMS0xLTA_3e42ebbb-81af-42d8-bc49-eb213d18e1db"
      unitRef="usd">37807000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNDUvZnJhZzo4ZjNmZTIxYWZhMjY0MDhhYmUxMmRiZmIwZGJlMmZhZS90YWJsZTo1OTIzNDNkYmU2OWQ0MzdkOWNmMGZkYmY1NzZiZmFkMC90YWJsZXJhbmdlOjU5MjM0M2RiZTY5ZDQzN2Q5Y2YwZmRiZjU3NmJmYWQwXzExLTMtMS0xLTA_63de8253-3e2b-4df2-9995-5bd238c8b312"
      unitRef="usd">40375000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODM_2e71e150-2d44-4ed2-af87-0fa270da2558">Leases&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office space, manufacturing facilities and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's corporate headquarters lease, which is classified as a finance lease. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the operating lease costs disclosed above, the Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $9.9&#160;million and $0.1&#160;million for the years ended December 31, 2020 and 2019, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification at December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $25.1 million incurred by the Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODM_52261b68-b4f2-4879-86c1-8387a9d57627">Leases&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio consists primarily of office space, manufacturing facilities and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's corporate headquarters lease, which is classified as a finance lease. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the operating lease costs disclosed above, the Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $9.9&#160;million and $0.1&#160;million for the years ended December 31, 2020 and 2019, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification at December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $25.1 million incurred by the Company under these additional agreements have been classified within&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.</us-gaap:LesseeFinanceLeasesTextBlock>
    <insm:LeaseRemainingLeaseTerm
      contextRef="i2f74877e573149a898ea49344d4209eb_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI5NjI_fe598305-91cd-4908-a3b4-c662371981bc">P1Y</insm:LeaseRemainingLeaseTerm>
    <insm:LeaseRemainingLeaseTerm
      contextRef="i13a7dcb8a06842e7ad8e6b069114005d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI5Njg_d4fb1fc9-4738-4f7a-906d-8fc32c7d2c6b">P10Y10M</insm:LeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODQ_dab1eb1a-3bfb-44e5-b691-9341ece469d6">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows for finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzQtMS0xLTEtMA_3635457e-e5c0-4e58-86b2-69e9fecc9049"
      unitRef="usd">1078000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzQtMy0xLTEtMzA2_9673a01c-9dbd-495b-97a1-c6b3303b3220"
      unitRef="usd">360000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzUtMS0xLTEtMA_1458258d-0f87-4da5-b549-29fd05f73f81"
      unitRef="usd">1301000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzUtMy0xLTEtMzA2_bfe13277-e59f-4859-863e-29980be85a5d"
      unitRef="usd">440000</us-gaap:FinanceLeaseInterestExpense>
    <insm:FinanceLeaseCost
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzYtMi0xLTEtMA_18c7cf55-d92b-4617-a4d6-59a7d3aeef3a"
      unitRef="usd">2379000</insm:FinanceLeaseCost>
    <insm:FinanceLeaseCost
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzYtNC0xLTEtMzE1_a328c85b-f442-40cc-a9ae-23834e768e1d"
      unitRef="usd">800000</insm:FinanceLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzctMi0xLTEtMA_a180a9e3-6870-4da1-bf4b-48acf41b9108"
      unitRef="usd">8664000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzctNC0xLTEtMzE4_b097b62f-8f52-476f-89cf-17243aacddb0"
      unitRef="usd">12218000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtMi0xLTEtMjE3NA_3507bf6f-6b48-4d44-b264-6df6b25eea39"
      unitRef="usd">9950000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtNC0xLTEtMjE4Mw_490a9930-7ee4-4753-a166-6f121b1024a3"
      unitRef="usd">92000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtMi0xLTEtMA_916a0b5d-249e-4235-86b9-e33044e28bad"
      unitRef="usd">20993000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzgtNC0xLTEtMzE4_a1fd2a29-97b2-41ac-a684-790d7b25e202"
      unitRef="usd">13110000</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEyLTItMS0xLTA_5c84a656-9633-4582-99cf-0df300e209e5"
      unitRef="usd">1301000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEyLTQtMS0xLTMyMQ_0a890078-c279-48dd-ad44-9f8162958d70"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEzLTItMS0xLTA_88320428-5f45-472c-9ed0-74ad881de473"
      unitRef="usd">8813000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzEzLTQtMS0xLTMyMQ_732e53e9-1d20-48cc-99d7-d8980a4ec4ce"
      unitRef="usd">10060000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE0LTItMS0xLTA_fb0f2844-44da-4bd5-836a-36a1cf9f5aaa"
      unitRef="usd">936000</us-gaap:FinanceLeasePrincipalPayments>
    <insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE0LTQtMS0xLTMyMQ_10d9937e-c047-450d-9197-052e6f62ec42"
      unitRef="usd">-4503000</insm:PaymentsForProceedsFromFinancingLeaseTenantAllowance>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE1LTItMS0xLTA_497c3d97-b48c-4806-bd32-6de842efcfdf"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE1LTQtMS0xLTMyMQ_d6d6a5ed-6922-4d8f-bf29-82cc1f845248"
      unitRef="usd">20310000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE2LTItMS0xLTA_6a13aebd-4bda-46e3-a1ee-712bbd50793e"
      unitRef="usd">1205000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE2LTQtMS0xLTMyMQ_61acdcd7-bb18-4ee6-850b-36371cb79562"
      unitRef="usd">47436000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE3LTItMS0xLTA_dac4043b-c8e6-48d6-837b-8c11d40befb4">P9Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE3LTQtMS0xLTMyMQ_b4b806d8-68d7-49fe-832d-3a315d331d52">P10Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE4LTItMS0xLTA_15ec43cc-35ee-4be5-bee3-5b2b875570d7">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE4LTQtMS0xLTMyMQ_cd02e1fa-191e-4a66-b840-57ea63e8df19">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE5LTItMS0xLTA_b0aa34d7-1bff-4609-84cc-6bc0bd6bc1ae"
      unitRef="number">0.086</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzE5LTQtMS0xLTMyMQ_d9a764e7-673b-45a4-af20-a40139a794fb"
      unitRef="number">0.086</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzIwLTItMS0xLTA_d5e9b6bd-156f-4c19-a038-64c4acf3d8b9"
      unitRef="number">0.074</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTowOTcwM2FlYzVjNzI0OGZjYjVlNDBmYzM5NzIwZjY5Mi90YWJsZXJhbmdlOjA5NzAzYWVjNWM3MjQ4ZmNiNWU0MGZjMzk3MjBmNjkyXzIwLTQtMS0xLTMyMQ_20cb2196-a480-403c-a6a5-193d3c4bf6ff"
      unitRef="number">0.074</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:VariableLeasePayment
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI3NDg3NzkwNzkwNTU_1dffa2e5-523b-4f07-b481-c1a617a89f95"
      unitRef="usd">9900000</us-gaap:VariableLeasePayment>
    <us-gaap:VariableLeasePayment
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzI3NDg3NzkwNzkwNjE_d6218d57-fc31-4056-95ea-009ebc40ac88"
      unitRef="usd">100000</us-gaap:VariableLeasePayment>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODU_f479e907-8726-46ea-83ca-cf5c10c99254">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification at December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU4ODU_f831d803-bf73-4674-b6c3-881d921bc073">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.334%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet Classification at December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEtMS0xLTEtMA_ce5c13b7-d990-413b-a6de-490b575c1e36"
      unitRef="usd">2381000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEtMy0xLTEtMA_a5bdb981-d56f-4638-abb1-00b4a13517fd"
      unitRef="usd">13329000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzItMS0xLTEtMA_cda22e36-cd17-4317-9e11-7e2ce6988d9f"
      unitRef="usd">1819000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzItMy0xLTEtMA_9fc313e8-5848-4452-8f96-c0b6c9c61852"
      unitRef="usd">6339000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzMtMS0xLTEtMA_b9a6ec73-2f3e-4ebf-a0b2-d59cae53630b"
      unitRef="usd">1670000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzMtMy0xLTEtMA_ff374de0-1f4a-432e-bb4e-d2412c32348e"
      unitRef="usd">6090000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzQtMS0xLTEtMA_6508f2ff-6091-420f-8106-a22037079ba9"
      unitRef="usd">2556000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzQtMy0xLTEtMA_8c7a1299-874c-4280-b496-f8a7fac2b94d"
      unitRef="usd">6000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzUtMS0xLTEtMA_bac47da8-51f2-4503-ae7c-ea76f32b090a"
      unitRef="usd">2615000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzUtMy0xLTEtMA_3268b985-2a4b-4660-aa29-6b449c0d7427"
      unitRef="usd">6000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzYtMS0xLTEtMA_b319e275-7a09-40d0-bdc7-e54149ecfc6d"
      unitRef="usd">12732000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzYtMy0xLTEtMA_333081e7-f7c5-4d3b-8127-b568a1863aff"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzctMS0xLTEtMA_f3d27941-35fc-428e-b4e5-d9f60e92e3bc"
      unitRef="usd">23773000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzctMy0xLTEtMA_739a084f-09b9-44b1-9397-cc3065c758f0"
      unitRef="usd">37758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzgtMS0xLTEtMA_dbf9bf78-b892-42ce-a7ca-8c0d1a22ea48"
      unitRef="usd">7979000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzgtMy0xLTEtMA_feb0318d-effe-4d1a-aeec-4f7d08751291"
      unitRef="usd">5028000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzktMS0xLTEtMA_b61ee198-5a0b-4679-9b29-ac9dd0a3155d"
      unitRef="usd">15794000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzktMy0xLTEtMA_5f980216-823e-4475-a6d5-0d144ed6419d"
      unitRef="usd">32730000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzExLTEtMS0xLTA_66122073-1423-4f1b-8e9b-66f1c7ebf319"
      unitRef="usd">1081000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzExLTMtMS0xLTA_f2e28cd2-0e5b-4407-8dfe-ad8e2be19aec"
      unitRef="usd">11475000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEyLTEtMS0xLTA_1cde5741-5e10-41a8-b4b9-14a6aadb41f5"
      unitRef="usd">14713000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEyLTMtMS0xLTA_2f52bfb3-f0c4-40e1-bfe5-4030292ea933"
      unitRef="usd">21255000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEzLTEtMS0xLTA_c45e7748-dbbe-408b-9f27-79f580d687d3"
      unitRef="usd">15794000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90YWJsZTo3NzI4ODk1OWUwNjM0NjlhOWIxMTE5MDI1YWZkZWYwMC90YWJsZXJhbmdlOjc3Mjg4OTU5ZTA2MzQ2OWE5YjExMTkwMjVhZmRlZjAwXzEzLTMtMS0xLTA_d7884512-1c6f-4432-a0d1-daeec718ad06"
      unitRef="usd">32730000</us-gaap:OperatingLeaseLiability>
    <insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTQvZnJhZzo5NTM2ZDA1NWMwMjE0NDAzYTYzN2M5MzlmMzE0YzljNS90ZXh0cmVnaW9uOjk1MzZkMDU1YzAyMTQ0MDNhNjM3YzkzOWYzMTRjOWM1XzU1NDY_90fb26ae-f5db-4ecd-835d-6d3210c5536b"
      unitRef="usd">25100000</insm:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzM_311ff473-dfe8-475a-813a-f31f499188da">Debt&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of $50.0 million. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#x2019;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#x2019;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6%, and accordingly, the residual equity component on the date of issuance was $140.9 million. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately 4.04 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the twelve months ended December&#160;31, 2020, total interest expense related to the Convertible Notes was $28.3 million, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#x2019;s debt balance as of December&#160;31, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of $55.0 million for the principal amount and an additional $3.2 million in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a $2.2 million loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of December&#160;31, 2020 and 2019, the fair value of the Company's debt approximated the carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and the finance lease for the years ended December&#160;31, 2020, 2019, and 2018, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of back-end fee on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE0Mw_f44d4bfb-1883-40fd-882f-5d1b46d517eb"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <insm:DebtInstrumentOptionToPurchaseAdditionalDebt
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI5OA_67330e03-678e-450e-b1ad-df95f9ccfe34"
      unitRef="usd">50000000.0</insm:DebtInstrumentOptionToPurchaseAdditionalDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQzNA_db029b95-01e4-4429-aec0-2a4207da558e"
      unitRef="usd">14200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i7789efc1fa15465a824da338e733666d_D20180101-20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ1Nw_8583e3c1-aa10-4b8a-9113-802f4a6ef317"
      unitRef="usd">435800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzEyMzA_6f5c6f12-507e-47c2-9abe-ea0594eb5cc0"
      unitRef="usdPerShare">39.16</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE4MzU_d05d3762-4191-44fa-b367-feccfa76eea1"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzE4ODA_71ec0dd2-edce-4489-a638-de615b19c242"
      unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i8f297f3913a54143ac40949dafdbb77b_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzIxNDk_faed630a-96a4-49a3-b8e7-4630e80a1e09"
      unitRef="number">0.98</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI2MDg_f5c30f19-8966-43b6-91fe-8e18bb07821d"
      unitRef="day">45</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzI4Mjk_f3136279-37d7-4469-9eef-7cb38178f46f"
      unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i5f71923f583545cb84ee82349f2dcc96_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzMxNjk_b0f7f435-bf52-40ed-8355-aa3d26809dc8"
      unitRef="number">0.10</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange
      contextRef="i9e454efc09a14c9f9b4641cc444070e4_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQwNDY_7df9d567-a6dc-4eae-9380-ca1b33484132"
      unitRef="day">30</insm:DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQzMzQ_a7a60c8b-6b27-4a42-8540-6ea7579126b9"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ0MDA_a4b71096-abc8-4f7f-aa9a-0934dd15db26"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ia962faac0e554b0eade20b47d690b557_D20180101-20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzQ1MzM_71cf140c-da26-4b75-ab99-f3b6cbd76ad3"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY3MjA_85ced016-d526-4f0b-a573-a94c75b0b4af"
      unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY3NTk_13de7359-6fe5-4723-9968-cddfdd247387"
      unitRef="number">0.076</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i3ca69534f44544678e6345d4061172bd_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY4Mzg_318feefe-e8b7-45d3-9990-5b0b58d52cf0"
      unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i7789efc1fa15465a824da338e733666d_D20180101-20180131"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzY5Nzc_b3a9d658-7e03-476d-959d-97863b0b5605">P4Y14D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:InterestExpense
      contextRef="i1f292dc67c894e10a48cb3e934955825_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzcwNTc_aaf372c2-3846-431c-b0f2-44dfc26e6bd3"
      unitRef="usd">28300000</us-gaap:InterestExpense>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzU_7e87f013-11f0-4161-9c10-b3be03ebf92a">The following table presents the carrying value of the Company&#x2019;s debt balance as of December&#160;31, 2020 and 2019 (in thousands):&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;1.75% convertible senior notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Debt issuance costs, unamortized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Discount on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(107,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b38925e110b406fb8d690af86e404ef_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzEtMC0xLTEtMC90ZXh0cmVnaW9uOmViNmJkMWQ4ZjE1MzQ0M2ViNzBmZDhlZTNiN2U4NmNjXzU_dd806a81-1e40-4ec2-ac2b-9ea942b14a6f"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SecuredDebt
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzEtMS0xLTEtMA_763cf242-0b68-46b3-bc84-541dd590fd25"
      unitRef="usd">450000000</us-gaap:SecuredDebt>
    <us-gaap:SecuredDebt
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzItMy0xLTEtNDA1Ng_f0113270-03ff-44d1-930d-c854e32d3a7b"
      unitRef="usd">450000000</us-gaap:SecuredDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzItMS0xLTEtMA_78c16e63-4a53-46f8-987f-6110e22017a4"
      unitRef="usd">5646000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzMtMy0xLTEtNDA2MA_bb129f12-2470-45e5-a2ff-622fc924866e"
      unitRef="usd">7043000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzMtMS0xLTEtMA_17823d57-cde4-4c9f-a1af-cadd64ffcded"
      unitRef="usd">88036000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzQtMy0xLTEtNDA2MA_d87927d1-306b-4837-942d-8a73d3035af1"
      unitRef="usd">107017000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzQtMS0xLTEtMA_8167ef7e-b573-4638-85fb-aaacbf8f6582"
      unitRef="usd">356318000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTowODBmMjI1ZDIxMzY0NzYyODM4NjMzMjk2N2YyZjZjZC90YWJsZXJhbmdlOjA4MGYyMjVkMjEzNjQ3NjI4Mzg2MzMyOTY3ZjJmNmNkXzUtMy0xLTEtNDA2NA_b4b15663-00b8-4389-be43-e65380d67608"
      unitRef="usd">335940000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1MzY_e59eba6e-3174-4e57-a54e-150996abae7b">As of December&#160;31, 2020, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ending December&#160;31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzEtMS0xLTEtMA_846d0d2f-c233-41a1-8d4a-6160f7f31e92"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzItMS0xLTEtMA_ef5dfb85-4f2a-47bf-abca-dcac7ba3ed12"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzMtMS0xLTEtMA_2b52822f-57e2-4e62-8a7a-47d5ce8ee58a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzQtMS0xLTEtMA_ba010a06-9f57-4674-81fe-65df7351e2ee"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzUtMS0xLTEtMA_35c6a06b-4840-4e8f-a4e3-b9ffb5de3a0a"
      unitRef="usd">450000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebt
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZToxNGM2MDEzZTI0MTU0ZWQ2OTU1OWE3ODk2ZTExMDYyNS90YWJsZXJhbmdlOjE0YzYwMTNlMjQxNTRlZDY5NTU5YTc4OTZlMTEwNjI1XzgtMS0xLTEtMA_18493766-f2be-4e52-b0fd-053edf6b492c"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i207c67bfeb704bc880cce0755881858e_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc2ODk_5c5fa8ff-0875-44ac-b426-f19aeecd267f"
      unitRef="usd">55000000.0</us-gaap:RepaymentsOfDebt>
    <insm:RepaymentsOfDebtFeesAndOutstandingInterest
      contextRef="i207c67bfeb704bc880cce0755881858e_D20180201-20180228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc3MzU_13b13f93-bc65-4537-aa83-e08f583ef415"
      unitRef="usd">3200000</insm:RepaymentsOfDebtFeesAndOutstandingInterest>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0ea99db509d54adeb7486a066eb4eb62_D20180101-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzc4Mjc_69834e78-6a34-48b8-8e2b-bbda1b2514c5"
      unitRef="usd">-2200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90ZXh0cmVnaW9uOjJkOTc2OWEwZjU0MTRjM2NiZTU2N2YwNzU5Y2ZlYTRkXzg1Mzc_859a6860-d906-4979-a66f-73beaf36afd7">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense related to debt and the finance lease for the years ended December&#160;31, 2020, 2019, and 2018, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.868%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of back-end fee on debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total convertible debt interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItMS0xLTEtMA_4b62a0da-c23b-41ac-a447-f1bd04a39459"
      unitRef="usd">7885000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItMy0xLTEtMA_84a98f1b-0e0f-461c-a1a6-5dd7f59dc9ec"
      unitRef="usd">7883000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzItNS0xLTEtMA_1d262b20-15f0-41ca-90a8-d5fad87fdac0"
      unitRef="usd">8183000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtMS0xLTEtMA_7dfc448d-9bfb-4fe2-a291-98c4e7f81799"
      unitRef="usd">1397000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtMy0xLTEtMA_4ec6dcd4-151e-4090-a7cc-322f2def07d1"
      unitRef="usd">1397000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzMtNS0xLTEtMA_a96ba089-1f46-4a7a-a217-89e4f1952294"
      unitRef="usd">1350000</us-gaap:AmortizationOfFinancingCosts>
    <insm:AmortizationOfBackendFee
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtMS0xLTEtMA_04c49378-910b-4920-a749-d6509d18a242"
      unitRef="usd">0</insm:AmortizationOfBackendFee>
    <insm:AmortizationOfBackendFee
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtMy0xLTEtMA_ea0080b1-6bf1-4e3a-954a-95d91858e208"
      unitRef="usd">0</insm:AmortizationOfBackendFee>
    <insm:AmortizationOfBackendFee
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzQtNS0xLTEtMA_fbe99177-40d7-465b-9c8e-e8f593a4b1d5"
      unitRef="usd">50000</insm:AmortizationOfBackendFee>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtMS0xLTEtMA_5b15a491-f358-4a76-8e97-6ea966d4bcaf"
      unitRef="usd">18981000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtMy0xLTEtMA_a4696e29-b9c1-49d7-ae63-99b99d3515d1"
      unitRef="usd">17985000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzUtNS0xLTEtMA_07c7ecc9-c360-43f1-8c7a-063563a2dd60"
      unitRef="usd">15889000</us-gaap:AmortizationOfDebtDiscountPremium>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtMS0xLTEtMA_59c9da53-dd13-4963-916b-57719e29ed44"
      unitRef="usd">28263000</insm:ConvertibleDebtInterestExpenseTotal>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtMy0xLTEtMA_993f334d-684d-4c35-a1e0-a7af129951ac"
      unitRef="usd">27265000</insm:ConvertibleDebtInterestExpenseTotal>
    <insm:ConvertibleDebtInterestExpenseTotal
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzYtNS0xLTEtMA_c8e8b64b-15e7-4359-a542-ccb6d60920b1"
      unitRef="usd">25472000</insm:ConvertibleDebtInterestExpenseTotal>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctMS0xLTEtMA_6ba57d72-3883-4435-b07c-c96d61a85fa1"
      unitRef="usd">1301000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctMy0xLTEtMA_bf524723-16e6-4436-90d0-576fbeb11cc8"
      unitRef="usd">440000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzctNS0xLTEtMA_3943be6b-a320-4bed-b339-50dd082af647"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:InterestExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtMS0xLTEtMA_d92fe7a0-e31e-4526-bd82-d16ee7b2cad4"
      unitRef="usd">29564000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtMy0xLTEtMA_bc46dffc-b80c-41c1-8890-1c4e65c724f2"
      unitRef="usd">27705000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNTcvZnJhZzoyZDk3NjlhMGY1NDE0YzNjYmU1NjdmMDc1OWNmZWE0ZC90YWJsZTo4N2JlMDZlZTIzNDg0MjgxODc4ZTFmMjk2OWY0ZDUwOS90YWJsZXJhbmdlOjg3YmUwNmVlMjM0ODQyODE4NzhlMWYyOTY5ZjRkNTA5XzgtNS0xLTEtMA_916ec2c4-f16d-475d-8a5e-a7db53cdc874"
      unitRef="usd">25472000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIxMzg_516484ce-9728-4070-911d-677e795677a7">Shareholders' Equity&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of December&#160;31, 2020, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 and 102,763,060 shares of common stock issued and outstanding. In addition, as of December&#160;31, 2020, the Company had reserved 12,263,402 shares of common stock for issuance upon the exercise of outstanding common stock options and 844,391 shares of common stock for issuance upon the vesting of restricted stock units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2020, the Company completed an underwritten public offering of 11,155,000 shares of the Company's common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, at a public offering price of $23.25 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $13.5&#160;million, were $245.9&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2019, the Company completed an underwritten public offering of 10,657,692 shares of the Company's common stock, including 1,042,307 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares at a public offering price of $26.00. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $16.0&#160;million, were $261.1&#160;million. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;offering also included the sale of 400,000 shares from the Company's Chair and Chief Executive Officer, from which the Company received no proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company completed an underwritten public offering of $450.0&#160;million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $309.1&#160;million, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as $140.9&#160;million using the residual method, as further described in Note 8 Debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;As of December&#160;31, 2020 and 2019, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 and no shares of preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1ODI_f78419ef-380b-4732-a3b7-f48fd4de2676"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1ODY_5fcc9889-cb30-4c5b-913c-bb83f0b2a33e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzOQ_91c69160-5b6f-4fde-9d44-357275ba465a"
      unitRef="shares">102763060</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzOQ_b9dc2df1-a23a-464c-a4d3-a097af147e9d"
      unitRef="shares">102763060</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIzNw_ec4de8a2-88a2-43b2-a3d3-d31279d78bbd"
      unitRef="shares">12263402</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzMzNA_e0df9fa6-96b1-4037-b4e2-b0e4957a949f"
      unitRef="shares">844391</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i632484c618934954b43bf3c619cf75d9_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzI5OTI_b9449d35-3b80-4402-88b8-e441f3176092"
      unitRef="shares">11155000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iff5a8670240445378f8c05d86d5621bb_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMDc_061839e4-974c-4253-9de7-74c8f1a9f666"
      unitRef="shares">1455000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1d2b7e722ba84d7184fe6cd2065c3016_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMTY_c22b4e7b-2625-407e-acc3-29c55e8c5be3"
      unitRef="usdPerShare">23.25</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i349a3db24a104296871f679b48d0727b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwMzI_75947adc-84d5-4502-93d1-49a5629c1d8b"
      unitRef="usd">13500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i632484c618934954b43bf3c619cf75d9_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzMwODA_5c2abef2-c677-4fe0-971a-1c953a5d4c0e"
      unitRef="usd">245900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzUwNQ_ac225814-82e4-4be1-b208-d6e055607a0b"
      unitRef="shares">10657692</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id7d4ce336b0d4998950db423777b2a69_D20190524-20190524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzYzMA_0a04ce63-acbd-4b18-a738-1e06eb93f648"
      unitRef="shares">1042307</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iefb0a77979724e36a4b8762928d10239_I20190524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzY4NQ_e52a6717-06ec-4b29-84f1-bb540921392f"
      unitRef="usdPerShare">26.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i60e46a7dfb16496c852ec9544e1b781f_D20190524-20190524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzg3NA_3372c38a-03a1-4270-ac18-b567b63bd5cb"
      unitRef="usd">16000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1d1a8f5ae5c742f684c5641814f1ccbd_D20190524-20190524"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzg4Mw_3f095b29-8e57-4033-b221-360ce5fb2c58"
      unitRef="usd">261100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i818541d9894e4786bafa4a7f073c56da_D20190524-20190524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzkyNg_1e56d07d-b47e-4ad5-85a1-b59c0b2076d2"
      unitRef="shares">400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzExMTI_42d57f5d-04d1-4d3d-8994-be39fe6929d7"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzEzNzM_c7d1bedf-aeb8-4735-a6cb-4aad6849f77a"
      unitRef="usd">309100000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i2ab005c49d7049b480307e85adfed0ea_I20180131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzE0OTg_170e8f0f-6680-4a2b-a499-a704588d623b"
      unitRef="usd">140900000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTA_20a35900-085e-44ed-81c2-dda561c6ffbb"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTA_bedeb14e-164d-4eed-b66e-a0d7bf6f3af3"
      unitRef="shares">200000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTQ_24527175-e04a-4e85-8989-ddc8fa9ea41d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzI3NDg3NzkwNzE1OTQ_755ab726-683d-468d-b201-4de36186dcba"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_161c85f3-ae91-4cb9-8cb5-eef71d3d6916"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_a825397d-23b9-413a-beca-50d0db2525d1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_c1cf94a8-6f91-4cc8-a781-f3c861cf54ed"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjMvZnJhZzo5YjgyOTMwYWZhOGE0NWVkYjc1ODhlYzhhNDg2OTlhZi90ZXh0cmVnaW9uOjliODI5MzBhZmE4YTQ1ZWRiNzU4OGVjOGE0ODY5OWFmXzIwODE_e83a0b9b-0df1-4abe-af2d-b142bd80aeb6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTU_567d5050-c361-49df-b11b-e6ff121eb264">Stock-Based Compensation&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s current equity compensation plan, the 2019 Incentive Plan, was approved by shareholders at the Company&#x2019;s Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. As of&#160;December&#160;31, 2020,&#160;5,200,879&#160;shares remained for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#x2019; employment compensation in connection with the Company&#x2019;s equity grant program. During the&#160;twelve months ended December&#160;31, 2020 and 2019, the Company granted inducement stock options covering 996,830&#160;and 305,180&#160;shares, respectively, of the Company's common stock to new employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22%-1.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35% - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$13.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020, 2019 and 2018, the volatility factor was based on the Company&#x2019;s historical volatility during the expected option term.&#160;The company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). The Company had no performance options outstanding as of December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for stock options granted for the years ended December&#160;31, 2020, 2019 and 2018 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in '000)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(494,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,381,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,413,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(909,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,492,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,028,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $24.0 million, $16.5 million and $5.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $59.7 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 1.8 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock and Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive one share of the Company's common stock upon the completion of a specific period of continued service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU awards granted during the years ended December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January&#160;1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there was $15.0 million of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended December&#160;31, 2020, 2019 and 2018 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- On May 15, 2018, the Company's shareholders approved the Company&#x2019;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $1.2 million, $1.6&#160;million and $0.9&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibb14027d5bff4fac80225d11be8c578f_I20190516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzU4ODY_508d8f7a-0af4-4e4d-af11-9479e423a4c3"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i7cb5fa6b23cb4fad903933f28e806e98_D20200512-20200512"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzU4OTg_f01a64ad-df66-4a7a-a6b0-11c7ca35e646"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzEwNTY_bdecffd0-4cff-4dc4-9005-ba5be96fa540"
      unitRef="shares">5200879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzE1OTM_3f28efb0-99a2-4d38-9519-5d9e4f82d272"
      unitRef="shares">996830</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzE2MDA_1db5afd2-4245-4fd6-9e18-0adc7da40b69"
      unitRef="shares">305180</insm:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMDQ_b0073202-be09-45db-bf07-09568c86e2dd">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended December&#160;31, 2020, 2019 and 2018.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66%-71%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67% - 70%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66% - 68%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22%-1.67%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.35% - 2.56%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% - 2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.09&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of stock options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$13.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMS0xLTEtMC90ZXh0cmVnaW9uOmZjMjU2ODQ1YTEwNTRlN2Y5MGI0OWVlY2E3NGVhNmMyXzQ_240f3221-0d2b-4f43-8596-cb8488ea84fc"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i24b05e9462b7490284e2dec768389895_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMS0xLTEtMC90ZXh0cmVnaW9uOmZjMjU2ODQ1YTEwNTRlN2Y5MGI0OWVlY2E3NGVhNmMyXzc_ea78ce1b-5c2f-4054-aabd-f84129653d09"
      unitRef="number">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMy0xLTEtMC90ZXh0cmVnaW9uOjZmNDg0MzNhNmE2NjQ3MWM5NzVhZjY2MWJhM2Q4NDUzXzQ_aef44403-9218-46bf-9ebd-409612a55e24"
      unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtMy0xLTEtMC90ZXh0cmVnaW9uOjZmNDg0MzNhNmE2NjQ3MWM5NzVhZjY2MWJhM2Q4NDUzXzk_17d453ac-642f-4d6f-8519-4dad8d9fc2fd"
      unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtNS0xLTEtMC90ZXh0cmVnaW9uOjQ1ZTRmMTU2ZWE4YjQ0YzVhZGNlZjAyZGNlMWE2OGM5XzQ_a80ad4de-7692-498d-a6b4-afc903bc545b"
      unitRef="number">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzEtNS0xLTEtMC90ZXh0cmVnaW9uOjQ1ZTRmMTU2ZWE4YjQ0YzVhZGNlZjAyZGNlMWE2OGM5Xzk_d8b27466-fb70-4b71-baef-49f0f24a1538"
      unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1f7373ca743b48c8bc9123d1e9049da0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjBmZmRhZjczZDU3NDQ5MjY5ZGYxMTc2ZjhlN2RiZDY3XzQ_6138f5f9-bf16-4ade-b7d4-a48f71f3730d"
      unitRef="number">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i24b05e9462b7490284e2dec768389895_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMS0xLTEtMC90ZXh0cmVnaW9uOjBmZmRhZjczZDU3NDQ5MjY5ZGYxMTc2ZjhlN2RiZDY3Xzc_38c276bb-0f50-4f0a-9a7d-0c30e90ba7a4"
      unitRef="number">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i13aa7344083a4f8c8361363835e0bc13_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmJjNTk5N2IzYjBhOTRmZjA5OTFiYjE2ZjU4N2I4NjQ3XzQ_fe78f7ab-4e16-43ad-873f-879b97ea91d4"
      unitRef="number">0.0135</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iddbf2cbf637148f2855a033f81f321fe_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItMy0xLTEtMC90ZXh0cmVnaW9uOmJjNTk5N2IzYjBhOTRmZjA5OTFiYjE2ZjU4N2I4NjQ3Xzk_c3bbb30c-4a76-455e-9e5d-ab40bb082c7d"
      unitRef="number">0.0256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if8c503b60770497cb069c4ad78baa76e_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItNS0xLTEtMC90ZXh0cmVnaW9uOjgxNjgxMmIyYmMyOTQ5NDI5Y2JiZDI0ZDg2MDFmZjIwXzQ_fe99602f-52db-437e-a7df-c2babe0f6c5f"
      unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4cead566d4b04200b78ddb02ce820b90_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzItNS0xLTEtMC90ZXh0cmVnaW9uOjgxNjgxMmIyYmMyOTQ5NDI5Y2JiZDI0ZDg2MDFmZjIwXzk_8663de2d-0cf1-43cb-8dfa-b13db82cf30a"
      unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtMS0xLTEtMA_6c7215c5-9697-44af-a464-af7a0bead63a"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtMy0xLTEtMA_cd3d4776-9c96-4c84-b9d2-aef3893ec5eb"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzMtNS0xLTEtMA_f51bff96-af1b-4aef-8e20-53b3f5db89e9"
      unitRef="number">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtMS0xLTEtMA_39f0a3af-232b-4a01-8b6f-df7cad03e307">P5Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtMy0xLTEtMA_07b12719-e69a-49b6-8567-70c12e848e3e">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzQtNS0xLTEtMA_f4bc4db9-9d71-42be-895b-644017942d8d">P5Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtMS0xLTEtMA_083e0e7d-95ae-48a5-ac69-c5f10f0dfc56"
      unitRef="usdPerShare">13.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtMy0xLTEtMA_b4a7673e-2e31-433e-a762-281705d456fd"
      unitRef="usdPerShare">8.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTplMmJkN2Q0MGI3YWE0ZGNkODMwNGE5MjlkNmNmMjdjMy90YWJsZXJhbmdlOmUyYmQ3ZDQwYjdhYTRkY2Q4MzA0YTkyOWQ2Y2YyN2MzXzUtNS0xLTEtMA_1d0a7388-3b00-47d3-9cd7-ef8f938302e8"
      unitRef="usdPerShare">16.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1015f33ba83642e796387fad13fc1078_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_28be2604-38d9-4ba4-9e7f-38e2ff53aadb"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i827d3608f7854deb81221457676b5339_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_5ca2d841-79cf-48e0-8fd0-508aac045e8b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id29981174a85438ab8f4063d1cd73795_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI5Nzc_afb03d17-bb73-4814-b953-489dfd26ab1c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTc_e0c32194-8647-49d2-8b83-e09c2f58ab22">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for stock options granted for the years ended December&#160;31, 2020, 2019 and 2018 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Life in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in '000)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at January 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,608,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,755,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(494,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,381,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,649,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,434,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,413,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(909,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,492,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,719,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,678,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited and expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(541,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,263,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,028,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE1LTEtMS0xLTA_67db53e8-1df5-4510-8127-52c0d54d74cc"
      unitRef="shares">8608921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if0573aa1bb72428a95e7d4716d768ca1_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE1LTMtMS0xLTA_6d807f1d-c694-45a3-bf5f-66867c96c383"
      unitRef="usdPerShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE2LTEtMS0xLTA_f051c7b5-3f06-48ec-bf68-3c3df87b37d2"
      unitRef="shares">1755600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE2LTMtMS0xLTA_29779572-a96a-4eac-906f-4325c601cbc6"
      unitRef="usdPerShare">27.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE3LTEtMS0xLTA_6b817412-a820-47c5-a3ec-e7e1097ba9d5"
      unitRef="shares">494351</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE3LTMtMS0xLTA_3dba8d92-f85f-4892-aca1-62ad8cdecfed"
      unitRef="usdPerShare">14.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE4LTEtMS0xLTA_f9c0818f-43c6-40b8-a7e0-e4ed2b5b8a32"
      unitRef="shares">488440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE4LTMtMS0xLTA_55e327fd-dc75-4242-b9b7-5e21d1944e8a"
      unitRef="usdPerShare">19.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE5LTEtMS0xLTA_bad37343-7f12-4e03-92ba-852e21faad37"
      unitRef="shares">9381730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzE5LTMtMS0xLTA_a3994758-812c-4d0c-ab08-f40be7ff8277"
      unitRef="usdPerShare">16.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIxLTEtMS0xLTA_4938be3a-2663-4ab4-9ed2-d0dad7ad593c"
      unitRef="shares">5649698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIxLTMtMS0xLTA_9bdd24cd-d461-4fac-aea5-094f5cb4436a"
      unitRef="usdPerShare">13.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIzLTEtMS0xLTA_12f79fa0-c666-4eee-acc0-1e0ccd93a465"
      unitRef="shares">3434270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzIzLTMtMS0xLTA_195dd693-086f-49bf-ac52-eef4583cb5cd"
      unitRef="usdPerShare">15.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI0LTEtMS0xLTA_ad234bd1-66af-4edd-be32-605c8353e437"
      unitRef="shares">1413341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI0LTMtMS0xLTA_c0f83277-4178-41ea-a981-d9c226b71679"
      unitRef="usdPerShare">11.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI1LTEtMS0xLTA_a5fcf023-3b62-4a31-bf6f-866dae3a7a98"
      unitRef="shares">909713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI1LTMtMS0xLTA_34a764e3-51fb-415c-a041-307a2d0b06b1"
      unitRef="usdPerShare">19.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI2LTEtMS0xLTA_49de1295-bd1a-4a07-9d62-e9fbf82d51ae"
      unitRef="shares">10492946</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI2LTMtMS0xLTA_8a195668-f04e-498b-9622-8af40c394c37"
      unitRef="usdPerShare">16.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI4LTEtMS0xLTA_fd437a7e-37fe-4d7d-8ae6-e975eefe6014"
      unitRef="shares">5719818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI4LTMtMS0xLTA_59013183-3dc4-422e-a6f3-6794fbbb37ab"
      unitRef="usdPerShare">15.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI5LTEtMS0xLTA_e294a32b-6146-4ae0-ada4-bc57fad9dd28"
      unitRef="shares">3990740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzI5LTMtMS0xLTA_9441ac1b-f484-4183-b36c-030c100b39f0"
      unitRef="usdPerShare">24.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMwLTEtMS0xLTA_3fcf08aa-1773-40be-b09b-bb65d3b51e57"
      unitRef="shares">1678604</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMwLTMtMS0xLTA_f6f2efe6-f35a-44c5-8b42-6d9db8a5b828"
      unitRef="usdPerShare">14.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMxLTEtMS0xLTA_23fa8d04-cf33-499f-8e3c-9f77bda5dfe3"
      unitRef="shares">541680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMxLTMtMS0xLTA_32bc20fe-a773-47c9-b86d-4b5d63af8b50"
      unitRef="usdPerShare">23.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTEtMS0xLTA_305f68d3-90ed-4995-b009-d7a17ba98b93"
      unitRef="shares">12263402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTMtMS0xLTA_1809e7a6-90ea-411c-8c2b-41ee89f06a5d"
      unitRef="usdPerShare">18.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTUtMS0xLTA_55f66330-2244-479a-9618-1f83e292a83f">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzMyLTctMS0xLTA_1315c3f2-2569-4f81-9190-473b1809be8b"
      unitRef="usd">177480000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTEtMS0xLTA_00e913a7-d50b-4d51-8bc3-0f429fa44f4f"
      unitRef="shares">6028261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTMtMS0xLTA_abb4d532-97cd-47f0-929a-676967785c42"
      unitRef="usdPerShare">16.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTUtMS0xLTA_1bc11416-98c3-4947-9880-dbab73bca8b1">P5Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTpiOGI2NGIxZjM3OWI0YzdkOGY1YzcxNjUxODkzODYwZS90YWJsZXJhbmdlOmI4YjY0YjFmMzc5YjRjN2Q4ZjVjNzE2NTE4OTM4NjBlXzM0LTctMS0xLTA_20b58a34-0286-4cca-a2f2-4c1a67a3ff6a"
      unitRef="usd">103306000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNTE_674bcfbd-1f98-4ca1-8d39-2765d828557c"
      unitRef="usd">24000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8d986e645bf145889f874249c82e4942_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNTU_af371a92-466e-4c54-9808-ae2ffee15976"
      unitRef="usd">16500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i472e72cb054d49e5950e4aa854065b8c_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMyNjI_23c1e792-b8c3-4f5a-a879-07fac1ceea85"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3b9b2f09f9234b4c8309645b2c63ca2a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzMzMDA_a0caf206-8a2b-4bdf-af2b-5fb18be6dbef"
      unitRef="usd">59700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9130dcad975741fe9b37e3e99ece0577_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzM0NDQ_5318582f-79c6-4403-b64c-b0ed72b97453">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit
      contextRef="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzM4MTQ_318c1c05-a8a1-4ba7-b80f-d9915988e691"
      unitRef="shares">1</insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMjA_3d0e0979-e4bf-410f-b7dc-7cd2ba9c4ae6">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU awards granted during the years ended December&#160;31, 2020, 2019 and 2018:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January&#160;1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;844,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzktMi0xLTEtMA_ad95b07a-959f-4066-b929-aa48e4a999b3"
      unitRef="shares">46914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6a4d7f5c0f034f7ea812eb9bdd080a27_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzktNC0xLTEtMA_519266ed-4675-45ad-81d0-174e9630f205"
      unitRef="usdPerShare">17.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEwLTItMS0xLTA_02d35cca-13d2-48c5-9d67-5d021450c35d"
      unitRef="shares">253586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEwLTQtMS0xLTA_119a09fc-6b5c-44e6-955b-6de3255dec68"
      unitRef="usdPerShare">29.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzExLTItMS0xLTA_bdc2880b-2a6c-4adb-b817-d81a3f517cdb"
      unitRef="shares">51992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzExLTQtMS0xLTA_42daa81f-4312-490e-a018-6a8b2afb1f93"
      unitRef="usdPerShare">18.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEyLTItMS0xLTA_14e11006-3ac7-482a-ad60-297521bb7f6c"
      unitRef="shares">20682</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7daa5829bc564872bab33523184cce28_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEyLTQtMS0xLTA_6102e3a0-afed-4858-9774-7e29460166b0"
      unitRef="usdPerShare">29.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0be8cbb20b3e471da2e0aead19d7a176_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEzLTItMS0xLTA_d03618c6-8a53-4332-86cd-ce4297b25d76"
      unitRef="shares">227826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0be8cbb20b3e471da2e0aead19d7a176_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzEzLTQtMS0xLTA_9d62395f-6647-4de5-a21b-cabb10a59eb6"
      unitRef="usdPerShare">29.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE0LTItMS0xLTA_e8d5ebb0-db49-4ecb-9e17-4fa1b929795b"
      unitRef="shares">407655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE0LTQtMS0xLTA_29e29f22-ac53-4f4a-a2a6-b1abd354378c"
      unitRef="usdPerShare">27.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE1LTItMS0xLTA_2c95f3fa-81a9-43f4-b0de-5f011d8e7c8e"
      unitRef="shares">92145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE1LTQtMS0xLTA_71f3500d-8291-46a7-88b4-28454802dd94"
      unitRef="usdPerShare">28.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE2LTItMS0xLTA_e39b51d3-021a-40b5-b39d-c385a36fcbcf"
      unitRef="shares">42514</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i96147cba6cea4f1691a29dfbc0ca296a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE2LTQtMS0xLTA_d14ce06f-aed0-4ede-b369-f3aeb3f8a026"
      unitRef="usdPerShare">29.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0ce04f79cefd429f9fa32b6a5866706c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE3LTItMS0xLTA_239e74b0-8b7f-4c51-ab46-304dc834abee"
      unitRef="shares">500822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0ce04f79cefd429f9fa32b6a5866706c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE3LTQtMS0xLTA_b64feed8-ea5e-4eae-b47a-273aede654ae"
      unitRef="usdPerShare">28.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE4LTItMS0xLTA_452806d5-f90c-4b48-a5c0-db276c778abb"
      unitRef="shares">559054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE4LTQtMS0xLTA_f7c04c99-38f8-4e49-8d2c-c15315e9756b"
      unitRef="usdPerShare">23.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE5LTItMS0xLTA_98d361ec-aed8-4fc5-8dcd-be23f72af5b0"
      unitRef="shares">161774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzE5LTQtMS0xLTA_91a4bf53-14c0-4ac6-a733-d9d409695cb4"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIwLTItMS0xLTA_12e15430-79c7-4533-b90d-f598f100d954"
      unitRef="shares">53711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ie7fd7853cf11438eb6058388ee4d158a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIwLTQtMS0xLTA_711049e3-ba2d-4a88-8458-9a0dd322a2db"
      unitRef="usdPerShare">25.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIxLTItMS0xLTA_898510d8-bea2-4858-879e-165e1c1fc1b0"
      unitRef="shares">844391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9654b342b1b943d1b4904dcb5401b4a9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo3MTQ3MDdlYzE2ZTc0OTlhYjE2YjNiMzcwZmZlNWJmYi90YWJsZXJhbmdlOjcxNDcwN2VjMTZlNzQ5OWFiMTZiM2IzNzBmZmU1YmZiXzIxLTQtMS0xLTA_d88da81f-626c-4e57-a0af-c5c5dccffdf8"
      unitRef="usdPerShare">25.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i96db1220ab75430ab3c6ae0bc9042f63_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzQzMDQ_89a6aa5a-0440-46e3-a557-1917bdef1d16"
      unitRef="usd">15000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzQ0NDE_c9efb62c-c423-4dc4-880d-713661a9dd9d">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUxMTA_2341873b-5a0d-4967-b798-c4eca08d51ec">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended December&#160;31, 2020, 2019 and 2018 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.071%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i74916538d9974ba79e0b9d63850374aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItMi0xLTEtMA_e260ed04-6ea3-45a5-89ab-6d407d808f59"
      unitRef="usd">11800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i364ee03e6c7541a69698fc45ca2ba4ce_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItNC0xLTEtMA_786f4269-e389-4812-a3f5-3ea89a3497f1"
      unitRef="usd">8200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib38d1bbcd50f449aa39ec92d1409abba_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzItNi0xLTEtMA_a2848d2d-d6ac-46f7-b3aa-042abc1318c6"
      unitRef="usd">9400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i93060279fbe94fc7a1a08779106fc2f4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtMi0xLTEtMA_db256fac-6fd2-4d31-9a0e-6b5fc30357cd"
      unitRef="usd">24400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifba3be11a88b4bfca6f5772ebff95bcb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtNC0xLTEtMA_d98e45df-8be3-496b-9dca-d3d839e824f2"
      unitRef="usd">18800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c0e4ce89f3d4ea4bb96ff17f982a182_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzMtNi0xLTEtMA_5ca41a84-a1a6-4509-947f-e6ddd4698e8f"
      unitRef="usd">16800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic353257bd6e34e7dbe0b8636bd5d2538_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtMi0xLTEtMA_11f34448-c1d2-403d-81b1-fca51a2ac3a8"
      unitRef="usd">36200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifa29866a032b4f66bcfd69a12e24036c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtNC0xLTEtMA_64423a81-323d-40fb-b43e-4b693b7e0340"
      unitRef="usd">27000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12b57931b8a04017a81e641841a99233_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90YWJsZTo4ZGRiYWMzNDEzNGU0Y2Y4YmUzNzY4Yjc0ZDM1MTU2Mi90YWJsZXJhbmdlOjhkZGJhYzM0MTM0ZTRjZjhiZTM3NjhiNzRkMzUxNTYyXzQtNi0xLTEtMA_55369888-2cae-4105-8baa-bc23b68b2c0e"
      unitRef="usd">26200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifd1672f5e51546618f0cf07a08a28df1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUwNDg_2b14df25-9828-45b5-871d-8bb0737fda38"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01f3c32373d84f8d8b6e8ad92ddfe7a5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzUwNTU_4e444c0d-f657-442e-a7e4-31a57917dc72"
      unitRef="usd">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21187a96ab01431487e85f22a31a8d4d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjYvZnJhZzowODc3YzQ0NDdhOTI0NzA3YjhhZTQzNzYyNDE1NDE5Ni90ZXh0cmVnaW9uOjA4NzdjNDQ0N2E5MjQ3MDdiOGFlNDM3NjI0MTU0MTk2XzI3NDg3NzkwNzQ2MDM_7bfcbd78-5dce-4d3e-a2a1-57a020321ad9"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDA_d428cbce-4e1f-4ed7-bc37-ffa4a2b8ddd5">Income Taxes&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax provision was $1.4 million, $0.8 million and $0.2 million and the effective rates were approximately 0%, 0% and 0% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid alternative minimum tax. In addition, the income tax provision for the years ended December&#160;31, 2020, 2019 and 2018 reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries and certain state income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2020 and 2019, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. The Company's loss before income taxes in the US and globally was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's income tax provision consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Irish trading status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The trading income tax rate for an Irish company is 12.5% and the non-trading income tax rate is 25%. During 2019, the Company determined that it qualifies as a non-trading company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As such, the Company&#x2019;s Irish NOLs were revalued to the higher rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Further, not all expenses incurred will result in a non-trading company loss carryforward.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These changes had no impact to income tax expense as a result of the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net deferred tax assets (prior to applying the valuation allowance) of $509.8 million and $413.5 million at December&#160;31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a valuation allowance on its net deferred tax assets by increasing the valuation allowance by $96.3 million and $80.9 million in 2020 and 2019, respectively, as it was more likely than not that such tax benefits will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company had federal net operating loss carryforwards for income tax purposes of approximately $1.2 billion. Due to the limitation on NOLs as more fully discussed below, $1.0 billion of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately $456.7 million of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below). The Company has $202.8&#160;million of non-trading loss carryforwards for Irish tax purposes. The Company has disallowed interest expense carryover of $6.1&#160;million which carryforward indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually 3 years). Since the Company's formation in 1999, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Law Changes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains numerous income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#x2019;s income taxes for 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, the Company would recognize a tax benefit of $5.6 million. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2016 and later, and is generally open for certain states for the years 2015 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded no such expense. As of December&#160;31, 2020 and 2019, the Company has recorded reserves for unrecognized income tax benefits of $5.6 million and $4.8 million, respectively. As any adjustment to the Company&#x2019;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzY4_9038aec1-641b-4c5d-a59b-126e62d9bd2a"
      unitRef="usd">1400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzcy_7c1835c1-eae8-4bb9-9bc3-16accf6e3874"
      unitRef="usd">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc5_83c28841-f641-42d4-bfd7-c53ee0eafda7"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyNQ_3856a811-32f5-4c39-ad2a-3203c0d77209"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyOQ_da6f678c-1cfc-467f-ba7f-dad5cc13d68c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEzNg_2caa07e5-2107-48e1-a064-71307f49013f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDc_af962fb1-9f6f-45f6-adc4-a6b9ff4917b5">The Company's loss before income taxes in the US and globally was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(207,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(286,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,568)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItMS0xLTEtMA_15856f29-30fa-4143-98ec-207039b6754d"
      unitRef="usd">-207120000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItMy0xLTEtMA_d02c6c34-3877-4e31-b6e0-a3a67163657d"
      unitRef="usd">-201161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzItNS0xLTEtMA_641a92e7-f5c8-40cd-96d9-bebf1228c8aa"
      unitRef="usd">-286211000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtMS0xLTEtMA_f6de1fa4-f273-4484-92de-4ee8f75dfc42"
      unitRef="usd">-85568000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtMy0xLTEtMA_3a81c2dc-b619-4acf-982e-ab2271d789e3"
      unitRef="usd">-52399000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzMtNS0xLTEtMA_0fe619c6-0be4-4d63-a2da-07b933784f07"
      unitRef="usd">-37865000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtMS0xLTEtMA_e19ed881-3ffa-42b6-8b2a-cf72d4cc5c77"
      unitRef="usd">-292688000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtMy0xLTEtMA_4681d248-a577-4911-97bc-5a91588ac3f9"
      unitRef="usd">-253560000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTplNjExZTMxNmFmZDQ0Y2IwOThhMWRjNzljN2QyYTI0ZS90YWJsZXJhbmdlOmU2MTFlMzE2YWZkNDRjYjA5OGExZGM3OWM3ZDJhMjRlXzQtNS0xLTEtMA_5d7c81bb-a9be-4852-954c-a4f4d1c52bcb"
      unitRef="usd">-324076000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDg_f1ff357c-64b8-4100-ba09-3b6a53e13dac">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's income tax provision consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtMS0xLTEtMA_94ab2df3-351f-45ce-bec3-5e2350c7a5d0"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtMy0xLTEtMA_3cab68ca-bb6d-4d2e-8d21-ee22bcd5e8e5"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzMtNS0xLTEtMA_ee7da077-df48-4335-8e18-fd853203c9ca"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtMS0xLTEtMA_2e1707fe-f6ed-4a17-8bef-510a9d8a4d9d"
      unitRef="usd">268000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtMy0xLTEtMA_4d25af89-b88d-4e37-856d-fa4cf8b15afd"
      unitRef="usd">10000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzQtNS0xLTEtMA_3dda620a-b3f4-42a4-8a6a-f6037500dffe"
      unitRef="usd">4000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtMS0xLTEtMA_8daaa11c-adff-4c20-ac04-8d9e5e005b8c"
      unitRef="usd">1134000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtMy0xLTEtMA_4055c37f-d4d1-4b4c-8584-b0c9eb5ea5c2"
      unitRef="usd">767000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzUtNS0xLTEtMA_66180fb1-46fc-442f-b448-39103f661739"
      unitRef="usd">197000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtMS0xLTEtMA_4967481a-044e-4634-adc7-cbe5adec42bb"
      unitRef="usd">1402000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtMy0xLTEtMA_4b278b7f-9080-42c7-a714-1e3465aa2c4f"
      unitRef="usd">777000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzYtNS0xLTEtMA_772f990a-64bb-4410-aebe-47012fca4bc7"
      unitRef="usd">201000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtMS0xLTEtMA_246f640b-5711-4d51-aa2b-2c648cdaa805"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtMy0xLTEtMA_672db627-5d82-41a8-bf2b-4e97e0617212"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzgtNS0xLTEtMA_e52ec066-edee-4e77-95fa-056efbb4b5a5"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktMS0xLTEtMA_cf733e0e-8b3d-4b29-80ba-069f4d2170a1"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktMy0xLTEtMA_9021f720-75e9-490b-840f-036be5e48775"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzktNS0xLTEtMA_361526cb-a7d2-42f4-bbb7-3d64265b4ff2"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTEtMS0xLTA_ca49010b-e4a1-4aa5-87a6-d97df6caa2c3"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTMtMS0xLTA_5be8bfad-3ef4-4b63-b2ad-23d4f789209a"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEwLTUtMS0xLTA_7332d19a-3a4e-4df7-a54e-0e1d45e6fb85"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTEtMS0xLTA_c6a82685-8c19-4919-ae12-bcc11f4bcd78"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTMtMS0xLTA_38335aba-d158-4e23-9c98-630512b84683"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzExLTUtMS0xLTA_81e2942c-bcc9-47c4-908b-b55842a3e027"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTEtMS0xLTA_8ccd7a08-fc1c-48a6-a149-2caefe3cf69e"
      unitRef="usd">1402000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTMtMS0xLTA_628f0781-0329-4f52-a354-400cac5f05bb"
      unitRef="usd">777000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTpjZGQ3MGM5M2JjNGQ0MWMwODNjODM5MGY2NjU4YjU2Yi90YWJsZXJhbmdlOmNkZDcwYzkzYmM0ZDQxYzA4M2M4MzkwZjY2NThiNTZiXzEyLTUtMS0xLTA_32bc878f-047a-4cc1-a789-57b7d6a33fef"
      unitRef="usd">201000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc1OTU_0abfb3b7-ebc8-4d4a-ac1d-33300aa09b84">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in Irish trading status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItMS0xLTEtMA_3300a629-25cc-44a8-959b-41f7c34abb9e"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItMy0xLTEtMA_25e3642b-8760-40da-92aa-7f469af6e88b"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzItNS0xLTEtMA_826911dc-8906-437e-b85a-b77b0ccfc4fe"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtMS0xLTEtMA_81942cae-079d-46d5-b6da-be1507e09a78"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtMy0xLTEtMA_fe6ad75f-f2fa-42d3-8f39-928f71ac9d2d"
      unitRef="number">-0.01</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <insm:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzMtNS0xLTEtMA_22e26d5a-2bd3-4d49-a05b-8177fc1b01a5"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtMS0xLTEtMA_37dbd4d5-746b-428e-8342-ab8d4aa4ccca"
      unitRef="number">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtMy0xLTEtMA_439acaa9-e220-42c2-8b27-6af769044103"
      unitRef="number">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzQtNS0xLTEtMA_efea428a-9f99-4057-8ecd-e53d87a6e2fd"
      unitRef="number">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtMS0xLTEtMA_7106e7f1-1864-4ac8-9ca5-e593af173601"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtMy0xLTEtMA_4c9976c5-24aa-4c5f-8ac6-95226c94a5e3"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzUtNS0xLTEtMA_12b6e247-7f4b-4a47-94f3-d0437dbabdc4"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtMS0xLTEtMA_8147e122-edc0-4f10-abdb-9a5dbb606ca8"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtMy0xLTEtMA_ea9c4627-e9c2-4d30-9d42-af0999e5b8fa"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzYtNS0xLTEtMA_f84315b4-fb94-4ebd-9585-6fd4fe737f47"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtMS0xLTEtMA_3998c644-d34c-401b-ab6b-74f00e1aef21"
      unitRef="number">-0.32</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtMy0xLTEtMA_f46962e3-0dbc-43f3-ab6e-58b5d301b4aa"
      unitRef="number">-0.32</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzgtNS0xLTEtMA_f758bd4b-ca49-453e-a2ee-19b13f893d1e"
      unitRef="number">-0.27</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktMS0xLTEtMA_4b7622c5-ecea-4579-859a-844f8d7fb926"
      unitRef="number">0.04</insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent>
    <insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktMy0xLTEtMA_fe4cac83-3fbb-4a58-a387-ec4cf30d509c"
      unitRef="number">0.03</insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent>
    <insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzktNS0xLTEtMA_ee5624b0-0ac4-4e7c-be13-6ed6d5f0a50b"
      unitRef="number">0</insm:EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTEtMS0xLTA_f1f38629-09fb-4659-b3de-b50300f09e95"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTMtMS0xLTA_a4c84582-0e6f-4b78-aeff-0c034370b939"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo3ODgwMjI2NTE2ZTk0OTdkOTc5OTk3YjA1MmRkZWMyMS90YWJsZXJhbmdlOjc4ODAyMjY1MTZlOTQ5N2Q5Nzk5OTdiMDUyZGRlYzIxXzExLTUtMS0xLTA_dd8123cc-e412-4229-a109-0e3c1f48f70f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <insm:EffectiveIncomeTaxRateReconciliationTradingIncomePercent
      contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEyOTI_1eaccf3b-dc5f-45ae-9656-5cb77fc144f6"
      unitRef="number">0.125</insm:EffectiveIncomeTaxRateReconciliationTradingIncomePercent>
    <insm:EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent
      contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzEzMzQ_8b2a69de-6fc3-404c-a7ec-0e80edfb5ba5"
      unitRef="number">0.25</insm:EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc1OTc_bfc59180-d1fb-447c-acd9-4269170a9b91">The components of the deferred tax assets and liabilities consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product license&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,524)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,691)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(509,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzMtMS0xLTEtMA_085fd5d9-6bee-42f7-b2b6-4e324866b6ff"
      unitRef="usd">377093000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzMtMy0xLTEtMA_07c77d1d-d0f1-4f36-aa92-2b13103d874e"
      unitRef="usd">304266000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzQtMS0xLTEtMA_bc79120b-146c-48f1-bb5e-8a7ee438db55"
      unitRef="usd">123305000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzQtMy0xLTEtMA_bca0398d-154a-4b01-bd9f-9c019e452d9f"
      unitRef="usd">114887000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
    <insm:DeferredTaxAssetsLicensePayment
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzUtMS0xLTEtMA_66b38d67-83a1-43de-b5c6-7c2203e529e6"
      unitRef="usd">5652000</insm:DeferredTaxAssetsLicensePayment>
    <insm:DeferredTaxAssetsLicensePayment
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzUtMy0xLTEtMA_993ecdc8-1190-448d-9011-45fd01b5a6b6"
      unitRef="usd">6456000</insm:DeferredTaxAssetsLicensePayment>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzYtMS0xLTEtMA_6eb6de45-b753-4d2e-9ce1-0141a697fc30"
      unitRef="usd">3767000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzYtMy0xLTEtMA_302d6b1f-9f54-40d0-ad40-d4c843ea5b2d"
      unitRef="usd">3129000</us-gaap:DeferredTaxAssetsInventory>
    <insm:DeferredTaxAssetsLeaseLiabilities
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzctMS0xLTEtMA_6e3f76e8-a662-4670-b0fe-8d47e53d283f"
      unitRef="usd">12421000</insm:DeferredTaxAssetsLeaseLiabilities>
    <insm:DeferredTaxAssetsLeaseLiabilities
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzctMy0xLTEtMA_1002f620-b8f8-44f5-8031-9f3ddd3f4e3d"
      unitRef="usd">16439000</insm:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMS0xLTEtMzU2MA_d59a8681-aa95-45eb-9765-3e0b55b76da5"
      unitRef="usd">21664000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMy0xLTEtMzU1Ng_c98c3a01-e7fd-4b12-8b46-5244ac5d280d"
      unitRef="usd">20587000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMS0xLTEtMA_04ae7698-c402-4c93-813a-021a3a3fd94c"
      unitRef="usd">8550000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzgtMy0xLTEtMA_51a4bd29-e1ff-41d8-b0d7-6d5e06b932c8"
      unitRef="usd">6038000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzktMS0xLTEtMA_6ba090fc-42e6-4085-902b-864acf01895e"
      unitRef="usd">552452000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzktMy0xLTEtMA_143bc455-874e-476b-8000-742493971a88"
      unitRef="usd">471802000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzExLTEtMS0xLTA_3811026f-5625-41a7-ac9b-77f42d5ab6e1"
      unitRef="usd">9163000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzExLTMtMS0xLTA_b73b6ebe-449e-4292-b660-df8bf7df37e3"
      unitRef="usd">14316000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTEtMS0xLTM2MjI_b874a7c3-139c-4811-9b11-6a10a0eb6c6d"
      unitRef="usd">11054000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTMtMS0xLTM2MzA_51c8e7b5-c006-4dfb-87e8-e4ff062382c1"
      unitRef="usd">15485000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <insm:DeferredTaxLiabilitiesConvertibleDebt
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEyLTEtMS0xLTA_7bd0b9c7-4ad7-4f17-8b79-d4c75966c212"
      unitRef="usd">22474000</insm:DeferredTaxLiabilitiesConvertibleDebt>
    <insm:DeferredTaxLiabilitiesConvertibleDebt
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEyLTMtMS0xLTA_221a1080-2aec-45b4-aa5a-9cfc49739260"
      unitRef="usd">28524000</insm:DeferredTaxLiabilitiesConvertibleDebt>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTEtMS0xLTA_e87b71b6-38f8-46de-bcc9-a1a5aca0c83a"
      unitRef="usd">42691000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzEzLTMtMS0xLTA_c4080626-6b09-4342-a477-38eb57e7b740"
      unitRef="usd">58325000</us-gaap:DeferredIncomeTaxLiabilities>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE0LTEtMS0xLTA_3b4174a1-8c7c-448b-ae58-7fb602253816"
      unitRef="usd">509761000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE0LTMtMS0xLTA_9747cffa-9bdf-4454-b45a-a640188e10df"
      unitRef="usd">413477000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE1LTEtMS0xLTA_9784c0ab-7415-4034-a880-1522c5a12c15"
      unitRef="usd">509761000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE1LTMtMS0xLTA_ac441fc6-d625-420b-a1e6-985df5fd8a16"
      unitRef="usd">413477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE2LTEtMS0xLTA_16366fba-2aae-4449-a08d-919a387af434"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTphNGI4N2RiYzkxZWY0ZDViOTIwMDYwNTlmYzhiODAwOS90YWJsZXJhbmdlOmE0Yjg3ZGJjOTFlZjRkNWI5MjAwNjA1OWZjOGI4MDA5XzE2LTMtMS0xLTA_8635de2b-12ec-4438-bcfa-9a055771b7e9"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIwNDQ_87120dd5-f9c2-4f60-92d7-72d2abc9ddb2"
      unitRef="usd">509800000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIwNTE_1026c0a1-5098-4d34-9598-6fb400695491"
      unitRef="usd">413500000</insm:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIzMjY_5b515c3e-21ad-4f9d-bd49-37d515894989"
      unitRef="usd">96300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzIzMzM_aa774fa3-873f-48b6-899a-82a185d47d97"
      unitRef="usd">80900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <insm:OperatingLossCarryforwardsTotal
      contextRef="i60c1a8f856324526bc222644c67d2afb_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI1NDY_6ae43444-fd1b-4516-b94b-f4e54ab3a4d6"
      unitRef="usd">1200000000</insm:OperatingLossCarryforwardsTotal>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i60c1a8f856324526bc222644c67d2afb_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI2MTE_2c450fbd-54f0-47d4-bdec-6410e6cd6307"
      unitRef="usd">1000000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i5509be6b4fb84159b9c6b41efd84a675_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzI4MzA_882b74a5-9eaa-4dd9-8abe-8ca0427c7f43"
      unitRef="usd">456700000</us-gaap:OperatingLossCarryforwards>
    <insm:OperatingLossCarryforwardsNonTradingLoss
      contextRef="ibc948d8df4a94b7eb93b753074d45f0a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzQzOTgwNDY1MjEzNTg_2d5f06c6-b80d-4857-9d74-f137e6cbec4d"
      unitRef="usd">202800000</insm:OperatingLossCarryforwardsNonTradingLoss>
    <insm:OperatingLossCarryforwardsDisallowedInterestExpense
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzQzOTgwNDY1MjEzNzU_2718f5e8-b6e3-497e-ab09-eb61ac11ecc7"
      unitRef="usd">6100000</insm:OperatingLossCarryforwardsDisallowedInterestExpense>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzYzOTc_0de8f878-9971-4ddc-bfbb-db4c712e503f"
      unitRef="usd">5600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3Xzc2MDY_b1547f05-7c2d-4f59-954a-cb0357ee5422">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions related to current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzEtMS0xLTEtMA_b7de3836-2ce0-4938-ac41-45634192fd72"
      unitRef="usd">4836000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iff6225cad52544c692427c26bd334021_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzEtMy0xLTEtMA_fcb24436-f9a0-47f7-a45e-718591e4ccfe"
      unitRef="usd">4087000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzItMS0xLTEtMA_e5f12668-903e-4f65-9731-36e699483d8d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzItMy0xLTEtMA_573a6939-8b7a-4b87-be1f-af80be3c18a3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzMtMS0xLTEtMA_2e690bba-e134-44f9-9741-afd9f8f5f036"
      unitRef="usd">32000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzMtMy0xLTEtMA_4f97d7eb-31d0-4461-9bb6-9804d7d81caa"
      unitRef="usd">60000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzQtMS0xLTEtMA_4a84a617-63eb-4606-a4f0-3c339b0f7036"
      unitRef="usd">829000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzQtMy0xLTEtMA_6a6e4dde-19bf-4229-955c-79994573c809"
      unitRef="usd">809000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzYtMS0xLTEtMA_9dd1ac78-8317-46cd-8d40-437b166437bb"
      unitRef="usd">5633000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90YWJsZTo2ODNlN2I0MThjYjA0NGU2ODg2MGUxOWY3NjA0M2NlZi90YWJsZXJhbmdlOjY4M2U3YjQxOGNiMDQ0ZTY4ODYwZTE5Zjc2MDQzY2VmXzYtMy0xLTEtMA_0ba9d151-aa67-4cfb-8dd4-d556e44b45da"
      unitRef="usd">4836000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcxNDY_2945edc9-aede-49f6-a268-b2fed46a38d3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcxNDY_366fc08a-a3f7-44b7-9ba2-e582a89b67a3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcyNTQ_ac64cc14-6ca0-4c58-abcb-e72e7029efdb"
      unitRef="usd">5600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic2ee174a408b4a3e956206fe10d829f3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNjkvZnJhZzozZWUxZGI4YTkxNjQ0ZjEwOGVjZWIwMTE3ZWExOWVkNy90ZXh0cmVnaW9uOjNlZTFkYjhhOTE2NDRmMTA4ZWNlYjAxMTdlYTE5ZWQ3XzcyNjE_25cd8cb1-4938-4b43-8ca7-fd00c000942c"
      unitRef="usd">4800000</us-gaap:UnrecognizedTaxBenefits>
    <insm:LicenseAndOtherAgreementsTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzg1MjM_78bdf785-eb3e-4219-ae40-d65f7a8c5a93">License and Other Agreements&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;PARI Pharma&#160;GmbH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit the system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture the nebulizers except as permitted under the commercialization agreement with PARI, which is described in further detail below. The Lamira Nebulizer System has been approved for use in the US (in combination with ARIKAYCE) and the EU. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA and EMA approval of ARIKAYCE, the Company paid PARI additional milestone payments of &#x20ac;1.0 million, &#x20ac;1.5 million and &#x20ac;0.5 million, respectively. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. As a result, PARI is entitled to receive royalty &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. See below for information related to the commercialization agreement with PARI. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cystic Fibrosis Foundation Therapeutics,&#160;Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received $1.7 million and $2.2 million in research funding for the development of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;owes milestone payments to CFFT of $13.4 million in the aggregate, of which $1.0 million has been paid through December&#160;31, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which are payable through 2025. Furthermore, if certain global sales milestones are met within five years of the commercialization of ARIKAYCE, the Company would owe up to an additional $3.9 million. The Company has determined the likelihood of meeting such global sales milestones and have accrued for these contingent obligations proportionally based on net sales of ARIKAYCE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Resilience Biotechnologies Inc. (successor to Therapure Biopharma&#160;Inc.)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma Inc., which was assumed by Resilience Biotechnologies&#160;Inc. (Resilience) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Resilience collaborated to construct a production area for the manufacture of ARIKAYCE in Resilience's existing manufacturing facility in Canada. The agreement has an initial term of five years, which began in October 2018, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay a minimum of $6 million for commercial ARIKAYCE batches produced and certain manufacturing activities each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PARI Pharma&#160;GmbH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In July 2014, the Company entered into a commercialization agreement with PARI (the Commercialization Agreement) for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of fifteen years from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ajinomoto Althea,&#160;Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of $2.7 million for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional two-year periods upon mutual written agreement of the Company and Althea at least one year prior to the expiration of its then-current term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AstraZeneca AB&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed brensocatib). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of $30.0 million, which was included as research and development expense in the fourth quarter of 2016. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company incurred a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.5 million milestone payment obligation&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; upon the first dosing in a Phase 3 clinical trial of brensocatib. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also obligated to make a series of additional contingent milestone payments totaling up to an additional $72.5 million upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop brensocatib for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to $42.5 million, the first of which occurs at the initiation of a Phase 3 trial in the additional indication. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on brensocatib and one additional payment of $35.0 million upon the first achievement of $1.0 billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patheon UK Limited&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#x2019;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PPD Development, L.P.&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which it retained PPD to perform clinical development services in connection with certain of its clinical research programs. The master services agreement has an initial term of five years. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days&#x2019; written notice, (ii) any project addendum in the event of the other party&#x2019;s breach of the master services agreement or such project addendum upon 30 days&#x2019; written notice, provided that such breach is not cured within such 30-day period, (iii) the master services agreement or any project addendum immediately upon the occurrence of an insolvency event with respect to the other party or (iv) any project addendum upon 30 days&#x2019; written notice if (a) the continuation of the services under such project addendum would post material ethical or safety risks to study participants, (b) any approval from a regulatory authority necessary to perform the applicable study is revoked, suspended or expires without renewal or (c) in the reasonable opinion of such party, continuation of the services provided under such project addendum would be in violation of applicable law. The Company entered into project addenda with PPD to perform clinical development services over several years for, but not limited to, its ARISE, ENCORE and ASPEN studies.&lt;/span&gt;&lt;/div&gt;</insm:LicenseAndOtherAgreementsTextBlock>
    <insm:CollaborativeArrangementMilestonePayment
      contextRef="i6cf490c2bd404047bb4076dfbe4a9035_D20080401-20080430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzExMTU_4c803688-59e9-4ed0-b886-8ef566989105"
      unitRef="eur">1000000.0</insm:CollaborativeArrangementMilestonePayment>
    <insm:CollaborativeArrangementMilestonePayment
      contextRef="if80ed6a320744417ad76e4542ce13f86_D20080401-20080430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzExMjI_4d089764-04a9-4e33-a075-5bdf3f58668f"
      unitRef="eur">1500000</insm:CollaborativeArrangementMilestonePayment>
    <insm:CollaborativeArrangementMilestonePayment
      contextRef="i7e1cd387ddb44953ad773aa9410675d5_D20080401-20080430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzEwOTk1MTE2MzY4MjM_92a75e8d-3fcd-4704-9f1b-00c3aec78118"
      unitRef="eur">500000</insm:CollaborativeArrangementMilestonePayment>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i579a8c2c42bf45ff98f87f2c584c06ea_D20040101-20041231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIwNjY_8a10b967-27e6-44da-9453-bfbd8151b090"
      unitRef="usd">1700000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="iea44e908cf7e4040bb2902ceff09e1f2_D20090101-20091231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIwNzM_c268d5d0-e8c6-439e-8911-fab6c77fc63c"
      unitRef="usd">2200000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="ibad33e6bc291434cbfb0f351cbf0d854_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzEwOTk1MTE2NDQ3MjM_db29853e-dae5-4e0b-b375-87a0cd32906c"
      unitRef="usd">13400000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyExpense
      contextRef="i2cfcedfa9eec4b33b05c236c449b48a7_D20040101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI3NDg3NzkwODY0MDE_6a2fed12-abe2-4b8f-b057-14a91593e372"
      unitRef="usd">1000000.0</us-gaap:RoyaltyExpense>
    <insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments
      contextRef="ifb4bec08f1b8439f95f590be3ffee05d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzIzNzY_58253b5c-881c-46e9-ad10-1147b97c21f1">P5Y</insm:PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments>
    <insm:AdditionalRoyaltyGuaranteesCommitmentsAmount
      contextRef="ibad33e6bc291434cbfb0f351cbf0d854_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI0NTg_ab33c764-7c28-4f5e-8bc6-92160b8c3c47"
      unitRef="usd">3900000</insm:AdditionalRoyaltyGuaranteesCommitmentsAmount>
    <insm:InitialTermOfContractManufacturingAgreement
      contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMwODg_3ec8518c-edc4-43f9-a433-6e8709b318b9">P5Y</insm:InitialTermOfContractManufacturingAgreement>
    <insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement
      contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMxNzY_cbcd4ca4-b0e4-4883-bbaa-3f0e7c1c0d2f">P2Y</insm:PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement>
    <insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
      contextRef="i62b23ec5644c4ecaa232b1910e2bb332_D20140201-20140228"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzMyNDU_c2a8f993-0099-4910-9ce1-ed0c00000990">P2Y</insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement>
    <insm:CommercialServicesAgreementMinimumObligation
      contextRef="i49b84c0ce9224662b5305154df7099d8_I20140228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzM0OTM_333e3313-13ee-4916-8353-58c8e3b981d7"
      unitRef="usd">6000000</insm:CommercialServicesAgreementMinimumObligation>
    <insm:InitialTermOfContractManufacturingAgreement
      contextRef="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQyMjM_b3326826-79f0-4ed3-a6cf-1d168b1c8072">P15Y</insm:InitialTermOfContractManufacturingAgreement>
    <insm:AdditionalTermOfContractManufacturingAgreement
      contextRef="iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzODA_aa207c41-7e56-4d4c-93f2-b0dd682bf977">P5Y</insm:AdditionalTermOfContractManufacturingAgreement>
    <insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement
      contextRef="id633afd47e954538a26c547411ecfe02_D20140701-20140731"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQ0Mjg_04abc7b8-7002-4ad2-be2a-776563e4a3bd">P1Y</insm:WrittenNoticePeriodForTerminationOfContractManufacturingAgreement>
    <insm:CommercialServicesAgreementMinimumObligation
      contextRef="ib05c0670068f485e8afcc6417da49edf_I20150930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzUwMDI_9eea10da-1475-4376-93a4-0a93a0ad922b"
      unitRef="usd">2700000</insm:CommercialServicesAgreementMinimumObligation>
    <insm:CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement
      contextRef="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjAwNTQ_4c114796-da57-45ca-a5ab-ee9646e75d3e">P2Y</insm:CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement>
    <insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement
      contextRef="i7f31fad9008e4d81b95e3728446d896e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzU0MTY_71827d98-79af-4c0b-bf79-aaa69162d92b">P1Y</insm:CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement>
    <insm:CollaborativeArrangementUpfrontPayment
      contextRef="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzYwMTA_48e5efa2-766e-431f-805d-1a8824e61c92"
      unitRef="usd">30000000.0</insm:CollaborativeArrangementUpfrontPayment>
    <insm:CollaborativeArrangementPhase3StudyPayment
      contextRef="i2e18d5761c034e77ade451b5e01c0ecd_D20160101-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzI3NDg3NzkwNzk2MzE_bb3ed7be-5ee6-4905-9029-f5e1b959fd0f"
      unitRef="usd">12500000</insm:CollaborativeArrangementPhase3StudyPayment>
    <insm:PaymentsUponAchievementOfClinicalMilestonesAmount
      contextRef="i13e3ed8648004855b71e7b4adb845d68_I20161031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzYyMDk_cab75c06-9373-416a-944c-b20d0e47fd65"
      unitRef="usd">72500000</insm:PaymentsUponAchievementOfClinicalMilestonesAmount>
    <insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication
      contextRef="i13e3ed8648004855b71e7b4adb845d68_I20161031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY0Nzk_5e384465-82e3-4db2-8a56-44e4752d5109"
      unitRef="usd">42500000</insm:CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication>
    <us-gaap:PaymentsForRoyalties
      contextRef="if28faba5eb55435f9579cbc04ed74d86_D20161001-20161031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY3NzU_9e13a91f-6166-4af5-9d3f-295154a96822"
      unitRef="usd">35000000.0</us-gaap:PaymentsForRoyalties>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1957ada0d9cd42738836fe4ca797ec73_D20161001-20161031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzY4MDg_cec21dc1-33fc-47e5-bc13-21f359058f0d"
      unitRef="usd">1000000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <insm:InitialTermOfClinicalDevelopmentServicesAgreement
      contextRef="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjcxMzM_cfed4bbb-22f2-44f2-9d47-43909dac86a2">P5Y</insm:InitialTermOfClinicalDevelopmentServicesAgreement>
    <insm:WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement
      contextRef="i7c4ca84cd81f45c6ba898458545b5d0a_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzIvZnJhZzpkMDZkNWE5OTRkM2U0YTQ0YTY1MDBlMDhhMTJmY2ZlMy90ZXh0cmVnaW9uOmQwNmQ1YTk5NGQzZTRhNDRhNjUwMGUwOGExMmZjZmUzXzQzOTgwNDY1MjcxNTA_f601be2e-cbce-457e-892b-abfed2b64301">P30D</insm:WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzE5MDc_47e9eaad-cefd-4b0c-a55d-77d39a642e11">Commitments and Contingencies&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company entered into a lease for its new corporate headquarters in Bridgewater, New Jersey. The initial lease term commenced in October 2019 and expires in September 2030. In July 2016, the Company signed an operating lease for laboratory space, also located in Bridgewater, for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for laboratory space located in Bridgewater, which commenced in January 2019. Future minimum rental payments under the Bridgewater leases are $24.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense charged to operations was $3.7 million, $3.2 million, and $2.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total $83.1 million. These amounts do not represent the Company's entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend amounts or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i667f6be698f043288e59286e0ec72ad8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzYwNg_48961223-404d-4bff-acd5-4ebad4ed4e19"
      unitRef="usd">24900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY0OQ_0e99cbc0-33f6-445a-a569-249f9264171f"
      unitRef="usd">3700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY1Mw_1b10b8b3-c5c8-43c6-8a9a-e8a9cdcc2559"
      unitRef="usd">3200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzY2MQ_9713e7ab-6e61-4e63-8478-6a8bb4c85cd4"
      unitRef="usd">2100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:PurchaseObligation
      contextRef="iebde4d2934ac45c684584d4c433bdde3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzUvZnJhZzo2MTBjNjdiNDMzZjE0YzhmODNhNzhlMjk5ZWM1YTIwYi90ZXh0cmVnaW9uOjYxMGM2N2I0MzNmMTRjOGY4M2E3OGUyOTllYzVhMjBiXzEwODQ_c9dea49c-f1d1-4be7-9de5-69e8f9d32000"
      unitRef="usd">83100000</us-gaap:PurchaseObligation>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzU2OA_96b7e9a5-b0b8-467c-a0ac-fe936ce8736d">Retirement PlanThe Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum). Employer contributions for the year ended December&#160;31, 2020, 2019 and 2018 were $2.9 million, $2.8 million and $2.2 million, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzI1Mg_0e826234-304c-4675-9129-377f238a47e0"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzMwMw_dbcadda5-0ad9-433b-89cb-2c82f5cb3527"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzQxMQ_2b6b59bd-07b8-44b0-a2a2-d5955c72e4b7"
      unitRef="usd">2900000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i8c826cb488d548b29991ab78334baabf_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzQxNQ_cd2b76e1-e496-47ba-94bf-9bebc7d438f4"
      unitRef="usd">2800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="id0bdd3cf2f6c4a1b8023571d098b864f_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI3MDA3NWM0ZjVjMTQzYmRhOGU3ZmZmMTdlNjJjNzc5L3NlYzpiNzAwNzVjNGY1YzE0M2JkYThlN2ZmZjE3ZTYyYzc3OV8xNzgvZnJhZzo1ZTFjOWQzZWNjYjA0YTg4YmEyNDQyMzYwMTkxYTkyZS90ZXh0cmVnaW9uOjVlMWM5ZDNlY2NiMDRhODhiYTI0NDIzNjAxOTFhOTJlXzI3NDg3NzkwNzAxNjA_daf6455b-b145-4e1b-af3e-7207d2f564e0"
      unitRef="usd">2200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024616973160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 22, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-30739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSMED INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">54-1972729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">700 US Highway 202/206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bridgewater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">977-9900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INSM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,043,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Portions of the registrant's definitive Proxy Statement for its 2021 Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission no later </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">than April 30, 2021 an</span>d to be delivered to shareholders in connection with the 2021 Annual Meeting of Shareholders, are herein incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001104506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024613685592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 532,756<span></span>
</td>
<td class="nump">$ 487,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">16,562<span></span>
</td>
<td class="nump">19,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">49,592<span></span>
</td>
<td class="nump">28,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">23,982<span></span>
</td>
<td class="nump">20,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">622,892<span></span>
</td>
<td class="nump">555,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">49,261<span></span>
</td>
<td class="nump">53,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">53,953<span></span>
</td>
<td class="nump">60,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">10,334<span></span>
</td>
<td class="nump">15,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">32,946<span></span>
</td>
<td class="nump">37,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">26,769<span></span>
</td>
<td class="nump">20,314<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">796,155<span></span>
</td>
<td class="nump">742,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">42,853<span></span>
</td>
<td class="nump">13,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">37,807<span></span>
</td>
<td class="nump">40,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">25,591<span></span>
</td>
<td class="nump">19,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">11,475<span></span>
</td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">118,807<span></span>
</td>
<td class="nump">85,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, long-term</a></td>
<td class="nump">356,318<span></span>
</td>
<td class="nump">335,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, long-term</a></td>
<td class="nump">14,713<span></span>
</td>
<td class="nump">19,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">21,255<span></span>
</td>
<td class="nump">29,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">9,178<span></span>
</td>
<td class="nump">10,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">520,271<span></span>
</td>
<td class="nump">480,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 500,000,000 authorized shares, 102,763,060 and 89,682,387 issued and outstanding shares at December&#160;31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,105,252<span></span>
</td>
<td class="nump">1,797,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,830,589)<span></span>
</td>
<td class="num">(1,536,499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">193<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">275,884<span></span>
</td>
<td class="nump">261,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 796,155<span></span>
</td>
<td class="nump">$ 742,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608955816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="nump">102,763,060<span></span>
</td>
<td class="nump">89,682,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="nump">102,763,060<span></span>
</td>
<td class="nump">89,682,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024617010200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenues, net</a></td>
<td class="nump">$ 164,413<span></span>
</td>
<td class="nump">$ 136,467<span></span>
</td>
<td class="nump">$ 9,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="nump">39,872<span></span>
</td>
<td class="nump">24,212<span></span>
</td>
<td class="nump">2,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">181,157<span></span>
</td>
<td class="nump">131,711<span></span>
</td>
<td class="nump">145,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">203,613<span></span>
</td>
<td class="nump">210,796<span></span>
</td>
<td class="nump">168,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">429,645<span></span>
</td>
<td class="nump">371,712<span></span>
</td>
<td class="nump">317,173<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(265,232)<span></span>
</td>
<td class="num">(235,245)<span></span>
</td>
<td class="num">(307,338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Investment income</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">9,921<span></span>
</td>
<td class="nump">10,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(29,564)<span></span>
</td>
<td class="num">(27,705)<span></span>
</td>
<td class="num">(25,472)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">405<span></span>
</td>
<td class="num">(531)<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(292,688)<span></span>
</td>
<td class="num">(253,560)<span></span>
</td>
<td class="num">(324,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (294,090)<span></span>
</td>
<td class="num">$ (254,337)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss (in dollars per share)</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average basic and diluted common shares outstanding (in shares)</a></td>
<td class="nump">97,605<span></span>
</td>
<td class="nump">84,560<span></span>
</td>
<td class="nump">76,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (294,090)<span></span>
</td>
<td class="num">$ (254,337)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation gains (losses)</a></td>
<td class="nump">203<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (293,887)<span></span>
</td>
<td class="num">$ (254,338)<span></span>
</td>
<td class="num">$ (324,283)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024647428280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 361,059<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 1,318,181<span></span>
</td>
<td class="num">$ (957,885)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,611,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(324,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(324,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">$ 8,815<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">8,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="nump">494,351<span></span>
</td>
<td class="nump">645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible debt</a></td>
<td class="nump">$ 136,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">26,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">208,266<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">1,489,664<span></span>
</td>
<td class="num">(1,282,162)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(254,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(254,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">19,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="nump">1,413,341<span></span>
</td>
<td class="nump">1,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 261,074<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">260,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,658,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">26,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">261,674<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">1,797,286<span></span>
</td>
<td class="num">(1,536,499)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(294,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(294,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance</a></td>
<td class="nump">$ 26,072<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">26,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options and ESPP shares issuance (in shares)</a></td>
<td class="nump">1,678,604<span></span>
</td>
<td class="nump">1,795,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 245,866<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">245,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for vesting of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation expense</a></td>
<td class="nump">36,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 275,884<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 2,105,252<span></span>
</td>
<td class="num">$ (1,830,589)<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024626647224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (294,090)<span></span>
</td>
<td class="num">$ (254,337)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">9,147<span></span>
</td>
<td class="nump">5,188<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">36,158<span></span>
</td>
<td class="nump">26,971<span></span>
</td>
<td class="nump">26,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense', window );">Accretion of debt discount and back-end fee on debt</a></td>
<td class="nump">18,981<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">15,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Noncash operating lease expense</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NoncashOperatingLeaseExpense', window );">Noncash operating lease expense</a></td>
<td class="nump">5,932<span></span>
</td>
<td class="nump">9,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,670<span></span>
</td>
<td class="num">(13,717)<span></span>
</td>
<td class="num">(5,515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(21,180)<span></span>
</td>
<td class="num">(21,281)<span></span>
</td>
<td class="num">(7,032)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,114)<span></span>
</td>
<td class="num">(8,718)<span></span>
</td>
<td class="num">(5,514)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(6,261)<span></span>
</td>
<td class="num">(16,008)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">29,825<span></span>
</td>
<td class="num">(4,966)<span></span>
</td>
<td class="nump">3,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accrued expenses and other</a></td>
<td class="num">(10,675)<span></span>
</td>
<td class="nump">4,789<span></span>
</td>
<td class="nump">19,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">5,781<span></span>
</td>
<td class="num">(3,068)<span></span>
</td>
<td class="nump">10,011<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(219,348)<span></span>
</td>
<td class="num">(250,649)<span></span>
</td>
<td class="num">(257,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(6,240)<span></span>
</td>
<td class="num">(42,268)<span></span>
</td>
<td class="num">(13,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">PARI milestone upon regulatory approvals</a></td>
<td class="num">(582)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,822)<span></span>
</td>
<td class="num">(42,268)<span></span>
</td>
<td class="num">(14,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of 1.75% convertible senior notes due 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payment of debt principal and extinguishment costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(57,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</a></td>
<td class="nump">245,866<span></span>
</td>
<td class="nump">261,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options, ESPP, and RSU vesting</a></td>
<td class="nump">26,073<span></span>
</td>
<td class="nump">19,701<span></span>
</td>
<td class="nump">8,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows for finance leases</a></td>
<td class="num">(936)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance', window );">Proceeds from tenant improvement allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</a></td>
<td class="nump">271,003<span></span>
</td>
<td class="nump">285,278<span></span>
</td>
<td class="nump">386,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="nump">494<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">45,327<span></span>
</td>
<td class="num">(7,643)<span></span>
</td>
<td class="nump">113,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">487,429<span></span>
</td>
<td class="nump">495,072<span></span>
</td>
<td class="nump">381,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">532,756<span></span>
</td>
<td class="nump">487,429<span></span>
</td>
<td class="nump">495,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9,186<span></span>
</td>
<td class="nump">7,883<span></span>
</td>
<td class="nump">6,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount Premium And Accretion Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Operating Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for (Proceeds from) Financing Lease Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024606795752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior note due 2025 | Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024609390632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">Description of Business and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States as ARIKAYCE (amikacin liposome inhalation suspension) and in the EU as ARIKAYCE&#174; Liposomal 590 mg Nebuliser Dispersion. ARIKAYCE received accelerated approval in the United States (US) in September 2018 for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mycobacterium avium complex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension and other rare pulmonary disorders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the Commonwealth of Virginia on November&#160;29, 1999 and its principal executive offices are located in Bridgewater, New Jersey. The Company has legal entities in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $532.8&#160;million in cash and cash equivalents as of December&#160;31, 2020 and reported a net loss of $294.1 million for the year ended December&#160;31, 2020. Historically, the Company has funded its operations primarily through public offerings of equity securities and debt financings. The Company commenced commercial shipments of ARIKAYCE in October 2018. The Company expects to continue to incur operating losses both at its US and certain international entities while funding research and development (R&amp;D) activities for ARIKAYCE, brensocatib, TPIP and its other pipeline programs, continuing and commencing commercialization activities for ARIKAYCE in the US and Europe, respectively, continuing to invest in pre-commercial and regulatory activities for ARIKAYCE in Japan, and funding other general and administrative activities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects its future cash requirements to be substantial, and the Company may need to raise additional capital to fund operations, including the continued commercialization of ARIKAYCE and additional clinical trials related to ARIKAYCE, to develop brensocatib and TPIP and to develop, acquire, in-license or co-promote other products or product candidates, including those that address orphan or rare diseases. The source, timing and availability of any future financing or other transaction will depend principally upon continued progress in the Company&#8217;s commercial, regulatory and development activities. Any equity or debt financing will also be contingent upon equity and debt market conditions and interest rates at the time. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The Company believes it currently has sufficient funds to meet its financial needs for at least the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;There are many uncertainties regarding the novel coronavirus (COVID-19) pandemic, and the Company is closely monitoring the impact of the pandemic on all aspects of its business, including how the pandemic will impact its patients, employees, suppliers, vendors, business partners and distribution channels. While the pandemic did not materially affect the Company's financial results and business operations for the year ended December 31, 2020, the Company is unable to predict the impact that COVID-19 will have on its financial position and operating results in future periods due to numerous uncertainties. The Company will continue to assess the evolving impact of the COVID-19 pandemic and will make adjustments to its operations as necessary.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, and Insmed Italy S.R.L.. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605559976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and </span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Income and Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accounts receivable are recorded net of customer allowances for prompt pay discounts, chargebacks, and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, expected credit losses have not been material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of three years to five years are used for computer equipment. Estimated useful lives of seven years are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets. The Company determined that no indicators of impairment of finite-lived intangible assets or long-lived assets existed at December&#160;31, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's only financial assets and liabilities which were measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019 were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemptions and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"><tr><td style="width:1.0%"/><td style="width:32.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during 2020 and 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company held no securities that were in an unrealized loss or gain position.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the liability component of the 1.75% convertible senior notes due 2025 (the Convertible Notes) (categorized as a Level 2 liability for fair value measurement purposes) as of December&#160;31, 2020 was $516.4 million, determined using current market factors and the ability of the Company to obtain debt on comparable terms to the Convertible Notes. The $356.3 million carrying value of the Convertible Notes as of December&#160;31, 2020 excludes the $88.0 million of the unamortized portion of the debt discount.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.933%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Gross Product Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</span></div><div style="text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist primarily of net sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. The Company's customers in the US include specialty pharmacies and specialty distributors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees for services are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and fees and, therefore, deducts the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"><tr><td style="width:1.0%"/><td style="width:37.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Credits, Fees and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks and Co-pay Assistance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for prior period sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to certain early access programs (EAPs) in Europe, consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation, or ATU) and from the named patient program in Germany and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other countries. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. In December 2020, the Company began recognizing product revenue from commercial sales to Germany subsequent to receiving approval by the EC.</span></div><div style="margin-bottom:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first-out (FIFO) flow of goods.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, including medical affairs. R&amp;D expense also includes other internal operating expenses, the cost of manufacturing a product candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. The Company's expenses related to manufacturing its product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture its clinical product supply of ARIKAYCE, brensocatib and TPIP. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. The Company may also grant performance-based stock options to employees from time-to-time. The grant-date fair value of performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that is more likely than not to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term on the balance sheet. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of comprehensive income in the same line item as expenses arising from fixed lease payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 842, leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information presented prior to January 1, 2019 has not been adjusted and is presented in accordance with ASC 840. Refer to the Recently Adopted Accounting Pronouncements section within this note below and Note 7 - Leases for details about the Company's lease portfolio, including Topic 842 required disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company currently operates in one business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has one reportable segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8212; Credit Losses, which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. This ASU amends the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 effective January 1, 2020. Different aspects of the guidance required modified retrospective or prospective adoption. Adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Accounting for Convertible Instruments, to reduce the complexity associated with applying US GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company is currently evaluating the impact of adoption of ASU 2020-06 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610328600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands): </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"/><td style="width:49.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.306%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,313&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>Inventory is stated at the lower of cost and net realizable value and consists of raw materials, work-in-process and finished goods. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. The Company has not recorded any significant inventory write downs since that time. The Company currently uses a limited number of third-party contract manufacturing organizations (CMOs) to produce its inventory.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605584312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&amp;D, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value as well as milestones paid to PARI for the license to use PARI's Lamira&#174; Nebulizer System for the delivery of ARIKAYCE to patients of $1.7 million as a result of the FDA approval of ARIKAYCE in September 2018 and $0.6 million as a result of the EMA approval of ARIKAYCE in October 2020. Total intangible assets, net was $49.3 million and $53.7 million as of December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company began amortizing its finite-lived intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's finite-lived intangible assets for the years ended December&#160;31, 2020 and 2019 follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"><tr><td style="width:1.0%"/><td style="width:30.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,850)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,993)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608871576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets, net</a></td>
<td class="text">Fixed Assets, NetFixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):<div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.877%"><tr><td style="width:1.0%"/><td style="width:40.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.663%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.666%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $9.1 million, $5.2 million and $3.6 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605495592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:71.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024626828456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office space, manufacturing facilities and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's corporate headquarters lease, which is classified as a finance lease. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the operating lease costs disclosed above, the Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $9.9&#160;million and $0.1&#160;million for the years ended December 31, 2020 and 2019, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"><tr><td style="width:1.0%"/><td style="width:53.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $25.1 million incurred by the Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio consists primarily of office space, manufacturing facilities and fleet vehicles. All of the Company's leases are classified as operating leases, except for the Company's corporate headquarters lease, which is classified as a finance lease. The terms of the Company's lease agreements that have commenced range from less than one year to ten years, ten months. In its assessment of the term of each such lease, the Company has not included any options to extend or terminate the lease due to the absence of economic incentives in its lease agreements. Leases that qualify for treatment as a short-term lease are expensed as incurred. These short-term leases are not material to the Company's financial position. Furthermore, the Company does not separate lease and non-lease components for all classes of underlying assets. The Company's leases do not contain residual value guarantees and it does not sublease any of its leased assets. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company outsources its manufacturing operations to CMOs. Upon review of the agreements with its CMOs, the Company determined that these contracts contain embedded leases for dedicated manufacturing facilities. The Company obtains substantially all of the economic benefits from the use of the manufacturing facilities, has the right to direct how and for what purpose the facility is used throughout the period of use, and the supplier does not have the right to change the operating </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instructions of the facility. The operating lease right-of-use assets and corresponding lease liabilities associated with the manufacturing facilities is the sum of the minimum guarantees over the life of the production contracts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the operating lease costs disclosed above, the Company also records variable consideration for variable lease payments in excess of fixed fees or minimum guarantees. Variable consideration related to the Company's leasing arrangements was $9.9&#160;million and $0.1&#160;million for the years ended December 31, 2020 and 2019, respectively. Variable costs related to CMO manufacturing agreements are direct costs related to the manufacturing of ARIKAYCE and are capitalized within inventory in the Company's consolidated balance sheet, while the variable costs related to other leasing arrangements, not related to the manufacturing of ARIKAYCE, have been classified within operating expenses in the Company's consolidated statements of comprehensive loss.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"><tr><td style="width:1.0%"/><td style="width:53.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Company's lease agreements that have previously commenced and are reflected in the consolidated financial statements, the Company has entered into additional lease agreements that have not yet commenced. The Company entered into certain agreements with Patheon related to increasing its long-term production capacity for ARIKAYCE commercial inventory. The Company has determined that these agreements with Patheon contain an embedded lease for the manufacturing facility and the specialized equipment contained therein. Costs of $25.1 million incurred by the Company under these additional agreements have been classified within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>other assets in the Company's consolidated balance sheet. Upon the commencement date, prepaid costs and minimum guarantees specified in the agreement will be combined to establish an operating lease ROU asset and operating lease liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605514824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of the Convertible Notes, in which the Company sold $450.0 million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriters' option to purchase additional Convertible Notes of $50.0 million. The Company's net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses of $14.2 million, were approximately $435.8 million. The Convertible Notes bear interest payable semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2018. The Convertible Notes mature on January 15, 2025, unless earlier converted, redeemed, or repurchased. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after October&#160;15, 2024, until the close of business on the second scheduled trading day immediately preceding January 15, 2025, holders may convert their Convertible Notes at any time. Upon conversion, holders may receive cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's option. The initial conversion rate is 25.5384 shares of common stock per $1,000 principal amount of Convertible Notes (equivalent to an initial conversion price of approximately $39.16 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes prior to October 15, 2024, only under the following circumstances, subject to the conditions set forth in an indenture, dated as of January 26, 2018, between the Company and Wells Fargo Bank, National Association (Wells Fargo), as trustee, as supplemented by the first supplemental indenture, dated January 26, 2018, between the Company and Wells Fargo (as supplemented, the Indenture): (i) during the five business day period immediately after any five consecutive trading day period (the measurement period) in which the trading price per $1,000 principal amount of convertible notes, as determined following a request by a holder of the convertible notes, for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the common stock and the conversion rate on such trading day, (ii) the Company elects to distribute to all or substantially all holders of the common stock (a) any rights, options or warrants (other than in connection with a stockholder rights plan for so long as the rights issued under such plan have not detached from the associated shares of common stock) entitling them, for a period of not more than 45 days from </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the declaration date for such distribution, to subscribe for or purchase shares of common stock at a price per share that is less than the average of the last reported sale prices of the common stock for the 10 consecutive trading day period ending on, and including, the trading day immediately preceding the declaration date for such distribution, or (b) the Company&#8217;s assets, debt securities or rights to purchase securities of the Company, which distribution has a per share value, as reasonably determined by the board of directors, exceeding 10% of the last reported sale price of the common stock on the trading day immediately preceding the declaration date for such distribution, (iii) if a transaction or event that constitutes a fundamental change or a make-whole fundamental change occurs, or if the Company is a party to (a) a consolidation, merger, combination, statutory or binding share exchange or similar transaction, pursuant to which the common stock would be converted into, or exchanged for, cash, securities or other property or assets, or (b) any sale, conveyance, lease or other transfer or similar transaction in one transaction or a series of transactions of all or substantially all of the consolidated assets of the Company and its subsidiaries, taken as a whole, all or any portion of the Convertible Notes may be surrendered by a holder for conversion at any time from or after the date that is 30 scheduled trading days prior to the anticipated effective date of the transaction, (iv) if during any calendar quarter commencing after the calendar quarter ending on March&#160;31, 2018 (and only during such calendar quarter), the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, or, (v) if the Company sends a notice of redemption, a holder may surrender all or any portion of its Convertible Notes, to which the notice of redemption relates, for conversion at any time on or after the date the applicable notice of redemption was sent until the close of business on (a)&#160;the second business day immediately preceding the related redemption date or (b)&#160;if the Company fails to pay the redemption price on the redemption date as specified in such notice of redemption, such later date on which the redemption price is paid.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes can be settled in cash, common stock, or a combination of cash and common stock at the Company's option, and thus, the Company determined the embedded conversion options in the convertible notes are not required to be separately accounted for as a derivative. However, since the Convertible Notes are within the scope of the accounting guidance for cash convertible instruments, the Company is required to separate the Convertible Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated equity component. The fair value was based on data from readily available pricing </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sources which utilize market observable inputs and other characteristics for similar types of instruments. The carrying amount of the equity component representing the embedded conversion option was determined by deducting the fair value of the liability component from the gross proceeds of the Convertible Notes. The excess of the principal amount of the liability component over its carrying amount is amortized to interest expense over the expected life of a similar liability that does not have an associated equity component using the effective interest method. The equity component is not remeasured as long as it continues to meet the conditions for equity classification in the accounting guidance for contracts in an entity&#8217;s own equity.  The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $309.1 million using an effective interest rate of 7.6%, and accordingly, the residual equity component on the date of issuance was $140.9 million. The discount is being amortized to interest expense over the term of the Convertible Notes and has a remaining period of approximately 4.04 years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December&#160;31, 2020, total interest expense related to the Convertible Notes was $28.3 million, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount, as described in the table below. The following table presents the carrying value of the Company&#8217;s debt balance as of December&#160;31, 2020 and 2019 (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"/><td style="width:48.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Debt issuance costs, unamortized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,318&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,940&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.327%"><tr><td style="width:1.0%"/><td style="width:61.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company used part of the net proceeds from the issuance of the Convertible Notes to pay off its outstanding debt to Hercules Capital (Hercules). The payments to Hercules consisted of $55.0 million for the principal amount and an additional $3.2 million in back-end fees, outstanding interest, and prepayment penalty fees, which resulted in a $2.2 million loss on extinguishment of debt in the quarter ended March 31, 2018.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the debt (categorized as a Level&#160;2 liability for fair value measurement purposes) is determined using current market factors and the ability of the Company to obtain debt at comparable terms to those that are currently in place. As of December&#160;31, 2020 and 2019, the fair value of the Company's debt approximated the carrying amount.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and the finance lease for the years ended December&#160;31, 2020, 2019, and 2018, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:58.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of back-end fee on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024627520840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="margin-bottom:8pt;margin-top:8pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of December&#160;31, 2020, the Company had 500,000,000 shares of common stock authorized with a par value of $0.01 and 102,763,060 shares of common stock issued and outstanding. In addition, as of December&#160;31, 2020, the Company had reserved 12,263,402 shares of common stock for issuance upon the exercise of outstanding common stock options and 844,391 shares of common stock for issuance upon the vesting of restricted stock units.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, the Company completed an underwritten public offering of 11,155,000 shares of the Company's common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares from the Company, at a public offering price of $23.25 per share. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $13.5&#160;million, were $245.9&#160;million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2019, the Company completed an underwritten public offering of 10,657,692 shares of the Company's common stock, including 1,042,307 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares at a public offering price of $26.00. The Company's net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and other offering expenses of $16.0&#160;million, were $261.1&#160;million. The </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offering also included the sale of 400,000 shares from the Company's Chair and Chief Executive Officer, from which the Company received no proceeds.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company completed an underwritten public offering of $450.0&#160;million aggregate principal amount of Convertible Notes, including the exercise in full of the underwriter's option to purchase additional Convertible Notes. The fair value of the liability component of the Convertible Notes on the date of issuance was estimated at $309.1&#160;million, and accordingly, the equity component (included in additional paid-in capital) on the date of issuance was calculated as $140.9&#160;million using the residual method, as further described in Note 8 Debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;As of December&#160;31, 2020 and 2019, the Company had 200,000,000 shares of preferred stock authorized with a par value of $0.01 and no shares of preferred stock were issued and outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605640472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s current equity compensation plan, the 2019 Incentive Plan, was approved by shareholders at the Company&#8217;s Annual Meeting of Shareholders in May 2019. The 2019 Incentive Plan is administered by the Compensation Committee of the Board of Directors of the Company. Under the terms of the 2019 Incentive Plan, the Company is authorized to grant a variety of incentive awards based on its common stock, including stock options (both incentive stock options and non-qualified stock options), RSUs, performance options/shares and other stock awards to eligible employees and non-employee directors. On May 16, 2019, upon the approval of the 2019 Incentive Plan by shareholders, 3,500,000 shares were authorized for issuance thereunder, plus any shares subject to then-outstanding awards under the 2017 Incentive Plan, the 2015 Incentive Plan and the 2013 Incentive Plan that subsequently were canceled, terminated unearned, expired, were forfeited, lapsed for any reason or were settled in cash without the delivery of shares. On May 12, 2020, at the Company's 2020 Annual Meeting of Shareholders, the Company's shareholders approved an amendment of the 2019 Incentive Plan providing for the issuance of an additional 4,500,000 shares under the plan. As of&#160;December&#160;31, 2020,&#160;5,200,879&#160;shares remained for future issuance under the 2019 Incentive Plan. The 2019 Incentive Plan will terminate on May 16, 2029 unless it is extended or terminated earlier pursuant to its terms. In addition, from time to time, the Company makes inducement grants of stock options.&#160;These awards are made pursuant to the Nasdaq inducement grant exception as a component of new hires&#8217; employment compensation in connection with the Company&#8217;s equity grant program. During the&#160;twelve months ended December&#160;31, 2020 and 2019, the Company granted inducement stock options covering 996,830&#160;and 305,180&#160;shares, respectively, of the Company's common stock to new employees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company calculates the fair value of stock options granted using the Black-Scholes valuation model. The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66%-71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66% - 68%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22%-1.67%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35% - 2.56%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% - 2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.03</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020, 2019 and 2018, the volatility factor was based on the Company&#8217;s historical volatility during the expected option term.&#160;The company accounts for forfeitures as they occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company grants performance-condition options to certain employees. Vesting of these options is subject to the Company achieving certain performance criteria established at the date of grant and the individuals fulfilling a service condition (continued employment). The Company had no performance options outstanding as of December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for stock options granted for the years ended December&#160;31, 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in '000)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(494,351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,381,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649,698&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434,270&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,413,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,492,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719,818&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990,740&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,028,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2020, 2019 and 2018 was $24.0 million, $16.5 million and $5.6 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $59.7 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 1.8 years. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company may grant Restricted Stock (RS) and Restricted Stock Units (RSUs) to employees and non-employee directors. Each share of RS vests upon and each RSU represents a right to receive one share of the Company's common stock upon the completion of a specific period of continued service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RS and RSU awards granted are valued at the market price of the Company's common stock on the date of grant. The Company recognizes noncash compensation expense for the fair values of these RS and RSUs on a straight-line basis over the requisite service period of these awards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU awards granted during the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,711)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there was $15.0 million of unrecognized compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.3 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended December&#160;31, 2020, 2019 and 2018 (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"/><td style="width:54.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.071%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On May 15, 2018, the Company's shareholders approved the Company&#8217;s 2018 Employee Stock Purchase Plan (ESPP). As part of the ESPP, eligible employees may acquire an ownership interest in the Company by purchasing common stock, at a discount, through payroll deductions. The ESPP is compensatory under GAAP and the Company recorded stock compensation expense of $1.2 million, $1.6&#160;million and $0.9&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607472472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax provision was $1.4 million, $0.8 million and $0.2 million and the effective rates were approximately 0%, 0% and 0% for the years ended December&#160;31, 2020, 2019 and 2018, respectively. As a result of the Tax Cuts and Jobs Act (the Tax Act), the Company recorded a noncurrent receivable to reflect the refund due to the Company in future periods relating to the previously paid alternative minimum tax. In addition, the income tax provision for the years ended December&#160;31, 2020, 2019 and 2018 reflected current income tax expense recorded as a result of the taxable income in certain of the Company's non-US subsidiaries and certain state income taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2020 and 2019, the Company was also subject to foreign income taxes as a result of legal entities established for activities in Europe and Japan. The Company's loss before income taxes in the US and globally was as follows (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,211)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292,688)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,076)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's income tax provision consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Irish trading status</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading income tax rate for an Irish company is 12.5% and the non-trading income tax rate is 25%. During 2019, the Company determined that it qualifies as a non-trading company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As such, the Company&#8217;s Irish NOLs were revalued to the higher rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, not all expenses incurred will result in a non-trading company loss carryforward.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These changes had no impact to income tax expense as a result of the valuation allowance.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets and liabilities are determined based on the difference between financial statement and tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The components of the deferred tax assets and liabilities consist of the following:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net deferred tax assets (prior to applying the valuation allowance) of $509.8 million and $413.5 million at December&#160;31, 2020 and 2019, respectively, primarily consist of net operating loss carryforwards for income tax purposes. Due to the Company's history of operating losses, the Company recorded a valuation allowance on its net deferred tax assets by increasing the valuation allowance by $96.3 million and $80.9 million in 2020 and 2019, respectively, as it was more likely than not that such tax benefits will not be realized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company had federal net operating loss carryforwards for income tax purposes of approximately $1.2 billion. Due to the limitation on NOLs as more fully discussed below, $1.0 billion of the NOLs are available to offset future taxable income, if any. The NOL carryovers and general business tax credits expire in various years beginning in 2018. For state tax purposes, the Company has approximately $456.7 million of New Jersey NOLs available to offset against future taxable income. The Company also has California and Virginia NOLs that are entirely limited due to Section&#160;382 (as discussed below). The Company has $202.8&#160;million of non-trading loss carryforwards for Irish tax purposes. The Company has disallowed interest expense carryover of $6.1&#160;million which carryforward indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2014 through 2017, the Company completed an Internal Revenue Code Section&#160;382 (Section&#160;382) analysis in order to determine the amount of losses that are currently available for potential offset against future taxable income, if any. It was determined that the utilization of the Company's NOL and general business tax credit carryforwards generated in tax periods up to and including December 2010 were subject to substantial limitations under Section&#160;382 due to ownership changes that occurred at various points from the Company's original organization through December 2010. In general, an ownership change, as defined by Section&#160;382, results from transactions increasing the ownership of shareholders that own, directly or indirectly, 5% or more of a corporation's stock, in the stock of a corporation by more than 50 percentage points over a testing period (usually 3 years). Since the Company's formation in 1999, it has raised capital through the issuance of common stock on several occasions which, combined with the purchasing shareholders' subsequent disposition of those shares, have resulted in multiple changes in ownership, as defined by Section&#160;382. These ownership changes resulted in substantial limitations on the use of the Company's NOLs and general business tax credit carryforwards up to and including December 2010. The Company </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continues to track all of its NOLs and tax credit carryforwards but has provided a full valuation allowance to offset those amounts.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Law Changes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted into law in response to the COVID-19 pandemic. The CARES Act contains numerous income tax provisions, such an enhanced interest deductibility, repeal of the 80% limitation with respect to net operating losses arising in taxable years 2018-2020, and additional depreciation deductions related to qualified improvement property. The Company has concluded the analysis of these provisions as of year-end and the CARES Act did not have a material impact on the Company&#8217;s income taxes for 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The financial statement recognition of the benefit for a tax position is dependent upon the benefit being more likely than not to be sustainable upon audit by the applicable taxing authority. If this threshold is met, the tax benefit is then measured and recognized at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If such unrecognized tax benefits were realized and not subject to valuation allowances, the Company would recognize a tax benefit of $5.6 million. The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"/><td style="width:62.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,633&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to US federal and state income taxes and the statute of limitations for tax audit is open for the federal tax returns for the years ended 2016 and later, and is generally open for certain states for the years 2015 and later. The Company has incurred net operating losses since inception, except for the year ended December&#160;31, 2009. Such loss carryforwards would be subject to audit in any tax year in which those losses are utilized, notwithstanding the year of origin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to recognize interest accrued related to unrecognized tax benefits and penalties in income tax expense. The Company has recorded no such expense. As of December&#160;31, 2020 and 2019, the Company has recorded reserves for unrecognized income tax benefits of $5.6 million and $4.8 million, respectively. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions. The Company does not anticipate any material changes in the amount of unrecognized tax positions over the next 12&#160;months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024606908936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndOtherAgreementsAbstract', window );"><strong>License and Other Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LicenseAndOtherAgreementsTextBlock', window );">License and Other Agreements</a></td>
<td class="text">License and Other Agreements<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-License Agreements</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">PARI Pharma&#160;GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;In April 2008, the Company entered into a licensing agreement with PARI Pharma&#160;GmbH (PARI) for use of the optimized Lamira Nebulizer System for delivery of ARIKAYCE in treating patients with NTM lung infections, CF and bronchiectasis. Under the licensing agreement, the Company has rights under several US and foreign issued patents and patent applications involving improvements to the optimized Lamira Nebulizer System, to exploit the system with ARIKAYCE for the treatment of such indications, but the Company cannot manufacture the nebulizers except as permitted under the commercialization agreement with PARI, which is described in further detail below. The Lamira Nebulizer System has been approved for use in the US (in combination with ARIKAYCE) and the EU. Under the licensing agreement, the Company paid PARI an upfront license fee and certain milestone payments. Upon FDA acceptance of the Company's New Drug Application and the subsequent FDA and EMA approval of ARIKAYCE, the Company paid PARI additional milestone payments of &#8364;1.0 million, &#8364;1.5 million and &#8364;0.5 million, respectively. In October 2017, the Company exercised an option to buy-down the royalties that will be paid to PARI on ARIKAYCE net sales. As a result, PARI is entitled to receive royalty </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">payments in the mid-single digits on the annual global net sales of ARIKAYCE, pursuant to the licensing agreement, subject to certain specified annual minimum royalties. See below for information related to the commercialization agreement with PARI. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation Therapeutics,&#160;Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In 2004 and 2009, the Company entered into research funding agreements with Cystic Fibrosis Foundation Therapeutics,&#160;Inc. (CFFT) whereby it received $1.7 million and $2.2 million in research funding for the development of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARIKAYCE. As a result of the US approval of ARIKAYCE and in accordance with the agreements, as amended, the Company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owes milestone payments to CFFT of $13.4 million in the aggregate, of which $1.0 million has been paid through December&#160;31, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are payable through 2025. Furthermore, if certain global sales milestones are met within five years of the commercialization of ARIKAYCE, the Company would owe up to an additional $3.9 million. The Company has determined the likelihood of meeting such global sales milestones and have accrued for these contingent obligations proportionally based on net sales of ARIKAYCE.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Resilience Biotechnologies Inc. (successor to Therapure Biopharma&#160;Inc.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In February 2014, the Company entered into a contract manufacturing agreement with Therapure Biopharma Inc., which was assumed by Resilience Biotechnologies&#160;Inc. (Resilience) for the manufacture of ARIKAYCE, on a non-exclusive basis, at a 200 kg scale. Pursuant to the agreement, the Company and Resilience collaborated to construct a production area for the manufacture of ARIKAYCE in Resilience's existing manufacturing facility in Canada. The agreement has an initial term of five years, which began in October 2018, and will renew automatically for successive periods of two years each, unless terminated by either party by providing the required two years prior written notice to the other party. Notwithstanding the foregoing, the parties have rights and obligations under the agreement prior to the commencement of the initial term. Under the agreement, the Company is obligated to pay a minimum of $6 million for commercial ARIKAYCE batches produced and certain manufacturing activities each calendar year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PARI Pharma&#160;GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In July 2014, the Company entered into a commercialization agreement with PARI (the Commercialization Agreement) for the manufacture and supply of Lamira Nebulizer Systems and related accessories (the Device) as optimized for use with ARIKAYCE. Under the Commercialization Agreement, PARI manufactures the Device except in the case of certain defined supply failures, when the Company will have the right to make the Device and have it made by third parties (but not certain third parties deemed under the Commercialization Agreement to compete with PARI). The Commercialization Agreement has an initial term of fifteen years from the first commercial sale of ARIKAYCE in October 2018 (the Initial Term). The term of the agreement may be extended by the Company for an additional five years by providing written notice to PARI at least one year prior to the expiration of the Initial Term. Notwithstanding the foregoing, the parties have certain rights and obligations under the agreement prior to the commencement of the Initial Term. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ajinomoto Althea,&#160;Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In September 2015, the Company entered into a Commercial Fill/Finish Services Agreement (the Fill/Finish Agreement) with Ajinomoto Althea,&#160;Inc., a Delaware corporation (Althea), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form at a 50 kg scale. Under the Fill/Finish Agreement, the Company is obligated to pay a minimum of $2.7 million for the batches of ARIKAYCE produced by Althea each calendar year during the term of the Fill/Finish Agreement. The Fill/Finish Agreement became effective as of January&#160;1, 2015, and following an extension in 2018, is expected to remain in effect through December 31, 2021. The Fill/Finish Agreement may be extended for additional two-year periods upon mutual written agreement of the Company and Althea at least one year prior to the expiration of its then-current term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AstraZeneca AB</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October 2016, the Company entered into a license agreement (AZ License Agreement) with AstraZeneca AB, a Swedish corporation (AstraZeneca). Pursuant to the terms of the AZ License Agreement, AstraZeneca granted the Company exclusive global rights for the purpose of developing and commercializing AZD7986 (renamed brensocatib). In consideration of the licenses and other rights granted by AstraZeneca, the Company made an upfront payment of $30.0 million, which was included as research and development expense in the fourth quarter of 2016. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company incurred a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.5 million milestone payment obligation</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the first dosing in a Phase 3 clinical trial of brensocatib. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also obligated to make a series of additional contingent milestone payments totaling up to an additional $72.5 million upon the achievement of clinical development and regulatory filing milestones. If the Company elects to develop brensocatib for a second indication, the Company will be obligated to make an additional series of contingent milestone payments to AstraZeneca totaling up to $42.5 million, the first of which occurs at the initiation of a Phase 3 trial in the additional indication. The Company is not obligated to make any additional milestone payments for additional indications. In addition, the Company will pay AstraZeneca tiered royalties ranging from a high single-digit to mid-teens on net sales of any approved product based on brensocatib and one additional payment of $35.0 million upon the first achievement of $1.0 billion </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in annual net sales. The AZ License Agreement provides AstraZeneca with the option to negotiate a future agreement with the Company for commercialization of brensocatib in chronic obstructive pulmonary disease or asthma.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patheon UK Limited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In October 2017, the Company entered into certain agreements with Patheon UK Limited (Patheon) related to the increase of its long-term production capacity for ARIKAYCE commercial inventory. The agreements provide for Patheon to manufacture and supply ARIKAYCE for its anticipated commercial needs.&#160;Under these agreements, the Company is required to deliver to Patheon the required raw materials, including active pharmaceutical ingredients, and certain fixed assets needed to manufacture ARIKAYCE.&#160;Patheon's supply obligations will commence once certain technology transfer and construction services are completed. The Company's manufacturing and supply agreement with Patheon will remain in effect for a fixed initial term, after which it will continue for successive renewal terms unless either party has given written notice of termination. The technology transfer agreement will expire when the parties agree that the technology transfer services have been completed. The agreements may also be terminated under certain other circumstances, including by either party due to a material uncured breach of the other party or the other party&#8217;s insolvency. These early termination clauses may reduce the amounts due to the relevant parties.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PPD Development, L.P.&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which it retained PPD to perform clinical development services in connection with certain of its clinical research programs. The master services agreement has an initial term of five years. Either party may terminate (i) any project addendum under the master services agreement for any reason and without cause upon 30 days&#8217; written notice, (ii) any project addendum in the event of the other party&#8217;s breach of the master services agreement or such project addendum upon 30 days&#8217; written notice, provided that such breach is not cured within such 30-day period, (iii) the master services agreement or any project addendum immediately upon the occurrence of an insolvency event with respect to the other party or (iv) any project addendum upon 30 days&#8217; written notice if (a) the continuation of the services under such project addendum would post material ethical or safety risks to study participants, (b) any approval from a regulatory authority necessary to perform the applicable study is revoked, suspended or expires without renewal or (c) in the reasonable opinion of such party, continuation of the services provided under such project addendum would be in violation of applicable law. The Company entered into project addenda with PPD to perform clinical development services over several years for, but not limited to, its ARISE, ENCORE and ASPEN studies.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LicenseAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LicenseAndOtherAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This entire text block refers to License and Other Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LicenseAndOtherAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605544440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company entered into a lease for its new corporate headquarters in Bridgewater, New Jersey. The initial lease term commenced in October 2019 and expires in September 2030. In July 2016, the Company signed an operating lease for laboratory space, also located in Bridgewater, for which the initial lease term expires in September 2021. In October 2018, the Company expanded its lease for laboratory space located in Bridgewater, which commenced in January 2019. Future minimum rental payments under the Bridgewater leases are $24.9&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense charged to operations was $3.7 million, $3.2 million, and $2.1 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. Rent expense is recorded on a straight-line basis over the term of the applicable leases. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to rent, the Company has several firm purchase commitments, primarily related to the manufacturing of ARIKAYCE and annual minimum royalties on global net sales of ARIKAYCE. Future firm purchase commitments under these agreements, the last of which ends in 2034, total $83.1 million. These amounts do not represent the Company's entire anticipated purchases in the future, but instead represent only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend amounts or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is a party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of business. While the outcomes of these matters are uncertain, management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607139320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text">Retirement PlanThe Company has a 401(k) defined contribution plan for the benefit for all US employees and permits voluntary contributions by employees subject to IRS-imposed limitations. Effective January 1, 2018, the Company matched 100% of eligible employee contributions on the first 4% of employee salary (up to the IRS maximum). Employer contributions for the year ended December&#160;31, 2020, 2019 and 2018 were $2.9 million, $2.8 million and $2.2 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024617157640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Celtrix Pharmaceuticals,&#160;Inc., Insmed Holdings Limited, Insmed Ireland Limited, Insmed France SAS, Insmed Germany&#160;GmbH, Insmed Limited, Insmed Netherlands&#160;B.V., Insmed Godo Kaisha, Insmed Switzerland GmbH, and Insmed Italy S.R.L.. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and </span>judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, and accounting for research and development costs. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InvestmentIncomeExpensePolicyTextBlock', window );">Investment Income and Interest Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Income and Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Investment income consists of interest income earned on the Company's cash and cash equivalents. Interest expense consists primarily of interest costs related to the Company's debt.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers cash equivalents to be highly liquid investments with maturities of three months or less from the date of purchase.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Accounts receivable are recorded net of customer allowances for prompt pay discounts, chargebacks, and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, expected credit losses have not been material.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fixed Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fixed assets are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets. Estimated useful lives of three years to five years are used for computer equipment. Estimated useful lives of seven years are used for laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying value of the asset exceeds the fair value of the asset.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, Net and Impairment Assessment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finite-lived intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the acquired ARIKAYCE R&amp;D intangible asset, at the date of subsequent adjustments of fair value. The fair values assigned to the Company's intangible assets are based on reasonable estimates and assumptions given available facts and circumstances. </span>Impairment Assessment&#8212;The Company reviews the recoverability of its finite-lived intangible assets and long-lived assets for indicators of impairments. Events or circumstances that may require an impairment assessment include negative clinical trial results, a significant decrease in the market price of the asset, or a significant adverse change in legal factors or the manner in which the asset is used. If such indicators are present, the Company assess the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing to the carrying value of the assets to the fair value of the assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Debt issuance costs are amortized to interest expense using the effective interest rate method over the term of the debt. Debt issuance costs paid to the lender and third parties are reflected as a discount to the debt in the consolidated balance sheets. Unamortized debt issuance costs associated with extinguished debt are expensed in the period of the extinguishment.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company categorizes its financial assets and liabilities measured and reported at fair value in the financial statements on a recurring basis based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs used to determine the fair value of financial assets and liabilities, are as follows:</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the assets or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Inputs reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.&#160;Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each major category of financial assets and liabilities measured at fair value on a recurring basis is categorized based upon the lowest level of significant input to the valuations. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Financial instruments in Level 1 generally include US treasuries and mutual funds listed in active markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's only financial assets and liabilities which were measured at fair value as of December&#160;31, 2020 and December&#160;31, 2019 were Level 1 assets comprised of cash and cash equivalents. The Company's cash and cash equivalents permit daily redemptions and the fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"><tr><td style="width:1.0%"/><td style="width:32.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers in or out of Level&#160;1, Level&#160;2 or Level&#160;3 during 2020 and 2019. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, the Company held no securities that were in an unrealized loss or gain position.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the status of each security quarterly to determine whether an other-than-temporary impairment has occurred. In making its determination, the Company considers a number of factors, including: (1) the significance of the decline; (2)&#160;whether the security was rated below investment grade; (3)&#160;how long the security has been in an unrealized loss position; and (4) the Company's ability and intent to retain the investment for a sufficient period of time for it to recover.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has operations in the US, France, Germany, Ireland, Italy, the Netherlands, Switzerland, the United Kingdom (UK), and Japan. The results of its non-US dollar based functional currency operations are translated to US dollars at the average exchange rates during the period. Assets and liabilities are translated at the exchange rate prevailing at the balance sheet date. Equity is translated at the prevailing exchange rate at the date of the equity transaction. Translation adjustments are included in shareholders' equity, as a component of accumulated other comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company realizes foreign currency transaction gains (losses) in the normal course of business based on movements in the applicable exchange rates. These gains (losses) are included as a component of other income, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash equivalents with high credit-quality financial institutions and may invest its short-term investments in US treasury securities, mutual funds and government agency bonds. The Company has established guidelines relative to credit ratings and maturities that seek to maintain safety and liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to risks associated with extending credit to customers related to the sale of products. The Company does not require collateral to secure amounts due from its customers. The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.933%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Gross Product Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:42.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third-party manufacturers and suppliers for manufacturing and supply of its products. The inability of the suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with the suppliers or manufacturer, or an adverse change in their business, could materially impact future operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (1) identify the contracts with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when or as the entity satisfies a performance obligation. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. For all contracts that fall into the scope of ASC 606, the Company has identified one performance obligation: the sale of ARIKAYCE to its customers. The Company has not incurred or capitalized any incremental costs associated with obtaining contracts with customers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues, net consist primarily of net sales of ARIKAYCE in the US. Product revenues are recognized once the Company performs and satisfies all five steps mentioned above. The Company's customers in the US include specialty pharmacies and specialty distributors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recorded at net selling price (transaction price), which includes estimates of variable consideration for which reserves are established for (a) customer credits, such as invoice discounts for prompt pay and specialty pharmacies fees, (b) estimated government rebates, such as Medicaid and Medicare Part D reimbursements, and estimated managed care rebates, (c) estimated chargebacks, and (d) estimated costs of co-payment assistance. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (prompt pay discounts and chargebacks), prepaid expenses (co-payment assistance), or as a current liability (rebates). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer credits: The Company's customers are offered various forms of consideration, including fees for enhanced services and prompt payment discounts. The payment terms for sales to specialty pharmacies for prompt payment discounts and </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees for services are based on contractual rates agreed with the respective specialty pharmacies. The Company anticipates that its customers will earn these discounts and fees and, therefore, deducts the full amount of these discounts and fees from total gross product revenues at the time such revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates: The Company contracts with government agencies and managed care organizations, or collectively, third-party payors, so that ARIKAYCE will be eligible for purchase by, or partial or full reimbursement from, such third-party payors. The Company estimates the rebates it will provide to third-party payors and deducts these estimated amounts from total gross product revenues at the time the revenues are recognized. These reserves are recorded in the same period in which the revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability. The current liability is included in accrued expenses on the consolidated balance sheets. The Company estimates the rebates that it will provide to third-party payors based upon (i) the Company's contracts with these third-party payors, (ii) the government mandated discounts applicable to government-funded programs, (iii) a range of possible outcomes that are probability-weighted for the estimated payor mix, and (iv) information obtained from the Company's specialty pharmacies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks: Chargebacks are discounts that occur when certain contracted customers, currently public health service institutions and federal government entities purchasing via the Federal Supply Schedule, purchase directly from the Company's specialty distributor. Contracted customers generally purchase the product at a discounted price and the specialty distributor, in turn, charges back to the Company the difference between the price the specialty distributor initially paid and the discounted price paid by the contracted customers. The Company estimates chargebacks provided to the specialty distributor and deducts these estimated amounts from gross product revenues, and from accounts receivable, at the time revenues are recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-payment assistance: Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Based upon the terms of the program and information regarding programs provided for similar specialty pharmaceutical products, the Company estimates the average co-pay mitigation amounts and the percentage of patients that it expects to participate in the program in order to establish accruals for co-payment assistance. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue. The Company adjusts its accruals for co-pay assistance based on actual redemption activity and estimates of future redemptions related to sales in the current period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any, or all, of the Company's actual experience varies from its estimates, the Company may need to adjust prior period accruals, affecting revenue in the period of adjustment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"><tr><td style="width:1.0%"/><td style="width:37.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Credits, Fees and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks and Co-pay Assistance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for prior period sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recognizes revenue related to certain early access programs (EAPs) in Europe, consisting of sales to the French National Agency for Medicines and Health Products Safety, which granted ARIKAYCE a Temporary Authorization for Use (Autorisation Temporaire d'Utilisation, or ATU) and from the named patient program in Germany and </span></div>other countries. EAPs are intended to make products available on a named patient basis before they are commercially available in accordance with local regulations. In December 2020, the Company began recognizing product revenue from commercial sales to Germany subsequent to receiving approval by the EC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock', window );">Inventory and cost of product revenues (excluding amortization of intangible assets)</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory and Cost of Product Revenues (excluding amortization of intangible assets)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Inventory is stated at the lower of cost and net realizable value. The Company began capitalizing inventory costs following FDA approval of ARIKAYCE in September 2018. Inventory is sold on a first-in, first-out (FIFO) basis. The Company periodically reviews inventory for expiry and obsolescence and, if necessary, writes down accordingly. If quality specifications are not met during the manufacturing process, such inventory is written off to cost of product revenues (excluding amortization of intangible assets) in the period identified.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenues (excluding amortization of intangible assets) consist primarily of direct and indirect costs related to the manufacturing of ARIKAYCE sold, including third-party manufacturing costs, packaging services, freight, and allocation of overhead costs, in addition to royalty expenses and revenue-based milestones. Cost is determined using a standard cost method, which approximates actual cost, and assumes a first-in, first-out (FIFO) flow of goods.</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of ARIKAYCE, the Company expensed all inventory related costs in the period incurred. Inventory used for clinical development purposes is expensed to research and development (R&amp;D) expense when consumed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation, for personnel serving in the Company's research and development functions, including medical affairs. R&amp;D expense also includes other internal operating expenses, the cost of manufacturing a product candidate, including the medical devices for drug delivery, for clinical study, the cost of conducting clinical studies, and the cost of conducting preclinical and research activities. In addition, R&amp;D expenses include payments to third parties for the license rights to products in development (prior to marketing approval), such as brensocatib. The Company's expenses related to manufacturing its product candidates and medical devices for clinical study are primarily related to activities at contract manufacturing organizations that manufacture its clinical product supply of ARIKAYCE, brensocatib and TPIP. The Company's expenses related to clinical trials are primarily related to activities at contract research organizations that conduct and manage clinical trials on the Company's behalf. These contracts set forth the scope of work to be completed at a fixed fee or amount per patient enrolled. Payments under these contracts primarily depend on performance criteria such as the successful enrollment of patients or the completion of clinical trial milestones as well as time-based fees. Expenses are accrued based on contracted amounts applied to the level of patient enrollment and to activity according to the clinical trial protocol. Nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are then recognized as an expense as the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes stock-based compensation expense for awards of equity instruments to employees and directors based on the grant-date fair value of those awards. The grant-date fair value of the award is recognized as compensation expense ratably over the requisite service period, which generally equals the vesting period of the award. The Company may also grant performance-based stock options to employees from time-to-time. The grant-date fair value of performance-based stock options is recognized as compensation expense over the implicit service period using the accelerated attribution method once it is probable that the performance condition will be achieved. Stock-based compensation expense is included in both R&amp;D and SG&amp;A expenses in the consolidated statements of comprehensive loss.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce the deferred tax assets to the amount that is expected to be realized. In evaluating the need for a valuation allowance, the Company takes into account various factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in the evaluation of a valuation allowance, the Company records a change in valuation allowance through income tax expense in the period such determination is made.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based solely on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that is more likely than not to be sustained upon ultimate settlement. As any adjustment to the Company&#8217;s uncertain tax positions would not result in a cash tax liability, it has not recorded any accrued interest or penalties related to its uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy for interest and penalties related to income tax exposures is to recognize interest and penalties as a component of the income tax provision in the consolidated statements of comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares and other dilutive securities outstanding during the period. Potentially dilutive securities from stock options and restricted stock units would be anti-dilutive as the Company incurred a net loss in all periods presented. Potentially dilutive common shares resulting from the assumed exercise of outstanding stock options would be determined based on the treasury stock method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous generally accepted accounting principles. ASU 2016-02 requires a lessee to recognize a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term on the balance sheet. </span><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lease is a contract, or part of a contract, that conveys the right to control the use of explicitly or implicitly identified property, plant or equipment in exchange for consideration. Control of an asset is conveyed to the Company if the Company obtains the right to obtain substantially all of the economic benefits of the asset or the right to direct the use of the asset. The Company recognizes ROU assets and lease liabilities at the lease commencement date based on the present value of future, fixed lease payments over the term of the arrangement. ROU assets are amortized on a straight-line basis over the term of the lease or are amortized based on consumption, if this approach is more representative of the pattern in which benefit is expected to be derived from the underlying asset. Lease liabilities accrete to yield and are reduced at the time when the lease payment is payable to the vendor. Variable lease payments are recognized at the time when the event giving rise to the payment occurs and are recognized in the statement of comprehensive income in the same line item as expenses arising from fixed lease payments. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Topic 842, leases are measured at present value using the rate implicit in the lease or, if the implicit rate is not determinable, the lessee's implicit borrowing rate. As the implicit rate is not typically available, the Company uses its implicit borrowing rate based on the information available at the lease commencement date to determine the present value of future lease payments. The implicit borrowing rate approximates the rate the Company would pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information presented prior to January 1, 2019 has not been adjusted and is presented in accordance with ASC 840. Refer to the Recently Adopted Accounting Pronouncements section within this note below and Note 7 - Leases for details about the Company's lease portfolio, including Topic 842 required disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company currently operates in one business segment, which is the development and commercialization of therapies for patients with rare diseases. A single management team that reports to the Chief Executive Officer comprehensively manages the entire business. The Company does not operate separate lines of business with respect to its products or product candidates. Accordingly, the Company has one reportable segment.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and (Not Yet Adopted)</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8212; Credit Losses, which requires financial assets measured at an amortized cost basis to be presented at the net amount expected to be collected. This ASU amends the impairment model to utilize an expected loss methodology in place of the incurred loss methodology for financial instruments, including trade receivables. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted ASU 2016-13 effective January 1, 2020. Different aspects of the guidance required modified retrospective or prospective adoption. Adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements (Not Yet Adopted)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Accounting for Convertible Instruments, to reduce the complexity associated with applying US GAAP to certain financial instruments with characteristics of liabilities and equity. For convertible instruments, the number of accounting models for convertible debt instruments is reduced, which results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Only convertible instruments that meet the definition of a derivative or are issued with substantial premiums will continue to be subject to the separation models. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2021. A modified retrospective and a fully retrospective transition method are both permitted. The Company is currently evaluating the impact of adoption of ASU 2020-06 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InvestmentIncomeExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for components of investment income and interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InvestmentIncomeExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622562920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Carrying Value and Fair Value of Assets and Liabilities</a></td>
<td class="text">The following table shows assets and liabilities that are measured at fair value on a recurring basis and their carrying value (in millions):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:74.853%"><tr><td style="width:1.0%"/><td style="width:32.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.743%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.339%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.939%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.528%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December&#160;31, 2019</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor</a></td>
<td class="text">The following table presents the percentage of gross product revenue represented by the Company's three largest customers as of the year ended December&#160;31, 2020 and 2019.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:50.146%"><tr><td style="width:1.0%"/><td style="width:51.669%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.932%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.933%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Total Gross Product Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock', window );">Contract with Customer, Asset, Allowance for Credit Loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary roll-forward of the Company's sales allowances and related accruals for the years ended December&#160;31, 2020 and 2019, which have been deducted in arriving at product revenues, net (in thousands).</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:88.596%"><tr><td style="width:1.0%"/><td style="width:37.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.705%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Customer Credits, Fees and Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Chargebacks and Co-pay Assistance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowances for prior period sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,742)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for current period sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Allowances for prior period sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation of the weighted average number of shares used to compute basic and diluted net loss per share for the years ended December 31, 2020, 2019 and 2018.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr style="height:14pt"><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares used in calculation of basic net loss per share:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding used in calculation of diluted net loss per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.01)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computations of diluted weighted average common shares outstanding as of December&#160;31, 2020, 2019 and 2018 as their effect would have been anti-dilutive (in thousands).</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605544440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's inventory balance consists of the following (in thousands): </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:79.678%"><tr><td style="width:1.0%"/><td style="width:49.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.306%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,313&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608414392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the Company's finite-lived intangible assets for the years ended December&#160;31, 2020 and 2019 follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:82.602%"><tr><td style="width:1.0%"/><td style="width:30.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.360%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,850)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestones</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1,</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired ARIKAYCE R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,849)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARI milestone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,993)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,682&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024605530360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets</a></td>
<td class="text">Fixed assets are stated at cost and depreciated using the straight-line method, based on useful lives as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:75.877%"><tr><td style="width:1.0%"/><td style="width:40.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.663%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.666%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress (CIP)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,953&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,180&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024606793784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:42.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.345%"><tr><td style="width:1.0%"/><td style="width:71.737%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.104%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued technical operation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales allowances and related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued construction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610094648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company's total lease costs included in its consolidated financial statements, as well as other required quantitative disclosures (in thousands). </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.807%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows for operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows for finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate - operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Operating Lease Liabilities</a></td>
<td class="text">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"><tr><td style="width:1.0%"/><td style="width:53.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Maturity of Finance Lease Liabilities</a></td>
<td class="text">The table below presents the maturity of lease liabilities on an annual basis for the remaining years of the Company's commenced lease agreements (in thousands).<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:84.064%"><tr><td style="width:1.0%"/><td style="width:53.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet Classification at December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Current lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024609776232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Components of Debt Balance</a></td>
<td class="text">The following table presents the carrying value of the Company&#8217;s debt balance as of December&#160;31, 2020 and 2019 (in thousands):<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.520%"><tr><td style="width:1.0%"/><td style="width:48.740%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.660%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.662%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;1.75% convertible senior notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Debt issuance costs, unamortized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,043)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Discount on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,318&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,940&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Principal Repayments of Debt</a></td>
<td class="text">As of December&#160;31, 2020, future principal repayments of the debt for each of the fiscal years through maturity were as follows (in thousands):&#160;<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:39.327%"><tr><td style="width:1.0%"/><td style="width:61.725%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ending December&#160;31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Summary of Interest Expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense related to debt and the finance lease for the years ended December&#160;31, 2020, 2019, and 2018, which includes the contractual interest coupon payable semi-annually in cash, the amortization of the issuance costs, and accretion of debt discount is as follows (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.099%"><tr><td style="width:1.0%"/><td style="width:58.661%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.865%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of back-end fee on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total convertible debt interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024606925592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Fair Value Assumptions for Stock Options</a></td>
<td class="text">The following table summarizes the grant date fair value and assumptions used in determining the fair value of all stock options granted, including grants of inducement options, during the years ended December&#160;31, 2020, 2019 and 2018.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:53.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66%-71%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67% - 70%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66% - 68%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22%-1.67%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.35% - 2.56%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% - 2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.09</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of stock options granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$13.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.76</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.03</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for stock options granted for the years ended December&#160;31, 2020, 2019 and 2018 as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Life in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in '000)</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,608,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(494,351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,381,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2018</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,649,698&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,434,270&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,413,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(909,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,492,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,719,818&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990,740&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,678,604)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(541,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,263,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,028,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU awards granted during the years ended December&#160;31, 2020, 2019 and 2018:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.327%"><tr><td style="width:1.0%"/><td style="width:72.058%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.618%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January&#160;1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407,655&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,145)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,514)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,054&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,711)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Allocation of Employee Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation recorded in the consolidated statements of comprehensive loss related to stock options and RSUs during the years ended December&#160;31, 2020, 2019 and 2018 (in millions):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.766%"><tr><td style="width:1.0%"/><td style="width:54.763%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.071%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024538155528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes in the US and Globally</a></td>
<td class="text">The Company's loss before income taxes in the US and globally was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(207,120)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201,161)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286,211)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,568)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,399)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292,688)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,560)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,076)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components Income Tax (Benefit) Provision</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's income tax provision consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between the federal statutory tax rates and the Company's effective tax rate is as follows:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Irish trading status</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The components of the deferred tax assets and liabilities consist of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product license</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,485)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,474)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,524)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,691)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,325)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">The following table summarizes the gross amounts of unrecognized tax benefits (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:78.070%"><tr><td style="width:1.0%"/><td style="width:62.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.315%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.298%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions related to prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions related to current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,633&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608633768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 532,756<span></span>
</td>
<td class="nump">$ 487,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (294,090)<span></span>
</td>
<td class="num">$ (254,337)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608494520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fixed Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember', window );">Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful live of fixed assets</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_EquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024612769512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Measurements (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FairValueLevel1Level2Level3TransfersAmount', window );">Fair value transfers in or out of Level 1, Level 2 or Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities', window );">Securities in an unrealized gain or loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">$ (88,036,000)<span></span>
</td>
<td class="num">$ (107,017,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">$ (88,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement | Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 532,800,000<span></span>
</td>
<td class="nump">487,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value Measurement | Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="nump">356,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">532,800,000<span></span>
</td>
<td class="nump">487,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="nump">516,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement | Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FairValueLevel1Level2Level3TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Level 1, Level 2, Level 3 Transfers, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FairValueLevel1Level2Level3TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607874280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration Risk (Details) - Sales Revenue, Product Line - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerCMember', window );">Customer C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024626658264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Allowance for Credit Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">$ 5,635<span></span>
</td>
<td class="nump">$ 922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">21,975<span></span>
</td>
<td class="nump">15,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales', window );">Allowances for prior period sales</a></td>
<td class="num">(288)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(22,351)<span></span>
</td>
<td class="num">(10,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">4,971<span></span>
</td>
<td class="nump">5,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember', window );">Customer Credits, Fees and Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="nump">3,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales', window );">Allowances for prior period sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(3,742)<span></span>
</td>
<td class="num">(2,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember', window );">Rebates, Chargebacks and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward', window );"><strong>Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Balance at beginning</a></td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales', window );">Allowances for current period sales</a></td>
<td class="nump">18,244<span></span>
</td>
<td class="nump">12,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales', window );">Allowances for prior period sales</a></td>
<td class="num">(288)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits', window );">Payments and credits</a></td>
<td class="num">(18,609)<span></span>
</td>
<td class="num">(7,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Ending balance</a></td>
<td class="nump">$ 4,518<span></span>
</td>
<td class="nump">$ 5,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Allowance For Current Period Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Asset, Allowance For Prior Period Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_CustomerFeesDiscountsandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=insm_RebatesChargebacksandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622589000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (294,090)<span></span>
</td>
<td class="num">$ (254,337)<span></span>
</td>
<td class="num">$ (324,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares used in calculation of basic net loss per share (in shares)</a></td>
<td class="nump">97,605<span></span>
</td>
<td class="nump">84,560<span></span>
</td>
<td class="nump">76,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">97,605<span></span>
</td>
<td class="nump">84,560<span></span>
</td>
<td class="nump">76,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (in dollars per share)</a></td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (3.01)<span></span>
</td>
<td class="num">$ (4.22)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608745176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">12,263<span></span>
</td>
<td class="nump">10,493<span></span>
</td>
<td class="nump">9,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">501<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607003656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024609044728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory, Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 21,601<span></span>
</td>
<td class="nump">$ 16,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">18,754<span></span>
</td>
<td class="nump">6,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">9,237<span></span>
</td>
<td class="nump">5,845<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="nump">$ 49,592<span></span>
</td>
<td class="nump">$ 28,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024609021784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">New drug milestone payment</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,261<span></span>
</td>
<td class="nump">53,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of intangible assets, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of intangible assets, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of intangible assets, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of intangible assets, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization of intangible assets, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,682<span></span>
</td>
<td class="nump">$ 58,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,003)<span></span>
</td>
<td class="num">(4,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,261<span></span>
</td>
<td class="nump">53,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,289<span></span>
</td>
<td class="nump">52,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,139<span></span>
</td>
<td class="nump">56,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,850)<span></span>
</td>
<td class="num">(4,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,289<span></span>
</td>
<td class="nump">52,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Finite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangibles, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="nump">$ 1,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,972<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610171896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 82,303<span></span>
</td>
<td class="nump">$ 79,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(28,350)<span></span>
</td>
<td class="num">(19,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">53,953<span></span>
</td>
<td class="nump">60,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 10,352<span></span>
</td>
<td class="nump">9,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 5,917<span></span>
</td>
<td class="nump">5,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 7,267<span></span>
</td>
<td class="nump">6,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 1,567<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 35,289<span></span>
</td>
<td class="nump">33,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress (CIP)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 21,823<span></span>
</td>
<td class="nump">$ 21,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=insm_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622664264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedClinicalTrialExpenses', window );">Accrued clinical trial expenses</a></td>
<td class="nump">$ 6,733<span></span>
</td>
<td class="nump">$ 5,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">8,594<span></span>
</td>
<td class="nump">12,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedTechnicalOperationExpenses', window );">Accrued technical operation expenses</a></td>
<td class="nump">9,164<span></span>
</td>
<td class="nump">6,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty payable</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">3,631<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedSalesAllowancesandRelatedCosts', window );">Accrued sales allowances and related costs</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">5,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AccruedConstructionLiabilitiesCurrent', window );">Accrued construction costs</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">847<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 37,807<span></span>
</td>
<td class="nump">$ 40,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedConstructionLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Construction Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedConstructionLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedSalesAllowancesandRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Allowances and Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedSalesAllowancesandRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AccruedTechnicalOperationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AccruedTechnicalOperationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024635408552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payments</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lease cost, future right-of-use asset</a></td>
<td class="nump">$ 25.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_LeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">10 years 10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622686776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease, Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1,078<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease interest expense</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_FinanceLeaseCost', window );">Total finance lease cost</a></td>
<td class="nump">2,379<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">8,664<span></span>
</td>
<td class="nump">12,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9,950<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">20,993<span></span>
</td>
<td class="nump">13,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CashFlowLesseeAbstract', window );"><strong>Cash Flow, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows for finance leases</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">8,813<span></span>
</td>
<td class="nump">10,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows for finance leases</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance', window );">Proceeds from tenant improvement allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for new finance lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="nump">$ 47,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance leases</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - operating leases</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance leases</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - operating leases</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for (Proceeds from) Financing Lease Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024616899848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">1,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">2,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">23,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value discount</a></td>
<td class="nump">7,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">15,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, long-term</a></td>
<td class="nump">14,713<span></span>
</td>
<td class="nump">19,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">15,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">13,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">6,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">6,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">37,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value discount</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">32,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">11,475<span></span>
</td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">21,255<span></span>
</td>
<td class="nump">$ 29,308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 32,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610039720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,646,000<span></span>
</td>
<td class="nump">$ 7,043,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 450,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,564,000<span></span>
</td>
<td class="nump">27,705,000<span></span>
</td>
<td class="nump">25,472,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57,835,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,209,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member', window );">1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0255384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember', window );">A&amp;R Loan Agreement with Hercules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest', window );">Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt', window );">Option to purchase additional debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Underwriting discounts and commissions and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Initial conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 309,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining discount amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember', window );">Conversion Term (i) | Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember', window );">Conversion Term (ii) | Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember', window );">Conversion Term (iii) | Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange', window );">Threshold trading days following fundamental change | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember', window );">Conversion Term (iv) | Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentOptionToPurchaseAdditionalDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Option To Purchase Additional Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentOptionToPurchaseAdditionalDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_RepaymentsOfDebtFeesAndOutstandingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Debt Fees And Outstanding Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_RepaymentsOfDebtFeesAndOutstandingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermiiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DebtInstrumentConversionTermAxis=insm_ConversionTermivMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024608242888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">1.75% convertible senior notes due 2025</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="num">(5,646)<span></span>
</td>
<td class="num">(7,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">(88,036)<span></span>
</td>
<td class="num">(107,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">356,318<span></span>
</td>
<td class="nump">$ 335,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Discount on debt</a></td>
<td class="num">$ (88,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, unamortized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,200)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622624968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Future Principal Repayments of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622664264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Contractual interest expense</a></td>
<td class="nump">$ 7,885<span></span>
</td>
<td class="nump">$ 7,883<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AmortizationOfBackendFee', window );">Accretion of back-end fee on debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of debt discount</a></td>
<td class="nump">18,981<span></span>
</td>
<td class="nump">17,985<span></span>
</td>
<td class="nump">15,889<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ConvertibleDebtInterestExpenseTotal', window );">Total convertible debt interest expense</a></td>
<td class="nump">28,263<span></span>
</td>
<td class="nump">27,265<span></span>
</td>
<td class="nump">25,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease interest expense</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="nump">$ 29,564<span></span>
</td>
<td class="nump">$ 27,705<span></span>
</td>
<td class="nump">$ 25,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AmortizationOfBackendFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Backend Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AmortizationOfBackendFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ConvertibleDebtInterestExpenseTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Debt, Interest Expense, Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ConvertibleDebtInterestExpenseTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024613809848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 24, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,763,060<span></span>
</td>
<td class="nump">89,682,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,763,060<span></span>
</td>
<td class="nump">89,682,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollars per share)</a></td>
<td class="nump">$ 26.00<span></span>
</td>
<td class="nump">$ 23.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">10,657,692<span></span>
</td>
<td class="nump">11,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="nump">$ 261,100,000<span></span>
</td>
<td class="nump">$ 245,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">1,042,307<span></span>
</td>
<td class="nump">1,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember', window );">Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,263,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt securities | 1.75% convertible senior note due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes ($450.0 face value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Equity component of convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024616851720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross', window );">Inducement stock option granted to new employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,830<span></span>
</td>
<td class="nump">305,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock, maximum authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognizing unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of inducement share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=insm_A2019IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610464872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of the year (in shares)</a></td>
<td class="nump">10,492,946<span></span>
</td>
<td class="nump">9,381,730<span></span>
</td>
<td class="nump">8,608,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3,990,740<span></span>
</td>
<td class="nump">3,434,270<span></span>
</td>
<td class="nump">1,755,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,678,604)<span></span>
</td>
<td class="num">(1,413,341)<span></span>
</td>
<td class="num">(494,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited and expired (in shares)</a></td>
<td class="num">(541,680)<span></span>
</td>
<td class="num">(909,713)<span></span>
</td>
<td class="num">(488,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the year (in shares)</a></td>
<td class="nump">12,263,402<span></span>
</td>
<td class="nump">10,492,946<span></span>
</td>
<td class="nump">9,381,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">6,028,261<span></span>
</td>
<td class="nump">5,719,818<span></span>
</td>
<td class="nump">5,649,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 16.24<span></span>
</td>
<td class="nump">$ 16.30<span></span>
</td>
<td class="nump">$ 14.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">24.12<span></span>
</td>
<td class="nump">15.02<span></span>
</td>
<td class="nump">27.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">14.04<span></span>
</td>
<td class="nump">11.87<span></span>
</td>
<td class="nump">14.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited and expired (in dollars per share)</a></td>
<td class="nump">23.98<span></span>
</td>
<td class="nump">19.02<span></span>
</td>
<td class="nump">19.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding end of the year (in dollars per share)</a></td>
<td class="nump">18.84<span></span>
</td>
<td class="nump">16.24<span></span>
</td>
<td class="nump">16.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 16.15<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 13.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 177,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 103,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">5 years 2 months 1 day<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted (in dollars per share)</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="nump">$ 8.76<span></span>
</td>
<td class="nump">$ 16.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember', window );">Common stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value and assumptions used in determining fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-condition options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of the year (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of the year (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WeightedAverageRemainingContractualLifeInYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WeightedAverageRemainingContractualLifeInYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024613095240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit', window );">Number of common shares each award holder is entitled to receive (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to unvested awards</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period for recognized and unrecognized compensation expense</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock and restricted stock units&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">500,822<span></span>
</td>
<td class="nump">227,826<span></span>
</td>
<td class="nump">46,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">559,054<span></span>
</td>
<td class="nump">407,655<span></span>
</td>
<td class="nump">253,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(161,774)<span></span>
</td>
<td class="num">(92,145)<span></span>
</td>
<td class="num">(51,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(53,711)<span></span>
</td>
<td class="num">(42,514)<span></span>
</td>
<td class="num">(20,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">844,391<span></span>
</td>
<td class="nump">500,822<span></span>
</td>
<td class="nump">227,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="nump">$ 28.32<span></span>
</td>
<td class="nump">$ 29.14<span></span>
</td>
<td class="nump">$ 17.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">23.85<span></span>
</td>
<td class="nump">27.89<span></span>
</td>
<td class="nump">29.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="nump">28.90<span></span>
</td>
<td class="nump">28.05<span></span>
</td>
<td class="nump">18.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">25.43<span></span>
</td>
<td class="nump">29.11<span></span>
</td>
<td class="nump">29.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding Weighted Average Grant Price (in dollars per share)</a></td>
<td class="nump">$ 25.43<span></span>
</td>
<td class="nump">$ 28.32<span></span>
</td>
<td class="nump">$ 29.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">$ 36.2<span></span>
</td>
<td class="nump">$ 27.0<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember', window );">Stock options and RSUs | Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">24.4<span></span>
</td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">16.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">ESPP compensation expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_RestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=insm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607273464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 1,402,000<span></span>
</td>
<td class="nump">$ 777,000<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Net deferred tax assets (prior to applying the valuation allowance)</a></td>
<td class="nump">$ 509,761,000<span></span>
</td>
<td class="nump">$ 413,477,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">96,300,000<span></span>
</td>
<td class="nump">80,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_OperatingLossCarryforwardsDisallowedInterestExpense', window );">Disallowed interest expense</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Tax benefit</a></td>
<td class="nump">5,633,000<span></span>
</td>
<td class="nump">4,836,000<span></span>
</td>
<td class="nump">$ 4,087,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_OperatingLossCarryforwardsTotal', window );">Net operating loss carryforwards for income tax purposes</a></td>
<td class="nump">1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember', window );">New Jersey Division of Taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards available to offset future taxable income</a></td>
<td class="nump">$ 456,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=insm_IrelandTaxMember', window );">Ireland Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>NOL carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent', window );">Effective tax rate, trading income of Irish company</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent', window );">Effective tax rate, non-trading income of Irish company</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_OperatingLossCarryforwardsNonTradingLoss', window );">Operating loss carryforwards, non-trading loss</a></td>
<td class="nump">$ 202,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Non-trading Income, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Trading Income, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_OperatingLossCarryforwardsDisallowedInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Disallowed Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_OperatingLossCarryforwardsDisallowedInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_OperatingLossCarryforwardsNonTradingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Non-Trading Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_OperatingLossCarryforwardsNonTradingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_OperatingLossCarryforwardsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, for income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_OperatingLossCarryforwardsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=insm_IrelandTaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=insm_IrelandTaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024538209720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Loss Before Income Taxes in the US and Globally (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">US</a></td>
<td class="num">$ (207,120)<span></span>
</td>
<td class="num">$ (201,161)<span></span>
</td>
<td class="num">$ (286,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(85,568)<span></span>
</td>
<td class="num">(52,399)<span></span>
</td>
<td class="num">(37,865)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (292,688)<span></span>
</td>
<td class="num">$ (253,560)<span></span>
</td>
<td class="num">$ (324,076)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024622565448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax (Benefit) Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">268<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax provision (benefit)</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax provision (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024607765992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">R&amp;D and other tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income taxes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.00%)<span></span>
</td>
<td class="num">(32.00%)<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent', window );">Change in Irish trading status</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Foreign Trading Status, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024613876392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 377,093<span></span>
</td>
<td class="nump">$ 304,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business credits</a></td>
<td class="nump">123,305<span></span>
</td>
<td class="nump">114,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLicensePayment', window );">Product license</a></td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">6,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">3,767<span></span>
</td>
<td class="nump">3,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">12,421<span></span>
</td>
<td class="nump">16,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">21,664<span></span>
</td>
<td class="nump">20,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">8,550<span></span>
</td>
<td class="nump">6,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">552,452<span></span>
</td>
<td class="nump">471,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(9,163)<span></span>
</td>
<td class="num">(14,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(11,054)<span></span>
</td>
<td class="num">(15,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxLiabilitiesConvertibleDebt', window );">Convertible debt</a></td>
<td class="num">(22,474)<span></span>
</td>
<td class="num">(28,524)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(42,691)<span></span>
</td>
<td class="num">(58,325)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances', window );">Net deferred tax assets</a></td>
<td class="nump">509,761<span></span>
</td>
<td class="nump">413,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(509,761)<span></span>
</td>
<td class="num">(413,477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxAssetsLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxAssetsLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_DeferredTaxLiabilitiesConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_DeferredTaxLiabilitiesConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024538158648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net deferred tax assets as of January 1</a></td>
<td class="nump">$ 4,836<span></span>
</td>
<td class="nump">$ 4,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions related to prior period tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions related to prior period tax positions</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions related to current period tax positions</a></td>
<td class="nump">829<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Net deferred tax assets as of December 31</a></td>
<td class="nump">$ 5,633<span></span>
</td>
<td class="nump">$ 4,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024533032120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Other Agreements (Details)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">204 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th">
<div>Feb. 28, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2008 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2009 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2004 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember', window );">PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfContractManufacturingAgreement', window );">Initial term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalTermOfContractManufacturingAgreement', window );">Additional term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember', window );">PARI Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement', window );">Written notice period required for termination of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember', window );">CFFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Compensation earned under research funding agreements with CFFT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalty payable on approval of ARIKAYCE as commercialized drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense paid for ARIKAYCE approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments', window );">Period for meeting sales milestones for additional royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount', window );">Royalty payable on meeting certain sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember', window );">Resilience Biotechnologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfContractManufacturingAgreement', window );">Initial term of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement', window );">Period of each automatic renewal of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement', window );">Written notice period required for termination of contract manufacturing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementMinimumObligation', window );">Minimum obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember', window );">Fill/Finish Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementMinimumObligation', window );">Minimum obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement', window );">Periods upon written extension agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement', window );">Period prior to expiration for extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca | Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementPhase3StudyPayment', window );">Phase 3 study payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember', window );">License Agreement with AstraZeneca | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_PaymentsUponAchievementOfClinicalMilestonesAmount', window );">Aggregate payment upon the achievement of certain clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication', window );">Additional contingent payments upon second indication to develop INS1007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=insm_PPDDevelopmentLPAgreementMember', window );">PPD Development, L.P. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_InitialTermOfClinicalDevelopmentServicesAgreement', window );">Initial term of clinical development services agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement', window );">Written notice termination term of clinical development services agreement</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service | License Agreement with AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Annual net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember', window );">Milestone, New Drug Application | PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementMilestonePayment', window );">PARI milestone upon FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember', window );">Milestone, FDA Approval | PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementMilestonePayment', window );">PARI milestone upon FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_MilestonePaymentAxis=insm_MilestoneEMAApprovalMember', window );">Milestone, EMA Approval | PARI Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_insm_CollaborativeArrangementMilestonePayment', window );">PARI milestone upon FDA approval | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalRoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of royalty payments if entity meets certain milestones under a research and development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalRoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_AdditionalTermOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional extension period of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_AdditionalTermOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional series of contingent milestone payments if selects to develop for second indication.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementPhase3StudyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Phase 3 Study Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementPhase3StudyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CollaborativeArrangementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment paid during the period under collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CollaborativeArrangementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial Services Agreement, Extension Period, Period Upon Written Extension Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_CommercialServicesAgreementMinimumObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum obligation due under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_CommercialServicesAgreementMinimumObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InitialTermOfClinicalDevelopmentServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Term of Clinical Development Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InitialTermOfClinicalDevelopmentServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_InitialTermOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial period of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_InitialTermOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PaymentsUponAchievementOfClinicalMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate payment upon the achievement of certain clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PaymentsUponAchievementOfClinicalMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for meeting sales milestones for additional royalty payments after the drug is commercialized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period of each automatic renewal of contract manufacturing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the written notice period required for termination of contract manufacturing agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written Notice Termination Term Of Clinical Development Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>insm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_PRIPharmaGmbhCommercializationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_CommercialFilVFinishServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_LicenseAgreementWithAstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=insm_PPDDevelopmentLPAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=insm_PPDDevelopmentLPAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MilestonePaymentAxis=insm_MilestoneNewDrugApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MilestonePaymentAxis=insm_MilestoneFDAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_insm_MilestonePaymentAxis=insm_MilestoneEMAApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">insm_MilestonePaymentAxis=insm_MilestoneEMAApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024609341960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum rental payments under Bridgewater</a></td>
<td class="nump">$ 37,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense charged to operations</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense charged to operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Future minimum commitments due for firm purchase</a></td>
<td class="nump">83,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember', window );">Bridgewater, NJ Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future minimum rental payments under Bridgewater</a></td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=insm_BridgewaterNewJerseyFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140024610061096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MW@:T?68VK^+S,&*6]2^T6A/M[@8T=^"3Z:/A]85TXSZU&GX5$&?[0_7$-9G
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M 7Z?*V5W)^X!^\]"_?\ 4$L#!!0    ( *X[65+E.#HR^ 4  %48   8
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE9EK;]LV%(;_"N$5VPK8,2^ZMDZ
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M&(RQ%JKMGNW$R-HUH*4TV,[<L,0?#B@;@/LK*<WKQ/:T_A>6_0502P,$%
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MM%DW/+$!3>*(# QJHXA/\ "U<J*HVYY1QSR:9/Z52\[J=(O@H$.:/4#]V.G
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M1&E^;CG+>*T!\/^3$.KXH!?H[FP7_P-02P,$%     @ KCM94O&ZVS=<!@
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MX!M57!H@*R)8+._NNDP">=-L57;97 ^,5 Y#I.5[;(KT'188X84AC.P!AOL
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M;?B]H@L)'*\M#V(TPAV:_@#%/U!+ P04    " "N.UE2@L-:]V,*  "1&
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M?'8(LU<?L>0J'LVH#]M %N9X/5P1K7N%7F,D7N:MEJXM ,(J-1>V _!IKMQ
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M9I@H[@B]'QY?U=POC2E2@V=@15+F%3X6G0?+1=PW(@ULU%_ES()-@@"QN9
M MJB2VG! X+?K&"%@3&D^N"\+4JH01&!1J?0DPU#(]+R!\1$8<E<0%PBVX9E
MG2KD@DG(P"Y,(G.J8LJZ3)Y7O9HOR<0%$?;IPU^O_G7]+OOTQWR[^_KM 4!3
M@<%K.-<M'' JL6GQ<Z<:$WX)@+%6B0&%N< ]&%+LPQB(U(N7_N.V]]JB(,IO
M<UNR7@"9PJ,2=H.3"62!)^,<_3E@.S!S.]$:??9",EP]<HQH+1_(#1(5S/-U
MPY:6APCE=Y 8B9@@Z8#<+ZY)C\+SL!76LJ"SS#HG:EF"-B%5VZ+F4GMRBOHF
M\M<*LVQ(-(HM#_;9%Z!8L-26*7%/$;CTV;P Y*!]1T(.9RAA\9(.@3;9R)05
ML#_^'#B->0HX$R43"0+7P4\1AI 6Q/J?QH0C>QXY'^\A"-J!O0N#4A]P 7QM
M5R-\3JO+,P!5R2ODC!,@-T7%(W*OIY4_I!/CEE;P+/'"H3A/MRF2P,7"2J:/
M"&"Q5RD.NQ$.>T"*.1TS(L%ZOJ:B#KD7";&J1VF8Q,##C('FP0%?F'NP"5G>
MO06;>+L 2M$0RPR^6H!/ _Q.7N4U.0K"L_23U9_8ATA-@;8./H:Z(ITC1*'Z
M)TI!1O&#4$4!WL&_BNP(-AD81^R*#*T,:/ 2#AR- DUW<GYM TYLWI OP;;#
MJE0*!792:M)G"YI[(%Z0>M:S[',5-EH,H<*Y6FQ,4@/F'AW0SL+S\@!"(VCQ
MGKQXW;+=\ S;@^^1:/Y!1//WX"T,>V"P\AI,_5\E5A'"'2,QA:#XR/!7:[V-
M*56 ' R=D"$-S 2N!)XP&]&L2[J=*,L2G6W<G,9*#K!$W%6!(<R"B8(_#)AH
MXUC3_=D"WX+31T*6YDYB#P6(ZV5;[ON>;>!E4*@_$PVB\'H"*)X=!UCX,01/
MF3E0$:%+Z5[3J<U?? UF-6+E5$\1;!A:E,SZBA6] 6/BEZY&V$@QD#W+$6U1
M&*+@"D JH2-B^>B0Q:"(74VD[ED/EGD?E@F'JD@@]^$@K4<$+!LY8LJV](@_
M!%&_^@DLF>96/<E8/D80HZG:U-UZ RS5T"&B@RL! M*2 'P^MBEV7F3RHDM#
MG+8"GZ_#L;33EU_C>0'F[(X( #V1/E+.^D@121+%*OU<"Q)Y8C3AFG=L1K!J
M1VF$*U&X@Z)+'>M_Q*F*1U;0"39&3^]:PBV\1:M6F= [.!A?8'8X#393Z$ND
M6Q[>FN6FLK]TQD<+!Q\05I YMW5AP!E_AY'";?XSFDTL</9/X87$RH[9:$B&
M6!<)L^) I-1WB&LO66+SB$!6B/V&7=]$SC8B1P##I:M#$!J('=D)Z1!CT/=V
M"Q"P%<(!]8B*!3VX431U^B.[ZG L>JN""0I-1I+MO4=@(%07L5@45U>S\_,-
MV)D\F9CIVX[BF"NP=\"@8BU_(#;Z4:BZ@CD?/3\6LN3QC!QE3N;)@45!,_6^
M/7W%,^G>9$TTJX 2#6G#!Z*=*?RC U&U;BURC"654!AU893L$^^.Q 1Q90A-
M!N_(D]]C0AG#)+8(?C=&3^BPDP.V;1=3)BD(D@-$+FZ#ENW(27#T;?P<!EE*
M=FR;OJDZ@1UL;5DB,$>OP5$;/L3(#KG6"?BCGJ'J$16=UZ/'\E5V<3:?74;_
MJY@-?PW" 63SGX7C_/+E[#SZ_Q".U$V5B :<09-7;H71[H5I[S!<R<8(J2JU
MF0;$S13=(9C+._JF(F*G_,LO78[A,R().%[B$##_PUHP,8A=#/;"([+?J=\P
M_*1[+EB^>/9#U,U&SU9'I,X0!;)@>8>4%%$>@64I[M-5('Y*DM&4B $(UCDJ
MM=I13'G60U_P\M&*[)S?N:RQ5Q24^]3V KG)B;.*,VC':)8<@QT*-BLF1".?
M:(-B:$GA;71R,8[\A=S0UOD))944[S:D+_*LZ@@_%&0AKSJ*I[_.)F#MT!:\
MV@E>.WCV&$_^.IO,CSS0-%@W> ?@25@.RR,B89.MF[S 1\^.0&;<D=^6/HM;
MH]#X,/85ZU_3@4[.CWJQ'V]35.0I2J*U,6WN];V'9<6!APZ#R!:_B+P4NV4+
MSLKSY$SS44?1P@-G-Q@U*.;KR@3G^G3V\N(/> 0P44ONJS.5A24H%PO4;)!0
M+[();R@,^P%_/\HFL;5 /I[R1%@4(8Z BBVJ7=< [G"B,16&I_;5Q>D+$!(B
M*Z>QH\X>KJ94Q.;3B(Q/R*;9$24\0&&]H",@#[&N)+A >@!7<"&*U]LXX_RK
MLXL7LS.%:R02<?#LZ%;-/1D7S*9?75[.3OS4/AX3W&#T&:.?: OJ7X--4S<&
MN"2[)LPL]T->*_'K3@Q9YTL%;J;9^R:G5-7W@ 02F1_0(< @ZX<V+_?,OS\0
MC^'7P*4W('U_Y4_3N.+@KX"/HMYFD\]_/>(TUU]R6)SQITE?B316=74,AE4!
M&CEO1/>#/4451:"[E[J5"&;4Q22DO<_I)_#^5XX!IS7Z]Q*Y:W(F[4:M?^:P
MF02Q#[1^;Q%5'_%T&+O#J"R%]?GW)(0AK@,F<H$.K1N8+YHAG;H7EZ:U>1Z:
M)%^*O)<9*2T9!:QSTAG!;W0;^ 8M(Y"X?Y*9ILRZB73(09)O.P:1'5*R$<T&
MB\1N#0F^OI8AF4C.,1&?/[$(4%)3X.-RXO%(J:["E&J)Z?^&;?@%<C;&)7V$
M?.MS8/),OMN5H 0H9)Z<+8$%T_262C!QN&'>)!<"3#$U3:[>$GX-WNPU9TT_
MH<\6TAP#W@/IZUV-HMZ2YR#1C[X 6L8K$"=(8I;<0BDE2"L)GF:=9[LR7THX
MZL#\(J\>JP)DM6-0_BRJ!RUE=G#RO:@IFI,2CL<4+HRM=CB:X!OM(PMFFGI(
M..,:M5?%D:DUT<FBAM_2;:"0@MGAE#F8M^[ 5D!-+S442(J(1\%:CC$\!;A-
MK"=GS!?V+3%8BYR0KXPH92Z-  RDBUO*[=42D,(C&0PU@B5)6HAA0&BDH.&@
MSL/! 5#Y1%,7W?(@ %T;1Y%R37]@=A]S\9C6$',PE!>A;J:Z##IB77'8JY'4
M@E-QAS2',A% 63=DP3! OB*H,:$62;RI8,YPDKW$=",6M/C-YCXE@+ER-+#-
M@?^9F,4?$TA^JD&Y9-\3/!\%GD\"#SU(;LBU%HM<9?/+/\"LV1_"=V^R^<L_
M9/-Y_-UU-C^#[U[ =ZFT*JUF%FU3'&.@:!]EZHT8$%B' 2,;COFEF7S_N\^6
MI0<+W)2:'F&R9"XCU0I=N0*%KU,*%?B\8VHT8R1+"S5*ML,!7Y*D$14)((J.
M!>46):XXF\3*PFWL+L1@1P'DA%@UD 5CWU;E]?1W@*:'_(F]/!*V(?Q'%65-
M0<J4X(R*+F]:.(*\ 8%R71?D$M##DZN;ZZ/LQ<F+J9^;. 7D.56;B@14$G&I
M0Q(YF\H.%#W*0Z$2VXU<_];4I;#TE@(HZ[HN"'T8@K)44\=>@X3"21A).-/Y
MU$>(*,:@<&6!$VO?</XF:#L-N!XLZ4,A7/KCO;G W@'3Y' T#4X8BL*$2,"<
MW!%O D(9GS%T<))8"B55 E[D4-&-:\W.L<O&<?+57O<:'T' *7MNR5B9G]T\
M4 #KU%+5J=AQ2],%L<5!\:*OR2W# C.I0QD8HU+ZR>N2MW=Q%"@F)1A$K)-8
M T4VL9+2K<BF'%D$^+3U"Z Q8G:''C/GA,51&#Q[ID0Y2/+S_9Q<ARFXPBFP
MO-('ML:V+I4(O*RZUURZ&M-]! <J3_!'@$V7;:KF6L1-Q&1YX+,T8S1R2 @K
MQM7D++URC6I'AK?1/Y6143"W'E1!GA0N%1$N ;#"[\"0J)_ )VC#"&%;LF7'
MEGZ=& F^9@53NX<Z/IX=C09 -(5>J*PBW]E6(A1DR%1+5B1D8P]E3%FBD1F3
M<FBTZL?42'!D)0\;J?@#[L,E&_$NYN%<OHA0"I?0+AX6-J1T R/!,02!D^$>
M 9&X[068EP<!:V^K>%!\3!^)!Q06L.D.7*1MOM30?O@!Z;FQBPZC"T%M2<65
M5C_2UDU92G$^;&-R0,1'FCJ5Q>/R=D 8UJR3W99J!I34_!C:9LVM8"TVCW'(
M)#\*FHJ-4JSKYM(,M-9K!,I7U/9+;=,M1[A8&3SRR>(H"C9%-GQC%@A_6.GO
M!HLG+">Y^0- ^Q'LK.PMC+;;!3I[6RZ;I0)Y/RUG^=#%(:J0B2?+>.F#.N!)
MD?Q<2XWWL@;;;J\)<,NU1NHB)HCTKF800\Z7A#=2W;<L<[L-P]3 9V+7HE<8
M!$L1MY-T0U)7!R\?J(J>#)4ZLY,7=@E$0_=';'258#*XNZ.I2+G<A\9".&XB
M^#R:9?^D:#?XT4T-9$D%PIR("=38XFT0DG,I+>8960QD^8#!3N&MNFO1>791
M60#,O)"%C^_HUI80J2^GUF"=4DWJ:CQ>0TVR"AU+HEL,;E,];FP\3S4[3474
M2!O*'8MNKW:\8G&7MZ <,3WTXRUE_10GGE0T%9U"FF2A0VV45V8](Z]6 4"Z
MC.R#TB=<A;8X!JDSA6B'[CJ^P?* V(BC/\,J%7W[!3^&Q=F5%*98=_!LD.M2
M,U=QPH C8AS9)OU,V^+3+]6^2/+%*/@;1Y&& ;4OL2<4[#V;]5?26"#U4>=1
MNH',:W4O?"Q/B"+<Q4F1 IX'G13Y6619<X@CO7H2'W!\!06Y.+FWHHDG!N(6
M,R,TA7^H9\%1@,[UN4VU M<I2)E_106*J7M.TA($$P4[TFHFXB.B!"JI7!BZ
MV/*EJN_ N+SNJ877H_H1F;=&5 !>] H5Z]\^*N,K#Z@B^%93M<'UBV"5$H]Y
M*<?U%"KIF)#U:R9[G(4I#4,?@_HHT5OIC,SQ"DT (I;RL?#@F'"^;DQ<D119
ME$,0I'98*&EQR@,Q0HEF\<SDT = U> Y"!B059CGH%B"4%99ICPR/ <3+D52
M!B,[/BQ.R20BEA$3# T<4A0)D?3-PWX0S]=#Q!J\;M8YS)G+;1>Z@$'W5@"S
MG$X($1@X2LK[N9JQZ(U'0B!(*0/6LM5:)KV'E"WV-"^5^\#>,>6$&$O,#$*.
MV">'2Z:G&6G C3=!4*P1&.)>L^3K3R0NEC\[%V?G5"#]MG-B&$:.:<"2\?:H
M^O'YU@N(I#*Y26U8GG(J8HV2MUS2( 9,%+M,9%&[B<Q0+9 =,#X8QX<V24_3
M@(G4="8R<^HGU(@^?GJJF9YPA%'ER<3VT[D]%N C'J+AB95G(R[98L0*X8^8
M-ZAV@":,/<98.16\U.LFW_*$,..#ME=PY<=,KS9)%Q.LV=;>BQ%M;X^2*V[L
M&.*CARIQ6"A>!Y/U=?Q!ZD1UUP0H*W#RRY>FH;"\8C>RTYRW^$!=[SJ@LF6V
M,;#P)D0;^OF*E2DH<!ZAGJPL%% B-2A7:W/:U'L9?L.QUYLE>%,=5JE[">/+
M*1]$1.0BSGR\,=Y*5$WFI^;\'[,5&4I1V3W;6<ID@PM1@!$,CTHO1R+]+K_T
M[J!P%I',&[H?K>4SO+@5=WMP@0Q+W3F8NU.'CF?K@4F_+M)(7[SY,2Z-O)Q0
MQ:6QE4&(GBQCAZ6KN 0X8, ?FR;"=U3P7@_Y7J_!PVTM!U(W-=^L!,Z$W6M>
MK:/L.FM)S TKX;-B8X&8Q/[Y1@R'?T>\V3=II5SB.8CXD.J3P-F-6>=-P6$*
M%C !]V0UV:W%3/P!EYN.RYXUV9':MJGLU>P[PPURIM4PFYZ2$E.:EMHI$E5H
M1Z%P7]/;^FR&[I'JM/ ^ M_?8X7$^B0OG=S]?&H\X#=H40X"_/O:M&=2BIN
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MBCOO#W74FJ+MK1RP49B=X2Z1<3W6$HT9V$U2D@!_HR6"G;-X(<UR^$"5<()
M+6JSUY8FZ$"<]\Y@3L]1E%$D).;P9MK#4%I\2#+D(&\913HI@V"BGAQR03O%
MC>\Y%DY_'\PUWU E!1EH%"1X7<ZR'^JJ,9B2X!YUQ2UAR\L&Y*3#8D2^N"BI
M.])[5/R!!R,ZT >A1L1\3*?43VYE&FV=$=6YS;(;.B[%"/L_4:$AW_FH@B+0
MY% IE4P(.J] HEF*?O#LX_2Q4 K&]6K)7+2#99ALX-)E0M/T>X2%^MR;2#]>
M1_IQN%N3][G'U*K?'I7UWE%M--[UE)M'\165.@./MJSW&AMBPS-DOX25R7$^
MINM'_:N%6#K*:[!D>F"H#.RU)\O=,/"@A('(]J$O#<7#'?"E3_BP>>6]>Y]4
M,;]0! X?PFLII F3/B\$1^H,8<B1[ +:0"P,!,.$;; .1!;&F&.''SFXK8_Q
M_T=0\=CD3T.01XS=8N[0MCV\1*U_,/A22D.ZO.4$"DZEK7^0B8?*==I>A:SO
M5^G9.5]N+#!JCX@'X>TE>!=@=WES VGOYGOZ<!7;'H<IW[@#SFKP/IITA/T)
M>]0.<9!/]G"'LM#0-N@*:082WP+<"[*P&Y)('WAHK$M KY)53221<_@@;HHB
M'B0GY$PT_QM2="[)T0TT NKW$F16OY= VAAXOA]!5-Z"4'&O93+IO1G,77YQ
ME4Q"XN[I2/!=$I@83<5*"Y_B>IM8*.9D J$.RN\E.D6G(W3 D?0HZT)EZSZ
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M6G2S#<Y%@Q/MP0DCN)6E66JX+G/,=P&Z1*IE%FV9740'$:\PZT <^A %47
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MF4:3>3H"W:_CGK&J]2MPIRPM5$]6] =#[13HOE3*GAGG8/@GKO\!4$L#!!0
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M_ F,L.D]&XT$),1SG:BJ6*B,_++1!"D17W4*A6?/XL>!5 LBY4@9SD-1,##
M2&[AI'/8A2K5DACF,*2?:J?:7<]=%G$0T0Y+B924DVF+W"W6P&A&,C#]2%)6
M-9#&A0AJ"&P(6FK'>K"F7JUA _X=VM8F8R^AH"4ZM.SJJLJULEL;,X[L79^N
M&4MH;0N#T("W=1H,V(C4\A#T=0"9@=XKLWQ%2@CNPFP +^&!L'RVW9MKN>C
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MLV'(7Z-D3JL) '&&#'X9C4:\,,+"Y33&0CR/:6&,4Y/))2W$O##!PN5PTBQ
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M /#(+0J]_/M\2A"L1Z6W%5#+1(FJP$0P/-JI7<21./_@R5G3M&LN(F"56C'
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M+I">%44R/LI>YN46G"=4W(U&WDKAD7.TZ+3$WDGQTTX'PJ"7FXY;CY&CP>/
MT6&KP <5T1Q+86FE]Z!9V\V5%&A5@5WYR[(DFTP>9'<+[8W;"2!A4@O5!0VR
MI-BU7.6N[2P%Z)DWNQI*S:I.J;6'GEJHU2@BV:"]J+%=]@GG:NVALJ;99H>E
MX*G<'L35HH*Q]/+Q,)^P%J4*"$/VRTYH&L^NUAH!4&Z!.ZY@33(Z1C\5Z8T=
MJA,A53L!T$(IG3"=]K$,2#.4HR\+@_OMAB#<X='HHM@'V7@XP0:M5*CM)5A
MWL5D>+1>?#+[V=%KLI\FT\EA,CW*_T7VTR)/QNGA?Y?]?\KU=)BF_\\,([-'
M&9YFPVR386+=&W/ES$IJ5'2;<+';B1^^#QCP1<VE#8PN:@D5N[P#T='\PGZN
M*I3*)M%J64M1[U2.Q7XJJ5EJTTL62N]'KK'B[JG89J\HMH-BDFYT8'RQL+#@
M>(YB"K60+2::-R0P;;XP^A:LEW.,FPY;MUU[SZPK5./INGKD).:A(@7[XXM
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M"BQMP.>50?E7-^2@_S [_1M02P,$%     @ KCM94N>,#=!W"P  6!\  !D
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MYL01]B8<G"!TX;9O,P> AKD^F,&I< %D)&X2B;G+F>+/YTZ4/!<LL)@Y7I"
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MQT=V*AD>VF;-WTYOF[9M*OZYDAF<2!NPOFB:=G@@ >/']#?_!5!+ P04
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MYV#P6ES:=@E4=@'4:>S:N5-_MN1:EH/+5^]FP16(S@0S>W7/<TTRL?J^CB0
M>>'LV?F/IY,36E!@Z;B_]C1>X[W#Y9/^\ACUV-6**VJQF2 7B=^RQLSAX^G)
MZ?.M_/*%XL;A".%0 @'$(M#G[>8H-VM_FM9L9 '  RPK20%54)1X>["63<)C
M'0@JT!4G8==$S(!'4@=E>.P7(OI@I6X*Q0];E2GH&?;8]%X(D53J_(@"HE B
MUTM-[O$W@)@6_EL69H[_NBV'[J];ZUJ)DPHHWQE?.- _X"U:$R.'W*<7FKW"
MVZ"XZ[(M>U=,Q"VBC;'"P8_4QSS$TZ%"-MZ\KP;GY'X-N0#8=":N-7(H<J>X
M-@"\%P!P6EFK%O>13=Y6*,-]*4$1.>?0P(_O'Z@F.!8E+1+" G('/@EY_=L4
M.+RXOOXX0H[!#O.-0)8,9YN+)Z>3YX.@?3*=3+L+NKJO2LRC.5)^8>J82>/)
M#@(KXI?*P@X0\H::*&9F;,Z 9^LXB#J+QY1:)7Z"&0U]9M:(JATPA0?)8MKJ
MR>G9Y#RUQ\N&\"4"84Q+?.I]DB"ZSZ(>2"MKVN5*@%.IDK :>96(>5M:WEW.
M"]6MQH*G$W'M,WB)@C@6>M&%<0"'!T9G@F-)I?+11P6  +C! ;CHROLANS>K
MK4U;Y.0DI&/R"=)(DMZ>G$V^CP;[FI)6=U0<*F:5R@,Z/X-XK(S):;L2K)E"
M@:OG7DMPMBL)]7&ZM@V%"+(<V5#1\QPY\T(O PU @-3&>O6*#3<-.>64G1ED
M(CXHIPMP'43-&VT:E:TJ4Y@E)4,?]5 O4\[1MB; @LHW%M>>C=&R40+/:S6W
M+5HL2L;G#Y(]LL""#B2\8 ?SV[=G#)LU!38H4@G!P.6C!O4+1AT,4V(RB 3"
MLZA,=01^4K2. FE.1 ]P EFA#"0^XP@S.'8B;K:R\9X:3V>::(DFJI!S8V-*
MA5=<8]N,Y.,P\S9TD&!<C^E+T.PE?T>L2CL.LJ&'\0MK4(VP_D)6,I<^=GO/
M4_1*@CH"'7%)84P;]4B*WI\C!7!*2$HP*#[9R'74J@ID0[9H)1&@&<<D61'"
MBN2!\&F3>VRN30"JDMEJ# :(@'7"HX@=A!-6FBM)+2TLP-^4$C5G52[FX"Z:
M@JR7A=8#.ZXML4H P4 /U?'B7M9$O#<-A9P#;>KD$0M?&OSE#Y%64BPQ* -[
M)V-3"/:\M7>HUR&MF#BAF/;I6NKJE#+N"2*4J["ECQHD3L1++..4LY]UB9C\
MW6>\/EKFLLF02D*4,1E(R.40D\2V-%M.)R,HX%$K+7MX\E#C]W-;?%4J^ H.
M(0Z#A*VE':?8#6BRRK5@NMSO[>'\_A0CLY$AYY&]O.FENM.4, "+OI.*3<&
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ME7^QK"1P*QQ'%T2:.7[(&UV8-BMK:WN2 $AOI97M&I93 ,'P0QGH=10:Q"1
MQ?I.$6NQZ4TF[ SL:@ 06>).$WBLRU$$+8$SZ@95,(T/.AI6!O!W38/3 O7
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MZ!D,//E$ J5\B%AVF&!HX)"B2(BD;Q[V8XR^:B'6X'6S4#"FDG,35$5/)R
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M##\X=/T+I;ZQ:NU^6RR5Q5.:FV8@4M D@.]7"BNHN2$#[7^LR[\!4$L#!!0
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M8T-_$]1.@;[72MGSQ3D8_T^;_P!02P,$%     @ KCM94C?X6^C4 @  %P8
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M$-6$Z*.$N";$KC)5*JX."=5TV%=R391%&S6[<,5T;),^$[;M4ZW,6V9X>I@
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MT>1T;-^?ZAI(-S&R\45[+8UM 7Y8VZ:+RAVP^Z649C]Q"D(;G_T&4$L#!!0
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MJ1F6:.L"#8V@002^LDS& OR4121J!S!5GE6RZ);L&DU&W)+P =CP#B +60-
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MPG,#]?S(F+P-\A=4_W]8_@-02P,$%     @ KCM94FZ_T+(.!   #0\  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULM5=MC^(V$/XK5KJJ;J4[\D*
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M&E75RU43(Y>NNYE)@[V2&^;8_X*R!K@_EUBB>F(/:#KJ_C]02P,$%     @
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M0(8+4C!S(]<_L$JHY_A2R;3_A'5YMM<)("VTD;P"6P6<BO*;/%5&; 'B_AY
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;*58VV[C-A#]%<+8 KM
M$HF4+-F!8R"Q&[1 %PV2O3P4?:"EL2VL)+HD;2?]^@XE1;)UB[)]L25J+N?,
MD#,D9T<A?Z@M@";/29RJF]%6Z]VU9:E@"PE75V('*7Y9"YEPC:]R8ZF=!!YF
M2DEL,=OVK(1'Z6@^R\8>Y'PF]CJ.4GB01.V3A,N7.XC%\69$1Z\#C]%FJ\V
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M3J=Q?Q2\! +D#USJY#[E2/$\$1+E0G,4K;DA:^#@#_9L;_:. 1FN-7F\IW"
M8BRMK"ZWD4RWU<^\TC2I![8/#@5T[+<'#A-K!G&:<?$'RU9_WJ%W@N7H8BDY
M+_)ED^@8O>$R7*?/F;D[D6T ^*@.@&T+P.X><%"-7N(6J <NX&&+:^SF==.
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MBZSX&G,&QU8S 'Y?"$CSZL),L'TG//L?4$L#!!0    ( *X[65)T')\A&P,
M "D*   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+56:T_;,!3]*U<1
MDT "\DY;U%8:K:8QL:F"L7V8]L%-;EN+Q.YLA\*T'S_;#:&E:8:8Z(?&CWN.
MSSU^]E=<W,H%HH+[(F=RX"R46IZYKDP76!!YRI?(=,^,BX(H715S5RX%DLR"
MBMP-/"]Q"T*9,^S;MHD8]GFI<LIP(D"614'$PSGF?#5P?.>QX8K.%\HTN,/^
MDLSQ&M7-<B)TS:U9,EH@DY0S$#@;.._]L[$?&H"-^$9Q)3?*8%*9<GYK*A?9
MP/&,(LPQ58:"Z,\=CC#/#9/6\:LB=>HQ#7"S_,C^P2:ODYD2B2.>?Z>96@R<
MK@,9SDB9JRN^^HA50K'A2WDN[3^LUK%)QX&TE(H7%5@K*"A;?\E]9<0&P(_V
M ((*$+P4$%: \*6 J )$UIEU*M:',5%DV!=\!<)$:S93L&9:M$Z?,C/OUTKH
M7JIQ:CC&J8(3&/%BR1DR)8'/P#8>CE$1FLLCW7US/8;#@R,X ,K@ZX*7DK!,
M]EVE%1@>-ZU&.U^/%NP=+3V%T#^&P N\!OCHQ7"_UP ?M\,_$5;#N]MP5]M6
M>Q?4W@66+VSS[H)))4J]$Q3\N-0!<*&PD#];Z,.:/K3TT1YZ_[03OX.4LSL4
MBDYS!(F,<@&,*Y20E6ALC)MF84W<L<1FY]\-H]C3O[Y[M^GV/\.V=$>U[JA5
MM[6%2ED2EJ+6+Y4\AI*1@NLT?F/6)'C-F&PH.8F3*'FFMR&JXT5AL]RXEANW
MRZ4RY:6>/GT*95IZD[QX=^!NUPN?ZVL(\[V.YW>:%2:UPJ15X25G\Q.%HK#Z
MCH%AH\AD9_0P3D*STK=$)CN3'H9Q+]HSZ9U:8Z=5XVACF7ZQZW-"'HBNM6R$
M;LW=?8M]UJOI>_^] 'H[IID%L&^G^-[3Z>N]SC;X ZW[?\_VWY:Q<0GX;^&P
M_W12^D%KGA=,KU^4"@31V@^)! )+%*D>[*CQ&FFGL]:T"7LZ8_WV0_85A]78
MWSTW3_PHV%D-[L:U;!Y1GXF84R8AQYD&>CH'!\3Z7;*N*+ZT-_64*WWOV^)"
MO^50F #=/^-ZYJN*N?SKU^'P+U!+ P04    " "N.UE2[FTJC3L"  #N!0
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MV@78_:U2>)RX)M&V^.0-4$L#!!0    ( *X[65(.W4.P00,  (\*   9
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;(U6RV[;,!#\%4+H(0':Z&$] ]M
M8K5H#P6")FD/10^TM+:)2*1+4G':KR])R8HCTZXNMDC-#'>X2VJG.\:?Q 9
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M?Q9WO[(FH,CX2T2FZK_HKK'U/9142HN\ 0.#G!?;__1[DX@. /P, T@#(/N
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M+FG;]#!Y$NFNSAQC3HXS=YGL,K<-%;L[ZG5UF_&DZ=8/$N/HU-@V.AP^PR2
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M!WVGO63F1GNA$^ >:)JV(3ZA2H\$APU.RSAWDF:2@TX4ML&9[1V4@V-PNH&
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MJVOMZD7RK;[H?>)2\EP_;AA-6*D \'W%N3R^J F:_UR8_PM02P,$%     @
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M*-^,'=_9+CR19:7,@IN-5G@)4U"SU:/0,[>+4I(:F"2<(0&+L7/C7^>)P5O
M3P(;N3-&QLF<\Q<SN2O'CF<$ 85"F0A8?U[A%B@U@;2,OVU,ITMIB+OC;?1O
MUKOV,L<2;CG]14I5C9W4024L\)JJ)[[Y :V?V,0K.)7V%VU:K.>@8BT5KUNR
M5E 3UGSQ6UN''8*?'"$$+2$X)$1'"&%+"#]+B%I"9"O36+%UR+'"V4CP#1(&
MK:.9@2VF96O[A)ECGRJA=XGFJ>R.%;P&](S?0*)+=,^E1!/0?R= >UN$(54!
MFDT19B7Z3OD<4_J.SG-0F%!YH;FS:8[.SR[0F0$_5WPM-52.7*5EFF1NT4J:
M-)*"(Y+\ #UPIBJ)OK(2ROT KO;7F0RV)B?!R8@Y%%<H]+^@P N\'D&WGZ;[
MPQYZ_GEZ>L)-V!U9:..%_STRE!-94"[7^K1^W\RE$OH:_3F1(NI21#9%="3%
M;-IW; UG8#FFG;QFEX$W\$U)7W>KV8OS_<3?Q^5]N#0)_ _<GOBX$Q^?%*_[
M@;[MK,]!0TQV,Z9QG*0'!GI@<1 .AP?Z>V#A($WB?OE))S\Y*=]>P7ES!4ES
MU,I<P3X_24\%AT&2'AKJP\5AG!R<7-Z#"X/(&R0'EMR=AE.#6-K&+5'!UTPU
MU[);[=Z&&]L2#]8G^LUH6OQ'F.;!><!B29A$%!8ZI'<UT-4631-O)HJO;%N;
M<Z6;I!U6^MT#80!Z?\&YVDY,@NXES?X!4$L#!!0    ( *X[65*V%$^1&P,
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MDATV, 60]Q>4BOU /:#NV4?_ 5!+ P04    " "N.UE28D0XE%D#   R#0
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MLLY;T4]W,4KZ3OGR;&0Z@$RNA[P11X>Z(7JE/^X5TR4QN2=G8D.T31V=^V*
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M09+@>;#PGZ[CXY#AD,9Q)_L!..R PTG@/W@%M 7:GC0\L;@0%&&<H(VG^(J
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MU1O%.FI'>=\?Q1#C#P>)R[49Y8XENY7";B/*7BG8%;/8!:S3 KN<W5YI,C$
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M8YR@DJI9[0QA(W_',2G9M(ZZ-P?AHAKYF]F>/ZX*-M^-T3]02P,$%     @
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M6V_B.!2 _XK%RW:EZ0*YT(M*I5ZFNY78#BJS\SHRP8#5Q&9MIY?Y]7N2E/9
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M4$L! A0#%     @ KCM94@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "N.UE2RKV!F^\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" "N.UE2F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( *X[65+^?(?E8@8  "(:   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" "N.UE2Y3@Z,O@%  !5&   &               @(&F#@  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ KCM94O"\4)]] @  S@8  !@
M             ("!U!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( *X[65)2C**^M04  +\5   8              " @8<7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "N.UE2\;K;-UP&  #$
M'P  &               @(%R'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ KCM94@!LVZ=P"   BB0  !@              ("!!"0
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( *X[65)^GI67
M]0$   T$   8              " @:HL  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " "N.UE2@L-:]V,*  "1&   &
M@('5+@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ KCM9
M4LY@L>YP*   1X$  !@              ("!;CD  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( *X[65+1[(G?=0(  ",%   9
M      " @11B  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ KCM94A!<RU-T!   50H  !D              ("!P&0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " "N.UE2D7*UZX$#   ?!P
M&0              @(%K:0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( *X[65*L W4\S@(  !\&   9              " @2-M  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ KCM94IQ+6Q(R
M"0  0"L  !D              ("!*'   'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " "N.UE2_@E>/V4.  !-*0  &0
M@(&1>0  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *X[
M65)YQGB%U 0  *0-   9              " @2V(  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ KCM94N>,#=!W"P  6!\  !D
M         ("!.(T  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " "N.UE2QZP*KD .  "V)@  &0              @('FF   >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( *X[65)!G" I#0\   LL
M   9              " @5VG  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ KCM94@(=MW97!0  ' P  !D              ("!H;8
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "N.UE2#WZL
M1\<"   <!@  &0              @($OO   >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( *X[65+74W%"*"@   :%   9
M  " @2V_  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
MKCM94H(;9"; !@  TQ(  !D              ("!C.<  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " "N.UE2*E.<MXL"   W!0  &0
M            @(&#[@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( *X[65*)EB=("@,  *H&   9              " @47Q  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ KCM94B3-],-> P
MJP8  !D              ("!AO0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " "N.UE2-_A;Z-0"   7!@  &0              @($;
M^   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *X[65*O
M,T0]\ 0  !X/   9              " @2;[  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ KCM94ET \%5>!   Q0H  !D
M     ("!30 ! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *X[65)3DO%&F00  #05   9              "
M@4L7 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ KCM9
M4A>4#,ZC @  W@@  !D              ("!&QP! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " "N.UE2(/L62BH$  "+$   &0
M        @('U'@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( *X[65)NO]"R#@0   T/   9              " @58C 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ KCM94F5Y:P<E P  70L
M !D              ("!FR<! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " "N.UE26OB%TBH"  #_!   &0              @('W*@$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( *X[65(T[+";
M= (  $T&   9              " @5@M 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ KCM94BEG(GS)!   [!8  !D
M ("! S ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " "N
M.UE2W!6M [D$  !Z%@  &0              @($#-0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( *X[65+"Z-$G#0,  +T)   9
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M970T-RYX;6Q02P$"% ,4    " "N.UE2=!R?(1L#   I"@  &0
M    @(%\3P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M *X[65+N;2J-.P(  .X%   9              " @<Y2 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ KCM94@[=0[!! P  CPH  !D
M             ("!0%4! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " "N.UE2TFF]6VX%  !.%P  &0              @(&X6 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( *X[65*!@39WJP,
M -0+   9              " @5U> 0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ KCM94EC65!:$!@  1A\  !D              ("!
M/V(! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " "N.UE2
M:1ON(<T%  !H&   &0              @('Z: $ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( *X[65)17H'78P0  &$0   9
M      " @?YN 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ KCM94L75@!*S @  50<  !D              ("!F',! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " "N.UE2MA1/D1L#  "_"P
M&0              @(&"=@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( *X[65)B1#B460,  #(-   9              " @=1Y 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ KCM94AS+^UGJ
M P  Y T  !D              ("!9'T! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " "N.UE2YB!.^ H#  !S"   &0
M@(&%@0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( *X[
M65(@-^<E4P<  -4C   9              " @<:$ 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ KCM94N91Q^'@ @  C0@  !D
M         ("!4(P! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
M    " "N.UE2BME[:84"  #^!@  &0              @(%GCP$ >&PO=V]R
M:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( *X[65++*^%G>P(  $0.
M   -              "  2.2 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< :!,  #*? 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>196</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1106101 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101102 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103103 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2113104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Fixed Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsnet</Role>
      <ShortName>Fixed Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2138111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2151113 - Disclosure - License and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LicenseandOtherAgreements</Role>
      <ShortName>License and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2153114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2155115 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangibleAssetsNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Fixed Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsnetTables</Role>
      <ShortName>Fixed Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsnet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2326306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/Debt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2339308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2344309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails</Role>
      <ShortName>Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fixed Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Inventory - Schedule of Inventory, Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails</Role>
      <ShortName>Inventory - Schedule of Inventory, Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Fixed Assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/FixedAssetsnetDetails</Role>
      <ShortName>Fixed Assets, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/FixedAssetsnetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/AccruedExpensesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Leases - Lease, Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesLeaseCostDetails</Role>
      <ShortName>Leases - Lease, Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/DebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Debt - Components of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtComponentsofDebtDetails</Role>
      <ShortName>Debt - Components of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Debt - Future Principal Repayments of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails</Role>
      <ShortName>Debt - Future Principal Repayments of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/ShareholdersEquity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails</Role>
      <ShortName>Income Taxes - Loss Before Income Taxes in the US and Globally (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails</Role>
      <ShortName>Income Taxes - Income Tax (Benefit) Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - License and Other Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/LicenseandOtherAgreementsDetails</Role>
      <ShortName>License and Other Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/LicenseandOtherAgreements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="insm-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Retirement Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.insmed.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.insmed.com/role/RetirementPlan</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="insm-20201231.htm">insm-20201231.htm</File>
    <File>insm-20201231.xsd</File>
    <File>insm-20201231_cal.xml</File>
    <File>insm-20201231_def.xml</File>
    <File>insm-20201231_lab.xml</File>
    <File>insm-20201231_pre.xml</File>
    <File>insm20201231ex1052.htm</File>
    <File>insm20201231ex1053.htm</File>
    <File>insm20201231ex1054.htm</File>
    <File>insm20201231ex106.htm</File>
    <File>insm20201231ex211.htm</File>
    <File>insm20201231ex231.htm</File>
    <File>insm20201231ex311.htm</File>
    <File>insm20201231ex312.htm</File>
    <File>insm20201231ex321.htm</File>
    <File>insm20201231ex322.htm</File>
    <File>insm20201231ex45.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>insm-20201231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "insm-20201231.htm": {
   "axisCustom": 2,
   "axisStandard": 22,
   "contextCount": 196,
   "dts": {
    "calculationLink": {
     "local": [
      "insm-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "insm-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "insm-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "insm-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "insm-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "insm-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 602,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 5
   },
   "keyCustom": 53,
   "keyStandard": 410,
   "memberCustom": 30,
   "memberStandard": 35,
   "nsprefix": "insm",
   "nsuri": "http://www.insmed.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.insmed.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113104 - Disclosure - Inventory",
     "role": "http://www.insmed.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Intangible Assets, Net",
     "role": "http://www.insmed.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Fixed Assets, net",
     "role": "http://www.insmed.com/role/FixedAssetsnet",
     "shortName": "Fixed Assets, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Accrued Expenses",
     "role": "http://www.insmed.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Leases",
     "role": "http://www.insmed.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Debt",
     "role": "http://www.insmed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Shareholders' Equity",
     "role": "http://www.insmed.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.insmed.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Income Taxes",
     "role": "http://www.insmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:LicenseAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151113 - Disclosure - License and Other Agreements",
     "role": "http://www.insmed.com/role/LicenseandOtherAgreements",
     "shortName": "License and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:LicenseAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.insmed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155115 - Disclosure - Retirement Plan",
     "role": "http://www.insmed.com/role/RetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Inventory (Tables)",
     "role": "http://www.insmed.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.insmed.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Fixed Assets, net (Tables)",
     "role": "http://www.insmed.com/role/FixedAssetsnetTables",
     "shortName": "Fixed Assets, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.insmed.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326306 - Disclosure - Leases (Tables)",
     "role": "http://www.insmed.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Debt (Tables)",
     "role": "http://www.insmed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.insmed.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.insmed.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)",
     "role": "http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails",
     "shortName": "Description of Business and Basis of Presentation Description of Business and Basis of Presentation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i766b0daf1b2f4d9ebf49f5bb07f0991d_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Fixed Assets, Net (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails",
     "shortName": "Summary of Significant Accounting Policies - Fixed Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i0ff79db52eb84c4598d7b7afcb119dfe_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:FairValueLevel1Level2Level3TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:FairValueLevel1Level2Level3TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i2557ec52f167465a9db110f78f63cea9_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i2557ec52f167465a9db110f78f63cea9_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ic2ee174a408b4a3e956206fe10d829f3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails",
     "shortName": "Summary of Significant Accounting Policies - Allowance for Credit Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iff6225cad52544c692427c26bd334021_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Summary of Significant Accounting Policies - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i50d91d73e44c4dcd97703de93a4a7452_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Inventory - Schedule of Inventory, Current (Details)",
     "role": "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails",
     "shortName": "Inventory - Schedule of Inventory, Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net (Details)",
     "role": "http://www.insmed.com/role/IntangibleAssetsNetDetails",
     "shortName": "Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iaea9273eb15745909fef99e6b81de5ee_D20180928-20180928",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Fixed Assets, net (Details)",
     "role": "http://www.insmed.com/role/FixedAssetsnetDetails",
     "shortName": "Fixed Assets, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.insmed.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "insm:AccruedClinicalTrialExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.insmed.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableLeasePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Leases - Lease, Cost (Details)",
     "role": "http://www.insmed.com/role/LeasesLeaseCostDetails",
     "shortName": "Leases - Lease, Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "insm:FinanceLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Debt (Details)",
     "role": "http://www.insmed.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i207c67bfeb704bc880cce0755881858e_D20180201-20180228",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Debt - Components of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtComponentsofDebtDetails",
     "shortName": "Debt - Components of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Debt - Future Principal Repayments of Debt (Details)",
     "role": "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails",
     "shortName": "Debt - Future Principal Repayments of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "if0573aa1bb72428a95e7d4716d768ca1_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "if0573aa1bb72428a95e7d4716d768ca1_I20171231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.insmed.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.insmed.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iefb0a77979724e36a4b8762928d10239_I20190524",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ic2ee174a408b4a3e956206fe10d829f3_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Stock Options (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "if0573aa1bb72428a95e7d4716d768ca1_I20171231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iab01e3848c594db49f19b65d1cb861fa_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "insm:NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Income Taxes - Loss Before Income Taxes in the US and Globally (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails",
     "shortName": "Income Taxes - Loss Before Income Taxes in the US and Globally (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Income Taxes - Income Tax (Benefit) Provision (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
     "shortName": "Income Taxes - Income Tax (Benefit) Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ic2ee174a408b4a3e956206fe10d829f3_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:InitialTermOfContractManufacturingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - License and Other Agreements (Details)",
     "role": "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
     "shortName": "License and Other Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iaee4fc2dc83e46b4bedb05c0ac670aec_D20140701-20140731",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "insm:InitialTermOfContractManufacturingAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "iebde4d2934ac45c684584d4c433bdde3_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Retirement Plan (Details)",
     "role": "http://www.insmed.com/role/RetirementPlanDetails",
     "shortName": "Retirement Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "i1b38925e110b406fb8d690af86e404ef_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1106101 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101102 - Disclosure - Description of Business and Basis of Presentation",
     "role": "http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103103 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "insm-20201231.htm",
      "contextRef": "ieac0fead0e3b41bdb2a5dad31511c262_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.insmed.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "insm_A2019IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Incentive Plan [Member]",
        "label": "2019 Incentive Plan [Member]",
        "terseLabel": "2019 Incentive Plan"
       }
      }
     },
     "localname": "A2019IncentivePlanMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial expenses.",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedConstructionLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Construction Liabilities, Current",
        "label": "Accrued Construction Liabilities, Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "AccruedConstructionLiabilitiesCurrent",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedSalesAllowancesandRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sales Allowances and Related Costs",
        "label": "Accrued Sales Allowances and Related Costs",
        "terseLabel": "Accrued sales allowances and related costs"
       }
      }
     },
     "localname": "AccruedSalesAllowancesandRelatedCosts",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AccruedTechnicalOperationExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for technical operation expenses.",
        "label": "Accrued Technical Operation Expenses",
        "terseLabel": "Accrued technical operation expenses"
       }
      }
     },
     "localname": "AccruedTechnicalOperationExpenses",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalRoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of royalty payments if entity meets certain milestones under a research and development agreement.",
        "label": "Additional Royalty Guarantees Commitments Amount",
        "terseLabel": "Royalty payable on meeting certain sales milestones"
       }
      }
     },
     "localname": "AdditionalRoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AdditionalTermOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional extension period of contract manufacturing agreement.",
        "label": "Additional Term Of Contract Manufacturing Agreement",
        "terseLabel": "Additional term of contract manufacturing agreement"
       }
      }
     },
     "localname": "AdditionalTermOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_AmortizationOfBackendFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Backend Fee",
        "label": "Amortization Of Backend Fee",
        "terseLabel": "Accretion of back-end fee on debt"
       }
      }
     },
     "localname": "AmortizationOfBackendFee",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AmortizationOfDebtDiscountPremiumAndAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Debt Discount Premium And Accretion Expense",
        "label": "Amortization Of Debt Discount Premium And Accretion Expense",
        "terseLabel": "Accretion of debt discount and back-end fee on debt"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremiumAndAccretionExpense",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "label": "Available-for-sale Securities, Gross Unrealized Gain (Loss), Number of Securities",
        "verboseLabel": "Securities in an unrealized gain or loss position"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesGrossUnrealizedGainLossNumberofSecurities",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_BridgewaterNewJerseyFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the Bridgewater location in New Jersey where the entity has leased office and laboratory space.",
        "label": "Bridgewater New Jersey Facility [Member]",
        "terseLabel": "Bridgewater, NJ Facility"
       }
      }
     },
     "localname": "BridgewaterNewJerseyFacilityMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Cash Flow, Lessee [Abstract]"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional series of contingent milestone payments if selects to develop for second indication.",
        "label": "Collaborative Arrangement Additional Contingent Payments Upon Second Indication",
        "terseLabel": "Additional contingent payments upon second indication to develop INS1007"
       }
      }
     },
     "localname": "CollaborativeArrangementAdditionalContingentPaymentsUponSecondIndication",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CollaborativeArrangementMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment",
        "label": "Collaborative Arrangement, Milestone Payment",
        "terseLabel": "PARI milestone upon FDA approval"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePayment",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CollaborativeArrangementPhase3StudyPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Phase 3 Study Payment",
        "label": "Collaborative Arrangement, Phase 3 Study Payment",
        "terseLabel": "Phase 3 study payment"
       }
      }
     },
     "localname": "CollaborativeArrangementPhase3StudyPayment",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CollaborativeArrangementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment paid during the period under collaborative arrangement.",
        "label": "Collaborative Arrangement, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontPayment",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CommercialFilVFinishServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the Commercial Fill/Finish Services Agreement (the \"Fill/Finish Agreement\") with Ajinomoto Althea, Inc., a Delaware corporation (\"Althea\"), for Althea to produce, on a non-exclusive basis, ARIKAYCE in finished dosage form.",
        "label": "Commercial Fil V Finish Services Agreement [Member]",
        "terseLabel": "Fill/Finish Agreement"
       }
      }
     },
     "localname": "CommercialFilVFinishServicesAgreementMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period prior to the expiration of the agreement in which an agreement for extension may be entered into upon mutual agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Services Agreement, Extension Period, Period Prior To Expiration For Extension Agreement",
        "terseLabel": "Period prior to expiration for extension"
       }
      }
     },
     "localname": "CommercialServicesAgreementExtensionPeriodPeriodPriorToExpirationForExtensionAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Services Agreement, Extension Period, Period Upon Written Extension Agreement",
        "label": "Commercial Services Agreement, Extension Period, Period Upon Written Extension Agreement",
        "terseLabel": "Periods upon written extension agreement"
       }
      }
     },
     "localname": "CommercialServicesAgreementExtensionPeriodPeriodUponWrittenExtensionAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_CommercialServicesAgreementMinimumObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum obligation due under the terms of the agreement.",
        "label": "Commercial Services Agreement, Minimum Obligation",
        "terseLabel": "Minimum obligation"
       }
      }
     },
     "localname": "CommercialServicesAgreementMinimumObligation",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased computer hardware and software applications.",
        "label": "Computer Hardware And Software [Member]",
        "terseLabel": "Computer hardware and software",
        "verboseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ContractWithCustomerAssetAllowanceForCurrentPeriodSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Allowance For Current Period Sales",
        "label": "Contract With Customer, Asset, Allowance For Current Period Sales",
        "terseLabel": "Allowances for current period sales"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForCurrentPeriodSales",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ContractWithCustomerAssetAllowanceForPriorPeriodSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Asset, Allowance For Prior Period Sales",
        "label": "Contract With Customer, Asset, Allowance For Prior Period Sales",
        "terseLabel": "Allowances for prior period sales"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForPriorPeriodSales",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits",
        "label": "Contract With Customer, Assets, Allowance For Credit Loss, Payments and Credits",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ContractWithCustomerAssetsAllowanceForCreditLossPaymentsandCredits",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Line Items]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Line Items]"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossLineItems",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ContractwithCustomerAssetAllowanceforCreditLossTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Table]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Table]"
       }
      }
     },
     "localname": "ContractwithCustomerAssetAllowanceforCreditLossTable",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ConversionTermiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Term (i) [Member]",
        "label": "Conversion Term (i) [Member]",
        "terseLabel": "Conversion Term (i)"
       }
      }
     },
     "localname": "ConversionTermiMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Term (ii) [Member]",
        "label": "Conversion Term (ii) [Member]",
        "terseLabel": "Conversion Term (ii)"
       }
      }
     },
     "localname": "ConversionTermiiMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermiiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Term (iii) [Member]",
        "label": "Conversion Term (iii) [Member]",
        "terseLabel": "Conversion Term (iii)"
       }
      }
     },
     "localname": "ConversionTermiiiMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConversionTermivMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Term (iv) [Member]",
        "label": "Conversion Term (iv) [Member]",
        "terseLabel": "Conversion Term (iv)"
       }
      }
     },
     "localname": "ConversionTermivMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ConvertibleDebtInterestExpenseTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Debt, Interest Expense, Total",
        "label": "Convertible Debt, Interest Expense, Total",
        "totalLabel": "Total convertible debt interest expense"
       }
      }
     },
     "localname": "ConvertibleDebtInterestExpenseTotal",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A [Member]",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B [Member]",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer C [Member]",
        "label": "Customer C [Member]",
        "terseLabel": "Customer C"
       }
      }
     },
     "localname": "CustomerCMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CustomerFeesDiscountsandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Fees, Discounts and Other [Member]",
        "label": "Customer Fees, Discounts and Other [Member]",
        "terseLabel": "Customer Credits, Fees and Discounts"
       }
      }
     },
     "localname": "CustomerFeesDiscountsandOtherMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the agreement with Cystic Fibrosis Foundation Therapeutics, Inc., for research funding for the development of ARIKAYCE product.",
        "label": "Cystic Fibrosis Foundation Therapeutics Inc Collaboration Agreements [Member]",
        "terseLabel": "CFFT"
       }
      }
     },
     "localname": "CysticFibrosisFoundationTherapeuticsIncCollaborationAgreementsMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConversionTermAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Axis]",
        "terseLabel": "Debt Instrument Conversion Term [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermAxis",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_DebtInstrumentConversionTermDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Debt Instrument Conversion Term [Axis]",
        "label": "Debt Instrument Conversion Term [Domain]",
        "terseLabel": "Debt Instrument Conversion Term [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentConversionTermDomain",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "label": "Debt Instrument Convertible Trading Days Prior To Effective Data Of Fundamental Change",
        "terseLabel": "Threshold trading days following fundamental change"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTradingDaysPriorToEffectiveDataOfFundamentalChange",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "insm_DebtInstrumentOptionToPurchaseAdditionalDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Option To Purchase Additional Debt",
        "label": "Debt Instrument, Option To Purchase Additional Debt",
        "terseLabel": "Option to purchase additional debt"
       }
      }
     },
     "localname": "DebtInstrumentOptionToPurchaseAdditionalDebt",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets (Liabilities) Net before Valuation Allowances",
        "terseLabel": "Net deferred tax assets (prior to applying the valuation allowance)",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxAssetsLicensePayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as License payment.",
        "label": "Deferred Tax Assets, License Payment",
        "terseLabel": "Product license"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicensePayment",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_DeferredTaxLiabilitiesConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Convertible Debt",
        "label": "Deferred Tax Liabilities, Convertible Debt",
        "negatedTerseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesConvertibleDebt",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Foreign Trading Status, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Change in Foreign Trading Status, Percent",
        "terseLabel": "Change in Irish trading status"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInForeignTradingStatusPercent",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Non-trading Income, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Non-trading Income, Percent",
        "terseLabel": "Effective tax rate, non-trading income of Irish company"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNonTradingIncomePercent",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EffectiveIncomeTaxRateReconciliationTradingIncomePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Trading Income, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Trading Income, Percent",
        "terseLabel": "Effective tax rate, trading income of Irish company"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTradingIncomePercent",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "insm_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_EquipmentFurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equipment, furniture and fixtures.",
        "label": "Equipment Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory equipment, office equipment, manufacturing equipment and furniture and fixtures"
       }
      }
     },
     "localname": "EquipmentFurnitureAndFixturesMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_FairValueLevel1Level2Level3TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "label": "Fair Value Level 1, Level 2, Level 3 Transfers, Amount",
        "terseLabel": "Fair value transfers in or out of Level 1, Level 2 or Level 3"
       }
      }
     },
     "localname": "FairValueLevel1Level2Level3TransfersAmount",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/LeasesLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "terseLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the sum of accrued expenses and Other Current Liabilities.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_InitialTermOfClinicalDevelopmentServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term of Clinical Development Services Agreement",
        "label": "Initial Term of Clinical Development Services Agreement",
        "terseLabel": "Initial term of clinical development services agreement"
       }
      }
     },
     "localname": "InitialTermOfClinicalDevelopmentServicesAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_InitialTermOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the initial period of contract manufacturing agreement.",
        "label": "Initial Term of Contract Manufacturing Agreement",
        "terseLabel": "Initial term of contract manufacturing agreement"
       }
      }
     },
     "localname": "InitialTermOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]",
        "label": "Inventory and Cost of Product Revenues (Excluding Amortization of Intangible Assets) [Policy Text Block]",
        "terseLabel": "Inventory and cost of product revenues (excluding amortization of intangible assets)"
       }
      }
     },
     "localname": "InventoryandCostofProductRevenuesExcludingAmortizationofIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_InvestmentIncomeExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for components of investment income and interest expense.",
        "label": "Investment Income (Expense) [Policy Text Block]",
        "terseLabel": "Investment Income and Interest Expense"
       }
      }
     },
     "localname": "InvestmentIncomeExpensePolicyTextBlock",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_IrelandTaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ireland Tax",
        "label": "Ireland Tax [Member]",
        "terseLabel": "Ireland Tax"
       }
      }
     },
     "localname": "IrelandTaxMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_LeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Remaining Lease Term",
        "label": "Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LeaseRemainingLeaseTerm",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount",
        "terseLabel": "Lease cost, future right-of-use asset"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_LicenseAgreementWithAstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to license agreement with AstraZeneca AB, a Swedish corporation (AstraZeneca).",
        "label": "License Agreement With Astrazeneca [Member]",
        "terseLabel": "License Agreement with AstraZeneca"
       }
      }
     },
     "localname": "LicenseAgreementWithAstrazenecaMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_LicenseAndOtherAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "License and Other Agreements",
        "terseLabel": "License and Other Agreements"
       }
      }
     },
     "localname": "LicenseAndOtherAgreementsAbstract",
     "nsuri": "http://www.insmed.com/20201231",
     "xbrltype": "stringItemType"
    },
    "insm_LicenseAndOtherAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This entire text block refers to License and Other Agreement.",
        "label": "License and Other Agreements [Text Block]",
        "terseLabel": "License and Other Agreements"
       }
      }
     },
     "localname": "LicenseAndOtherAgreementsTextBlock",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "insm_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents manufacturing equipment used to produce goods and services.",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestoneEMAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone, EMA Approval",
        "label": "Milestone, EMA Approval [Member]",
        "terseLabel": "Milestone, EMA Approval"
       }
      }
     },
     "localname": "MilestoneEMAApprovalMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestoneFDAApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone, FDA Approval [Member]",
        "label": "Milestone, FDA Approval [Member]",
        "terseLabel": "Milestone, FDA Approval"
       }
      }
     },
     "localname": "MilestoneFDAApprovalMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestoneNewDrugApplicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone, New Drug Application [Member]",
        "label": "Milestone, New Drug Application [Member]",
        "terseLabel": "Milestone, New Drug Application"
       }
      }
     },
     "localname": "MilestoneNewDrugApplicationMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_MilestonePaymentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment [Axis]",
        "label": "Milestone Payment [Axis]",
        "terseLabel": "Milestone Payment [Axis]"
       }
      }
     },
     "localname": "MilestonePaymentAxis",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_MilestonePaymentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone Payment [Axis]",
        "label": "Milestone Payment [Domain]",
        "terseLabel": "Milestone Payment [Domain]"
       }
      }
     },
     "localname": "MilestonePaymentDomain",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Operating Lease Expense",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Noncash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock each restricted stock award entitles the holder to receive upon completion of a specific period of service or achievement of a specified milestone.",
        "label": "Number Of Common Shares To Be Received In Lieu Of Per Restricted Stock And Restricted Stock Unit",
        "terseLabel": "Number of common shares each award holder is entitled to receive (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonSharesToBeReceivedInLieuOfPerRestrictedStockAndRestrictedStockUnit",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "label": "One Point Seven Five Percent Convertible Senior Note Due 2025 [Member]",
        "terseLabel": "1.75% convertible senior note due 2025"
       }
      }
     },
     "localname": "OnePointSevenFivePercentConvertibleSeniorNoteDue2025Member",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_OperatingLossCarryforwardsDisallowedInterestExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Disallowed Interest Expense",
        "label": "Operating Loss Carryforwards, Disallowed Interest Expense",
        "terseLabel": "Disallowed interest expense"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsDisallowedInterestExpense",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_OperatingLossCarryforwardsNonTradingLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Non-Trading Loss",
        "label": "Operating Loss Carryforwards, Non-Trading Loss",
        "terseLabel": "Operating loss carryforwards, non-trading loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNonTradingLoss",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_OperatingLossCarryforwardsTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, for income tax purposes.",
        "label": "Operating Loss Carryforwards Total",
        "terseLabel": "Net operating loss carryforwards for income tax purposes"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTotal",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_PPDDevelopmentLPAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPD Development, L.P. Agreement",
        "label": "PPD Development, L.P. Agreement [Member]",
        "terseLabel": "PPD Development, L.P. Agreement"
       }
      }
     },
     "localname": "PPDDevelopmentLPAgreementMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_PRIPharmaGmbhCommercializationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the agreement with PARI Pharma GmbH, for the manufacture and supply of eFlow nebulizer systems and related accessories, liposomal amikacin for inhalation.",
        "label": "P R I Pharma Gmbh Commercialization Agreement [Member]",
        "terseLabel": "PARI Agreement"
       }
      }
     },
     "localname": "PRIPharmaGmbhCommercializationAgreementMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_PaymentsForProceedsFromFinancingLeaseTenantAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for (Proceeds from) Financing Lease Tenant Allowance",
        "label": "Payments for (Proceeds from) Financing Lease Tenant Allowance",
        "negatedTerseLabel": "Proceeds from tenant improvement allowance",
        "terseLabel": "Proceeds from tenant improvement allowance"
       }
      }
     },
     "localname": "PaymentsForProceedsFromFinancingLeaseTenantAllowance",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_PaymentsUponAchievementOfClinicalMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate payment upon the achievement of certain clinical milestones.",
        "label": "Payments Upon Achievement Of Clinical Milestones Amount",
        "terseLabel": "Aggregate payment upon the achievement of certain clinical milestones"
       }
      }
     },
     "localname": "PaymentsUponAchievementOfClinicalMilestonesAmount",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for meeting sales milestones for additional royalty payments after the drug is commercialized.",
        "label": "Period for Meeting Sales Milestones for Additional Royalty Payments",
        "terseLabel": "Period for meeting sales milestones for additional royalty payments"
       }
      }
     },
     "localname": "PeriodForMeetingSalesMilestonesForAdditionalRoyaltyPayments",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of each automatic renewal of contract manufacturing agreement.",
        "label": "Period of Each Automatic Renewal of Contract Manufacturing Agreement",
        "terseLabel": "Period of each automatic renewal of contract manufacturing agreement"
       }
      }
     },
     "localname": "PeriodOfEachAutomaticRenewalOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer",
        "label": "Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer [Member]",
        "terseLabel": "Public Stock Offering - Shares From Company's Chairman and Chief Executive Officer"
       }
      }
     },
     "localname": "PublicStockOfferingSharesFromCompanysChairmanAndChiefExecutiveOfficerMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RebatesChargebacksandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates, Chargebacks, and Co-Pay Assistance [Member]",
        "label": "Rebates, Chargebacks, and Co-Pay Assistance [Member]",
        "terseLabel": "Rebates, Chargebacks and Co-pay Assistance"
       }
      }
     },
     "localname": "RebatesChargebacksandCoPayAssistanceMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RepaymentsOfDebtFeesAndOutstandingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Debt Fees And Outstanding Interest",
        "label": "Repayments Of Debt Fees And Outstanding Interest",
        "terseLabel": "Repayments of debt, back end fees, outstanding interest, and prepayment penalty fees"
       }
      }
     },
     "localname": "RepaymentsOfDebtFeesAndOutstandingInterest",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "insm_ResilienceBiotechnologiesIncContractManufacturingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the agreement with Resilience Biotechnologies Inc., for manufacture of the entity product ARIKAYCE, liposomal amikacin for inhalation.",
        "label": "Resilience Biotechnologies Inc. Contract Manufacturing Agreement [Member]",
        "terseLabel": "Resilience Biotechnologies"
       }
      }
     },
     "localname": "ResilienceBiotechnologiesIncContractManufacturingAgreementMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_RestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares and stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Line Items]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedLineItems",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ScheduleofEarningsPerShareBasicandDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted [Table]"
       }
      }
     },
     "localname": "ScheduleofEarningsPerShareBasicandDilutedTable",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of inducement share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Inducement Options Grants In Period Gross",
        "terseLabel": "Inducement stock option granted to new employees (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementOptionsGrantsInPeriodGross",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "insm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract that gives the holder the right, but not the obligation, either to purchase or to sell a certain number of shares of stock at a predetermined price for a specified period of time. It also includes stock units that an entity has not yet issued because the agreed-upon consideration, such as employee services, has not yet been received.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock options and RSUs"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "insm_WeightedAverageRemainingContractualLifeInYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life in Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsAbstract",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "insm_WrittenNoticePeriodForTerminationOfContractManufacturingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the written notice period required for termination of contract manufacturing agreement by either party.",
        "label": "Written Notice Period for Termination of Contract Manufacturing Agreement",
        "terseLabel": "Written notice period required for termination of contract manufacturing agreement"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfContractManufacturingAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "insm_WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written Notice Termination Term Of Clinical Development Services Agreement",
        "label": "Written Notice Termination Term Of Clinical Development Services Agreement",
        "terseLabel": "Written notice termination term of clinical development services agreement"
       }
      }
     },
     "localname": "WrittenNoticeTerminationTermOfClinicalDevelopmentServicesAgreement",
     "nsuri": "http://www.insmed.com/20201231",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r137",
      "r200",
      "r204",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r135",
      "r200",
      "r202",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/LeasesNarrativeDetails",
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r136",
      "r200",
      "r203",
      "r370",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r138",
      "r139",
      "r201"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails",
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r167"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r210",
      "r212",
      "r246",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r212",
      "r240",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "ESPP compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r77",
      "r91",
      "r315"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 4.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Accretion of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r71",
      "r91",
      "r317"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 3.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r91",
      "r154",
      "r161"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from computations of diluted weighted-average shares outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities excluded from computations of diluted weighted-average common shares outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r134",
      "r348",
      "r361"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r54"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r213",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Reported Value Measurement"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r36",
      "r93"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r94",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r93",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding shares (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 500,000,000 authorized shares, 102,763,060 and 89,682,387 issued and outstanding shares at December\u00a031, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r308",
      "r309",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r308",
      "r309",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r119",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r125",
      "r126",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r122",
      "r125",
      "r126",
      "r127",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress (CIP)"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Balance at beginning"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForCreditLossRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAllowanceforCreditLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Contract with Customer, Asset, Allowance for Credit Loss"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible notes ($450.0 face value)"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible debt securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r15",
      "r349",
      "r359",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of product revenues (excluding amortization of intangible assets)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r278",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r280"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r278",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax provision (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r278",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r349",
      "r351",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component of convertible debt"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Initial conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r47",
      "r189",
      "r192",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining discount amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r316",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r46",
      "r180",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r48",
      "r101",
      "r189",
      "r193",
      "r194",
      "r195",
      "r315",
      "r316",
      "r318",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Discount on debt"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r279",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r40",
      "r317"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt issuance costs, unamortized",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r279",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r99",
      "r279",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax provision (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r269",
      "r350",
      "r358"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r279",
      "r282"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "insm_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowances",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r253",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r252",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r253",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness": {
     "auth_ref": [
      "r274",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, General Business",
        "terseLabel": "General business credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r252",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r253",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r253",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent of match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r91",
      "r165"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r91",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss (in dollars per share)",
        "verboseLabel": "Basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r103",
      "r258",
      "r259"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails",
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r258",
      "r259",
      "r281"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r258",
      "r259",
      "r281"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r258",
      "r259",
      "r281"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r258",
      "r259",
      "r281"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "R&amp;D and other tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r258",
      "r259",
      "r281"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesReconciliationBetweenFederalStatutoryTaxRateandEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted average period for recognized and unrecognized compensation expense",
        "verboseLabel": "Expected weighted average period for recognizing unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r294",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r293",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r296",
      "r297",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r294",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r294",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r294",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r298",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r97",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r321",
      "r329",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Finance lease interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails",
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r324",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows for finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r320",
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity of Finance Lease Liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, long-term"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: present value discount"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r323",
      "r332"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Financing cash flows for finance leases",
        "terseLabel": "Financing cash flows for finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r321",
      "r329",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Noncash operating lease expense",
        "verboseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible assets estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "Amortization of intangible assets, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "Amortization of intangible assets, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "Amortization of intangible assets, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "Amortization of intangible assets, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "Amortization of intangible assets, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r155",
      "r157",
      "r160",
      "r163",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r160",
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangibles, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r155",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "verboseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Finite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r156"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r311",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r91",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r97",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net and Impairment Assessment"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "US"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r68",
      "r107",
      "r346",
      "r353",
      "r367"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesLossBeforeIncomeTaxesintheUSandGloballyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r99",
      "r133",
      "r283"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total",
        "verboseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/IncomeTaxesIncomeTaxBenefitProvisionDetails",
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r97",
      "r256",
      "r257",
      "r267",
      "r268",
      "r273",
      "r284",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r111",
      "r115"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r67",
      "r131",
      "r314",
      "r317",
      "r355"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "totalLabel": "Total interest expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r77",
      "r181"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtInterestExpenseDetails": {
       "order": 1.0,
       "parentTag": "insm_ConvertibleDebtInterestExpenseTotal",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Summary of Interest Expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r87",
      "r95"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r152"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r53",
      "r151"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r152"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r152"
     ],
     "calculation": {
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryScheduleofInventoryCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense charged to operations"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "terseLabel": "Future minimum rental payments under Bridgewater",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r352",
      "r364"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "License and Service"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "A&amp;R Loan Agreement with Hercules"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r177",
      "r351",
      "r362"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r105",
      "r173"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtFuturePrincipalRepaymentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Debt, long-term",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/DebtComponentsofDebtDetails",
      "http://www.insmed.com/role/DebtDetails",
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r89",
      "r92"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r60",
      "r63",
      "r69",
      "r92",
      "r115",
      "r354",
      "r366"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentationDescriptionofBusinessandBasisofPresentationNarrativeDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r107",
      "r109"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and (Not Yet Adopted)"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey Division of Taxation"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r330",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense charged to operations"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r325",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r319"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards available to offset future taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DescriptionofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/AccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r14",
      "r347",
      "r360"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r288",
      "r289",
      "r290"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation gains (losses)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r61",
      "r64",
      "r288",
      "r289",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r44"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalty payment"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "PARI milestone upon regulatory approvals",
        "verboseLabel": "New drug milestone payment"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-condition options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r213",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in shares)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of 1.75% convertible senior notes due 2025",
        "verboseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r243"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options, ESPP, and RSU vesting"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r166"
     ],
     "calculation": {
      "http://www.insmed.com/role/FixedAssetsnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Fixed Assets, Net",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r168",
      "r365"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.insmed.com/role/FixedAssetsnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/FixedAssetsnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r97",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life (years)",
        "verboseLabel": "Estimated useful live of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Future minimum commitments due for firm purchase"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Payment of debt principal and extinguishment costs",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.insmed.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Compensation earned under research funding agreements with CFFT"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r249",
      "r377"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r97",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock and restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r196",
      "r363"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Product revenues, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "verboseLabel": "Annual net sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r333",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r333",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense paid for ARIKAYCE approval"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Royalty payable on approval of ARIKAYCE as commercialized drug"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate net proceeds from stock offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold in offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Sales Revenue, Product Line"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potentially Dilutive Securities Excluded from Computations of Diluted Weighted Average Common Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components Income Tax (Benefit) Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Components of Debt Balance"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Federal Statutory Tax Rate and Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r212",
      "r239",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Allocation of Employee Stock-Based Compensation"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Carrying Value and Fair Value of Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r155",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r155",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes in the US and Globally"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r10",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Principal Repayments of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/FixedAssetsnetDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesFixedAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r213",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r217",
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Fair Value Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r50",
      "r100",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of the Weighted Average Number of Shares Used to Compute Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r122",
      "r125",
      "r126",
      "r127",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk, by Risk Factor"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r17",
      "r351",
      "r362"
     ],
     "calculation": {
      "http://www.insmed.com/role/DebtComponentsofDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "Secured Debt",
        "terseLabel": "1.75% convertible senior notes due 2025"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/DebtComponentsofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding Weighted Average Grant Price (in dollars per share)",
        "periodStartLabel": "Outstanding Weighted Average Grant Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value and assumptions used in determining fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock Based Compensation disclosures",
        "verboseLabel": "Stock Option disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock, maximum authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited and expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited and expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r219",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of the year (in shares)",
        "periodStartLabel": "Options outstanding beginning of the year (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding end of the year (in dollars per share)",
        "periodStartLabel": "Options outstanding beginning of the year (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r211",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails",
      "http://www.insmed.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.insmed.com/role/StockBasedCompensationRestrictedStockandRestrictedStockUnitsDetails",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails",
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r97",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r234",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r52",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r188",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r188",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r188",
      "r196",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options and ESPP shares issuance (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.insmed.com/role/StockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r188",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r188",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r188",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options and ESPP shares issuance"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r145"
     ],
     "calculation": {
      "http://www.insmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets",
      "http://www.insmed.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r261",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LicenseandOtherAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r254",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Net deferred tax assets as of December 31",
        "periodStartLabel": "Net deferred tax assets as of January 1",
        "terseLabel": "Tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails",
      "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Reductions related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions related to current period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r117",
      "r118",
      "r120",
      "r121",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r331",
      "r338"
     ],
     "calculation": {
      "http://www.insmed.com/role/LeasesLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeasePayment": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.",
        "label": "Variable Lease, Payment",
        "terseLabel": "Variable lease payments"
       }
      }
     },
     "localname": "VariableLeasePayment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average common shares outstanding used in calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average basic and diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "calculation": {
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares used in calculation of basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.insmed.com/role/SummaryofSignificantAccountingPoliciesNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r381": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r382": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r383": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r384": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r385": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r386": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001104506-21-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104506-21-000005-xbrl.zip
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M '#/N-&,"Z!898MB1 B9K1;%9<1,?JQ%K]NU]8%Y8)7,.,:=4(R#;C''*+4
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M;T705%KN&3+.,I=V=U1."Q,\G8,MK&=52 \(DHX*@E*&+?42:#RR(9J(B59
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M?4Q[1<\OW$Y!A-/!5H*QDD:+-"S/*&8J32:.A!@*X9UG-]>,6XIP]H#4.LW
M]GQD1C,K@]742DZ19)[QB.9@*;@J1FJ;T_IH>-@OH&HW)I5N%*%C>A[NF)-!
M*H%<6HQ'\;3F&"= 1 DA@C$GI"<FVGF4R76S6H.K@V'N5ONCWK XFQ.Y<(ZT
M#0*" POTD6NK'?S (8(#,T+.P2ZS7[.5R3VM</)/* ;A;"W_G*?'-R,\8!YG
M19V'DM/%?C!A5'RY'\R@SPB6+QN[VY/'[[TEC'"1:>2(]0S"!R:M94@*'VT
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M1VKWF@]N/$KS<M2#UDYW08.8F:E+=EB$^-?*?WU;['+E5=O83LCZ,4N]U&G
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MN;MCLW_6:M=)<\U_@K;YU.J^0WOP-V$X?#O?A'KOO]D[@_JP_8Y"'RG#$9@
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M.DD5(8!*>)QTKRP"HK5D2>.:CX-B,*CT36#EXS>.-3E%L#Z/*99-%E> $75
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M.JM)+2])]C6R%'I%O]/)RH=+AS<8I="J<E83K2Z[3:JV*BMQM4-N7!$HX"
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MZY8]2D\]Q#GV:]7X9:\/$)FFU?9[!BP/0N7?5C??;ZS5L/X]2^,$(:E!,E%
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M1_LS D."R'!X9$ZV2S*!K#(:45!5EW34 '74';$Y9,TZ/Y^%U&FYFB-RET"
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MZC&-,:BW%;C,-BBR9LPQC]>,D^\/OT@C!G(VA@G'?/0$C-)QQK5I-"L\)O@
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M'#P=>-%B* [>%//XM8Z([U:>7F-L6E945^26%O*W2IW.%O+N?)@5?UQ]Y']
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M:BP;P@D0) 0".&S+(TXTPU;7\\DTZ?'==>6]E,-?>O+#-B2^JXU08$NX#'7
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MQ29LOS,>W8$,&B17FJ)8X2R4WK&I?:TE+,_;LUYT*H5% ?A*IN9P<G(TZ9#
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M!U#+ =3RH$$M'\OA=I:4\,@0A3'6=LE!E>@A^7"3>=0OL1"TZ;T"7*"E$RV
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M)^XOCN9"L7<_4O4P>!88:$A[5:Q78N^E^QK9R;(V5\SSY5VRB+TE>>BR?^N
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MZ&WW72P7D[$8\[Z/\76)D'P2K\4<]L/%JYEG*2HNVQ*J2[AV,:/QPI/=Y#C
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M.)O5>>,O*<,.G%-K@%"NLVV*MV7MCFM78P9.-QR4->6RHF@"8[=5[<\- #P
M ^[SY9AI+1<BKK7%C6;*RSY;A"QH&#NR!_UY(F$A)08]MQ^Z9_GG-7H?QGM^
M]A_/YPEB'/O**3*1/R<20*:Q-1;RWO"3#0M0HI@6]FU.W8\;2<NS)>GR;9(5
M+JSF8-[T/IR!X!!0SXO?D2<S:$M2Y!8*6JZSBF;L2R[/.HGYY/V0XBB1:B \
M0_@O?J>".J:[#0,P@ELJ^G(1%UXG6M^)1EA\Q%R1J;[AK+%KLM;^@&PFO'S6
M0]]RG_V'5U.C/^>"5OD2&]MX:Z\[4U3/2R-GVQEY-6&QE:;%FRY_%F4SS)22
M5R=R;_&IAE;=\)-)G+]!4Y<N&23%I;BP]YI)+C,R"9#UYX-[2MT2;E6/JOG8
MB^VX,>UM5K[U6#9\FCFWMHDJ00@Q$ H=IC-0')-<"-U,5%)<"Z?E7?388$8C
M5<;BVWT"<*"[2WMT3CS@$SA#:H$:CK--IUE^S^3/G<D)V4\F-HCX61)HCF8O
MK/2QI$P<R]UT61@G!4BT/0"=+RP5&%SV9QP^8;5^U\QN3I-_5H(K 980SZP_
MY,\BL?=TVJ*LJ+Q%8?=<*3^C0?:R%]#>[QM+E4@S*831HNOE>H::L'^+X&]?
M<H<SE4?2P7SH^V58SR/2H[$,!H\K*Y?3Z??-%Y]_^>3S9\_.:0GDV^HH^Y[I
M@;9A(,.#=;FKC&SXLIA"Y2![&EEB!I'@A2UT-?%&(BW'35M\!#'8/M+W6#G8
M'4C<2!MINCT9 E+TU50[2=NR6DVV;2>M<0KI)Y\[&21;?,OB^N$OCFPJ8[->
M/D^>!"Z*/&8B&EIU+FNBGD#%0].F=5V^BQW)=EOFTO&MK)L!F9C.!\413?@,
M4ST2ID??BPL+!9!N$>+;=\G761%5.GN7PD:B5L(0;8/OR XWXXC]\-A1K4VK
MI_E>BBENJD72,F/F!MDRL[@!8J>'CQ"E\Q,+OC=@NV;D=/1CO$&\KB8%0.S9
M;5<&^KKS.'P"5C&?GXI)^"CGTI6(5&X]/!1?*>CK6[Z>5R*4%3-;20KZIA0
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M_ SV>?C[PPZOZOE%0M(D1*#$B:7'\@AU<CG5B:2"\VTU2:HK&Q2-+AD^8+E
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MGVVH+UC"9R?9L..9]?GT$0X8#X_Q^.: \3A@/ X8C_>PRLX2*'=&YARA>&8
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MM ^<  ?)"?FJRWN)AP-..0( LTY79:9 D$M(W&J=-6GR\ 4C?J<_0$:]#CX
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M3QX]><2,GN(61*%Y=>F#=5?_7\Z(JE.RVNTR.%_$L%F)JJU17A#G!KQ5.RT
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MD)CUX4[#R-V/$1VZMVSS"H6"5Y3596^&9NMI!L5Z%0?FS-4KJ0XA/+K$G*K
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MUZV1N)2?7.>#)-_N1-MT(!R]*^'H0)_";M1MAM)5OCR!??SR6B4RG_V"R$9
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MX%W@909K##PZZ#6;<3$2)G=B$BC#,1V86"+-8-+ZLP55J0-B4$?/SZDO0EQ
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M"Q!Z,;$IL(9.0\_F,K_.&)8NQ(D8N.(&J!?W\=K46^?2(O@JP5MHD\.4S/Y
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MJOZ+ 7:0N8)7']NS;WXSRIH^_9RAHL2O=FJ&UCZ^^OSK:P6_OBO'[O*:@$_
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M\V>%7FYQDVOS5!583LLY7^_'=C%VI;ES_KQP8*: %\HNUL9F1"\>C,1:__D
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MHMO<B+<V^MVBZQ;=4V*>-^.-O;V57W2/Y*L\:]9@P5$$!8LN<[!P?-XWQ(!
M)L6K_7S7P.(../KE!''>;!,VXNWU!_9!K&BWPPK.$FM@=-.TW-/TTC;3MQT?
M2WC \C[J$B:+C]@DFXV2034K[!-W31'W-P$[\?Z]6V.7V,=^H;.T'F_U[\L-
MVLW2$\_23KRU_X(FZ<6%JSL;O:TN7%T\/I_,Q6R<0/M('/UK9A^HFH/*Y*P
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M1[" "_0!IC61@S T#SX[RA[/DL4I5IVZ5[0.C_F403T/(-XHG-M=F3./8XI
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M5[D@X=7PS6-X4T;$>Y^7N>LAB2AST(]CH)-)F:X>4^Z]J-J2EKX T?D+GHX
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M^9NBQMED46-HFB4R)#5_7M: _@0$ V0G2JG;!TM<80\ZH.1Z*X]?]%H37Y[
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MTMK#B-UT-O56K2HF"H$LS_X!SGYVKNU< &%^]&D2EVZOWQ .Y+6L\UH&Z(3
M.0-U&"ZZ\2*K9!A<GK(LY%'1@7PNY:L6KZDF5Q2^RB)RPHS/8K+/O,MMR\9G
M\<I9P@H$?_$ML^E1348M_0-1T\BXLE_T_LO1 1S2:GSR X^$$JM,^5RHW],K
MC.;R:&TPA:6@=2%&.%V+]'+F[D'GZTV>./0MC:[Y$.NUS8G:-J_L<1RK'\B
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MLV&L5/0A9YC7]J(.0\1I!IH>M_<1 \+OR)K37,1BF::(2%.?:BS<>7UZ732
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M'AA7=.V_T7N$CF,VG4I\C8<"63YV*#J/IJ.%B\8A52P67E;AX3=)6Z4@NU6
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M>MDH%RD#_T.&X]^4KZ!H7_!?'!R<%-?/)T;R[E(72<Z'G(NJT7I#TR0;@CX
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M;K(=[^=<FT>@._1ID& @P>!^8&#6P&"+PA"+]F$^@SU(2'Y*=][MN*Q(8);
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M F_>*:^3-_RU&.Y-!PG/=OM !@0ST,[ZE(**-]-DH%P (AB6^W?@,:W/.9O
M_PR9FLA[(HPSVL>%@;5]D,*:ZOO,%VV4]Q0HWN:QMRWQNK,^@;>E Q".^:]*
M[S_39')]YQ=>OE%NVAG)^\I'((.5=M2IO0'_]?I2;.HHG0"- E;C@QJOK:1(
MM8#BRPDN$;A#.8&KE1#]7#%'URP)T:M!=,C8 ET?')F1K6ZJNEH"?#MMZ(M\
M&,**"*R"_;I*WM4E0SX5A3V=N?B_"QG5>5Y,AO81$+W"% R05]RF2$#^"0;H
M$Y#X 6;)9S0"DYE&DA]>(#^\&(8X)".0-JP3 PH$]!(I(%5"T(!!_263-+M6
MQJ!CXR])EF' '#_<PA1S@8\;7:O%/A<%)19]+8G^[]7M_E]=\U_=ZJ3UX(#$
M;R;I&']\\#MP6\,!^^>]0T5W=D3BZMQ_?SP^/>0"_^SSX6'W].O"T[QM@YP4
M$R#T41DP>:(8")@."AF/!\ (0#8["[?TF&&SC8F0.8LC9"LP@6Z43/  <349
M.FOUMS_Y6K8G2K8(GQZ5 ]LA^6S_TU'W_/-I[VRUL]A"(#ZIN=S1F,SH?Z9)
M5O-.-1WVJ CH]NOH3>F.ORVE#C]T2B\2[$PR0@T[5R*LX _)- ?KDZG?&;=N
M80D!57*X?EX#FL 2 MHG@Q@+3O%!C,[Y!]B3,SH=P;?8 \ETTD\SV'K;-"36
M#=_0%PN:N0CN \5K?7_'X_'15>.UEK/CNG>+U][T6&/']_VU/Q46ZQO6.N*U
M*ZK3<-)/I$MS2EO"<M@F V'_Z.RPMZ?L'^T>GYX<GW;/>WL,^HCR5X(,DQ"E
M"!L 2K _O:ZX_4V;\?S<+_K..WK2B_YP_>Y^.^(">Z/V]#9_R^_JR_[!P7[W
MD*5>]K[LG]V%+)?PL:SBCN'2!/4!^*S"(B=*<2+WR$39(%N&CUZ<27I=V1/P
MM,S]0"M@3WR73&"_X3)NR]ORA#?A5%?<TXV9S2V9/_=P,CTC;7Q)C;M2J5'=
M9OYLH54'=)!>%=ITE1(P!JV:^<-'A<(M7E;3W)'^DA'[;4C&).1+@&/#?*.[
M*=TOTKOC/FK^L_332#_-O;.9I2V\\;;P8ZK?WFU.--Z]!Q9 )M.,;H]=L=S&
MUF'_;=ZNSI/)@*[)7F_?W3")H@'="+U^?4:[W-0C;*H][4*_J2?JAO#>6CT5
MS_)N9S:5I5?\W\96;O!V4YVY2)<R?N](^7=U+6T@6RST'JWH@[L'?JS7[;?N
MU6W'-9;H=M8][2H?CH_.SGO[1Q+:MFN#"XK'9@&M^@ ;2#%?+K8,OGDO ]\:
MY7D2W+8;W/:Z?^WO*:<[RH?3WM%15^+;EFUP+\EH.$DSJ7]51T(N8>U(TAD=
M :Q+B-INB.H>?#SM[2D?=Y3NP?GQ8?=T7X+4=FU0@M3<D70'<88EISLX>!P>
MER42IK8;IG8/ )G.SKK*7N_LC^[IWO[164<Y^7UG;T?"U79M4,+5O!D] (3*
M<Z+LT?P;R6#E.1!W?S7BEK"U.1=:>;?0J]4]5?[847I'GWH'9[VCCG(H46OK
M-BA1:]Y3A1XJDC':'EW004Y'*].V!*W-N<\9K]67';C8P]U/^Z>G$JRV:X,2
MK!:XK3A-AY^2+),@M=T@U3O8_[O[H7?^.V#4OWH]I7NTUSL].Y8N]BW;H,2J
MN2/I#9*?)*"3/D#5ORCV>XI8+KZ$K.V&K,/>P5_[1\K9[]W3XW]]E7;@-FY0
MPM5\PR ZN$Q&K&=E^OU:FH#/ :H.>L?*0:]WUVN4//_,>?Z ILH!7:6,0[+Y
MYMQ>%54#3>1 Z>XH9[N_=S_V5G'T2'Y_2?R^"[)]P @E[).8WL][LG @TI+=
M^&ZI[7Z1%<3>>OK#V:_>R[IC67>\J77'&]P?KNC&C7-/(CJFK'6$Z)5 ,1GI
M9!H,DK">_?XQR89W[E#Q1$!SSIM0U <4L*1^_.6'E&01&[<@!&B^8 S,YFZZ
M_6Z/Q\F(3<_AK2[:)ADLH/''E--8^_Z%\G[59!HE$\JOA838NY>,KI'FPOI(
MAD#,RLCYK(SVRU)>\U$.[!%O9@9JB/&W\U,U>*>2 7M XYUY8_I$V)BK,4CS
MO .KJ0^_H'SX!>M/CZ,JXG)4!25AO^A),@$(*P97B(8D8SC!-)II@M]<;Z<D
MW6*I(S:^XC5<UP";'%[2P37\#10>Y.!)BKO'C^,P%$/[K;&QN*2*:HOL<_IO
M;W;@1)5TFBDIIR1^/K=^78&SR1%&8I)D@^L.;HT,!N6T%EA:/H9UYOQYU2,*
M!:8X'G%["IG<?G/5D>33 ;\E;+J8PGD2WB&==7V!7SW ?<!GX51P/@%>.DYL
M4C[OG.TH%W0$KQ]@2\<PI&PP%*F =,PKC08TG^\KLX0@>@(F)8,\;7 JOUO8
M4A8QEF1;QV,#:AA%@*MEKQ\A1XHKK5=37;)&F/V)0.+7GT=).? E?Z.\/MGM
M'G]XTZF3Q*]X/T!-(Z :UNX;U'PV<J(BIJP<OG,3[W< 37+>\B?,$D:?"LU1
MTT\ 7EB;H/WB1;O\12K^XH*#S,>,#.E5FGU7DCR?(C9=%\L$4IA0IG*<C9%C
M,K;7[(*,DI^DUK.?*N>@I$:@F_)OY3ERP&N@:E.)B\?SH>#(BJ(;DAA.T]JE
M2*$_D -Q6T ET]%_IJ!HQ GN4D@$UF\T'6T8V;5+L0\D3SBG"GFV68MNYY7S
M/B!@.SB"E"B "NDB"9(!@D83\H"^AV5#^QWEF%U\X_,)&U<D;AKO.6U*>_&@
M<OY5ZUI*VD?*8BR=[RC(Y[!&HHPYR]80*P;5#Q92*H<ENS,6932*7Q6]OB+1
M!C>I:9;L&P+_JWE+'!,60 E#TIA&B*1*7K4,&Y"K2HFK.K KV100E?T!5CH=
M-'FMUG(,/U&V':NQ7O%(MJ<-8Y&%R P@&$U#UKRLO,KEL9GM5#GOIWG]K^(:
MX2,@@*\H'Y^ IP,R$64=/WA\%=YD&K"!)(!E>3IB%T$ $C/V:A*D4WA$GR+P
MS C]&=:(,PZ:I;* UU)\I%,^(YI21O]9!L  _P&DG$:<4<K-AX,I"FVQ6BYQ
MTY!&TXS/^H+U(>\P9DSR[_G"UQ;GU+;H6Y;4J1_8[!+P7#E;1YP7\/S94G:4
MLRFH);4/E]NA/X"$1O"H#C(N44!&3I"1<0P[O4R RT+DP N6D'W![VB(#,PI
M/DKR$!16\<R%VVH<)1/[U0(NR6!*)N7#VQ0:9<JE3\2Z];%!GG",L-($#QC!
M+:(H*RN08],SKRBHB?"_,Z] R8X*I- K25U';%_\%YQ],TCHI:#>&E/ F>(I
MP<G52#4HA4Q-W=TPWI]O=H2\OXMH%N(X4\:(AS@@:[Z+YNH+-]G_/:R(9"H7
M6SQ'$3;=B\UL&4Y'HA<C;_,(ET.*/V/1 1-&Q6 Q0/0,N52HZOQ9-Y"' #2@
ML\:;TFQ6<#7^+(05?WI8ZG=<6I#).^6U_D889!Q=.%_D^-PZT[&7(]*54".>
MW Z).&C0> /<=YD.+@6\,_&9,+L"Q!?8?*,+A@?Y-/C&[;]B],V _E"^3:,+
MP19\-%NQJ1H7M5]$E,)Z1SC?9( _HC@!,8V::HU+"H7C5K,0%'CRG8[8E%P
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M<0_4"6+;=)H7T/=BLPAD*X[L>349:]_V'@TF'660CB[4"<V&TL:1P<7'LF2
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MI\00]RR@W \$1:F)UQPLA\0+&Q4V6CLV6M!G4=AH=6PT]53H'%]B)J%(\P5
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M*4BNSE[Z8V\PA(72UEH +>62&T&L5(X1IQ*1EOF(5R"D"[J7B.[IS7#&P8S
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MT,VT][FYAT,R>1X8=B[9W)^=-:EM; G=K+.;I$#Z22 ]]:!$L)P5X1)):S%
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M%<NZ;UU8M+#HEK'H/"TKL#9*&.J2=HY;2@PCN;(R93@X8_DW:'3^3A6%3Y?
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M(Y.6ML+3\7Q)2S_5Q7M[)Z_S#A66FHNE_KI6M$$ZHIA@2!,O$9=<(IVH0L&
M".(N24=##HPRTZ3$RN*T;+8M4:"\,BA/;0D%0,8X"D1BRG>+P:IP6! 4*7:.
M::]H, 7*&P_EYTM8*E!>",JSZ4I4B"Q_D0E<(,XY14Y[@XSFU'..F1>I@K(H
M08CGLQV\'\1KAD/H##W,;]2RO=#*TT41ODDQYEA%B4P\MRW1Z0W/;E!6=G+L
M37;MS2">=<9GKWKA:F?WZ\2S0F5S4=G^YTG;H+IE.NRC-Q:4$24"<%ENF2Z(
MS5J*,%+"AE,&7*;;1B^<%U$\G,U%^"I,C(+PU2'\\ KA(-D2#UPAI@A'G#F*
MK%(>B>@L$R+AI#4@7 '"14'XYB)\%99'0?CJ$/[A"N&PE3(F+7,LP^3*"1PY
MBGVN@1*,2H8&E>T1T3:L!#.>#:JU_1U;W6B'L65G0QOE!D4#[(]+K\EDGW[)
MV_0V#_<X?1C6E[QFF:TPUGR,]>6:U6&9MU$(Q'#T8'58@:SU%IE(+1;P;0K5
MA2^LRI6*#8;U$HR.@MW58'=J3V!L-<62():(S\5>& )5TB"LB*6*&$:"S/>A
MFN3[+,A]6&',*I&MN*A7U4*EWZO*U$[+T]:ZX2+JX%:8LBMS1T]VZ*I55B58
MBLGZ*"%R<4T!5$H&;# RRD3$0Z[< 38LTDF'0*+W3,9<B\<PVB"+M?BDFJ<
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M9,&,C9(;EF^TT39=*,1;8-U@6*\RQEM@_82PGOHRA!$*.X(12UXC'IA$6GF
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MZMIL#*,OO<[7075NW^=C6YC[4<Q]K66S-X8E:@("M1&8VS",K)5 Y%9A#G:
M\<+L[&JRK&I>2X'',^=<%WHL]-@<\[O0X]+I<:9&&C,FD: 1\=8B[JLRK=*@
MP(,)5%C8.;6SR]B2KZ45>GQ J*LPY+>79V-(<@E>@4*22R?)J?6?A([6!8LT
M!?61>VJ1H]PAP@W7R6KGO-W9)>*Y=<BEYN?\8V3AN?!_Z'S:_2=\N1SVF1V<
M='J7H], ALEO\HCT=;;R,3NAZM]T>@%^>DET1:8KAB2]'9I_HA%43WS9&<$"
M^ >,Z5V,+>L!KC":BUQ)H=?/1;='_98=A\XH9I'5JU*P;/YATNK(=F'D\(NS
M:_7U;N[4Y(-X=MR<]X>=*LUH$+MVU/D4?_C<":/32[*:>==D8_'T+=;! ,:C
M^]]R:\>?:8.UN+X6LU_S<"OF<PIC)3Q/PA/. -8ZJI0245%2KY3Y@S"V<_FN
MT\'E',[M241N$.U?R":8XDO;_6POACO_N X.P,%D2(:_R M_<\WN79F4GFQE
M:@""Q.@/ZEPSX)PXR'\%8[*-&4OK=)#EX7_\_1:!3OH^TU/.IGN=16D% [M[
M+Q3F)ZTG/\+JSB-\</3N<'^O=7#T^OCMF^.WK][O[ZW_I(Z.W^^_:[T_;KT^
M/GIW_,O!7IY6ZZ>#HU='KP]>_=)Z]QY^<;A_]/[=7?A] -'L_M,-_G''[C\4
M\'+G(<O[=*MWK]"X>SW)B[E;U]6*R='X#,;@E^#"O*YP'@].;*_SM0+TZRMY
M!3^\ZH4W@SC,:;#YQ^/TTZ4 >W<EO_:NLF/?PYA^[/;]7\^NI'Z<**G]SX=[
M\+R?#S@HIOP8/@\^ Q3.?YT>_?SAR]&_]R^.SGX51UF)!87S]_\YQ?[LMY[]
MMQD?_PF?=_;Q\\<_3SN_[YV(CU]_Y? 9\)Q]_/O[??+Q_0']?>\O N\5N>[Q
MX=ZO?T@KM3,^(!&U0CS$A(R.' 43$\=>.A=C;3MT>N,87N4P8.1)24V($IIP
MYY(#NR$)R[2UA$L/^GX$U?\\@V<P!K[?@Q\'G?/*)@'V_'$\A.,U'%;7E'^T
MPTZ5H3R[9Y=*[>3LW$ 9O#893_7'];[][9B^@3-YG<;D)8U-U$<F&X3#>];R
MB37,O]%QJXZD![WA&:B+L)NV==+M.U 87:=_?FH'9];'<:7[MR9:9^[P8EMG
MG>$PSP,TS]$ !I#CS*W1:6QU05FL#L4Y['!U>?US9W3:RN/KC^MS,["#F)/<
M<P6]X8O6>WC7Z_K9_V\(*NM@.,J?!<>GTES/!_TP]J-VZ]7;@_]^]?'U?KL:
MYWG5%C[D4M+Y8S_T*NVWH@EX=7CUUZWO8-W^LA[^KML!'35'^3J]4]NM#^!P
M/#R/O3R5[ZNQ31ZW_V'V&4"*BO_0^J5^/XQ)&-PZ.X%-<.,NS&/0 E(ZCX/\
MF!?33QY$'SMYC*"QQVX<5"IY/7!XQIT#_^[#NZHZ]KMX#G3GX,G9A*\BE/F/
M1Z!0CC(+Y@5NEF5R>.'AW'@0LIWQ6<M^RE_SB>G&+\]YP%O?';YZ_7VK.P9;
M:7+D\LZ>VT&UAC:/T8&0J0Z#!6::S"%?PQB,3V /3V XO6H';!AW1S?.=;=S
M5NT?O-P#(ZP+[^U5!M/L7E60'^9]M?# E,W]_N ",#$")CQYT3KHM8[A5_5V
M4]RNC^!XT#^/L&* C4NT?;</<[DZ^E<'[<[C 1P\&L,C_;B;@7<VW1^8VW='
M[P\GJ]+IY7*5U0"]'0_K'KFP:-5P\XQOS/3VO#Z?]ENAGTW1UJF%F?N+(3 &
M(-D-P"8$A,.'7=^!ZQ_TW>?3CC^M9C#A@;Q* *?*KAU6?S/[]N]KHJIHQ%9E
M,4"C;_G30;\''WLU'WB@S>U_>_7'M3J#0?R409HM@?IY]@S,M$G)C5[+Q5:R
M<-YO4I*'8U5Y/\"(AC\_[YS'?-!RSD!W'."L@IT'2HR'?7?5PV")8(M@$7H=
MX"_;A87K=&=9Y[S_&:R8UG?OWQR\^?Y%Z\>9]U=3&P+)=%MG_6Z$W8MM.%VV
MVV[-#!^>U7$=.$5YIP,,"+8B7,"'5=_D)2;MUNUEA8<'>$BW?YY]!W<>F^O'
M&W:PYT\[L*"5K*]6&]X"AQVD IS/TTX7@>3H5-0V0^DPKVHFO7K6L4JR.!M/
MI@\?,_G<F64"FL^ NWOMZJF<69 ^"4X&+%'HY&]@I/5G3Z1$_C]U8('RW,['
MW;-^SP+2 .WUN3^] )H>U80_,YOJ*$W_'"92><V&+QYH3#VK%O)-_ILYR:W/
M=ECEN0S.^[4LFHB@3##]WN<(['6:]^:W3IY)QV9)?P1,D^50;1=0TVX18TPM
M*N&0G _@@1W8IE;\ F>U(C[8H8[/0AC6M)M/=?U)/PXZX21^AA\'[6IV_X(%
MCA?7P ;\,6QUXTE^'NQL[JUX)2??M5L_@:;A 0X_1]!+>A?MUD%V3_4"? .P
MO:AY\RCF+<V_'K9;[^ 4?ZU_:L^*V_^&\Q_Z9R!O__O[=C6;?UD8P&;M]ZD-
MK?]\^I(Q8LZKP;>[WKP:O;:#0?9G_F:[8'5<1A_DUAEV^^3PZ^$?TF@=J72(
M".$0-X$C)Z1&5K/@G$H8MJ0J[_+BO@:Y<+*ZE7WUC48K6;0"VO= 2YTBG('<
MR+M<*^H1F*)26H'O1P#F8?6.N<[4@@E/XC'- X "ZIC6+S#B;3Y-]'!O_P_)
M9>3,&D0-EXA'KI'QC*,8O5+2Q> MG"9X\06Y=9I:EP?I4E>XB':0:Y'!H;C[
MX+QH_5=G"(I)5I@N*7F6W=.X>G,6'J#>UD[=2HX GP(=PM\/^N.34Y#&#@R/
M6MP#,50'+Q_>4=:;_7A0"X=\2D-TH\M(!_SA=8%2&9(@-,*L23D\[9Q7OJ3\
MT"LMNC.KA1-]_3GQRSDH095&>NE0R=^#]!L/+B<"*E6&2%8(0:W(1=OR+#^\
MJ]$'>H?M].H+CK6],2OE0,')6@LL3GY,]J?8@3^=S*_2V"H%[;NW_]>>G?^P
M!U; 5??A:F^FQO&,,MJN%;%+85WK.E?J*ZA*)P-[!E)R,J/\R=50ZS7+/TX7
M;>*NN^]SIV*Z>D1MO&25=9C7#=2"?!9F/J=:NT]QF/M#P4@BFMF>FGI.LK:8
MS:1O?&(EM&OY?;ET]21/8@^VI'Z4#6>@S0Q'@]HNFSYNLZ3]Y0G-.YW&H_$@
MUHP_R*@9U+[3O.Q@Y0S'#DR9K#IWZ\6;!6E6LGLQ&WI]T(L[V5X.H3,YK]Z>
M9X] ?BTO^ R$VQ-SJ-I<>-R5V_&.,S2+NGJ'IA\PL;7 #H W#%M5_+$>S/2(
MPP\34-PRO:X._/1O8(J^6H(\1 2D N^(V6#W?008..N/XB4T:B-BF%^\-"C
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M_#7;?Q=\^^/H]6Q_YU,BF4@Y"_R(,.53J0*?A8;Y08 ),1A1*8TNKR=]-^R
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M^9PERB=PYH9$I8:R[-E+QK:#]6345$]N2W9B#;_.3U8NU;5 %V#I'1?6G!:
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MTRK0E8>F)S@.#<J+7\_QWS?V"N1I6^6.PT\RXJ'0L?$#RH5/4RU]$7#J:PD
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M)8:HD,H!!-V?C-[O@J T);@MQ@^DHC[E(O0%B0$.)9E).25$<V#M*+TE$+1
M^M\%@E:PSZ/$.8QR$V8TC($[*$DR'A EB5$F,R:423#@G'OEH1;G*"$CSB+M
M*Y$!YPBE_0SU"IK0*.%<!&&"BD3THSAG];DQ0)F-@3(/V=CSZC:4VL<(973&
M5<Q!64D8P)<X$I(HG8$*8W@0Z5@-4.;^Q'"OE+2*>)H(0WR:*>53)HV?D<CX
M:4:5C"BAJ10@AI<#T>[=GO/HH0P-!2'2Z)1F"4TCQE*>"9J86(B0)U0/4.9>
M>:B%,D&<&4%4Y),LXL!(&J ,)8!L>!;%B8Y4E"&426[)9#- F9\)9:Z1V7&5
MLPJ-MM/X :;B:"-T1NC1-\7XF;Q0_BDO9N<>=#''P/9YH:O0]G*.H37X"?,I
MM+_;\*SZ]_,Z[JSO\)9/%H+BV\9Z;>$7LZEGYB.3CT9UDY5WG/.'7(BJE]/Y
MR'HFPD)8MU!,;2-GT 0V5X>UP1"KN+AM;\>KPH*JB"'G]#B=E"?YJ?/PNW2
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MN4/,SVN32;V*IWP&X&0"A]PAYM49C>HU:4BEPLX+(Q48H-7CXCZ86 #9TUH
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M:$ZHS#1S,-PVNH,@FDO@+Q,135E"PX1S$@$>"N)4&Y*"TOSL1A#CGJ3YZJ6
M&4>::Y8:)FE&&0LE8T0+D>HL(]P\>SF%T[7P[,(7L.#;'H()C\.QG*-\40Z
MC/D7C:>N@P+\*\]'3@Y-X.#OG\V" _3PA(9C7^/1?6X;D],Q@$"9\Q$"F.9]
M., !S0 TM7=(9Z"E>*,I($P /\>HG<!$8$A[D_9B"7-=;EE(4.,GH8]AN6L
MA=13#;1!4A9%M"-H 5$-'LJY*/5_YCC\F<5B.O^*#?%3:.HKO"'.;9>O7VVO
M@A5=NNQ!WELHN]&Y?]Z;P'0 0IWCA?(4E#E3@;.W;I[EZV]R-$<@OS.> E)W
M^&MJ]B8S/CG.8;W=;;5EKO,C&->OL-A?'JA^]_'?)X$<_\^$_YW-#S_OP+OJ
MY,/G]V0_ KULU^I\]'#W[>A@_.'B</<O<K"[?_[AZ#WY]\4^//N!?HIB:J)
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MCJ0[AH;E[>P2-A(ND-&D'LKL)"^4?\H+()7^6[;A+< $\@L_QB]@0;[F0!=
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M2"[SV<*Z5$8@.U\XLD<(Z"V$@.-,S&U3SB $NRP1CV&_((Z%/=7L<549,EI
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M->]JEAL#"Z+MFY:I?3<?C_'L!BI^!YL$QYSDDYFWTQY9%ESB:;EV79H YJY
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M=N(UVN-6K83A$H_A3^ WNV%]7IS;1;+2 KFVEH[U M<<LE6+K>8!]WCI3:;
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M]U:JN\;\'VCT]+Q4B]>Q0FFJHHQ0+FDL$T9C1D&!H 1T<J7)I[T?SI#2J )
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MQ2W'VG'+HA&28IDBP4%3DPJXNV=BF KN'A[NIEE?E/:8><&18=$CCIU'#H>
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M_YX-5EB@1B11CX(Q#N 5O%& 6(&P%CY9;K61*9^GKTLE'C8:^P!J]#+6I"I
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MWN3B7#H7:;/(8!F03IZ!*Q"HEVYE;1B[90&N>BV_[<!<[9\S3JNU+; %H,J
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M/F:F4V.D7LOZ7(A*GM,ZX,S@*,*-?L;VR1P899R< :$/C>T: /0HP5-'_0*
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M\):!D3=.OWX/6 2F)$6<Y(*0/%GDF%0H17"1K9(Q6K*REH :G,?%,WJ3Z0N
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MG-P>NNA.F1O4]G^J['9RVK8^UFLWI8<,>TNLS^GQ.>KC6XYBU+8J3/:Z*+?
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MV6'-YD;IH[:=-_8%_B-VBU5;GN#,E8X_;'>W^_DL-RK\,X]M]-.5E/2E9/]
M).\-6.?(.X81][D8!6%@NCO-$H8-G3'8(7!]1G!(T2WQ!>##6%_Q-[STVU>[
M'\'&\!+L#(R$DPGEG1:9P#D"^Y JX2R7PMY@:Z[.FN[T>N=O&N^+Y70F>!H2
M098RB[CDN9=08,ABDR/ON8HFK&T03->59.M87H?X.V-^JYCP0N7'VL?7:SLG
MM6P,YFO7<W/4!:@%_$SL_HB+8@ASQM&$33*4 ='TFF$CN7#42^8MM4N6M_?V
M-#.]4NP^]8?\H=/]<'X&YLE.OXS\&Y;$G:OFQ4'TP"BTI4CG/\!TSF0#)!%L
M0:I,4-JY+(DTI[NM<SRCG_P<N<L]A(>U^HM6OUF,XM^QZUN]@FZ,B>/DI9W3
M?.?>/;8I(P5WC%-'G.$L$,<-YL$[P3&\MJ82L:<5L<95<_,@XI!,LA(9Z0A8
MPDPAQR-%#D=NA+*&F[2VH3E?9V8&65E(OG[$WEF6)_AV]FZ" 9R[79=79-'I
MW;7/O)RT4^4J]?0NGK070?)#[;_GMGL6N_F!KX,U3-AI.YX5\ ^/'V+WHMLZ
M.XLGM=-S!S8P7)5@$.5\+:9IDM'LWI!$ W\PH'4 '8G!OXU/2@33]R#QO@<)
M2X;OKW*?07UV4Z%RS?.\0\$_QMC$SLE>%R:T'/<;UK9Q(V%'[.[M ,_@/!>-
M0<QI,!( OP'GG4:1<Y(843GK!="=K!,A;K,DQP3K?WL3NKC>;_>>!6DQ*4I)
M6"T5IAQS+IC227LL@I9!2$J<JZ3H>:6H<='8\@<8M)R9R)%10%0Y%0R,CZ@0
M_$LG8DV24N9$!'Z+$/6IZ.EY-\/V6>VL,\D)6B>U=-YN#X1M"%B%=[,D!?D:
MN-X?YFR@ 7^U[<$OI&[G>%Q0@=F>92_'%-J=PKYP;X\'"=2IJ"AU%LPE131/
M4?I L12>82)+CC%35.?*XQ]Y0)6;8UKV]O8//,PSC\HA*JG(;O2(K/<,4>.%
MB-H+%]G:!F5U>CTBH78*&V,A&?7:W@1ZG<0S$(*.CS&,"4T/9GT@?*5 @?RD
MO+N&&,Y]02PF!#._,:@U6=+5#(L@YD/ZVH'O=T>"UX]6[=TJ>].F$S? RAWE
MEF!.C=2*)*F,XSI@1=5M.(G$ C#YA[T\!HK3ZXOF@,5.MHV0;UTTKW8.E#!<
MV> 1P "(IH#-U8#-@6"M8/<RG@3M !99?5ZL#)##=F%^7\1N7$@>'LB^%I*'
M,9AZ#V+= MDOSHX^11];8._LSMPWW[J [&YM'@A/K8N)(B]ST> 4,>R@Q"+B
MC6!6!.YQ!.SBHCZO\%=?0NJU.UHM=S]-7R&KA9@GLUI((%8#YXS"*TZ3!!T2
MDA-->"+>N]"/2Q24H\&+BF\^LMY\N6A^/+"PSPM8!J0I\$SN(D&.8HV"C%@(
MB97%&4OQNA1J79H;W5"/8:@$!=H:&9,.!VZ,-@('QRE32CEJI:D$Y^D%9_\J
M5U>T&!9&,F"%+H#@$(VL8AJ1B&5TAB7)=;9-@#:M,WR]M]K3V2;+MT1B<M@J
M9>#_E$<F+7=: ?.@.A!,6>'MG".+E25RFW!Q0*4H0+<540AD"0Q?1PUPO030
ME!W*AA)F:((-7-9G&+TOW>20.')I54B.2&ZDUX)&X"V<1^*4)ND6Q*M,CH?+
M(+#)S0/&%/5,6X29!=N"*@Q0!RCGA%1.,A>$SSLCR.#2K8P'LJ7*RG@,F>"-
MBP.6L!$%&D61NY$P!FR)$L0D]E$D1[W0&9=(?5YED*%AD4%JTKBX,7BWS^ES
MF-X_3SN]8HM[UXUM^.:/^,^+5C@[',2]CUW5MT[PZ!+K>IWV^=G\2\9BDGW,
ML>K/9+<8,S4[8W\>=@>C.;7?(G+=:+^C KW?V?:%O>RM_3)IJX%9UK^YX?4\
MA?.>_OYAR2D]VF24IB3H;Z=4S7?%II2_!<.Q*S.6VF$WH]?_W!X3KM8V]G(8
M>]X:WV?@.\D-Y>V,&/.%C.TGE=K9D:L[S<^-[:W:3O/][J<_=C]M[FUOO?R'
M:N[N;7^N[>W6WN\V/^_^OK.5'ZOV8:>YV7R_L_E[[?,>O-'8;NY]KOWT?A"P
M_/-MS_WR _UG18$O,@.+K_R\5(S%T&O.7>9_>$,(^W)#TI]IKQER=J!/G;ZK
M FS2<3MA,:^%)EIPF QM>.1*2V>3Y58EK!@PN6 KK\73$[COE\UO!R3"]&,5
MD.,J(FZ#0%H O7?">.PH5C+0M0U^2WCW]&DG6)GO#VVK6YB![P];,=6V_X[^
M/'.SVFY*8-EWU\NK+@Y;_G#"Z]KM$^W:26=HI]XU6&:EW<[_MH 4W<OL:-8/
M<#0O8CA1ZS &YF&"PCR?TF&&5805#BD&'(M(QYS(^9 PM+)";.^L>YY-YP_6
MQ\WC[!1XP[;1]M^-O9T#3H-0202$>3Z,"RP@;0Q'+C*3HC045@5T2^#;+.::
M_?:M&[_9LYC==">^=6K;-5M,<I\Q#MN%Y-2WWKAW^8Z^0]#8FWV'UWZDM-A2
MUO)AWD:^:;ME7:N==_XLU9V36 ZR%/>I>]3ZP7(A/QI\:1A&=V%[M1Q =VP+
MI3A[ J%?R$DP52#Y \Q"D2 RRCI\R^ZB[:OF5>/ JT!<# G9Z'3.'A+(2N]@
MD[%!:FZ24L"&&#:W^0;6BVW$>C"QLDBW+TOPC"6_'$G93T.BTCH9%]U3VPJP
M ]1\&23[\XU2!VOFS]NEV/563>PFH79,"-_;;O<2YJ9$WMT$JEG2[_>#V7G+
MXHAW]X#I*!QUP@E)F2,0+77(<F.0A=426@=)679?<GS;&7CMO#< 5E#S5C@'
M$3N.9X>=4*0OI/-NX?<.L>>[+5=*8T:[FJ[E]5L2E8%QKE*&ZA_=" RE"T_[
M$I)4"T"Y?MZ_FMFJPZFM$E9O3$7<VSR@V#)A,$98"[!F> 3&13Q%(5@AB9<I
M.;=H<IJG,1+%+<?:<<NB$9)BF2+!05.36'FV62WQ$RTQ &ITA$=$9&X4$W-E
M5"DCLC@HEV1B-N4PS!MRDF^*V#@=PMCJYRE/"DV5JGRK\'P\H%Q0191 $7,+
MPJ,%6&3: #YXG:R)EI-P<Z&D.8OZ )"H%O6!BZJ$L$Y1B:0&"YM+'7+$5C:X
M(Y-$R^"=G9-_OHR$].7L#T!V?-XC+L#&Z<63NVP0;SZ!>>=B=VO[@,#&KD5B
M8&8:6'3O#-+>@8K'I$A@(6>K/T]"^CW6M"HT,%I8JZE@1@4$AIE!G#"+7/0V
MUT#'P5%!B_[C+V1A*V4MUM03GPRW&LE4**O/09*:H,2\!CU. BC[\Q#T2ED?
MM+!1,XN=<0CG8A+<.F#DB<).3#AU06,;':#P2>?V+?A!?+V(+)M3:.(NP45W
M+>$G7W0)/X)7K8;?R&^^F[(W)I[T^D%WA2NVB+\LE.Y7VXMA$*6Y.I7]]@=*
M!\K@V?[51]S<"H>[>SL8[L/VCPX/O\)O-J_V+YM;V[F$J&A>4[I-WKP*1\TM
MN)9NB\;11QAS:.W^]J'=W&JPYM$.;NQ]@?^^T_]<??D;7A\(J8+  B,/1!=Q
M$Q+H&W$H2I!62J*CDD^7S#.P,I%(QYD1W$9F"?,V<H-!SIWPZEIEOZQ7J)CV
MVOC*W*.ZW^T_/3E43@6.%"L:DN1)1QV<@D<BUCCLN(LWA5*L;M6$L6#LPE.I
M_MFK^7/ L).S\2.-P3S73MOVI'13YFVLMG.2 V#R.?H?Q0?YS,*>GG8[^<3<
M79;8V(_!R0=G9S-^;O/D)#NM&S$.2E2,1^YD?W7#%L?4ICSDF_'# +(U&XY;
M)ZU>+M];_/3@IX9#SP5*\C'V\&SPUX[MAL(MV^I&?];I3J?)U&M?\IED\1;<
M]WCX^<QG'_?=YO&,G#5GG=JW;LZ>L+4?MMN*,*GYH&=XO;V @?1JKA#K+)]G
M\_-S)DO!_ 0"=CAVI^N%8D IT']A?ENI-=R7^I__O%[[]/E+;SWG Q?<(Y\Z
M]3_[99"=,8R<[[N@RJ'"$\5VZUMQ=AJ/3]N=RQA'OS=XIQ8&$UNO[9;+2.1Z
MW]4]K$U2RHMMWS"YTZ*TOJ!5[&#CQQ3@R:7$D_4:T\S7B<N9TDJG048(V&;W
MC_,9;@CC4K?9A87_%O,&\>OEM3UC,\_F9%302CI:GWI#&7>K ,O+9?VP#CHI
MB[!-''$PFX#1$8(,5R9RRBSW;&V#K8M;8H,*2C:FFA/E<K*<QR(, 72B?9X%
M^G)P8>_<'8$L]Q.@3M!XE::^4IP/P0*D2<W$!_A 3,MVUIK^9VSZL[-# $WX
MZ1Y@,;S?OBP?P.?AMF-8+V"I=5(<$)^?1-L]R6_&OT]!\4(_M0$>,<766?YW
MVY[V^@]=QC;9'N@._*OX8B^>G;7+$T)O>X>%CQD>LSR=!G7_$;L%<)4S,E)I
M.BB(-@GP_]LK3[=NQO?UJ4LF=XS!5I*G"10F'(_%;\S"B?SU5K$F^1GSMX:+
M"U?9B8/XQ2!$>2>2E8XR[P!"@L',,)8H$ $LH]%]6BD(18,7SX@EF\/'K%!E
M'JKL?3M(F%C);4# Z238B8 OL,08@:6@O&4B2@ZV%;\554::G_E1O5:<]I:F
MRISB@1-VS H=[RYK%_MA6^V<0_"AT_TM4Y\W+';;%\V]_0-8.Y]2R"5I4T(\
M>(X,H 1R5KAH9+*"X[4-L9[/"K6:%_31E[=N/+9 Y4LD3T55O;&B;^/;T#1"
MSJ?0%ZUV>[2=9!HZXFO4P%W;L0=L_"QS6Q!) .-,5KOC.Q#L/^T6_/9XMG#F
ML@5WGBJM60;I@BE3[*CP]R2!/K;?<_;Q23CWA=B5!+H@X!,<MN\Z@(?J#7DT
M3!%<'^*UK.6F[07[WVMWA<?QL0PWS.;+9*3@"=A9A[";]OKV2I_N%E=/6$9Y
MU^R<G,12DXOSV5G63M^H*G\8MBMX<5RO;9UW^U$\Y?.<7<0V+ Q8 &>'<$TQ
MUPL%CQ3W+_;RX;-.V@8>]M7NX@G_#^S[=S<P:IWTCN^/1#O#1]XMG[4 H-[.
MR1_PP)WP6[?3Z[UE."*[>XV#@KDDV.J,R?5- ]/("&*0"$"GDZ:!*IJS_.2Z
M9O/B@1<_G7Q@_[-*>IY?>B@\SP$)3M@40' H%[GLMD0F$@W&6? J6(Z=-#F8
M5JP3/4]Z!FG]\,=I!LT?,8?2WEBG).-XQN.AQV%9T8NTKE8I?+'P<M;Z\K<"
MP8MC3L)11'*O6*C)B/O)+6:P!XTB5']M6_\=??9@W\'U^;)R[SSN@'U9KSVR
M6Q]^-X;S(AMKINH7T]Z?]3\'8]L$6G5<OE<DQ;YI+__6QP.'L6(PP\A%;! 7
MP2&7L$+8" GP+B,-8=IUS@1+@G*X($;.*3741)&( 8[&<TN/:2]_D<K1:;<[
M%X7@%+G(L J@P2"[I=R5_*F(F1\3P2(R?[1@('FE.R/$DJ4.Y'!2:BT0WYF2
M.^YW'?'/,4K5__YZ+0SY6^T26/#-E*WT@ Z(FZ[??'AQXZ'"K$S4F:<=MR[!
MQK_Z\SPH35#T2@.@*7Q&[P8O_AE:/;!Q+]^U3@JX*"Z:;HP&&-M/X3>FK@7+
M6?S]-NS]V_<3_.M%@O]4=[?R,\'J@M"Y'^,ZF?O93;?-90?Y_$MONNW-GPE6
M#5;PN]VV:)77%X@9G4;G-12]X:LSNH"6^O!,/2^O[>M%*8NL_-,M#=_6\Q/S
MQI]?3SS_+8IP:\O=E]#\]L].KH+3+EKPW;KTMW7VO-Z[<T;[SCM/QVK5U;FY
M+>Y)X5^=KD25%%/,6\6!% /[<C[;S(%$@[D)%M_BC:%+\_X.4T['Z')NH9O;
M3(P$X!/0M:'MC.@+9=!E2]W3=N/XW]^;]"-N_+;#]G.[W=^:WW>W&A?-WS*3
M;G]O'C>/&T?AJ'$YU5+W^,OE_O%']G7KX\7^43C<W_OT?9]^Y(VK3;R_]_UR
M]Z^/=)_";]+&%1C<9XU!2]WW4^P=GJAQ](7N;GTD^WO9R_P)GG-?P'CP[E]_
MMO?I-FO^]N<AC.+R/U<YW0 GELMAX4 =&.V<(2V,1-YIKG6TFB>_MB'E-7O]
M'V@QJ:3<81$-E]0I;C#5'(R"Z)74+.<WB$HJ*ZGL2Z4_B%9I'XE#PM.$.!8<
M6>L"2IH3:J1@ 9NU#74]6^(?4Q&42^Q<7VU,#]Z8F+6*<8XULSS!SL0D89)I
M)B)VGK!;'+T5!+P("+B< P%'7X^+'O-735#S;=K,;J6_&@*>__#KT3YM_/7O
MPP;<M[GUY2IO3#8F#J+"D*%$(RY=0B;FJL782$*M$)%RV)BN%RG^1PW-/X"8
M*9<AN$2]2Y(IPG6B6@B+&4N:P-9(4JSDLI++OEQ^/R J<,&L1Y+GK2G(!(2)
M&'AE@PXFP8858&NZ?L!1;4TKO#7!;B0P<Q*K7!A%>8>E\=SFEHZP9\D2 O0
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M1^ ^$>A ;;& *^LPB4QS[87AP7&3B,FEOHAW6I)D%RR(4: /;)D7'8".>#(
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MXZA Q];N;Q_:S:T&:Q[MX,;>%_CO._W/U<>KQM9'X'Q66BLLPIQCQ"48TU8
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MO8,^O9XYNUMMB&K.)N9,+P(O3^JO>N4'PY]B#P ?C/I, D/\$=N=T\Q !^Z
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MN25#VOE"#M6O1C 4VH.P1K>M\74G/KJCH!LS7"'2_G!=Y]O#)9)L3\UU>_1
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M'=#5!W%+9MK-=D )5VRVX<8^(&([5-*L0?$VH+@W'5A)N4LQ1LZ:!%&?)@B
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M@\:1LK!@C38LDQD&TJL@?['6.6,7*]SSD3CG)!6M32M! 59,;B/$"Z?4HF)
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MH_;.YL;9SFQ<S<E6LG=\2/;__/?QSN['SO[QEQ^M[]NL>0QC/]Y(=[[O'^_
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M*6TT<AP[GF#IO-57UZQ8ID9Q]6Y?L=O'6P>8&2N,3O.\0[ #26@;P)&W26)
M89(4&[ +KV@+.-VS*.)*K/YO@V$2RQ!--VD;5V@:=4O5>"HHHE ]0\V<O!QK
MU#A!/2VJLW>*)G_GXP*V^:5E.[?P[D*Y&FM;,?ZSU)\J*E= I@7#F%:H;,_E
M[PD%84W[-!@=X?-Q,:I*'=KIXM.7M+K)1&,]WV'LU/EKV$AQ42X<..-HMHS=
ME85>;VT,1DJ_MC1G&M).;Z^/+T\51WSK*HZ/5&LGEN'_JVV"X 459P?VO+]Q
MV'>QI-3RE-BYV"X@Z/1'<W/_1^O[%MO9_?*CB;\E>[N?X;^]M+GY1Z>Y>734
MW/WWR1[>[S1G(>CD\UGKY',*T,5:?WZ^V-_]<@0P=-0Z_G;6_/,;P-C6KR:\
M>?_DV\5_+@[3YG'S@ MM/1<,.1TR:' :M%N:()LQSY4P3$DR6V)'\Q#E9GWH
M$4&=E%I+0I1SGJ<RP>Q2B9UB\:-DBLO?F*S_U15RYA:NN?[UT\,E&-073F@&
M<HY:#C-6.$V(HYX;G@"A+*O%>\NRE=M=5*YT=7V?O7K>S:<1R_!\VOBRW?AT
MI$"WR''ASQ/]?\MI/$>!OR*=9+O;V#CMMSO!=R.F5?-8MJ6L9ZE 2(9=B&7V
MRGW(RT?.G5KC7?CX?:[)3^J:]TZ'[9,HM_Z"2?45S$:/@D>GW_AZ/ABZDWB#
M=1V0_'G+57C*_]O8^[ 5Q6 HMA?KU,,_@0[R ;1VFXW.*!:H]'E=]L%JX\/'
MR)FZW^N:HS9\K 9MD,#?8B^"O ?;I?G,,4W"BI4=#,KR]-^^QD>'5L @(&-%
M>YA0$.#=TK,2?R\K%):M 7[V.C]C'<U)O<M!J<E<NS"KX4JPM#J]=EZ0<)"O
M5UR!\2*5;KJX4G&+>D5QP=!:H!C*:BR*.]5"0W6#)@)$-?*@B\7.%%&)*,8P
M*-V H9!NZ$@Q#-K.:+R6H9"_ZX=2D67KA3DTLEHX]6)1R('IMW5>%=^/^A$^
MK0.5J9-W7\I5I44T$G9&.]?-VXO]='9,9H6N!#L4:I;E;0,JE4[+=7H_]NAN
M?;L539RJMLT)'CAV=.J!NH;%7<'1FTN#4OD#K@5-L==U<-MYW&UX5Z@"^7%S
M(RB4L*!E)X29FO_ XIO]T2&PYIB )C[H28.#^)Q0G[:Y42Q%7NBUG.;"L4\*
MM5X>8W@ @ /)Z.\+[2TWZL_V'#2>RL1@;6D"_^-:TX1GUFM'E4P("ZI, A(N
MJC+A%Y+<K?70AU"@3<?Z\#_=1K\?=.0P[F8YD4_Y/);'#'MR'0A^W_UV0(U(
M2"8$8M))1)U-D!8B0\)YEF52R#1A"_H0CLVPV].!%XFSF2(XX932E"O+,T<9
MF'PN)5YD-1T\*1T<;Q]0FPC),XH2X$2@ T*0 BL-,5"1B6<BRX0/='!57W;
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M&\'W@]5Q8ZRU9W*=QM%.7*=@M] BL"&15WA/0V!#;#KD1WFTFII@523>VR\
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M!CEK**+$@WY!"4&9$SR1FJ1"RZOTBY*E-)A>T12KQ$^(/ $\!D'T71=00XT
M;%6L4 #0':BRP*KP_+P6Z. YZ2773W?\EC)'&^58OX2AJTY-0+,$]"LHJ$8;
M2XVB8*4Y(" A"-):*41\XKA)36*Q7UD?GO46Z*<.EGH5E$@0W(-&KDU$1 -<
M=NUX;'2J^@ Y\'?P;;7'F?)]]]]1NS_)Y'YR8OG>#S'$W58/:,2-+9O=8@J
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MUC(:=!]\9>#"U$GT95?NXL..-^B=$HN]4__4/7L._QP-3SKK_S]02P,$%
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M4=369NZ/E=:O$V['[?O'^/.$^#1NSES?66F.#ZCUP?0< .AU]5Y?C]LB)J;
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M!4P](!9&5]'?R*J^+EC8+PC!DH;E2_I;D3O\ZA]E->*4\Q.',:97<*M3(05
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M-M=*%\VVY9]Q2J;"A! ]SV?D/"Z6U7#XC)>@4DPR\&"AL$"@I"6/,5H+-=N
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MH 7W+%GRWDN7@^^[4(844]U/YW=,F<.&NXW3<[TFZPI"RB*[X#V@KA"<3?7
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MI(TY-A:X_OM/*[JB8/J/@<_EP?SCBY/IG\.>Q[MZ:+MS>.MQKQSV\M+&&$P
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M_\A^,SLM/A0V+K[6D_P+6GI^_>^S\7+A^9:-$ 6D5HXS[V*]UMH*\I8P, $
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M1,*X'%D(F29\#AC1:HZNBT/6R7PWWKR_A;67[J=#*&[ 5-L2"'RY!L091[Z
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M1H8ME#UTAN?U!-],247O\#-.7GPKD;VVAKW#R7@ZJRO9+V=(P;ZYS&!XG9)
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MEZ!J[;+ -$?!(J!F/!0Z^T6)D+I=KG<=\?3GZ&=3UKU+^D$8&:8NZHYZ,7<
MU^S7.=GES]DESNG@^/7-;+Y<$19WJZG]#O,IYI$PP7'N1<U%DXS6%6"Q]I).
M17EOE.'>#I*BTW069RC9YU?#$%6I9C]@<OWCCQNHO7=PZ5A_'5^O#+O*4P+!
MC10Z,2NB9SHES0*9B'&+7"E.WT$S2+_>IZ&=LPC;\C; $]<:X29('63(P<G
ME"1(FIPH%D [9I56:(S5I@RIHF?+%OC5%',,'ZW3HE=M'&E5?(]8GWT_ ^WW
MMYM^[1!WD?.2%YBL8:\]@<6(:VZ3,(8YX+CNWZ.Q,%XX2A^5R:E;=GT/$&>H
MHI/RUC"1>HG[ :K'ELU<O,BUH01BC3.3Q3-?/+"LO>/:J RJ6Y>$0T8]5T4-
MQDSKA.FWE0^8_(GSKQ_+QL%[#].;0O^]F=.7X?;P/_(F! 3,# 4ZVGA]9)$4
MSG@2Q7AA+>1N2]0!@YZK@(;BI6'V]9VE\V/Y'>C@<'--)KX>IT\XQ>\P>1(X
M!E5<<LALEH6$SS.+AKP=5-GY9)0VVARPYQV'XEP5=C+F6N=U_W,^OK[&Z8<9
MX<7;K;M^4\;3Y0GT2?2V (]&9I9K$2\=%#"?HF6)%W0\A62 =])=;RCG*K[3
M<M@ZE[QNX3A/M#Y_QOG?-(/%+:[W1.#7FZ\?XV3\93F1$=(6GK)/S"EMF?9T
M( &>Z/L"JD0;M*5_.MZZ=A_U7'4U&#,-\\NW',1.6[Q4!DRVDFGNR$74,3#/
MZ9 ;!:*-$$WH6+SOL''/548#LM,R,?TIR?]>G_UJZ-!JA5W]^M>WV72]_-[^
M_.=4 +FJM[,L(#F4NF1)7P>P3&9TIDA4#KK50FD*ZUQU^'S<MDQA/VHJE_3+
M_,_9[__Z-EZ5727_8,><@B<O@.? K%1(;@!WS$>++'LEZ2#MN<7>NVL/?/\5
M[K.QO4/!_6JG[K/L7]^(A>GUYDW712==5)X)63N$::M9T!&9X$*IB"[)+#HJ
MLLMXYZNPYFSL4$R_]X!]&"^O8('J\_5-WMPCCS+WM4AB8M(DS;20DH$/!+OV
M\# 6B\=N=VO=Q_RO<IJRLD,]_6[W-T\,=5._2%=C_'L)D[Q1^NOC!).?+Q3K
MB^2 RA=!ZZ&WM<=4X9QYDTRMRBA . <J=ZNN>_#0YZJE83G:(:E^M_W[C/;S
MO+.J=_\%;U?0Y=0^UTCT_'::QZO.0Z, 2=&Z"LQ)01LQ7S8#HGW99S0 T2L?
MN]V@M4)TK@)\%D9WZ+)W#=<-.'+\5D]F8UR,3) ^:\D91EY;6RG#O$J9T=HK
MBI?)\6U?JDUPQ2XP9ZBP9MSL$,S1;P _P]7^QND-OB&S;:YG_CF^OGIU0\LM
MG3W>3M/DIE8>K:D3]&^-P!\1-"6]E;3D&L(L-/VN%,D,:F&4"*J40<I:'8'U
MC.4V-+,[U-CO/>#^8^UZY[\30_G@##Q2RM5"^\"D570L$5;5^A^%1;!<FEQ
MQ6Y]X0\>^@QU=0*.=DBJW_O O0>R.^]B!^"/X)S-2&==HVOM;4$+M$^)!2?
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M!>LLEM%>I&OIU5\BN4;_^S__#U!+ P04    " "N.UE2Z3_L+U8\ 0 ZAP$
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M]GM$PQ!Q#1?A<?)VZ91)U6$;P;*!%Z*K(</25]!#W_OU>Z:^1J)UN(YZFE6
M",2E(9J2,[#D*FQ+?]P"Z)K.]*;XHW7 5Q0_8F_/O"A8$LXJZ8_6V&K>(BN0
M_[H3IR\Y]D6W8^5?3RIJLFH15YR2N"/%-=ER&TUJ06MT&N6 I W7)#>MR7P<
M.#7;O10>' '.?S0;JQ B;HM7C-;-2LM8>;U#ZK/Y:C[83W;MPQ-;3K"*$1<)
M2@'1V"9SIFE[/&3L BH\SU-4SN.ZLX8(PJI(I'3(D,JQ5-F=US^I""X(7]IQ
M.71V___ZDB, *F>+.G(1>",K"</#],%.._4AF@UPW:N^U,$A*)G*.C#P@[[8
MG>N4/G,N-G,^N*#D*TESGUC@K:'9!S9RA:0&#K!JS-4QZ8_!8@9A,EAR$0)T
M0LJJ.;V>A(GL1AL_"VQ%)H5>B9CC/7B(&&/A<35T>ZJ]GX_L\#W7_CM#W]62
M,)\?QR%V_G^W>D^3+OCO6DW%]S.9/O>>R76+ OK<NSQDOYWG814Q/4I1K[JP
M_&C':)HQ-32%>1"KMIJ4#58U^$]66>J/%A:F+$1M^3Z_[?3NL0?XT6_EQ:CP
M[GG%.O8@^"[1K]Q#2=DF]&+@G?[V3/?F1WQ:/YQNO/QK@E#]7V0L<OY&7N/?
M-=?X?X:<]BU0\?>B4ETR]TTTO&KFO?E6JR@^3NWHT-/2N3C@<C:*MT.6J_8S
M7,\1T,;=$]!DE<)-T%L:0&BL"FU<:58!9K./>NVE$D3Z=XZ73#PV8#?9%@?O
MW_V")^023N7QG:F)>7[H-68OTP'* 6UZ" #:HR2@2.I%X_BL)\TV2V9)?5?J
M]_?'OO1NM! UK>;/%]\#AAM_W@&V0:3'3"?H-QCDA*?;L\I,UH3FYX,.^!8'
M+5BH*<^>;WXU_K@UT^&^M!JSQ9WBFGZT*F?N3LQ4V90>Z$#&=B%F7E%\,T [
MLE,WR[QK7A9DU278O6^\;?G"X,XKBPN1V@_S9U+TAX9ZLNVKG_V-]=//J_SZ
MX2+@E_92E$</?._8<].#47[)A\=K(H6I>.<LS0 UC8S[)L^?/O^DH;4K&\7_
M7K!*_B=A=8'AB1DG-$04;06C5TH9 -2]D)QJ>6YW;V7 C>&RO,=?OTAI^9TD
MO-#R"/UY\\C.%/Y3P.N**L/I4S_9HL;/H=->-!VFW&D[R/-)8&MFL5R' DCJ
MUDM[.V7?\ ,$YT;">\:_ ]_3[WU:X..-,^< @5*SY70+5IHE@@.(Z*R>9AR%
M[%Z#C;8.,<'A;AF[O]_#CHCY[(A)Z*2:>/>Z0WFT:*I=&G?,[^S8A^EFJ[VW
MC*D)*E)J^L!6GUF^\60Z8+/-54^U]LU/^3GEK9=_ AJR<>4AURRY?8\$CZY!
M.CHWV0A4'KVTA77/<F\ETYKF2PA[_FU>EW98JO)$WMVCE_U://JR#/:< &YZ
MOZ9V9 *ZHH\ (<!9J(]4CU_A.BN!V,D.BZ^$1L3J,B,*=6C\Z#A\C 0^Z=@"
MF>Q(V5D@LAW9&&B.7PJ_/UB9V,?7(WQ%1FH"LP,R */[BBQ'.W9"_12[I%^A
MLJAK.R^!'.!VY$%)D;7&GJR<$H_K<V)=6Q_+UJ;G*"UYFO[G7)Q@16E P9>'
M9EE5 ;5>Y\[W>;]H:DV\G'GFH$O.37&IXN>A FAMR!6<M/\,A8,CW9M\'W'K
MN:,F_@;BA+6M6=$1:YX"_\R%_IOB![WJ+5(!88FF"%5H\%S+>$2LHE,!!W"9
M",%?.=O\OF_,0:]HX.GS'CKP7C 1+<8!A'@Q4WEX$:R?E!B[AP.(L[<OS:M
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MQY8,ZB0ZV*\<U>?.=%1X, \;?6!Q/C"UOD+1]V#J8P&?J !%)6#!HI_0L)9
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MA8? E<53$:VF@T+NVQ J@5CS^'6N3;*S"5$"-NX/$4Y-EX$7U+JY!60;U(9
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M^"Z]F"I7R33"]JE@=HTS3Z*VWIQ'UJ+>*26&DY$B(]CL7Q>..54(O%7O0"Y
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MK_W/.KQ:NA%+XD)H&/!J&Y)M>9N:!3\Y$57CT?G!^*[7'WU:+?EX8<'%0/4
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M3]^=51'.F/7PNOS&Y^2U?6ESE(6 ^X> HTU-[V>_PFDI3,N=?-*%;0AXS&6
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M)$?LZ<>2Y&/OM 3FWG2^-<WS]QFPQ!$E%PX5*7[?AG0$T[XNC2N'3)(_HX^
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MU9*.*6D [0>A>_\;>V\>U$37[HL&09F)S#-1 1$1H@BB@$1$9C$B*@)*0%1
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M;#CWUF4U7*<QJ[5B_-'E=#\?Y<%[B#6L_T<BOAK,M"2'B8%;"/7,%D^"- F
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M4R,!Q3Y$:P>$;YZX/#FIM%:CSUWOBFDSXU"-^^SEPZC]&Q6:YL>7;71&D<_
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M1A;W[D4FQ>(/]NJ_W! O%!5E-.4^&+-_X,VV2RMJ265786^FGTD8_8+)W!#
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MW^N-!#ZQ:P.?_!CYK!)ZL*#O;9#FJZ(8&=K:%?&>@G=V5[\WSI.VH6E-Q?L
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MR\NBCP+BAO9@/RSN$?RYP.X?H]!*$<U-^1S]Z (XJ+6>9;FWEJO'*VT[Q-B
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M9]/=:XCFOX<AB3@;-!\7$C'L]FW(3PMXJR!G=PR!HYH+1F^N36]#['^RR^&
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M.T7'U-''B5,D1,9%K][BRL&,-4GR1=&<*I+U@1GBNX&>Z#RD"-H,S*!!L^&
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M,98H!U^HVJI>G0[12XY]PIGA'!O[\Z739"\^_.B90J9U2SOS<#8/)'/ GO&
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MTQ_=^TH?/2K^-3"T?+#2-?#*Z.73,\>MWS23LY& M3YX(&@@,LL4,?!A9 8
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MPE%:!U+8AAK2>?SUOY5*^^N,NMAQ1?,?,Z;?E&YF0GX3>+#$XW#_;4@J9S_
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MVQJ'$,6<:KRS!+(@XHK1**%)U.+=M0,;#^WCO<[&P_J5Y'6$((@]H6WG2_.
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M,B!)G""(<&SJZH<,,IK%$"N>B5 0%#@&P%\><VKDO"4R6"PK4UG__T9)\&,
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MB2,J6!+"+&4<(FKV%0A%D*I(*AX+E3(K2CPSQM0HKRY%8\0T9S]&4.>TIG.
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M_-<+FWWFZ_>0?IQWM] LJ^?[V^;)FU)*<4JU21>GD*B,:T,/<T@3%L$LXC+
M/$L3Z=30\]Q@4V.TM:QN-'463SM6\H72P"2T%G.';P:I%66#B$^".3O>J'QB
MH_D^?5C=,W*-I;;(P^NOLN"YMM>Z.@]UJV--<D6^*'/>E+_!D42X[B"L]-0@
MQA%D6:3_$Y* $8DI)^.43W(0>FKL58L(\DY&\%07[5LJ4-9UWY9M@3?9JB:
M6!5U$N07V9[5CE0\R>7%L/2736RZA_; 75_R:%W4:*WZ=EVCM>:3*6#48Z(F
M49O(1>Z_1MFA'C/AK:)0G['=\^5N]7BB/E:9T_L9RE+.4(+U=Z0H1'%J#&*%
MH) ,Q3R+" ^M3EL/GCRU]6,M'##2V2?'[<)UGK"O F%@5K74WRD3[JBN5^3
M[3YOM.RWHVILY[T=O^!Y#,[WJZK4.VCC)]PK*=;QQH<BYW(6*<Q13#!,ZH:9
MF#&(4_V=JY"@B$4\4EDT:PRC3Q4MJG$L3TOI7;Z;?1V&^X1:'<!RHP1@\CY?
MU-4VM"EJ;,UODA;/6[W3\46AB@=)(#7O"]-OD>G_L$"_,F%*5<"17A84:E^4
MUPOQ%W]-.@W&?4DT>_QE7X]QMB@#3/A?:)>RI?V1JJL= J"&8#J[%<<YF]*&
MQ5;TO]2>Q7$^?&];7(>_KF! <WBPE>GZ3E8OI%H6<E.6?1VX/Q,4QQ$+$90R
MC"%",88D%3&D1"51R%A,J54RUE523&U'I&4U+?J:U.V*?@6T.6S[_E&OE(6I
M'D8?'^??.B?:T[JA NU4LERRKIN[@+(@4QA#'B@%M3UB.LGA%*H8IP$6"4(X
ML"G4--[<C5#*Z<3<C3$?YPV"T5 >>'D_UA'N^RTU?@!F"EBMR7:OD;4N8TQ%
MO]H2@TW)2,DH3?&X#GM#1GQ=*O$(2=7=%0^_%4"KJLC9JJH;PE2F6ZF)=ZNC
M#BKY\+@L3(L@D2M]HZP?8T(3."V*;ZHI2M>$Q!T\?=XE\!V,H']+3S[>5V/4
M:R?:MER&V\.?I8)&+_U/%=7H][!^/J+7M# N!5,?L3:Y/BSG.?^V.77/9! E
M/*':+*8)-!T#(1%(01JGB2 X25#F%*AU8;PI&BZF:)PYT&GV5VY;YTOPVFUY
M/8(V\%K62;K!ZP8TTH+?VS\'"7*P1,CGQO#2D*-NZ"SUW]^(V=[6CUO,YJZ0
M7_3^+G^230%&_3V]5R;X.@D%UB^3 =:43<P2 EF*,L@IRS*6I5& J$M-U#-C
M3<V@;L(+^+; /:JDG@/7CE4\038PH^Q(N5LY]:8VC+51I"6^ ;=[)M ':A)*
M_5&,!5P^Z>7<<*-2BX7>^[1B<TL_2C&E==[IM^7V:VY*2$210$S"A*=ZNYYH
M$%F<"$@1IRF-8LQIY&*;;#]\:H9(7:+)" =^-^(YQG_OP&;'#GW!&)@.K'%P
M_KZ/*>SS@]YY_JA?\#'-]C_9H]=<VQ[J=E'E(I^O3%&L3Y*OBGHWTR2?2-$D
MISP\KJJVE/N^-=(T"V(QY31+3%OR.(0H34T "0M@E,:A2)'>G)"T7X\H'^)-
MC2>V&PQMZP<V"H).PRXK;*VCN>G0@K^V6Y27M\#R;/#9YG;H(\!GF-8KFD?Y
M1'^8#E)>)'RF-E(^T3W=2\KK*'TWD'5)Q:(>XF->_O%"+OB7!UK\T15P$0FF
M$</:^,,<HBB2D 5A! .)&.-1FB$D7-:&2P-.C>UWY 5&8+"6N&?AEHN8VVXN
M_2$Y^ [S&A![["/MD/&[F;PPYL@[2CL$#K>5EO?U8YO;AV51Y?]L^<S4L#8Y
M0.8 Z$,A'_+5PPP1&@1AJN'%*8-(;S AXX$&7,8D3) *$^)4O.7BB%/CFUO.
M"]F9%*8C !"MP&XD<QEJ.Y;Q"N# -+,MJX'/2 LZ<<'WK< >VP%9@^.3:2X/
M.BK56&.PSS7V-_8CF[>F[()<URRN"[2NZ[&V(4_EJY5\)[]6G_^4\R?YZW)1
M?2EG0J:$4DRA8EAOAX,@@DR1#,8TX0%6<:SBT(6#^@HR-6J*@BAT(Z'>4V#'
M36, .S!E-2J8Z-&NM'9;"7JMQTT7:%K> *T+,,J 1AO0J../SZX%U"?-]99E
M5/:[%K%]4KSZ>5<[%+7]L9)B*S2BWF9NSM,9C00*!((*:6)$"#.(F=X?RE!A
M%@<L%K'3D8#]T%/CPU9>\/JK";!UK7OO +FS9\XCD&-ZW5H\M^1N/6C#1#2X
M S:0H^S2Z,_E!+-$Y8R#R_8)5Q;_?*\^F;H!7Y9S?7/Y^C]7FBS7M98B&F>2
MB1 &(N#F=".#-),4DB0)"><*8Q3WJ@=Z;M2I<=6F$*;^T+;%_E?0"-Z[\)7=
M)%A2F&]HAV8O'ZCV+SIJ@](@=4C/#OP\I4EML#A9K=3JYFLMJS?Y(J^T,?<D
M#\IF[:WW41S+(%5*4U2H-Z TT7\C/#$UU#,J>*C_8]6XXPH9)L=?G9UP4$ZN
MK]5E/QVNYM<@((]HAS7RPUJ!(^7[QC')G$$<QC:S%^.9C#1GG$Y;:^Z/ZNF8
MR[F)6UO<W]X7LN;?LFT%&$D>8QHR&%.L((JXWEM&F, XCC.6IK&*4Z?*S2='
MFAJ]K04%&TD=76TG0;7TI?F :FAGV1&4/#95M(;"JYOKY&#C^K$NZ7S@J+IX
M0X^4X-H*:S.0;Q?BH]0F6,XK*>I?_*;IJ7NI*>$RI41"G)H<8!6DD"E*82!I
M@!0529(EUCG UL-.C38^[53+,REM'S_]YI*L: _X>189#L;!=W &P:[,QZU!
M<"UVLZ,#M>!].M[:@^N0^CD(R"/E>GZ4C_IQ-6OSKE!^]856X%[;'&6=E]YL
MP>J_%J;LP U@JPHLEE7]HR6;Y_>UD#= YOHG=6+[HY;O"RWUK^M_EM)4G@9<
M%A7-%V"Q,FC4M25-T%2YJ3*I!Z9 2R2D_E8?\H6>\4=3U*#N#$A!^2AYKG+S
MTZ;WF2GZDC_('\&=OG%>+D&^J".URO9YJ_I%J16B"Z#5- X +5@M_C=9@;PL
MC7^324Y76ERC$37L*>#J<;DPF)2YD$6K8+GB7X"^6SX\SI??I-2*%4]:O/)F
MYZ%,R@4H))?&;O.5=^K\EIU--+5_VGB9I<X:[J22NM\]Z?IB'Y?S>9L'/4OC
M0$8\PY K)O3*BCDD,4I@8+H'X$@PA)PZMHVOPM16Z;XU@*;R1ECZ/R8]ST.;
M$<]4/VH8__*SS>1?L*K4MA;_%0M,'9FE9ZHU=4R2ODTE>&$"*U[)YL^[Q3K@
MXB5]S"LZ7Y];R8!(E!(.4QE+B$2:08Q2O1H&<1IRSD,FE5N+"=NAI[:*O?QB
MIK,NO;U<!RNU1:;,SG.^.>3]^;__2Y@&_\/O?UW[7%A/L=WR-LS$#;PL=4*#
M[SNQ?S#SMPDV:T4?9!EQ1\QOCPSKT4?NF.&*RF'_#.<G]"XN\;!<U#N:FK^W
MB7HF$D5":4KOQ1F!*.$"X@03&*H(<40)BIE5$3Z;P29'A;6LS:[_9J<V;.MB
M,"5AF[\ZUH$]"[D=4?D"<F!J:C'\U&#82+IC^WHM*W$1$<]U)4Z/-W9AB8N:
M'ZDL<?F>'K[]NT+J%\ 4W^I<^$D6QVD:PRQ#AD&2$+(T%3!,"):(I#$15IF%
M1Y\^-<IHY3O;]=,",PLO_#5(#&V.;$#HXT\_0,/!;7X-*B-YQVU>$3<O[BFE
MSSIK#VX:SR=[2MX=U^O)B]PXJ2RJV:_T_RR+KF%K65=NT5R48!HSF' 4090%
M>K^G%(:!2D3*A<HBNU(8QQ\_-5;JA'.J>',"N?/4=#T>0]LCEE!8?X'G-3YC
M;^@;MVP-_:]].^/$DT?Y3L]KU7VH%Z[JMQUY0_.B;I=TMWC4)LE;^23G8;L2
M(!5F"D4Q3!FC$)$@@31" >24!@&C.(ZE4P6;,V--[1NN90..B7GGL+3;9GA"
M:."OVDC9](4SC>*,H#>@!6R P"$+3'SN,\X--^HVPT+O_5V&S2WNW=!>UV?N
M+^L*!O.[A9!?_U_Y;48"P6BJ4IAQR2$*L@2R@! 81SP-%19IFF+;KFA'1Y@:
M)31"@E9*4(L)M)SV?=*. WF>&;S ,S ?."/CU$'MK/97=%([_MS1.JJ=56N[
ML]KY"WOX#+J$U]\>EXM;_B77+-&D:[S4=^2<SG_-YU);& M9-G7D9XS3,!*"
M0)7%"40LB2 +8PS#("$)QHD4R*I^2+_AIT8$M_?WA;RGE02/[6%S'6A4!QYM
M]#&!35VT%&\U P]KU1QVZ.[S9>'0&'06!N:;3G9@A =;TH/W"G3R@XT"H-%@
M4,@=O":#0C]6@PD?WX"ON+K>@)YUV;@_=3R?3F^-=YP^_9_2-T) T[-^8)O:
M/V,!C14.*,0X1= 4J8(L8AD4L4I1)&48!7RVJ%\S\=DE&F!G&*NOAS1?S\%@
M0YXB-U("V8CI>A*_"V7 .4)1Q"!E6;U5#R%&*(2"XC04/)$HB&=/LF#+(5%L
M.6A[G+\*@"33;YVDD89-A!#%E$,J];L8(RPSD45<J<BEKO\5\(U7RS_W"J&=
MB^,*8(8^2.G0>'T!C1Y!&T=U]AN9L3O$R.$71_4[C+$X?EG/#D!M!/^G)H#_
M>+S<N^7B28\H11T:5]:O_?;O7R[+ZMVR^H>L/DJ^O%_D_VRCS=LHNIGBJ:!9
MBB&)3/-W&NNM#\,15(IP@4+$9.94.G$4J:>V8_IM4:SEK!N(K"-Y6^(!YOC)
M!.162[!J=6_S/]H\+,?V1:.\&W:$-[D9'YA&CT9C;\)6;\!:U]T@[1M@E-2_
M;3)P-GK>7-J_N7==&G-*O/9N&D7P<3M C3D7!WVD1AW\NM8Q;1GK- E$0"/3
MZ]74#T\#!(E*!4QX@I"V4D40.94.WWW\U%:.K;8IO:J"[X%GQ]C](1G:\66/
M1N\V,L,5\]X;X5E:R9POU'WBJKYUU/:+'VF2D*8:[WQ9KHJM4C@B#56@"(,B
MB05$B<H@-><5D=ZY1RQCF"JG AW6(T_M:Z_Y=Z_8EVO=-%O0[:A@$"B'-L".
ME4PS8H.-W.#W82H-N<+EMY":[> C%U-SQ.2PH)KK WH<"KY<SO7?ER;CX4EN
MF>NW0N3&BC$FS\)D0^B?;?N-/VF39R'N%B)O.DS/%,DBJB2!.$4*(BD9I"AA
M>M(P5HHGJ<JL4AB\2C4UHMO(7]=L:!3HCE+*YBREK'4 ^5J)I@/WDYPO'\'=
MNT]A$&0.1UK>)MCB</$YIFU@4MU1:2<!>6LN-UJ!W3/*1C&PT>PY)L[AB/(Y
M)G#TDTNZF;A2%GE3Q&3K<UP?5&X^S%R90BB2FXHDFX_15#8Y^%I]'6[ZGHJS
M9Y[>!AOO*-0W/CLGI-X?WF\K\5LIWZO7994_Z/>VG$DDTS#32ZQ2IJ!?FJ20
MQ5R9BB(AQH&@/'"JO;S[^*FME;^5=?W,M7QN&X(]Z.RL_OZ #+P*[6,Q3I/Z
MXW#X--WW1AC5/C^NW;X1?N*J?M_S^^*>+MHF/9I 2CUWHBGOL! ?FF)>;0.?
M-_F"+GA.Y^NJRN6QS6R*%5=*8L@$01 QFD&"P@P*%9$L0U'"].A.Q_^^19Q>
M_, K6?(B?^S:6KU8E?E"EDW9A1>TS&MS8%M5-^+Q/L=VU/6<\S8P^6VK9@Z+
MMI2K)VU;O;;B<J,@V&@XO MDJ GP2;?>91R5L(=">)_R!QNG=U-938R5*1]M
M_#^EMC=-_>@N[SN@F9 40QJ&>@4(&8<$!Q&D6%N*6:822J5C1]G3HTW-1-P2
MMG9TEJ 5U[F%[!F$[?C7&VZ#^S-.0#9 !I<5)I[;QIX9<.R>L9=U/](PUN*F
MD8M?KI/+;LMR]= <;9M(+E.@\V_+N7Z,Z:;V41/@C%#$)>$2JD@S$F**0:9Y
M",:8<$RE$)R['6@-+_/4*&TCW4B5+!VFU_+H;%J3-O2AV_6U*C=IM6!+\QO0
MZ0XVR@.C_01J4[I/U22*43J(_=>H/ND^#][*3?88NF<<5&$J)%;?3)!&I4UP
M<Q3Z:,1XJ_?M=]KL+F>!675(+*"B7!O!7 J(2<(@3F(6,:$(=>MS?GG(J2T;
M;_*O)JZR+B!Y ]Y)Q_[F%AB+,!!4A1ABFF80!2J$F-,,RCB5&<$BBU3HYFKR
MB_(XSJ-.YAM02UW[']9R>\?<;L'UB^/ Z^59 ,'O1F10R^PSQ,T:(*]A;Y='
M'3<4SAJ%@_ X^SN';2X_"Y$DFF\22(FI<A>: L(IH9"0V/2Z(E1DS"5;RW9@
M)[H?*XUKF.[Q,X*)"454D/+,M*1FVFQEG,$X8"@(8X%1YM2R8!",QUA25Y7Q
M%C_DB_QA]0 *X_:;;\7J+$QKE1=%+N[EG]K**0::#KLU8 B0!UX)&I%OMNHG
MUU+?K#M6FS6BE?P&:-D]]B1S1,MKBS+;L<?M6.:(R$$#,]?[/>\%-L=E)%,!
M9A)!H1*]%U FJ!JI"$8IYA'/DHB'5O6)[(><&G'M=A_=[ L\F:>N)Y-^ 7Q>
M\W3 9JWV,(UBI#[3&9\]"M9&JJ]SN%O.339B^;'N#F9>!+W-?KDJC&$P$S@0
M&0\4C$WX!>*1WB>GJ8**2TR$)"FS*[]L,]C4^*:3M>V;YG[^=A99.Y+QA=?
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M=0U -M@Y< N=9Q;I&1LH:X/:W Z\,1L&!BA:;!:X17.BC8*OXED]3N\15%L
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M;8/%2:RUU<TW+],^5SF638G[\F-9[G3QC_Z2(",T2F*$@5J5)6H2DV- 8I*
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MVFT.O>U;O;_/[;IW[':&32?;[EAXZKH)-R6N]]4TVPTCD/2SHV!CR"MM&HS
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MZ0RN2AQ8;"%8=8'!QHLO8#V/''5U@\[N=AP(OJV#UO9@;WQ5#,$7R!:[-[[
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M!]KZH#5?:XK_HCU0:Y,_]R)C]UYXR78?#Z+3^%E[*Z8-K!V-TDG$[?@GC4S
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M93$.UL$5@^4CIUL)C//U8(8_\A$CAI*''5T6K!+X_:*WD]5SFV@*QK @"'.
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M@3*.F=66PVD3<WOYFW-O+;?XM'L*U-KLJ=C6Q]Y\5\?(RF+S%#PWGMC-2<Y
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MF"A;[UY*>4H#F<* :&,%\5#13IA"3$(DXB3+<1H9^Y<]"C8UEFI4:\W\3CD
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MA3&DB"+(HS#,A$C#)& SI3]=FEI;XRI@\^WOJC$<!>@:&'6[@.\=%Y"6"]K
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MF$>$PD1@SA-*618;)?49CS@]XOH.&HE!)[*.<.Z$MN.MRWB;L957% ?FJ L
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MR^9#3XYPNWX'I9(3_$0J0'1NEI;V9]OS!6/X38\7A@!U\-,%JAO,=E+?@ W
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MJ^ $YGVDM?/-Y]]N[1UX8GI7[*'&'F^='QB]/>M@Z+$&ZM]\H:'FQV4I1=V
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M_Y LI;/S,EX&TGD1/&UY?WG]12S8XQ,I_UYGYH=AG.4<AS#,@Q2BA!-(XX3
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ML,7*P0[H1>)J2^#TTT>V!7I5/+8&^B]W*6]9+'21I W)S/) 1+E@ 619JJP
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M,.*,>LHPP(S['"W) 4LX QI"1IDF,(%A]8+[4#.W"P3%"(9G"73?C/;I!)-
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M!;**,L<N@+ZD!>&, A$[4< -YH02+HG5K3M$]2!D=J)BSTIN%6P<&U=1ML[
MKHSR+G/B_:WX>;/</N3%LD7V$M"WJ,^N-0N>*?=B;.ETV(:"PMP(\8Q$QYSD
M-2(.FU.,O8I*?B;:E(#N4A-MSD3MIL;=I+ >5 ,@V]B4JL_\TW6I&@"%H[95
M0\S7X6*[5FKS9/0/X0RQZ]5J_>P=8EN1Z;NB*&X>FEPX-38F$&L C>_0[$L)
M,\XU0$9!0X@T2+6J$=Y^R;E=5B71T=93'8D#V7E6Q[Z <)YW$" *VX'?XB8:
M'-*1[YP]FCG!T?4QFB7-15["X&@&7"&#HSK193$ NF$W0A!0C;*_W4S32?D@
MSH[D>=@GPU-@/V6[Y>[EQX-9K6X*Q7A!<:PU%BG0#$I 4JL 2Q@",A$\\5%B
MFK1R+]9//S>)7% 8Y21&-R&VP1GXFN5L?U#&UN-#\ A*D3W/=H\\V9I))TN6
M/<]0-6.V850'1>LDQI!''6^70CKM+B]&R[DEUB()*,,)()0I('UC:4)8JMU_
M40E;'=]VR\WM..?T1:M7 @-N_LO8MM"A!D7L/0*&!8*W(R$8H#<-BN1$.E-/
M1,/TI=8 ->I*EV>93D]JS=&1CM3^4UWUH^]/<K54?ZW68K?@UEC.E5.*E"*
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MD\6W7^G!OU9AU&\V4@'&SU7Q7^Z\="N?_:B_6(&?Z;.3J)4-Q@607AE:/L:
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M.>UV0;#A<@\/$+%;>5;WV<LA1-P%5O[78G9&"EANCH>7JPF27$SB9/A$UL2
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M!?P/]>295+M>+Z?Q;+WE?WO'\E+$N@Y5-CZ!P$)L1UMH79;::%<K9(+8SDV
M.Q#]NP'ZG^*890R-[PUTVASBHC'4WRR6M!?-MTV=TX_/RS!?$8.5_WG>_#3;
M(B'_W[/M^=0.8IH$+-YEJ<$P*T%Q1OX\I\C0A61E0E85>,P%T83+D2M-QT#R
MCJMI?%!UL+G<(Y?+IBY*%&,#1T"/BEBIHT"\H6TS6.<=6B=TDY8HC]"T&YK_
M*8Y'A]),_\TMKE\FVP07-]N7W.#CL'MQ]SR]X<6XIW@9_F;<(\U62@A2LLA
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M6'F@V_ Y,R[[&!B99.D+,<-#AJ"2 *V9#"46R=,Q^ST_ T/-CDN&Q]!P*N@
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MUJ-H_&=.";R9?B<CL D"?L?U 4W\#GG=T1(&.W#;/G_ 1:KW VJ'8>>!C*N
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M 23O]W/>+/'?SVK/VXVO8S(Y-4DQ0&8Y*.\2K3*O(8H4I'(D/6P;8S],V[@
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MY_8V1FV4%O54VY#/B+5Z-V8/,: R%/QD<AN;',<^1E5?.-I'[7=[N VD@PX
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M M(NDIBP.SD!SWMOMW4'ST'#C0V]H=P[R"F]J+O"9=UUT8;'VEC2EEHIAKQ
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MYDVZE[:;W7:QB[PO]POZ]?<T.R.9OB$C4 ^!S[9Z?G]GTSD_?+,E)>D8K?C
MR'>O.0>?<^U>PR*Y(SF$U$) P[+1;47P<_!WIRYN/$UWL,\?R//+'_<_8%.M
MR'@I.L0,%)S*.FJ9 E9&\O I:",B9R&UJ=IOQ]/(57DC0O5VS7,GN.EV"5VK
M["G&>G+M"F1$0>$%??$N(&B17=0\&1Z;](M_BK"1S7DO"-H)V7NJ<^QBJHNR
MV4V L,1$'UU=*Z&]J ^3&6U1,=9S;P=*>0%1" =)R5*43M+()[WG9[RO1^#M
MJ^!%6VEW8-]NU;N>,U&':I:"!1*2:!23&4*A[Y*QJ"R+/+7IIG0O->.>/34!
MU'#2[P!"3]6G6FLC-S:"U:K>*0X>(FH&=> B:FV%;U/VWG65<5-8#:F1#@!V
MH#-QE0HNSB1!=AGJ8!I0B9%,(S-@A%5,U5.N-GGUH1@8^:[&/TV LA\B?OZ5
M\.*TYE@FA7$7ZOZBD >2/"L0-OW=&7.TM7!4KDF^:A#J>W0O6P-O6/3O@8*?
M>=K()SRI-0YOYV6Q/-V\L?DIPL.O/-H)PHY<MS\]\#SEHEF Q'2],D=8B]D$
M"*IX[W),V3?Q_MJ='EQ4);S_BG6.S_SD7-:K"8IDC$\2I&&;<; *G IU<(8)
MF6/-8C<QK ]2U&U._SFHN%.+/XC\.]C-+QCYB%\7RTV9UB4G5G"3B_6@%;&C
MLB;GR*@ZC,4E'XOT5C7Q5!\F:>0HO"V4#M1 G]OC6PH"YX3 '_ML=%?_>( M
MZP%*!MI\+I]^59%V"0YEG(W".C#!9'*S$D+4PH-)DI2H-/E:IDVEZH,T'5Z_
M>^?1GTF2+^DS_Z@SG5$J%! "BZ!$#%L+F%"'J)6SOLV5Q<>(&G<3&@H==XMN
M!U)#Y\9C$ZSOY2O??L20AN0^JHY@3K(K%HOB=1R1!J4U.1BI4/QF0DI%9I93
MD_;L#<W)55;G\B7G':(W,K["M&)!.XL1C"SD7%DIP/&DH#"E+<?D!<\M>-^5
MP'[-S'-0\W !RX#JZ=SD7!7YWN;Y@,C]&4\?TE ]DY<CV#"O=. H+;"4""@^
MD:ML5:DG %BRURG()H4[QW")/H8__AH(I-,PJRU.JV._PN4W7$V"BM+)&,%C
M[=Q3<FVN%NH !FF-R,A)*$VY?I"T?NW6<Y#RH'LTC$HZB-8O.?K[8OF/M_,/
MRT7"U2V6BHRRCJ<':\BK5)8S""G4MN":HPTZ,M76_7Z8MG'C]^8P&T@I/>'L
MS70^7='N\9?%(M]B*3N,3,<,@M80J,@5B2Q:\"::@DZE[)LD&G>@;=QC]>8X
M&T@I/>&,N)@D9M!%$4#6,87*A@ ^UTLKRI-C:<A_Y6T!142,.X.B.7*>*^;!
M[BL.[*2OP_RD5I9LAV54O>WEC=]]S"!N]Q/4#>1?U]7_QW0V>S'/MU]Y#WR$
MINV'L0S!VWH#,2J(0J9ZUUJI3/&9:N,5/(O*P\W)0V^XBE$CMQJY9<!C422(
MP"&R4B EAY*9:'-IY!X]2=NX7G@[/-TU1\.JJ==4PAT[<$@>\Z&'M;%8#7.;
MS\-9-)+96G/(D"&H)#@X*37DQ-%SI33339R"H]JMJP1;=>W6^&[Z#>^\]E:N
M34OE@^4<T"$)1O"TN8Q&G@&26R Y"M;$CNU!Z\]DUYZ#MX?SI&W4^-/8N8-2
MI \^K8VE:YD"?1[T/#>*Y5 3\X8 @-F#*[)^H2U/JY*,;G*+ZZBF[F*$W>?%
MB_3O9],EWG[E) ;KA60)DDFU)E?0BM"YCJ#@WBD,&D.3X_(G*?N9S-ASL'3;
MC VKH@%;0.R/ND?L<0V)K156.,W!BE!;6@AR9DTRH!,:0U(TT3?92Q\G:]QL
MZ?'P-J!R.@?;WU98SF;OI@4G(=KHZ^J1F_-805(+U<\(6;N88F".-2E)W86X
M<=.G/0!O3T5UD%%]9#&].%TLU]/_V"CR]?<Z50)_)T?G\Q\X^X9_7<S77U:3
MX)*31B70BGQ2E4.&& *%]>2FRI1JFXLFX=9A9(^;M>T!L(,K]Z>#\O_!L/S\
MQV*2I3-&Z C28KU2X@)XH0H(87)$KXWG3;SHO:@==S1PK\#=1Y4_)UX)@#@I
MNJ2$VH+@M2 +HP O0[T)96R.EM'J;%+4MB>].V'6_*?$[+/5^5.B]LWB;#F)
M44;%2@:3O0<5JU!YL&"9S25DA[I-^G$_<G?"K/W/B-EG*_/GA"Q]=L*U25:;
M )@(6DK*#+XH 3'ZD)3SV;LF#47V(W<GR+K_E)!]KC([@.SN1P.3K TG@1K@
MAB50RB!XXQ-PD5R]3BAT:MS)\2D2=X*F__FAV4AI'<#Q$7Y>_OAK^+^+Y:M9
M6&U;G06O14WK@D"601GC(407(1)/5EM&T6.31LS/H+&7IHG#PF1W0WF0SOJ&
MXQ5CU_H2"2V54UZ#9)G$J&O5=D@6=.$\E()"IF/OY/?1.2XLF^%E=UP>K+P.
ML'E9T%UK;(F2+[7W'G[#V>)K/24[[V;%+,\&O0&5;=@V17<Y<G":1,B<,3(T
M2>?O1%VW.#P<'W<JRX965@<(?#=-Y/I.YR<O3I:XG95SSDCB3#HNR.MU8E,3
M[( BN3IV5V2>*8R+L8FK^"!%XQY9'A-IPRBE W0](K1WEYVBI A%2]2@M3!5
M4G6>3C# A-(J)8OR=OO6YAONN]X:THWE_.VGI;Z1]W$QF[U9+.LL^XE7K.A:
M"5R"W32AU!!L*"0V)9-5UEAV;&?O&GG=[JU[PF)WW.VKH[Z1]Y=E':X<A4LY
M!7()8KT6F@K6QJ<)BG(DPUP[T[DC8VY#6+=HVQL,N^/M^9KI!FFS>[.;V^*Z
MS">\KD*>$.B_VILA(@D,/4AK2Y \HF%-;L/O0ERW'MVPB!M00]V@[OZ<>DIG
MIV>S4*>%74NO3ZQ*/ABEP>9Z*Y!E"5$;"S';XI0ECE63KC+/)W7<ZK1Q;> 0
MVGL^/OT6GW,\J2_^? R8UL)/KF+4R3I(67DR];655=0:1/%6.UJ0,JLC0W+T
M&\+CPN^Y6NGSPLJ;Z7=:/AN&YOO='+[UA $NICQ&TT"743XL%U]QN?[Q85:;
M]<[S:]K<-EFQR[,R&3GC]!^H$B(HF3,$X13X%(4-)LN8F^P!3U)V\*63AUYP
M[\W39!S+JC:A1I*"SUC'4!/=SBLIM(BTL(XJA>YN"@^+I#O73UHIZV>P1OO?
M$+[W.8-;IH;W@I]&E7:.(Y>2E)U)V=J1EQ/KY-EDA#=&**V;1.7CV:<KH.=B
MM19"0TRIT+9;IXR[*, D[66T#I-L4M;\-&F]VZ+GH&9G6[2?8GX&"W3 W=W[
M'S2X#6IY8_=I.!4>&.=) M9.W 0G!HXT70O/K-#,L&R.ZQX,WX3@8=1OSC&$
MX]H[DT$S;DD"/$&0V4 .Q63.4D%L<D%W5P)[-TC/0=##)6D#*JF#C-6#W+S\
M\9D>L2E2$<QK@RC!:BYK2QA'_B3Q90RSY.XEAZK)0= .M/52@#8D*';="O?4
M4,^@JPR=UPBHXB3J4@\8"BW6F"P$Q0QP9Z+2Q)QK4_VX VV=VKE]\;"SZ[6?
M<CK VR4+%V-:31!)% O<XH;\ZD367@HE<,Q!:&QSV?86'9WB:%\]+X83>@>8
M>7.VG$_7M:)]GLD-KM]=%!H50\M+(D+1D8,2K("+4=5.0JGP[(22;:Y@/4C2
MN(>%K9$TD"K&GMB]G<N'R_\1EOF/L.'FTZ*LZ[?GW&CNA%2"C'4(Y"9X6R!8
MKX%+SHRD8-KY\E0LN-NKQCW+:P68!F+NP!*]+V6:\(XY=99KPQ29T\S.*\<3
M)Y>2F'-!*:MR:&&$[J5FW+.YUO;G< 6,;7K^&N9GA4+@L^5T?G*;$>29Z>P\
MZ)!J>22+$#-]8<P6--Z30<T[69W'WC)NPX6F!F<PX79@:]YA6.&7Q2R_/?VZ
M7'R[65\M [.,><A1R@IX!,^S *=M"BJ)J$T3B_,(3>.V1&AM=X921@>X>K68
MK];+LU15L[DK<D*ZNN#%80A*2PLI!*1HU2&$K"R4DE5FSBG:K%L ZS&BQFU<
MT!I9@ZEC1&BMENO)QS _V68\C/4,N5+@).W!JO;K#R%[2%KJH$5 *W>I6:*'
M7L,/_70;.S?>VLL-B ;9Q_VEVP,D+HRD"M'8*,'*6HU55'7Y=01!YC*R7*1D
MNQR8[ Z*,?,Z!VCLML[W$-_(6O_K=#X]/3L])SQ&:9EPB0A/Q+S-$;S/9,%8
MP%@/?]#NXJGLI/<;;QY9\_OH;3&$$,?6?OA^C7"K+6V,*H(*=7BSLJDN@@2:
M6V.4XX7M-'1^-^U??_,XV\%@VM];B!WXEP_N@.\N;V/Q$FHVD$$=^PN*&P[T
M' \\D)N30J8 _KCU ^^>=9&R63)NW$/,_?331;OA!WG:7IBB$,SYXC)Q(32H
M5 >_*NU!2N.82CZC.&[17 <7V8:&P:XH>[Y&.K!IU^Z<_(9$1)IN]$3?SW"C
ML/F-NR@/,C]A@@7)BX6,R9-!5QE<S &BX#X%A=Z()D?I0S'0Z>G6,)@=1<N'
M7D5J:S_K;9>,"D/2#+*A%:JT0(I?% =6FX=YDUQ1QRV[W?4&TO$/S1K;SN=J
M8[#1A0V0=:V]O&%%T'80(*?:>I/7Z08Y:_!.*:7)F<EM)MKO0%NGIVF-<;:G
M;CK8J'>QVQ,>63*E7@6T82,S5LO5,S"6K1)&<M9FNLXNQ'5Z.#<,X ;7SH#!
MQZ#7"<B36)YA/F_8NM=%@MN/&. *P:-4#75Y(/S87(^J6JVO"[/5M7F9F50J
MR,OGIM2M2X 3B4Q+#5I3EK+15/9':!H@,%B<S=>K\U=<O(%0. UQ.INNIWCO
M:$^GA8\$< C%40"/ZO]G[TV7VTIR==$G0IR<AY\NN]SA&U6VP^7N'?V+D0/2
M9K1,UB$I5WD__4%2E*R)$H>57$GUW;';I8%:"\.72 ")!!A$KPUH*1TG.8B0
M2J,XX!!Z1PY5!\+4(_Y^<^7U>=WIGB4X_,;EXP\:WE:UO'/Y!+JTMK[DPB!A
MU702$AR/"8+.F864F6SDF;:S6#]SC _!?F\N9XTHLB&W#[VJ!U>*N*=='X2S
MCOF,CK=)T^Y.8K]V:1_D;+_@-*B*SL(4'7'U<LN3AC=&32]?/H$II>O^QA+Y
MPTB><<P*?+WR+S&9G+C"J)K<E6A@C=;5>ANQOJ9?3E.X^+R8AHMK&4^2R,E9
MDR$QXT I%V@!L0B!)XE*A9(#?PX1S[ZE7_NQCZ[OE$ .)M0.HOD-+Q25%EPN
M22OAXBWB\O7EHHIW$CCZ4(0#G4(]%M<9O!8,>"I2B& CMAES]C19(Z?(!\94
M U6,78&]8>4SIJ_K)?+A3US<GJ^RG"C!I-4R0;2RMH*7CES]E*&0E^^$,J+<
M;S3QM.W9_JJ1\]@-#=! XNW'"GV:_P@7U06[QGPBA/M,2$=?;)T8)< KK0GX
M+ LC4XB9-S0_]^D9.57=UNX<)?P.,/1N1L_"Y6HCIFLN%+-)9\(_3ZZ "H'5
M$7FU=%Q@T!0UE#;=?!XG9^3<<R,$#2#Z3G:L/T(5S\7%_*\P2[@,L_P)UZ?5
MK^?+U7(BI1,^U4W7N-H LPYHKJ%A4<Z$0/NPU\_&4+N_;N3['@UWK@'%W EP
M;M\QN)5+N%X*FCF,T4?0)==\II#@DT.H5S"%<8P8COL Y^G7C7R=HV7,-9R8
M.]BR/JR^XN)A NK&?A:E5!WB8#.Y;BJ2V^^5E"!U(&D5[9UH<E/H:;+&G1C9
M:@L;4!4= &L[(V@D6B49L.1%[619(*+PH#4*G3AQXYJDVX^#4[,ICXU]ZB,5
M,%AQT:#IY/5%S8/2QYN_'"!=_!@- Z6'KQY]@X)HK?8A:XA95GW)2"BP",YF
MX6K'<XJT6RR8NV0<?]-YN43<Y EF7ZX>_O.,@Y!>?,H2"I<!E/+KQNX,G"]"
M.8O$8Y,@Z6FRQDT='X&#AU>;!Y-^!YO+%3=OI[/JN]_G1;I"_V\\>'MUDZ8V
M' P*N,<2BC&AQ";=\YXB:MQT\> X&D#R?9Y3;C@ZN%+BSM\/MLDTK(NX#PTI
M$F.IMC.WCL)>SL%+92%'8Q.2X\!+DTD40V\U]+0:Q]\[1S=)1 *B@^*O)CI$
M<(87X,4$2T:.6_3-N'M(3U^;RQZ:?[1OQI'R[F97N;M'7KO//WX/M=_,ZL<]
M%KE)GL?L(1I-L@N%?&FI"P2C;)!.1B6;!#,'T-K7'G04W-KJJ0,HWMY@GV4M
M.!&XSQ!Y[3WJZ2M7;  O4@Y:2\U4DT+W/6@<]P!T0.BUTDO/WM#[L*@+[3L>
M4;6UY4F#>4A/T]C&5V+!2(O.@5"6=K?:W] Y4W<WE>HT*N;"V83EZV>^P65:
M3/^L&KBZ@&YX7E\X PR!UPDW&;QA C+),G/I4)A&_M)6FKKRF?9!P..;V/%R
M[Z'[S[H!CA)>26,UD'&MXT&D@:"$!9&Y3HHI,GN[%$HT: C5$ X#Z?#1'E#[
M"+0'%%RWZ=35G6(>O).6&$=;3]MK*DGDY%ET)>_B$9]C#ZB]-+:E!]0^XAN[
M"]"=]D5*9:O0N]I?/(#*1'CT7$/)*H:B?1$[14+GV@-J+[UM[0&UCQ#'UOZ=
M]D4F.72< BIO,X*R,D$(#D%;KB6+46N[2]7ZN?: .EC[!PNQ@R#U\>WOMYM+
MQ,Y+FS1F,+5_0;U)#L2?@:B*$<[2QF@;)N*WTC5V'F18GZ&%,L8N:%IS\0EK
MU]7K_,YG7'R;:,/)&L8$3A59AVT&6A\H0$I'/Z:O KMW56U+"=.6%_3H31ZH
MP?G XNS W/PK+*9UF:P9^!A^K)OP>),Q1"6@:*E!&<O!:Y<A"VXRSX',9I-C
MX\>(Z=&P' >?P40_OD5Y)&5<_WD_7_T;5Z_GWXBEM)XU?TFL1>.8MD%!B;4?
M2DP"ZFA-<**$I)*CP-[O:&CV>>_8:=)F]J>9\'O.F]Z<BAV=-WWPI,'RID_3
MV"9OZG-V@2)A(&TJVG9<[9MF*%3&Q&HV/L?29/AZHS/F&[XXH8N;I"!PYT Y
MX2%XE:!XX0I+WBG>;ES#;4K&=F,.UO;6<^6#9-R!RW+[N.C3],O7U8?RSR6N
MY_O>[8:$QF1E-6BA,K%E/$1!T9_4UD0,/CFS2P?EHX[PGJ"O T =CH(G3O"&
M4DD7W7%O,W9]&VIS&7/B N?H#4*IU\*5D@C1TG*,S"K-'&W>NOD1\3V:QG:6
M6V'J&-&/[27?YJ,*9^*2X$*0/"SY\B24$,ENUS9P+.GL#!?)[-:>X?Z3Q_9T
MA]#^\2+K8(>ZZY5?<6 B%Q85\%)'/.JH:C\;#=GPK+6/RNLF7<L>DC+N9>=A
M;<21@NX *G>2 &L&(@N!22S@7;TD:76B( T-*3@FBRDI$YML*P\H&?=.\[!
M.4[,'>#D)^%>64.HSA"")L)5D,1"*8#!2$6.OU*Z47'D/KAH=GUY6%P<)M81
MFT-?#8<-RZ]O+^9_7>6 ;@0AHT@9"['@ZT18HSDX)NIP/<VM]859OUN"[?'G
M=^!<'A<!#R6[#LS!8\[Q)H7\X>8"]8\)]UE04"4@E!A!I7KVE;, 9+*H6(*3
M;;(GNY$W3@0\& IVB%>.5$D'0+OK86WX64Z""5(8SR'Y>MNUNEI>I 0F:2^-
M"#G+$[BSU^2,8YE: 6D D7< G-O+X>-B.DO3/\/%#3-9:)<RZ5=1Q XJ![+<
MFLPW>NDB9J?+3I4M1QFF!U2-$S^?PAX=IX"Q,RC71+^=+SXNY@DQ+]^2^*X8
M_'GX/JN-]Z][STQD8HD"/P1N,=>BKT .@I:078["(19NU4[.T"%O'R?&'AI)
MIQ%^![;J7LKZ0UR%Z0SSN]FO?Z>OM2"-F'_TDLI$(R/_DX29A*G'MYF6D4D1
M8O*R:(HPK6YR7>%@BCO($0YSC'4:G9T).+=<VYN(+ RY#0I8J0-!@G(0HQ5@
MF1/$L\I<-O'_CZ"Y@_3DZ0 ZA-XZ@.CM=?8_6/G&_.H[L?;ED0HY/E&A!)^C
M!*%KJL61$QMC#" %\T'9$I-ITAQ_/S([2'\. \2&VND >W>7T [\!5I)WA%K
M,2GB3U/L78=$TQ[@7&8E26N:A![[$MI!FG48_#754 <(?&)]U1$XM?SN4UCA
M1URD6N%I;0A""0'>UBF$5S/M:]Z9*^6,2C+G)@7\^Y$Y;JO)TUB_8[73 ?:>
M7%N/\9>1 D$6-!@K:O-G3JO,H*<%)B23.46-3?;>?0D=MQOEJ:S?L1KJN5+W
MNH'#O-QQ;J='#:K9]=&#U?+NR46;XE[M$95C% [$0A%K1 VN'ET7*X2VV1<5
MFBS:88M['XO&28[7":8WES^S53JC3=XZ2+GFC[Q@$%VPX$5!Z4U1)T@//TUB
M!]6;A^%CE^8K VBE@[WQT>S/+;[>TV+]_!=>?,??Y[/5U^4D1B63"0R,(@NO
M$MIZTUP".NET*<DR;#)A?E]"Q\5>*\#LTA1H*.V= 3K_C6'Q^:_YQ ?MDO$.
M9/"U]7D@+X0S ?1%"CE$P7GS9,D3](U;%-()%@_1U;E D#"%$V:84<@3&*YC
MO4.=(!86@5M>/6.6M6U>1_(DA>,>:_0$P[WU=29 ?#N_7$R<YRJ&)$$[1XX.
M!6'@N4S 54@1@XV,-9D;M2N!XQY>= 3#O;5U+BB<?L>)2"(FEP4H,O%DYJV
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M'Z!P31*I5V(#MQFXLC(SCD'>3_7LAH9]X-!F#.4)X7"(,'O#PS4/&+/V5GI
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M4L1L=)/P\AFZ=D/4&>7RA]1#IVT$UT5R]V]>W:5YQQZ"CS]IB :".] X5/?
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M326YUTZ*5)OH82"2D6)9:R-8RPRSHM8PM9G8NG=GV%/,[S@E$I[L([N/6CK
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M+VR=HLAY'T6/G8[?L816Q2B%]1FR,PX4.@-.D-^O:5]"CT%I'?[_(N?!0'%
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M@;-.0U(ZUSYPG'46 !W$9N<G-6W76\>(^N]8;YN6X"(+B8G%>N6-!&-5 ;)
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M: GJ%^T2W$T5/B\XH4Q C 98<"0XY3GYA2Y"#CHFDJ"0Y:RSU\-8@W-.;[\
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M\E4LN3\&:^16('+Z5NI@M$O"/IA]>D2CD;OO[C?U> CF3J& #B*573A\/&6
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M3Z*P3$==P#I-8;E2M-H,<^"#1Z-4ULZU-GF'4=YEWOAH2&TWD2?0[_Z ]E>
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MBUAHC4*GB,$R14FL *+UFP'!R[S_;S$HI#X<&*)90^(Y4(":^]4(RV*E[:B
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ML1-C)>Z>V$Q'"GK:VS\\-N.)C&?T_Q:TCX/Z"&*3/KR0-M5##8U3WQBH&<M
MB4EFDPS>IZ=+K(*#3*RYT0F,F2 [X3NG<3*&R9S&GB!XP3(2H\3J&R4N(AD#
M+8F0H!\"^+R@%S_*B84Y36;8[W2DAR,Q@B<&N!1$E;R1.I*#2'E22C-HBZ,H
M$H .XP2T%PPP4E;I&)I)F(55(E A[$D@Z#TF"+H'TO!5 F2)L9(QJKTK()@:
MC<N-V]^"'U&1K8@?3T/:7+>20!/J?UHM8LJC*ZL4VP0F#B,]3&&[+3*(AFT&
MPR.A!Z8Z'5$'M/(M;!R039)0[U5> :X4:CR)S P[IL9)%J6XYM!UHF&6$OXJ
M>Z.',%&9D^ %HK;G/ %XS[&\V(1N\"^,I8'>HS#4D09V3)CU)A.8!_+/%KX<
MRQETC%NLPA#YV['DLVYW]_"2B2B6@=[O((]BJ[F/$5:!_V!&J351RU&&ZSB5
M-IAK-T!^5"@TL/[P8FP"'6IX*8<@0P&L2#03B1&1@;61B-8@#-QHR/(.7<<F
MA7V; )HGT!J6>J0'&F5O,/NV7'LO*-JDQ)@*L! =ZAUD0)#%5ALO?[/($;#S
MK,Y6J<G:XL+CIP<J@K\2J[8$[.$<+.>8> ),BW.A27EPO,(7S#(E(6C5\9DQ
M$!FP)(P.J0GURI@>9A;>MTN?=4B:*&ANH#E/A#T!;,H+CEV VA@"9"L16C.N
M2"8RO1/."=#.:  2#G)QY>9:7PUGJ, GT,D8!KA,S?!:$$ I/^C$HA@V/#V!
M25$/J$X185!:(A 5Q#A&DM=26_%6VFN8V!\RRJ@?DC0_-+>K;$9;]%&LW? $
MAREK-)9D"0/%?V<@/"3/"=%LN#4N%I(A8]YEG:O'<C/ZB(#5:1^OEX"$2]@S
M[&F_V_5;>FP"-4>4^JCL4">D*Z7?01G"]C(D [WSR.#%9"(#1*#M2(4LZX?S
M>+#8J5HS&&F6T$[[?O"A$<0JZ]M]ZM>W&=;ZN40>YQ*Y6FRKL5H-?4(316:*
M[-J$)14G8SGC=7:?-7)>A86V2SRTG!>_K._[7F6Y1OS9?O(,UZ'W<:*=KX&
MN#X\R!:50O)0@<5BIJ1-"A54@>^2CJU-B+7L'5%Q$0-]AZPX:/_RJ/-D]W#^
M]^I8%+F1%)Q:%X.O]W&H)BGJ6J]?T;$ 4P><&#D9)6*O)?8)#!^WV#&H<.]
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MJU6RYH#OJFJBL/S%%C ,&N]K5$Z.'[37C: 50 N$G2H+9E-,I,I-,@NV'P"
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MLE4HU_K35?9%OX[W9W]X\)^0L_X"]%\=<NZYGV6E'XA]\S]02P,$%     @
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M$PP#5!EN"-^2IM?"]"<#SD(#,,;*9817/!H[0KY RG#!+7A"-@_M18!T7EO
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M_*Q2.SU!_6J01OO)]+'J*T;U5>T_OG9T5CFO;;Y<J[@;K[W0M%4CLA4;EJ^
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MI/7'P_W.X:CT)W,E_'3<[_5^: 31L]/,%![K6<R//Z.:367<3J O,=Z;?'P
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MYQ',$1^W-]N0"IB(JG>QI2>F\A]?^S'<QN^D)>U7LD]OV5BRW F%[)81@W#
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MCA^K9G+CHG>5R&'EWFH*3Y#-E=^<\HF[X?IOO*D.=^9G_P=02P,$%     @
MKCM94O(\_<]]!P   1\  !4   !I;G-M,C R,#$R,S%E>#,Q,BYH=&W=6=MR
M&[D1?<]78.F*+57Q?EE9E*PJ6Y)K57MS>95R\I3"S&!(E## +( AS7Q]3@-#
MD12I6-0ZZS!^D#F#1J.OI[LQY]]=_7IY^X\/UVSJ"\4^_.W=3S>7K-'J=#X-
M+CN=J]LK]L/MSS^Q8;O;8[>6:R>]-)JK3N?ZEP9K3+TOQYW.?#YOSP=M8R>=
MVX\=8C7L*&.<:&<^:UR<TQO\%3R[^,OY=ZT6NS)I50CM66H%]R)CE9-ZPCYE
MPMVQ5JNFNC3EPLK)U+-^M]]CGXR]DS,>U[WT2EPL^9QWXO-Y)QQRGIAL<7&>
MR1F3V9N&S$?)0(RZO2Q+NL-\U#_MY\/7IR?#$S%(TI0/_]F#D!V0QSW.+Y1X
MTRBD;DT%G3\>]MLGH]*?S67FI^->M_O71B"].,^-]CC/8G_\&=EL,^-V GZ)
M\=X4XUX?S+SX[%M<R8D>!RT;D=MR1VJ4L>,7W?#OC%9:.2^D6HQ?W<I"./:+
MF+./IN#Z5=/!,RTGK,PCH9/_$N-3G!&>YE&)$[!14HNE4KT^J7']]Q]NWMW<
MLD&OW7_YHO=]]VQ3DV?IL,,BC_+Y?I--"G<*^[5MT>L^R1B_B93B.]IAT.VS
M2V&]S&7*5Z^_@EI[FN>_;HSA3F/<--EOW'+VSFCGA=1-=CF5(F?OI>8ZE5RQ
M7W.81EAF<G:C78$\OM&IL:6QE-1-E@;K+9B?<O_RQ>CU'K;[1CH?]8[9#9OR
MF6!6S*280R<_E8YQK2MH; 64\\QH]M[8(@9$K]OZ\1$30.G3 U"Z?\S><0?9
MH5>Q8'?:S)7()J(9=:^5S@R.U :@#8Y<:MADP2KM;24@,=0-B Y#<%;@R5*$
MY#S%*T1((3WS)M)M$6B1"N>X71!)P>\$SEWCZ? N@S X4H5R@#.(()46\ \R
MC>V0)$,HSJ<RG3)7T9_5_KFPHF9""A32*=0)*CESZ:=0T)7(?#J=^)80S610
M<X9M&4L6ZV8X$)<._H-+!<OO4WAEI";\"7(LV[5UJ7,$>H __$Y5E8$G'+%F
MD2:<**U:L!)VI!"@T%!JY>/:O.[!T0BC++033:*H% C@6 /KA^-<D"?E;LIR
M9>9NZ74K)M)Y]"*><7H9Y8:4S37GN:4P6](>B/^&Q^QV0]E7KO9-#:H4O*;&
M7S+ #>-6!%/#=#)1@DS"!/R;*.FF1$YD!1*7DI>>,^E295R%?932UJAH\]*:
M5&1X[=@13)P)^"S:\?IS.N5Z(MA;9,O'2@E70^" MWJC(W$<]O=&67R*CY(J
MGXX.IT,8Y=5:'$2_D$#[G99OG);C--+X88B @N!\S_)S5O*,\*&E1.['@V\8
M"/PX*GTE'/H(&"9@VY==UR3837GEGKZ%\"\1\$!]4D144UDP0%K-I O)"BJA
M Q^JZZLT7X<**Q0/+JTA=>619@TCM"B1\I#%&26S, :X*G$RD]Q*4D!&X _@
MI8E3Y0B,0QJX@-PAM3%G0" , &%3R1%+::4X(1+4"D*L0!T[8HE8KVSXE0@B
M!&A@_]YU^W\G6I*=T?+D#-P*FJ?G[I-C!_$VDQF%!'<8)0FIN$,X416G..$V
M6_H,421Y(I7T"T+_7<=2! ?W!L_%X-L@7>L" B!^KA4J*S1I#J:G:I6B9<N"
M *$?F B-(J000%@1)44FD:#7B4&"")9E@*,##9.T#I/K&5=5R#RRH<ASFG]F
MT-[M*+>H0$_ D/BXN_:&>,!&Y+^+%3XQE7_\[*>@'+^G%M2^Y%_NX%BR;(Q"
MB(MH@S#?P9UTP"&Z-%MF?K39MNVI6Z_K:5AYX-H],IU0WZ1I9<FV:Q"[P:\P
MSN,-S;W@XE*P^+T"-H/IT19QCL! WCV@J\5$"RC"6*$WI[#C*,F4N_L:1!D;
M HFF3V1[T+Z&F06&ASNAZAGC 7WS#QCD&6'SK8)D5 ?)OJUE&(BS960U5QE$
M";WNZ54RD<?VJ#M;?0*$XN@2O+'N'N3#"S K,$UZ(79"5&)00&@EDY I;#]"
M)  1'"$._J<N91FRXO=*0N00I)4.ES_N^.![Q;>8OJ@.AYLKR$$]=2H%C%X#
M]'W/-A?\CA WUL& N:&"AYE].8GMY<JZO8K#R([4XQDV.G&?>3O<7E=\$,.#
M*,S-"/@.:.^J O:'38(:-;+MG%8/&LR7;=Q;8'9N$?9-F%6$'(5CPA5&[<%F
M!$&I9T;-!"&AYI/Z)L;6:2V*4IF%P.I\:F(N\XWX@#__8%%H[W%I_(Q+T+5M
M?[8OWHO$HAXMHD/ZHV;X&/&\2^#E%;D/76^](T&$"]N"/HJ73HR7/\Z MZ7B
MB['40:JPZ6Q&$(TB67/TIJP_2HR&[?[@E+Y+>)C59TOV]2>+=OADT?'9]MKI
MZ_9I]_'E;KMWO]8)O"-_R.E*KM\T!HWEACI_QOWR,^MMJDXI]5#X:*0_WZ]!
MV9<OAB=G+OS=O.:^=^T3%*Y]!R^,H2\+@RQ;RGY(UGBV!0Y)R4<^7_R_JGOT
M(0ZJT'2E,Y7-MZM9MC;!\;8-.@%OOAZ@/_B2BMD[W/V.XTW13&Q]6UWE6#BH
MN]K"$R1:Y;>W?.%S;/TW?AP.GZDO_@U02P,$%     @ KCM94DH-#G-Z!0
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M(5:X'=-,V,S>9ENS/Q=<,TNV<AORM-BM:R1WR1[@]@K:NW3O%JN[!7*[.$K
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M6*I!#0G75O= OC^YMJ1*-&7UH!**95!#E1E\.B<N288047D,VQ*.13$ET1O
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M,#(P,3(S,2YX<V102P$"% ,4    " "N.UE279XU.4HL  !WSP$ %0
M        @ %WT , :6YS;2TR,#(P,3(S,5]C86PN>&UL4$L! A0#%     @
MKCM94NWSG%WD8   -2T$ !4              ( !]/P# &EN<VTM,C R,#$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( *X[65+I/^PO5CP! #J' 0 4
M      "  0M>! !I;G-M+3(P,C Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( *X[
M65)_)O$I"",! -/^"P 5              "  9.:!0!I;G-M+3(P,C Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    " "N.UE2&[T'#/.C   IBP< %0
M    @ '.O08 :6YS;2TR,#(P,3(S,5]P<F4N>&UL4$L! A0#%     @ KCM9
M4E''(H8K#P  FE<  !8              ( !]&$' &EN<VTR,#(P,3(S,65X
M,3 U,BYH=&U02P$"% ,4    " "N.UE2P:!KA603  #1<@  %@
M    @ %3<0< :6YS;3(P,C Q,C,Q97@Q,#4S+FAT;5!+ 0(4 Q0    ( *X[
M65+7+R#;2@\  'M6   6              "  >N$!P!I;G-M,C R,#$R,S%E
M>#$P-30N:'1M4$L! A0#%     @ KCM94HCT==GN"0  +T   !4
M     ( !:90' &EN<VTR,#(P,3(S,65X,3 V+FAT;5!+ 0(4 Q0    ( *X[
M65*. EERC0,  #,<   5              "  8J>!P!I;G-M,C R,#$R,S%E
M>#(Q,2YH=&U02P$"% ,4    " "N.UE2ZCT.$4T#  "F"P  %0
M    @ %*H@< :6YS;3(P,C Q,C,Q97@R,S$N:'1M4$L! A0#%     @ KCM9
M4LX5:-Z/!P  CA\  !4              ( !RJ4' &EN<VTR,#(P,3(S,65X
M,S$Q+FAT;5!+ 0(4 Q0    ( *X[65+R//W/?0<   $?   5
M  "  8RM!P!I;G-M,C R,#$R,S%E>#,Q,BYH=&U02P$"% ,4    " "N.UE2
M2@T.<WH%  !A%0  %0              @ $\M0< :6YS;3(P,C Q,C,Q97@S
M,C$N:'1M4$L! A0#%     @ KCM94MLBX^9K!0  #18  !4
M ( !Z;H' &EN<VTR,#(P,3(S,65X,S(R+FAT;5!+ 0(4 Q0    ( *X[65*%
MA2):6@L  '4Q   4              "  8? !P!I;G-M,C R,#$R,S%E>#0U
:+FAT;5!+!08     $@ 2 *\$   3S <    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
